1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	O
6	5	B
7	-	I
8	nucleotidase	I
9	.	O
1	Colorectal	O
2	polyps	O
3	should	O
4	be	O
5	removed	O
6	endoscopically	O
7	whenever	O
8	possible	O
9	.	O
1	Anti	O
2	-	O
3	anxiety	O
4	action	O
5	of	O
6	diazepam	O
7	after	O
8	intra	O
9	-	O
10	amygdaloid	O
11	application	O
12	in	O
13	the	O
14	rat	O
15	.	O
1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	I
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	sojourn	O
11	with	O
12	Professor	O
13	Dan	O
14	H	O
15	.	O
1	A	O
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O
1	In	O
2	the	O
3	matched	O
4	control	O
5	group	O
6	the	O
7	acquisition	O
8	-	O
9	rate	O
10	of	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	0acteriuria	O
16	was	O
17	over	O
18	12	O
19	%,	O
20	a	O
21	figure	O
22	similar	O
23	to	O
24	the	O
25	percentage	O
26	of	O
27	women	O
28	present	O
29	in	O
30	the	O
31	practice	O
32	population	O
33	during	O
34	one	O
35	year	O
36	with	O
37	transient	O
38	,	O
39	symptomatic	O
40	,	O
41	and	O
42	persistent	O
43	A	O
44	.	O
45	B	O
46	.	O
1	Preface	O
2	.	O
1	Prazosin	O
2	alone	O
3	was	O
4	effective	O
5	in	O
6	volume	O
7	responsive	O
8	patients	O
9	at	O
10	a	O
11	dose	O
12	of	O
13	5	O
14	+/-	O
15	1	O
16	.	O
17	0	O
18	mg	O
19	daily	O
20	.	O
1	59	O
2	cases	O
3	of	O
4	surgically	O
5	resectable	O
6	cancers	O
7	(	O
8	T1	O
9	,	O
10	T2	O
11	,	O
12	T3	O
13	,	O
14	N0	O
15	,	O
16	N1	O
17	)	O
18	had	O
19	a	O
20	minimum	O
21	followup	O
22	of	O
23	two	O
24	years	O
25	(	O
26	average	O
27	4	O
28	years	O
29	+/-	O
30	3	O
31	months	O
32	).	O
1	Hemolytic	O
2	disease	O
3	of	O
4	African	O
5	newborn	O
6	.	O
1	VII	O
2	.	O
1	These	O
2	observations	O
3	have	O
4	led	O
5	us	O
6	to	O
7	conclude	O
8	that	O
9	an	O
10	elevated	O
11	VIII	O
12	-	O
13	ratio	O
14	is	O
15	a	O
16	very	O
17	sensitive	O
18	indicator	O
19	of	O
20	intravascular	O
21	coagulation	O
22	.	O
1	Prediction	O
2	of	O
3	the	O
4	times	O
5	of	O
6	sandfly	O
7	development	O
1	Native	O
2	human	B
3	fibrinogen	I
4	was	O
5	brought	O
6	to	O
7	coagulation	O
8	by	O
9	adding	O
10	thrombin	B
11	.	O
1	The	O
2	inner	O
3	ears	O
4	were	O
5	exposed	O
6	by	O
7	microdissection	O
8	,	O
9	and	O
10	the	O
11	vestibular	O
12	sensory	O
13	regions	O
14	were	O
15	either	O
16	sectioned	O
17	and	O
18	studied	O
19	with	O
20	light	O
21	or	O
22	electron	O
23	microscopy	O
24	,	O
25	or	O
26	prepared	O
27	and	O
28	studied	O
29	with	O
30	the	O
31	surface	O
32	specimen	O
33	technique	O
34	.	O
1	Riboflavin	O
2	did	O
3	not	O
4	affect	O
5	the	O
6	percentage	O
7	of	O
8	aflatoxin	O
9	-	O
10	treated	O
11	animals	O
12	with	O
13	abnormal	O
14	urinary	O
15	excretion	O
16	patterns	O
17	,	O
18	but	O
19	did	O
20	increase	O
21	the	O
22	magnitude	O
23	of	O
24	the	O
25	disturbances	O
26	in	O
27	elimination	O
28	of	O
29	kynurenic	O
30	and	O
31	xanthurenic	O
32	acids	O
33	.	O
1	Technetium	O
2	-	O
3	99m	O
4	stannous	O
5	pyrophosphate	O
6	myocardial	O
7	scintigrams	O
8	were	O
9	obtained	O
10	in	O
11	138	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	260	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O
1	Workers	O
2	with	O
3	""""	O
4	sensitivity	O
5	""""	O
6	to	O
7	toluene	O
8	diisocyanate	O
9	(	O
10	TDI	O
11	)	O
12	studied	O
13	in	O
14	depth	O
15	in	O
16	an	O
17	attempt	O
18	to	O
19	determine	O
20	mechanisms	O
21	of	O
22	bronchial	O
23	hyperreactivity	O
24	.	O
1	In	O
2	both	O
3	these	O
4	respects	O
5	,	O
6	however	O
7	,	O
8	the	O
9	DBP	B
10	mRNA	I
11	resembles	O
12	the	O
13	late	O
14	messengers	O
15	of	O
16	SV40	O
17	and	O
18	polyoma	O
19	viruses	O
20	.	O
1	Serum	B
2	ACTH	I
3	did	O
4	not	O
5	respond	O
6	to	O
7	insulin	B
8	and	O
9	metyrapone	O
10	.	O
1	The	O
2	uterine	O
3	response	O
4	to	O
5	prostaglandin	O
6	E2	O
7	(	O
8	PGE2	O
9	)	O
10	and	O
11	prostaglandin	O
12	F2alpha	O
13	(	O
14	administered	O
15	by	O
16	intravenous	O
17	and	O
18	intrauterine	O
19	routes	O
20	)	O
21	was	O
22	evaluated	O
23	during	O
24	different	O
25	phases	O
26	of	O
27	the	O
28	menstrual	O
29	cycle	O
30	in	O
31	five	O
32	functionally	O
33	infertile	O
34	women	O
35	.	O
1	High	O
2	levels	O
3	of	O
4	serum	O
5	calcitonin	B
6	were	O
7	found	O
8	in	O
9	patients	O
10	with	O
11	chronic	O
12	renal	O
13	failure	O
14	.	O
1	Detection	O
2	of	O
3	anti	O
4	-	O
5	lymphocyte	O
6	antibodies	O
7	using	O
8	the	O
9	immunoperoxidase	B
10	antiglobulin	I
11	technic	O
12	.	O
1	Williams	O
2	,	O
3	2	O
4	August	O
5	1977	O
6	.	O
1	255	O
2	-	O
3	61	O
4	.	O
1	202	O
2	-	O
3	8	O
4	.	O
1	Bone	O
2	marrow	O
3	transplantation	O
4	-	O
5	1979	O
6	.	O
1	In	O
2	this	O
3	article	O
4	,	O
5	the	O
6	clinical	O
7	actions	O
8	of	O
9	the	O
10	principal	O
11	dopamine	B
12	receptor	I
13	stimulating	O
14	agents	O
15	(	O
16	apomorphine	O
17	and	O
18	its	O
19	derivatives	O
20	;	O
21	piribedil	O
22	,	O
23	rye	O
24	-	O
25	ergot	O
26	derivatives	O
27	)	O
28	are	O
29	discussed	O
30	on	O
31	the	O
32	basis	O
33	of	O
34	their	O
35	biochemical	O
36	and	O
37	pharmacological	O
38	properties	O
39	.	O
1	The	O
2	IDF	O
3	standard	O
4	method	O
5	for	O
6	the	O
7	detection	O
8	of	O
9	penicillin	O
10	in	O
11	milk	O
12	is	O
13	not	O
14	suitable	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	sulphonamide	O
20	residues	O
21	in	O
22	milk	O
23	.	O
1	Capsular	O
2	antigens	O
3	of	O
4	Staphylococcus	O
5	aureus	O
1	The	O
2	course	O
3	of	O
4	endotoxin	O
5	fever	O
6	remained	O
7	uninfluenced	O
8	by	O
9	ALS	O
10	.	O
1	Accurate	O
2	pathologic	O
3	staging	O
4	identifies	O
5	patients	O
6	who	O
7	are	O
8	potentially	O
9	curable	O
10	with	O
11	radiotherapy	O
12	.	O
1	It	O
2	was	O
3	concluded	O
4	,	O
5	that	O
6	on	O
7	a	O
8	given	O
9	section	O
10	,	O
11	75	O
12	,	O
13	7	O
14	per	O
15	cent	O
16	of	O
17	the	O
18	trabeculae	O
19	were	O
20	in	O
21	contact	O
22	with	O
23	vascular	O
24	cavities	O
25	.	O
1	Isolation	O
2	of	O
3	T	O
4	.	O
5	gambiense	O
6	strains	O
7	in	O
8	Zaire	O
9	and	O
10	their	O
11	adaptation	O
12	to	O
13	laboratory	O
14	animals	O
1	Intestinal	O
2	adaptation	O
3	(	O
4	first	O
5	of	O
6	two	O
7	parts	O
8	).	O
1	These	O
2	techniques	O
3	have	O
4	been	O
5	used	O
6	by	O
7	many	O
8	people	O
9	for	O
10	many	O
11	years	O
12	and	O
13	no	O
14	claim	O
15	is	O
16	being	O
17	made	O
18	for	O
19	any	O
20	innovation	O
21	in	O
22	this	O
23	regard	O
24	.	O
1	A	O
2	prospective	O
3	trail	O
4	comparing	O
5	hysterectomy	O
6	,	O
7	hysterectomy	O
8	plus	O
9	vaginal	O
10	radium	O
11	,	O
12	and	O
13	uterine	O
14	radium	O
15	plus	O
16	hysterectomy	O
17	in	O
18	stage	O
19	I	O
20	endometrial	O
21	carcinoma	O
22	.	O
1	Data	O
2	were	O
3	processed	O
4	with	O
5	a	O
6	semi	O
7	-	O
8	automatic	O
9	computer	O
10	program	O
11	which	O
12	develops	O
13	an	O
14	averaged	O
15	-	O
16	volume	O
17	curve	O
18	from	O
19	an	O
20	assigned	O
21	LV	O
22	region	O
23	-	O
24	of	O
25	-	O
26	interest	O
27	.	O
1	Effects	O
2	of	O
3	methylene	O
4	chloride	O
5	,	O
6	trichloroethane	O
7	,	O
8	trichloroethylene	O
9	,	O
10	tetrachloroethylene	O
11	and	O
12	toluene	O
13	on	O
14	the	O
15	development	O
16	of	O
17	chick	O
18	embryos	O
19	.	O
1	The	O
2	biochemistry	O
3	of	O
4	amniotic	O
5	fluid	O
6	with	O
7	poor	O
8	fetal	O
9	growth	O
10	.	O
1	This	O
2	expression	O
3	assumes	O
4	:	O
5	(	O
6	1	O
7	)	O
8	a	O
9	laminar	O
10	flow	O
11	regimen	O
12	during	O
13	expiration	O
14	,	O
15	and	O
16	(	O
17	2	O
18	)	O
19	a	O
20	constant	O
21	CT	O
22	value	O
23	over	O
24	the	O
25	range	O
26	of	O
27	VT	O
28	.	O
1	These	O
2	characteristics	O
3	indicated	O
4	the	O
5	pronounced	O
6	activity	O
7	of	O
8	collagenous	O
9	fiber	O
10	synthesis	O
11	and	O
12	the	O
13	matrix	O
14	of	O
15	the	O
16	osteoid	O
17	tissue	O
18	.	O
1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	gallium	O
11	by	O
12	tumor	O
13	cells	O
14	.	O
1	Irradiation	O
2	of	O
3	human	O
4	blood	O
5	platelets	O
6	with	O
7	UV	O
8	-	O
9	A	O
10	in	O
11	vitro	O
12	impairs	O
13	their	O
14	ability	O
15	to	O
16	aggregate	O
17	after	O
18	challenge	O
19	with	O
20	collagen	B
21	.	O
1	Although	O
2	Grice	O
3	'	O
4	s	O
5	operation	O
6	has	O
7	been	O
8	used	O
9	all	O
10	over	O
11	the	O
12	world	O
13	,	O
14	no	O
15	systematic	O
16	account	O
17	of	O
18	it	O
19	has	O
20	been	O
21	found	O
22	in	O
23	the	O
24	literature	O
25	(	O
26	including	O
27	publications	O
28	dealing	O
29	with	O
30	technique	O
31	),	O
32	which	O
33	presents	O
34	it	O
35	in	O
36	terms	O
37	related	O
38	to	O
39	the	O
40	basic	O
41	""""	O
42	classical	O
43	""""	O
44	principles	O
45	on	O
46	which	O
47	the	O
48	operation	O
49	was	O
50	conceived	O
51	.	O
1	Of	O
2	the	O
3	compounds	O
4	tested	O
5	,	O
6	alpha	O
7	-(	O
8	3	O
9	-	O
10	methyl	O
11	-	O
12	2	O
13	-	O
14	quinoxalinyl	O
15	)-	O
16	N	O
17	-	O
18	methylnitrone	O
19	1	O
20	,	O
21	4	O
22	-	O
23	dioxide	O
24	(	O
25	2	O
26	)	O
27	was	O
28	the	O
29	most	O
30	active	O
31	agent	O
32	in	O
33	vivo	O
34	against	O
35	the	O
36	gram	O
37	-	O
38	negative	O
39	and	O
40	the	O
41	gram	O
42	-	O
43	positive	O
44	organisms	O
45	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	stereotypy	O
6	can	O
7	be	O
8	evoked	O
9	also	O
10	in	O
11	the	O
12	case	O
13	when	O
14	the	O
15	striatal	O
16	dopaminergic	O
17	tone	O
18	is	O
19	normal	O
20	or	O
21	even	O
22	below	O
23	normal	O
24	:	O
25	it	O
26	is	O
27	the	O
28	equilibrium	O
29	of	O
30	the	O
31	striatal	O
32	cholinergic	O
33	-	O
34	dopaminergic	O
35	systems	O
36	which	O
37	must	O
38	be	O
39	shifted	O
40	towards	O
41	dopamine	O
42	,	O
43	which	O
44	is	O
45	necessary	O
46	for	O
47	the	O
48	development	O
49	of	O
50	this	O
51	behavioral	O
52	manifestation	O
53	.	O
1	In	O
2	the	O
3	duodenum	O
4	a	O
5	small	O
6	part	O
7	of	O
8	the	O
9	administered	O
10	dose	O
11	was	O
12	transformed	O
13	to	O
14	3H	O
15	-	O
16	alpha	O
17	-	O
18	acetyldigoxin	O
19	.	O
1	Nursing	O
2	of	O
3	patients	O
4	with	O
5	gynecological	O
6	diseases	O
1	Ovarian	O
2	allotransplantation	O
3	in	O
4	human	O
5	.	O
1	In	O
2	one	O
3	patient	O
4	with	O
5	severe	O
6	diarrhea	O
7	the	O
8	estriol	O
9	concentration	O
10	in	O
11	serum	O
12	was	O
13	low	O
14	until	O
15	the	O
16	intestinal	O
17	function	O
18	normalised	O
19	and	O
20	the	O
21	estriol	O
22	concentration	O
23	went	O
24	up	O
25	exactly	O
26	when	O
27	the	O
28	diarrhea	O
29	stopped	O
30	.	O
1	Serum	O
2	levels	O
3	of	O
4	IgG	B
5	and	O
6	IgM	B
7	were	O
8	also	O
9	raised	O
10	,	O
11	but	O
12	contrary	O
13	to	O
14	the	O
15	findings	O
16	of	O
17	other	O
18	observers	O
19	IgA	B
20	levels	O
21	were	O
22	normal	O
23	.	O
1	1	O
2	The	O
3	effects	O
4	in	O
5	normal	O
6	subjects	O
7	of	O
8	a	O
9	single	O
10	oral	O
11	dose	O
12	of	O
13	Motival	O
14	(	O
15	one	O
16	tablet	O
17	,	O
18	containing	O
19	fluphenazine	O
20	0	O
21	.	O
22	5	O
23	mg	O
24	and	O
25	nortriptyline	O
26	10	O
27	mg	O
28	)	O
29	on	O
30	the	O
31	contingent	O
32	negative	O
33	variation	O
34	(	O
35	CNV	O
36	),	O
37	reaction	O
38	time	O
39	,	O
40	heart	O
41	rate	O
42	,	O
43	blood	O
44	pressure	O
45	and	O
46	self	O
47	-	O
48	rating	O
49	scales	O
50	for	O
51	alertness	O
52	,	O
53	anxiety	O
54	,	O
55	tension	O
56	,	O
57	detachment	O
58	and	O
59	depression	O
60	were	O
61	compared	O
62	with	O
63	those	O
64	of	O
65	diazepam	O
66	(	O
67	5	O
68	mg	O
69	and	O
70	7	O
71	.	O
72	5	O
73	mg	O
74	)	O
75	and	O
76	placebo	O
77	or	O
78	propranolol	O
79	(	O
80	60	O
81	mg	O
82	).	O
1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	B
32	-	I
33	and	I
34	beta	I
35	-	I
36	adrenoceptors	I
37	.	O
1	Three	O
2	patients	O
3	with	O
4	four	O
5	renoureteral	O
6	units	O
7	have	O
8	undergone	O
9	single	O
10	-	O
11	stage	O
12	reconstruction	O
13	involving	O
14	ureteroureterostomy	O
15	and	O
16	ipsilateral	O
17	ureteroneocystostomy	O
18	following	O
19	temporary	O
20	loop	O
21	cutaneous	O
22	ureterostomy	O
23	.	O
1	Action	O
2	of	O
3	strontium	O
4	-	O
5	90	O
6	and	O
7	metaphos	O
8	on	O
9	Cyprinus	O
10	carpio	O
1	Diagnosis	O
2	and	O
3	differential	O
4	diagnosis	O
1	Cortisone	O
2	induced	O
3	bone	O
4	changes	O
5	and	O
6	its	O
7	response	O
8	to	O
9	lipid	O
10	clearing	O
11	agents	O
12	.	O
1	2	O
2	)	O
3	The	O
4	time	O
5	-	O
6	sharing	O
7	principle	O
8	was	O
9	applied	O
10	to	O
11	gain	O
12	high	O
13	stability	O
14	.	O
1	Angiotensin	B
2	effect	O
3	in	O
4	the	O
5	human	O
6	kidney	O
7	.	O
1	Incidental	O
2	findings	O
3	in	O
4	the	O
5	epidermis	O
6	and	O
7	in	O
8	the	O
9	intraepidermal	O
10	eccrine	O
11	sweat	O
12	duct	O
13	units	O
14	.	O
1	These	O
2	consisted	O
3	of	O
4	beading	O
5	and	O
6	strictures	O
7	mainly	O
8	of	O
9	the	O
10	intrahepatic	O
11	biliary	O
12	tree	O
13	(	O
14	IHB	O
15	).	O
1	Orthop	O
2	.	O
1	Residues	O
2	removed	O
3	from	O
4	transcripts	O
5	by	O
6	splicing	O
7	were	O
8	identified	O
9	.	O
1	Serum	B
2	relaxin	I
3	levels	O
4	in	O
5	prostaglandin	O
6	E2	O
7	induced	O
8	abortions	O
9	.	O
1	Effect	O
2	of	O
3	indoramin	O
4	in	O
5	small	O
6	doses	O
7	on	O
8	the	O
9	central	O
10	vasomotor	O
11	loci	O
12	has	O
13	been	O
14	studied	O
15	in	O
16	chloralose	O
17	anesthetized	O
18	cats	O
19	by	O
20	localizing	O
21	it	O
22	to	O
23	the	O
24	central	O
25	sites	O
26	.	O
1	The	O
2	December	O
3	armed	O
4	revolt	O
5	in	O
6	Moscow	O
7	and	O
8	the	O
9	paramedical	O
10	personnel	O
1	Significant	O
2	increases	O
3	in	O
4	mean	O
5	serum	O
6	E2	O
7	concentration	O
8	(	O
9	100	O
10	to	O
11	150	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	were	O
17	noted	O
18	at	O
19	6	O
20	and	O
21	8	O
22	hours	O
23	after	O
24	administration	O
25	on	O
26	day	O
27	1	O
28	and	O
29	at	O
30	8	O
31	hours	O
32	on	O
33	day	O
34	4	O
35	.	O
1	Patients	O
2	were	O
3	subclassified	O
4	into	O
5	age	O
6	-	O
7	matched	O
8	groups	O
9	of	O
10	primary	O
11	untreated	O
12	cancer	O
13	(	O
14	21	O
15	),	O
16	recurrent	O
17	cancer	O
18	(	O
19	18	O
20	),	O
21	and	O
22	""""	O
23	cured	O
24	""""	O
25	patients	O
26	who	O
27	had	O
28	been	O
29	free	O
30	of	O
31	disease	O
32	for	O
33	at	O
34	least	O
35	9	O
36	months	O
37	(	O
38	16	O
39	).	O
1	Bacteriostatic	O
2	and	O
3	bacteriacidal	O
4	activity	O
5	of	O
6	hydroxy	O
7	-	O
8	9	O
9	ellipticine	O
10	in	O
11	vitro	O
1	Dialyzable	O
2	transfer	B
3	factor	I
4	.	O
1	Rheumatoid	B
2	factor	I
3	and	O
4	antinuclear	O
5	antibody	O
6	tests	O
7	were	O
8	frequently	O
9	positive	O
10	,	O
11	and	O
12	reactions	O
13	to	O
14	gold	O
15	therapy	O
16	were	O
17	more	O
18	frequent	O
19	than	O
20	in	O
21	other	O
22	rheumatoid	O
23	populations	O
24	.	O
1	This	O
2	report	O
3	presents	O
4	an	O
5	analysis	O
6	of	O
7	the	O
8	vocal	O
9	repertoire	O
10	of	O
11	howler	O
12	monkeys	O
13	(	O
14	Alouatta	O
15	palliata	O
16	)	O
17	observed	O
18	during	O
19	a	O
20	field	O
21	study	O
22	in	O
23	southwestern	O
24	Panama	O
25	.	O
1	Diallylnitrosamine	O
2	(	O
3	DAN	O
4	),	O
5	one	O
6	of	O
7	the	O
8	few	O
9	nitrosamines	O
10	tested	O
11	thus	O
12	far	O
13	that	O
14	has	O
15	not	O
16	induced	O
17	neoplasms	O
18	in	O
19	rats	O
20	,	O
21	caused	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	respiratory	O
27	tract	O
28	tumors	O
29	in	O
30	Syrian	O
31	golden	O
32	hamsters	O
33	treated	O
34	sc	O
35	with	O
36	single	O
37	or	O
38	weekly	O
39	doses	O
40	of	O
41	the	O
42	compound	O
43	.	O
1	Self	O
2	-	O
3	emasculation	O
4	is	O
5	the	O
6	end	O
7	result	O
8	of	O
9	an	O
10	unusual	O
11	psychiatric	O
12	disorder	O
13	,	O
14	which	O
15	initially	O
16	requires	O
17	surgical	O
18	treatment	O
19	.	O
1	Levels	O
2	of	O
3	both	O
4	PGF	O
5	and	O
6	PGFM	O
7	were	O
8	significantly	O
9	higher	O
10	during	O
11	early	O
12	spontaneous	O
13	labour	O
14	,	O
15	at	O
16	a	O
17	cervical	O
18	dilatation	O
19	of	O
20	less	O
21	than	O
22	4	O
23	cm	O
24	,	O
25	than	O
26	before	O
27	the	O
28	onset	O
29	of	O
30	labour	O
31	.	O
1	The	O
2	most	O
3	common	O
4	cause	O
5	of	O
6	renal	O
7	deterioration	O
8	in	O
9	the	O
10	spinal	O
11	cord	O
12	injured	O
13	patient	O
14	is	O
15	irreversible	O
16	vesicoureteral	O
17	reflux	O
18	.	O
1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	the	O
6	rat	O
7	larynx	O
8	to	O
9	be	O
10	an	O
11	important	O
12	organ	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	irritancy	O
18	of	O
19	inhaled	O
20	materials	O
21	.	O
1	The	O
2	difficulties	O
3	to	O
4	analyse	O
5	prostaglandins	O
6	(	O
7	PG	O
8	)	O
9	by	O
10	gas	O
11	-	O
12	liquid	O
13	chromatography	O
14	are	O
15	mainly	O
16	due	O
17	to	O
18	the	O
19	lack	O
20	of	O
21	sensitivity	O
22	of	O
23	the	O
24	gas	O
25	-	O
26	chromatograph	O
27	itself	O
28	(	O
29	higher	O
30	than	O
31	200	O
32	ng	O
33	)	O
34	and	O
35	to	O
36	the	O
37	poor	O
38	resolution	O
39	of	O
40	the	O
41	packed	O
42	columns	O
43	.	O
1	After	O
2	giving	O
3	a	O
4	survey	O
5	on	O
6	the	O
7	situation	O
8	of	O
9	antibiotic	O
10	resistance	O
11	in	O
12	the	O
13	region	O
14	of	O
15	Northern	O
16	Bavaria	O
17	during	O
18	1973	O
19	/	O
20	74	O
21	and	O
22	comparing	O
23	the	O
24	activity	O
25	of	O
26	a	O
27	sulfamethoxazole	O
28	(	O
29	SMZ	O
30	)	O
31	trimethoprim	O
32	(	O
33	TMP	O
34	)	O
35	combination	O
36	to	O
37	other	O
38	commonly	O
39	used	O
40	antibiotics	O
41	and	O
42	chemotherapeutic	O
43	agents	O
44	,	O
45	the	O
46	results	O
47	of	O
48	tests	O
49	with	O
50	the	O
51	new	O
52	combination	O
53	of	O
54	N1	O
55	-(	O
56	4	O
57	,	O
58	5	O
59	-	O
60	dimethyl	O
61	-	O
62	2	O
63	-	O
64	oxazolyl	O
65	)-	O
66	sulfanilamide	O
67	)	O
68	(	O
69	sulfamoxole	O
70	)	O
71	and	O
72	2	O
73	,	O
74	4	O
75	-	O
76	diamino	O
77	-	O
78	5	O
79	-(	O
80	3	O
81	,	O
82	4	O
83	,	O
84	5	O
85	-	O
86	trimethoxy	O
87	-	O
88	benzyl	O
89	)-	O
90	pyrimidine	O
91	(	O
92	trimethoprim	O
93	)	O
94	at	O
95	a	O
96	ratio	O
97	of	O
98	5	O
99	:	O
100	1	O
101	(	O
102	CN	O
103	3123	O
104	;	O
105	Nevin	O
106	,	O
107	Supristol	O
108	)	O
109	are	O
110	compared	O
111	to	O
112	those	O
113	of	O
114	tests	O
115	with	O
116	TMP	O
117	/	O
118	SMZ	O
119	.	O
1	Letter	O
2	:	O
3	Is	O
4	actinic	O
5	(	O
6	solar	O
7	)	O
8	damage	O
9	the	O
10	provoking	O
11	cause	O
12	of	O
13	'	O
14	post	O
15	-	O
16	inflammatory	O
17	elastolysis	O
18	and	O
19	cutis	O
20	laxa	O
21	(	O
22	PECL	O
23	)'?	O
1	Batch	O
2	cultures	O
3	of	O
4	S	O
5	.	O
6	mutans	O
7	serotype	O
8	a	O
9	demonstrated	O
10	no	O
11	growth	O
12	on	O
13	MSB	O
14	agar	O
15	.	O
1	Pregnant	O
2	women	O
3	at	O
4	term	O
5	had	O
6	the	O
7	lowest	O
8	levels	O
9	of	O
10	antithrombin	B
11	III	I
12	.	O
1	The	O
2	performance	O
3	of	O
4	three	O
5	commonly	O
6	used	O
7	chemical	O
8	cartridge	O
9	respirators	O
10	for	O
11	SO2	O
12	was	O
13	measured	O
14	under	O
15	working	O
16	conditions	O
17	in	O
18	a	O
19	copper	O
20	smelter	O
21	.	O
1	Stimulation	O
2	of	O
3	macrophage	O
4	function	O
5	by	O
6	killed	O
7	Bordetella	O
8	pertussis	O
9	cells	O
10	did	O
11	not	O
12	show	O
13	any	O
14	beneficial	O
15	effect	O
16	as	O
17	an	O
18	increased	O
19	susceptibility	O
20	became	O
21	apparent	O
22	.	O
1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O
1	Since	O
2	myoglobin	B
3	is	O
4	co	O
5	-	O
6	extracted	O
7	with	O
8	the	O
9	hemoglobin	B
10	,	O
11	the	O
12	2	O
13	heme	O
14	pigments	O
15	are	O
16	separated	O
17	in	O
18	one	O
19	portion	O
20	of	O
21	the	O
22	extract	O
23	by	O
24	precipitating	O
25	the	O
26	hemoglobin	B
27	in	O
28	an	O
29	85	O
30	%	O
31	(	O
32	NH4	O
33	)	O
34	2SO4	O
35	solution	O
36	.	O
1	I	O
2	.	O
1	Infrared	O
2	measurements	O
3	of	O
4	temperature	O
5	changes	O
6	and	O
7	estimates	O
8	of	O
9	the	O
10	heating	O
11	produced	O
12	at	O
13	the	O
14	mical	O
15	.	O
1	Critique	O
2	of	O
3	""""	O
4	Interactive	O
5	Effects	O
6	of	O
7	Test	O
8	Anxiety	O
9	and	O
10	Credit	O
11	/	O
12	No	O
13	Credit	O
14	or	O
15	A	O
16	-	O
17	F	O
18	Grade	O
19	Condition	O
20	upon	O
21	Short	O
22	-	O
23	term	O
24	and	O
25	Long	O
26	-	O
27	term	O
28	Recall	O
29	of	O
30	Course	O
31	Information	O
32	.	O
1	After	O
2	90	O
3	d	O
4	a	O
5	subsurface	O
6	,	O
7	radiolucent	O
8	caries	O
9	-	O
10	like	O
11	lesion	O
12	was	O
13	observed	O
14	in	O
15	two	O
16	specimens	O
17	only	O
18	.	O
1	As	O
2	stands	O
3	shifted	O
4	in	O
5	dominance	O
6	from	O
7	pine	O
8	to	O
9	fir	O
10	with	O
11	age	O
12	,	O
13	subalpine	O
14	fir	O
15	appeared	O
16	to	O
17	maintain	O
18	gradually	O
19	increasing	O
20	rates	O
21	of	O
22	whole	O
23	-	O
24	forest	O
25	productivity	O
26	until	O
27	stands	O
28	were	O
29	approximately	O
30	400	O
31	years	O
32	old	O
33	.	O
1	Lymphocyte	O
2	subpopulations	O
3	,	O
4	serum	B
5	IgE	I
6	and	O
7	total	O
8	eosinophil	O
9	counts	O
10	in	O
11	patients	O
12	with	O
13	bronchial	O
14	asthma	O
15	.	O
1	Technique	O
2	for	O
3	obtaining	O
4	refined	O
5	ceramics	O
6	with	O
7	dense	O
8	mass	O
1	The	O
2	correcting	O
3	action	O
4	of	O
5	tropatepine	O
6	hydrochloride	O
7	upon	O
8	the	O
9	extrapyramidal	O
10	effects	O
11	induced	O
12	by	O
13	neuroleptics	O
14	has	O
15	been	O
16	studied	O
17	in	O
18	32	O
19	acute	O
20	psychotic	O
21	states	O
22	.	O
1	The	O
2	records	O
3	from	O
4	1948	O
5	through	O
6	1967	O
7	of	O
8	344	O
9	previously	O
10	untreated	O
11	patients	O
12	with	O
13	squamous	O
14	cell	O
15	carcinoma	O
16	of	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	oropharynx	O
22	,	O
23	supraglottic	O
24	larynx	O
25	and	O
26	hypopharynx	O
27	who	O
28	had	O
29	clinically	O
30	positive	O
31	cervical	O
32	lymph	O
33	node	O
34	metastases	O
35	staged	O
36	N1	O
37	,	O
38	N2A	O
39	,	O
40	or	O
41	N2B	O
42	,	O
43	and	O
44	whose	O
45	initial	O
46	neck	O
47	treatment	O
48	consisted	O
49	of	O
50	external	O
51	radiation	O
52	therapy	O
53	alone	O
54	were	O
55	reviewed	O
56	.	O
1	Effect	O
2	of	O
3	ingestion	O
4	of	O
5	Norbiogest	O
6	during	O
7	the	O
8	quiescent	O
9	period	O
10	of	O
11	the	O
12	genital	O
13	organs	O
1	Risk	O
2	of	O
3	infection	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	fractures	O
1	Liver	O
2	microsomes	O
3	of	O
4	the	O
5	shag	O
6	showed	O
7	smaller	O
8	than	O
9	8	O
10	%	O
11	of	O
12	the	O
13	epoxide	B
14	hydrase	I
15	activity	O
16	and	O
17	smaller	O
18	than	O
19	14	O
20	%	O
21	of	O
22	the	O
23	hydroxylating	O
24	capacity	O
25	of	O
26	liver	O
27	microsomes	O
28	from	O
29	the	O
30	rat	O
31	.	O
1	A	O
2	clinical	O
3	,	O
4	serological	O
5	and	O
6	prognostic	O
7	study	O
1	The	O
2	American	O
3	Burkitt	O
4	Lymphoma	O
5	Registry	O
6	:	O
7	a	O
8	progress	O
9	report	O
10	.	O
1	This	O
2	sequence	O
3	is	O
4	almost	O
5	identical	O
6	with	O
7	that	O
8	of	O
9	human	B
10	luteinizing	I
11	hormone	I
12	(	O
13	Sairam	O
14	,	O
15	M	O
16	.	O
1	Glucose	B
2	-	I
3	6	I
4	-	I
5	phosphate	I
6	dehydrogenase	I
7	(	O
8	G	B
9	-	I
10	6	I
11	-	I
12	PD	I
13	)	O
14	deficiency	O
15	in	O
16	the	O
17	newborn	O
18	.	O
1	Prostaglandins	O
2	F	O
3	(	O
4	PGF	O
5	)	O
6	were	O
7	measured	O
8	in	O
9	uterine	O
10	vein	O
11	,	O
12	ovarian	O
13	artery	O
14	,	O
15	and	O
16	jugular	O
17	vein	O
18	plasma	O
19	and	O
20	in	O
21	the	O
22	endometrial	O
23	tissues	O
24	at	O
25	various	O
26	times	O
27	during	O
28	the	O
29	bovine	O
30	estrous	O
31	cycle	O
32	,	O
33	and	O
34	were	O
35	compared	O
36	to	O
37	peripheral	O
38	plasma	O
39	progesterone	O
40	levels	O
41	.	O
1	Groups	O
2	of	O
3	ten	O
4	dependent	O
5	and	O
6	ten	O
7	saline	O
8	mice	O
9	were	O
10	singly	O
11	tested	O
12	in	O
13	both	O
14	light	O
15	and	O
16	dark	O
17	conditions	O
18	in	O
19	each	O
20	of	O
21	five	O
22	covered	O
23	cylinders	O
24	(	O
25	2	O
26	-	O
27	23	O
28	in	O
29	high	O
30	).	O
1	D	O
2	.	O
1	Air	O
2	ion	O
3	action	O
4	on	O
5	bacteria	O
6	.	O
1	Following	O
2	retransfusion	O
3	,	O
4	the	O
5	affected	O
6	epithelial	O
7	lining	O
8	appeared	O
9	greatly	O
10	distended	O
11	over	O
12	the	O
13	oedematous	O
14	lamina	O
15	propria	O
16	,	O
17	with	O
18	almost	O
19	complete	O
20	loss	O
21	of	O
22	structural	O
23	detail	O
24	.	O
1	2	O
2	-	O
3	Chemical	O
4	occlusion	O
5	of	O
6	vas	O
7	is	O
8	quite	O
9	effective	O
10	in	O
11	producing	O
12	a	O
13	block	O
14	in	O
15	the	O
16	vas	O
17	deferens	O
18	of	O
19	dogs	O
20	.	O
1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	4	O
7	groups	O
8	receiving	O
9	NLA	O
10	II	O
11	with	O
12	or	O
13	without	O
14	nalorphine	O
15	,	O
16	morphine	O
17	or	O
18	Micoren	O
19	.	O
1	The	O
2	alterations	O
3	of	O
4	5	O
5	-	O
6	HT	O
7	and	O
8	5	O
9	-	O
10	HIAA	O
11	levels	O
12	in	O
13	several	O
14	regions	O
15	of	O
16	the	O
17	brain	O
18	under	O
19	the	O
20	conditions	O
21	examined	O
22	may	O
23	indicate	O
24	that	O
25	IDPN	O
26	'	O
27	s	O
28	neurotoxicity	O
29	primarily	O
30	affects	O
31	5	O
32	-	O
33	HT	O
34	-	O
35	containing	O
36	neurones	O
37	.	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	increased	O
6	pulmonary	O
7	blood	O
8	flow	O
9	and	O
10	decreased	O
11	pulmonary	O
12	vascular	O
13	resistance	O
14	with	O
15	advancing	O
16	gestation	O
17	are	O
18	due	O
19	to	O
20	an	O
21	increase	O
22	in	O
23	the	O
24	total	O
25	number	O
26	of	O
27	vessels	O
28	and	O
29	increased	O
30	vasomotor	O
31	reactivity	O
32	is	O
33	related	O
34	to	O
35	an	O
36	increase	O
37	in	O
38	the	O
39	total	O
40	amount	O
41	of	O
42	smooth	O
43	muscle	O
44	while	O
45	the	O
46	thickness	O
47	of	O
48	muscle	O
49	in	O
50	individual	O
51	vessels	O
52	remains	O
53	constant	O
54	.	O
1	The	O
2	authors	O
3	found	O
4	that	O
5	except	O
6	for	O
7	fear	O
8	and	O
9	pugnacity	O
10	all	O
11	husband	O
12	-	O
13	wife	O
14	trait	O
15	correlations	O
16	were	O
17	positive	O
18	,	O
19	in	O
20	contrast	O
21	to	O
22	Winch	O
23	'	O
24	s	O
25	principle	O
26	of	O
27	type	O
28	I	O
29	complementarity	O
30	.	O
1	A	O
2	note	O
3	on	O
4	the	O
5	phase	O
6	-	O
7	plane	O
8	technique	O
9	representation	O
10	of	O
11	cardiac	O
12	action	O
13	potentials	O
14	.	O
1	Acquired	O
2	factor	B
3	VIII	I
4	inhibitor	O
5	in	O
6	non	O
7	-	O
8	hemophilic	O
9	patients	O
1	The	O
2	authors	O
3	report	O
4	the	O
5	results	O
6	of	O
7	a	O
8	series	O
9	of	O
10	toxicological	O
11	tests	O
12	conducted	O
13	on	O
14	plastic	O
15	materials	O
16	(	O
17	polyethylene	O
18	)	O
19	activated	O
20	with	O
21	tetraphenylbutadiene	O
22	(	O
23	TPB	O
24	)	O
25	an	O
26	additive	O
27	recently	O
28	proposed	O
29	as	O
30	a	O
31	sensitizer	O
32	capable	O
33	of	O
34	photodegrading	O
35	plastic	O
36	materials	O
37	.	O
1	Nuclear	O
2	extracts	O
3	prepared	O
4	from	O
5	both	O
6	neural	O
7	and	O
8	non	O
9	-	O
10	neural	O
11	cell	O
12	lines	O
13	,	O
14	mouse	O
15	brain	O
16	,	O
17	and	O
18	mouse	O
19	liver	O
20	contain	O
21	proteins	O
22	that	O
23	recognize	O
24	and	O
25	bind	O
26	to	O
27	the	O
28	PROX	O
29	and	O
30	PAL	O
31	sequences	O
32	indicating	O
33	that	O
34	proteins	O
35	which	O
36	bind	O
37	to	O
38	these	O
39	target	O
40	sequences	O
41	are	O
42	widespread	O
43	.	O
1	Rabbit	B
2	skeletal	I
3	muscle	I
4	glycogenin	I
5	.	O
1	A	O
2	statistically	O
3	significant	O
4	improvement	O
5	due	O
6	to	O
7	the	O
8	administration	O
9	of	O
10	Bromergon	O
11	was	O
12	observed	O
13	in	O
14	symptoms	O
15	associated	O
16	with	O
17	overreactiveness	O
18	to	O
19	normal	O
20	prolactin	B
21	levels	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	abdominal	O
28	tension	O
29	,	O
30	edema	O
31	,	O
32	weight	O
33	gain	O
34	and	O
35	breast	O
36	tenderness	O
37	.	O
1	This	O
2	analysis	O
3	,	O
4	together	O
5	with	O
6	a	O
7	consideration	O
8	of	O
9	the	O
10	SCBs	O
11	found	O
12	upstream	O
13	of	O
14	known	O
15	SWI4	B
16	,	I
17	6	I
18	-	O
19	dependent	O
20	genes	O
21	,	O
22	leads	O
23	to	O
24	the	O
25	proposal	O
26	of	O
27	a	O
28	revised	O
29	consensus	O
30	sequence	O
31	for	O
32	this	O
33	important	O
34	regulatory	O
35	element	O
36	.	O
1	These	O
2	studies	O
3	show	O
4	that	O
5	UCRBP	B
6	binds	O
7	to	O
8	various	O
9	target	O
10	motifs	O
11	that	O
12	are	O
13	distinct	O
14	from	O
15	the	O
16	UCR	O
17	motif	O
18	:	O
19	the	O
20	adeno	B
21	-	I
22	associated	I
23	virus	I
24	P5	I
25	promoter	I
26	and	O
27	elements	O
28	in	O
29	the	O
30	immunoglobulin	B
31	light	I
32	-	I
33	and	I
34	heavy	I
35	-	I
36	chain	I
37	genes	O
38	,	O
39	as	O
40	well	O
41	as	O
42	elements	O
43	in	O
44	ribosomal	B
45	protein	I
46	genes	I
47	.	O
1	Both	O
2	Rep78	B
3	and	O
4	Rep68	B
5	cut	O
6	the	O
7	terminal	O
8	AAV	O
9	sequence	O
10	at	O
11	the	O
12	same	O
13	site	O
14	(	O
15	nucleotide	O
16	124	O
17	).	O
1	The	O
2	goal	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	determine	O
10	the	O
11	feasibility	O
12	of	O
13	retrovirus	O
14	mediated	O
15	expression	O
16	of	O
17	rp47phox	B
18	in	O
19	the	O
20	HL60	O
21	and	O
22	U937	O
23	human	O
24	hematopoietic	O
25	cell	O
26	lines	O
27	,	O
28	and	O
29	in	O
30	an	O
31	Epstein	O
32	-	O
33	Barr	O
34	virus	O
35	transformed	O
36	B	O
37	-	O
38	lymphocyte	O
39	cell	O
40	line	O
41	(	O
42	EBV	O
43	-	O
44	BCL	O
45	)	O
46	derived	O
47	from	O
48	a	O
49	p47phox	B
50	-	O
51	deficient	O
52	CGD	O
53	patient	O
54	.	O
1	Comparison	O
2	with	O
3	the	O
4	sequence	O
5	databanks	O
6	show	O
7	that	O
8	Tactile	B
9	is	O
10	a	O
11	member	O
12	of	O
13	the	O
14	immunoglobulin	B
15	gene	I
16	superfamily	I
17	,	O
18	with	O
19	similarity	O
20	to	O
21	Drosophila	B
22	amalgam	I
23	,	O
24	the	O
25	melanoma	B
26	Ag	I
27	MUC	I
28	-	I
29	18	I
30	,	O
31	members	O
32	of	O
33	the	O
34	carcinoembryonic	B
35	Ag	I
36	family	I
37	,	O
38	the	O
39	poliovirus	B
40	receptor	I
41	,	O
42	and	O
43	the	O
44	neural	B
45	cell	I
46	adhesion	I
47	molecule	I
48	.	O
1	The	O
2	phenotypes	O
3	of	O
4	the	O
5	ICP0	B
6	nonsense	O
7	mutants	O
8	were	O
9	intermediate	O
10	between	O
11	those	O
12	of	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	virus	O
18	and	O
19	7134	O
20	in	O
21	that	O
22	the	O
23	more	O
24	ICP0	B
25	-	I
26	coding	I
27	sequence	I
28	expressed	O
29	by	O
30	a	O
31	given	O
32	nonsense	O
33	mutant	O
34	,	O
35	the	O
36	more	O
37	wild	O
38	type	O
39	-	O
40	like	O
41	was	O
42	its	O
43	phenotype	O
44	.	O
1	After	O
2	the	O
3	first	O
4	28	O
5	patients	O
6	vincristine	O
7	was	O
8	replaced	O
9	by	O
10	teniposide	O
11	(	O
12	VM	O
13	-	O
14	26	O
15	)	O
16	due	O
17	to	O
18	neurotoxicity	O
19	.	O
1	METHODS	O
2	:	O
3	IgG	B
4	antibodies	I
5	vs	O
6	HHV	O
7	-	O
8	6	O
9	(	O
10	anti	B
11	-	I
12	HHV	I
13	-	I
14	6	I
15	-	I
16	IgG	I
17	)	O
18	were	O
19	determined	O
20	by	O
21	indirect	O
22	immunofluorescence	O
23	in	O
24	100	O
25	IVDA	O
26	(	O
27	29	O
28	seronegative	O
29	and	O
30	71	O
31	seropositive	O
32	for	O
33	HIV	O
34	-	O
35	1	O
36	of	O
37	which	O
38	45	O
39	were	O
40	in	O
41	stage	O
42	II	O
43	and	O
44	26	O
45	in	O
46	IV	O
47	-	O
48	C1	O
49	of	O
50	CDC	O
51	)	O
52	as	O
53	well	O
54	as	O
55	in	O
56	100	O
57	healthy	O
58	subjects	O
59	of	O
60	a	O
61	similar	O
62	age	O
63	(	O
64	control	O
65	group	O
66	).	O
1	A	O
2	position	O
3	-	O
4	independent	O
5	activation	O
6	domain	O
7	which	O
8	contained	O
9	conserved	O
10	regions	O
11	II	O
12	and	O
13	III	O
14	was	O
15	identified	O
16	at	O
17	the	O
18	carboxyl	O
19	terminus	O
20	of	O
21	the	O
22	HNF	B
23	-	I
24	3	I
25	beta	I
26	protein	I
27	(	O
28	amino	O
29	acids	O
30	361	O
31	to	O
32	458	O
33	).	O
1	NSCL	B
2	-	I
3	1	I
4	is	O
5	expressed	O
6	in	O
7	a	O
8	larger	O
9	number	O
10	of	O
11	these	O
12	cell	O
13	lines	O
14	.	O
1	A	O
2	single	O
3	MEF	B
4	-	I
5	2	I
6	site	I
7	is	O
8	a	O
9	major	O
10	positive	O
11	regulatory	O
12	element	O
13	required	O
14	for	O
15	transcription	O
16	of	O
17	the	O
18	muscle	O
19	-	O
20	specific	O
21	subunit	O
22	of	O
23	the	O
24	human	B
25	phosphoglycerate	I
26	mutase	I
27	gene	I
28	in	O
29	skeletal	O
30	and	O
31	cardiac	O
32	muscle	O
33	cells	O
34	.	O
1	Although	O
2	the	O
3	E	O
4	-	O
5	box	O
6	consensus	O
7	is	O
8	minimally	O
9	defined	O
10	as	O
11	CANNTG	O
12	,	O
13	the	O
14	adjacent	O
15	nucleotides	O
16	of	O
17	functional	O
18	E	O
19	-	O
20	boxes	O
21	are	O
22	variable	O
23	for	O
24	genes	O
25	regulated	O
26	by	O
27	the	O
28	bHLH	B
29	proteins	I
30	.	O
1	Intermediate	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	B
10	enhancers	I
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	MCK	B
19	left	I
20	E	I
21	-	I
22	box	I
23	site	I
24	or	O
25	from	O
26	the	O
27	Ig	B
28	kappa	I
29	E2	I
30	E	I
31	-	I
32	box	I
33	.	O
1	Lastly	O
2	,	O
3	there	O
4	are	O
5	multiple	O
6	instances	O
7	in	O
8	which	O
9	short	O
10	oligonucleotide	O
11	direct	O
12	repeats	O
13	flank	O
14	a	O
15	region	O
16	absent	O
17	from	O
18	either	O
19	variola	O
20	or	O
21	vaccinia	O
22	virus	O
23	.	O
1	This	O
2	soluble	O
3	form	O
4	of	O
5	the	O
6	HGFr	B
7	(	O
8	sHGFr	B
9	)	O
10	bound	O
11	HGF	B
12	with	O
13	an	O
14	affinity	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	authentic	O
21	,	O
22	membrane	O
23	-	O
24	associated	O
25	receptor	O
26	.	O
1	Also	O
2	,	O
3	the	O
4	human	B
5	glycoprotein	I
6	alpha	I
7	-	I
8	subunit	I
9	promoter	I
10	was	O
11	induced	O
12	10	O
13	-	O
14	fold	O
15	by	O
16	FSK	B
17	in	O
18	GH4	O
19	rat	O
20	pituitary	O
21	cells	O
22	.(	O
23	ABSTRACT	O
24	TRUNCATED	O
25	AT	O
26	400	O
27	WORDS	O
28	)	O
1	Laboratory	O
2	studies	O
3	using	O
4	Ca45	O
5	labeled	O
6	teeth	O
7	and	O
8	biologically	O
9	stained	O
10	teeth	O
11	confirmed	O
12	that	O
13	the	O
14	dentifrice	O
15	did	O
16	not	O
17	decalcify	O
18	enamel	O
19	or	O
20	bleach	O
21	teeth	O
22	.	O
1	We	O
2	have	O
3	cloned	O
4	and	O
5	characterized	O
6	a	O
7	55	O
8	-	O
9	kb	O
10	region	O
11	of	O
12	DNA	O
13	surrounding	O
14	HRAS1	B
15	.	O
1	Mutational	O
2	studies	O
3	revealed	O
4	that	O
5	it	O
6	was	O
7	the	O
8	homeodomain	B
9	binding	I
10	site	I
11	II	I
12	sequence	I
13	that	O
14	was	O
15	required	O
16	for	O
17	this	O
18	regulation	O
19	.	O
1	Interaction	O
2	of	O
3	H	B
4	-	I
5	2Eb	I
6	with	O
7	an	O
8	IAP	B
9	retrotransposon	I
10	in	O
11	the	O
12	A20	O
13	/	O
14	2J	O
15	B	O
16	cell	O
17	lymphoma	O
18	.	O
1	Finally	O
2	,	O
3	we	O
4	determined	O
5	that	O
6	the	O
7	P68	B
8	amino	O
9	terminus	O
10	was	O
11	both	O
12	necessary	O
13	and	O
14	sufficient	O
15	for	O
16	binding	O
17	dsRNA	O
18	as	O
19	we	O
20	were	O
21	able	O
22	to	O
23	transfer	O
24	dsRNA	O
25	-	O
26	binding	O
27	properties	O
28	to	O
29	a	O
30	reporter	O
31	gene	O
32	product	O
33	previously	O
34	unable	O
35	to	O
36	bind	O
37	RNA	O
38	.	O
1	Visual	O
2	acuity	O
3	may	O
4	be	O
5	decreased	O
6	by	O
7	transient	O
8	changes	O
9	in	O
10	refractive	O
11	error	O
12	caused	O
13	by	O
14	sulfonamides	O
15	,	O
16	the	O
17	antifungal	O
18	agent	O
19	metronidazole	O
20	,	O
21	thiazide	O
22	diuretics	O
23	,	O
24	and	O
25	carbonic	B
26	anhydrase	I
27	inhibitors	O
28	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	21	O
6	-	O
7	mer	O
8	subrepeat	O
9	structure	O
10	is	O
11	also	O
12	present	O
13	in	O
14	each	O
15	unit	O
16	.	O
1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterised	O
6	a	O
7	differentially	O
8	-	O
9	regulated	O
10	gene	O
11	family	O
12	in	O
13	the	O
14	protozoan	O
15	parasite	O
16	Leishmania	O
17	major	O
18	.	O
1	At	O
2	some	O
3	sites	O
4	,	O
5	%	O
6	T	O
7	is	O
8	greatly	O
9	increased	O
10	by	O
11	Cl	O
12	-	O
13	concentrations	O
14	up	O
15	to	O
16	1	O
17	M	O
18	,	O
19	while	O
20	at	O
21	other	O
22	sites	O
23	%	O
24	T	O
25	is	O
26	reduced	O
27	or	O
28	unaffected	O
29	by	O
30	these	O
31	conditions	O
32	.	O
1	The	O
2	initial	O
3	translation	O
4	protein	O
5	encoded	O
6	by	O
7	the	O
8	cDNA	O
9	is	O
10	53	O
11	,	O
12	932	O
13	kDa	O
14	and	O
15	possesses	O
16	a	O
17	hydrophilic	O
18	amino	O
19	acid	O
20	composition	O
21	with	O
22	glutamic	O
23	acid	O
24	comprising	O
25	22	O
26	%	O
27	of	O
28	the	O
29	total	O
30	amino	O
31	acid	O
32	residues	O
33	.	O
1	Genetic	O
2	and	O
3	biochemical	O
4	evidence	O
5	suggests	O
6	that	O
7	v	B
8	-	I
9	Crk	I
10	can	O
11	induce	O
12	transformation	O
13	of	O
14	chicken	O
15	embryo	O
16	fibroblasts	O
17	by	O
18	influencing	O
19	the	O
20	activity	O
21	of	O
22	cellular	O
23	proteins	O
24	involved	O
25	in	O
26	growth	O
27	regulation	O
28	.	O
1	The	O
2	chick	O
3	axon	O
4	-	O
5	associated	O
6	surface	O
7	glycoprotein	O
8	neurofascin	B
9	is	O
10	implicated	O
11	in	O
12	axonal	O
13	growth	O
14	and	O
15	fasciculation	O
16	as	O
17	revealed	O
18	by	O
19	antibody	O
20	perturbation	O
21	experiments	O
22	.	O
1	Surprisingly	O
2	,	O
3	the	O
4	full	O
5	-	O
6	deletion	O
7	mutant	O
8	showed	O
9	a	O
10	strong	O
11	block	O
12	in	O
13	virus	O
14	release	O
15	,	O
16	suggesting	O
17	that	O
18	NC	B
19	is	O
20	involved	O
21	in	O
22	virus	O
23	assembly	O
24	.	O
1	Furthermore	O
2	it	O
3	was	O
4	suggested	O
5	that	O
6	FK506	O
7	plasma	O
8	levels	O
9	were	O
10	concerned	O
11	with	O
12	the	O
13	appearance	O
14	of	O
15	side	O
16	effect	O
17	.	O
1	Thirty	O
2	percent	O
3	of	O
4	patients	O
5	were	O
6	tapered	O
7	off	O
8	all	O
9	steroids	O
10	,	O
11	and	O
12	the	O
13	average	O
14	steroid	O
15	dose	O
16	in	O
17	the	O
18	group	O
19	who	O
20	received	O
21	steroids	O
22	was	O
23	8	O
24	.	O
25	6	O
26	mg	O
27	of	O
28	prednisone	O
29	per	O
30	day	O
31	.	O
1	The	O
2	pulpal	O
3	tissues	O
4	of	O
5	the	O
6	permanent	O
7	mandibular	O
8	molars	O
9	were	O
10	amputated	O
11	and	O
12	then	O
13	dressed	O
14	with	O
15	calcium	O
16	hydrate	O
17	.	O
1	If	O
2	no	O
3	reply	O
4	was	O
5	received	O
6	,	O
7	telephone	O
8	contact	O
9	or	O
10	home	O
11	visits	O
12	were	O
13	made	O
14	.	O
1	Although	O
2	a	O
3	wide	O
4	range	O
5	of	O
6	cognitive	O
7	functions	O
8	had	O
9	been	O
10	tested	O
11	,	O
12	all	O
13	but	O
14	one	O
15	seizure	O
16	occurred	O
17	during	O
18	assessment	O
19	of	O
20	memory	O
21	performance	O
22	.	O
1	The	O
2	experiments	O
3	show	O
4	that	O
5	it	O
6	is	O
7	the	O
8	micromilieu	O
9	of	O
10	the	O
11	alveoli	O
12	and	O
13	the	O
14	condition	O
15	of	O
16	the	O
17	AM	O
18	(	O
19	certain	O
20	physiological	O
21	activation	O
22	states	O
23	,	O
24	such	O
25	as	O
26	phagocytic	O
27	activity	O
28	)	O
29	that	O
30	essentially	O
31	determine	O
32	the	O
33	degree	O
34	of	O
35	recovery	O
36	.	O
1	In	O
2	humans	O
3	,	O
4	four	O
5	AMP	B
6	deaminase	I
7	variants	I
8	,	O
9	termed	O
10	M	B
11	(	O
12	muscle	O
13	),	O
14	L	B
15	(	O
16	liver	O
17	),	O
18	E1	B
19	,	O
20	and	O
21	E2	B
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	distinguished	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	immunological	O
35	criteria	O
36	.	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	endogenous	O
6	N	O
7	-	O
8	methylation	O
9	of	O
10	salsolinol	O
11	into	O
12	N	O
13	-	O
14	methylsalsolinol	O
15	occurs	O
16	in	O
17	the	O
18	brain	O
19	in	O
20	vivo	O
21	.	O
1	Alignment	O
2	of	O
3	the	O
4	selected	O
5	sequences	O
6	allowed	O
7	us	O
8	to	O
9	predict	O
10	a	O
11	consensus	O
12	sequence	O
13	for	O
14	binding	O
15	of	O
16	the	O
17	individual	O
18	homodimeric	O
19	Rel	B
20	-	I
21	related	I
22	proteins	I
23	,	O
24	and	O
25	DNA	O
26	-	O
27	protein	O
28	binding	O
29	analysis	O
30	of	O
31	the	O
32	selected	O
33	DNA	O
34	sequences	O
35	revealed	O
36	sequence	O
37	specificity	O
38	of	O
39	the	O
40	proteins	O
41	.	O
1	Using	O
2	either	O
3	a	O
4	p50	B
5	-	O
6	or	O
7	p65	B
8	-	I
9	selected	I
10	kappa	I
11	B	I
12	motif	I
13	,	O
14	which	O
15	displayed	O
16	differential	O
17	binding	O
18	with	O
19	respect	O
20	to	O
21	the	O
22	other	O
23	protein	O
24	,	O
25	little	O
26	to	O
27	no	O
28	binding	O
29	was	O
30	observed	O
31	with	O
32	the	O
33	heterodimeric	B
34	NF	I
35	-	I
36	kappa	I
37	B	I
38	complex	I
39	.	O
1	By	O
2	screening	O
3	a	O
4	Y1	O
5	cell	O
6	cDNA	O
7	library	O
8	with	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	region	O
14	of	O
15	the	O
16	H	B
17	-	I
18	2RIIBP	I
19	nuclear	I
20	hormone	I
21	receptor	I
22	cDNA	I
23	,	O
24	we	O
25	isolated	O
26	a	O
27	cDNA	O
28	that	O
29	is	O
30	selectively	O
31	expressed	O
32	in	O
33	steroidogenic	O
34	cells	O
35	.	O
1	PaO2	O
2	threshold	O
3	was	O
4	determined	O
5	through	O
6	an	O
7	indwelling	O
8	O2	O
9	sensor	O
10	catheter	O
11	.	O
1	Thus	O
2	,	O
3	chronic	O
4	hematocrit	O
5	decrease	O
6	induced	O
7	by	O
8	H	O
9	or	O
10	P	O
11	resulted	O
12	in	O
13	a	O
14	significant	O
15	fall	O
16	in	O
17	blood	O
18	pressure	O
19	compared	O
20	to	O
21	control	O
22	(	O
23	201	O
24	+/-	O
25	3	O
26	v	O
27	175	O
28	+/-	O
29	4	O
30	,	O
31	167	O
32	+/-	O
33	4	O
34	mm	O
35	Hg	O
36	,	O
37	respectively	O
38	;	O
39	P	O
40	<	O
41	.	O
42	05	O
43	).	O
1	The	O
2	effects	O
3	of	O
4	diltiazem	O
5	were	O
6	stereoselective	O
7	,	O
8	thus	O
9	the	O
10	potentiation	O
11	induced	O
12	by	O
13	d	O
14	-	O
15	cis	O
16	diltiazem	O
17	was	O
18	significantly	O
19	greater	O
20	in	O
21	all	O
22	cases	O
23	than	O
24	that	O
25	induced	O
26	by	O
27	l	O
28	-	O
29	cis	O
30	diltiazem	O
31	,	O
32	which	O
33	suggests	O
34	that	O
35	calcium	O
36	channel	O
37	blockade	O
38	plays	O
39	a	O
40	role	O
41	in	O
42	these	O
43	interactions	O
44	.	O
1	In	O
2	a	O
3	prospective	O
4	,	O
5	randomized	O
6	clinical	O
7	trial	O
8	we	O
9	compared	O
10	the	O
11	efficacy	O
12	of	O
13	subcutaneously	O
14	(	O
15	SC	O
16	)	O
17	administered	O
18	(	O
19	every	O
20	8	O
21	h	O
22	)	O
23	calcium	O
24	heparin	O
25	to	O
26	intravenous	O
27	(	O
28	IV	O
29	)	O
30	sodium	O
31	heparin	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	proximal	O
37	deep	O
38	-	O
39	vein	O
40	thrombosis	O
41	(	O
42	DVT	O
43	).	O
1	It	O
2	corresponds	O
3	to	O
4	the	O
5	complete	O
6	mitochondrial	O
7	presequence	O
8	and	O
9	the	O
10	lipoyl	O
11	-	O
12	bearing	O
13	domain	O
14	that	O
15	are	O
16	encoded	O
17	by	O
18	exons	O
19	I	O
20	through	O
21	IV	O
22	of	O
23	the	O
24	functional	O
25	E2	B
26	gene	I
27	.	O
1	The	O
2	second	O
3	method	O
4	,	O
5	the	O
6	""""	O
7	macro	O
8	""""	O
9	assay	O
10	,	O
11	has	O
12	a	O
13	sensitivity	O
14	range	O
15	of	O
16	0	O
17	.	O
18	03	O
19	-	O
20	5	O
21	.	O
22	0	O
23	micrograms	O
24	phosphorus	O
25	with	O
26	100	O
27	-	O
28	500	O
29	microliters	O
30	HClO4	O
31	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	decreased	O
6	class	O
7	I	O
8	enhancer	O
9	activity	O
10	in	O
11	Ad12	O
12	-	O
13	transformed	O
14	cells	O
15	may	O
16	,	O
17	at	O
18	least	O
19	in	O
20	part	O
21	,	O
22	be	O
23	due	O
24	to	O
25	the	O
26	higher	O
27	levels	O
28	of	O
29	an	O
30	enhancer	O
31	-	O
32	specific	O
33	factor	O
34	,	O
35	possibly	O
36	acting	O
37	as	O
38	a	O
39	repressor	O
40	.	O
1	A	O
2	second	O
3	domain	O
4	,	O
5	located	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	437	O
12	amino	O
13	acids	O
14	of	O
15	IE1	B
16	,	O
17	is	O
18	required	O
19	for	O
20	inhibitory	O
21	and	O
22	DNA	O
23	-	O
24	binding	O
25	activities	O
26	.	O
1	In	O
2	order	O
3	to	O
4	investigate	O
5	the	O
6	blood	O
7	compatibility	O
8	of	O
9	autogenous	O
10	vein	O
11	graft	O
12	(	O
13	AVG	O
14	),	O
15	changes	O
16	in	O
17	prostacyclin	O
18	(	O
19	PGI2	O
20	)	O
21	production	O
22	following	O
23	harvesting	O
24	and	O
25	arterial	O
26	implantation	O
27	were	O
28	studied	O
29	experimentally	O
30	.	O
1	Anti	B
2	-	I
3	CRK	I
4	antibodies	I
5	detect	O
6	a	O
7	53kDa	O
8	protein	O
9	in	O
10	extracts	O
11	of	O
12	C	O
13	.	O
14	fasciculata	O
15	in	O
16	agreement	O
17	with	O
18	the	O
19	size	O
20	predicted	O
21	from	O
22	the	O
23	nucleotide	O
24	sequence	O
25	of	O
26	the	O
27	cloned	O
28	gene	O
29	.	O
1	Respiratory	O
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	O
7	sedation	O
8	with	O
9	midazolam	O
10	.	O
1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O
1	One	O
2	air	O
3	embolism	O
4	occurred	O
5	;	O
6	this	O
7	was	O
8	the	O
9	only	O
10	filter	O
11	-	O
12	or	O
13	retrieval	O
14	-	O
15	related	O
16	complication	O
17	.	O
1	Laboratory	O
2	studies	O
3	showed	O
4	that	O
5	the	O
6	direct	O
7	fluorescent	O
8	-	O
9	antibody	O
10	kits	O
11	were	O
12	the	O
13	least	O
14	sensitive	O
15	in	O
16	this	O
17	case	O
18	and	O
19	did	O
20	not	O
21	detect	O
22	fewer	O
23	than	O
24	10	O
25	(	O
26	4	O
27	)	O
28	elementary	O
29	bodies	O
30	per	O
31	ml	O
32	,	O
33	while	O
34	most	O
35	ELISA	O
36	kits	O
37	detected	O
38	between	O
39	130	O
40	and	O
41	600	O
42	elementary	O
43	bodies	O
44	per	O
45	ml	O
46	.	O
1	For	O
2	this	O
3	reason	O
4	,	O
5	the	O
6	particle	O
7	forming	O
8	capacity	O
9	of	O
10	derivatives	O
11	of	O
12	the	O
13	HIV	B
14	-	I
15	1	I
16	group	I
17	specific	I
18	core	I
19	antigen	I
20	p55	I
21	gag	I
22	was	O
23	assayed	O
24	and	O
25	compared	O
26	dependent	O
27	on	O
28	various	O
29	expression	O
30	systems	O
31	:	O
32	recombinant	O
33	bacteria	O
34	,	O
35	vaccinia	O
36	-	O
37	and	O
38	baculoviruses	O
39	were	O
40	established	O
41	encoding	O
42	the	O
43	entire	O
44	core	B
45	protein	I
46	p55	I
47	either	O
48	in	O
49	its	O
50	authentic	O
51	sequence	O
52	or	O
53	lacking	O
54	the	O
55	myristylation	O
56	consensus	O
57	signal	O
58	.	O
1	This	O
2	may	O
3	result	O
4	in	O
5	more	O
6	reabsorption	O
7	and	O
8	hence	O
9	reduced	O
10	renal	O
11	clearance	O
12	.	O
1	The	O
2	major	O
3	pathological	O
4	findings	O
5	of	O
6	the	O
7	placenta	O
8	were	O
9	prematuration	O
10	and	O
11	hypoplasia	O
12	.	O
1	We	O
2	investigated	O
3	the	O
4	diagnostic	O
5	value	O
6	of	O
7	a	O
8	new	O
9	in	O
10	vitro	O
11	test	O
12	,	O
13	Pharmacia	O
14	CAP	O
15	System	O
16	(	O
17	Pharmacia	O
18	Diagnostics	O
19	AB	O
20	,	O
21	Uppsala	O
22	,	O
23	Sweden	O
24	),	O
25	for	O
26	the	O
27	quantitative	O
28	measurement	O
29	of	O
30	allergen	B
31	-	I
32	specific	I
33	IgE	I
34	antibodies	I
35	by	O
36	comparison	O
37	with	O
38	RAST	O
39	in	O
40	2	O
41	groups	O
42	of	O
43	patients	O
44	,	O
45	71	O
46	atopic	O
47	and	O
48	48	O
49	non	O
50	-	O
51	atopic	O
52	.	O
1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	demonstrate	O
7	that	O
8	strongyloidiasis	O
9	was	O
10	the	O
11	cause	O
12	of	O
13	sudden	O
14	death	O
15	.	O
1	A	O
2	second	O
3	large	O
4	group	O
5	of	O
6	disorders	O
7	in	O
8	pregnancy	O
9	is	O
10	caused	O
11	by	O
12	effects	O
13	of	O
14	infections	O
15	of	O
16	the	O
17	mother	O
18	without	O
19	pathogens	O
20	being	O
21	transmitted	O
22	to	O
23	the	O
24	embryo	O
25	or	O
26	the	O
27	placenta	O
28	.	O
1	Four	O
2	short	O
3	nucleotide	O
4	sequences	O
5	(	O
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	O
13	the	O
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	parsley	B
19	chalcone	I
20	synthase	I
21	promoter	I
22	.	O
1	The	O
2	mean	O
3	blood	O
4	flow	O
5	in	O
6	the	O
7	penile	O
8	foreskin	O
9	was	O
10	estimated	O
11	to	O
12	be	O
13	15	O
14	ml	O
15	/	O
16	min	O
17	/	O
18	100	O
19	g	O
20	and	O
21	it	O
22	increased	O
23	to	O
24	150	O
25	-	O
26	200	O
27	%	O
28	after	O
29	the	O
30	induction	O
31	of	O
32	anesthesia	O
33	,	O
34	and	O
35	then	O
36	decreased	O
37	to	O
38	72	O
39	%	O
40	at	O
41	the	O
42	tip	O
43	of	O
44	the	O
45	created	O
46	parameatal	O
47	foreskin	O
48	flap	O
49	.	O
1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	SNF2	B
7	,	O
8	SNF5	B
9	,	O
10	and	O
11	SNF6	B
12	function	O
13	interdependently	O
14	in	O
15	transcriptional	O
16	activation	O
17	,	O
18	possibly	O
19	forming	O
20	a	O
21	heteromeric	O
22	complex	O
23	.	O
1	Mutations	O
2	in	O
3	either	O
4	gene	O
5	block	O
6	some	O
7	crucial	O
8	late	O
9	step	O
10	in	O
11	assembly	O
12	of	O
13	F1	B
14	,	O
15	causing	O
16	the	O
17	alpha	O
18	and	O
19	beta	O
20	subunits	O
21	to	O
22	accumulate	O
23	in	O
24	mitochondria	O
25	as	O
26	inactive	O
27	aggregates	O
28	(	O
29	Ackerman	O
30	,	O
31	S	O
32	.	O
1	There	O
2	was	O
3	however	O
4	,	O
5	no	O
6	significant	O
7	difference	O
8	in	O
9	the	O
10	prevalence	O
11	of	O
12	chronic	O
13	respiratory	O
14	symptoms	O
15	between	O
16	animal	O
17	food	O
18	workers	O
19	with	O
20	positive	O
21	and	O
22	negative	O
23	skin	O
24	tests	O
25	to	O
26	house	O
27	dust	O
28	or	O
29	to	O
30	fish	O
31	flour	O
32	or	O
33	among	O
34	those	O
35	with	O
36	increased	O
37	or	O
38	normal	O
39	IgE	B
40	(	O
41	except	O
42	for	O
43	dyspnea	O
44	).	O
1	A	O
2	comparison	O
3	of	O
4	the	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	the	O
10	T	O
11	.	O
12	thermophilus	O
13	enzyme	O
14	with	O
15	that	O
16	of	O
17	the	O
18	Escherichia	O
19	coli	O
20	enzyme	O
21	showed	O
22	(	O
23	i	O
24	)	O
25	a	O
26	37	O
27	%	O
28	overall	O
29	similarity	O
30	;	O
31	(	O
32	ii	O
33	)	O
34	the	O
35	conservation	O
36	of	O
37	the	O
38	Ser	O
39	residue	O
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	phosphorylated	O
47	in	O
48	the	O
49	E	O
50	.	O
51	coli	O
52	enzyme	O
53	,	O
54	and	O
55	of	O
56	the	O
57	surrounding	O
58	sequence	O
59	;	O
60	and	O
61	(	O
62	iii	O
63	)	O
64	the	O
65	presence	O
66	of	O
67	141	O
68	extra	O
69	residues	O
70	at	O
71	the	O
72	C	O
73	terminus	O
74	of	O
75	the	O
76	T	O
77	.	O
78	thermophilus	O
79	enzyme	O
80	.	O
1	Mature	B
2	tobacco	I
3	L12	I
4	protein	I
5	has	O
6	44	O
7	%	O
8	amino	O
9	acid	O
10	identity	O
11	with	O
12	ribosomal	O
13	protein	O
14	L7	B
15	/	O
16	L12	B
17	of	O
18	Escherichia	O
19	coli	O
20	.	O
1	Characterization	O
2	of	O
3	these	O
4	R	O
5	subunits	O
6	by	O
7	their	O
8	8	O
9	-	O
10	azido	O
11	-	O
12	cAMP	O
13	photoaffinity	O
14	labeling	O
15	and	O
16	immunoreactivity	O
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	phosphorylation	O
24	-	O
25	dependent	O
26	mobility	O
27	shift	O
28	on	O
29	sodium	O
30	dodecyl	O
31	sulfate	O
32	-	O
33	polyacrylamide	O
34	gel	O
35	electrophoresis	O
36	(	O
37	SDS	O
38	-	O
39	PAGE	O
40	),	O
41	indicated	O
42	subunit	O
43	sizes	O
44	of	O
45	RII	B
46	beta	I
47	(	O
48	53	O
49	kDa	O
50	)	O
51	greater	O
52	than	O
53	RII	B
54	alpha	I
55	dephosphoform	O
56	(	O
57	51	O
58	kDa	O
59	)	O
60	greater	O
61	than	O
62	RI	B
63	alpha	I
64	(	O
65	49	O
66	kDa	O
67	).	O
1	Proprotein	O
2	processing	O
3	occurs	O
4	intracellularly	O
5	.	O
1	Stringent	O
2	hybridization	O
3	of	O
4	EHS	B
5	-	I
6	1	I
7	back	O
8	to	O
9	primate	O
10	genomic	O
11	DNA	O
12	indicates	O
13	two	O
14	distinct	O
15	EHS	B
16	-	I
17	1	I
18	loci	I
19	in	O
20	normal	O
21	human	O
22	DNA	O
23	,	O
24	an	O
25	identical	O
26	band	O
27	pattern	O
28	in	O
29	chimpanzee	O
30	DNA	O
31	,	O
32	and	O
33	a	O
34	single	O
35	locus	O
36	in	O
37	rhesus	O
38	monkey	O
39	DNA	O
40	.	O
1	This	O
2	vector	O
3	transfected	O
4	into	O
5	the	O
6	yeast	O
7	Saccharomyces	O
8	cerevisiae	O
9	directs	O
10	expression	O
11	of	O
12	a	O
13	secreted	O
14	mature	O
15	protein	O
16	at	O
17	levels	O
18	up	O
19	to	O
20	200	O
21	mg	O
22	of	O
23	LAPP	O
24	/	O
25	liter	O
26	of	O
27	culture	O
28	medium	O
29	.	O
1	This	O
2	DNA	O
3	motif	O
4	represents	O
5	a	O
6	novel	O
7	protein	O
8	-	O
9	binding	O
10	sequence	O
11	.	O
1	Hence	O
2	temperature	O
3	and	O
4	virF	B
5	are	O
6	both	O
7	required	O
8	for	O
9	the	O
10	induction	O
11	of	O
12	the	O
13	yop	B
14	regulon	I
15	.	O
1	The	O
2	recently	O
3	developed	O
4	gamma	B
5	-	I
6	interferon	I
7	(	O
8	IFN	B
9	-	I
10	gamma	I
11	)	O
12	assay	O
13	system	O
14	for	O
15	the	O
16	diagnosis	O
17	of	O
18	bovine	O
19	tuberculosis	O
20	in	O
21	cattle	O
22	has	O
23	been	O
24	accredited	O
25	by	O
26	the	O
27	Standing	O
28	Committee	O
29	on	O
30	Agriculture	O
31	for	O
32	use	O
33	in	O
34	Australia	O
35	.	O
1	The	O
2	Klebsiella	B
3	aerogenes	I
4	gene	I
5	maoA	I
6	,	O
7	which	O
8	is	O
9	involved	O
10	in	O
11	the	O
12	synthesis	O
13	of	O
14	monoamine	B
15	oxidase	I
16	,	O
17	was	O
18	induced	O
19	by	O
20	tyramine	O
21	and	O
22	the	O
23	related	O
24	compounds	O
25	,	O
26	subjected	O
27	to	O
28	catabolite	O
29	and	O
30	ammonium	O
31	ion	O
32	repression	O
33	,	O
34	and	O
35	cloned	O
36	.	O
1	To	O
2	determine	O
3	the	O
4	genetic	O
5	basis	O
6	for	O
7	the	O
8	differences	O
9	between	O
10	the	O
11	cardiac	O
12	and	O
13	brain	B
14	AE3	I
15	variants	I
16	,	O
17	we	O
18	isolated	O
19	and	O
20	characterized	O
21	the	O
22	rat	O
23	gene	O
24	.	O
1	Protein	B
2	tyrosine	I
3	kinases	I
4	(	O
5	PTKs	B
6	)	O
7	are	O
8	implicated	O
9	in	O
10	the	O
11	control	O
12	of	O
13	cell	O
14	growth	O
15	by	O
16	virtue	O
17	of	O
18	their	O
19	frequent	O
20	appearance	O
21	as	O
22	products	O
23	of	O
24	retroviral	O
25	oncogenes	O
26	,	O
27	as	O
28	intracellular	O
29	signal	O
30	transducers	O
31	,	O
32	and	O
33	as	O
34	growth	B
35	factor	I
36	receptors	I
37	or	O
38	components	O
39	thereof	O
40	.	O
1	Unlike	O
2	the	O
3	typical	O
4	enhancer	O
5	element	O
6	,	O
7	this	O
8	region	O
9	functions	O
10	in	O
11	an	O
12	orientation	O
13	-	O
14	dependent	O
15	manner	O
16	.	O
1	SEA	O
2	was	O
3	recorded	O
4	with	O
5	bidirectional	O
6	filters	O
7	at	O
8	25	O
9	-	O
10	250	O
11	HZ	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	Simson	O
19	method	O
20	.	O
1	Drug	O
2	-	O
3	drug	O
4	interactions	O
5	are	O
6	most	O
7	likely	O
8	to	O
9	occur	O
10	in	O
11	patients	O
12	receiving	O
13	multiple	O
14	medications	O
15	and	O
16	with	O
17	drugs	O
18	that	O
19	have	O
20	a	O
21	narrow	O
22	therapeutic	O
23	window	O
24	.	O
1	A	O
2	724	O
3	-	O
4	bp	O
5	segment	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	consisting	O
13	of	O
14	the	O
15	proximal	O
16	E	O
17	-	O
18	box	O
19	flanked	O
20	upstream	O
21	by	O
22	a	O
23	mammalian	O
24	-	O
25	specific	O
26	352	O
27	-	O
28	bp	O
29	region	O
30	was	O
31	sufficient	O
32	for	O
33	maximal	O
34	transcriptional	O
35	activation	O
36	in	O
37	postconfluent	O
38	BC3H1	O
39	myoblasts	O
40	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	baculovirus	O
6	-	O
7	expressed	O
8	TR	B
9	mediates	O
10	transcriptional	O
11	activation	O
12	and	O
13	repression	O
14	in	O
15	a	O
16	promoter	O
17	-	O
18	specific	O
19	manner	O
20	in	O
21	vitro	O
22	.	O
1	And	O
2	the	O
3	natural	O
4	barriers	O
5	?	O
1	The	O
2	serum	O
3	erythropoietin	B
4	(	O
5	EPO	B
6	)	O
7	concentrations	O
8	of	O
9	15	O
10	male	O
11	triathletes	O
12	(	O
13	26	O
14	.	O
15	3	O
16	U	O
17	.	O
18	ml	O
19	-	O
20	1	O
21	)	O
22	were	O
23	significantly	O
24	lower	O
25	than	O
26	those	O
27	of	O
28	45	O
29	male	O
30	distance	O
31	runners	O
32	(	O
33	31	O
34	.	O
35	6	O
36	U	O
37	.	O
38	ml	O
39	-	O
40	1	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	).	O
1	His	O
2	HC	B
3	II	I
4	activity	O
5	and	O
6	antigen	O
7	levels	O
8	were	O
9	49	O
10	%	O
11	and	O
12	50	O
13	%,	O
14	respectively	O
15	,	O
16	and	O
17	his	O
18	daughter	O
19	also	O
20	showed	O
21	similar	O
22	low	O
23	levels	O
24	.	O
1	These	O
2	results	O
3	support	O
4	the	O
5	diagnostic	O
6	validity	O
7	of	O
8	NFPD	O
9	in	O
10	CP	O
11	/	O
12	NCA	O
13	patients	O
14	,	O
15	because	O
16	such	O
17	patients	O
18	had	O
19	a	O
20	family	O
21	history	O
22	of	O
23	panic	O
24	disorder	O
25	similar	O
26	to	O
27	patients	O
28	with	O
29	a	O
30	more	O
31	classical	O
32	panic	O
33	disorder	O
34	presentation	O
35	.	O
1	Furthermore	O
2	,	O
3	no	O
4	transcripts	O
5	of	O
6	the	O
7	same	O
8	size	O
9	and	O
10	having	O
11	the	O
12	same	O
13	developmental	O
14	profile	O
15	as	O
16	those	O
17	generated	O
18	by	O
19	the	O
20	wild	B
21	-	I
22	type	I
23	E10	I
24	fragment	I
25	were	O
26	identified	O
27	by	O
28	probes	O
29	covering	O
30	the	O
31	remainder	O
32	of	O
33	the	O
34	cloned	O
35	region	O
36	.	O
1	In	O
2	an	O
3	ongoing	O
4	study	O
5	the	O
6	performance	O
7	of	O
8	the	O
9	SMSP	O
10	is	O
11	being	O
12	compared	O
13	with	O
14	that	O
15	of	O
16	the	O
17	Mini	O
18	Speech	O
19	Processor	O
20	(	O
21	MSP	O
22	).	O
1	These	O
2	mutant	O
3	proteins	O
4	retained	O
5	the	O
6	ability	O
7	to	O
8	competitively	O
9	inhibit	O
10	kappa	B
11	B	I
12	-	O
13	mediated	O
14	transcriptional	O
15	activation	O
16	of	O
17	the	O
18	human	B
19	immunodeficiency	I
20	virus	I
21	long	I
22	terminal	I
23	repeat	I
24	but	O
25	failed	O
26	to	O
27	efficiently	O
28	transform	O
29	chicken	O
30	lymphoid	O
31	cells	O
32	both	O
33	in	O
34	vitro	O
35	and	O
36	in	O
37	vivo	O
38	.	O
1	Therefore	O
2	,	O
3	with	O
4	a	O
5	biopsy	O
6	from	O
7	the	O
8	stoma	O
9	site	O
10	there	O
11	is	O
12	a	O
13	risk	O
14	of	O
15	missing	O
16	early	O
17	rejection	O
18	.	O
1	But	O
2	the	O
3	application	O
4	solutions	O
5	of	O
6	instrument	O
7	disinfectants	O
8	should	O
9	not	O
10	be	O
11	used	O
12	longer	O
13	than	O
14	one	O
15	day	O
16	.	O
1	Two	O
2	cDNAs	O
3	encoding	O
4	casein	B
5	kinase	I
6	-	I
7	1	I
8	have	O
9	been	O
10	isolated	O
11	from	O
12	a	O
13	yeast	O
14	cDNA	O
15	library	O
16	and	O
17	termed	O
18	CKI1	B
19	and	O
20	CKI2	B
21	.	O
1	However	O
2	,	O
3	butyrate	O
4	was	O
5	at	O
6	least	O
7	2	O
8	-	O
9	fold	O
10	more	O
11	effective	O
12	in	O
13	stimulating	O
14	CAT	B
15	activity	O
16	of	O
17	fusion	O
18	genes	O
19	containing	O
20	upstream	O
21	sequences	O
22	(-	O
23	834	O
24	to	O
25	-	O
26	576	O
27	)	O
28	than	O
29	those	O
30	containing	O
31	proximal	O
32	sequences	O
33	(-	O
34	456	O
35	to	O
36	-	O
37	172	O
38	),	O
39	suggesting	O
40	two	O
41	regions	O
42	in	O
43	the	O
44	PSG1	B
45	-	I
46	I	I
47	gene	I
48	that	O
49	mediate	O
50	the	O
51	butyrate	O
52	response	O
53	.	O
1	An	O
2	examination	O
3	of	O
4	the	O
5	role	O
6	of	O
7	the	O
8	carboxyl	O
9	terminus	O
10	in	O
11	regulating	O
12	NGFI	B
13	-	I
14	B	I
15	transcriptional	O
16	activity	O
17	revealed	O
18	that	O
19	,	O
20	in	O
21	accordance	O
22	with	O
23	other	O
24	nuclear	O
25	receptors	O
26	,	O
27	mutants	O
28	lacking	O
29	portions	O
30	of	O
31	the	O
32	carboxyl	O
33	terminus	O
34	had	O
35	greatly	O
36	decreased	O
37	activity	O
38	.	O
1	The	O
2	reason	O
3	that	O
4	nitrous	O
5	oxide	O
6	does	O
7	not	O
8	produce	O
9	hydroxyl	O
10	radicals	O
11	readily	O
12	might	O
13	be	O
14	that	O
15	the	O
16	one	O
17	-	O
18	electron	O
19	reduction	O
20	proceeds	O
21	through	O
22	an	O
23	N2O	O
24	-	O
25	intermediate	O
26	which	O
27	is	O
28	energetically	O
29	very	O
30	unfavourable	O
31	:	O
32	EO	O
33	(	O
34	N2O	O
35	/	O
36	N2O	O
37	-)	O
38	=	O
39	-	O
40	1	O
41	.	O
42	1	O
43	V	O
44	.	O
1	All	O
2	mutant	B
3	JCV	I
4	T	I
5	antigens	I
6	bound	O
7	to	O
8	JCV	O
9	and	O
10	SV40	O
11	origins	O
12	of	O
13	DNA	O
14	replication	O
15	.	O
1	The	O
2	relation	O
3	between	O
4	myocardial	B
5	beta	I
6	-	I
7	adrenergic	I
8	receptor	I
9	and	O
10	left	O
11	ventricular	O
12	(	O
13	LV	O
14	)	O
15	function	O
16	was	O
17	studied	O
18	in	O
19	10	O
20	patients	O
21	,	O
22	aged	O
23	41	O
24	to	O
25	61	O
26	years	O
27	(	O
28	average	O
29	51	O
30	),	O
31	with	O
32	LV	O
33	volume	O
34	overload	O
35	mainly	O
36	due	O
37	to	O
38	chronic	O
39	mitral	O
40	regurgitation	O
41	.	O
1	In	O
2	addition	O
3	to	O
4	the	O
5	previously	O
6	identified	O
7	and	O
8	characterized	O
9	attenuator	B
10	1	I
11	situated	O
12	93	O
13	nucleotides	O
14	downstream	O
15	from	O
16	the	O
17	major	O
18	late	O
19	transcription	O
20	start	O
21	site	O
22	,	O
23	a	O
24	second	O
25	attenuator	O
26	,	O
27	attenuator	B
28	2	I
29	,	O
30	situated	O
31	55	O
32	nucleotides	O
33	downstream	O
34	from	O
35	it	O
36	,	O
37	has	O
38	been	O
39	identified	O
40	.	O
1	Discrepant	O
2	results	O
3	with	O
4	a	O
5	latex	O
6	agglutination	O
7	test	O
8	in	O
9	the	O
10	assessment	O
11	of	O
12	cytomegalovirus	O
13	antibody	O
14	status	O
15	of	O
16	cardiac	O
17	transplant	O
18	donors	O
19	.	O
1	We	O
2	have	O
3	identified	O
4	SWI5	B
5	'	O
6	s	O
7	nuclear	O
8	localization	O
9	signal	O
10	(	O
11	NLS	O
12	)	O
13	and	O
14	show	O
15	that	O
16	it	O
17	can	O
18	confer	O
19	cell	O
20	cycle	O
21	-	O
22	dependent	O
23	nuclear	O
24	entry	O
25	to	O
26	a	O
27	heterologous	O
28	protein	O
29	.	O
1	Intron	O
2	K1	B
3	cox1	I
4	.	I
5	2	I
6	is	O
7	not	O
8	found	O
9	in	O
10	S	O
11	.	O
12	cerevisiae	O
13	and	O
14	appears	O
15	at	O
16	an	O
17	unique	O
18	location	O
19	in	O
20	K	O
21	.	O
22	lactis	O
23	.	O
1	Temafloxacin	O
2	400	O
3	mg	O
4	b	O
5	.	O
6	i	O
7	.	O
8	d	O
9	.	O
10	administered	O
11	orally	O
12	for	O
13	28	O
14	days	O
15	represents	O
16	a	O
17	safe	O
18	and	O
19	effective	O
20	treatment	O
21	for	O
22	chronic	O
23	bacterial	O
24	prostatitis	O
25	.	O
1	During	O
2	coronary	O
3	stenosis	O
4	,	O
5	on	O
6	the	O
7	contrary	O
8	,	O
9	intracoronary	O
10	procaterol	O
11	at	O
12	the	O
13	same	O
14	dose	O
15	significantly	O
16	deteriorated	O
17	regional	O
18	myocardial	O
19	dysfunction	O
20	without	O
21	changing	O
22	LCX	O
23	flow	O
24	,	O
25	global	O
26	hemodynamics	O
27	and	O
28	cardiac	O
29	lactate	O
30	metabolism	O
31	.	O
1	This	O
2	exon	O
3	,	O
4	here	O
5	named	O
6	exon	O
7	0	O
8	,	O
9	contained	O
10	the	O
11	entire	O
12	5	O
13	'	O
14	untranslated	O
15	region	O
16	and	O
17	the	O
18	N	O
19	-	O
20	terminal	O
21	signal	O
22	sequence	O
23	of	O
24	the	O
25	polypeptide	O
26	.	O
1	Induction	O
2	of	O
3	Jurkat	O
4	leukemic	O
5	T	O
6	cells	O
7	with	O
8	phorbol	O
9	12	O
10	-	O
11	myristate	O
12	13	O
13	-	O
14	acetate	O
15	and	O
16	ionomycin	O
17	did	O
18	not	O
19	affect	O
20	the	O
21	level	O
22	of	O
23	FKBP	B
24	mRNA	I
25	.	O
1	Recently	O
2	,	O
3	studies	O
4	of	O
5	agents	O
6	that	O
7	disrupt	O
8	collagen	B
9	synthesis	O
10	and	O
11	deposition	O
12	have	O
13	yielded	O
14	several	O
15	new	O
16	angiogenesis	O
17	inhibitors	O
18	.	O
1	Whereas	O
2	cDNA	O
3	hybridization	O
4	to	O
5	genomic	O
6	DNA	O
7	blots	O
8	indicated	O
9	a	O
10	small	O
11	subfamily	O
12	of	O
13	G0S19	B
14	genes	I
15	,	O
16	simple	O
17	patterns	O
18	of	O
19	bands	O
20	indicated	O
21	that	O
22	most	O
23	cDNAs	O
24	,	O
25	including	O
26	G0S30	B
27	cDNA	I
28	,	O
29	corresponded	O
30	to	O
31	single	O
32	-	O
33	copy	O
34	genes	O
35	.	O
1	It	O
2	is	O
3	,	O
4	however	O
5	,	O
6	extremely	O
7	homologous	O
8	to	O
9	a	O
10	third	O
11	'	O
12	non	O
13	-	O
14	classical	O
15	'	O
16	gene	O
17	,	O
18	HLA	B
19	-	I
20	5	I
21	.	I
22	4	I
23	,	O
24	and	O
25	to	O
26	the	O
27	chimpanzee	O
28	gene	O
29	,	O
30	Ch28	B
31	.	O
1	The	O
2	SH2	B
3	and	O
4	SH3	B
5	domains	I
6	of	O
7	pp60src	B
8	direct	O
9	stable	O
10	association	O
11	with	O
12	tyrosine	O
13	phosphorylated	O
14	proteins	O
15	p130	B
16	and	O
17	p110	B
18	.	O
1	Chem	O
2	.	O
1	This	O
2	report	O
3	substantiates	O
4	that	O
5	at	O
6	least	O
7	two	O
8	of	O
9	the	O
10	18	O
11	kDa	O
12	hsps	B
13	in	O
14	maize	O
15	are	O
16	products	O
17	of	O
18	different	O
19	but	O
20	related	O
21	genes	O
22	.	O
1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	O
8	extracellular	O
9	matrix	O
10	glycoprotein	O
11	undulin	B
12	.	O
1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	CDC2	B
9	-	I
10	related	I
11	kinase	I
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	B
17	yeast	I
18	cdc28	I
19	mutation	O
20	.	O
1	In	O
2	patients	O
3	with	O
4	osteomyelitis	O
5	and	O
6	joint	O
7	empyema	O
8	(	O
9	n	O
10	=	O
11	48	O
12	)	O
13	PMN	B
14	elastase	I
15	had	O
16	a	O
17	sensitivity	O
18	of	O
19	77	O
20	%,	O
21	which	O
22	was	O
23	only	O
24	exceeded	O
25	by	O
26	that	O
27	of	O
28	the	O
29	unspecific	O
30	erythrocyte	O
31	sedimentation	O
32	rate	O
33	(	O
34	sensitivity	O
35	89	O
36	%).	O
1	E	O
2	.,	O
3	Hession	O
4	,	O
5	C	O
6	.,	O
7	Goff	O
8	,	O
9	D	O
10	.,	O
11	Griffiths	O
12	,	O
13	B	O
14	.,	O
15	Tizard	O
16	,	O
17	R	O
18	.,	O
19	Newman	O
20	,	O
21	B	O
22	.,	O
23	Chi	O
24	-	O
25	Rosso	O
26	,	O
27	G	O
28	.,	O
29	and	O
30	Lobb	O
31	,	O
32	R	O
33	.,	O
34	(	O
35	1990	O
36	)	O
37	Cell	O
38	63	O
39	,	O
40	1349	O
41	-	O
42	1356	O
43	).	O
1	An	O
2	approximately	O
3	2	B
4	-	I
5	kilobase	I
6	B2	I
7	transcript	I
8	was	O
9	expressed	O
10	in	O
11	all	O
12	alfalfa	O
13	organs	O
14	tested	O
15	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	sulfhydryl	O
7	group	O
8	of	O
9	certain	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	can	O
15	potentiate	O
16	their	O
17	effect	O
18	on	O
19	the	O
20	endogenous	O
21	nitrovasodilator	O
22	EDRF	B
23	.	O
1	Analysis	O
2	of	O
3	the	O
4	deduced	O
5	amino	O
6	acid	O
7	sequence	O
8	suggests	O
9	that	O
10	CHIP28	B
11	protein	I
12	contains	O
13	six	O
14	bilayer	O
15	-	O
16	spanning	O
17	domains	O
18	,	O
19	two	O
20	exofacial	O
21	potential	O
22	N	O
23	-	O
24	glycosylation	O
25	sites	O
26	,	O
27	and	O
28	intracellular	O
29	N	O
30	and	O
31	C	O
32	termini	O
33	.	O
1	The	O
2	qualitative	O
3	concentrations	O
4	of	O
5	HCG	B
6	had	O
7	a	O
8	sensitivity	O
9	of	O
10	37	O
11	.	O
12	5	O
13	%	O
14	and	O
15	a	O
16	specificity	O
17	of	O
18	100	O
19	%.	O
1	The	O
2	first	O
3	transfusion	O
4	resulted	O
5	in	O
6	a	O
7	platelet	O
8	increment	O
9	to	O
10	32	O
11	Gpt	O
12	/	O
13	l	O
14	(	O
15	CCI	O
16	11	O
17	).	O
1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	O
10	gene	B
11	32	I
12	protein	O
13	.	O
1	In	O
2	some	O
3	early	O
4	B	O
5	cells	O
6	and	O
7	Abelson	O
8	murine	O
9	leukemia	O
10	virus	O
11	-	O
12	transformed	O
13	pre	O
14	-	O
15	B	O
16	-	O
17	cell	O
18	lines	O
19	,	O
20	LT	B
21	mRNA	I
22	is	O
23	constitutively	O
24	expressed	O
25	.	O
1	The	O
2	genome	O
3	of	O
4	Thogoto	O
5	virus	O
6	comprises	O
7	six	O
8	segments	O
9	of	O
10	single	O
11	-	O
12	stranded	O
13	,	O
14	negative	O
15	sense	O
16	RNA	O
17	.	O
1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	B
7	protein	I
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	B
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O
1	The	O
2	primary	O
3	pancreatic	O
4	insult	O
5	seemed	O
6	to	O
7	be	O
8	unaffected	O
9	by	O
10	the	O
11	treatment	O
12	,	O
13	because	O
14	neither	O
15	the	O
16	rise	O
17	in	O
18	plasma	B
19	lipase	I
20	nor	O
21	the	O
22	development	O
23	of	O
24	ascites	O
25	or	O
26	the	O
27	extension	O
28	of	O
29	the	O
30	pancreatic	O
31	necrosis	O
32	were	O
33	diminished	O
34	.	O
1	BACKGROUND	O
2	:	O
3	The	O
4	effectiveness	O
5	of	O
6	monoamine	B
7	oxidase	I
8	inhibitors	O
9	(	O
10	MAOIs	O
11	)	O
12	in	O
13	tricyclic	O
14	resistant	O
15	depression	O
16	has	O
17	received	O
18	surprisingly	O
19	little	O
20	systematic	O
21	study	O
22	.	O
1	Patients	O
2	with	O
3	moderate	O
4	PDDAT	O
5	were	O
6	impaired	O
7	on	O
8	all	O
9	serial	O
10	positions	O
11	for	O
12	both	O
13	spatial	O
14	order	O
15	and	O
16	spatial	O
17	recognition	O
18	memory	O
19	.	O
1	One	O
2	patients	O
3	had	O
4	plasma	B
5	C	I
6	-	I
7	peptide	I
8	greater	O
9	than	O
10	3	O
11	pM	O
12	and	O
13	was	O
14	therefore	O
15	excluded	O
16	from	O
17	analysis	O
18	.	O
1	To	O
2	overcome	O
3	this	O
4	problem	O
5	,	O
6	we	O
7	have	O
8	overexpressed	O
9	Kex2p	B
10	using	O
11	the	O
12	baculovirus	O
13	/	O
14	insect	O
15	cell	O
16	expression	O
17	system	O
18	.	O
1	This	O
2	study	O
3	confirms	O
4	,	O
5	although	O
6	individual	O
7	reaction	O
8	is	O
9	remarkably	O
10	different	O
11	,	O
12	transportation	O
13	as	O
14	a	O
15	potent	O
16	stressor	O
17	for	O
18	Beagle	O
19	dogs	O
20	.	O
1	Growth	O
2	factor	O
3	stimulation	O
4	of	O
5	cells	O
6	causes	O
7	the	O
8	phosphorylation	O
9	of	O
10	the	O
11	c	B
12	-	I
13	Myc	I
14	transcriptional	I
15	activation	I
16	domain	I
17	at	O
18	Ser62	O
19	within	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	region	O
25	that	O
26	is	O
27	highly	O
28	conserved	O
29	among	O
30	members	O
31	of	O
32	the	O
33	Myc	B
34	family	I
35	(	O
36	Alvarez	O
37	,	O
38	E	O
39	.,	O
40	Northwood	O
41	,	O
42	I	O
43	.	O
44	C	O
45	.,	O
46	Gonzalez	O
47	,	O
48	F	O
49	.	O
1	Amino	O
2	acid	O
3	residues	O
4	147	O
5	-	O
6	167	O
7	of	O
8	the	O
9	previously	O
10	reported	O
11	sequence	O
12	are	O
13	replaced	O
14	by	O
15	new	O
16	residues	O
17	147	O
18	to	O
19	150	O
20	.	O
1	Pulmonary	O
2	hypertension	O
3	,	O
4	with	O
5	or	O
6	without	O
7	coronary	O
8	arterial	O
9	narrowing	O
10	,	O
11	is	O
12	the	O
13	major	O
14	condition	O
15	leading	O
16	to	O
17	isolated	O
18	atrial	O
19	infarction	O
20	.	O
1	12	O
2	-	O
3	O	O
4	-	O
5	Tetradecanoylphorbol	O
6	13	O
7	-	O
8	acetate	O
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	rapidly	O
14	and	O
15	potently	O
16	the	O
17	expression	O
18	of	O
19	mRNAs	O
20	coding	O
21	for	O
22	the	O
23	myogenic	O
24	regulators	O
25	CMD1	B
26	and	O
27	myogenin	B
28	.	O
1	These	O
2	introns	O
3	belong	O
4	to	O
5	the	O
6	class	O
7	of	O
8	nuclear	O
9	pre	O
10	-	O
11	mRNA	O
12	introns	O
13	and	O
14	contain	O
15	typical	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	consensus	O
22	sequences	O
23	,	O
24	as	O
25	well	O
26	as	O
27	unique	O
28	features	O
29	.	O
1	In	O
2	this	O
3	report	O
4	,	O
5	almost	O
6	6	O
7	kb	O
8	of	O
9	DNA	O
10	sequence	O
11	is	O
12	presented	O
13	,	O
14	including	O
15	1251	O
16	bp	O
17	5	O
18	'	O
19	to	O
20	the	O
21	gene	O
22	,	O
23	over	O
24	4	O
25	kb	O
26	of	O
27	exon	O
28	and	O
29	exon	O
30	-	O
31	intron	O
32	junctions	O
33	,	O
34	and	O
35	583	O
36	bp	O
37	3	O
38	'	O
39	to	O
40	the	O
41	gene	O
42	.	O
1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	detecting	O
7	targeted	O
8	events	O
9	at	O
10	the	O
11	mu	B
12	heavy	I
13	chain	I
14	gene	I
15	which	O
16	relies	O
17	on	O
18	co	O
19	-	O
20	conversion	O
21	(	O
22	or	O
23	co	O
24	-	O
25	exchange	O
26	)	O
27	of	O
28	a	O
29	point	O
30	mutation	O
31	with	O
32	a	O
33	selectable	O
34	marker	O
35	contained	O
36	on	O
37	a	O
38	replacement	O
39	vector	O
40	.	O
1	Two	O
2	potential	O
3	regulatory	O
4	sequences	O
5	for	O
6	DNA	O
7	binding	O
8	proteins	O
9	were	O
10	found	O
11	in	O
12	the	O
13	non	O
14	-	O
15	coding	O
16	5	O
17	'	O
18	region	O
19	:	O
20	a	O
21	HAP2	B
22	/	O
23	HAP3	B
24	consensus	O
25	recognition	O
26	sequence	O
27	at	O
28	nucleotide	O
29	-	O
30	154	O
31	and	O
32	a	O
33	BAF1	B
34	consensus	I
35	recognition	I
36	sequence	I
37	at	O
38	nucleotide	O
39	-	O
40	136	O
41	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	combined	O
7	treatment	O
8	with	O
9	a	O
10	thromboxane	B
11	synthetase	I
12	inhibitor	O
13	and	O
14	a	O
15	thromboxane	B
16	receptor	I
17	antagonist	O
18	provides	O
19	a	O
20	better	O
21	protection	O
22	against	O
23	digoxin	O
24	intoxication	O
25	than	O
26	with	O
27	either	O
28	agent	O
29	alone	O
30	.	O
1	Interspecific	O
2	backcross	O
3	analysis	O
4	using	O
5	progeny	O
6	derived	O
7	from	O
8	matings	O
9	of	O
10	(	O
11	C57BL	O
12	/	O
13	6J	O
14	x	O
15	Mus	O
16	spretus	O
17	)	O
18	F1	O
19	x	O
20	C57BL	O
21	/	O
22	6J	O
23	mice	O
24	indicates	O
25	that	O
26	the	O
27	thrombospondin	B
28	gene	I
29	is	O
30	tightly	O
31	linked	O
32	to	O
33	the	O
34	Fshb	B
35	,	O
36	Actcl	B
37	,	O
38	Ltk	B
39	,	O
40	and	O
41	B2M	B
42	loci	I
43	on	O
44	murine	O
45	chromosome	O
46	2	O
47	.	O
1	Using	O
2	an	O
3	image	O
4	-	O
5	processing	O
6	computer	O
7	,	O
8	regional	O
9	LV	O
10	time	O
11	-	O
12	density	O
13	curves	O
14	were	O
15	constructed	O
16	for	O
17	one	O
18	cardiac	O
19	cycle	O
20	.	O
1	In	O
2	a	O
3	second	O
4	patient	O
5	the	O
6	VT	O
7	became	O
8	nonsustained	O
9	.	O
1	However	O
2	,	O
3	it	O
4	was	O
5	synthesized	O
6	at	O
7	both	O
8	temperatures	O
9	after	O
10	addition	O
11	of	O
12	A23187	O
13	.	O
1	Relatively	O
2	little	O
3	is	O
4	known	O
5	regarding	O
6	the	O
7	role	O
8	of	O
9	5	B
10	-	I
11	HT2	I
12	receptor	I
13	activity	O
14	in	O
15	male	O
16	rat	O
17	sexual	O
18	behavior	O
19	.	O
1	Arsenic	O
2	contents	O
3	in	O
4	native	O
5	copper	O
1	In	O
2	ten	O
3	other	O
4	experiments	O
5	(	O
6	5	O
7	experimental	O
8	and	O
9	5	O
10	control	O
11	rats	O
12	)	O
13	99mTc	O
14	-	O
15	sulfur	O
16	colloid	O
17	was	O
18	injected	O
19	intravenously	O
20	.	O
1	These	O
2	results	O
3	were	O
4	superior	O
5	to	O
6	those	O
7	in	O
8	24	O
9	patients	O
10	with	O
11	conventional	O
12	end	O
13	-	O
14	to	O
15	-	O
16	end	O
17	sutures	O
18	on	O
19	clinical	O
20	testing	O
21	.	O
1	RU486	O
2	and	O
3	ONO	O
4	802	O
5	in	O
6	combination	O
7	have	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	effective	O
13	in	O
14	early	O
15	termination	O
16	of	O
17	pregnancy	O
18	.	O
1	Examples	O
2	are	O
3	using	O
4	more	O
5	subjects	O
6	or	O
7	an	O
8	improved	O
9	research	O
10	design	O
11	,	O
12	developing	O
13	consensus	O
14	statements	O
15	or	O
16	using	O
17	meta	O
18	-	O
19	analysis	O
20	.	O
1	A	O
2	two	O
3	phase	O
4	slug	O
5	flow	O
6	tubular	O
7	heat	O
8	exchanger	O
9	was	O
10	used	O
11	for	O
12	the	O
13	thermal	O
14	inactivation	O
15	of	O
16	Listeria	O
17	monocytogenes	O
18	in	O
19	natural	O
20	infected	O
21	milk	O
22	from	O
23	seven	O
24	cows	O
25	.	O
1	Different	O
2	doses	O
3	of	O
4	15	O
5	-	O
6	methyl	O
7	-	O
8	PGF2	O
9	alpha	O
10	(	O
11	0	O
12	.	O
13	125	O
14	-	O
15	10	O
16	mg	O
17	)	O
18	were	O
19	used	O
20	to	O
21	induce	O
22	luteolysis	O
23	and	O
24	oestrus	O
25	in	O
26	7	O
27	heifers	O
28	with	O
29	28	O
30	treatments	O
31	on	O
32	day	O
33	8	O
34	-	O
35	12	O
36	of	O
37	the	O
38	oestrous	O
39	cycle	O
40	.	O
1	After	O
2	treatment	O
3	with	O
4	tunicamycin	O
5	,	O
6	the	O
7	transfectants	O
8	secreted	O
9	unglycosylated	O
10	18	O
11	-	O
12	kDa	O
13	polypeptides	O
14	which	O
15	could	O
16	also	O
17	bind	O
18	IgE	B
19	.	O
1	The	O
2	abundance	O
3	of	O
4	transcripts	O
5	from	O
6	several	O
7	unrelated	O
8	genes	O
9	is	O
10	decreased	O
11	in	O
12	cdc68	B
13	-	I
14	1	I
15	mutant	I
16	cells	O
17	after	O
18	transfer	O
19	to	O
20	the	O
21	restrictive	O
22	temperature	O
23	,	O
24	while	O
25	at	O
26	least	O
27	one	O
28	transcript	O
29	,	O
30	from	O
31	the	O
32	HSP82	B
33	gene	I
34	,	O
35	persists	O
36	in	O
37	an	O
38	aberrant	O
39	fashion	O
40	.	O
1	The	O
2	RNA	O
3	genome	O
4	of	O
5	rabbit	O
6	hemorrhagic	O
7	disease	O
8	virus	O
9	(	O
10	RHDV	O
11	)	O
12	was	O
13	molecularly	O
14	cloned	O
15	.	O
1	Therefore	O
2	,	O
3	we	O
4	have	O
5	developed	O
6	a	O
7	system	O
8	to	O
9	study	O
10	nuclear	O
11	targeting	O
12	in	O
13	plants	O
14	and	O
15	have	O
16	established	O
17	that	O
18	the	O
19	nuclear	O
20	transport	O
21	machinery	O
22	is	O
23	similar	O
24	in	O
25	monocots	O
26	and	O
27	dicots	O
28	.	O
1	Chagas	O
2	'	O
3	disease	O
4	,	O
5	visceral	O
6	leishmaniasis	O
7	,	O
8	anti	B
9	-	I
10	nuclear	I
11	factor	I
12	,	O
13	schistosomiasis	O
14	,	O
15	rheumatoid	B
16	factor	I
17	and	O
18	normal	O
19	controls	O
20	.	O
1	Suggestive	O
2	evidence	O
3	was	O
4	obtained	O
5	that	O
6	cstA	B
7	is	O
8	involved	O
9	in	O
10	peptide	O
11	utilization	O
12	.	O
1	The	O
2	effects	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	were	O
8	further	O
9	dissected	O
10	by	O
11	showing	O
12	that	O
13	c	B
14	-	I
15	myc	I
16	can	O
17	inhibit	O
18	differentiation	O
19	independently	O
20	of	O
21	Id	B
22	,	O
23	a	O
24	negative	O
25	regulator	O
26	of	O
27	muscle	O
28	differentiation	O
29	.	O
1	The	O
2	rad9	B
3	.	I
4	192	I
5	DNA	I
6	repair	I
7	mutant	I
8	from	I
9	the	I
10	fission	I
11	yeast	I
12	,	I
13	Schizosaccharomyces	I
14	pombe	I
15	,	O
16	is	O
17	sensitive	O
18	to	O
19	both	O
20	UV	O
21	and	O
22	ionising	O
23	radiation	O
24	.	O
1	The	O
2	patient	O
3	was	O
4	a	O
5	78	O
6	-	O
7	year	O
8	-	O
9	old	O
10	male	O
11	in	O
12	whom	O
13	skin	O
14	lesions	O
15	preceded	O
16	the	O
17	diagnosis	O
18	of	O
19	myelofibrosis	O
20	.	O
1	Plate	O
2	luting	O
3	,	O
4	a	O
5	technique	O
6	that	O
7	uses	O
8	polymethylmethacrylate	O
9	(	O
10	PMMA	O
11	)	O
12	interposed	O
13	between	O
14	the	O
15	plate	O
16	and	O
17	the	O
18	bone	O
19	,	O
20	as	O
21	well	O
22	as	O
23	between	O
24	the	O
25	screw	O
26	heads	O
27	and	O
28	the	O
29	plate	O
30	,	O
31	to	O
32	improve	O
33	the	O
34	stability	O
35	of	O
36	internal	O
37	fixation	O
38	was	O
39	tested	O
40	in	O
41	vitro	O
42	using	O
43	20	O
44	paired	O
45	equine	O
46	third	O
47	metacarpal	O
48	bones	O
49	with	O
50	mid	O
51	-	O
52	diaphyseal	O
53	osteotomies	O
54	plated	O
55	with	O
56	six	O
57	-	O
58	hole	O
59	broad	O
60	ASIF	O
61	compression	O
62	plates	O
63	.	O
1	Young	O
2	CD	O
3	-	O
4	1	O
5	mice	O
6	,	O
7	4	O
8	days	O
9	old	O
10	,	O
11	exposed	O
12	to	O
13	0	O
14	.	O
15	1	O
16	%	O
17	nicotine	O
18	sulfate	O
19	on	O
20	gestational	O
21	days	O
22	6	O
23	-	O
24	20	O
25	were	O
26	compared	O
27	with	O
28	untreated	O
29	pups	O
30	of	O
31	the	O
32	same	O
33	age	O
34	to	O
35	determine	O
36	its	O
37	effect	O
38	on	O
39	the	O
40	development	O
41	of	O
42	mandibular	O
43	first	O
44	molars	O
45	.	O
1	Chlamydia	O
2	trachomatis	O
3	and	O
4	Chlamydia	O
5	psittaci	O
6	were	O
7	not	O
8	affected	O
9	by	O
10	methanol	O
11	fixation	O
12	.	O
1	Out	O
2	of	O
3	40	O
4	patients	O
5	,	O
6	who	O
7	initially	O
8	did	O
9	not	O
10	show	O
11	eye	O
12	complications	O
13	due	O
14	to	O
15	leprosy	O
16	,	O
17	37	O
18	patients	O
19	were	O
20	essentially	O
21	the	O
22	same	O
23	10	O
24	years	O
25	later	O
26	.	O
1	Thus	O
2	,	O
3	two	O
4	very	O
5	different	O
6	regulatory	O
7	elements	O
8	are	O
9	used	O
10	to	O
11	mediate	O
12	estrogen	O
13	induction	O
14	of	O
15	related	O
16	genes	O
17	in	O
18	chickens	O
19	and	O
20	amphibians	O
21	.	O
1	The	O
2	IE0	B
3	gene	I
4	product	O
5	also	O
6	transactivated	O
7	the	O
8	IE1	B
9	promoter	I
10	but	O
11	did	O
12	not	O
13	affect	O
14	expression	O
15	from	O
16	its	O
17	own	O
18	promoter	O
19	.	O
1	Increases	O
2	in	O
3	the	O
4	perfusate	O
5	PCO2	O
6	but	O
7	not	O
8	in	O
9	the	O
10	perfusate	O
11	H	O
12	+	O
13	were	O
14	highly	O
15	correlated	O
16	with	O
17	decreases	O
18	in	O
19	both	O
20	myocardial	O
21	contractility	O
22	and	O
23	oxygen	O
24	consumption	O
25	(	O
26	r2	O
27	=	O
28	.	O
29	88	O
30	).	O
1	Analysis	O
2	of	O
3	mRNA	O
4	expression	O
5	shows	O
6	that	O
7	AT	B
8	-	I
9	BP1	I
10	and	O
11	AT	B
12	-	I
13	BP2	I
14	are	O
15	expressed	O
16	in	O
17	all	O
18	the	O
19	tissues	O
20	examined	O
21	.	O
1	Sequence	O
2	requirements	O
3	for	O
4	premature	O
5	transcription	O
6	arrest	O
7	within	O
8	the	O
9	first	O
10	intron	O
11	of	O
12	the	O
13	mouse	B
14	c	I
15	-	I
16	fos	I
17	gene	I
18	.	O
1	Disruption	O
2	of	O
3	the	O
4	chromosomal	B
5	AAR1	I
6	gene	I
7	in	O
8	alpha	O
9	and	O
10	a	O
11	/	O
12	alpha	O
13	cells	O
14	conferred	O
15	the	O
16	nonmating	O
17	phenotype	O
18	,	O
19	and	O
20	the	O
21	a	O
22	/	O
23	alpha	O
24	diploids	O
25	could	O
26	not	O
27	sporulate	O
28	.	O
1	Lengthy	O
2	and	O
3	repeated	O
4	hemodialyses	O
5	were	O
6	required	O
7	to	O
8	lower	O
9	lithemia	O
10	to	O
11	nontoxic	O
12	ranges	O
13	.	O
1	Bronchial	O
2	mucosa	O
3	tattooing	O
4	in	O
5	persons	O
6	exposed	O
7	to	O
8	different	O
9	industrial	O
10	aerosols	O
11	did	O
12	not	O
13	depend	O
14	on	O
15	the	O
16	forms	O
17	of	O
18	PC	O
19	,	O
20	DB	O
21	and	O
22	the	O
23	diseases	O
24	'	O
25	stages	O
26	.	O
1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O
1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	ROSP	O
7	undergoes	O
8	a	O
9	number	O
10	of	O
11	fluctuations	O
12	in	O
13	the	O
14	negative	O
15	and	O
16	positive	O
17	directions	O
18	with	O
19	a	O
20	gradually	O
21	decreasing	O
22	amplitude	O
23	in	O
24	the	O
25	course	O
26	of	O
27	5	O
28	-	O
29	25	O
30	days	O
31	following	O
32	the	O
33	operation	O
34	,	O
35	after	O
36	which	O
37	relatively	O
38	stable	O
39	negative	O
40	values	O
41	of	O
42	the	O
43	ROSP	O
44	are	O
45	established	O
46	on	O
47	the	O
48	average	O
49	in	O
50	electrodes	O
51	implanted	O
52	to	O
53	the	O
54	level	O
55	of	O
56	the	O
57	dura	O
58	mater	O
59	,	O
60	and	O
61	positive	O
62	values	O
63	in	O
64	electrodes	O
65	implanted	O
66	to	O
67	the	O
68	level	O
69	of	O
70	the	O
71	pia	O
72	mater	O
73	.	O
1	In	O
2	group	O
3	III	O
4	,	O
5	patients	O
6	also	O
7	received	O
8	their	O
9	own	O
10	mediastinal	O
11	drainage	O
12	blood	O
13	,	O
14	shed	O
15	for	O
16	6	O
17	hours	O
18	after	O
19	operation	O
20	,	O
21	after	O
22	concentration	O
23	and	O
24	washing	O
25	in	O
26	a	O
27	MBRS	O
28	.	O
1	Both	O
2	groups	O
3	then	O
4	underwent	O
5	hypnotic	O
6	induction	O
7	,	O
8	and	O
9	completed	O
10	the	O
11	test	O
12	again	O
13	(	O
14	R2	O
15	).	O
1	Applications	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	analysis	O
7	to	O
8	the	O
9	auditory	O
10	P300	O
11	.	O
1	Recombinant	B
2	human	I
3	TFIID	I
4	supported	O
5	weak	O
6	basal	O
7	transcription	O
8	in	O
9	heat	O
10	-	O
11	treated	O
12	nuclear	O
13	extracts	O
14	whereas	O
15	a	O
16	partially	O
17	purified	O
18	TFIID	B
19	fraction	O
20	from	O
21	HeLa	O
22	cells	O
23	reconstituted	O
24	a	O
25	maximal	O
26	level	O
27	of	O
28	transcription	O
29	.	O
1	Only	O
2	after	O
3	a	O
4	pretreatment	O
5	aimed	O
6	at	O
7	increasing	O
8	its	O
9	oxide	O
10	surface	O
11	layer	O
12	was	O
13	titanium	O
14	powder	O
15	found	O
16	to	O
17	accelerate	O
18	the	O
19	precipitation	O
20	from	O
21	solutions	O
22	containing	O
23	2	O
24	mmol	O
25	/	O
26	L	O
27	CaCl2	O
28	,	O
29	2	O
30	mmol	O
31	/	O
32	L	O
33	KH2PO4	O
34	,	O
35	50	O
36	mmol	O
37	/	O
38	L	O
39	Hepes	O
40	,	O
41	pH	O
42	7	O
43	.	O
44	2	O
45	,	O
46	and	O
47	to	O
48	induce	O
49	precipitation	O
50	from	O
51	metastable	O
52	solutions	O
53	containing	O
54	1	O
55	.	O
56	2	O
57	mmol	O
58	/	O
59	L	O
60	CaCl2	O
61	,	O
62	1	O
63	.	O
64	2	O
65	mmol	O
66	/	O
67	L	O
68	KH2PO4	O
69	,	O
70	50	O
71	mmol	O
72	/	O
73	L	O
74	Hepes	O
75	,	O
76	pH	O
77	7	O
78	.	O
79	2	O
80	,	O
81	at	O
82	37	O
83	degrees	O
84	C	O
85	.	O
1	(	O
2	2	O
3	)	O
4	Diffusion	O
5	limitation	O
6	in	O
7	the	O
8	heterogeneous	O
9	model	O
10	sets	O
11	in	O
12	at	O
13	a	O
14	lower	O
15	O2	O
16	requirement	O
17	value	O
18	,	O
19	and	O
20	increases	O
21	more	O
22	gradually	O
23	with	O
24	increasing	O
25	O2	O
26	requirement	O
27	,	O
28	than	O
29	in	O
30	the	O
31	corresponding	O
32	homogeneous	O
33	models	O
34	with	O
35	the	O
36	same	O
37	average	O
38	cylinder	O
39	diameter	O
40	.	O
1	The	O
2	antihypertensive	O
3	effect	O
4	of	O
5	Estulic	O
6	has	O
7	been	O
8	examined	O
9	over	O
10	a	O
11	12	O
12	-	O
13	month	O
14	period	O
15	in	O
16	101	O
17	hypertensive	O
18	patients	O
19	.	O
1	Confocal	O
2	fluorescence	O
3	microscopy	O
4	in	O
5	modern	O
6	cell	O
7	biology	O
8	.	O
1	Adult	O
2	H	O
3	,	O
4	but	O
5	not	O
6	R	O
7	,	O
8	manifested	O
9	the	O
10	burrowing	O
11	preference	O
12	whenever	O
13	offered	O
14	the	O
15	opportunity	O
16	.	O
1	Four	O
2	putative	O
3	positive	O
4	cDNA	O
5	clones	O
6	were	O
7	isolated	O
8	,	O
9	and	O
10	the	O
11	largest	O
12	insert	O
13	(	O
14	pASB	B
15	-	I
16	1	I
17	)	O
18	was	O
19	sequenced	O
20	in	O
21	both	O
22	orientations	O
23	.	O
1	DNA	O
2	sequence	O
3	and	O
4	evolution	O
5	of	O
6	the	O
7	CPS	B
8	domain	I
9	of	O
10	the	O
11	Syrian	B
12	hamster	I
13	multifunctional	I
14	protein	I
15	CAD	I
16	.	O
1	A	O
2	high	O
3	-	O
4	frequency	O
5	restriction	O
6	fragment	O
7	length	O
8	polymorphism	O
9	was	O
10	evident	O
11	in	O
12	the	O
13	DNA	O
14	from	O
15	29	O
16	unrelated	O
17	individuals	O
18	using	O
19	the	O
20	enzyme	O
21	BglII	B
22	.	O
1	Although	O
2	heart	O
3	rate	O
4	and	O
5	diastolic	O
6	pressure	O
7	rose	O
8	in	O
9	some	O
10	degree	O
11	1	O
12	min	O
13	after	O
14	intubation	O
15	,	O
16	free	O
17	and	O
18	total	O
19	CA	O
20	concentrations	O
21	did	O
22	not	O
23	increase	O
24	during	O
25	study	O
26	period	O
27	.	O
1	Induction	O
2	requires	O
3	the	O
4	ACE1	B
5	gene	I
6	product	I
7	,	O
8	which	O
9	binds	O
10	to	O
11	specific	O
12	sites	O
13	in	O
14	the	O
15	promoter	O
16	region	O
17	of	O
18	the	O
19	CUP1	B
20	gene	I
21	.	O
1	Adenylosuccinate	B
2	synthetase	I
3	(	O
4	IMP	O
5	:	O
6	L	B
7	-	I
8	aspartate	I
9	ligase	I
10	(	O
11	GDP	O
12	),	O
13	EC	B
14	6	I
15	.	I
16	3	I
17	.	I
18	4	I
19	.	I
20	4	I
21	)	O
22	plays	O
23	an	O
24	important	O
25	role	O
26	in	O
27	purine	O
28	biosynthesis	O
29	catalyzing	O
30	the	O
31	GTP	O
32	-	O
33	dependent	O
34	conversion	O
35	of	O
36	IMP	O
37	to	O
38	AMP	O
39	.	O
1	DNA	O
2	-	O
3	protein	O
4	UV	O
5	cross	O
6	-	O
7	linking	O
8	studies	O
9	indicated	O
10	that	O
11	UHF	B
12	-	I
13	1	I
14	has	O
15	an	O
16	electrophoretic	O
17	mobility	O
18	on	O
19	sodium	O
20	dodecyl	O
21	sulfate	O
22	-	O
23	acrylamide	O
24	gels	O
25	of	O
26	approximately	O
27	85	O
28	kDa	O
29	and	O
30	suggested	O
31	that	O
32	additional	O
33	proteins	O
34	,	O
35	specific	O
36	to	O
37	each	O
38	promoter	O
39	,	O
40	bind	O
41	to	O
42	each	O
43	site	O
44	.	O
1	The	O
2	results	O
3	strengthen	O
4	the	O
5	conclusion	O
6	that	O
7	predominantly	O
8	dynamic	O
9	activity	O
10	increases	O
11	the	O
12	G4	B
13	content	O
14	of	O
15	mature	O
16	innervated	O
17	fast	O
18	muscles	O
19	.	O
1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	Pseudomonas	B
7	putida	I
8	PpG7	I
9	salicylate	I
10	hydroxylase	I
11	gene	I
12	(	O
13	nahG	B
14	)	O
15	and	O
16	its	O
17	3	O
18	'-	O
19	flanking	O
20	region	O
21	.	O
1	The	O
2	first	O
3	follow	O
4	-	O
5	up	O
6	was	O
7	at	O
8	a	O
9	nearly	O
10	constant	O
11	interval	O
12	of	O
13	5	O
14	.	O
15	1	O
16	years	O
17	in	O
18	Caerphilly	O
19	and	O
20	3	O
21	.	O
22	2	O
23	years	O
24	in	O
25	Speedwell	O
26	;	O
27	251	O
28	major	O
29	IHD	O
30	events	O
31	had	O
32	occurred	O
33	.	O
1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	report	O
7	a	O
8	detailed	O
9	study	O
10	of	O
11	the	O
12	structure	O
13	and	O
14	the	O
15	functional	O
16	role	O
17	of	O
18	the	O
19	MalT	B
20	binding	I
21	sites	I
22	located	O
23	in	O
24	the	O
25	adjacent	O
26	and	O
27	divergent	O
28	pulAp	B
29	and	O
30	pulCp	B
31	promoters	I
32	.	O
1	After	O
2	6	O
3	months	O
4	,	O
5	definite	O
6	improvement	O
7	in	O
8	strength	O
9	occurred	O
10	in	O
11	4	O
12	of	O
13	7	O
14	carnitine	O
15	-	O
16	treated	O
17	patients	O
18	and	O
19	in	O
20	none	O
21	of	O
22	7	O
23	controls	O
24	.	O
1	A	O
2	dose	O
3	of	O
4	3	O
5	and	O
6	6	O
7	micrograms	O
8	/	O
9	kg	O
10	/	O
11	day	O
12	GM	B
13	-	I
14	CSF	I
15	reduces	O
16	the	O
17	severity	O
18	of	O
19	neutropenia	O
20	and	O
21	thrombocytopenia	O
22	after	O
23	carboplatin	O
24	-	O
25	cyclophosphamide	O
26	chemotherapy	O
27	,	O
28	which	O
29	may	O
30	lead	O
31	to	O
32	more	O
33	effective	O
34	chemotherapy	O
35	for	O
36	ovarian	O
37	cancer	O
38	in	O
39	the	O
40	future	O
41	.	O
1	The	O
2	C4BP	B
3	alpha	I
4	gene	I
5	is	O
6	organized	O
7	as	O
8	follows	O
9	:	O
10	the	O
11	first	O
12	exon	O
13	codes	O
14	for	O
15	the	O
16	first	O
17	198	O
18	nucleotides	O
19	of	O
20	the	O
21	5	O
22	'	O
23	UTR	O
24	.	O
1	Using	O
2	an	O
3	ELISA	O
4	,	O
5	we	O
6	found	O
7	that	O
8	surfactant	B
9	protein	I
10	A	I
11	(	O
12	SP	B
13	-	I
14	A	I
15	)	O
16	was	O
17	markedly	O
18	elevated	O
19	in	O
20	the	O
21	pneumonia	O
22	patients	O
23	.	O
1	We	O
2	purified	O
3	a	O
4	Ca2	B
5	+/	I
6	calmodulin	I
7	(	I
8	CaM	I
9	)-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	CaM	B
15	kinase	I
16	)	O
17	from	O
18	the	O
19	yeast	O
20	Saccharomyces	O
21	cerevisiae	O
22	with	O
23	properties	O
24	similar	O
25	to	O
26	mammalian	B
27	type	I
28	II	I
29	CaM	I
30	kinases	I
31	.	O
1	Genomic	O
2	clones	O
3	encompassing	O
4	the	O
5	human	B
6	ETS1	I
7	gene	I
8	were	O
9	isolated	O
10	and	O
11	utilized	O
12	to	O
13	define	O
14	its	O
15	molecular	O
16	organization	O
17	.	O
1	Most	O
2	of	O
3	the	O
4	expressed	O
5	human	B
6	E3	I
7	polypeptides	I
8	(	O
9	five	O
10	bands	O
11	)	O
12	were	O
13	found	O
14	in	O
15	the	O
16	insoluble	O
17	pellet	O
18	while	O
19	primarily	O
20	full	B
21	-	I
22	length	I
23	mature	I
24	E3	I
25	was	O
26	found	O
27	in	O
28	the	O
29	soluble	O
30	fraction	O
31	.	O
1	The	O
2	alpha	B
3	4	I
4	gene	I
5	5	O
6	'	O
7	flanking	O
8	region	O
9	acted	O
10	as	O
11	a	O
12	promoter	O
13	in	O
14	transfection	O
15	assays	O
16	.	O
1	To	O
2	facilitate	O
3	the	O
4	availability	O
5	of	O
6	important	O
7	new	O
8	therapeutic	O
9	agents	O
10	,	O
11	the	O
12	Food	O
13	and	O
14	Drug	O
15	Administration	O
16	(	O
17	FDA	O
18	)	O
19	in	O
20	the	O
21	mid	O
22	-	O
23	1970s	O
24	began	O
25	assigning	O
26	therapeutic	O
27	ratings	O
28	to	O
29	investigational	O
30	new	O
31	drugs	O
32	and	O
33	holding	O
34	end	O
35	-	O
36	of	O
37	-	O
38	phase	O
39	II	O
40	conferences	O
41	with	O
42	drug	O
43	sponsors	O
44	.	O
1	3	O
2	.	O
1	Furthermore	O
2	,	O
3	the	O
4	DNA	B
5	polymerase	I
6	II	I
7	complex	I
8	was	O
9	difficult	O
10	to	O
11	obtain	O
12	from	O
13	dpb2	B
14	-	I
15	1	I
16	mutant	O
17	cells	O
18	,	O
19	suggesting	O
20	that	O
21	a	O
22	stable	O
23	DNA	B
24	polymerase	I
25	II	I
26	complex	I
27	requires	O
28	DPB2	B
29	and	O
30	is	O
31	essential	O
32	for	O
33	chromosomal	O
34	replication	O
35	.	O
1	To	O
2	determine	O
3	whether	O
4	mononuclear	O
5	cell	O
6	secretory	O
7	products	O
8	contribute	O
9	to	O
10	the	O
11	changes	O
12	in	O
13	bone	O
14	turnover	O
15	that	O
16	characterize	O
17	the	O
18	development	O
19	of	O
20	postmenopausal	O
21	osteoporosis	O
22	,	O
23	we	O
24	evaluated	O
25	the	O
26	effects	O
27	of	O
28	oophorectomy	O
29	and	O
30	subsequent	O
31	estrogen	O
32	replacement	O
33	on	O
34	the	O
35	spontaneous	O
36	secretion	O
37	of	O
38	interleukin	B
39	1	I
40	(	O
41	IL	B
42	-	I
43	1	I
44	)	O
45	and	O
46	tumor	B
47	necrosis	I
48	factor	I
49	alpha	I
50	(	O
51	TNF	B
52	-	I
53	alpha	I
54	)	O
55	and	O
56	on	O
57	the	O
58	phytohemagglutinin	B
59	A	I
60	-	O
61	induced	O
62	secretion	O
63	of	O
64	granulocyte	B
65	-	I
66	macrophage	I
67	colony	I
68	-	I
69	stimulating	I
70	factor	I
71	(	O
72	GM	B
73	-	I
74	CSF	I
75	)	O
76	from	O
77	peripheral	O
78	blood	O
79	mononuclear	O
80	cells	O
81	.	O
1	Hemorrhagic	O
2	shock	O
3	and	O
4	bacterial	O
5	translocation	O
6	in	O
7	a	O
8	swine	O
9	model	O
10	.	O
1	Very	O
2	small	O
3	deletions	O
4	within	O
5	the	O
6	conserved	O
7	region	O
8	completely	O
9	abolished	O
10	transforming	O
11	activity	O
12	of	O
13	dbl	B
14	,	O
15	while	O
16	extensive	O
17	deletion	O
18	outside	O
19	of	O
20	this	O
21	region	O
22	had	O
23	no	O
24	effect	O
25	.	O
1	The	O
2	stimulus	O
3	threshold	O
4	for	O
5	EER	O
6	showed	O
7	a	O
8	less	O
9	individual	O
10	variation	O
11	than	O
12	amplitude	O
13	.	O
1	An	O
2	RME1	B
3	-	O
4	independent	O
5	pathway	O
6	for	O
7	sporulation	O
8	control	O
9	in	O
10	Saccharomyces	O
11	cerevisiae	O
12	acts	O
13	through	O
14	IME1	B
15	transcript	I
16	accumulation	O
17	.	O
1	In	O
2	all	O
3	cases	O
4	,	O
5	high	O
6	-	O
7	level	O
8	expression	O
9	of	O
10	the	O
11	truncated	B
12	avian	I
13	integrins	I
14	was	O
15	obtained	O
16	.	O
1	In	O
2	adulthood	O
3	these	O
4	rats	O
5	were	O
6	hyperactive	O
7	and	O
8	learned	O
9	the	O
10	active	O
11	avoidance	O
12	response	O
13	later	O
14	than	O
15	the	O
16	controls	O
17	.	O
1	The	O
2	encoded	O
3	sequence	O
4	revealed	O
5	a	O
6	typical	O
7	signal	O
8	peptide	O
9	,	O
10	a	O
11	predominantly	O
12	hydrophilic	O
13	707	O
14	amino	O
15	acid	O
16	residue	O
17	domain	O
18	with	O
19	8	O
20	N	O
21	-	O
22	glycosylation	O
23	sites	O
24	,	O
25	a	O
26	transmembrane	O
27	domain	O
28	,	O
29	and	O
30	a	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	of	O
36	52	O
37	amino	O
38	acids	O
39	.	O
1	A	O
2	new	O
3	semi	O
4	-	O
5	automatic	O
6	method	O
7	for	O
8	quantifying	O
9	regional	O
10	cerebral	O
11	uptake	O
12	of	O
13	99m	O
14	technetium	O
15	-	O
16	hexamethylpropylene	O
17	amine	O
18	oxime	O
19	(	O
20	99mTc	O
21	-	O
22	HMPAO	O
23	)	O
24	was	O
25	used	O
26	to	O
27	assess	O
28	single	O
29	photon	O
30	emission	O
31	tomograms	O
32	from	O
33	5	O
34	normal	O
35	subjects	O
36	,	O
37	14	O
38	patients	O
39	with	O
40	Alzheimer	O
41	'	O
42	s	O
43	disease	O
44	,	O
45	14	O
46	patients	O
47	with	O
48	dementia	O
49	of	O
50	frontal	O
51	lobe	O
52	type	O
53	and	O
54	4	O
55	patients	O
56	with	O
57	dementia	O
58	with	O
59	motor	O
60	neurone	O
61	disease	O
62	.	O
1	Effect	O
2	of	O
3	separate	O
4	and	O
5	combined	O
6	effects	O
7	of	O
8	plutonium	O
9	-	O
10	239	O
11	,	O
12	hexachlorobutadiene	O
13	and	O
14	tributyl	O
15	phosphate	O
16	on	O
17	the	O
18	thymus	O
19	gland	O
20	of	O
21	rats	O
1	Data	O
2	collection	O
3	was	O
4	made	O
5	with	O
6	a	O
7	query	O
8	language	O
9	,	O
10	and	O
11	data	O
12	analysis	O
13	performed	O
14	with	O
15	an	O
16	interactive	O
17	knowledge	O
18	-	O
19	based	O
20	statistical	O
21	tool	O
22	,	O
23	MAXITAB	O
24	,	O
25	employing	O
26	a	O
27	multivariate	O
28	tabular	O
29	analysis	O
30	technique	O
31	.	O
1	Diuresis	O
2	was	O
3	induced	O
4	by	O
5	scheduled	O
6	drinking	O
7	of	O
8	tea	O
9	(	O
10	150	O
11	ml	O
12	/	O
13	h	O
14	).	O
1	The	O
2	5	O
3	'	O
4	regions	O
5	of	O
6	these	O
7	two	O
8	soybean	B
9	actin	I
10	genes	I
11	contain	O
12	many	O
13	unusual	O
14	features	O
15	including	O
16	(	O
17	CT	O
18	)	O
19	repeats	O
20	and	O
21	long	O
22	stretches	O
23	of	O
24	pyrimidine	O
25	-	O
26	rich	O
27	DNA	O
28	.	O
1	All	O
2	8	O
3	(	O
4	100	O
5	%)	O
6	patients	O
7	with	O
8	fulminant	O
9	hepatic	O
10	failure	O
11	who	O
12	received	O
13	grafts	O
14	survived	O
15	,	O
16	including	O
17	3	O
18	who	O
19	received	O
20	ABO	O
21	-	O
22	incompatible	O
23	grafts	O
24	,	O
25	though	O
26	2	O
27	of	O
28	these	O
29	subsequently	O
30	required	O
31	retransplantation	O
32	.	O
1	However	O
2	,	O
3	overexpression	O
4	of	O
5	both	O
6	the	O
7	STE4	B
8	and	O
9	STE18	B
10	proteins	I
11	did	O
12	not	O
13	generate	O
14	a	O
15	stronger	O
16	pheromone	O
17	response	O
18	than	O
19	overexpression	O
20	of	O
21	STE4	B
22	in	O
23	the	O
24	presence	O
25	of	O
26	wild	O
27	-	O
28	type	O
29	levels	O
30	of	O
31	STE18	B
32	.	O
1	This	O
2	Mr	O
3	is	O
4	similar	O
5	to	O
6	those	O
7	of	O
8	the	O
9	purified	B
10	smg	I
11	p25A	I
12	GDI	I
13	estimated	O
14	by	O
15	sodium	O
16	dodecyl	O
17	sulfate	O
18	-	O
19	polyacrylamide	O
20	gel	O
21	electrophoresis	O
22	and	O
23	sucrose	O
24	density	O
25	gradient	O
26	ultracentrifugation	O
27	,	O
28	which	O
29	are	O
30	about	O
31	54	O
32	,	O
33	000	O
34	and	O
35	65	O
36	,	O
37	000	O
38	,	O
39	respectively	O
40	.	O
1	Yeast	O
2	mutants	O
3	assigned	O
4	to	O
5	the	O
6	pet	B
7	complementation	O
8	group	O
9	G104	O
10	were	O
11	found	O
12	to	O
13	lack	O
14	alpha	B
15	-	I
16	ketoglutarate	I
17	dehydrogenase	I
18	activity	O
19	as	O
20	a	O
21	result	O
22	of	O
23	mutations	O
24	in	O
25	the	O
26	dihydrolipoyl	B
27	transsuccinylase	I
28	(	O
29	KE2	B
30	)	O
31	component	O
32	of	O
33	the	O
34	complex	O
35	.	O
1	We	O
2	also	O
3	discovered	O
4	a	O
5	V	B
6	lambda	I
7	pseudogene	I
8	,	O
9	called	O
10	psi	B
11	V	I
12	lambda	I
13	1	I
14	,	O
15	3	O
16	kb	O
17	upstream	O
18	of	O
19	the	O
20	U266	B
21	lambda	I
22	gene	I
23	.	O
1	Managing	O
2	dysphagia	O
3	in	O
4	a	O
5	chronic	O
6	care	O
7	setting	O
8	:	O
9	an	O
10	introduction	O
11	.	O
1	Furthermore	O
2	,	O
3	expression	O
4	of	O
5	the	O
6	promoter	O
7	in	O
8	embryonic	O
9	Drosophila	O
10	melanogaster	O
11	cells	O
12	that	O
13	lack	O
14	MyoD1	B
15	and	O
16	Sp1	B
17	is	O
18	strictly	O
19	dependent	O
20	on	O
21	all	O
22	three	O
23	sites	O
24	remaining	O
25	intact	O
26	and	O
27	on	O
28	the	O
29	presence	O
30	of	O
31	exogenously	O
32	supplied	O
33	Sp1	B
34	and	O
35	MyoD1	B
36	.	O
1	Additionally	O
2	,	O
3	although	O
4	c	B
5	-	I
6	fos	I
7	and	O
8	egr	B
9	-	I
10	1	I
11	mRNAs	I
12	are	O
13	expressed	O
14	at	O
15	elevated	O
16	levels	O
17	in	O
18	stimulated	O
19	liver	O
20	cells	O
21	,	O
22	fos	B
23	-	I
24	B	I
25	,	O
26	fra	B
27	-	I
28	1	I
29	,	O
30	and	O
31	egr	B
32	-	I
33	2	I
34	are	O
35	not	O
36	,	O
37	which	O
38	suggests	O
39	that	O
40	factors	O
41	in	O
42	addition	O
43	to	O
44	the	O
45	serum	B
46	response	I
47	factor	I
48	participate	O
49	in	O
50	the	O
51	regulation	O
52	of	O
53	immediate	B
54	-	I
55	early	I
56	gene	I
57	induction	O
58	.	O
1	Of	O
2	848	O
3	patients	O
4	,	O
5	819	O
6	cases	O
7	with	O
8	complete	O
9	description	O
10	of	O
11	patient	O
12	'	O
13	s	O
14	background	O
15	were	O
16	evaluable	O
17	:	O
18	Group	O
19	A	O
20	(	O
21	surgery	O
22	+	O
23	MMC	O
24	+	O
25	5	O
26	-	O
27	FU	O
28	:	O
29	chemotherapy	O
30	)	O
31	253	O
32	cases	O
33	,	O
34	group	O
35	B	O
36	(	O
37	surgery	O
38	+	O
39	MMC	O
40	+	O
41	5	O
42	-	O
43	FU	O
44	+	O
45	OK	O
46	-	O
47	432	O
48	or	O
49	PSK	O
50	:	O
51	immunochemotherapy	O
52	)	O
53	282	O
54	and	O
55	group	O
56	C	O
57	(	O
58	surgery	O
59	alone	O
60	)	O
61	284	O
62	.	O
1	A	O
2	bacteriological	O
3	relapse	O
4	requiring	O
5	treatment	O
6	occurred	O
7	by	O
8	5	O
9	years	O
10	in	O
11	16	O
12	.	O
13	8	O
14	%	O
15	of	O
16	113	O
17	R3	O
18	,	O
19	5	O
20	.	O
21	2	O
22	%	O
23	of	O
24	97	O
25	R5	O
26	,	O
27	and	O
28	20	O
29	.	O
30	0	O
31	%	O
32	of	O
33	115	O
34	Z5	O
35	patients	O
36	with	O
37	organisms	O
38	sensitive	O
39	to	O
40	streptomycin	O
41	and	O
42	isoniazid	O
43	initially	O
44	.	O
1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	has	O
7	the	O
8	greatest	O
9	homology	O
10	(	O
11	61	O
12	%)	O
13	to	O
14	the	O
15	green	B
16	alga	I
17	Scenedemus	I
18	obliquus	I
19	plastocyanin	I
20	.	O
1	The	O
2	experimental	O
3	group	O
4	consisted	O
5	of	O
6	61	O
7	examinees	O
8	class	O
9	II	O
10	/	O
11	2	O
12	orthodontic	O
13	anomalies	O
14	.	O
1	In	O
2	that	O
3	case	O
4	,	O
5	the	O
6	ratio	O
7	of	O
8	brush	O
9	abrasion	O
10	was	O
11	0	O
12	.	O
13	268	O
14	,	O
15	compressive	O
16	and	O
17	transverse	O
18	strength	O
19	,	O
20	124	O
21	.	O
22	3	O
23	and	O
24	86	O
25	.	O
26	3	O
27	MPa	O
28	respectively	O
29	,	O
30	hardness	O
31	,	O
32	43	O
33	.	O
34	2	O
35	Hk	O
36	,	O
37	water	O
38	absorption	O
39	14	O
40	.	O
41	2	O
42	micrograms	O
43	/	O
44	mm3	O
45	and	O
46	thermal	O
47	expansion	O
48	coefficient	O
49	,	O
50	47	O
51	.	O
52	4	O
53	x	O
54	10	O
55	(-	O
56	6	O
57	)/	O
58	degrees	O
59	C	O
60	.	O
1	Impaction	O
2	of	O
3	gastrostomy	O
4	tube	O
5	in	O
6	the	O
7	abdominal	O
8	wall	O
9	.	O
1	TCR	B
2	alpha	I
3	and	I
4	beta	I
5	gene	I
6	expression	O
7	may	O
8	be	O
9	regulated	O
10	by	O
11	a	O
12	common	O
13	set	O
14	of	O
15	T	B
16	-	I
17	cell	I
18	nuclear	I
19	proteins	I
20	in	O
21	that	O
22	the	O
23	T	B
24	beta	I
25	2	I
26	element	I
27	binding	O
28	a	O
29	set	O
30	of	O
31	cyclic	B
32	AMP	I
33	response	I
34	element	I
35	-	I
36	binding	I
37	proteins	I
38	that	O
39	are	O
40	also	O
41	bound	O
42	by	O
43	the	O
44	T	B
45	alpha	I
46	1	I
47	element	I
48	of	O
49	the	O
50	human	O
51	TCR	B
52	alpha	I
53	enhancer	O
54	and	O
55	the	O
56	decamer	O
57	element	O
58	present	O
59	in	O
60	a	O
61	large	O
62	number	O
63	of	O
64	human	O
65	and	O
66	murine	O
67	TCR	B
68	beta	I
69	promoters	O
70	.	O
1	The	O
2	deleted	O
3	nucleotide	O
4	sequence	O
5	corresponded	O
6	to	O
7	sequences	O
8	that	O
9	,	O
10	by	O
11	analogy	O
12	to	O
13	the	O
14	organization	O
15	of	O
16	the	O
17	type	B
18	I	I
19	collagen	I
20	genes	I
21	,	O
22	should	O
23	be	O
24	precisely	O
25	encoded	O
26	by	O
27	exon	O
28	41	O
29	of	O
30	the	O
31	COL3A1	B
32	gene	I
33	.	O
1	Fluid	O
2	(	O
3	AVLF	O
4	)	O
5	31	O
6	.	O
1	Critical	O
2	study	O
1	Whether	O
2	or	O
3	not	O
4	there	O
5	are	O
6	sequences	O
7	conferring	O
8	cAMP	O
9	responsiveness	O
10	which	O
11	are	O
12	common	O
13	both	O
14	to	O
15	P	B
16	-	I
17	450scc	I
18	and	O
19	the	O
20	other	O
21	steroidogenic	O
22	P	B
23	-	I
24	450	I
25	genes	I
26	remains	O
27	to	O
28	be	O
29	established	O
30	.	O
1	It	O
2	is	O
3	the	O
4	human	O
5	homolog	O
6	of	O
7	the	O
8	mouse	B
9	Mx	I
10	protein	I
11	involved	O
12	in	O
13	resistance	O
14	to	O
15	influenza	O
16	virus	O
17	.	O
1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	destrin	B
8	is	O
9	165	O
10	residues	O
11	long	O
12	and	O
13	is	O
14	very	O
15	similar	O
16	(	O
17	71	O
18	%	O
19	identical	O
20	)	O
21	to	O
22	that	O
23	of	O
24	cofilin	B
25	,	O
26	a	O
27	widely	O
28	distributed	O
29	,	O
30	pH	O
31	-	O
32	sensitive	O
33	actin	B
34	-	O
35	modulating	O
36	protein	O
37	.	O
1	We	O
2	have	O
3	determined	O
4	the	O
5	nucleotide	O
6	(	O
7	nt	O
8	)	O
9	sequence	O
10	of	O
11	the	O
12	7	B
13	.	I
14	5	I
15	-	I
16	kb	I
17	COR	I
18	segment	I
19	that	O
20	encompasses	O
21	a	O
22	cluster	O
23	of	O
24	six	O
25	genes	O
26	(	O
27	CYC1	B
28	,	O
29	UTR1	B
30	,	O
31	UTR3	B
32	,	O
33	OSM1	B
34	,	O
35	tRNA	B
36	(	I
37	Gly	I
38	)	I
39	and	O
40	RAD7	B
41	)	O
42	located	O
43	on	O
44	chromosome	O
45	X	O
46	of	O
47	the	O
48	yeast	O
49	Saccharomyces	O
50	cerevisiae	O
51	.	O
1	No	O
2	recombination	O
3	signal	O
4	sequences	O
5	have	O
6	been	O
7	found	O
8	contiguous	O
9	to	O
10	the	O
11	recombination	O
12	point	O
13	.	O
1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	the	O
7	deduced	O
8	amino	O
9	acid	O
10	sequence	O
11	of	O
12	the	O
13	3T3	O
14	-	O
15	L1	O
16	adipocyte	B
17	insulin	I
18	receptor	I
19	of	O
20	the	O
21	mouse	O
22	was	O
23	determined	O
24	.	O
1	The	O
2	cDNA	O
3	sequence	O
4	has	O
5	an	O
6	813	O
7	-	O
8	bp	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	whose	O
16	predicted	O
17	amino	O
18	acid	O
19	sequence	O
20	is	O
21	97	O
22	.	O
23	6	O
24	%	O
25	identical	O
26	to	O
27	the	O
28	272	O
29	carboxy	O
30	-	O
31	terminal	O
32	amino	O
33	acids	O
34	of	O
35	the	O
36	human	B
37	ets	I
38	-	I
39	1	I
40	protein	I
41	.	O
1	The	O
2	protein	O
3	product	O
4	of	O
5	orfD	B
6	,	O
7	which	O
8	is	O
9	probably	O
10	a	O
11	new	O
12	tra	B
13	gene	I
14	(	O
15	named	O
16	traX	B
17	),	O
18	contains	O
19	65	O
20	%	O
21	hydrophobic	O
22	amino	O
23	acids	O
24	,	O
25	especially	O
26	rich	O
27	in	O
28	alanine	O
29	and	O
30	leucine	O
31	.	O
1	The	O
2	diagnosis	O
3	of	O
4	miliary	O
5	tuberculosis	O
6	should	O
7	be	O
8	systematically	O
9	considered	O
10	in	O
11	ARDS	O
12	of	O
13	unknown	O
14	origin	O
15	.	O
1	The	O
2	26S	B
3	rRNA	I
4	binding	I
5	ribosomal	I
6	protein	I
7	equivalent	O
8	to	O
9	bacterial	B
10	protein	I
11	L11	I
12	is	O
13	encoded	O
14	by	O
15	unspliced	O
16	duplicated	O
17	genes	O
18	in	O
19	Saccharomyces	O
20	cerevisiae	O
21	.	O
1	Significant	O
2	correlations	O
3	were	O
4	obtained	O
5	between	O
6	changes	O
7	in	O
8	SSEP	O
9	in	O
10	response	O
11	to	O
12	AS	O
13	and	O
14	the	O
15	presence	O
16	of	O
17	not	O
18	deep	O
19	residual	O
20	-	O
21	organic	O
22	disturbances	O
23	,	O
24	so	O
25	-	O
26	called	O
27	""""	O
28	ground	O
29	""""	O
30	in	O
31	psychogenic	O
32	disorders	O
33	.	O
1	The	O
2	E6	B
3	/	O
4	E7	B
5	promoter	O
6	of	O
7	all	O
8	genital	O
9	human	O
10	papillomaviruses	O
11	is	O
12	responsible	O
13	for	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	transforming	O
19	genes	O
20	.	O
1	The	O
2	characterized	O
3	Y	B
4	'	I
5	repeated	I
6	sequence	I
7	families	I
8	provide	O
9	an	O
10	experimental	O
11	system	O
12	in	O
13	which	O
14	repeated	O
15	sequence	O
16	interactions	O
17	and	O
18	subsequent	O
19	evolution	O
20	can	O
21	be	O
22	studied	O
23	.	O
1	The	O
2	electrically	O
3	induced	O
4	motile	O
5	responses	O
6	were	O
7	not	O
8	suppressed	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	dinitrophenol	O
14	or	O
15	cytochalasin	O
16	B	O
17	.	O
1	This	O
2	emancipation	O
3	of	O
4	the	O
5	ability	O
6	to	O
7	copulate	O
8	from	O
9	hormonal	O
10	influence	O
11	makes	O
12	female	O
13	sexual	O
14	motivation	O
15	the	O
16	primary	O
17	regulator	O
18	of	O
19	mating	O
20	in	O
21	primates	O
22	.	O
1	No	O
2	therapy	O
3	exists	O
4	for	O
5	halting	O
6	the	O
7	progression	O
8	of	O
9	the	O
10	disease	O
11	with	O
12	the	O
13	possible	O
14	exception	O
15	of	O
16	laser	O
17	photocoagulation	O
18	treatment	O
19	used	O
20	to	O
21	ablate	O
22	subretinal	O
23	neovascular	O
24	membranes	O
25	in	O
26	an	O
27	attempt	O
28	to	O
29	avoid	O
30	complications	O
31	of	O
32	subretinal	O
33	hemorrhages	O
34	.	O
1	Yeast	B
2	Gal11	I
3	protein	I
4	mediates	O
5	the	O
6	transcriptional	O
7	activation	O
8	signal	O
9	of	O
10	two	O
11	different	O
12	transacting	O
13	factors	O
14	,	O
15	Gal4	B
16	and	O
17	general	B
18	regulatory	I
19	factor	I
20	I	I
21	/	O
22	repressor	B
23	/	I
24	activator	I
25	site	I
26	binding	I
27	protein	I
28	1	I
29	/	I
30	translation	I
31	upstream	I
32	factor	I
33	.	O
1	Among	O
2	known	O
3	flea	O
4	larvae	O
5	,	O
6	the	O
7	genus	O
8	Anomiopsyllus	O
9	(	O
10	Anomiopsyllinae	O
11	,	O
12	Anomiopsyllini	O
13	)	O
14	is	O
15	as	O
16	distinctive	O
17	in	O
18	larval	O
19	form	O
20	as	O
21	are	O
22	the	O
23	adults	O
24	.	O
1	Clinical	O
2	nutrition	O
3	of	O
4	adult	O
5	horses	O
6	.	O
1	The	O
2	3	O
3	'	O
4	region	O
5	,	O
6	GA2	B
7	,	O
8	is	O
9	necessary	O
10	for	O
11	maximal	O
12	expression	O
13	.	O
1	The	O
2	efficacy	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	novel	O
8	percutaneous	O
9	anaesthetic	O
10	preparation	O
11	based	O
12	on	O
13	amethocaine	O
14	has	O
15	been	O
16	investigated	O
17	in	O
18	the	O
19	paediatric	O
20	clinical	O
21	environment	O
22	.	O
1	The	O
2	urinary	O
3	protein	O
4	,	O
5	serum	O
6	albumin	B
7	,	O
8	BUN	O
9	and	O
10	SCr	O
11	all	O
12	had	O
13	very	O
14	significant	O
15	improvement	O
16	.	O
1	Within	O
2	this	O
3	sequence	O
4	the	O
5	MSAS	B
6	gene	I
7	was	O
8	identified	O
9	as	O
10	a	O
11	5322	O
12	-	O
13	bp	O
14	-	O
15	long	O
16	open	O
17	reading	O
18	frame	O
19	coding	O
20	for	O
21	a	O
22	protein	O
23	of	O
24	1774	O
25	amino	O
26	acids	O
27	and	O
28	190	O
29	,	O
30	731	O
31	Da	O
32	molecular	O
33	mass	O
34	.	O
1	This	O
2	last	O
3	includes	O
4	tissue	O
5	O2	O
6	transfer	O
7	(	O
8	Ft	O
9	')	O
10	and	O
11	mitochondrial	O
12	O2	O
13	utilization	O
14	(	O
15	Fm	O
16	').	O
1	Primer	O
2	extension	O
3	analysis	O
4	and	O
5	RNA	O
6	sequencing	O
7	demonstrates	O
8	that	O
9	the	O
10	transcription	O
11	start	O
12	point	O
13	of	O
14	rat	B
15	ODC	I
16	mRNA	I
17	is	O
18	located	O
19	303	O
20	nt	O
21	upstream	O
22	from	O
23	the	O
24	A	O
25	residue	O
26	in	O
27	the	O
28	start	O
29	codon	O
30	.	O
1	For	O
2	85Sr	O
3	,	O
4	larger	O
5	-	O
6	than	O
7	-	O
8	expected	O
9	distribution	O
10	coefficients	O
11	were	O
12	obtained	O
13	in	O
14	the	O
15	desorption	O
16	experiments	O
17	,	O
18	an	O
19	indication	O
20	of	O
21	the	O
22	irreversible	O
23	formation	O
24	of	O
25	metal	O
26	-	O
27	oxyhydroxides	O
28	during	O
29	a	O
30	slow	O
31	reaction	O
32	.	O
1	This	O
2	growth	O
3	arrest	O
4	is	O
5	partly	O
6	suppressed	O
7	on	O
8	minimal	O
9	medium	O
10	or	O
11	under	O
12	conditions	O
13	in	O
14	which	O
15	the	O
16	cells	O
17	are	O
18	less	O
19	dependent	O
20	on	O
21	mitochondrial	O
22	metabolism	O
23	.	O
1	Droperidol	O
2	-	O
3	induced	O
4	extrapyramidal	O
5	symptoms	O
6	in	O
7	an	O
8	adolescent	O
9	following	O
10	strabismus	O
11	surgery	O
12	.	O
1	As	O
2	in	O
3	mammals	O
4	,	O
5	considerable	O
6	nucleotide	O
7	diversity	O
8	was	O
9	observed	O
10	at	O
11	the	O
12	junctions	O
13	of	O
14	the	O
15	variable	O
16	,	O
17	diversity	O
18	,	O
19	and	O
20	joining	O
21	elements	O
22	in	O
23	chicken	B
24	TCR	I
25	beta	I
26	cDNAs	I
27	.	O
1	The	O
2	SUP44	B
3	suppressor	I
4	mutation	I
5	occurs	O
6	near	O
7	a	O
8	region	O
9	of	O
10	the	O
11	protein	O
12	that	O
13	corresponds	O
14	to	O
15	the	O
16	known	O
17	positions	O
18	of	O
19	alterations	O
20	in	O
21	E	B
22	.	I
23	coli	I
24	S5	I
25	ram	I
26	mutations	I
27	.	O
1	This	O
2	interaction	O
3	occurs	O
4	over	O
5	a	O
6	wide	O
7	range	O
8	of	O
9	both	O
10	parameters	O
11	;	O
12	for	O
13	charge	O
14	density	O
15	from	O
16	at	O
17	least	O
18	10	O
19	to	O
20	800	O
21	microC	O
22	/	O
23	cm2	O
24	and	O
25	,	O
26	for	O
27	charge	O
28	per	O
29	phase	O
30	,	O
31	from	O
32	at	O
33	least	O
34	0	O
35	.	O
36	05	O
37	to	O
38	5	O
39	.	O
40	0	O
41	microC	O
42	per	O
43	phase	O
44	.	O
1	Sequence	O
2	and	O
3	genetic	O
4	organization	O
5	of	O
6	a	O
7	Zymomonas	O
8	mobilis	O
9	gene	O
10	cluster	O
11	that	O
12	encodes	O
13	several	O
14	enzymes	O
15	of	O
16	glucose	O
17	metabolism	O
18	.	O
1	Plasma	O
2	Al	O
3	was	O
4	obtained	O
5	during	O
6	each	O
7	baseline	O
8	and	O
9	drug	O
10	course	O
11	.	O
1	Effects	O
2	of	O
3	cisapride	O
4	on	O
5	upper	O
6	-	O
7	gastrointestinal	O
8	motility	O
9	and	O
10	digestive	O
11	hormones	O
1	Coenzyme	O
2	Q10	O
3	:	O
4	blood	O
5	levels	O
6	and	O
7	metabolic	O
8	demand	O
9	.	O
1	In	O
2	26	O
3	patients	O
4	with	O
5	angina	O
6	pectoris	O
7	,	O
8	the	O
9	changes	O
10	of	O
11	LVEF	O
12	,	O
13	LVESV	O
14	and	O
15	PSP	O
16	/	O
17	LVESV	O
18	were	O
19	more	O
20	sensitive	O
21	for	O
22	the	O
23	detection	O
24	of	O
25	exercise	O
26	-	O
27	induced	O
28	ischemia	O
29	than	O
30	the	O
31	appearance	O
32	of	O
33	chest	O
34	pain	O
35	and	O
36	the	O
37	changes	O
38	of	O
39	ECG	O
40	.	O
1	The	O
2	inspiratory	O
3	oxygen	O
4	concentration	O
5	needed	O
6	(	O
7	FiO2	O
8	)	O
9	and	O
10	the	O
11	Horowitz	O
12	quotient	O
13	differed	O
14	in	O
15	a	O
16	highly	O
17	significant	O
18	manner	O
19	beginning	O
20	on	O
21	the	O
22	1st	O
23	day	O
24	after	O
25	trauma	O
26	.	O
1	The	O
2	corn	O
3	and	O
4	mineral	O
5	oil	O
6	emulsions	O
7	were	O
8	almost	O
9	as	O
10	effective	O
11	as	O
12	milk	O
13	but	O
14	less	O
15	effective	O
16	than	O
17	sucrose	O
18	(	O
19	0	O
20	.	O
21	3M	O
22	)	O
23	in	O
24	stimulating	O
25	ingestion	O
26	.	O
1	Effect	O
2	of	O
3	biliary	O
4	obstruction	O
5	and	O
6	cholangitis	O
7	on	O
8	serum	B
9	SPan	I
10	-	I
11	1	I
12	level	O
1	By	O
2	introducing	O
3	a	O
4	series	O
5	of	O
6	deletions	O
7	in	O
8	the	O
9	vimentin	B
10	promoter	O
11	,	O
12	we	O
13	further	O
14	restrict	O
15	these	O
16	sequences	O
17	to	O
18	30	O
19	base	O
20	pairs	O
21	,	O
22	located	O
23	between	O
24	241	O
25	and	O
26	210	O
27	base	O
28	pairs	O
29	upstream	O
30	of	O
31	the	O
32	mRNA	O
33	cap	O
34	site	O
35	.	O
1	Thyrotropin	B
2	-	O
3	induced	O
4	expression	O
5	of	O
6	a	O
7	gene	O
8	for	O
9	a	O
10	ribosomal	B
11	protein	I
12	related	O
13	to	O
14	the	O
15	trk	B
16	oncogene	I
17	.	O
1	To	O
2	define	O
3	the	O
4	mechanism	O
5	responsible	O
6	for	O
7	the	O
8	loss	O
9	of	O
10	transcription	O
11	elongation	O
12	blockage	O
13	and	O
14	resulting	O
15	c	B
16	-	I
17	myc	I
18	deregulation	O
19	in	O
20	Burkitt	O
21	'	O
22	s	O
23	lymphoma	O
24	,	O
25	we	O
26	analyzed	O
27	transcription	O
28	patterns	O
29	after	O
30	transfer	O
31	of	O
32	normal	O
33	and	O
34	Burkitt	O
35	'	O
36	s	O
37	lymphoma	O
38	c	B
39	-	I
40	myc	I
41	alleles	O
42	into	O
43	murine	O
44	cells	O
45	and	O
46	Xenopus	O
47	oocyte	O
48	germinal	O
49	vesicles	O
50	.	O
1	Erythrocyte	O
2	protoporphyrin	O
3	concentration	O
4	increased	O
5	significantly	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	14	O
16	days	O
17	in	O
18	dogs	O
19	fed	O
20	the	O
21	basal	O
22	diet	O
23	,	O
24	and	O
25	remained	O
26	significantly	O
27	high	O
28	relative	O
29	to	O
30	that	O
31	in	O
32	dogs	O
33	of	O
34	the	O
35	other	O
36	dietary	O
37	groups	O
38	for	O
39	the	O
40	remainder	O
41	of	O
42	the	O
43	study	O
44	.	O
1	The	O
2	coding	O
3	sequences	O
4	of	O
5	the	O
6	Crry	B
7	gene	I
8	encompass	O
9	over	O
10	25	O
11	kb	O
12	of	O
13	DNA	O
14	,	O
15	whereas	O
16	the	O
17	Crry	B
18	-	O
19	ps	B
20	sequences	O
21	are	O
22	included	O
23	within	O
24	a	O
25	single	O
26	5	B
27	.	I
28	6	I
29	-	I
30	kb	I
31	Eco	I
32	-	I
33	R1	I
34	fragment	I
35	.	O
1	Senior	O
2	systems	O
3	--	O
4	45	O
5	;	O
6	Mental	O
7	health	O
8	and	O
9	illness	O
10	in	O
11	old	O
12	age	O
13	--	O
14	3	O
15	.	O
1	Comparison	O
2	of	O
3	transmembrane	O
4	and	O
5	cytoplasmic	O
6	domains	O
7	to	O
8	a	O
9	third	O
10	cell	O
11	-	O
12	surface	O
13	proteoglycan	O
14	,	O
15	48K5	B
16	from	O
17	human	O
18	lung	O
19	fibroblasts	O
20	(	O
21	Marynen	O
22	,	O
23	P	O
24	.,	O
25	Zhang	O
26	,	O
27	J	O
28	.,	O
29	Cassiman	O
30	,	O
31	J	O
32	.,	O
33	Vanden	O
34	Berghe	O
35	,	O
36	H	O
37	.,	O
38	and	O
39	David	O
40	,	O
41	C	O
42	.	O
1	A	O
2	second	O
3	,	O
4	novel	O
5	C	O
6	subunit	O
7	(	O
8	CeCAT	O
9	alpha	O
10	',	O
11	374	O
12	residues	O
13	)	O
14	has	O
15	a	O
16	unique	O
17	56	O
18	-	O
19	residue	O
20	carboxyl	O
21	-	O
22	terminal	O
23	region	O
24	that	O
25	is	O
26	generated	O
27	by	O
28	the	O
29	alternative	O
30	splicing	O
31	of	O
32	the	O
33	C	B
34	pre	I
35	-	I
36	mRNA	I
37	.	O
1	Lars	O
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	dignified	O
8	life	O
9	with	O
10	care	O
11	at	O
12	home	O
13	.	O
1	Treating	O
2	renal	O
3	anaemia	O
4	with	O
5	recombinant	O
6	human	O
7	erythropoietin	B
8	.	O
1	Environmental	O
2	factors	O
3	were	O
4	more	O
5	important	O
6	in	O
7	the	O
8	older	O
9	cohorts	O
10	(	O
11	perhaps	O
12	because	O
13	of	O
14	less	O
15	reliable	O
16	recall	O
17	).	O
1	Drug	O
2	and	O
3	personnel	O
4	costs	O
5	were	O
6	reduced	O
7	when	O
8	batch	O
9	manufacturing	O
10	with	O
11	40	O
12	-	O
13	mL	O
14	multidose	O
15	vials	O
16	was	O
17	compared	O
18	with	O
19	extemporaneous	O
20	compounding	O
21	with	O
22	unit	O
23	-	O
24	dose	O
25	vials	O
26	.	O
1	The	O
2	findings	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	iodine	O
8	deficiency	O
9	is	O
10	the	O
11	most	O
12	probable	O
13	cause	O
14	of	O
15	goiter	O
16	among	O
17	immigrants	O
18	of	O
19	the	O
20	1928	O
21	cohort	O
22	,	O
23	where	O
24	the	O
25	native	O
26	population	O
27	is	O
28	concerned	O
29	(	O
30	both	O
31	men	O
32	and	O
33	women	O
34	),	O
35	some	O
36	other	O
37	goitrogenic	O
38	factor	O
39	(	O
40	s	O
41	)	O
42	must	O
43	be	O
44	involved	O
45	.	O
1	Co	O
2	-	O
3	administration	O
4	of	O
5	5FU	O
6	,	O
7	angiotensin	B
8	II	I
9	and	O
10	microspheres	O
11	via	O
12	the	O
13	hepatic	O
14	artery	O
15	may	O
16	reduce	O
17	drug	O
18	exposure	O
19	in	O
20	the	O
21	systemic	O
22	compartment	O
23	and	O
24	therefore	O
25	may	O
26	increase	O
27	the	O
28	therapeutic	O
29	ratio	O
30	of	O
31	5FU	O
32	administration	O
33	via	O
34	the	O
35	hepatic	O
36	artery	O
37	.	O
1	Transient	O
2	expression	O
3	of	O
4	human	B
5	and	I
6	chicken	I
7	progesterone	I
8	receptors	I
9	does	O
10	not	O
11	support	O
12	alternative	O
13	translational	O
14	initiation	O
15	from	O
16	a	O
17	single	O
18	mRNA	O
19	as	O
20	the	O
21	mechanism	O
22	generating	O
23	two	O
24	receptor	O
25	isoforms	O
26	.	O
1	On	O
2	histologic	O
3	examination	O
4	the	O
5	cuboidal	O
6	epithelium	O
7	of	O
8	the	O
9	mucous	O
10	membrane	O
11	was	O
12	found	O
13	to	O
14	be	O
15	changed	O
16	into	O
17	columnar	O
18	epithelium	O
19	,	O
20	with	O
21	uneven	O
22	distribution	O
23	of	O
24	enlarged	O
25	nuclei	O
26	in	O
27	the	O
28	vacuolized	O
29	cytoplasm	O
30	.	O
1	These	O
2	results	O
3	suggest	O
4	an	O
5	increased	O
6	risk	O
7	of	O
8	developing	O
9	cancer	O
10	among	O
11	polyp	O
12	patients	O
13	and	O
14	the	O
15	possibility	O
16	of	O
17	prophylactic	O
18	effect	O
19	of	O
20	polypectomy	O
21	against	O
22	subsequent	O
23	cancer	O
24	.	O
1	Fatal	O
2	encephalitis	O
3	in	O
4	a	O
5	patient	O
6	with	O
7	chronic	O
8	graft	O
9	-	O
10	versus	O
11	-	O
12	host	O
13	disease	O
14	.	O
1	The	O
2	pattern	O
3	for	O
4	catalytic	O
5	zinc	O
6	sites	O
7	included	O
8	two	O
9	ligands	O
10	close	O
11	in	O
12	sequence	O
13	,	O
14	a	O
15	sequence	O
16	-	O
17	distant	O
18	ligand	O
19	,	O
20	and	O
21	a	O
22	main	O
23	-	O
24	chain	O
25	hydrogen	O
26	bond	O
27	joining	O
28	two	O
29	ligands	O
30	.	O
1	Sprague	O
2	-	O
3	Dawley	O
4	newborn	O
5	rats	O
6	(	O
7	n	O
8	=	O
9	85	O
10	)	O
11	breathed	O
12	100	O
13	%	O
14	oxygen	O
15	(	O
16	O2	O
17	)	O
18	or	O
19	room	O
20	air	O
21	(	O
22	RA	O
23	)	O
24	during	O
25	the	O
26	first	O
27	8	O
28	days	O
29	of	O
30	life	O
31	,	O
32	and	O
33	then	O
34	RA	O
35	.	O
1	Antibodies	O
2	raised	O
3	against	O
4	a	O
5	bacterially	O
6	produced	O
7	beta	B
8	gal	I
9	-	O
10	trk	B
11	receptor	O
12	kinase	O
13	fusion	O
14	protein	O
15	recognized	O
16	a	O
17	44	O
18	kd	O
19	phosphoprotein	O
20	phosphorylated	O
21	on	O
22	serine	O
23	,	O
24	threonine	O
25	and	O
26	tyrosine	O
27	in	O
28	extracts	O
29	of	O
30	trk	B
31	-	I
32	2h	I
33	transformed	O
34	NIH3T3	O
35	cells	O
36	.	O
1	The	O
2	cDNAs	O
3	cross	O
4	-	O
5	hybridize	O
6	with	O
7	genomic	O
8	sequences	O
9	in	O
10	rat	O
11	,	O
12	human	O
13	,	O
14	and	O
15	chicken	O
16	DNA	O
17	,	O
18	but	O
19	not	O
20	with	O
21	DNA	O
22	from	O
23	frog	O
24	,	O
25	Drosophila	O
26	,	O
27	or	O
28	sea	O
29	urchin	O
30	.	O
1	ATP	O
2	gamma	O
3	S	O
4	inhibition	O
5	can	O
6	be	O
7	overcome	O
8	by	O
9	high	O
10	concentrations	O
11	of	O
12	ATP	O
13	,	O
14	dATP	O
15	,	O
16	araATP	O
17	,	O
18	or	O
19	ddATP	O
20	.	O
1	The	O
2	4	O
3	-	O
4	AP	O
5	(	O
6	4	O
7	-	O
8	20	O
9	mM	O
10	)	O
11	effect	O
12	resulted	O
13	in	O
14	a	O
15	decrease	O
16	of	O
17	the	O
18	sensory	O
19	activity	O
20	,	O
21	which	O
22	was	O
23	fully	O
24	restored	O
25	by	O
26	TEA	O
27	or	O
28	Ba2	O
29	+.	O
1	A	O
2	new	O
3	method	O
4	for	O
5	the	O
6	quantitative	O
7	analysis	O
8	of	O
9	sleep	O
10	spindles	O
11	during	O
12	continuous	O
13	overnight	O
14	EEG	O
15	recordings	O
16	.	O
1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	for	O
7	the	O
8	first	O
9	time	O
10	the	O
11	complete	O
12	primary	O
13	structure	O
14	of	O
15	type	B
16	X	I
17	collagen	I
18	,	O
19	based	O
20	on	O
21	cloning	O
22	and	O
23	sequencing	O
24	of	O
25	cDNA	O
26	and	O
27	genomic	O
28	DNA	O
29	.	O
1	Viable	O
2	flap	O
3	areas	O
4	were	O
5	established	O
6	following	O
7	vascular	O
8	pedicle	O
9	ligation	O
10	(	O
11	both	O
12	vessels	O
13	or	O
14	only	O
15	artery	O
16	or	O
17	vein	O
18	),	O
19	on	O
20	the	O
21	third	O
22	day	O
23	after	O
24	flap	O
25	replantation	O
26	in	O
27	both	O
28	island	O
29	and	O
30	free	O
31	flaps	O
32	.	O
1	Dopamine	O
2	caused	O
3	a	O
4	prominent	O
5	potassium	O
6	efflux	O
7	measured	O
8	as	O
9	86Rb	O
10	+	O
11	efflux	O
12	from	O
13	control	O
14	glands	O
15	,	O
16	but	O
17	was	O
18	without	O
19	effect	O
20	in	O
21	denervated	O
22	glands	O
23	.	O
1	Their	O
2	hydropathic	O
3	plots	O
4	are	O
5	very	O
6	similar	O
7	and	O
8	both	O
9	possess	O
10	three	O
11	hydrophobic	O
12	segments	O
13	that	O
14	are	O
15	likely	O
16	alpha	O
17	-	O
18	helical	O
19	transmembrane	O
20	segments	O
21	.	O
1	In	O
2	TNF	B
3	-	O
4	resistant	O
5	T24	O
6	bladder	O
7	carcinoma	O
8	cells	O
9	,	O
10	TNF	B
11	failed	O
12	to	O
13	alter	O
14	EGF	B
15	-	I
16	R	I
17	tyrosine	I
18	protein	I
19	kinase	I
20	activity	O
21	although	O
22	both	O
23	EGF	B
24	and	O
25	phorbol	O
26	ester	O
27	were	O
28	shown	O
29	to	O
30	modulate	O
31	the	O
32	enzymatic	O
33	activity	O
34	of	O
35	the	O
36	receptor	O
37	in	O
38	these	O
39	cells	O
40	.	O
1	Structural	O
2	organization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	mouse	B
8	estrogen	I
9	receptor	I
10	.	O
1	The	O
2	results	O
3	were	O
4	as	O
5	follows	O
6	:	O
7	1	O
8	)	O
9	Total	O
10	integrated	O
11	EMG	O
12	activity	O
13	of	O
14	FB	O
15	group	O
16	was	O
17	approximately	O
18	equal	O
19	in	O
20	any	O
21	occluded	O
22	position	O
23	,	O
24	whereas	O
25	that	O
26	of	O
27	CG	O
28	and	O
29	GF	O
30	group	O
31	varied	O
32	from	O
33	position	O
34	to	O
35	position	O
36	.	O
1	In	O
2	76	O
3	%	O
4	of	O
5	59	O
6	lead	O
7	-	O
8	toxic	O
9	children	O
10	,	O
11	bone	O
12	lead	O
13	values	O
14	measured	O
15	by	O
16	LXRF	O
17	were	O
18	equal	O
19	to	O
20	or	O
21	greater	O
22	than	O
23	those	O
24	measured	O
25	in	O
26	normal	O
27	and	O
28	industrially	O
29	exposed	O
30	adults	O
31	.	O
1	In	O
2	resting	O
3	3T3	O
4	cells	O
5	,	O
6	jun	B
7	-	I
8	D	I
9	is	O
10	expressed	O
11	at	O
12	a	O
13	higher	O
14	level	O
15	compared	O
16	to	O
17	c	B
18	-	I
19	jun	I
20	and	O
21	jun	B
22	-	I
23	B	I
24	,	O
25	and	O
26	its	O
27	transcription	O
28	is	O
29	stimulated	O
30	only	O
31	slightly	O
32	by	O
33	serum	O
34	growth	O
35	factors	O
36	.	O
1	Lowering	O
2	of	O
3	the	O
4	renal	O
5	blood	O
6	flow	O
7	alters	O
8	the	O
9	glomerular	O
10	and	O
11	tubular	O
12	excretion	O
13	processes	O
14	.	O
1	Growth	O
2	of	O
3	tracheal	O
4	anastomoses	O
5	in	O
6	growing	O
7	animals	O
1	In	O
2	all	O
3	sessions	O
4	under	O
5	IFN	B
6	,	O
7	the	O
8	latency	O
9	of	O
10	the	O
11	P100	O
12	component	O
13	of	O
14	the	O
15	VEP	O
16	was	O
17	shortened	O
18	as	O
19	compared	O
20	to	O
21	baseline	O
22	conditions	O
23	.	O
1	Current	O
2	status	O
3	and	O
4	future	O
5	perspectives	O
1	The	O
2	PETCO2	O
3	measurement	O
4	during	O
5	precordial	O
6	compression	O
7	predicted	O
8	the	O
9	success	O
10	of	O
11	defibrillation	O
12	with	O
13	return	O
14	of	O
15	spontaneous	O
16	circulation	O
17	.	O
1	The	O
2	other	O
3	patients	O
4	continued	O
5	the	O
6	trial	O
7	with	O
8	single	O
9	daily	O
10	doses	O
11	of	O
12	monotherapy	O
13	.	O
1	Neonatal	O
2	Chagas	O
3	disease	O
4	:	O
5	laboratory	O
6	diagnosis	O
7	during	O
8	the	O
9	first	O
10	year	O
11	of	O
12	life	O
1	Forty	O
2	patients	O
3	,	O
4	divided	O
5	according	O
6	to	O
7	their	O
8	initial	O
9	total	O
10	gastrointestinal	O
11	transit	O
12	times	O
13	and	O
14	presenting	O
15	symptoms	O
16	,	O
17	were	O
18	treated	O
19	with	O
20	cimetropium	O
21	bromide	O
22	50	O
23	mg	O
24	t	O
25	.	O
26	d	O
27	.	O
28	s	O
29	.	O
30	or	O
31	placebo	O
32	for	O
33	1	O
34	month	O
35	according	O
36	to	O
37	a	O
38	double	O
39	-	O
40	blind	O
41	,	O
42	parallel	O
43	group	O
44	design	O
45	.	O
1	Moreover	O
2	,	O
3	exons	O
4	2a	O
5	and	O
6	2b	O
7	share	O
8	the	O
9	same	O
10	5	O
11	'	O
12	sequence	O
13	but	O
14	differ	O
15	from	O
16	each	O
17	other	O
18	by	O
19	the	O
20	use	O
21	of	O
22	two	O
23	distinct	O
24	donor	O
25	splice	O
26	sites	O
27	171	O
28	bp	O
29	apart	O
30	in	O
31	the	O
32	gene	O
33	.	O
1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	HBV	O
6	markers	O
7	was	O
8	higher	O
9	among	O
10	staff	O
11	members	O
12	than	O
13	in	O
14	the	O
15	blood	O
16	donors	O
17	of	O
18	our	O
19	area	O
20	.	O
1	Quantitative	O
2	predictions	O
3	are	O
4	confirmed	O
5	for	O
6	the	O
7	positive	O
8	responses	O
9	,	O
10	but	O
11	not	O
12	for	O
13	the	O
14	negatives	O
15	,	O
16	suggesting	O
17	that	O
18	the	O
19	SSTS	O
20	model	O
21	is	O
22	incorrect	O
23	.	O
1	The	O
2	adenovirus	B
3	E1A	I
4	gene	I
5	encodes	O
6	a	O
7	protein	O
8	that	O
9	transcriptionally	O
10	activates	O
11	viral	B
12	early	I
13	genes	I
14	.	O
1	In	O
2	the	O
3	formalin	O
4	test	O
5	,	O
6	however	O
7	,	O
8	naloxone	O
9	attenuated	O
10	morphine	O
11	analgesia	O
12	at	O
13	the	O
14	lower	O
15	doses	O
16	(	O
17	0	O
18	.	O
19	1	O
20	and	O
21	0	O
22	.	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	)	O
28	and	O
29	potentiated	O
30	morphine	O
31	analgesia	O
32	at	O
33	the	O
34	highest	O
35	dose	O
36	(	O
37	10	O
38	mg	O
39	/	O
40	kg	O
41	).	O
1	We	O
2	have	O
3	isolated	O
4	cDNA	O
5	clones	O
6	from	O
7	rat	O
8	brain	O
9	and	O
10	human	O
11	liver	O
12	encoding	O
13	a	O
14	putative	O
15	isoform	O
16	of	O
17	the	O
18	Na	B
19	,	I
20	K	I
21	-	I
22	ATPase	I
23	beta	I
24	subunit	I
25	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	patients	O
6	who	O
7	undergo	O
8	postoperative	O
9	irradiation	O
10	for	O
11	low	O
12	grade	O
13	spinal	O
14	astrocytomas	O
15	and	O
16	localized	O
17	spinal	O
18	ependymomas	O
19	achieve	O
20	excellent	O
21	survival	O
22	.	O
1	Effects	O
2	of	O
3	nitrogen	O
4	(	O
5	PN2	O
6	:	O
7	5	O
8	and	O
9	14	O
10	MPa	O
11	)	O
12	and	O
13	helium	O
14	(	O
15	PHe	O
16	:	O
17	13	O
18	and	O
19	14	O
20	MPa	O
21	)	O
22	were	O
23	also	O
24	tested	O
25	.	O
1	The	O
2	application	O
3	of	O
4	ISH	O
5	and	O
6	IHC	O
7	did	O
8	not	O
9	change	O
10	significantly	O
11	the	O
12	routine	O
13	histologic	O
14	classification	O
15	of	O
16	pneumonias	O
17	into	O
18	CMV	O
19	-	O
20	IP	O
21	and	O
22	IIP	O
23	.	O
1	Validity	O
2	of	O
3	immunohistology	O
4	and	O
5	in	O
6	situ	O
7	hybridization	O
8	in	O
9	the	O
10	differential	O
11	diagnosis	O
12	of	O
13	cytomegalovirus	O
14	pneumonia	O
15	and	O
16	idiopathic	O
17	interstitial	O
18	pneumonia	O
19	after	O
20	allogenic	O
21	bone	O
22	marrow	O
23	transplantation	O
1	However	O
2	,	O
3	bilateral	O
4	diffuse	O
5	pulmonary	O
6	infiltrations	O
7	developed	O
8	21	O
9	days	O
10	later	O
11	.	O
1	VP5	B
2	,	O
3	which	O
4	encodes	O
5	the	O
6	major	B
7	capsid	I
8	protein	I
9	,	O
10	each	O
11	fused	O
12	to	O
13	the	O
14	chloramphenicol	B
15	acetyltransferase	I
16	gene	I
17	.	O
1	First	O
2	,	O
3	a	O
4	pet54	B
5	::	O
6	LEU2	B
7	cytoductant	O
8	bearing	O
9	the	O
10	'	O
11	short	O
12	'	O
13	mitochondrial	O
14	genome	O
15	that	O
16	lacks	O
17	both	O
18	COX1	B
19	introns	I
20	aI5	I
21	alpha	I
22	and	O
23	aI5	B
24	beta	I
25	is	O
26	defective	O
27	only	O
28	in	O
29	COX3	B
30	gene	I
31	expression	O
32	and	O
33	not	O
34	in	O
35	COX1	B
36	mRNA	I
37	splicing	O
38	or	O
39	mRNA	O
40	translation	O
41	.	O
1	There	O
2	has	O
3	been	O
4	similar	O
5	improvement	O
6	in	O
7	treating	O
8	ampullary	O
9	and	O
10	periampullary	O
11	cancer	O
12	,	O
13	gallbladder	O
14	cancer	O
15	,	O
16	or	O
17	extrahepatic	O
18	bile	O
19	duct	O
20	cancer	O
21	.	O
1	The	O
2	data	O
3	indicate	O
4	that	O
5	calcitonin	B
6	induced	O
7	a	O
8	beta	B
9	-	I
10	endorphin	I
11	increase	O
12	independent	O
13	of	O
14	enhanced	O
15	corticotrophin	B
16	-	O
17	cortisol	O
18	release	O
19	.	O
1	Rare	O
2	neurogenic	O
3	tumor	O
4	with	O
5	metastasis	O
6	to	O
7	mouth	O
8	,	O
9	jaw	O
10	and	O
11	face	O
12	regions	O
1	Haploid	O
2	cells	O
3	of	O
4	mating	O
5	type	O
6	A	O
7	of	O
8	the	O
9	basidiomycetous	O
10	yeast	O
11	Rhodosporidium	O
12	toruloides	O
13	secrete	O
14	a	O
15	mating	O
16	pheromone	O
17	,	O
18	rhodotorucine	B
19	A	I
20	,	O
21	which	O
22	is	O
23	an	O
24	undecapeptide	O
25	containing	O
26	S	O
27	-	O
28	farnesyl	O
29	cysteine	O
30	at	O
31	its	O
32	carboxy	O
33	terminus	O
34	.	O
1	No	O
2	significant	O
3	differences	O
4	were	O
5	found	O
6	in	O
7	relation	O
8	to	O
9	Type	O
10	A	O
11	behaviour	O
12	and	O
13	beta	B
14	-	I
15	adrenoceptor	I
16	blockade	O
17	.	O
1	Antihistamines	O
2	in	O
3	asthma	O
4	.	O
1	We	O
2	have	O
3	therefore	O
4	evaluated	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	doxazosin	O
11	,	O
12	a	O
13	new	O
14	orally	O
15	active	O
16	selective	O
17	alpha	B
18	1	I
19	blocker	O
20	,	O
21	in	O
22	patients	O
23	with	O
24	systemic	O
25	hypertension	O
26	with	O
27	concomitant	O
28	airflow	O
29	limitation	O
30	.	O
1	High	O
2	ATP	O
3	/	O
4	GTP	O
5	ratios	O
6	promoted	O
7	initiation	O
8	of	O
9	RNA	O
10	primer	O
11	synthesis	O
12	at	O
13	3	O
14	'-	O
15	dCTTT	O
16	sites	O
17	,	O
18	whereas	O
19	low	O
20	ATP	O
21	/	O
22	GTP	O
23	ratios	O
24	promoted	O
25	initiation	O
26	at	O
27	3	O
28	'-	O
29	dCCC	O
30	sites	O
31	.	O
1	The	O
2	GALT	O
3	-	O
4	primed	O
5	calves	O
6	had	O
7	increased	O
8	serum	O
9	IgG	B
10	,	O
11	lavage	O
12	IgG	B
13	and	O
14	IgA	B
15	and	O
16	increased	O
17	LNA	B
18	titers	O
19	in	O
20	both	O
21	lavage	O
22	fluids	O
23	and	O
24	serum	O
25	following	O
26	the	O
27	SC	O
28	dose	O
29	of	O
30	killed	O
31	bacteria	O
32	.	O
1	Recent	O
2	investigations	O
3	have	O
4	shown	O
5	that	O
6	Grenz	O
7	rays	O
8	can	O
9	suppress	O
10	the	O
11	allergic	O
12	contact	O
13	dermatitis	O
14	reaction	O
15	completely	O
16	and	O
17	that	O
18	Langerhans	O
19	cells	O
20	,	O
21	identified	O
22	by	O
23	OKT6	B
24	antibodies	I
25	and	O
26	electron	O
27	microscopy	O
28	,	O
29	disappear	O
30	from	O
31	the	O
32	epidermis	O
33	at	O
34	the	O
35	same	O
36	time	O
37	.	O
1	Four	O
2	full	O
3	-	O
4	thickness	O
5	skin	O
6	incisions	O
7	were	O
8	made	O
9	in	O
10	the	O
11	back	O
12	of	O
13	10	O
14	female	O
15	pigs	O
16	that	O
17	treated	O
18	twice	O
19	a	O
20	day	O
21	for	O
22	14	O
23	days	O
24	with	O
25	2	O
26	ml	O
27	of	O
28	epidermal	B
29	growth	I
30	factor	I
31	(	O
32	300	O
33	ng	O
34	/	O
35	ml	O
36	)	O
37	or	O
38	2	O
39	ml	O
40	of	O
41	Ringer	O
42	'	O
43	s	O
44	lactate	O
45	solution	O
46	in	O
47	a	O
48	single	O
49	-	O
50	blind	O
51	,	O
52	randomized	O
53	fashion	O
54	.	O
1	Animal	O
2	experimental	O
3	and	O
4	clinical	O
5	applications	O
6	of	O
7	plates	O
8	,	O
9	screws	O
10	and	O
11	spinal	O
12	segmental	O
13	replacement	O
14	implants	O
15	made	O
16	of	O
17	this	O
18	composite	O
19	material	O
20	have	O
21	shown	O
22	good	O
23	results	O
24	so	O
25	far	O
26	.	O
1	We	O
2	investigated	O
3	the	O
4	incidence	O
5	of	O
6	congenital	O
7	color	O
8	deficiency	O
9	among	O
10	Koreans	O
11	by	O
12	the	O
13	use	O
14	of	O
15	H	O
16	-	O
17	R	O
18	-	O
19	R	O
20	pseudoisochromatic	O
21	plates	O
22	.	O
1	Eighty	O
2	patients	O
3	presenting	O
4	to	O
5	HGGM	O
6	with	O
7	non	O
8	-	O
9	Hodgkin	O
10	'	O
11	s	O
12	lymphomas	O
13	between	O
14	1962	O
15	and	O
16	1986	O
17	,	O
18	were	O
19	reviewed	O
20	.	O
1	Retrograde	O
2	filling	O
3	consists	O
4	in	O
5	sealing	O
6	endodontics	O
7	system	O
8	directly	O
9	at	O
10	the	O
11	apical	O
12	zone	O
13	after	O
14	surgical	O
15	approach	O
16	.	O
1	Serological	O
2	studies	O
3	at	O
4	the	O
5	early	O
6	relapse	O
7	stage	O
8	of	O
9	this	O
10	disease	O
11	showed	O
12	increased	O
13	serum	B
14	ANA	I
15	,	O
16	IgA	B
17	and	O
18	IgM	B
19	level	O
20	with	O
21	normal	O
22	IgG	B
23	and	O
24	decrease	O
25	of	O
26	C3	B
27	and	O
28	C4	B
29	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	47	B
6	-	I
7	kilodalton	I
8	major	I
9	integral	I
10	membrane	I
11	immunogen	I
12	of	I
13	Treponema	I
14	pallidum	I
15	.	O
1	Many	O
2	studies	O
3	have	O
4	pointed	O
5	out	O
6	the	O
7	possibility	O
8	of	O
9	""""	O
10	masked	O
11	""""	O
12	organic	O
13	factors	O
14	in	O
15	erectile	O
16	impotence	O
17	,	O
18	detectable	O
19	only	O
20	by	O
21	means	O
22	of	O
23	laboratory	O
24	investigations	O
25	:	O
26	mild	O
27	hypogonadism	O
28	,	O
29	hyperprolactinemia	O
30	,	O
31	occlusions	O
32	selectively	O
33	located	O
34	at	O
35	the	O
36	site	O
37	of	O
38	the	O
39	sexual	O
40	arteries	O
41	,	O
42	venous	O
43	incompetence	O
44	,	O
45	subclinical	O
46	neuropathies	O
47	.	O
1	Doppler	O
2	echo	O
3	in	O
4	evaluating	O
5	arteriovenous	O
6	fistulae	O
7	for	O
8	dialysis	O
1	Following	O
2	the	O
3	patients	O
4	during	O
5	a	O
6	course	O
7	of	O
8	therapy	O
9	with	O
10	a	O
11	selective	O
12	vasodilator	O
13	calcium	O
14	antagonist	O
15	,	O
16	the	O
17	beta	O
18	-	O
19	adrenergic	O
20	reflex	O
21	vasodilation	O
22	became	O
23	substantially	O
24	attenuated	O
25	but	O
26	was	O
27	preserved	O
28	during	O
29	a	O
30	placebo	O
31	course	O
32	of	O
33	therapy	O
34	.	O
1	The	O
2	calcium	O
3	requirement	O
4	for	O
5	hypothermic	O
6	storage	O
7	of	O
8	the	O
9	cardiac	O
10	explant	O
11	.	O
1	The	O
2	p34	B
3	.	I
4	8	I
5	gene	I
6	has	O
7	a	O
8	strong	O
9	codon	O
10	usage	O
11	bias	O
12	which	O
13	is	O
14	strikingly	O
15	different	O
16	from	O
17	that	O
18	of	O
19	the	O
20	polyhedrin	B
21	gene	I
22	.	O
1	Four	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	showed	O
7	clinical	O
8	improvement	O
9	according	O
10	to	O
11	Ritchie	O
12	-	O
13	Index	O
14	,	O
15	pain	O
16	score	O
17	,	O
18	ESR	O
19	and	O
20	CRP	B
21	.	O
1	Mapping	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	complementation	O
7	group	O
8	identified	O
9	by	O
10	these	O
11	mutants	O
12	is	O
13	allelic	O
14	to	O
15	the	O
16	ag	B
17	alpha	I
18	1	I
19	mutation	O
20	identified	O
21	previously	O
22	.	O
1	Hybridization	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	size	O
7	of	O
8	the	O
9	mRNA	O
10	is	O
11	about	O
12	1	O
13	.	O
14	4	O
15	kilobases	O
16	.	O
1	The	O
2	R	B
3	.	I
4	meliloti	I
5	nifH	I
6	promoter	I
7	but	O
8	not	O
9	the	O
10	K	B
11	.	I
12	pneumoniae	I
13	nifH	I
14	promoter	I
15	showed	O
16	sigma	B
17	54	I
18	-	O
19	dependent	O
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	I
43	-	I
44	dependent	I
45	promoters	I
46	.	O
1	Major	O
2	clinical	O
3	symptoms	O
4	of	O
5	the	O
6	disease	O
7	were	O
8	defined	O
9	in	O
10	this	O
11	group	O
12	of	O
13	patients	O
14	.	O
1	In	O
2	order	O
3	to	O
4	study	O
5	the	O
6	structural	O
7	and	O
8	functional	O
9	organization	O
10	of	O
11	the	O
12	eukaryotic	O
13	nucleolus	O
14	,	O
15	we	O
16	have	O
17	started	O
18	to	O
19	isolate	O
20	and	O
21	characterize	O
22	nucleolar	O
23	components	O
24	of	O
25	the	O
26	yeast	O
27	Saccharomyces	O
28	cerevisiae	O
29	.	O
1	A	O
2	transcription	O
3	factor	O
4	exclusion	O
5	assay	O
6	was	O
7	used	O
8	to	O
9	show	O
10	that	O
11	the	O
12	PCF1	B
13	mutation	I
14	affects	O
15	two	O
16	distinct	O
17	stages	O
18	in	O
19	transcription	O
20	:	O
21	one	O
22	prior	O
23	to	O
24	and	O
25	one	O
26	after	O
27	stable	O
28	complex	O
29	formation	O
30	;	O
31	and	O
32	that	O
33	these	O
34	effects	O
35	are	O
36	mediated	O
37	by	O
38	a	O
39	component	O
40	of	O
41	the	O
42	stable	O
43	complex	O
44	.	O
1	Psychiatry	O
2	and	O
3	the	O
4	skin	O
5	.	O
1	The	O
2	incidence	O
3	of	O
4	fetal	O
5	breathing	O
6	movements	O
7	(	O
8	06	O
9	.	O
10	00	O
11	-	O
12	10	O
13	.	O
14	00	O
15	h	O
16	)	O
17	decreased	O
18	with	O
19	increasing	O
20	gestational	O
21	age	O
22	while	O
23	fetal	O
24	arterial	O
25	concentrations	O
26	of	O
27	plasma	O
28	PGE	O
29	increased	O
30	significantly	O
31	over	O
32	the	O
33	same	O
34	period	O
35	of	O
36	gestation	O
37	.	O
1	The	O
2	present	O
3	data	O
4	also	O
5	suggest	O
6	that	O
7	when	O
8	compared	O
9	to	O
10	the	O
11	systemic	O
12	vascular	O
13	bed	O
14	,	O
15	the	O
16	pulmonary	O
17	vascular	O
18	bed	O
19	is	O
20	less	O
21	responsive	O
22	to	O
23	bolus	O
24	administration	O
25	of	O
26	ET	B
27	-	I
28	1	I
29	.	O
1	The	O
2	encoded	O
3	protein	O
4	has	O
5	a	O
6	leader	O
7	sequence	O
8	of	O
9	27	O
10	amino	O
11	acids	O
12	.	O
1	The	O
2	stereoselectivity	O
3	of	O
4	drug	O
5	action	O
6	.	O
1	Chronic	O
2	dose	O
3	effects	O
4	of	O
5	methyl	O
6	parathion	O
7	on	O
8	nuthatches	O
9	:	O
10	cholinesterase	B
11	and	O
12	ptilochronology	O
13	.	O
1	Kidney	O
2	weight	O
3	and	O
4	kidney	O
5	-	O
6	to	O
7	-	O
8	body	O
9	weight	O
10	ratio	O
11	were	O
12	significantly	O
13	elevated	O
14	at	O
15	the	O
16	highest	O
17	dose	O
18	level	O
19	after	O
20	10	O
21	weeks	O
22	and	O
23	at	O
24	the	O
25	two	O
26	higher	O
27	dose	O
28	levels	O
29	after	O
30	15	O
31	weeks	O
32	of	O
33	exposure	O
34	.	O
1	Allelic	O
2	variation	O
3	in	O
4	HLA	B
5	-	I
6	B	I
7	and	O
8	HLA	B
9	-	I
10	C	I
11	sequences	I
12	and	O
13	the	O
14	evolution	O
15	of	O
16	the	O
17	HLA	B
18	-	I
19	B	I
20	alleles	I
21	.	O
1	Cosmid	O
2	clones	O
3	containing	O
4	both	O
5	VNTR	O
6	sequences	O
7	were	O
8	identified	O
9	,	O
10	and	O
11	restriction	O
12	mapping	O
13	showed	O
14	them	O
15	to	O
16	be	O
17	less	O
18	than	O
19	15	O
20	kb	O
21	apart	O
22	.	O
1	Among	O
2	booked	O
3	patients	O
4	the	O
5	maternal	O
6	mortality	O
7	rate	O
8	was	O
9	0	O
10	.	O
11	32	O
12	and	O
13	among	O
14	unbooked	O
15	patients	O
16	11	O
17	.	O
18	13	O
19	per	O
20	1000	O
21	deliveries	O
22	.	O
1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	by	O
8	S1	B
9	nuclease	I
10	mapping	O
11	.	O
1	Endometrial	O
2	biopsies	O
3	and	O
4	plasma	O
5	oestradiol	O
6	(	O
7	E2	O
8	)	O
9	and	O
10	progesterone	O
11	(	O
12	P4	O
13	)	O
14	levels	O
15	in	O
16	23	O
17	patients	O
18	were	O
19	evaluated	O
20	during	O
21	26	O
22	replacement	O
23	therapy	O
24	cycles	O
25	for	O
26	premature	O
27	ovarian	O
28	failure	O
29	.	O
1	Each	O
2	individual	O
3	shot	O
4	25	O
5	bullets	O
6	in	O
7	about	O
8	5	O
9	minutes	O
10	,	O
11	at	O
12	an	O
13	intensity	O
14	level	O
15	calculated	O
16	at	O
17	163	O
18	dB	O
19	.	O
1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	NF	B
7	-	I
8	4FA	I
9	,	O
10	NF	B
11	-	I
12	4FB	I
13	,	O
14	and	O
15	AP	B
16	-	I
17	1	I
18	sequences	O
19	are	O
20	each	O
21	necessary	O
22	for	O
23	full	O
24	enhancer	O
25	activity	O
26	.	O
1	Hence	O
2	follows	O
3	Kurti	O
4	'	O
5	s	O
6	demand	O
7	to	O
8	mete	O
9	out	O
10	appropriate	O
11	importance	O
12	to	O
13	the	O
14	arguments	O
15	.	O
1	The	O
2	author	O
3	gives	O
4	an	O
5	account	O
6	of	O
7	antipsychotic	O
8	,	O
9	analgetic	O
10	,	O
11	myorelaxing	O
12	and	O
13	vasodilatating	O
14	effects	O
15	of	O
16	some	O
17	calcium	O
18	antagonists	O
19	,	O
20	and	O
21	their	O
22	clinical	O
23	application	O
24	is	O
25	discussed	O
26	.	O
1	It	O
2	was	O
3	possible	O
4	to	O
5	classify	O
6	the	O
7	animals	O
8	into	O
9	high	O
10	and	O
11	low	O
12	responders	O
13	according	O
14	to	O
15	the	O
16	pattern	O
17	of	O
18	humoral	O
19	immune	O
20	response	O
21	.	O
1	1	O
2	-(	O
3	1	O
4	-	O
5	Naphthyl	O
6	)	O
7	piperazine	O
8	(	O
9	1	O
10	-	O
11	NP	O
12	)	O
13	has	O
14	been	O
15	reported	O
16	to	O
17	have	O
18	serotonin	O
19	antagonist	O
20	properties	O
21	at	O
22	the	O
23	5	B
24	-	I
25	HT2	I
26	subtype	I
27	of	O
28	receptor	O
29	,	O
30	and	O
31	it	O
32	has	O
33	been	O
34	suggested	O
35	that	O
36	it	O
37	may	O
38	have	O
39	agonist	O
40	actions	O
41	at	O
42	the	O
43	5	B
44	-	I
45	HT1	I
46	site	I
47	.	O
1	Electrocardiographic	O
2	right	O
3	ventricular	O
4	hypertrophy	O
5	was	O
6	seen	O
7	in	O
8	4	O
9	,	O
10	and	O
11	biventricular	O
12	hypertrophy	O
13	in	O
14	5	O
15	patients	O
16	.	O
1	Experiments	O
2	on	O
3	23	O
4	white	O
5	rats	O
6	and	O
7	10	O
8	guinea	O
9	pigs	O
10	have	O
11	shown	O
12	that	O
13	preliminarily	O
14	indomethacin	O
15	-	O
16	induced	O
17	inhibition	O
18	of	O
19	prostaglandins	O
20	synthesis	O
21	prevented	O
22	development	O
23	of	O
24	pulmonary	O
25	oedema	O
26	,	O
27	evoked	O
28	by	O
29	heterologous	O
30	serum	O
31	in	O
32	rats	O
33	and	O
34	by	O
35	vagotomy	O
36	in	O
37	guinea	O
38	pigs	O
39	.	O
1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	lack	O
7	of	O
8	conservation	O
9	of	O
10	the	O
11	membrane	O
12	attachment	O
13	sequence	O
14	arginine	O
15	-	O
16	glycine	O
17	-	O
18	aspartic	O
19	acid	O
20	argues	O
21	against	O
22	its	O
23	functional	O
24	importance	O
25	in	O
26	CgA	B
27	.	O
1	The	O
2	percentages	O
3	of	O
4	formed	O
5	cysts	O
6	and	O
7	growth	O
8	rates	O
9	were	O
10	monthly	O
11	estimated	O
12	and	O
13	analyzed	O
14	rhythmometrically	O
15	by	O
16	cosinor	O
17	for	O
18	5	O
19	clonal	O
20	cultures	O
21	of	O
22	Scripsiella	O
23	trochoidea	O
24	Stein	O
25	grown	O
26	for	O
27	2	O
28	years	O
29	under	O
30	laboratory	O
31	conditions	O
32	,	O
33	rended	O
34	as	O
35	constant	O
36	as	O
37	possible	O
38	from	O
39	the	O
40	view	O
41	point	O
42	of	O
43	environmental	O
44	temperature	O
45	(	O
46	24	O
47	+/-	O
48	1	O
49	degree	O
50	C	O
51	),	O
52	lighting	O
53	(	O
54	25	O
55	microEin	O
56	m	O
57	-	O
58	2	O
59	s	O
60	-	O
61	1	O
62	),	O
63	and	O
64	artificial	O
65	seawater	O
66	.	O
1	The	O
2	use	O
3	of	O
4	an	O
5	appropriate	O
6	solution	O
7	of	O
8	methylene	O
9	blue	O
10	(	O
11	0	O
12	.	O
13	2	O
14	%	O
15	in	O
16	0	O
17	.	O
18	9	O
19	M	O
20	NaCl	O
21	for	O
22	15	O
23	min	O
24	)	O
25	permits	O
26	the	O
27	staining	O
28	of	O
29	premalignant	O
30	areas	O
31	and	O
32	CIS	O
33	,	O
34	and	O
35	their	O
36	early	O
37	diagnosis	O
38	.	O
1	Lower	O
2	limits	O
3	(	O
4	to	O
5	10	O
6	micrograms	O
7	/	O
8	kg	O
9	)	O
10	were	O
11	detectable	O
12	,	O
13	but	O
14	with	O
15	lower	O
16	reliability	O
17	(	O
18	60	O
19	%).	O
1	The	O
2	subepicardial	O
3	lymphatic	O
4	capillaries	O
5	were	O
6	ramified	O
7	and	O
8	anastomosed	O
9	with	O
10	each	O
11	other	O
12	to	O
13	form	O
14	a	O
15	relatively	O
16	dense	O
17	network	O
18	which	O
19	extended	O
20	over	O
21	the	O
22	entire	O
23	surface	O
24	of	O
25	both	O
26	ventricles	O
27	.	O
1	During	O
2	sub	O
3	-	O
4	maximal	O
5	exercise	O
6	,	O
7	DCR	O
8	in	O
9	the	O
10	UT	O
11	dogs	O
12	decreased	O
13	from	O
14	a	O
15	resting	O
16	value	O
17	of	O
18	4	O
19	.	O
20	08	O
21	+/-	O
22	0	O
23	.	O
24	18	O
25	mm	O
26	Hg	O
27	X	O
28	ml	O
29	-	O
30	1	O
31	X	O
32	min	O
33	-	O
34	1	O
35	to	O
36	1	O
37	.	O
38	91	O
39	+/-	O
40	0	O
41	.	O
42	17	O
43	mm	O
44	Hg	O
45	X	O
46	ml	O
47	-	O
48	1	O
49	X	O
50	min	O
51	-	O
52	1	O
53	at	O
54	a	O
55	workload	O
56	of	O
57	6	O
58	.	O
59	4	O
60	kph	O
61	(	O
62	speed	O
63	)/	O
64	16	O
65	%	O
66	(	O
67	grade	O
68	).	O
1	Irmiere	O
2	,	O
3	and	O
4	W	O
5	.	O
1	The	O
2	lack	O
3	of	O
4	change	O
5	in	O
6	the	O
7	ratio	O
8	of	O
9	the	O
10	two	O
11	spliced	O
12	products	O
13	expressed	O
14	from	O
15	either	O
16	the	O
17	normal	O
18	or	O
19	the	O
20	5	B
21	'-	I
22	rearranged	I
23	myb	I
24	further	O
25	indicates	O
26	that	O
27	the	O
28	insertion	O
29	of	O
30	the	O
31	unique	O
32	121	O
33	amino	O
34	acids	O
35	in	O
36	the	O
37	larger	O
38	myb	B
39	transcripts	I
40	is	O
41	not	O
42	a	O
43	consequence	O
44	of	O
45	tumor	O
46	-	O
47	specific	O
48	activation	O
49	of	O
50	the	O
51	mouse	B
52	myb	I
53	oncogene	I
54	.	O
1	The	O
2	predicted	O
3	L	B
4	mRNA	I
5	was	O
6	6398	O
7	nucleotides	O
8	long	O
9	and	O
10	contained	O
11	a	O
12	single	O
13	open	O
14	reading	O
15	frame	O
16	corresponding	O
17	to	O
18	an	O
19	L	B
20	protein	I
21	encompassing	I
22	2109	I
23	amino	I
24	acids	I
25	with	O
26	a	O
27	MW	O
28	of	O
29	241	O
30	,	O
31	546	O
32	.	O
1	Mo	O
2	+	O
3	SV	O
4	M	O
5	-	O
6	MuLV	O
7	-	O
8	inoculated	O
9	animals	O
10	became	O
11	moribund	O
12	at	O
13	3	O
14	to	O
15	13	O
16	months	O
17	postinoculation	O
18	,	O
19	whereas	O
20	delta	O
21	Mo	O
22	+	O
23	SV	O
24	M	O
25	-	O
26	MuLV	O
27	-	O
28	inoculated	O
29	animals	O
30	became	O
31	moribund	O
32	at	O
33	6	O
34	to	O
35	24	O
36	months	O
37	postinoculation	O
38	.	O
1	In	O
2	these	O
3	cells	O
4	,	O
5	E2	B
6	proteins	I
7	had	O
8	little	O
9	or	O
10	no	O
11	stimulatory	O
12	effect	O
13	on	O
14	the	O
15	transcriptional	O
16	activity	O
17	of	O
18	the	O
19	HPV	B
20	-	I
21	11	I
22	enhancer	I
23	-	O
24	SV40	B
25	promoter	I
26	.	O
1	Chronic	O
2	E	O
3	-	O
4	B	O
5	virus	O
6	infection	O
7	terminated	O
8	in	O
9	malignant	O
10	lymphoma	O
11	:	O
12	a	O
13	case	O
14	report	O
1	Whereas	O
2	the	O
3	muscle	O
4	isoform	O
5	consists	O
6	of	O
7	997	O
8	amino	O
9	acids	O
10	and	O
11	terminates	O
12	with	O
13	the	O
14	sequence	O
15	Ala	O
16	-	O
17	Ile	O
18	-	O
19	Leu	O
20	-	O
21	Glu	O
22	,	O
23	the	O
24	second	O
25	isoform	O
26	is	O
27	1043	O
28	amino	O
29	acids	O
30	in	O
31	length	O
32	due	O
33	to	O
34	the	O
35	replacement	O
36	of	O
37	these	O
38	last	O
39	4	O
40	amino	O
41	acids	O
42	with	O
43	a	O
44	50	O
45	-	O
46	amino	O
47	acid	O
48	sequence	O
49	that	O
50	contains	O
51	a	O
52	potential	O
53	transmembrane	O
54	domain	O
55	followed	O
56	by	O
57	a	O
58	consensus	O
59	sequence	O
60	for	O
61	an	O
62	N	O
63	-	O
64	linked	O
65	glycosylation	O
66	site	O
67	.	O
1	Substitution	O
2	of	O
3	a	O
4	threonine	O
5	residue	O
6	by	O
7	an	O
8	alanine	O
9	residue	O
10	at	O
11	position	O
12	-	O
13	2	O
14	(	O
15	P2	O
16	)	O
17	of	O
18	this	O
19	cleavage	O
20	site	O
21	abolished	O
22	cleavage	O
23	,	O
24	whereas	O
25	substitution	O
26	of	O
27	a	O
28	tyrosine	O
29	residue	O
30	by	O
31	a	O
32	phenylalanine	O
33	residue	O
34	at	O
35	amino	O
36	acid	O
37	position	O
38	-	O
39	1	O
40	(	O
41	P1	O
42	)	O
43	of	O
44	the	O
45	cleavage	O
46	site	O
47	did	O
48	not	O
49	influence	O
50	processing	O
51	.	O
1	A	O
2	highly	O
3	hydrophobic	O
4	sequence	O
5	located	O
6	near	O
7	the	O
8	carboxyl	O
9	-	O
10	terminal	O
11	extremity	O
12	of	O
13	the	O
14	molecule	O
15	most	O
16	likely	O
17	constitutes	O
18	the	O
19	anchor	O
20	to	O
21	the	O
22	plasma	O
23	membrane	O
24	.	O
1	Elevated	O
2	IOP	O
3	developed	O
4	in	O
5	35	O
6	patients	O
7	(	O
8	44	O
9	eyes	O
10	)	O
11	during	O
12	the	O
13	study	O
14	.	O
1	Output	O
2	of	O
3	99mTcO	O
4	-	O
5	4	O
6	by	O
7	the	O
8	parotid	O
9	gland	O
10	closely	O
11	mimicked	O
12	fluctuations	O
13	in	O
14	parotid	O
15	saliva	O
16	flow	O
17	rate	O
18	.	O
1	Prenatal	O
2	exposure	O
3	to	O
4	the	O
5	fungicide	O
6	dinocap	O
7	causes	O
8	behavioral	O
9	torticollis	O
10	,	O
11	ballooning	O
12	and	O
13	cleft	O
14	palate	O
15	in	O
16	mice	O
17	,	O
18	but	O
19	not	O
20	rats	O
21	or	O
22	hamsters	O
23	.	O
1	Six	O
2	patients	O
3	with	O
4	human	O
5	T	O
6	-	O
7	cell	O
8	lymphotropic	O
9	virus	O
10	type	O
11	I	O
12	(	O
13	HTLV	O
14	-	O
15	I	O
16	)-	O
17	associated	O
18	myelopathy	O
19	(	O
20	HAM	O
21	)	O
22	were	O
23	studied	O
24	by	O
25	electrophysiologic	O
26	methods	O
27	.	O
1	Testing	O
2	blood	O
3	donors	O
4	for	O
5	non	O
6	-	O
7	A	O
8	,	O
9	non	O
10	-	O
11	B	O
12	hepatitis	O
13	:	O
14	irrational	O
15	,	O
16	perhaps	O
17	,	O
18	but	O
19	inescapable	O
20	.	O
1	In	O
2	a	O
3	randomised	O
4	double	O
5	-	O
6	blind	O
7	study	O
8	,	O
9	46	O
10	first	O
11	episode	O
12	schizophrenics	O
13	were	O
14	given	O
15	pimozide	O
16	or	O
17	flupenthixol	O
18	for	O
19	up	O
20	to	O
21	5	O
22	weeks	O
23	;	O
24	the	O
25	mean	O
26	daily	O
27	dose	O
28	at	O
29	the	O
30	end	O
31	was	O
32	18	O
33	.	O
34	8	O
35	mg	O
36	pimozide	O
37	and	O
38	20	O
39	mg	O
40	flupenthixol	O
41	.	O
1	Direct	O
2	and	O
3	inverted	O
4	repeat	O
5	elements	O
6	of	O
7	10	O
8	,	O
9	11	O
10	,	O
11	16	O
12	,	O
13	19	O
14	,	O
15	and	O
16	22	O
17	nucleotides	O
18	(	O
19	nt	O
20	)	O
21	flank	O
22	the	O
23	promoter	O
24	site	O
25	.	O
1	Transformed	O
2	bacterial	O
3	colonies	O
4	were	O
5	screened	O
6	for	O
7	recombinant	O
8	plasmids	O
9	containing	O
10	cDNA	O
11	coding	O
12	for	O
13	BiP	B
14	by	O
15	hybrid	O
16	-	O
17	selected	O
18	mRNA	O
19	translation	O
20	.	O
1	DPA	O
2	attenuated	O
3	the	O
4	increase	O
5	of	O
6	the	O
7	intensity	O
8	of	O
9	the	O
10	ischemic	O
11	and	O
12	pressure	O
13	pain	O
14	components	O
15	with	O
16	increasing	O
17	ischemia	O
18	duration	O
19	,	O
20	but	O
21	only	O
22	the	O
23	effect	O
24	on	O
25	the	O
26	pressure	O
27	pain	O
28	component	O
29	was	O
30	significant	O
31	.	O
1	This	O
2	loss	O
3	was	O
4	independent	O
5	of	O
6	drug	O
7	concentration	O
8	and	O
9	a	O
10	correction	O
11	factor	O
12	was	O
13	employed	O
14	to	O
15	calculate	O
16	the	O
17	true	O
18	free	O
19	diazepam	O
20	concentration	O
21	.	O
1	Pharmacology	O
2	studies	O
3	with	O
4	potassium	O
5	chloride	O
6	and	O
7	acetylcholine	O
8	suggest	O
9	that	O
10	raveron	O
11	acts	O
12	as	O
13	a	O
14	calcium	O
15	antagonist	O
16	by	O
17	blocking	O
18	the	O
19	influx	O
20	of	O
21	extracellular	O
22	calcium	O
23	.	O
1	On	O
2	admission	O
3	to	O
4	the	O
5	ICU	O
6	,	O
7	117	O
8	patients	O
9	(	O
10	61	O
11	percent	O
12	)	O
13	had	O
14	hypomagnesemia	O
15	(	O
16	serum	O
17	Mg	O
18	less	O
19	than	O
20	1	O
21	.	O
22	5	O
23	mEq	O
24	/	O
25	dl	O
26	),	O
27	66	O
28	patients	O
29	(	O
30	34	O
31	percent	O
32	)	O
33	had	O
34	normomagnesemia	O
35	(	O
36	1	O
37	.	O
38	5	O
39	to	O
40	2	O
41	.	O
42	0	O
43	mEq	O
44	/	O
45	dl	O
46	),	O
47	and	O
48	ten	O
49	patients	O
50	(	O
51	5	O
52	percent	O
53	)	O
54	had	O
55	hypermagnesemia	O
56	(	O
57	greater	O
58	than	O
59	2	O
60	.	O
61	0	O
62	mEq	O
63	/	O
64	dl	O
65	).	O
1	Hemodynamic	O
2	assessment	O
3	was	O
4	obtained	O
5	before	O
6	and	O
7	following	O
8	administration	O
9	of	O
10	digoxin	O
11	10	O
12	micrograms	O
13	/	O
14	kg	O
15	IV	O
16	or	O
17	dopamine	O
18	,	O
19	5	O
20	to	O
21	12	O
22	micrograms	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	IV	O
28	.	O
1	Successful	O
2	use	O
3	of	O
4	transureteroureterostomy	O
5	to	O
6	salvage	O
7	ureterosigmoidostomy	O
8	after	O
9	anastomotic	O
10	failure	O
11	.	O
1	The	O
2	data	O
3	indicates	O
4	the	O
5	presence	O
6	of	O
7	5	B
8	-	I
9	HT2	I
10	serotonergic	I
11	receptors	I
12	in	O
13	the	O
14	bronchial	O
15	artery	O
16	of	O
17	these	O
18	species	O
19	.	O
1	Platelet	O
2	function	O
3	and	O
4	platelet	O
5	-	O
6	polymorphonuclear	O
7	-	O
8	neutrophil	O
9	interaction	O
10	in	O
11	patients	O
12	with	O
13	deficient	O
14	platelet	B
15	lipoxygenase	I
16	activity	O
17	.	O
1	Thus	O
2	,	O
3	quantitative	O
4	analysis	O
5	of	O
6	thallium	O
7	-	O
8	201	O
9	uptake	O
10	and	O
11	washout	O
12	provided	O
13	objective	O
14	evidence	O
15	for	O
16	improved	O
17	myocardial	O
18	perfusion	O
19	after	O
20	coronary	O
21	angioplasty	O
22	.	O
1	Schedule	O
2	2	O
3	,	O
4	in	O
5	which	O
6	2	O
7	.	O
8	4	O
9	mg	O
10	/	O
11	kg	O
12	c	O
13	-	O
14	DDP	O
15	was	O
16	administered	O
17	immediately	O
18	before	O
19	X	O
20	-	O
21	ray	O
22	on	O
23	5	O
24	consecutive	O
25	days	O
26	produced	O
27	the	O
28	highest	O
29	degree	O
30	of	O
31	enhancement	O
32	of	O
33	radiation	O
34	effect	O
35	(	O
36	expressed	O
37	as	O
38	dose	O
39	-	O
40	effect	O
41	factor	O
42	);	O
43	and	O
44	the	O
45	next	O
46	greatest	O
47	enhancement	O
48	was	O
49	produced	O
50	by	O
51	12	O
52	mg	O
53	/	O
54	kg	O
55	c	O
56	-	O
57	DDP	O
58	administered	O
59	24	O
60	h	O
61	before	O
62	the	O
63	start	O
64	of	O
65	fractionated	O
66	daily	O
67	radiotherapy	O
68	.	O
1	The	O
2	cpc	B
3	-	I
4	1	I
5	-	I
6	encoded	I
7	transcript	I
8	contains	O
9	three	O
10	open	O
11	reading	O
12	frames	O
13	,	O
14	two	O
15	of	O
16	which	O
17	are	O
18	located	O
19	in	O
20	the	O
21	720	O
22	-	O
23	nucleotide	O
24	leader	O
25	segment	O
26	preceding	O
27	the	O
28	cpc	B
29	-	I
30	1	I
31	coding	I
32	region	I
33	.	O
1	Atomic	O
2	absorption	O
3	spectrophotometry	O
4	applied	O
5	to	O
6	bacterially	O
7	expressed	O
8	E1A	B
9	proteins	I
10	revealed	O
11	that	O
12	the	O
13	289	O
14	-	O
15	amino	O
16	acid	O
17	protein	O
18	binds	O
19	one	O
20	zinc	O
21	ion	O
22	,	O
23	whereas	O
24	the	O
25	243	O
26	-	O
27	amino	O
28	acid	O
29	protein	O
30	binds	O
31	no	O
32	zinc	O
33	.	O
1	The	O
2	absorbable	O
3	perisplenic	O
4	mesh	O
5	is	O
6	an	O
7	important	O
8	improvement	O
9	,	O
10	and	O
11	in	O
12	some	O
13	cases	O
14	it	O
15	may	O
16	replace	O
17	other	O
18	techniques	O
19	for	O
20	arresting	O
21	splenic	O
22	bleeding	O
23	.	O
1	A	O
2	rare	O
3	chronic	O
4	course	O
5	of	O
6	Budd	O
7	-	O
8	Chiari	O
9	syndrome	O
10	associated	O
11	with	O
12	thrombosis	O
13	of	O
14	the	O
15	portal	O
16	vein	O
17	was	O
18	observed	O
19	in	O
20	a	O
21	30	O
22	-	O
23	year	O
24	-	O
25	old	O
26	male	O
27	patient	O
28	suffering	O
29	from	O
30	postmyocarditic	O
31	cardiosclerosis	O
32	.	O
1	After	O
2	one	O
3	accommodation	O
4	night	O
5	,	O
6	sleep	O
7	EEG	O
8	recordings	O
9	were	O
10	performed	O
11	during	O
12	three	O
13	consecutive	O
14	nights	O
15	in	O
16	ten	O
17	drug	O
18	-	O
19	free	O
20	inpatients	O
21	presenting	O
22	generalized	O
23	anxiety	O
24	disorder	O
25	(	O
26	GAD	O
27	)	O
28	with	O
29	significant	O
30	depression	O
31	,	O
32	compared	O
33	with	O
34	a	O
35	age	O
36	-	O
37	and	O
38	sex	O
39	-	O
40	matched	O
41	group	O
42	of	O
43	patients	O
44	with	O
45	GAD	O
46	and	O
47	a	O
48	group	O
49	of	O
50	primary	O
51	major	O
52	depressive	O
53	disorder	O
54	(	O
55	MDD	O
56	)	O
57	patients	O
58	.	O
1	Evidence	O
2	for	O
3	a	O
4	role	O
5	of	O
6	endogenous	B
7	corticotropin	I
8	-	I
9	releasing	I
10	factor	I
11	in	O
12	cold	O
13	,	O
14	ether	O
15	,	O
16	immobilization	O
17	,	O
18	and	O
19	traumatic	O
20	stress	O
21	.	O
1	FK	O
2	33	O
3	-	O
4	824	O
5	,	O
6	a	O
7	methionine	O
8	-	O
9	enkephalin	B
10	analogue	O
11	,	O
12	suppressed	O
13	plasma	O
14	ACTH	B
15	to	O
16	85	O
17	%	O
18	of	O
19	basal	O
20	level	O
21	,	O
22	while	O
23	bromocriptine	O
24	(	O
25	CB	O
26	-	O
27	154	O
28	)	O
29	caused	O
30	no	O
31	significant	O
32	change	O
33	.	O
1	Examination	O
2	of	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	Punta	B
8	Toro	I
9	M	I
10	gene	I
11	product	I
12	reveals	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	hydrophobic	O
18	sequences	O
19	including	O
20	a	O
21	19	O
22	-	O
23	amino	O
24	acid	O
25	,	O
26	carboxy	O
27	-	O
28	proximal	O
29	,	O
30	hydrophobic	O
31	region	O
32	(	O
33	G2	O
34	).	O
1	The	O
2	210	O
3	kDa	O
4	precursor	O
5	is	O
6	converted	O
7	slowly	O
8	(	O
9	t	O
10	1	O
11	/	O
12	2	O
13	=	O
14	2	O
15	h	O
16	)	O
17	by	O
18	proteolytic	O
19	processing	O
20	into	O
21	a	O
22	125	O
23	kDa	O
24	(	O
25	alpha	O
26	')	O
27	and	O
28	83	O
29	kDa	O
30	(	O
31	beta	O
32	')	O
33	species	O
34	.	O
1	At	O
2	temperatures	O
3	permissive	O
4	for	O
5	transformation	O
6	,	O
7	6m2	O
8	cells	O
9	contain	O
10	P58gag	B
11	produced	O
12	from	O
13	the	O
14	4	O
15	.	O
16	0	O
17	-	O
18	kilobase	O
19	(	O
20	kb	O
21	)	O
22	viral	O
23	RNA	O
24	genome	O
25	and	O
26	P85gag	B
27	-	O
28	mos	B
29	translated	O
30	from	O
31	a	O
32	3	O
33	.	O
34	5	O
35	-	O
36	kb	O
37	spliced	O
38	mRNA	O
39	.	O
1	The	O
2	pet56	B
3	and	O
4	his3	B
5	genes	I
6	are	O
7	transcribed	O
8	divergently	O
9	from	O
10	initiation	O
11	sites	O
12	that	O
13	are	O
14	separated	O
15	by	O
16	only	O
17	192	O
18	bp	O
19	.	O
1	Comparison	O
2	of	O
3	sequences	O
4	of	O
5	ovine	O
6	and	O
7	bovine	O
8	,	O
9	rat	O
10	and	O
11	guinea	B
12	-	I
13	pig	I
14	alpha	I
15	s1	I
16	-	I
17	casein	I
18	mRNAs	I
19	has	O
20	revealed	O
21	a	O
22	greater	O
23	homology	O
24	in	O
25	the	O
26	3	O
27	'	O
28	and	O
29	especially	O
30	5	O
31	'	O
32	non	O
33	coding	O
34	regions	O
35	.	O
1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	3874	O
6	bp	O
7	of	O
8	cloned	O
9	R	O
10	.	O
11	sphaeroides	O
12	chromosomal	O
13	DNA	O
14	,	O
15	including	O
16	the	O
17	three	O
18	structural	O
19	genes	O
20	fbcF	B
21	,	O
22	fbcB	B
23	and	O
24	fbcC	B
25	has	O
26	been	O
27	determined	O
28	.	O
1	Two	O
2	copies	O
3	of	O
4	the	O
5	72	O
6	-	O
7	bp	O
8	repeat	O
9	provided	O
10	efficient	O
11	activation	O
12	of	O
13	gene	O
14	expression	O
15	.	O
1	Diazepam	O
2	(	O
3	3	O
4	mg	O
5	/	O
6	kg	O
7	)	O
8	generalized	O
9	to	O
10	Ro	O
11	11	O
12	-	O
13	6896	O
14	whereas	O
15	the	O
16	structurally	O
17	related	O
18	Ro	O
19	5	O
20	-	O
21	4864	O
22	(	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	and	O
28	30	O
29	mg	O
30	/	O
31	kg	O
32	)	O
33	did	O
34	not	O
35	.	O
1	The	O
2	hexanucleotide	O
3	5	O
4	'-	O
5	TGTCCT	O
6	-	O
7	3	O
8	',	O
9	thought	O
10	to	O
11	be	O
12	important	O
13	for	O
14	GRE	O
15	activity	O
16	,	O
17	not	O
18	only	O
19	was	O
20	found	O
21	in	O
22	this	O
23	sequence	O
24	and	O
25	in	O
26	the	O
27	5	O
28	'-	O
29	flanking	O
30	region	O
31	,	O
32	but	O
33	also	O
34	was	O
35	present	O
36	twice	O
37	in	O
38	the	O
39	3	O
40	'	O
41	end	O
42	of	O
43	the	O
44	gene	O
45	that	O
46	did	O
47	not	O
48	show	O
49	specific	O
50	receptor	O
51	binding	O
52	.	O
1	Translation	O
2	of	O
3	specific	O
4	cellular	O
5	genes	O
6	from	O
7	the	O
8	chimeric	O
9	viral	O
10	-	O
11	cellular	O
12	transcripts	O
13	seems	O
14	to	O
15	be	O
16	unlikely	O
17	.	O
1	Insertion	O
2	of	O
3	4	O
4	bp	O
5	reduced	O
6	SV40	B
7	early	I
8	promoter	I
9	-	O
10	dependent	O
11	chloramphenicol	B
12	acetyltransferase	I
13	(	O
14	CAT	B
15	)	O
16	expression	O
17	by	O
18	six	O
19	-	O
20	to	O
21	eightfold	O
22	.	O
1	Two	O
2	mutants	O
3	,	O
4	each	O
5	representative	O
6	of	O
7	a	O
8	separate	O
9	pet	B
10	complementation	O
11	group	O
12	,	O
13	have	O
14	been	O
15	analyzed	O
16	.	O
1	Constitutive	O
2	function	O
3	of	O
4	a	O
5	positively	O
6	regulated	O
7	promoter	O
8	reveals	O
9	new	O
10	sequences	O
11	essential	O
12	for	O
13	activity	O
14	.	O
1	ACTH	B
2	release	O
3	is	O
4	transiently	O
5	suppressed	O
6	in	O
7	some	O
8	children	O
9	after	O
10	exogenous	O
11	ACTH	B
12	treatment	O
13	.	O
1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	upstream	O
7	promoter	O
8	element	O
9	of	O
10	the	O
11	yeast	B
12	RP39A	I
13	gene	I
14	consists	O
15	of	O
16	these	O
17	identical	O
18	sequence	O
19	motifs	O
20	.	O
1	One	O
2	group	O
3	of	O
4	six	O
5	cDNA	O
6	clones	O
7	was	O
8	derived	O
9	from	O
10	a	O
11	2	O
12	.	O
13	9	O
14	-	O
15	kilobase	O
16	early	O
17	transcript	O
18	encoded	O
19	by	O
20	the	O
21	IR2	O
22	repeat	O
23	element	O
24	and	O
25	showed	O
26	restriction	O
27	site	O
28	polymorphism	O
29	for	O
30	the	O
31	enzyme	B
32	SmaI	I
33	.	O
1	Morphine	O
2	produced	O
3	a	O
4	dose	O
5	-	O
6	dependent	O
7	bradycardia	O
8	followed	O
9	by	O
10	tachycardia	O
11	.	O
1	The	O
2	presence	O
3	of	O
4	circulating	O
5	platelet	O
6	aggregates	O
7	and	O
8	elevated	O
9	levels	O
10	of	O
11	fibrinopeptide	B
12	A	I
13	(	O
14	a	O
15	cleavage	O
16	product	O
17	of	O
18	fibrin	B
19	)	O
20	suggests	O
21	that	O
22	platelet	O
23	activation	O
24	and	O
25	fibrin	B
26	deposition	O
27	may	O
28	play	O
29	a	O
30	role	O
31	in	O
32	the	O
33	pathogenesis	O
34	of	O
35	this	O
36	disorder	O
37	.	O
1	This	O
2	makes	O
3	these	O
4	compounds	O
5	attractive	O
6	as	O
7	vehicles	O
8	for	O
9	these	O
10	and	O
11	other	O
12	gases	O
13	in	O
14	-	O
15	vivo	O
16	and	O
17	in	O
18	-	O
19	vitro	O
20	.	O
1	The	O
2	relationship	O
3	between	O
4	primary	O
5	malignant	O
6	lymphoma	O
7	of	O
8	the	O
9	thyroid	O
10	and	O
11	chronic	O
12	thyroiditis	O
13	is	O
14	discussed	O
15	.	O
1	However	O
2	,	O
3	excretion	O
4	of	O
5	6	O
6	-	O
7	keto	O
8	-	O
9	prostaglandin	O
10	F1	O
11	alpha	O
12	was	O
13	further	O
14	reduced	O
15	in	O
16	the	O
17	smokers	O
18	who	O
19	used	O
20	oral	O
21	contraceptives	O
22	(	O
23	133	O
24	+/-	O
25	20	O
26	to	O
27	86	O
28	+/-	O
29	9	O
30	ng	O
31	/	O
32	gm	O
33	of	O
34	creatinine	O
35	,	O
36	p	O
37	less	O
38	than	O
39	0	O
40	.	O
41	05	O
42	).	O
1	Recurrence	O
2	of	O
3	oxalate	O
4	deposition	O
5	in	O
6	a	O
7	renal	O
8	transplant	O
9	during	O
10	ciclosporin	O
11	A	O
12	therapy	O
13	.	O
1	Modifications	O
2	of	O
3	the	O
4	involuntary	O
5	postcontraction	O
6	in	O
7	diseased	O
8	people	O
9	.	O
1	During	O
2	BH	O
3	the	O
4	ventilator	O
5	was	O
6	disconnected	O
7	and	O
8	a	O
9	bias	O
10	flow	O
11	of	O
12	50	O
13	%	O
14	O2	O
15	at	O
16	4	O
17	-	O
18	5	O
19	l	O
20	/	O
21	min	O
22	was	O
23	delivered	O
24	through	O
25	the	O
26	side	O
27	ports	O
28	of	O
29	a	O
30	small	O
31	catheter	O
32	whose	O
33	tip	O
34	was	O
35	positioned	O
36	1	O
37	cm	O
38	cephalad	O
39	of	O
40	the	O
41	carina	O
42	.	O
1	Significant	O
2	treatment	O
3	-	O
4	related	O
5	problems	O
6	appeared	O
7	during	O
8	the	O
9	second	O
10	decade	O
11	in	O
12	5	O
13	patients	O
14	,	O
15	including	O
16	one	O
17	chest	O
18	wall	O
19	sarcoma	O
20	;	O
21	all	O
22	of	O
23	these	O
24	patients	O
25	had	O
26	received	O
27	at	O
28	least	O
29	60	O
30	Gy	O
31	to	O
32	breast	O
33	and	O
34	regional	O
35	nodal	O
36	areas	O
37	.	O
1	Clinical	O
2	and	O
3	biological	O
4	correlates	O
5	of	O
6	panic	O
7	states	O
8	.	O
1	Effects	O
2	of	O
3	long	O
4	-	O
5	term	O
6	parenteral	O
7	nutrition	O
8	on	O
9	gastrin	B
10	release	O
11	in	O
12	dogs	O
13	.	O
1	Of	O
2	7	O
3	patients	O
4	treated	O
5	with	O
6	cyclophosphamide	O
7	,	O
8	hexamethylmelamine	O
9	,	O
10	adriamycin	O
11	and	O
12	cisplatin	O
13	(	O
14	CHAP	O
15	-	O
16	5	O
17	),	O
18	6	O
19	had	O
20	measurable	O
21	disease	O
22	,	O
23	of	O
24	whom	O
25	5	O
26	yielded	O
27	a	O
28	response	O
29	(	O
30	2	O
31	complete	O
32	responses	O
33	for	O
34	19	O
35	+	O
36	and	O
37	40	O
38	months	O
39	and	O
40	3	O
41	partial	O
42	responses	O
43	for	O
44	4	O
45	,	O
46	7	O
47	and	O
48	8	O
49	months	O
50	).	O
1	The	O
2	genetic	O
3	basis	O
4	for	O
5	the	O
6	expression	O
7	of	O
8	a	O
9	latent	O
10	VH	B
11	allotype	I
12	in	O
13	the	O
14	rabbit	O
15	was	O
16	investigated	O
17	.	O
1	HDL	B
2	-	I
3	cholesterol	I
4	(+	O
5	6	O
6	%,	O
7	P	O
8	less	O
9	than	O
10	.	O
11	01	O
12	)	O
13	and	O
14	apolipoprotein	B
15	A	I
16	-	I
17	I	I
18	(+	O
19	6	O
20	%,	O
21	P	O
22	less	O
23	than	O
24	.	O
25	01	O
26	)	O
27	concentrations	O
28	increased	O
29	significantly	O
30	only	O
31	in	O
32	the	O
33	young	O
34	.	O
1	Of	O
2	49	O
3	receptors	O
4	which	O
5	fired	O
6	in	O
7	phase	O
8	with	O
9	ventilation	O
10	,	O
11	13	O
12	behaved	O
13	like	O
14	mammalian	O
15	rapidly	O
16	adapting	O
17	pulmonary	O
18	stretch	O
19	receptors	O
20	,	O
21	19	O
22	like	O
23	mammalian	O
24	slowly	O
25	adapting	O
26	pulmonary	O
27	stretch	O
28	receptors	O
29	(	O
30	PSR	O
31	),	O
32	and	O
33	17	O
34	like	O
35	avian	O
36	intrapulmonary	O
37	CO2	O
38	-	O
39	sensitive	O
40	chemoreceptors	O
41	(	O
42	IPC	O
43	).	O
1	Symptomatic	O
2	hyperventilators	O
3	had	O
4	a	O
5	larger	O
6	number	O
7	of	O
8	sighs	O
9	and	O
10	abnormally	O
11	wide	O
12	fluctuations	O
13	in	O
14	baseline	O
15	for	O
16	inspiratory	O
17	time	O
18	,	O
19	expiratory	O
20	time	O
21	,	O
22	and	O
23	PETCO2	O
24	.	O
1	Sci	O
2	.	O
1	The	O
2	platelet	O
3	adhesion	O
4	rate	O
5	on	O
6	these	O
7	layers	O
8	were	O
9	tested	O
10	concerning	O
11	the	O
12	valuation	O
13	of	O
14	the	O
15	haemocompatibility	O
16	of	O
17	the	O
18	basic	O
19	-	O
20	polymers	O
21	polyurethane	O
22	(	O
23	PUR	O
24	),	O
25	polyvinylchloride	O
26	(	O
27	PVC	O
28	),	O
29	and	O
30	polystyrene	O
31	(	O
32	PS	O
33	)	O
34	in	O
35	two	O
36	different	O
37	worked	O
38	test	O
39	chambers	O
40	.	O
1	Conservative	O
2	treatment	O
3	of	O
4	bladder	O
5	carcinoma	O
6	by	O
7	partial	O
8	cystectomy	O
9	and	O
10	interstitial	O
11	iridium	O
12	192	O
13	.	O
1	Existence	O
2	and	O
3	uniqueness	O
4	of	O
5	solutions	O
6	of	O
7	the	O
8	appropriate	O
9	boundary	O
10	value	O
11	problems	O
12	are	O
13	established	O
14	,	O
15	in	O
16	the	O
17	case	O
18	of	O
19	small	O
20	permeability	O
21	coefficients	O
22	and	O
23	transport	O
24	rates	O
25	,	O
26	or	O
27	large	O
28	diffusion	O
29	coefficients	O
30	and	O
31	small	O
32	resistance	O
33	to	O
34	flow	O
35	constants	O
36	.	O
1	The	O
2	partial	O
3	sequence	O
4	of	O
5	the	O
6	62	B
7	-	I
8	kDa	I
9	nuclear	I
10	pore	I
11	glycoprotein	I
12	shows	O
13	little	O
14	similarity	O
15	to	O
16	other	O
17	characterized	O
18	proteins	O
19	and	O
20	elucidates	O
21	structural	O
22	features	O
23	of	O
24	a	O
25	member	O
26	of	O
27	the	O
28	family	O
29	of	O
30	nuclear	B
31	pore	I
32	glycoproteins	I
33	.	O
1	The	O
2	pathogenesis	O
3	of	O
4	Dupuytren	O
5	'	O
6	s	O
7	contracture	O
1	The	O
2	median	O
3	survival	O
4	is	O
5	not	O
6	reached	O
7	with	O
8	a	O
9	median	O
10	follow	O
11	-	O
12	up	O
13	time	O
14	of	O
15	9	O
16	.	O
17	6	O
18	years	O
19	.	O
1	Critical	O
2	evaluation	O
3	of	O
4	various	O
5	methods	O
6	of	O
7	determining	O
8	markers	O
9	of	O
10	fetal	O
11	maturity	O
12	in	O
13	amniotic	O
14	fluid	O
1	Recovery	O
2	was	O
3	characterized	O
4	by	O
5	rapid	O
6	improvement	O
7	such	O
8	that	O
9	all	O
10	measured	O
11	parameters	O
12	normalized	O
13	by	O
14	1	O
15	week	O
16	,	O
17	except	O
18	for	O
19	cross	O
20	-	O
21	sectional	O
22	cardiac	O
23	area	O
24	which	O
25	remained	O
26	dilated	O
27	up	O
28	to	O
29	4	O
30	weeks	O
31	(	O
32	14	O
33	+/-	O
34	3	O
35	cm2	O
36	,	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	05	O
43	versus	O
44	control	O
45	).(	O
46	ABSTRACT	O
47	TRUNCATED	O
48	AT	O
49	250	O
50	WORDS	O
51	)	O
1	Incorporation	O
2	of	O
3	0	O
4	.	O
5	1	O
6	or	O
7	0	O
8	.	O
9	2	O
10	M	O
11	sodium	O
12	dihydrogen	O
13	phosphate	O
14	in	O
15	the	O
16	sugar	O
17	solutions	O
18	resulted	O
19	in	O
20	a	O
21	decrease	O
22	in	O
23	the	O
24	shelf	O
25	-	O
26	life	O
27	of	O
28	diltiazem	O
29	.	O
1	None	O
2	had	O
3	a	O
4	past	O
5	history	O
6	of	O
7	opportunistic	O
8	infections	O
9	;	O
10	neither	O
11	did	O
12	any	O
13	have	O
14	lymphopenia	O
15	.	O
1	Fourteen	O
2	patients	O
3	were	O
4	in	O
5	the	O
6	multifocal	O
7	disease	O
8	group	O
9	;	O
10	13	O
11	were	O
12	detected	O
13	by	O
14	SPECT	O
15	and	O
16	10	O
17	by	O
18	TCT	O
19	.	O
1	In	O
2	one	O
3	of	O
4	these	O
5	tumors	O
6	the	O
7	observed	O
8	rearrangement	O
9	was	O
10	not	O
11	due	O
12	to	O
13	the	O
14	insertion	O
15	of	O
16	an	O
17	intact	O
18	MoMuLV	O
19	provirus	O
20	.	O
1	Finally	O
2	,	O
3	over	O
4	a	O
5	similar	O
6	range	O
7	of	O
8	QO2	O
9	,	O
10	oxygen	O
11	extraction	O
12	was	O
13	greater	O
14	in	O
15	patients	O
16	with	O
17	ARDS	O
18	compared	O
19	to	O
20	patients	O
21	with	O
22	non	O
23	-	O
24	ARDS	O
25	respiratory	O
26	failure	O
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	67	O
34	and	O
35	slope	O
36	=	O
37	-	O
38	0	O
39	.	O
40	62	O
41	vs	O
42	r	O
43	=	O
44	-	O
45	0	O
46	.	O
47	45	O
48	and	O
49	slope	O
50	=	O
51	-	O
52	0	O
53	.	O
54	35	O
55	;	O
56	p	O
57	less	O
58	than	O
59	0	O
60	.	O
61	05	O
62	).	O
1	Hyperprolactinaemia	O
2	,	O
3	moderate	O
4	hypogonadism	O
5	,	O
6	infraclinical	O
7	neuropathies	O
8	,	O
9	arterial	O
10	stenoses	O
11	and	O
12	moderate	O
13	venous	O
14	leakages	O
15	seem	O
16	to	O
17	play	O
18	a	O
19	partial	O
20	role	O
21	of	O
22	organic	O
23	starter	O
24	or	O
25	cofactor	O
26	,	O
27	the	O
28	sexual	O
29	consequences	O
30	of	O
31	which	O
32	are	O
33	amplified	O
34	by	O
35	psychological	O
36	factors	O
37	,	O
38	partly	O
39	secondary	O
40	to	O
41	the	O
42	initial	O
43	sexual	O
44	failures	O
45	.	O
1	Yang	O
2	and	O
3	H	O
4	.	O
1	In	O
2	contrast	O
3	,	O
4	we	O
5	observed	O
6	high	O
7	concentrations	O
8	in	O
9	29	O
10	of	O
11	75	O
12	patients	O
13	with	O
14	tumors	O
15	of	O
16	the	O
17	central	O
18	nervous	O
19	system	O
20	,	O
21	especially	O
22	in	O
23	meningioma	O
24	(	O
25	6	O
26	/	O
27	9	O
28	),	O
29	glioblastoma	O
30	(	O
31	9	O
32	/	O
33	23	O
34	),	O
35	and	O
36	neurinoma	O
37	(	O
38	5	O
39	/	O
40	5	O
41	).	O
1	Revascularization	O
2	after	O
3	anterior	O
4	maxillary	O
5	and	O
6	mandibular	O
7	osteotomy	O
1	The	O
2	German	O
3	Society	O
4	of	O
5	Pediatric	O
6	Oncology	O
7	in	O
8	1981	O
9	initiated	O
10	the	O
11	Cooperative	O
12	Ewing	O
13	'	O
14	s	O
15	Sarcoma	O
16	Study	O
17	(	O
18	CESS	O
19	81	O
20	)	O
21	using	O
22	a	O
23	four	O
24	-	O
25	drug	O
26	combination	O
27	of	O
28	chemotherapy	O
29	prior	O
30	to	O
31	definitive	O
32	local	O
33	control	O
34	with	O
35	surgery	O
36	and	O
37	/	O
38	or	O
39	radiation	O
40	.	O
1	Since	O
2	high	O
3	levels	O
4	of	O
5	immunoglobulin	B
6	G	I
7	were	O
8	demonstrated	O
9	against	O
10	the	O
11	surface	O
12	of	O
13	the	O
14	NVS	O
15	after	O
16	immunization	O
17	,	O
18	passive	O
19	transfer	O
20	experiments	O
21	were	O
22	initiated	O
23	.	O
1	Fifty	O
2	-	O
3	four	O
4	patients	O
5	were	O
6	divided	O
7	into	O
8	groups	O
9	according	O
10	to	O
11	their	O
12	clinical	O
13	presentation	O
14	;	O
15	seven	O
16	asymptomatic	O
17	volunteers	O
18	,	O
19	20	O
20	patients	O
21	with	O
22	duodenal	O
23	-	O
24	gastric	O
25	reflux	O
26	gastropathy	O
27	(	O
28	DRG	O
29	),	O
30	16	O
31	patients	O
32	with	O
33	recurrent	O
34	ulcers	O
35	of	O
36	the	O
37	duodenal	O
38	bulb	O
39	(	O
40	RUD	O
41	),	O
42	and	O
43	11	O
44	patients	O
45	with	O
46	Moynihan	O
47	'	O
48	s	O
49	disease	O
50	.	O
1	No	O
2	previous	O
3	studies	O
4	have	O
5	determined	O
6	the	O
7	pharmaco	O
8	-	O
9	dynamics	O
10	of	O
11	intravenous	O
12	procainamide	O
13	when	O
14	administered	O
15	in	O
16	a	O
17	dose	O
18	of	O
19	15	O
20	mg	O
21	/	O
22	kg	O
23	and	O
24	at	O
25	a	O
26	rate	O
27	of	O
28	50	O
29	mg	O
30	/	O
31	min	O
32	,	O
33	as	O
34	is	O
35	common	O
36	practice	O
37	during	O
38	electropharmacologic	O
39	testing	O
40	.	O
1	High	O
2	concentrations	O
3	of	O
4	tumor	O
5	-	O
6	associated	O
7	trypsin	B
8	inhibitor	O
9	in	O
10	hemodialyzed	O
11	patients	O
12	.	O
1	In	O
2	the	O
3	chicken	O
4	liver	O
5	,	O
6	levels	O
7	of	O
8	chicken	B
9	MT	I
10	mRNA	I
11	were	O
12	rapidly	O
13	induced	O
14	by	O
15	metals	O
16	(	O
17	Cd2	O
18	+,	O
19	Zn2	O
20	+,	O
21	Cu2	O
22	+),	O
23	glucocorticoids	O
24	and	O
25	lipopolysaccharide	O
26	.	O
1	Dosimetric	O
2	estimates	O
3	for	O
4	these	O
5	organs	O
6	were	O
7	2	O
8	.	O
9	3	O
10	+/-	O
11	1	O
12	.	O
13	1	O
14	and	O
15	2	O
16	.	O
17	3	O
18	+/-	O
19	1	O
20	.	O
21	4	O
22	rad	O
23	(.	O
24	02	O
25	+/-	O
26	.	O
27	01	O
28	Gy	O
29	),	O
30	respectively	O
31	,	O
32	with	O
33	a	O
34	whole	O
35	-	O
36	body	O
37	estimate	O
38	of	O
39	0	O
40	.	O
41	28	O
42	rad	O
43	(.	O
44	003	O
45	Gy	O
46	).	O
1	Nucleotide	O
2	sequencing	O
3	indicates	O
4	that	O
5	this	O
6	E1	B
7	alpha	I
8	cDNA	I
9	clone	O
10	is	O
11	1821	O
12	base	O
13	pairs	O
14	(	O
15	bp	O
16	)	O
17	in	O
18	length	O
19	with	O
20	an	O
21	open	O
22	reading	O
23	frame	O
24	of	O
25	1365	O
26	bp	O
27	and	O
28	a	O
29	3	O
30	'-	O
31	untranslated	O
32	region	O
33	of	O
34	356	O
35	bp	O
36	.	O
1	Practical	O
2	interest	O
3	of	O
4	such	O
5	studies	O
6	is	O
7	limited	O
8	since	O
9	the	O
10	pharmacokinetic	O
11	parameters	O
12	are	O
13	systematically	O
14	evaluated	O
15	in	O
16	man	O
17	during	O
18	phase	O
19	I	O
20	trials	O
21	.	O
1	Depending	O
2	on	O
3	the	O
4	location	O
5	and	O
6	size	O
7	of	O
8	the	O
9	mass	O
10	,	O
11	a	O
12	wide	O
13	range	O
14	of	O
15	clinical	O
16	presentations	O
17	is	O
18	associated	O
19	with	O
20	the	O
21	lesion	O
22	.	O
1	Statistical	O
2	analysis	O
3	of	O
4	the	O
5	degrees	O
6	of	O
7	secondary	O
8	spinal	O
9	cord	O
10	compression	O
11	was	O
12	performed	O
13	in	O
14	group	O
15	-	O
16	1	O
17	dogs	O
18	by	O
19	measuring	O
20	and	O
21	comparing	O
22	ratios	O
23	of	O
24	the	O
25	vertical	O
26	to	O
27	the	O
28	horizontal	O
29	diameters	O
30	of	O
31	the	O
32	transverse	O
33	spinal	O
34	cord	O
35	sections	O
36	from	O
37	locations	O
38	within	O
39	(	O
40	T12	O
41	to	O
42	L1	O
43	)	O
44	and	O
45	out	O
46	of	O
47	(	O
48	T11	O
49	,	O
50	T11	O
51	-	O
52	12	O
53	,	O
54	L1	O
55	-	O
56	2	O
57	,	O
58	and	O
59	L2	O
60	)	O
61	the	O
62	region	O
63	of	O
64	surgical	O
65	intervention	O
66	.	O
1	The	O
2	state	O
3	of	O
4	the	O
5	liver	O
6	in	O
7	generalized	O
8	forms	O
9	of	O
10	meningococcal	O
11	infection	O
1	Thin	O
2	melanomas	O
3	can	O
4	metastasize	O
5	and	O
6	be	O
7	lethal	O
8	.	O
1	Prolonged	O
2	suspension	O
3	induced	O
4	a	O
5	significant	O
6	change	O
7	in	O
8	the	O
9	geometric	O
10	configuration	O
11	of	O
12	the	O
13	femur	O
14	middiaphysis	O
15	by	O
16	increasing	O
17	the	O
18	minimum	O
19	diameter	O
20	(	O
21	12	O
22	%)	O
23	without	O
24	any	O
25	significant	O
26	alterations	O
27	in	O
28	cortical	O
29	area	O
30	,	O
31	density	O
32	,	O
33	mineral	O
34	,	O
35	and	O
36	collagen	B
37	concentrations	O
38	.	O
1	Thyroid	O
2	function	O
3	tests	O
4	were	O
5	performed	O
6	on	O
7	300	O
8	admissions	O
9	,	O
10	leaving	O
11	707	O
12	untested	O
13	.	O
1	Papers	O
2	of	O
3	the	O
4	Society	O
5	for	O
6	Clinical	O
7	Vascular	O
8	Surgery	O
9	.	O
1	Ischemic	O
2	heart	O
3	disease	O
4	,	O
5	age	O
6	of	O
7	more	O
8	than	O
9	75	O
10	years	O
11	,	O
12	and	O
13	the	O
14	fact	O
15	that	O
16	the	O
17	patient	O
18	was	O
19	a	O
20	woman	O
21	were	O
22	independent	O
23	predictors	O
24	of	O
25	poor	O
26	cardiac	O
27	function	O
28	.	O
1	Moreover	O
2	,	O
3	unlike	O
4	control	O
5	rats	O
6	operated	O
7	animals	O
8	did	O
9	not	O
10	show	O
11	aversion	O
12	to	O
13	the	O
14	highest	O
15	concentrations	O
16	of	O
17	saccharin	O
18	solutions	O
19	.	O
1	We	O
2	conclude	O
3	that	O
4	cephalothin	O
5	clearance	O
6	of	O
7	S	O
8	.	O
9	aureus	O
10	from	O
11	a	O
12	site	O
13	accessible	O
14	to	O
15	phagocytes	O
16	was	O
17	delayed	O
18	when	O
19	compared	O
20	to	O
21	a	O
22	phagocyte	O
23	-	O
24	inaccessible	O
25	site	O
26	.	O
1	Kf	O
2	,	O
3	c	O
4	and	O
5	CT	O
6	(	O
7	referenced	O
8	to	O
9	the	O
10	initial	O
11	lung	O
12	mass	O
13	)	O
14	decreased	O
15	linearly	O
16	with	O
17	reductions	O
18	in	O
19	lung	O
20	mass	O
21	%	O
22	delta	O
23	Kf	O
24	,	O
25	c	O
26	=	O
27	1	O
28	.	O
29	26	O
30	-	O
31	0	O
32	.	O
33	98	O
34	%	O
35	mass	O
36	removed	O
37	(	O
38	r	O
39	=	O
40	0	O
41	.	O
42	90	O
43	,	O
44	P	O
45	less	O
46	than	O
47	0	O
48	.	O
49	01	O
50	)	O
51	and	O
52	%	O
53	delta	O
54	CT	O
55	=	O
56	-	O
57	3	O
58	.	O
59	99	O
60	-	O
61	0	O
62	.	O
63	98	O
64	%	O
65	mass	O
66	removed	O
67	(	O
68	r	O
69	=	O
70	0	O
71	.	O
72	82	O
73	,	O
74	P	O
75	less	O
76	than	O
77	0	O
78	.	O
79	01	O
80	)	O
81	relationships	O
82	that	O
83	were	O
84	not	O
85	altered	O
86	by	O
87	blocker	O
88	pretreatment	O
89	.(	O
90	ABSTRACT	O
91	TRUNCATED	O
92	AT	O
93	250	O
94	WORDS	O
95	)	O
1	From	O
2	these	O
3	results	O
4	,	O
5	it	O
6	is	O
7	concluded	O
8	that	O
9	EDLF	O
10	has	O
11	clear	O
12	vasoconstrictor	O
13	properties	O
14	which	O
15	are	O
16	not	O
17	due	O
18	to	O
19	adrenergic	O
20	or	O
21	calcium	O
22	entry	O
23	mechanisms	O
24	and	O
25	that	O
26	there	O
27	are	O
28	differences	O
29	in	O
30	the	O
31	vasoconstrictor	O
32	effects	O
33	of	O
34	EDLFs	O
35	with	O
36	respect	O
37	to	O
38	different	O
39	vascular	O
40	beds	O
41	.	O
1	After	O
2	a	O
3	baseline	O
4	study	O
5	,	O
6	WPW	O
7	syndrome	O
8	was	O
9	simulated	O
10	by	O
11	stimulation	O
12	at	O
13	seven	O
14	different	O
15	sites	O
16	around	O
17	the	O
18	base	O
19	of	O
20	the	O
21	ventricles	O
22	,	O
23	and	O
24	RNV	O
25	'	O
26	s	O
27	were	O
28	obtained	O
29	.	O
1	A	O
2	stochastic	O
3	version	O
4	of	O
5	Kernell	O
6	'	O
7	s	O
8	(	O
9	1968	O
10	,	O
11	1972	O
12	)	O
13	model	O
14	with	O
15	cumulative	O
16	afterhyperpolarization	O
17	(	O
18	AHP	O
19	)	O
20	was	O
21	simulated	O
22	.	O
1	The	O
2	detectability	O
3	of	O
4	the	O
5	defects	O
6	in	O
7	RCA	O
8	or	O
9	LAD	O
10	region	O
11	was	O
12	80	O
13	%	O
14	in	O
15	single	O
16	-	O
17	position	O
18	scans	O
19	in	O
20	stress	O
21	studies	O
22	.	O
1	These	O
2	data	O
3	should	O
4	be	O
5	useful	O
6	in	O
7	developing	O
8	reagents	O
9	for	O
10	heterozygote	O
11	detection	O
12	and	O
13	prenatal	O
14	diagnosis	O
15	of	O
16	11	B
17	beta	I
18	-	I
19	hydroxylase	I
20	deficiency	O
21	,	O
22	the	O
23	second	O
24	most	O
25	frequent	O
26	cause	O
27	of	O
28	congenital	O
29	adrenal	O
30	hyperplasia	O
31	.	O
1	Hexsyn	O
2	is	O
3	the	O
4	Goodyear	O
5	Tire	O
6	and	O
7	Rubber	O
8	Company	O
9	tradename	O
10	for	O
11	a	O
12	polyolefin	O
13	rubber	O
14	synthesized	O
15	from	O
16	1	O
17	-	O
18	hexene	O
19	with	O
20	3	O
21	-	O
22	5	O
23	%	O
24	methylhexadiene	O
25	as	O
26	the	O
27	source	O
28	of	O
29	residual	O
30	double	O
31	bonds	O
32	for	O
33	vulcanization	O
34	.	O
1	Chimeric	O
2	phage	O
3	-	O
4	plasmid	O
5	expression	O
6	vectors	O
7	were	O
8	constructed	O
9	from	O
10	pUC18	O
11	/	O
12	19	O
13	plasmids	O
14	by	O
15	cloning	O
16	a	O
17	single	O
18	-	O
19	stranded	O
20	DNA	O
21	(	O
22	ssDNA	O
23	)	O
24	origin	O
25	of	O
26	replication	O
27	from	O
28	bacteriophage	O
29	f1	O
30	and	O
31	inserting	O
32	a	O
33	bacteriophage	O
34	T7	O
35	promoter	O
36	within	O
37	the	O
38	beta	B
39	-	I
40	galactosidase	I
41	gene	I
42	.	O
1	Neither	O
2	ethanol	O
3	nor	O
4	estrogen	O
5	has	O
6	been	O
7	shown	O
8	to	O
9	cause	O
10	UROD	B
11	-	O
12	deficiency	O
13	in	O
14	animals	O
15	.	O
1	Although	O
2	not	O
3	common	O
4	,	O
5	the	O
6	disorder	O
7	is	O
8	the	O
9	most	O
10	frequently	O
11	diagnosed	O
12	disturbance	O
13	of	O
14	porphyrin	O
15	metabolism	O
16	in	O
17	many	O
18	countries	O
19	,	O
20	and	O
21	further	O
22	insight	O
23	into	O
24	its	O
25	unusual	O
26	pathogenesis	O
27	may	O
28	clarify	O
29	the	O
30	hepatotoxic	O
31	effects	O
32	of	O
33	the	O
34	4	O
35	etiologic	O
36	agents	O
37	.	O
1	Five	O
2	out	O
3	of	O
4	eight	O
5	consecutive	O
6	cases	O
7	with	O
8	initial	O
9	symptoms	O
10	of	O
11	a	O
12	'	O
13	midline	O
14	granuloma	O
15	'	O
16	were	O
17	identified	O
18	as	O
19	malignant	O
20	histiocytosis	O
21	(	O
22	histiocytic	O
23	sarcoma	O
24	)	O
25	which	O
26	within	O
27	5	O
28	months	O
29	to	O
30	4	O
31	years	O
32	led	O
33	to	O
34	generalization	O
35	and	O
36	death	O
37	.	O
1	In	O
2	a	O
3	maxicell	O
4	system	O
5	a	O
6	protein	O
7	with	O
8	an	O
9	approximate	O
10	molecular	O
11	weight	O
12	of	O
13	36	O
14	,	O
15	000	O
16	was	O
17	synthesized	O
18	.	O
1	This	O
2	means	O
3	that	O
4	the	O
5	loss	O
6	of	O
7	recessives	O
8	must	O
9	be	O
10	calculated	O
11	by	O
12	using	O
13	a	O
14	hypergeometric	O
15	and	O
16	not	O
17	a	O
18	binomial	O
19	model	O
20	as	O
21	Fisher	O
22	did	O
23	.	O
1	In	O
2	vitro	O
3	translation	O
4	of	O
5	RNA	O
6	synthesized	O
7	from	O
8	the	O
9	cloned	O
10	cDNAs	O
11	predicts	O
12	that	O
13	P0	B
14	transcripts	I
15	are	O
16	translated	O
17	into	O
18	a	O
19	novel	O
20	12	O
21	.	O
22	5	O
23	-	O
24	kilodalton	O
25	protein	O
26	corresponding	O
27	to	O
28	the	O
29	first	O
30	open	O
31	reading	O
32	frame	O
33	.	O
1	SCL	O
2	prolonged	O
3	promptly	O
4	after	O
5	verapamil	O
6	,	O
7	and	O
8	sinus	O
9	arrest	O
10	developed	O
11	in	O
12	two	O
13	of	O
14	10	O
15	group	O
16	2	O
17	and	O
18	two	O
19	of	O
20	five	O
21	group	O
22	3	O
23	animals	O
24	.	O
1	The	O
2	latter	O
3	was	O
4	determined	O
5	as	O
6	follows	O
7	:	O
8	Type	O
9	I	O
10	-	O
11	solid	O
12	tumor	O
13	tissue	O
14	without	O
15	significant	O
16	peripheral	O
17	isolated	O
18	tumor	O
19	cells	O
20	;	O
21	Type	O
22	II	O
23	-	O
24	solid	O
25	tumor	O
26	tissue	O
27	associated	O
28	with	O
29	peripheral	O
30	isolated	O
31	tumor	O
32	cells	O
33	;	O
34	Type	O
35	III	O
36	-	O
37	isolated	O
38	tumor	O
39	cells	O
40	only	O
41	.	O
1	Due	O
2	to	O
3	its	O
4	relatively	O
5	soluble	O
6	chemical	O
7	form	O
8	,	O
9	90Sr	O
10	was	O
11	rapidly	O
12	translocated	O
13	from	O
14	lung	O
15	to	O
16	bone	O
17	where	O
18	a	O
19	substantial	O
20	portion	O
21	was	O
22	retained	O
23	for	O
24	a	O
25	long	O
26	period	O
27	of	O
28	time	O
29	.	O
1	Drugs	O
2	that	O
3	are	O
4	transformed	O
5	via	O
6	phase	O
7	II	O
8	reactions	O
9	usually	O
10	do	O
11	not	O
12	require	O
13	dosage	O
14	adjustment	O
15	.	O
1	Persistent	O
2	acantholytic	O
3	dermatosis	O
4	with	O
5	increased	O
6	light	O
7	sensitivity	O
1	It	O
2	is	O
3	largely	O
4	predicted	O
5	by	O
6	lupus	O
7	anticoagulant	O
8	(	O
9	estimated	O
10	by	O
11	activated	O
12	partial	O
13	thromboplastin	B
14	time	O
15	)	O
16	and	O
17	/	O
18	or	O
19	antibody	O
20	to	O
21	cardiolipin	O
22	.	O
1	The	O
2	presence	O
3	in	O
4	such	O
5	patients	O
6	of	O
7	antibodies	O
8	to	O
9	adrenaline	O
10	and	O
11	noradrenaline	O
12	is	O
13	indicative	O
14	of	O
15	considerable	O
16	disruption	O
17	of	O
18	catecholamine	O
19	biotransformation	O
20	.	O
1	In	O
2	addition	O
3	,	O
4	on	O
5	the	O
6	Cohler	O
7	'	O
8	s	O
9	maternal	O
10	scale	O
11	,	O
12	Korean	O
13	mothers	O
14	were	O
15	found	O
16	to	O
17	view	O
18	their	O
19	infants	O
20	as	O
21	more	O
22	passive	O
23	and	O
24	dependent	O
25	than	O
26	American	O
27	mothers	O
28	did	O
29	(	O
30	P	O
31	less	O
32	than	O
33	0	O
34	.	O
35	00	O
36	).	O
1	A	O
2	preoperative	O
3	teaching	O
4	booklet	O
5	for	O
6	pediatric	O
7	patients	O
8	.	O
1	Hyperthyroidism	O
1	The	O
2	statistical	O
3	significance	O
4	of	O
5	the	O
6	prognosis	O
7	factors	O
8	was	O
9	studied	O
10	by	O
11	uni	O
12	-	O
13	and	O
14	multivariative	O
15	methods	O
16	,	O
17	according	O
18	to	O
19	the	O
20	model	O
21	of	O
22	Cox	O
23	,	O
24	with	O
25	the	O
26	help	O
27	of	O
28	an	O
29	IMB	O
30	computer	O
31	.	O
1	These	O
2	changes	O
3	at	O
4	the	O
5	site	O
6	of	O
7	injection	O
8	consist	O
9	of	O
10	a	O
11	focal	O
12	abnormality	O
13	characterized	O
14	by	O
15	a	O
16	slight	O
17	increase	O
18	in	O
19	signal	O
20	intensity	O
21	on	O
22	T1	O
23	weighted	O
24	images	O
25	and	O
26	markedly	O
27	increased	O
28	signal	O
29	intensity	O
30	on	O
31	T2	O
32	weighted	O
33	images	O
34	.	O
1	Contraction	O
2	of	O
3	the	O
4	tracheal	O
5	muscle	O
6	and	O
7	the	O
8	activity	O
9	of	O
10	stretch	O
11	receptors	O
12	in	O
13	the	O
14	trachea	O
1	Factors	O
2	that	O
3	showed	O
4	significant	O
5	correlation	O
6	to	O
7	elevated	O
8	CIC	O
9	'	O
10	s	O
11	in	O
12	the	O
13	highly	O
14	elevated	O
15	portion	O
16	of	O
17	our	O
18	CIC	O
19	population	O
20	were	O
21	poor	O
22	NIH	O
23	score	O
24	,	O
25	increased	O
26	patient	O
27	age	O
28	,	O
29	low	O
30	peak	O
31	expiratory	O
32	flow	O
33	rate	O
34	,	O
35	and	O
36	elevated	O
37	total	O
38	serum	B
39	IgG	I
40	.	O
1	Nickel	O
2	is	O
3	the	O
4	most	O
5	common	O
6	cause	O
7	of	O
8	allergic	O
9	contact	O
10	dermatitis	O
11	in	O
12	Singapore	O
13	,	O
14	resulting	O
15	in	O
16	positive	O
17	reactions	O
18	in	O
19	patch	O
20	tests	O
21	between	O
22	7	O
23	and	O
24	14	O
25	%.	O
1	One	O
2	hundred	O
3	and	O
4	four	O
5	(	O
6	14	O
7	per	O
8	cent	O
9	)	O
10	second	O
11	primary	O
12	tumours	O
13	were	O
14	reported	O
15	.	O
1	Two	O
2	studies	O
3	assessed	O
4	two	O
5	types	O
6	of	O
7	reliability	O
8	of	O
9	the	O
10	student	O
11	Jenkins	O
12	Activity	O
13	Survey	O
14	(	O
15	JAS	O
16	;	O
17	a	O
18	questionnaire	O
19	measure	O
20	of	O
21	Type	O
22	A	O
23	behavior	O
24	).	O
1	The	O
2	combination	O
3	of	O
4	F1	O
5	and	O
6	F2	O
7	which	O
8	was	O
9	the	O
10	best	O
11	predictor	O
12	of	O
13	CHD	O
14	in	O
15	this	O
16	population	O
17	(	O
18	G1	O
19	)	O
20	might	O
21	be	O
22	interpreted	O
23	as	O
24	reflecting	O
25	trunk	O
26	adiposity	O
27	mainly	O
28	abdominal	O
29	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	during	O
6	pregnancy	O
7	there	O
8	are	O
9	increases	O
10	in	O
11	bone	O
12	formation	O
13	rates	O
14	contributing	O
15	to	O
16	the	O
17	increases	O
18	in	O
19	skeletal	O
20	mass	O
21	.	O
1	There	O
2	were	O
3	18	O
4	patients	O
5	with	O
6	Group	O
7	II	O
8	(	O
9	a	O
10	)	O
11	tumors	O
12	;	O
13	although	O
14	tumor	O
15	biopsy	O
16	was	O
17	attempted	O
18	on	O
19	eight	O
20	of	O
21	these	O
22	,	O
23	pathological	O
24	diagnosis	O
25	at	O
26	the	O
27	time	O
28	of	O
29	surgery	O
30	was	O
31	made	O
32	in	O
33	only	O
34	one	O
35	case	O
36	.	O
1	Seventeen	O
2	of	O
3	them	O
4	were	O
5	on	O
6	treatment	O
7	with	O
8	systemic	O
9	steroids	O
10	.	O
1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	survive	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	secondaries	O
29	,	O
30	survive	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O
1	From	O
2	life	O
3	-	O
4	table	O
5	analyses	O
6	of	O
7	these	O
8	patients	O
9	,	O
10	we	O
11	estimated	O
12	that	O
13	the	O
14	incidence	O
15	of	O
16	secondary	O
17	chondrosarcoma	O
18	in	O
19	patients	O
20	who	O
21	have	O
22	Ollier	O
23	disease	O
24	is	O
25	about	O
26	25	O
27	per	O
28	cent	O
29	at	O
30	the	O
31	age	O
32	of	O
33	forty	O
34	years	O
35	,	O
36	and	O
37	that	O
38	malignant	O
39	degeneration	O
40	is	O
41	almost	O
42	a	O
43	certainty	O
44	in	O
45	patients	O
46	who	O
47	have	O
48	Maffucci	O
49	syndrome	O
50	.	O
1	An	O
2	ion	O
3	chromatographic	O
4	method	O
5	was	O
6	used	O
7	to	O
8	determine	O
9	Br	O
10	ion	O
11	in	O
12	the	O
13	urine	O
14	of	O
15	Greyhounds	O
16	.	O
1	Intensification	O
2	of	O
3	human	O
4	myocardial	O
5	contractile	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O
1	Inhibition	O
2	of	O
3	histalog	O
4	-	O
5	stimulated	O
6	gastric	O
7	secretion	O
8	by	O
9	40	O
10	749	O
11	RP	O
12	,	O
13	a	O
14	new	O
15	long	O
16	-	O
17	acting	O
18	gastric	O
19	antisecretory	O
20	agent	O
21	.	O
1	Hisako	O
2	Minowa	O
3	who	O
4	has	O
5	worked	O
6	as	O
7	a	O
8	psychiatric	O
9	counsellor	O
10	in	O
11	industry	O
12	for	O
13	the	O
14	past	O
15	20	O
16	years	O
1	Single	O
2	photon	O
3	emission	O
4	computerized	O
5	tomography	O
6	(	O
7	SPECT	O
8	),	O
9	by	O
10	providing	O
11	three	O
12	-	O
13	dimensional	O
14	representation	O
15	of	O
16	myocardial	O
17	Tl	O
18	-	O
19	201	O
20	,	O
21	offers	O
22	promise	O
23	for	O
24	improved	O
25	localization	O
26	of	O
27	CAD	O
28	.	O
1	In	O
2	19	O
3	patients	O
4	vagotomy	O
5	not	O
6	only	O
7	curbed	O
8	the	O
9	bleeding	O
10	but	O
11	provided	O
12	definitive	O
13	therapy	O
14	(	O
15	Visick	O
16	I	O
17	-	O
18	II	O
19	);	O
20	4	O
21	patients	O
22	died	O
23	(	O
24	mortality	O
25	rate	O
26	16	O
27	%).	O
1	The	O
2	results	O
3	obtained	O
4	are	O
5	similar	O
6	to	O
7	those	O
8	described	O
9	with	O
10	the	O
11	previous	O
12	Cremophor	O
13	formulation	O
14	although	O
15	greater	O
16	variability	O
17	in	O
18	induction	O
19	and	O
20	recovery	O
21	times	O
22	was	O
23	noted	O
24	with	O
25	the	O
26	emulsion	O
27	formulation	O
28	.	O
1	The	O
2	H2	B
3	receptor	I
4	antagonists	O
5	and	O
6	sucralfate	O
7	cost	O
8	about	O
9	the	O
10	same	O
11	and	O
12	have	O
13	few	O
14	side	O
15	effects	O
16	.	O
1	The	O
2	Mean	O
3	was	O
4	74	O
5	,	O
6	3	O
7	+/-	O
8	53	O
9	,	O
10	6	O
11	micrograms	O
12	J	O
13	/	O
14	g	O
15	Cr	O
16	,	O
17	the	O
18	Median	O
19	61	O
20	micrograms	O
21	J	O
22	/	O
23	g	O
24	Cr	O
25	.	O
1	In	O
2	the	O
3	region	O
4	Walgau	O
5	with	O
6	mixed	O
7	industrial	O
8	-	O
9	rural	O
10	population	O
11	an	O
12	iodine	O
13	deficiency	O
14	I	O
15	was	O
16	found	O
17	in	O
18	81	O
19	%	O
20	and	O
21	an	O
22	iodine	O
23	deficiency	O
24	II	O
25	in	O
26	45	O
27	%.	O
1	The	O
2	distribution	O
3	of	O
4	patients	O
5	was	O
6	as	O
7	follows	O
8	:	O
9	group	O
10	1	O
11	--	O
12	complex	O
13	gamma	O
14	-	O
15	therapy	O
16	(	O
17	55	O
18	cases	O
19	),	O
20	group	O
21	2	O
22	--	O
23	complex	O
24	gamma	O
25	-	O
26	therapy	O
27	plus	O
28	iliac	O
29	lymphadenectomy	O
30	(	O
31	50	O
32	cases	O
33	)	O
34	and	O
35	group	O
36	3	O
37	--	O
38	complex	O
39	radiation	O
40	treatment	O
41	with	O
42	megavolt	O
43	bremsstrahlung	O
44	beam	O
45	from	O
46	the	O
47	luc	O
48	type	O
49	installation	O
50	and	O
51	iliac	O
52	lymphadenectomy	O
53	(	O
54	50	O
55	cases	O
56	).	O
1	The	O
2	availability	O
3	of	O
4	cryoprecipitate	O
5	and	O
6	DDAVP	O
7	offers	O
8	an	O
9	alternative	O
10	and	O
11	effective	O
12	treatment	O
13	for	O
14	the	O
15	temporary	O
16	reversal	O
17	of	O
18	uremic	O
19	bleeding	O
20	in	O
21	patients	O
22	who	O
23	require	O
24	urgent	O
25	invasive	O
26	procedures	O
27	.	O
1	Thrombophlebitis	O
2	and	O
3	pulmonary	O
4	embolism	O
5	in	O
6	congenital	O
7	factor	B
8	XII	I
9	deficiency	O
1	A	O
2	significant	O
3	degree	O
4	of	O
5	homology	O
6	was	O
7	also	O
8	found	O
9	among	O
10	these	O
11	genes	O
12	and	O
13	the	O
14	Mtase	B
15	gene	I
16	of	O
17	related	O
18	phage	O
19	SPR	O
20	,	O
21	which	O
22	codes	O
23	for	O
24	an	O
25	enzyme	O
26	with	O
27	different	O
28	modification	O
29	specificity	O
30	.	O
1	Thyrotropin	B
2	-	I
3	releasing	I
4	hormone	I
5	-	O
6	induced	O
7	contraction	O
8	of	O
9	urethral	O
10	and	O
11	vaginal	O
12	muscle	O
13	.	O
1	Mild	O
2	orbital	O
3	discomfort	O
4	occurred	O
5	in	O
6	some	O
7	patients	O
8	.	O
1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	psoriasis	O
6	was	O
7	4	O
8	.	O
9	79	O
10	%	O
11	in	O
12	men	O
13	and	O
14	4	O
15	.	O
16	85	O
17	%	O
18	in	O
19	women	O
20	.	O
1	The	O
2	possible	O
3	origin	O
4	and	O
5	role	O
6	of	O
7	CSF	B
8	prolactin	I
9	are	O
10	discussed	O
11	.	O
1	In	O
2	each	O
3	compartment	O
4	O2	O
5	is	O
6	removed	O
7	by	O
8	the	O
9	tissues	O
10	as	O
11	a	O
12	chemical	O
13	reaction	O
14	takes	O
15	place	O
16	between	O
17	O2	O
18	and	O
19	oxyhemoglobin	B
20	(	O
21	HbO2	B
22	).	O
1	Cortisol	O
2	excretion	O
3	,	O
4	appeared	O
5	to	O
6	be	O
7	markedly	O
8	affected	O
9	by	O
10	the	O
11	season	O
12	although	O
13	other	O
14	factors	O
15	such	O
16	as	O
17	social	O
18	and	O
19	environmental	O
20	stress	O
21	cannot	O
22	be	O
23	discounted	O
24	.	O
1	Hypersplenism	O
1	The	O
2	topography	O
3	and	O
4	trajectories	O
5	of	O
6	the	O
7	commissural	O
8	fibers	O
9	of	O
10	the	O
11	superior	O
12	temporal	O
13	region	O
14	(	O
15	STR	O
16	)	O
17	are	O
18	studied	O
19	using	O
20	the	O
21	autoradiographic	O
22	technique	O
23	.	O
1	To	O
2	assess	O
3	the	O
4	effects	O
5	of	O
6	alveolar	O
7	hypoxia	O
8	and	O
9	angiotensin	B
10	II	I
11	infusion	O
12	on	O
13	distribution	O
14	of	O
15	blood	O
16	flow	O
17	to	O
18	the	O
19	lung	O
20	we	O
21	performed	O
22	perfusion	O
23	lung	O
24	scans	O
25	on	O
26	anesthetized	O
27	mechanically	O
28	ventilated	O
29	lambs	O
30	.	O
1	Doctor	O
2	Berglund	O
3	warns	O
4	members	O
5	of	O
6	union	O
7	pitfalls	O
8	.	O
1	The	O
2	frequency	O
3	of	O
4	lactase	B
5	phenotypes	I
6	in	O
7	Aymara	O
8	children	O
9	.	O
1	Doxorubicin	O
2	,	O
3	dacarbazine	O
4	,	O
5	vincristine	O
6	,	O
7	and	O
8	cyclophosphamide	O
9	in	O
10	the	O
11	treatment	O
12	of	O
13	advanced	O
14	gastrointestinal	O
15	leiomyosarcoma	O
16	.	O
1	For	O
2	this	O
3	purpose	O
4	,	O
5	a	O
6	simple	O
7	respiration	O
8	-	O
9	control	O
10	device	O
11	has	O
12	been	O
13	developed	O
14	that	O
15	enables	O
16	the	O
17	patient	O
18	to	O
19	monitor	O
20	breath	O
21	-	O
22	holding	O
23	during	O
24	successive	O
25	scans	O
26	.	O
1	During	O
2	a	O
3	disease	O
4	remission	O
5	there	O
6	was	O
7	an	O
8	increase	O
9	in	O
10	GAG	O
11	secretion	O
12	with	O
13	urine	O
14	,	O
15	linked	O
16	with	O
17	hyperheparinuria	O
18	(	O
19	13	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	,	O
25	P	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	).	O
1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	diameters	O
15	under	O
16	2	O
17	cm	O
18	regardless	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	embedded	O
35	in	O
36	lung	O
37	parenchyma	O
38	.	O
1	Two	O
2	siblings	O
3	with	O
4	hemolytic	O
5	anemia	O
6	caused	O
7	by	O
8	triosephosphate	B
9	isomerase	I
10	deficiency	O
11	developed	O
12	a	O
13	progressive	O
14	neurological	O
15	syndrome	O
16	featuring	O
17	dystonic	O
18	movements	O
19	,	O
20	tremor	O
21	,	O
22	pyramidal	O
23	tract	O
24	signs	O
25	,	O
26	and	O
27	evidence	O
28	of	O
29	spinal	O
30	motor	O
31	neuron	O
32	involvement	O
33	.	O
1	55	O
2	+/-	O
3	11	O
4	%),	O
5	all	O
6	other	O
7	parameters	O
8	showed	O
9	a	O
10	significant	O
11	increase	O
12	:	O
13	RS	O
14	index	O
15	5	O
16	.	O
17	4	O
18	+/-	O
19	1	O
20	.	O
21	4	O
22	mVolt	O
23	to	O
24	6	O
25	.	O
26	0	O
27	+/-	O
28	1	O
29	.	O
30	7	O
31	mVolt	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	01	O
39	);	O
40	EDD	O
41	6	O
42	.	O
43	3	O
44	+/-	O
45	0	O
46	.	O
47	7	O
48	to	O
49	6	O
50	.	O
51	8	O
52	+/-	O
53	0	O
54	.	O
55	9	O
56	cm	O
57	(	O
58	p	O
59	less	O
60	than	O
61	0	O
62	.	O
63	001	O
64	);	O
65	HV	O
66	1017	O
67	+/-	O
68	151	O
69	ml	O
70	to	O
71	1099	O
72	+/-	O
73	261	O
74	ml	O
75	(	O
76	p	O
77	less	O
78	than	O
79	0	O
80	.	O
81	01	O
82	);	O
83	EDV	O
84	371	O
85	+/-	O
86	131	O
87	ml	O
88	to	O
89	441	O
90	+/-	O
91	175	O
92	ml	O
93	(	O
94	p	O
95	less	O
96	than	O
97	0	O
98	.	O
99	001	O
100	);	O
101	RBV	O
102	117	O
103	+/-	O
104	57	O
105	ml	O
106	to	O
107	151	O
108	+/-	O
109	77	O
110	ml	O
111	(	O
112	p	O
113	less	O
114	than	O
115	0	O
116	.	O
117	001	O
118	).	O
1	35	O
2	patients	O
3	with	O
4	acute	O
5	arterial	O
6	occlusions	O
7	[	O
8	27	O
9	]	O
10	and	O
11	graft	O
12	thromboses	O
13	[	O
14	8	O
15	],	O
16	responsible	O
17	for	O
18	severe	O
19	and	O
20	recent	O
21	ischemia	O
22	,	O
23	were	O
24	treated	O
25	by	O
26	fibrinolytic	O
27	therapy	O
28	(	O
29	Urokinase	B
30	:	O
31	1	O
32	000	O
33	units	O
34	/	O
35	kg	O
36	/	O
37	hour	O
38	,	O
39	and	O
40	Lys	O
41	Plasminogen	B
42	).	O
1	We	O
2	conclude	O
3	that	O
4	androgenic	O
5	hormones	O
6	reduce	O
7	HDL	B
8	-	I
9	cholesterol	I
10	concentrations	O
11	and	O
12	the	O
13	HDL2	B
14	-	I
15	cholesterol	I
16	subfraction	O
17	,	O
18	possibly	O
19	by	O
20	enhancing	O
21	hepatic	B
22	triglyceride	I
23	lipase	I
24	activity	O
25	.	O
1	Because	O
2	of	O
3	its	O
4	wide	O
5	spectrum	O
6	of	O
7	activity	O
8	particularly	O
9	against	O
10	ampicillin	O
11	resistant	O
12	strains	O
13	of	O
14	H	O
15	.	O
16	influenzae	O
17	and	O
18	because	O
19	of	O
20	its	O
21	good	O
22	tolerance	O
23	Cefaclor	O
24	is	O
25	very	O
26	useful	O
27	in	O
28	treatment	O
29	of	O
30	respiratory	O
31	tract	O
32	infections	O
33	in	O
34	children	O
35	.	O
1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O
1	Plasma	O
2	and	O
3	bladder	O
4	platinum	O
5	concentration	O
6	were	O
7	measured	O
8	following	O
9	intravesical	O
10	DDP	O
11	,	O
12	and	O
13	also	O
14	histopathological	O
15	examination	O
16	,	O
17	urinalysis	O
18	,	O
19	complete	O
20	blood	O
21	count	O
22	and	O
23	blood	O
24	chemistry	O
25	were	O
26	performed	O
27	in	O
28	order	O
29	to	O
30	know	O
31	the	O
32	toxicity	O
33	of	O
34	intravesical	O
35	DDP	O
36	.	O
1	Visidex	O
2	I	O
3	is	O
4	unsuitable	O
5	for	O
6	storage	O
7	and	O
8	re	O
9	-	O
10	reading	O
11	.	O
1	Duration	O
2	of	O
3	remission	O
4	in	O
5	advanced	O
6	gastric	O
7	cancer	O
8	patients	O
9	responding	O
10	to	O
11	sequential	O
12	dose	O
13	of	O
14	MTX	O
15	and	O
16	5	O
17	-	O
18	FU	O
1	National	O
2	Institutes	O
3	of	O
4	Health	O
5	Consensus	O
6	Development	O
7	Conference	O
8	Statement	O
9	.	O
1	Diagnosis	O
2	:	O
3	progressive	O
4	multifocal	O
5	leukoencephalopathy	O
6	.	O
1	The	O
2	rates	O
3	of	O
4	total	O
5	energy	O
6	use	O
7	(	O
8	mean	O
9	+/-	O
10	SD	O
11	=	O
12	39	O
13	.	O
14	3	O
15	+/-	O
16	1	O
17	.	O
18	2	O
19	vs	O
20	35	O
21	.	O
22	7	O
23	+/-	O
24	1	O
25	.	O
26	3	O
27	kJ	O
28	X	O
29	min	O
30	-	O
31	1	O
32	;	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	)	O
40	were	O
41	significantly	O
42	higher	O
43	at	O
44	-	O
45	10	O
46	degrees	O
47	C	O
48	than	O
49	at	O
50	22	O
51	degrees	O
52	C	O
53	.	O
1	Blood	O
2	eosinophils	O
3	in	O
4	patients	O
5	with	O
6	Taenia	O
7	saginata	O
8	taeniasis	O
9	.	O
1	The	O
2	recommendation	O
3	is	O
4	made	O
5	that	O
6	specific	O
7	sub	O
8	-	O
9	groups	O
10	of	O
11	attempters	O
12	need	O
13	to	O
14	be	O
15	identified	O
16	and	O
17	may	O
18	warrant	O
19	specialized	O
20	intervention	O
21	strategies	O
22	.	O
1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	B
16	and	I
17	serum	I
18	lysozyme	I
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O
1	Postnatal	O
2	volumetric	O
3	development	O
4	of	O
5	the	O
6	prefrontal	O
7	cortex	O
8	in	O
9	the	O
10	rat	O
11	.	O
1	Treatment	O
2	of	O
3	Paget	O
4	'	O
5	s	O
6	disease	O
7	.	O
1	HL	B
2	-	I
3	A	I
4	antibodies	I
5	in	O
6	polytransfused	O
7	patients	O
1	Aluminium	O
2	resin	O
3	for	O
4	the	O
5	treatment	O
6	of	O
7	the	O
8	hyperkalamia	O
9	of	O
10	renal	O
11	failure	O
12	.	O
1	Prevention	O
2	of	O
3	maternal	O
4	Rh	O
5	sensitization	O
6	:	O
7	anti	B
8	-	I
9	Rh	I
10	immune	I
11	globulin	I
12	.	O
1	Therapeutic	O
2	action	O
3	of	O
4	a	O
5	new	O
6	antibiotic	O
7	-	O
8	corticoid	O
9	association	O
10	used	O
11	for	O
12	instillations	O
13	in	O
14	otology	O
1	Enzyme	O
2	histochemical	O
3	findings	O
4	in	O
5	the	O
6	ultimobranchial	O
7	body	O
8	of	O
9	the	O
10	horse	O
1	Genesis	O
2	of	O
3	foam	O
4	cells	O
5	:	O
6	study	O
7	in	O
8	rats	O
9	after	O
10	administration	O
11	of	O
12	Cloforex	O
13	.	O
1	Pre	B
2	-	I
3	beta	I
4	-	I
5	1	I
6	lipoprotein	I
7	and	O
8	early	O
9	detection	O
10	of	O
11	risk	O
12	factors	O
13	for	O
14	coronary	O
15	heart	O
16	disease	O
17	.	O
1	Effect	O
2	of	O
3	noise	O
4	on	O
5	CO	O
6	-	O
7	induced	O
8	increases	O
9	of	O
10	LAP	B
11	and	O
12	GPT	B
13	activity	O
14	in	O
15	the	O
16	plasma	O
17	of	O
18	rats	O
1	Junctions	O
2	between	O
3	cells	O
4	of	O
5	the	O
6	human	O
7	enamel	O
8	organ	O
9	.	O
1	Changes	O
2	following	O
3	periodontal	O
4	surgery	O
5	.	O
1	Intracellular	O
2	pH	O
3	,	O
4	H	O
5	ion	O
6	flux	O
7	and	O
8	H	O
9	ion	O
10	permeability	O
11	coefficient	O
12	in	O
13	bullfrog	O
14	toe	O
15	muscle	O
16	.	O
1	Teratological	O
2	studies	O
3	on	O
4	SF	O
5	-	O
6	837	O
7	.	O
1	Directives	O
2	concerning	O
3	medical	O
4	care	O
1	Taxonomically	O
2	significant	O
3	colour	O
4	changes	O
5	in	O
6	Brevibacterium	O
7	linens	O
8	probably	O
9	associated	O
10	with	O
11	a	O
12	carotenoid	O
13	-	O
14	like	O
15	pigment	O
16	.	O
1	A	O
2	short	O
3	history	O
4	of	O
5	dermatology	O
6	in	O
7	Lagos	O
8	,	O
9	Nigeria	O
10	.	O
1	Resistance	O
2	pattern	O
3	of	O
4	Mycobacterium	O
5	tuberculosis	O
6	(	O
7	H	O
8	37	O
9	Rv	O
10	)	O
11	to	O
12	a	O
13	new	O
14	antibiotic	O
15	,	O
16	lividomycin	O
1	Pathological	O
2	processes	O
3	in	O
4	the	O
5	cervix	O
6	uteri	O
1	Benign	O
2	intramural	O
3	tumors	O
4	of	O
5	the	O
6	esophagus	O
1	Range	O
2	behavior	O
3	of	O
4	Hereford	O
5	,	O
6	Hereford	O
7	x	O
8	Holstein	O
9	and	O
10	Holstein	O
11	non	O
12	-	O
13	lactating	O
14	heifers	O
15	.	O
1	Pneumothorax	O
2	complicated	O
3	by	O
4	chronic	O
5	steroid	O
6	treatment	O
7	.	O
1	Change	O
2	in	O
3	the	O
4	makeup	O
5	of	O
6	the	O
7	blood	O
8	following	O
9	a	O
10	short	O
11	-	O
12	term	O
13	local	O
14	action	O
15	of	O
16	a	O
17	permanent	O
18	magnetic	O
19	field	O
20	on	O
21	the	O
22	human	O
23	body	O
1	Hematopoietic	O
2	system	O
3	in	O
4	streptococcal	O
5	allergy	O
6	.	O
1	Plastic	O
2	solution	O
3	of	O
4	elbow	O
5	joint	O
6	ankylosis	O
7	with	O
8	a	O
9	decorticated	O
10	cylindrical	O
11	flap	O
1	Effects	O
2	of	O
3	ionizing	O
4	radiation	O
5	in	O
6	the	O
7	human	O
8	oral	O
9	cavity	O
10	and	O
11	oropharynx	O
12	:	O
13	results	O
14	of	O
15	a	O
16	survey	O
17	.	O
1	Immunelectrophoretic	O
2	pattern	O
3	of	O
4	Wassermann	O
5	reagin	O
6	and	O
7	comparison	O
8	of	O
9	the	O
10	appearance	O
11	time	O
12	between	O
13	RPCF	B
14	and	O
15	FTA	B
16	antibodies	I
1	Motile	O
2	nocardoid	O
3	Actinomycetales	O
4	.	O
1	Labial	O
2	bar	O
3	.	O
1	Yusuf	O
2	Dawood	O
3	Docrat	O
4	L	O
5	.	O
6	R	O
7	.	O
8	C	O
9	.	O
10	P	O
11	.	O
1	Dr	O
2	.	O
1	Analysis	O
2	of	O
3	corticosteroids	O
4	.	O
1	Plasma	B
2	histaminase	I
3	in	O
4	patients	O
5	of	O
6	bronchial	O
7	asthma	O
8	and	O
9	the	O
10	effect	O
11	of	O
12	prednisolone	O
13	administration	O
14	on	O
15	it	O
16	.	O
1	Factors	O
2	affecting	O
3	the	O
4	inhibition	O
5	of	O
6	phagocytosis	O
7	by	O
8	chlorpromazine	O
9	.	O
1	Photopic	O
2	spectral	O
3	sensitivity	O
4	determined	O
5	electroretinographically	O
6	for	O
7	the	O
8	pigeon	O
9	eye	O
10	.	O
1	Clinical	O
2	and	O
3	angiographic	O
4	examinations	O
5	in	O
6	occlusion	O
7	disease	O
8	of	O
9	the	O
10	great	O
11	intestinal	O
12	arteries	O
1	Successful	O
2	treatment	O
3	of	O
4	candidiasis	O
5	with	O
6	transfer	B
7	factor	I
8	.	O
1	Conservative	O
2	treatment	O
3	of	O
4	central	O
5	nervous	O
6	system	O
7	injuries	O
1	New	O
2	alkaloids	O
3	from	O
4	bark	O
5	of	O
6	Erythrophleum	O
7	ivorense	O
8	.	O
1	Successive	O
2	abdominal	O
3	scintillation	O
4	with	O
5	131	O
6	-	O
7	I	O
8	-	O
9	tagged	O
10	BSP	O
11	--	O
12	description	O
13	of	O
14	the	O
15	thyroid	O
16	gland	O
17	,	O
18	kidney	O
19	and	O
20	spleen	O
21	(	O
22	comparison	O
23	with	O
24	131	O
25	-	O
26	I	O
27	-	O
28	RB	O
29	)	O
1	Pneumonia	O
2	in	O
3	children	O
1	Osteosarcoma	O
2	caused	O
3	by	O
4	3	O
5	,	O
6	4	O
7	-	O
8	benzopyrene	O
1	Influence	O
2	of	O
3	cigarette	O
4	smoking	O
5	on	O
6	some	O
7	blood	O
8	coagulation	O
9	tests	O
10	.	O
1	SAM	O
2	-	O
3	TR	O
4	-	O
5	68	O
6	-	O
7	54	O
8	.	O
1	Aedes	O
2	aegypti	O
3	(	O
4	L	O
5	.)	O
6	and	O
7	Aedes	O
8	albopictus	O
9	(	O
10	Skuse	O
11	)	O
12	in	O
13	Singapore	O
14	City	O
15	.	O
1	Spinal	O
2	cord	O
3	representation	O
4	of	O
5	the	O
6	micturition	O
7	reflex	O
8	.	O
1	Auto	O
2	-	O
3	and	O
4	isotopy	O
5	of	O
6	the	O
7	conjunctiva	O
1	IX	O
2	.	O
1	Renin	B
2	secretion	O
3	in	O
4	essential	O
5	and	O
6	accelerated	O
7	hypertension	O
8	.	O
1	Diminished	O
2	forearm	O
3	arteriolar	O
4	dilator	O
5	capacity	O
6	produced	O
7	by	O
8	mineralocorticoid	O
9	-	O
10	induced	O
11	salt	O
12	retention	O
13	in	O
14	man	O
15	.	O
1	Mae	O
2	West	O
3	and	O
4	the	O
5	doctor	O
6	shortage	O
7	.	O
1	V	O
2	.	O
1	3	O
2	.	O
1	Central	O
2	venous	O
3	catheter	O
4	used	O
5	for	O
6	recording	O
7	intracardiac	O
8	electrocardiogram	O
9	.	O
1	Positive	O
2	shifts	O
3	of	O
4	basal	O
5	skin	O
6	potentials	O
7	during	O
8	human	O
9	sleep	O
10	.	O
1	Investigation	O
2	on	O
3	the	O
4	exchange	O
5	of	O
6	Ca45	O
7	in	O
8	intact	O
9	and	O
10	burned	O
11	rats	O
12	by	O
13	the	O
14	kinetic	O
15	analysis	O
16	method	O
1	Nephrectomy	O
2	applied	O
3	to	O
4	cattle	O
1	Evaluation	O
2	of	O
3	automatic	O
4	blood	O
5	cell	O
6	counters	O
7	.	O
1	Trials	O
2	of	O
3	sevine	O
4	activity	O
5	against	O
6	mosquito	O
7	larvae	O
1	Hemodynamics	O
2	changes	O
3	in	O
4	man	O
5	during	O
6	flight	O
1	The	O
2	significance	O
3	of	O
4	the	O
5	phenolphthalein	B
6	sulphatase	I
7	test	O
8	for	O
9	the	O
10	differentiation	O
11	and	O
12	identification	O
13	of	O
14	Nocardia	O
15	species	O
16	.	O
1	Relationship	O
2	of	O
3	mast	O
4	cells	O
5	to	O
6	sarcoidosis	O
7	granuloma	O
8	of	O
9	the	O
10	skin	O
1	Experimental	O
2	chlorpromazine	O
3	cataracts	O
4	.	O
1	I	O
2	.	O
1	Functional	O
2	disorders	O
3	of	O
4	the	O
5	ureter	O
6	following	O
7	gynecologic	O
8	surgery	O
1	Clinical	O
2	trials	O
3	with	O
4	1	O
5	,	O
6	3	O
7	-	O
8	bis	O
9	(	O
10	2	O
11	-	O
12	chloroethyl	O
13	)-	O
14	1	O
15	-	O
16	nitrosourea	O
17	,	O
18	NSC	O
19	-	O
20	409962	O
21	.	O
1	Study	O
2	on	O
3	micromelias	O
4	in	O
5	the	O
6	mouse	O
7	fetus	O
8	caused	O
9	by	O
10	x	O
11	-	O
12	radiation	O
13	,	O
14	hypoxia	O
15	,	O
16	trypan	O
17	blue	O
18	injection	O
19	of	O
20	hypervitaminosis	O
21	-	O
22	A	O
23	upon	O
24	mother	O
25	animals	O
26	during	O
27	pregnancy	O
28	.	O
1	Story	O
2	of	O
3	a	O
4	hospital	O
5	that	O
6	filmed	O
7	its	O
8	employee	O
9	orientation	O
10	program	O
11	.	O
1	On	O
2	the	O
3	amount	O
4	and	O
5	significance	O
6	of	O
7	the	O
8	effective	O
9	glucose	O
10	level	O
11	in	O
12	tumors	O
13	.	O
1	Iron	O
2	and	O
3	folate	O
4	deficiency	O
5	in	O
6	pregnancy	O
1	Elevated	O
2	maternal	B
3	alpha	I
4	fetoproteins	I
5	and	O
6	oligoamnios	O
7	:	O
8	fetal	O
9	prognosis	O
1	Also	O
2	discussed	O
3	is	O
4	the	O
5	possibility	O
6	of	O
7	a	O
8	combined	O
9	genetic	O
10	and	O
11	environmental	O
12	etiology	O
13	.	O
1	Many	O
2	mammary	O
3	tumors	O
4	induced	O
5	by	O
6	mouse	O
7	mammary	O
8	tumor	O
9	virus	O
10	(	O
11	MMTV	O
12	)	O
13	contain	O
14	a	O
15	provirus	O
16	in	O
17	the	O
18	same	O
19	region	O
20	of	O
21	the	O
22	host	O
23	-	O
24	cell	O
25	genome	O
26	,	O
27	leading	O
28	to	O
29	expression	O
30	of	O
31	a	O
32	putative	O
33	cellular	O
34	oncogene	O
35	called	O
36	int	B
37	-	I
38	1	I
39	.	O
1	Endorphins	B
2	at	O
3	the	O
4	approach	O
5	of	O
6	death	O
7	.	O
1	Cardiac	O
2	taurine	O
3	levels	O
4	and	O
5	sarcolemmal	O
6	calcium	O
7	binding	O
8	activity	O
9	in	O
10	furazolidone	O
11	-	O
12	induced	O
13	cardiomyopathy	O
14	.	O
1	Plasma	O
2	and	O
3	erthrocyte	O
4	lipid	O
5	profile	O
6	and	O
7	lipoprotein	B
8	lipase	I
9	activity	O
10	in	O
11	postheparin	O
12	plasma	O
13	on	O
14	vasectomized	O
15	rabbits	O
16	were	O
17	studied	O
18	and	O
19	also	O
20	the	O
21	incidence	O
22	of	O
23	atherosclerosis	O
24	in	O
25	different	O
26	arterial	O
27	beds	O
28	.	O
1	Hybrid	O
2	-	O
3	selection	O
4	experiments	O
5	against	O
6	total	O
7	PB	O
8	-	O
9	inducible	O
10	RNA	O
11	were	O
12	performed	O
13	with	O
14	plasmid	O
15	DNA	O
16	derived	O
17	from	O
18	clones	O
19	enriched	O
20	in	O
21	PB	O
22	-	O
23	inducible	O
24	information	O
25	.	O
1	Glutamic	O
2	acid	O
3	in	O
4	a	O
5	dose	O
6	of	O
7	1	O
8	/	O
9	100	O
10	of	O
11	the	O
12	LD50	O
13	was	O
14	injected	O
15	in	O
16	the	O
17	form	O
18	of	O
19	sodium	O
20	salt	O
21	into	O
22	male	O
23	and	O
24	female	O
25	Wistar	O
26	rats	O
27	for	O
28	7	O
29	days	O
30	after	O
31	8	O
32	-	O
33	and	O
34	12	O
35	-	O
36	day	O
37	injections	O
38	of	O
39	dexazone	O
40	.	O
1	Serum	O
2	ascorbic	O
3	acid	O
4	had	O
5	an	O
6	inverse	O
7	and	O
8	the	O
9	strongest	O
10	association	O
11	with	O
12	systolic	O
13	blood	O
14	pressure	O
15	among	O
16	the	O
17	risk	O
18	factors	O
19	including	O
20	blood	O
21	pressure	O
22	,	O
23	total	O
24	cholesterol	O
25	,	O
26	triglyceride	O
27	,	O
28	gamma	B
29	-	I
30	GTP	I
31	and	O
32	obesity	O
33	.	O
1	In	O
2	several	O
3	cases	O
4	of	O
5	definite	O
6	SjS	O
7	,	O
8	labial	O
9	salivary	O
10	gland	O
11	examinations	O
12	after	O
13	more	O
14	than	O
15	a	O
16	one	O
17	year	O
18	interval	O
19	were	O
20	performed	O
21	on	O
22	two	O
23	occasions	O
24	,	O
25	and	O
26	the	O
27	clinical	O
28	and	O
29	histopathological	O
30	changes	O
31	were	O
32	investigated	O
33	.	O
1	A	O
2	polypeptide	O
3	chain	O
4	of	O
5	34	O
6	residues	O
7	of	O
8	the	O
9	deduced	O
10	yeast	O
11	amino	O
12	acid	O
13	sequence	O
14	closely	O
15	resembles	O
16	a	O
17	peptide	O
18	sequence	O
19	at	O
20	the	O
21	ADP	O
22	binding	O
23	site	O
24	of	O
25	bovine	B
26	muscle	I
27	pyruvate	I
28	kinase	I
29	.	O
1	Differential	O
2	drawing	O
3	size	O
4	associated	O
5	with	O
6	unilateral	O
7	brain	O
8	damage	O
9	.	O
1	Products	O
2	of	O
3	immune	O
4	cells	O
5	such	O
6	as	O
7	transfer	B
8	factor	I
9	and	O
10	lymphokines	O
11	form	O
12	the	O
13	third	O
14	and	O
15	possibly	O
16	most	O
17	important	O
18	group	O
19	of	O
20	immune	O
21	-	O
22	stimulating	O
23	agents	O
24	.	O
1	The	O
2	number	O
3	of	O
4	elements	O
5	and	O
6	their	O
7	sizes	O
8	relative	O
9	to	O
10	the	O
11	configuration	O
12	were	O
13	varied	O
14	in	O
15	a	O
16	series	O
17	of	O
18	five	O
19	experiments	O
20	.	O
1	Fibrin	B
2	gels	O
3	and	O
4	their	O
5	possible	O
6	implication	O
7	for	O
8	surface	O
9	hemorheology	O
10	in	O
11	health	O
12	and	O
13	disease	O
14	.	O
1	Synthesis	O
2	of	O
3	(+)-	O
4	lysergic	O
5	acid	O
6	diethylamide	O
7	tartrate	O
1	Because	O
2	RNase	B
3	III	I
4	host	I
5	mutants	I
6	are	O
7	defective	O
8	in	O
9	sib	B
10	regulation	O
11	,	O
12	processing	O
13	of	O
14	the	O
15	PL	B
16	mRNA	I
17	at	O
18	sib	B
19	by	O
20	this	O
21	endoribonuclease	O
22	may	O
23	cause	O
24	int	B
25	mRNA	I
26	decay	O
27	and	O
28	decrease	O
29	int	B
30	synthesis	O
31	.	O
1	At	O
2	least	O
3	one	O
4	clone	O
5	,	O
6	lambda	O
7	HHG	O
8	41	O
9	,	O
10	contains	O
11	,	O
12	in	O
13	addition	O
14	to	O
15	the	O
16	histone	B
17	genes	I
18	,	O
19	a	O
20	region	O
21	that	O
22	hybridizes	O
23	with	O
24	a	O
25	cytoplasmic	O
26	RNA	O
27	approximately	O
28	330	O
29	nucleotides	O
30	in	O
31	length	O
32	.	O
1	The	O
2	frequency	O
3	of	O
4	previous	O
5	transfusion	O
6	in	O
7	chronic	O
8	hepatitis	O
9	,	O
10	cirrhosis	O
11	and	O
12	hepatocellular	O
13	carcinoma	O
14	of	O
15	type	O
16	NANB	O
17	was	O
18	42	O
19	.	O
20	8	O
21	,	O
22	37	O
23	.	O
24	1	O
25	and	O
26	15	O
27	.	O
28	1	O
29	%,	O
30	respectively	O
31	,	O
32	whereas	O
33	the	O
34	incidence	O
35	of	O
36	early	O
37	posttransfusion	O
38	hepatitis	O
39	was	O
40	8	O
41	.	O
42	5	O
43	,	O
44	8	O
45	.	O
46	6	O
47	and	O
48	7	O
49	.	O
50	5	O
51	%,	O
52	respectively	O
53	.	O
54	in	O
55	chronic	O
56	liver	O
57	diseases	O
58	with	O
59	a	O
60	history	O
61	of	O
62	jaundice	O
63	and	O
64	/	O
65	or	O
66	hepatitis	O
67	,	O
68	previous	O
69	transfusions	O
70	are	O
71	more	O
72	frequently	O
73	associated	O
74	with	O
75	type	O
76	NANB	O
77	than	O
78	with	O
79	type	O
80	B	O
81	disease	O
82	.	O
1	In	O
2	49	O
3	patients	O
4	in	O
5	whom	O
6	gated	O
7	equilibrium	O
8	ventriculography	O
9	and	O
10	cardiac	O
11	catheterization	O
12	were	O
13	performed	O
14	within	O
15	a	O
16	6	O
17	day	O
18	interval	O
19	,	O
20	total	O
21	and	O
22	fractional	O
23	portions	O
24	of	O
25	global	O
26	and	O
27	regional	O
28	right	O
29	ventricular	O
30	ejection	O
31	fraction	O
32	(	O
33	RVEF	O
34	)	O
35	were	O
36	correlated	O
37	with	O
38	pulmonary	O
39	arterial	O
40	systolic	O
41	pressure	O
42	.	O
1	In	O
2	conclusion	O
3	,	O
4	these	O
5	studies	O
6	indicate	O
7	that	O
8	LiCl	O
9	(	O
10	1	O
11	)	O
12	decreases	O
13	histamine	O
14	-	O
15	stimulated	O
16	gastric	O
17	acid	O
18	secretion	O
19	,	O
20	and	O
21	(	O
22	2	O
23	)	O
24	diminishes	O
25	bile	O
26	-	O
27	induced	O
28	disruption	O
29	of	O
30	the	O
31	gastric	O
32	mucosal	O
33	barrier	O
34	in	O
35	the	O
36	canine	O
37	Heidenhain	O
38	pouch	O
39	.	O
1	Lung	O
2	density	O
3	increased	O
4	in	O
5	quartz	O
6	-	O
7	exposed	O
8	,	O
9	but	O
10	not	O
11	in	O
12	volcanic	O
13	-	O
14	ash	O
15	-	O
16	exposed	O
17	animals	O
18	.	O
1	The	O
2	junctions	O
3	between	O
4	viral	O
5	and	O
6	cellular	O
7	sequences	O
8	were	O
9	determined	O
10	by	O
11	DNA	O
12	sequence	O
13	analysis	O
14	to	O
15	be	O
16	517	O
17	nucleotides	O
18	into	O
19	the	O
20	p30	B
21	sequence	I
22	and	O
23	1	O
24	,	O
25	920	O
26	nucleotides	O
27	into	O
28	the	O
29	polymerase	O
30	sequence	O
31	.	O
1	Expression	O
2	of	O
3	herpes	O
4	simplex	O
5	virus	O
6	beta	O
7	and	O
8	gamma	O
9	genes	O
10	integrated	O
11	in	O
12	mammalian	O
13	cells	O
14	and	O
15	their	O
16	induction	O
17	by	O
18	an	O
19	alpha	O
20	gene	O
21	product	O
22	.	O
1	This	O
2	is	O
3	consistent	O
4	with	O
5	a	O
6	model	O
7	proposing	O
8	that	O
9	SSV	O
10	was	O
11	generated	O
12	by	O
13	recombination	O
14	between	O
15	proviral	O
16	DNA	O
17	of	O
18	a	O
19	simian	O
20	sarcoma	O
21	associated	O
22	virus	O
23	and	O
24	proto	B
25	-	I
26	sis	I
27	and	O
28	that	O
29	introns	O
30	were	O
31	spliced	O
32	out	O
33	subsequently	O
34	from	O
35	a	O
36	fused	O
37	viral	B
38	-	I
39	sis	I
40	messenger	I
41	RNA	I
42	.	O
1	Each	O
2	of	O
3	these	O
4	spliced	O
5	mRNAs	O
6	has	O
7	an	O
8	untranslated	O
9	leader	O
10	sequence	O
11	of	O
12	249	O
13	bases	O
14	and	O
15	a	O
16	single	O
17	intron	O
18	of	O
19	approximately	O
20	540	O
21	bases	O
22	which	O
23	are	O
24	contained	O
25	entirely	O
26	within	O
27	TRs	O
28	/	O
29	IRs	O
30	sequences	O
31	.	O
1	The	O
2	greatest	O
3	difference	O
4	between	O
5	the	O
6	Ad7	B
7	and	I
8	Ad5	I
9	DBPs	I
10	is	O
11	the	O
12	absence	O
13	,	O
14	in	O
15	the	O
16	Ad7	O
17	protein	O
18	,	O
19	of	O
20	12	O
21	amino	O
22	acids	O
23	located	O
24	between	O
25	the	O
26	two	O
27	functional	O
28	domains	O
29	in	O
30	the	O
31	Ad5	O
32	protein	O
33	(	O
34	amino	O
35	acids	O
36	151	O
37	-	O
38	162	O
39	).	O
1	No	O
2	significant	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	LVM	O
8	or	O
9	wall	O
10	thickness	O
11	and	O
12	body	O
13	surface	O
14	area	O
15	,	O
16	age	O
17	,	O
18	blood	O
19	pressure	O
20	,	O
21	heart	O
22	rate	O
23	,	O
24	cardiac	O
25	output	O
26	,	O
27	total	O
28	peripheral	O
29	resistance	O
30	and	O
31	left	O
32	ventricular	O
33	systolic	O
34	wall	O
35	stress	O
36	,	O
37	whereas	O
38	CD25	O
39	was	O
40	correlated	O
41	with	O
42	urinary	O
43	catecholamines	O
44	only	O
45	in	O
46	hypertensive	O
47	patients	O
48	(	O
49	r	O
50	=	O
51	0	O
52	.	O
53	606	O
54	,	O
55	p	O
56	less	O
57	than	O
58	0	O
59	.	O
60	001	O
61	).	O
1	Here	O
2	we	O
3	have	O
4	determined	O
5	the	O
6	nucleotide	O
7	sequence	O
8	of	O
9	3	O
10	.	O
11	5	O
12	kb	O
13	from	O
14	the	O
15	3	O
16	'	O
17	end	O
18	of	O
19	delta	B
20	gag	I
21	to	O
22	the	O
23	3	O
24	'	O
25	end	O
26	of	O
27	molecularly	O
28	cloned	O
29	proviral	O
30	MH2	O
31	DNA	O
32	,	O
33	in	O
34	order	O
35	to	O
36	elucidate	O
37	the	O
38	genetic	O
39	structure	O
40	of	O
41	the	O
42	virus	O
43	and	O
44	to	O
45	compare	O
46	it	O
47	with	O
48	other	O
49	mht	B
50	-	O
51	and	O
52	myc	B
53	-	O
54	containing	O
55	oncogenic	O
56	viruses	O
57	as	O
58	well	O
59	as	O
60	with	O
61	the	O
62	chicken	B
63	proto	I
64	-	I
65	myc	I
66	gene	I
67	.	O
1	Thirty	O
2	isolates	O
3	of	O
4	Haemophilus	O
5	influenzae	O
6	type	O
7	b	O
8	were	O
9	obtained	O
10	during	O
11	an	O
12	outbreak	O
13	of	O
14	invasive	O
15	H	O
16	.	O
17	influenzae	O
18	type	O
19	b	O
20	disease	O
21	and	O
22	were	O
23	classified	O
24	by	O
25	the	O
26	electrophoretic	O
27	profile	O
28	of	O
29	their	O
30	lipopolysaccharide	O
31	(	O
32	LPS	O
33	).	O
1	Enhancement	O
2	of	O
3	the	O
4	immune	O
5	response	O
6	by	O
7	aspecific	O
8	action	O
9	of	O
10	vaccine	O
11	additives	O
12	in	O
13	the	O
14	aerogenic	O
15	immunization	O
16	of	O
17	swine	O
18	against	O
19	swine	O
20	plague	O
1	Effects	O
2	of	O
3	negative	O
4	pleural	O
5	pressure	O
6	on	O
7	left	O
8	ventricular	O
9	hemodynamics	O
10	.	O
1	Resting	O
2	plasma	O
3	norepinephrine	O
4	(	O
5	NE	O
6	)	O
7	and	O
8	epinephrine	O
9	(	O
10	E	O
11	)	O
12	levels	O
13	were	O
14	lower	O
15	during	O
16	active	O
17	therapy	O
18	than	O
19	2	O
20	wk	O
21	after	O
22	withdrawal	O
23	(	O
24	guanfacine	O
25	and	O
26	control	O
27	:	O
28	plasma	O
29	NE	O
30	,	O
31	0	O
32	.	O
33	27	O
34	+/-	O
35	0	O
36	.	O
37	03	O
38	/	O
39	0	O
40	.	O
41	64	O
42	+/-	O
43	0	O
44	.	O
45	13	O
46	ng	O
47	/	O
48	ml	O
49	;	O
50	plasma	O
51	E	O
52	,	O
53	0	O
54	.	O
55	09	O
56	+/-	O
57	0	O
58	.	O
59	02	O
60	/	O
61	0	O
62	.	O
63	17	O
64	+/-	O
65	0	O
66	.	O
67	05	O
68	ng	O
69	/	O
70	ml	O
71	).	O
1	The	O
2	statistical	O
3	analysis	O
4	of	O
5	data	O
6	of	O
7	TRH	B
8	test	O
9	on	O
10	a	O
11	sample	O
12	of	O
13	57	O
14	healthy	O
15	volunteers	O
16	has	O
17	permitted	O
18	an	O
19	evaluation	O
20	of	O
21	the	O
22	upper	O
23	limits	O
24	of	O
25	the	O
26	normal	O
27	thyrotropin	B
28	response	O
29	;	O
30	the	O
31	secretory	O
32	area	O
33	(	O
34	As	O
35	)	O
36	was	O
37	shown	O
38	to	O
39	be	O
40	more	O
41	discriminating	O
42	.	O
1	These	O
2	children	O
3	were	O
4	grouped	O
5	into	O
6	four	O
7	diagnostic	O
8	categories	O
9	:	O
10	1	O
11	)	O
12	idiopathic	O
13	GH	B
14	deficiency	O
15	(	O
16	n	O
17	=	O
18	10	O
19	);	O
20	2	O
21	)	O
22	organic	O
23	hypopituitarism	O
24	(	O
25	n	O
26	=	O
27	7	O
28	);	O
29	3	O
30	)	O
31	intrauterine	O
32	growth	O
33	retardation	O
34	(	O
35	n	O
36	=	O
37	5	O
38	);	O
39	and	O
40	4	O
41	)	O
42	constitutional	O
43	delay	O
44	of	O
45	growth	O
46	and	O
47	/	O
48	or	O
49	familial	O
50	short	O
51	stature	O
52	(	O
53	n	O
54	=	O
55	18	O
56	),	O
57	by	O
58	standard	O
59	clinical	O
60	criteria	O
61	and	O
62	physiological	O
63	and	O
64	pharmacological	O
65	tests	O
66	of	O
67	GH	B
68	reserve	O
69	.	O
1	Cimetidine	O
2	800	O
3	mg	O
4	given	O
5	at	O
6	night	O
7	is	O
8	as	O
9	effective	O
10	as	O
11	400	O
12	mg	O
13	twice	O
14	daily	O
15	;	O
16	the	O
17	single	O
18	dose	O
19	regimen	O
20	may	O
21	improve	O
22	patient	O
23	compliance	O
24	,	O
25	thus	O
26	facilitating	O
27	treatment	O
28	.	O
1	Our	O
2	results	O
3	indicate	O
4	that	O
5	serum	B
6	BGP	I
7	is	O
8	a	O
9	valuable	O
10	measurement	O
11	of	O
12	bone	O
13	metabolism	O
14	.	O
1	Resting	O
2	VE	O
3	in	O
4	the	O
5	luteal	O
6	phase	O
7	was	O
8	7	O
9	.	O
10	8	O
11	%	O
12	greater	O
13	than	O
14	that	O
15	in	O
16	the	O
17	follicular	O
18	phase	O
19	.	O
1	This	O
2	experiment	O
3	was	O
4	conducted	O
5	to	O
6	determine	O
7	if	O
8	the	O
9	sex	O
10	or	O
11	actual	O
12	egg	O
13	production	O
14	was	O
15	the	O
16	important	O
17	factor	O
18	.(	O
19	ABSTRACT	O
20	TRUNCATED	O
21	AT	O
22	250	O
23	WORDS	O
24	)	O
1	In	O
2	two	O
3	experiments	O
4	,	O
5	neonatal	O
6	female	O
7	BALB	O
8	/	O
9	cCrgl	O
10	or	O
11	BALB	O
12	/	O
13	cfC3HCrgl	O
14	mice	O
15	were	O
16	given	O
17	subcutaneous	O
18	injections	O
19	of	O
20	5	O
21	micrograms	O
22	17	O
23	beta	O
24	-	O
25	estradiol	O
26	or	O
27	sesame	O
28	oil	O
29	for	O
30	the	O
31	first	O
32	3	O
33	days	O
34	of	O
35	life	O
36	and	O
37	were	O
38	ovariectomized	O
39	at	O
40	60	O
41	days	O
42	of	O
43	age	O
44	,	O
45	at	O
46	which	O
47	time	O
48	vaginal	O
49	concretions	O
50	(	O
51	Experiments	O
52	I	O
53	and	O
54	II	O
55	)	O
56	or	O
57	silica	O
58	(	O
59	Experiment	O
60	II	O
61	)	O
62	were	O
63	implanted	O
64	intravaginally	O
65	.	O
1	Significant	O
2	alterations	O
3	in	O
4	the	O
5	vasectomized	O
6	rats	O
7	from	O
8	sham	O
9	rats	O
10	included	O
11	:	O
12	testicular	O
13	and	O
14	epididymal	O
15	hypertrophy	O
16	,	O
17	formation	O
18	of	O
19	pathologic	O
20	vas	O
21	deferens	O
22	granulomas	O
23	,	O
24	decreased	O
25	total	O
26	serum	O
27	protein	O
28	,	O
29	lowered	O
30	alpha	B
31	-	I
32	globulin	I
33	levels	O
34	as	O
35	shown	O
36	by	O
37	serum	O
38	electrophoresis	O
39	,	O
40	and	O
41	increased	O
42	sperm	O
43	agglutinin	B
44	antibody	O
45	titers	O
46	.	O
1	E2	O
2	treatments	O
3	elevated	O
4	hen	O
5	plasma	O
6	TG	O
7	7	O
8	.	O
9	2X	O
10	,	O
11	PL	O
12	5	O
13	.	O
14	1X	O
15	,	O
16	and	O
17	C	O
18	7	O
19	.	O
20	2X	O
21	;	O
22	and	O
23	pullet	O
24	plasma	O
25	TG	O
26	6	O
27	.	O
28	8X	O
29	,	O
30	PL	O
31	3	O
32	.	O
33	7X	O
34	,	O
35	and	O
36	C	O
37	2	O
38	.	O
39	5X	O
40	.	O
1	By	O
2	contrast	O
3	,	O
4	kidneys	O
5	from	O
6	rats	O
7	with	O
8	chronic	O
9	metabolic	O
10	acidosis	O
11	produced	O
12	significantly	O
13	more	O
14	NH3	O
15	than	O
16	both	O
17	these	O
18	groups	O
19	(	O
20	2	O
21	.	O
22	73	O
23	+/-	O
24	0	O
25	.	O
26	29	O
27	mumol	O
28	X	O
29	min	O
30	-	O
31	1	O
32	X	O
33	g	O
34	-	O
35	1	O
36	).	O
1	Adenyl	B
2	cyclase	I
3	activity	O
4	of	O
5	gastric	O
6	mucosa	O
7	in	O
8	patients	O
9	with	O
10	duodenal	O
11	ulcer	O
12	before	O
13	and	O
14	after	O
15	treatment	O
1	Lymphocytes	O
2	from	O
3	all	O
4	3	O
5	species	O
6	yielded	O
7	maximum	O
8	responses	O
9	with	O
10	a	O
11	48	O
12	-	O
13	hour	O
14	prelabel	O
15	and	O
16	12	O
17	-	O
18	to	O
19	-	O
20	16	O
21	hour	O
22	postlabel	O
23	incubation	O
24	period	O
25	at	O
26	41	O
27	C	O
28	and	O
29	1	O
30	:	O
31	20	O
32	blood	O
33	dilution	O
34	.	O
1	The	O
2	segmental	O
3	and	O
4	regional	O
5	projections	O
6	of	O
7	the	O
8	sciatic	O
9	,	O
10	tibial	O
11	and	O
12	common	O
13	peroneal	O
14	nerves	O
15	to	O
16	the	O
17	substantia	O
18	gelatinosa	O
19	of	O
20	the	O
21	spinal	O
22	cord	O
23	in	O
24	rats	O
25	--	O
26	an	O
27	experimental	O
28	study	O
29	by	O
30	means	O
31	of	O
32	an	O
33	acid	B
34	phosphatase	I
35	(	O
36	ACP	B
37	)	O
38	method	O
39	.	O
1	Human	B
2	thyroid	I
3	stimulator	I
4	(	O
5	HTS	B
6	)	O
7	in	O
8	thyroid	O
9	diseases	O
1	An	O
2	experimental	O
3	long	O
4	-	O
5	term	O
6	study	O
7	.	O
1	The	O
2	Sarns	O
3	51F	O
4	cavoatrial	O
5	cannula	O
6	decompressed	O
7	the	O
8	venous	O
9	system	O
10	as	O
11	efficiently	O
12	as	O
13	the	O
14	double	O
15	caval	O
16	cannulas	O
17	.	O
1	During	O
2	a	O
3	single	O
4	LAD	O
5	occlusion	O
6	lasting	O
7	35	O
8	minutes	O
9	(	O
10	series	O
11	I	O
12	,	O
13	n	O
14	=	O
15	10	O
16	)	O
17	9	O
18	microns	O
19	TMs	O
20	were	O
21	infused	O
22	immediately	O
23	and	O
24	30	O
25	minutes	O
26	after	O
27	ligation	O
28	,	O
29	15	O
30	microns	O
31	TMs	O
32	being	O
33	infused	O
34	after	O
35	15	O
36	-	O
37	20	O
38	minutes	O
39	.	O
1	HL	O
2	02	O
3	type	O
4	oculomotor	O
5	stimulator	O
6	.	O
1	Combination	O
2	of	O
3	a	O
4	Shwachman	O
5	syndrome	O
6	and	O
7	a	O
8	complex	O
9	granulocyte	O
10	function	O
11	disorder	O
12	in	O
13	a	O
14	girl	O
1	The	O
2	subgroup	O
3	innervating	O
4	the	O
5	medial	O
6	rectus	O
7	lies	O
8	exclusively	O
9	along	O
10	the	O
11	medial	O
12	face	O
13	of	O
14	the	O
15	oculomotor	O
16	nucleus	O
17	,	O
18	with	O
19	no	O
20	aberrant	O
21	neurons	O
22	in	O
23	the	O
24	medial	O
25	longitudinal	O
26	fasciculus	O
27	,	O
28	as	O
29	have	O
30	been	O
31	found	O
32	in	O
33	other	O
34	mammals	O
35	.	O
1	The	O
2	authors	O
3	have	O
4	tested	O
5	the	O
6	interference	O
7	of	O
8	the	O
9	hemoglobin	B
10	by	O
11	two	O
12	routine	O
13	methods	O
14	(	O
15	Berthelot	O
16	classic	O
17	and	O
18	Berthelot	O
19	modified	O
20	)	O
21	for	O
22	the	O
23	determination	O
24	of	O
25	plasmatic	O
26	urea	O
27	.	O
1	Urinary	B
2	N	I
3	-	I
4	acetylglucosaminidase	I
5	activity	O
6	per	O
7	mg	O
8	creatinine	O
9	did	O
10	not	O
11	differ	O
12	significantly	O
13	between	O
14	groups	O
15	.	O
1	After	O
2	1	O
3	.	O
4	5	O
5	years	O
6	of	O
7	such	O
8	photoperiodic	O
9	control	O
10	,	O
11	all	O
12	ewes	O
13	were	O
14	blinded	O
15	by	O
16	bilateral	O
17	orbital	O
18	enucleation	O
19	.	O
1	The	O
2	range	O
3	of	O
4	serum	O
5	concentrations	O
6	,	O
7	mean	O
8	values	O
9	,	O
10	median	O
11	values	O
12	,	O
13	and	O
14	standard	O
15	deviations	O
16	for	O
17	each	O
18	analyte	O
19	are	O
20	reported	O
21	for	O
22	males	O
23	and	O
24	females	O
25	and	O
26	for	O
27	three	O
28	age	O
29	groups	O
30	(	O
31	25	O
32	-	O
33	44	O
34	,	O
35	45	O
36	-	O
37	59	O
38	,	O
39	60	O
40	-	O
41	70	O
42	).	O
1	The	O
2	Prolactin	B
3	levels	O
4	were	O
5	within	O
6	the	O
7	physiological	O
8	norms	O
9	;	O
10	the	O
11	responses	O
12	to	O
13	TRH	B
14	were	O
15	normal	O
16	,	O
17	and	O
18	elevated	O
19	only	O
20	in	O
21	a	O
22	few	O
23	cases	O
24	.	O
1	Antithrombin	B
2	III	I
3	in	O
4	hip	O
5	surgery	O
1	HBB	O
2	concentration	O
3	in	O
4	the	O
5	fetuses	O
6	indicated	O
7	little	O
8	,	O
9	if	O
10	any	O
11	accumulation	O
12	.	O
1	No	O
2	patient	O
3	with	O
4	bradyarrhythmia	O
5	-	O
6	related	O
7	SCD	O
8	had	O
9	manifest	O
10	atrioventricular	O
11	block	O
12	or	O
13	bundle	O
14	branch	O
15	block	O
16	.	O
1	The	O
2	maps	O
3	of	O
4	Case	O
5	2	O
6	showed	O
7	that	O
8	a	O
9	maximum	O
10	first	O
11	appeared	O
12	on	O
13	the	O
14	upper	O
15	right	O
16	back	O
17	and	O
18	then	O
19	moved	O
20	down	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	posterior	O
27	thorax	O
28	.	O
1	Single	O
2	tooth	O
3	replacement	O
4	with	O
5	the	O
6	aid	O
7	of	O
8	the	O
9	ITI	O
10	(	O
11	International	O
12	Team	O
13	fur	O
14	Implantologie	O
15	)	O
16	type	O
17	F	O
18	hollow	O
19	-	O
20	cylinder	O
21	implant	O
1	1	O
2	.	O
1	The	O
2	alterations	O
3	in	O
4	differentiation	O
5	of	O
6	osteoprogenitor	O
7	cells	O
8	,	O
9	together	O
10	with	O
11	the	O
12	failure	O
13	of	O
14	mineralization	O
15	,	O
16	resulted	O
17	in	O
18	significantly	O
19	lower	O
20	rates	O
21	of	O
22	bone	O
23	formation	O
24	(	O
25	as	O
26	measured	O
27	by	O
28	fluorochrome	O
29	labeling	O
30	)	O
31	in	O
32	the	O
33	magnesium	O
34	-	O
35	deficient	O
36	rats	O
37	.	O
1	Production	O
2	of	O
3	C	B
4	mu	I
5	RNAs	I
6	,	O
7	unlike	O
8	mu	B
9	mRNAs	I
10	,	O
11	does	O
12	not	O
13	require	O
14	recombination	O
15	with	O
16	the	O
17	joining	B
18	region	I
19	(	O
20	JH	B
21	)	O
22	locus	O
23	.	O
1	Transcripts	O
2	of	O
3	the	O
4	immunoglobulin	B
5	C	I
6	mu	I
7	gene	I
8	vary	O
9	in	O
10	structure	O
11	and	O
12	splicing	O
13	during	O
14	lymphoid	O
15	development	O
16	.	O
1	The	O
2	role	O
3	of	O
4	DNA	O
5	rearrangement	O
6	and	O
7	alternative	O
8	RNA	O
9	processing	O
10	in	O
11	the	O
12	expression	O
13	of	O
14	immunoglobulin	B
15	delta	I
16	genes	I
17	.	O
1	Although	O
2	the	O
3	mechanism	O
4	of	O
5	action	O
6	of	O
7	ICRF	O
8	-	O
9	159	O
10	and	O
11	187	O
12	has	O
13	not	O
14	been	O
15	clearly	O
16	defined	O
17	,	O
18	it	O
19	is	O
20	evident	O
21	from	O
22	both	O
23	preclinical	O
24	and	O
25	early	O
26	clinical	O
27	studies	O
28	that	O
29	these	O
30	compounds	O
31	are	O
32	of	O
33	interest	O
34	.	O
1	The	O
2	sympathetic	O
3	neuroeffector	O
4	influence	O
5	on	O
6	the	O
7	myocardium	O
8	with	O
9	ATCI	O
10	depends	O
11	to	O
12	a	O
13	large	O
14	measure	O
15	on	O
16	the	O
17	intensity	O
18	of	O
19	the	O
20	neurotransmitter	O
21	biosynthesis	O
22	and	O
23	function	O
24	of	O
25	cardiomyocyte	O
26	adrenoreceptors	O
27	.	O
1	The	O
2	already	O
3	elevated	O
4	prolactin	B
5	levels	O
6	in	O
7	nursing	O
8	women	O
9	were	O
10	not	O
11	influenced	O
12	by	O
13	chronic	O
14	oestradiol	O
15	administration	O
16	.	O
1	Comparison	O
2	of	O
3	three	O
4	different	O
5	preparations	O
6	of	O
7	disodium	O
8	cromoglycate	O
9	in	O
10	the	O
11	prevention	O
12	of	O
13	exercise	O
14	-	O
15	induced	O
16	bronchospasm	O
17	:	O
18	a	O
19	double	O
20	-	O
21	blind	O
22	study	O
23	.	O
1	Bile	O
2	bilirubin	O
3	did	O
4	not	O
5	rise	O
6	within	O
7	12	O
8	h	O
9	after	O
10	haem	O
11	infusion	O
12	a	O
13	finding	O
14	which	O
15	warrants	O
16	further	O
17	investigation	O
18	.	O
1	The	O
2	osmotic	O
3	diuretic	O
4	mannitol	O
5	was	O
6	administered	O
7	to	O
8	21	O
9	patients	O
10	.	O
1	Of	O
2	270	O
3	patients	O
4	with	O
5	well	O
6	-	O
7	defined	O
8	drug	O
9	reactions	O
10	,	O
11	190	O
12	(	O
13	70	O
14	per	O
15	cent	O
16	)	O
17	gave	O
18	a	O
19	positive	O
20	response	O
21	to	O
22	the	O
23	mast	O
24	cell	O
25	test	O
26	.	O
1	At	O
2	43	O
3	%	O
4	blood	O
5	pressure	O
6	reduction	O
7	,	O
8	PCO2	O
9	fell	O
10	by	O
11	0	O
12	.	O
13	53	O
14	kPa	O
15	,	O
16	a	O
17	decrease	O
18	which	O
19	could	O
20	not	O
21	explain	O
22	the	O
23	observed	O
24	CBF	O
25	fall	O
26	of	O
27	27	O
28	%.	O
1	Self	O
2	-	O
3	heating	O
4	after	O
5	deep	O
6	hypothermia	O
7	(	O
8	20	O
9	degrees	O
10	C	O
11	)	O
12	causes	O
13	a	O
14	considerable	O
15	increase	O
16	in	O
17	the	O
18	brain	O
19	tissues	O
20	glutaminase	B
21	activity	O
22	at	O
23	all	O
24	studied	O
25	incubation	O
26	temperatures	O
27	(	O
28	37	O
29	,	O
30	30	O
31	,	O
32	20	O
33	and	O
34	10	O
35	degrees	O
36	C	O
37	)	O
38	as	O
39	compared	O
40	to	O
41	control	O
42	rats	O
43	and	O
44	rats	O
45	under	O
46	hypothermia	O
47	.	O
1	Significant	O
2	GMBF	O
3	reductions	O
4	occurred	O
5	in	O
6	early	O
7	shock	O
8	in	O
9	both	O
10	treatment	O
11	groups	O
12	.	O
1	Detection	O
2	of	O
3	exercise	O
4	-	O
5	induced	O
6	asynergy	O
7	by	O
8	M	O
9	-	O
10	mode	O
11	echocardiography	O
12	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	significant	O
6	pulmonary	O
7	metabolism	O
8	of	O
9	5	O
10	-	O
11	HT	O
12	followed	O
13	by	O
14	efflux	O
15	of	O
16	5	O
17	-	O
18	HIAA	O
19	into	O
20	venous	O
21	output	O
22	occurs	O
23	during	O
24	single	O
25	-	O
26	pass	O
27	circulation	O
28	.	O
1	Disturbances	O
2	of	O
3	placental	O
4	maturation	O
5	,	O
6	2	O
7	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	histopathological	O
6	findings	O
7	,	O
8	the	O
9	origin	O
10	of	O
11	amyloid	O
12	appeared	O
13	to	O
14	be	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	fibroblasts	O
20	.	O
1	Both	O
2	groups	O
3	were	O
4	subjected	O
5	to	O
6	tests	O
7	of	O
8	delayed	O
9	hypersensitivity	O
10	with	O
11	Candidin	B
12	,	O
13	Trycophytin	B
14	and	O
15	Tuberculin	B
16	.	O
1	Echosismography	O
2	enables	O
3	to	O
4	improve	O
5	the	O
6	diagnosis	O
7	when	O
8	compared	O
9	with	O
10	classical	O
11	sonography	O
12	in	O
13	about	O
14	20	O
15	%	O
16	of	O
17	cases	O
18	.	O
1	Total	O
2	PGE	O
3	levels	O
4	in	O
5	synovial	O
6	fluid	O
7	remained	O
8	significantly	O
9	depressed	O
10	in	O
11	the	O
12	patient	O
13	group	O
14	for	O
15	24	O
16	hours	O
17	after	O
18	the	O
19	400	O
20	-	O
21	mg	O
22	test	O
23	dose	O
24	of	O
25	tolmetin	O
26	on	O
27	day	O
28	8	O
29	.	O
1	Survival	O
2	of	O
3	111	O
4	Indium	O
5	-	O
6	labelled	O
7	autologous	O
8	platelets	O
9	was	O
10	studied	O
11	in	O
12	2	O
13	patients	O
14	after	O
15	correction	O
16	of	O
17	platelet	O
18	count	O
19	and	O
20	was	O
21	still	O
22	found	O
23	shortened	O
24	.	O
1	When	O
2	O2	O
3	therapy	O
4	was	O
5	controlled	O
6	for	O
7	,	O
8	the	O
9	association	O
10	between	O
11	RBT	O
12	and	O
13	RLF	O
14	did	O
15	not	O
16	achieve	O
17	statistical	O
18	significance	O
19	(	O
20	P	O
21	=	O
22	.	O
23	07	O
24	).	O
1	Statistics	O
2	for	O
3	nurse	O
4	managers	O
5	--	O
6	3	O
7	.	O
1	Thus	O
2	it	O
3	appears	O
4	that	O
5	the	O
6	management	O
7	of	O
8	blood	O
9	,	O
10	including	O
11	washing	O
12	is	O
13	of	O
14	great	O
15	importance	O
16	.	O
1	Whereas	O
2	creatine	B
3	kinase	I
4	activity	O
5	declined	O
6	exponentially	O
7	from	O
8	a	O
9	single	O
10	peak	O
11	,	O
12	myoglobin	B
13	appeared	O
14	in	O
15	multiple	O
16	episodes	O
17	inadequately	O
18	represented	O
19	by	O
20	a	O
21	single	O
22	peak	O
23	value	O
24	and	O
25	having	O
26	no	O
27	clear	O
28	clinical	O
29	correlation	O
30	.	O
1	Specific	O
2	IgE	B
3	levels	O
4	decreased	O
5	slightly	O
6	,	O
7	but	O
8	always	O
9	remained	O
10	within	O
11	the	O
12	pathological	O
13	range	O
14	.	O
1	Endorphins	B
2	and	O
3	legal	O
4	issues	O
5	.	O
1	The	O
2	foregoing	O
3	results	O
4	show	O
5	that	O
6	CXD	O
7	has	O
8	high	O
9	efficacy	O
10	and	O
11	safety	O
12	and	O
13	it	O
14	can	O
15	be	O
16	said	O
17	that	O
18	it	O
19	is	O
20	a	O
21	drug	O
22	required	O
23	in	O
24	the	O
25	pediatric	O
26	field	O
27	.	O
1	(	O
2	1980	O
3	):	O
4	Science	O
5	210	O
6	,	O
7	77	O
8	-	O
9	72	O
10	)	O
11	that	O
12	stimulating	O
13	the	O
14	crossed	O
15	olivocochlear	O
16	bundle	O
17	(	O
18	COCB	O
19	)	O
20	can	O
21	change	O
22	the	O
23	magnitude	O
24	of	O
25	the	O
26	distortion	O
27	product	O
28	(	O
29	f2	O
30	-	O
31	f1	O
32	)	O
33	in	O
34	the	O
35	ear	O
36	-	O
37	canal	O
38	sound	O
39	pressure	O
40	.	O
1	We	O
2	compared	O
3	the	O
4	volume	O
5	of	O
6	the	O
7	pulmonary	O
8	extravascular	O
9	,	O
10	extracellular	O
11	water	O
12	space	O
13	using	O
14	sodium	O
15	and	O
16	sucrose	O
17	indicators	O
18	in	O
19	8	O
20	normal	O
21	and	O
22	11	O
23	edematous	O
24	rabbit	O
25	lungs	O
26	by	O
27	steady	O
28	-	O
29	state	O
30	techniques	O
31	.	O
1	Recommendations	O
2	to	O
3	deal	O
4	with	O
5	these	O
6	and	O
7	related	O
8	issues	O
9	are	O
10	presented	O
11	.	O
1	The	O
2	differential	O
3	investigation	O
4	of	O
5	lipoproteins	O
6	,	O
7	however	O
8	,	O
9	showed	O
10	that	O
11	the	O
12	high	B
13	-	I
14	density	I
15	lipoprotein	I
16	(	O
17	HDL	B
18	)	O
19	fractions	O
20	are	O
21	absolutely	O
22	or	O
23	relatively	O
24	decreased	O
25	with	O
26	respect	O
27	to	O
28	low	B
29	-	I
30	density	I
31	lipoproteins	I
32	(	O
33	LDL	B
34	)	O
35	in	O
36	cerebral	O
37	infarcts	O
38	and	O
39	in	O
40	transient	O
41	ischaemic	O
42	attacks	O
43	.	O
1	Samples	O
2	obtained	O
3	from	O
4	normal	O
5	volunteers	O
6	and	O
7	from	O
8	the	O
9	great	O
10	majority	O
11	of	O
12	the	O
13	patients	O
14	,	O
15	excluding	O
16	those	O
17	with	O
18	asthma	O
19	,	O
20	had	O
21	no	O
22	effect	O
23	on	O
24	ciliary	O
25	beating	O
26	.	O
1	Conjugated	O
2	and	O
3	unconjugated	O
4	phenylacetic	O
5	acid	O
6	and	O
7	m	O
8	-	O
9	and	O
10	p	O
11	-	O
12	hydroxyphenylacetic	O
13	acid	O
14	have	O
15	been	O
16	determined	O
17	in	O
18	the	O
19	plasma	O
20	of	O
21	normal	O
22	,	O
23	healthy	O
24	subjects	O
25	after	O
26	fasting	O
27	,	O
28	consumption	O
29	of	O
30	a	O
31	meal	O
32	and	O
33	ingestion	O
34	of	O
35	deuterium	O
36	labelled	O
37	amine	O
38	precursors	O
39	,	O
40	by	O
41	high	O
42	-	O
43	resolution	O
44	gas	O
45	chromatography	O
46	--	O
47	high	O
48	resolution	O
49	mass	O
50	spectrometry	O
51	with	O
52	selected	O
53	ion	O
54	monitoring	O
55	of	O
56	their	O
57	trifluoroethyl	O
58	-	O
59	pentafluoropropionyl	O
60	derivatives	O
61	.	O
1	CSF	O
2	adenosine	B
3	deaminase	I
4	activity	O
5	(	O
6	ADA	O
7	)	O
8	was	O
9	measured	O
10	at	O
11	the	O
12	same	O
13	time	O
14	.	O
1	Histamine	O
2	reactivity	O
3	had	O
4	returned	O
5	to	O
6	normal	O
7	in	O
8	half	O
9	the	O
10	workers	O
11	who	O
12	had	O
13	left	O
14	their	O
15	original	O
16	factories	O
17	,	O
18	but	O
19	in	O
20	only	O
21	one	O
22	worker	O
23	who	O
24	had	O
25	moved	O
26	within	O
27	her	O
28	original	O
29	factory	O
30	.	O
1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	EF	O
8	between	O
9	the	O
10	two	O
11	studies	O
12	,	O
13	both	O
14	at	O
15	rest	O
16	(	O
17	56	O
18	.	O
19	0	O
20	+/-	O
21	13	O
22	.	O
23	8	O
24	%	O
25	vs	O
26	58	O
27	.	O
28	2	O
29	+/-	O
30	11	O
31	.	O
32	7	O
33	%,	O
34	p	O
35	=	O
36	NS	O
37	)	O
38	and	O
39	with	O
40	exercise	O
41	(	O
42	51	O
43	.	O
44	1	O
45	+/-	O
46	17	O
47	.	O
48	6	O
49	%	O
50	vs	O
51	54	O
52	.	O
53	3	O
54	+/-	O
55	17	O
56	.	O
57	6	O
58	%,	O
59	p	O
60	=	O
61	NS	O
62	)	O
63	and	O
64	a	O
65	highly	O
66	significant	O
67	correlation	O
68	was	O
69	shown	O
70	between	O
71	the	O
72	two	O
73	groups	O
74	of	O
75	values	O
76	(	O
77	rest	O
78	r	O
79	=	O
80	0	O
81	.	O
82	90	O
83	,	O
84	exercise	O
85	r	O
86	=	O
87	0	O
88	.	O
89	93	O
90	,	O
91	p	O
92	less	O
93	than	O
94	0	O
95	.	O
96	001	O
97	).	O
1	After	O
2	MOPP	O
3	therapy	O
4	,	O
5	complete	O
6	remission	O
7	of	O
8	Hodgkin	O
9	'	O
10	s	O
11	disease	O
12	was	O
13	accompanied	O
14	by	O
15	normalization	O
16	of	O
17	the	O
18	glucocerebrosidase	B
19	level	O
20	and	O
21	disappearance	O
22	of	O
23	Gaucher	O
24	'	O
25	s	O
26	cells	O
27	.	O
1	Re	O
2	:	O
3	A	O
4	modified	O
5	method	O
6	for	O
7	the	O
8	in	O
9	vivo	O
10	labeling	O
11	of	O
12	red	O
13	blood	O
14	cells	O
15	with	O
16	Tc	O
17	-	O
18	99m	O
19	.	O
1	The	O
2	pia	O
3	mater	O
4	at	O
5	the	O
6	site	O
7	of	O
8	the	O
9	entry	O
10	of	O
11	blood	O
12	vessels	O
13	into	O
14	the	O
15	central	O
16	nervous	O
17	system	O
18	.	O
1	Asymptomatic	O
2	bacteriospermia	O
3	and	O
4	fertility	O
1	In	O
2	vitro	O
3	penetration	O
4	tests	O
5	of	O
6	human	O
7	sperm	O
8	into	O
9	cervical	O
10	mucus	O
11	were	O
12	introduced	O
13	in	O
14	order	O
15	to	O
16	study	O
17	the	O
18	interaction	O
19	between	O
20	sperm	O
21	and	O
22	cervical	O
23	mucus	O
24	.	O
1	Serum	B
2	creatine	I
3	kinase	I
4	(	O
5	SCK	B
6	)	O
7	was	O
8	measured	O
9	in	O
10	ten	O
11	subjects	O
12	in	O
13	the	O
14	laboratory	O
15	before	O
16	and	O
17	after	O
18	the	O
19	performance	O
20	of	O
21	bicycle	O
22	ergometry	O
23	and	O
24	a	O
25	lifting	O
26	task	O
27	.	O
1	It	O
2	is	O
3	postulated	O
4	that	O
5	altered	O
6	blood	O
7	flow	O
8	,	O
9	mediated	O
10	through	O
11	the	O
12	well	O
13	-	O
14	known	O
15	prostaglandin	B
16	synthetase	I
17	inhibitory	O
18	effects	O
19	of	O
20	ibuprofen	O
21	,	O
22	resulted	O
23	in	O
24	tubular	O
25	necrosis	O
26	.	O
1	Either	O
2	20	O
3	mg	O
4	mitomycin	O
5	/	O
6	20	O
7	ml	O
8	distilled	O
9	water	O
10	or	O
11	40	O
12	mg	O
13	/	O
14	40	O
15	ml	O
16	distilled	O
17	water	O
18	was	O
19	locally	O
20	instilled	O
21	into	O
22	the	O
23	bladder	O
24	with	O
25	a	O
26	catheter	O
27	after	O
28	emptying	O
29	it	O
30	and	O
31	was	O
32	left	O
33	for	O
34	about	O
35	25	O
36	-	O
37	l20	O
38	min	O
39	.	O
1	Lacrimal	O
2	secretion	O
3	in	O
4	hyperthyroidism	O
1	At	O
2	an	O
3	ambient	O
4	temperature	O
5	of	O
6	25	O
7	degrees	O
8	C	O
9	,	O
10	the	O
11	responses	O
12	to	O
13	spinal	O
14	cooling	O
15	are	O
16	reduced	O
17	during	O
18	the	O
19	dark	O
20	phase	O
21	.	O
1	Morphological	O
2	features	O
3	of	O
4	Jat	O
5	dentition	O
6	.	O
1	Following	O
2	extended	O
3	recovery	O
4	hippocampal	O
5	EEG	O
6	was	O
7	normal	O
8	despite	O
9	extensive	O
10	cellular	O
11	loss	O
12	in	O
13	areas	O
14	CA3	O
15	and	O
16	CA4	O
17	.	O
1	Evoked	O
2	potential	O
3	and	O
4	single	O
5	unit	O
6	responses	O
7	to	O
8	olfactory	O
9	nerve	O
10	volleys	O
11	in	O
12	the	O
13	isolated	O
14	turtle	O
15	olfactory	O
16	bulb	O
17	.	O
1	Cross	O
2	reactivity	O
3	in	O
4	theophylline	O
5	RIA	O
6	kit	O
7	decreased	O
8	.	O
1	Recording	O
2	of	O
3	the	O
4	digital	O
5	sphygmic	O
6	activity	O
7	in	O
8	the	O
9	lower	O
10	extremities	O
11	with	O
12	the	O
13	photoplethysmographic	O
14	and	O
15	strain	O
16	-	O
17	gauge	O
18	methods	O
19	.	O
1	The	O
2	oral	O
3	temperature	O
4	rose	O
5	and	O
6	the	O
7	serum	B
8	creatine	I
9	kinase	I
10	levels	O
11	fell	O
12	only	O
13	in	O
14	those	O
15	patients	O
16	who	O
17	were	O
18	actively	O
19	warmed	O
20	.	O
1	Determination	O
2	of	O
3	aortic	O
4	distensibility	O
5	and	O
6	its	O
7	variations	O
8	in	O
9	arterial	O
10	hypertension	O
11	.	O
1	Effects	O
2	of	O
3	early	O
4	monocular	O
5	deprivation	O
6	on	O
7	development	O
8	of	O
9	cortico	O
10	-	O
11	geniculate	O
12	projections	O
13	in	O
14	the	O
15	cat	O
16	.	O
1	Bilateral	O
2	Charnley	O
3	arthroplasty	O
4	as	O
5	a	O
6	single	O
7	procedure	O
8	.	O
1	The	O
2	new	O
3	semi	O
4	-	O
5	synthetic	O
6	oral	O
7	cephalosporin	O
8	,	O
9	CGP	O
10	9	O
11	,	O
12	000	O
13	,	O
14	has	O
15	been	O
16	evaluated	O
17	in	O
18	a	O
19	large	O
20	number	O
21	of	O
22	hospitalized	O
23	patients	O
24	with	O
25	urinary	O
26	infections	O
27	.	O
1	33	O
2	out	O
3	of	O
4	90	O
5	neurons	O
6	of	O
7	the	O
8	cat	O
9	medial	O
10	geniculate	O
11	body	O
12	revealed	O
13	the	O
14	selectivity	O
15	of	O
16	their	O
17	afterdischarges	O
18	to	O
19	movement	O
20	of	O
21	sound	O
22	when	O
23	velocity	O
24	of	O
25	the	O
26	movement	O
27	changed	O
28	from	O
29	30	O
30	to	O
31	180	O
32	deg	O
33	/	O
34	s	O
35	.	O
1	Based	O
2	on	O
3	AUC	O
4	infinity	O
5	analyses	O
6	,	O
7	the	O
8	pharmacokinetics	O
9	of	O
10	buflomedil	O
11	were	O
12	found	O
13	to	O
14	be	O
15	linear	O
16	within	O
17	the	O
18	dose	O
19	ranges	O
20	studied	O
21	(	O
22	50	O
23	to	O
24	200	O
25	mg	O
26	for	O
27	i	O
28	.	O
29	v	O
30	.	O
31	injection	O
32	and	O
33	150	O
34	to	O
35	450	O
36	mg	O
37	for	O
38	oral	O
39	administration	O
40	).	O
1	Gastrin	B
2	secretion	O
3	during	O
4	food	O
5	stimulation	O
6	in	O
7	digestive	O
8	system	O
9	diseases	O
1	Delayed	O
2	or	O
3	paradoxically	O
4	emptying	O
5	regions	O
6	of	O
7	the	O
8	left	O
9	ventricle	O
10	were	O
11	detected	O
12	by	O
13	a	O
14	relatively	O
15	new	O
16	nuclear	O
17	technique	O
18	--	O
19	phase	O
20	imaging	O
21	.	O
1	Nineteen	O
2	patients	O
3	with	O
4	non	O
5	-	O
6	visualized	O
7	gallbladder	O
8	with	O
9	OCG	O
10	subsequently	O
11	had	O
12	Tc	O
13	-	O
14	99m	O
15	-	O
16	PyG	O
17	cholescintigraphy	O
18	performed	O
19	.	O
1	Electron	O
2	microscopic	O
3	picture	O
4	of	O
5	the	O
6	cerebral	O
7	cortex	O
8	in	O
9	rats	O
10	cooled	O
11	to	O
12	22	O
13	degrees	O
14	C	O
1	A	O
2	simplified	O
3	thin	O
4	-	O
5	layer	O
6	chromatographic	O
7	determination	O
8	of	O
9	hippuric	O
10	acid	O
11	and	O
12	methylhippuric	O
13	acids	O
14	.	O
1	The	O
2	geometric	O
3	mean	O
4	hemagglutination	O
5	-	O
6	inhibition	O
7	antibody	O
8	titers	O
9	(	O
10	GMT	O
11	)	O
12	of	O
13	non	O
14	-	O
15	immunized	O
16	,	O
17	once	O
18	-	O
19	immunized	O
20	,	O
21	and	O
22	twice	O
23	-	O
24	immunized	O
25	chickens	O
26	were	O
27	compared	O
28	at	O
29	2	O
30	-	O
31	week	O
32	intervals	O
33	following	O
34	primary	O
35	immunization	O
36	,	O
37	secondary	O
38	immunization	O
39	,	O
40	and	O
41	challenge	O
42	.	O
1	2	O
2	.	O
3	numerous	O
4	narrow	O
5	shunt	O
6	vessels	O
7	departing	O
8	continuously	O
9	from	O
10	the	O
11	primary	O
12	arteries	O
13	to	O
14	feed	O
15	a	O
16	secondary	O
17	arterial	O
18	system	O
19	which	O
20	parallels	O
21	the	O
22	primary	O
23	one	O
24	.	O
1	The	O
2	authors	O
3	conclude	O
4	that	O
5	nonspecificity	O
6	of	O
7	low	O
8	platelet	B
9	MAO	I
10	as	O
11	a	O
12	possible	O
13	correlate	O
14	of	O
15	bipolar	O
16	affective	O
17	disorder	O
18	,	O
19	as	O
20	well	O
21	as	O
22	schizophrenia	O
23	,	O
24	increases	O
25	the	O
26	burden	O
27	of	O
28	proof	O
29	necessary	O
30	before	O
31	findings	O
32	of	O
33	low	O
34	platelet	B
35	MAO	I
36	can	O
37	be	O
38	accepted	O
39	as	O
40	primary	O
41	.	O
1	Ecthyma	O
2	,	O
3	a	O
4	known	O
5	disease	O
6	,	O
7	of	O
8	which	O
9	little	O
10	is	O
11	known	O
1	However	O
2	,	O
3	at	O
4	lower	O
5	temperature	O
6	the	O
7	positive	O
8	staircase	O
9	was	O
10	not	O
11	clear	O
12	and	O
13	rather	O
14	negative	O
15	staircase	O
16	appeared	O
17	(	O
18	1	O
19	--	O
20	3	O
21	Hz	O
22	).	O
1	A	O
2	16	O
3	-	O
4	year	O
5	follow	O
6	-	O
7	up	O
8	study	O
9	of	O
10	69	O
11	paraplegics	O
12	with	O
13	complete	O
14	lesions	O
15	from	O
16	T1	O
17	-	O
18	L3	O
19	is	O
20	presented	O
21	.	O
1	Cataract	O
2	extraction	O
3	in	O
4	primary	O
5	glaucoma	O
1	We	O
2	report	O
3	a	O
4	case	O
5	of	O
6	pheochromocytoma	O
7	manifesting	O
8	during	O
9	the	O
10	third	O
11	trimester	O
12	of	O
13	pregnancy	O
14	.	O
1	Fasting	O
2	plasma	O
3	and	O
4	lipoprotein	O
5	lipid	O
6	concentrations	O
7	,	O
8	adipose	B
9	tissue	I
10	lipoprotein	I
11	lipase	I
12	activity	O
13	,	O
14	anthropometric	O
15	data	O
16	,	O
17	alcohol	O
18	consumption	O
19	,	O
20	smoking	O
21	habits	O
22	,	O
23	weekly	O
24	mileage	O
25	run	O
26	and	O
27	performance	O
28	on	O
29	a	O
30	bicycle	O
31	ergometer	O
32	were	O
33	recorded	O
34	before	O
35	and	O
36	after	O
37	the	O
38	training	O
39	period	O
40	.	O
1	Our	O
2	study	O
3	differs	O
4	from	O
5	previous	O
6	studies	O
7	in	O
8	that	O
9	it	O
10	is	O
11	limited	O
12	to	O
13	one	O
14	diagnostic	O
15	entity	O
16	,	O
17	yet	O
18	at	O
19	the	O
20	same	O
21	time	O
22	evaluates	O
23	a	O
24	broad	O
25	range	O
26	of	O
27	social	O
28	and	O
29	work	O
30	-	O
31	related	O
32	factors	O
33	in	O
34	disability	O
35	.	O
1	In	O
2	a	O
3	control	O
4	group	O
5	both	O
6	common	O
7	carotid	O
8	arteries	O
9	(	O
10	CCA	O
11	)	O
12	were	O
13	ligated	O
14	.	O
1	At	O
2	pH	O
3	6	O
4	.	O
5	9	O
6	,	O
7	the	O
8	same	O
9	lidocaine	O
10	concentrations	O
11	significantly	O
12	reduced	O
13	resting	O
14	potential	O
15	(	O
16	3	O
17	-	O
18	10	O
19	%),	O
20	action	O
21	potential	O
22	amplitude	O
23	(	O
24	3	O
25	-	O
26	8	O
27	%)	O
28	and	O
29	Vmax	O
30	(	O
31	14	O
32	-	O
33	22	O
34	%).	O
1	The	O
2	operation	O
3	recommended	O
4	is	O
5	excision	O
6	of	O
7	3	O
8	mm	O
9	of	O
10	central	O
11	slip	O
12	followed	O
13	by	O
14	end	O
15	-	O
16	to	O
17	-	O
18	end	O
19	repair	O
20	of	O
21	the	O
22	tendon	O
23	.	O
1	In	O
2	the	O
3	unclipped	O
4	group	O
5	arterial	O
6	pressure	O
7	decreased	O
8	50	O
9	mmHg	O
10	to	O
11	normal	O
12	by	O
13	24	O
14	h	O
15	and	O
16	was	O
17	associated	O
18	with	O
19	increased	O
20	diuresis	O
21	and	O
22	a	O
23	small	O
24	decrease	O
25	in	O
26	blood	O
27	volume	O
28	(	O
29	9	O
30	.	O
31	8	O
32	%).	O
1	The	O
2	potentially	O
3	SLE	O
4	-	O
5	inducing	O
6	drugs	O
7	are	O
8	reviewed	O
9	.	O
1	Fourteen	O
2	different	O
3	species	O
4	(	O
5	eight	O
6	Platyhelmintha	O
7	,	O
8	one	O
9	Nematoda	O
10	and	O
11	five	O
12	Crustacea	O
13	)	O
14	have	O
15	been	O
16	inventorized	O
17	.	O
1	At	O
2	4	O
3	wk	O
4	however	O
5	,	O
6	tumor	O
7	relapse	O
8	was	O
9	noted	O
10	in	O
11	6	O
12	of	O
13	7	O
14	group	O
15	4	O
16	responders	O
17	,	O
18	10	O
19	of	O
20	12	O
21	in	O
22	group	O
23	5	O
24	,	O
25	13	O
26	of	O
27	16	O
28	in	O
29	group	O
30	7	O
31	,	O
32	but	O
33	only	O
34	4	O
35	of	O
36	19	O
37	group	O
38	8	O
39	responders	O
40	(	O
41	p	O
42	less	O
43	than	O
44	.	O
45	001	O
46	group	O
47	8	O
48	versus	O
49	4	O
50	,	O
51	5	O
52	,	O
53	7	O
54	).	O
1	Early	O
2	infection	O
3	was	O
4	detected	O
5	in	O
6	one	O
7	of	O
8	50	O
9	control	O
10	women	O
11	who	O
12	gave	O
13	birth	O
14	to	O
15	a	O
16	healthy	O
17	infant	O
18	.	O
1	Some	O
2	strains	O
3	of	O
4	A	O
5	.	O
6	parasiticus	O
7	produced	O
8	all	O
9	four	O
10	aflatoxins	O
11	B1	O
12	B2	O
13	G1	O
14	G2	O
15	,	O
16	while	O
17	the	O
18	other	O
19	ones	O
20	produced	O
21	AF	O
22	B1	O
23	+	O
24	G1	O
25	only	O
26	,	O
27	with	O
28	concentrations	O
29	of	O
30	aflatoxins	O
31	from	O
32	0	O
33	.	O
34	1	O
35	to	O
36	450	O
37	mg	O
38	/	O
39	kg	O
40	.	O
1	Both	O
2	classes	O
3	of	O
4	MHBst	B
5	proteins	I
6	were	O
7	found	O
8	to	O
9	form	O
10	dimers	O
11	;	O
12	an	O
13	which	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	the	O
19	dimerization	O
20	.	O
1	These	O
2	HPV16	O
3	E6	B
4	/	O
5	E7	B
6	cDNAs	O
7	were	O
8	cloned	O
9	under	O
10	the	O
11	SV40	B
12	enhancer	I
13	/	I
14	promoter	I
15	and	O
16	the	O
17	MMTV	B
18	LTR	I
19	to	O
20	examine	O
21	the	O
22	activities	O
23	of	O
24	ras	B
25	-	O
26	collaborative	O
27	transformation	O
28	and	O
29	induction	O
30	of	O
31	cellular	O
32	DNA	O
33	synthesis	O
34	,	O
35	both	O
36	of	O
37	which	O
38	depend	O
39	on	O
40	the	O
41	E7	B
42	gene	I
43	product	O
44	.	O
1	Correlation	O
2	coefficients	O
3	between	O
4	the	O
5	reference	O
6	methods	O
7	and	O
8	NIT	O
9	were	O
10	>	O
11	or	O
12	=	O
13	0	O
14	.	O
15	95	O
16	for	O
17	water	O
18	,	O
19	fat	O
20	,	O
21	crude	O
22	protein	O
23	and	O
24	connective	O
25	-	O
26	tissue	O
27	-	O
28	protein	O
29	frei	O
30	meat	O
31	protein	O
32	,	O
33	and	O
34	>	O
35	or	O
36	=	O
37	0	O
38	.	O
39	86	O
40	for	O
41	connective	O
42	-	O
43	tissue	O
44	-	O
45	protein	O
46	.	O
1	This	O
2	study	O
3	analyzed	O
4	whether	O
5	the	O
6	localization	O
7	of	O
8	an	O
9	accessory	O
10	pathway	O
11	could	O
12	be	O
13	predicted	O
14	by	O
15	using	O
16	the	O
17	polarity	O
18	of	O
19	the	O
20	QRS	O
21	complex	O
22	during	O
23	sinus	O
24	rhythm	O
25	on	O
26	the	O
27	surface	O
28	ECG	O
29	,	O
30	instead	O
31	of	O
32	the	O
33	delta	O
34	wave	O
35	polarity	O
36	as	O
37	used	O
38	in	O
39	many	O
40	reports	O
41	.	O
1	In	O
2	contrast	O
3	with	O
4	the	O
5	previously	O
6	reported	O
7	HMGR1	B
8	mRNA	I
9	(	O
10	HMGR1S	B
11	mRNA	I
12	),	O
13	which	O
14	is	O
15	detected	O
16	at	O
17	high	O
18	levels	O
19	in	O
20	all	O
21	tissues	O
22	of	O
23	the	O
24	plant	O
25	,	O
26	HMGR1L	B
27	mRNA	I
28	is	O
29	present	O
30	at	O
31	relatively	O
32	low	O
33	levels	O
34	and	O
35	its	O
36	expression	O
37	is	O
38	restricted	O
39	mostly	O
40	to	O
41	seedlings	O
42	,	O
43	roots	O
44	and	O
45	inflorescences	O
46	.	O
1	However	O
2	,	O
3	the	O
4	requirement	O
5	of	O
6	rev3	B
7	for	O
8	the	O
9	production	O
10	of	O
11	G	O
12	.	O
13	C	O
14	-->	O
15	T	O
16	.	O
17	A	O
18	transversions	O
19	by	O
20	the	O
21	rad18	B
22	mutator	I
23	,	O
24	which	O
25	induces	O
26	only	O
27	these	O
28	substitutions	O
29	,	O
30	was	O
31	similar	O
32	to	O
33	that	O
34	for	O
35	rad6	B
36	-	O
37	mediated	O
38	G	O
39	.	O
40	C	O
41	-->	O
42	T	O
43	.	O
44	A	O
45	transversion	O
46	.	O
1	The	O
2	identity	O
3	between	O
4	hnRNPs	B
5	H	I
6	and	O
7	H	B
8	'	I
9	is	O
10	96	O
11	%,	O
12	between	O
13	H	B
14	and	O
15	F	B
16	78	O
17	%,	O
18	and	O
19	between	O
20	H	B
21	'	I
22	and	O
23	F	B
24	75	O
25	%,	O
26	respectively	O
27	.	O
1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	13	O
7	latest	O
8	BPVs	O
9	,	O
10	age	O
11	ranged	O
12	from	O
13	three	O
14	days	O
15	to	O
16	13	O
17	.	O
18	1	O
19	years	O
20	(	O
21	mean	O
22	5	O
23	.	O
24	7	O
25	+/-	O
26	SD	O
27	4	O
28	.	O
29	8	O
30	years	O
31	).	O
1	The	O
2	effects	O
3	of	O
4	a	O
5	1	O
6	-	O
7	or	O
8	24	O
9	-	O
10	hour	O
11	pretreatment	O
12	regimen	O
13	with	O
14	monophosphoryl	O
15	lipid	O
16	A	O
17	(	O
18	MLA	O
19	,	O
20	35	O
21	micrograms	O
22	/	O
23	kg	O
24	i	O
25	.	O
26	v	O
27	.)	O
28	on	O
29	myocardial	O
30	stunning	O
31	produced	O
32	by	O
33	repetitive	O
34	coronary	O
35	occlusions	O
36	were	O
37	studied	O
38	in	O
39	barbital	O
40	-	O
41	anesthetized	O
42	dogs	O
43	.	O
1	These	O
2	observations	O
3	link	O
4	actin	B
5	plaque	O
6	assembly	O
7	to	O
8	increased	O
9	cell	O
10	substrate	O
11	adhesion	O
12	.	O
1	The	O
2	highest	O
3	decrease	O
4	in	O
5	mutagenic	O
6	activity	O
7	was	O
8	observed	O
9	when	O
10	enzymatic	O
11	bleaching	O
12	was	O
13	used	O
14	together	O
15	with	O
16	chlorine	O
17	.	O
1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O
1	Liver	O
2	transplantation	O
3	in	O
4	one	O
5	patient	O
6	resolved	O
7	metabolic	O
8	complications	O
9	but	O
10	did	O
11	not	O
12	improve	O
13	PMN	O
14	count	O
15	or	O
16	the	O
17	infectious	O
18	status	O
19	,	O
20	while	O
21	neutropenia	O
22	was	O
23	corrected	O
24	by	O
25	G	B
26	-	I
27	CSF	I
28	.	O
1	Two	O
2	promoters	O
3	were	O
4	identified	O
5	by	O
6	S1	B
7	nuclease	I
8	mapping	O
9	:	O
10	P1	O
11	,	O
12	which	O
13	lies	O
14	about	O
15	72	O
16	bp	O
17	upstream	O
18	from	O
19	the	O
20	structural	O
21	gene	O
22	;	O
23	and	O
24	P2	O
25	,	O
26	which	O
27	lies	O
28	about	O
29	35	O
30	bp	O
31	upstream	O
32	.	O
1	Organization	O
2	of	O
3	the	O
4	bovine	O
5	gene	O
6	encoding	O
7	the	O
8	endothelial	B
9	nitric	I
10	oxide	I
11	synthase	I
12	.	O
1	Effects	O
2	of	O
3	alterations	O
4	of	O
5	primer	O
6	-	O
7	binding	O
8	site	O
9	sequences	O
10	on	O
11	human	O
12	immunodeficiency	O
13	virus	O
14	type	O
15	1	O
16	replication	O
17	.	O
1	A	O
2	particularly	O
3	striking	O
4	HpaII	B
5	tiny	O
6	fragment	O
7	island	O
8	,	O
9	extending	O
10	over	O
11	nearly	O
12	2	O
13	,	O
14	000	O
15	base	O
16	pairs	O
17	,	O
18	surrounds	O
19	the	O
20	USF2	B
21	translation	I
22	initiation	I
23	site	I
24	.	O
1	A	O
2	chicken	B
3	paxillin	I
4	cDNA	I
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	B
21	paxil	I
22	-	I
23	lin	I
24	.	O
1	MBP	B
2	-	O
3	Rep68	B
4	delta	I
5	-	O
6	mediated	O
7	DNA	O
8	-	O
9	RNA	O
10	helicase	O
11	activity	O
12	required	O
13	ATP	O
14	hydrolysis	O
15	and	O
16	the	O
17	presence	O
18	of	O
19	Mg2	O
20	+	O
21	ions	O
22	and	O
23	was	O
24	inhibited	O
25	by	O
26	high	O
27	ionic	O
28	strength	O
29	.	O
1	Both	O
2	mutations	O
3	completely	O
4	abolished	O
5	binding	O
6	of	O
7	the	O
8	Abl	B
9	SH3	I
10	domain	O
11	to	O
12	proline	O
13	-	O
14	rich	O
15	target	O
16	proteins	O
17	in	O
18	a	O
19	filter	O
20	-	O
21	binding	O
22	assay	O
23	.	O
1	Morphologic	O
2	variables	O
3	included	O
4	cancer	O
5	volume	O
6	,	O
7	histologic	O
8	grade	O
9	,	O
10	capsular	O
11	penetration	O
12	,	O
13	seminal	O
14	vesicle	O
15	invasion	O
16	,	O
17	and	O
18	lymph	O
19	node	O
20	metastasis	O
21	.	O
1	The	O
2	fusion	O
3	proteins	O
4	were	O
5	tested	O
6	by	O
7	ELISA	O
8	for	O
9	reactivity	O
10	with	O
11	a	O
12	panel	O
13	of	O
14	human	B
15	anti	I
16	-	I
17	La	I
18	sera	I
19	in	O
20	order	O
21	to	O
22	define	O
23	the	O
24	nature	O
25	of	O
26	the	O
27	epitopes	O
28	.	O
1	We	O
2	showed	O
3	previously	O
4	that	O
5	a	O
6	fusion	O
7	protein	O
8	(	O
9	GAL4	B
10	-	O
11	p40	B
12	)	O
13	containing	O
14	the	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	of	O
20	GAL4	B
21	and	O
22	sequences	O
23	of	O
24	chicken	B
25	l	I
26	kappa	I
27	B	I
28	-	I
29	alpha	I
30	(	O
31	p40	B
32	)	O
33	inhibits	O
34	growth	O
35	in	O
36	the	O
37	yeast	O
38	Saccharomyces	O
39	cerevisiae	O
40	.	O
1	Specific	O
2	requirements	O
3	for	O
4	branched	O
5	-	O
6	chain	O
7	amino	O
8	acids	O
9	,	O
10	glutamine	O
11	,	O
12	and	O
13	arginine	O
14	are	O
15	evaluated	O
16	.	O
1	The	O
2	hypBFCDE	B
3	operon	I
4	from	O
5	Rhizobium	O
6	leguminosarum	O
7	biovar	O
8	viciae	O
9	is	O
10	expressed	O
11	from	O
12	an	O
13	Fnr	B
14	-	I
15	type	I
16	promoter	I
17	that	O
18	escapes	O
19	mutagenesis	O
20	of	O
21	the	O
22	fnrN	B
23	gene	I
24	.	O
1	Cyclin	B
2	D1	I
3	promoter	I
4	activity	O
5	was	O
6	stimulated	O
7	by	O
8	overexpression	O
9	of	O
10	mitogen	B
11	-	I
12	activated	I
13	protein	I
14	kinase	I
15	(	O
16	p41MAPK	B
17	)	O
18	or	O
19	c	B
20	-	I
21	Ets	I
22	-	I
23	2	I
24	through	O
25	the	O
26	proximal	O
27	22	O
28	base	O
29	pairs	O
30	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	R206S	B
6	HSF	I
7	substitution	O
8	exhibits	O
9	constitutive	O
10	transcriptional	O
11	activation	O
12	from	O
13	a	O
14	consensus	O
15	HSE	O
16	(	O
17	HSE2	O
18	).	O
1	Comparisons	O
2	of	O
3	rrnB	B
4	P1	I
5	-	O
6	lacZ	B
7	expression	O
8	at	O
9	different	O
10	ppGpp	O
11	levels	O
12	is	O
13	interpreted	O
14	for	O
15	the	O
16	rpoD	B
17	(	I
18	P504L	I
19	)	I
20	mutant	I
21	as	O
22	resulting	O
23	from	O
24	a	O
25	hypersensitivity	O
26	to	O
27	ppGpp	O
28	.	O
1	Characterization	O
2	of	O
3	the	O
4	3	O
5	'	O
6	ends	O
7	of	O
8	the	O
9	plus	O
10	-	O
11	strand	O
12	DNA	O
13	fragments	O
14	reveals	O
15	(	O
16	1	O
17	)	O
18	that	O
19	the	O
20	upstream	O
21	fragment	O
22	is	O
23	elongated	O
24	beyond	O
25	PPT2	B
26	creating	O
27	a	O
28	plus	O
29	-	O
30	strand	O
31	overlap	O
32	and	O
33	(	O
34	2	O
35	)	O
36	that	O
37	the	O
38	majority	O
39	of	O
40	plus	O
41	-	O
42	strand	O
43	strong	O
44	-	O
45	stop	O
46	DNA	O
47	fragments	O
48	bear	O
49	a	O
50	copy	O
51	of	O
52	the	O
53	minus	O
54	-	O
55	strand	O
56	primer	O
57	binding	O
58	site	O
59	in	O
60	agreement	O
61	with	O
62	the	O
63	accepted	O
64	model	O
65	of	O
66	retroviral	O
67	genomic	O
68	RNA	O
69	reverse	O
70	transcription	O
71	.	O
1	This	O
2	combined	O
3	intravenous	O
4	anaesthetic	O
5	regimen	O
6	gave	O
7	good	O
8	anaesthesia	O
9	and	O
10	analgesia	O
11	to	O
12	pigs	O
13	for	O
14	up	O
15	to	O
16	2	O
17	h	O
18	as	O
19	monitored	O
20	by	O
21	clinical	O
22	signs	O
23	.	O
1	A	O
2	general	O
3	model	O
4	for	O
5	ARE	O
6	-	O
7	mediated	O
8	mRNA	O
9	degradation	O
10	involving	O
11	a	O
12	potential	O
13	role	O
14	for	O
15	certain	O
16	heterogeneous	O
17	nuclear	O
18	ribonucleoproteins	O
19	and	O
20	ARE	B
21	-	I
22	binding	I
23	proteins	I
24	is	O
25	proposed	O
26	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	G	B
6	beta	I
7	gamma	I
8	-	O
9	stimulated	O
10	Shc	B
11	phosphorylation	O
12	represents	O
13	an	O
14	early	O
15	step	O
16	in	O
17	the	O
18	pathway	O
19	leading	O
20	to	O
21	p21ras	B
22	activation	O
23	,	O
24	similar	O
25	to	O
26	the	O
27	mechanism	O
28	utilized	O
29	by	O
30	growth	B
31	factor	I
32	tyrosine	I
33	kinase	I
34	receptors	I
35	.	O
1	All	O
2	carcasses	O
3	resulted	O
4	in	O
5	contamination	O
6	with	O
7	aerobic	O
8	mesophilic	O
9	bacteria	O
10	in	O
11	the	O
12	range	O
13	from	O
14	6	O
15	x	O
16	10	O
17	(	O
18	3	O
19	)	O
20	to	O
21	1	O
22	.	O
23	2	O
24	x	O
25	10	O
26	(	O
27	6	O
28	)	O
29	CFU	O
30	/	O
31	ml	O
32	liquid	O
33	washed	O
34	,	O
35	and	O
36	94	O
37	%	O
38	them	O
39	with	O
40	sporulate	O
41	bacteria	O
42	,	O
43	the	O
44	threshold	O
45	being	O
46	under	O
47	100	O
48	CFU	O
49	/	O
50	ml	O
51	(	O
52	Figure	O
53	1	O
54	).	O
1	As	O
2	for	O
3	31	O
4	stage	O
5	I	O
6	-	O
7	II	O
8	lung	O
9	cancer	O
10	patients	O
11	,	O
12	CR	O
13	has	O
14	been	O
15	observed	O
16	in	O
17	82	O
18	.	O
19	8	O
20	%	O
21	of	O
22	them	O
23	and	O
24	PR	O
25	in	O
26	13	O
27	.	O
28	8	O
29	%;	O
30	the	O
31	response	O
32	was	O
33	always	O
34	assessed	O
35	with	O
36	chest	O
37	radiography	O
38	,	O
39	CT	O
40	,	O
41	FBS	O
42	,	O
43	cytology	O
44	and	O
45	/	O
46	or	O
47	histology	O
48	.	O
1	Mibefradil	O
2	(	O
3	Ro	O
4	40	O
5	-	O
6	5967	O
7	)	O
8	is	O
9	a	O
10	novel	O
11	calcium	O
12	antagonist	O
13	from	O
14	a	O
15	new	O
16	chemical	O
17	class	O
18	and	O
19	is	O
20	the	O
21	first	O
22	that	O
23	selectively	O
24	blocks	O
25	the	O
26	T	O
27	-	O
28	type	O
29	calcium	O
30	channel	O
31	.	O
1	This	O
2	action	O
3	is	O
4	dependent	O
5	on	O
6	helix	B
7	-	I
8	loop	I
9	-	I
10	helix	I
11	factors	I
12	bound	O
13	to	O
14	the	O
15	E1	B
16	element	O
17	.	O
1	The	O
2	results	O
3	indicate	O
4	considerable	O
5	flexibility	O
6	in	O
7	the	O
8	spacing	O
9	between	O
10	DH	B
11	regulatory	O
12	sites	O
13	.	O
1	We	O
2	show	O
3	that	O
4	c	B
5	-	I
6	Fos	I
7	(	O
8	the	O
9	c	B
10	-	I
11	fos	I
12	protooncogene	I
13	product	I
14	),	O
15	which	O
16	is	O
17	an	O
18	intrinsically	O
19	unstable	O
20	nuclear	O
21	protein	O
22	,	O
23	is	O
24	metabolically	O
25	highly	O
26	stabilized	O
27	,	O
28	and	O
29	greatly	O
30	enhances	O
31	the	O
32	transforming	O
33	efficiency	O
34	of	O
35	NIH	O
36	3T3	O
37	cells	O
38	,	O
39	by	O
40	Mos	B
41	.	O
1	Cloning	O
2	,	O
3	sequencing	O
4	and	O
5	expression	O
6	of	O
7	the	O
8	3	B
9	-	I
10	phosphoglycerate	I
11	kinase	I
12	gene	I
13	of	O
14	Pyrococcus	O
15	woesei	O
16	in	O
17	Escherichia	O
18	coli	O
19	and	O
20	characterization	O
21	of	O
22	the	O
23	protein	O
24	.	O
1	We	O
2	also	O
3	isolated	O
4	two	O
5	alternatively	O
6	spliced	O
7	forms	O
8	of	O
9	human	B
10	CD6	I
11	cDNA	I
12	lacking	O
13	sequences	O
14	encoding	O
15	membrane	O
16	-	O
17	proximal	O
18	regions	O
19	of	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	which	O
24	maintain	O
25	the	O
26	same	O
27	reading	O
28	frame	O
29	as	O
30	CD6	B
31	-	O
32	PB1	B
33	.	O
1	In	O
2	Trial	O
3	1	O
4	,	O
5	eight	O
6	sows	O
7	were	O
8	allowed	O
9	to	O
10	farrow	O
11	naturally	O
12	(	O
13	d	O
14	114	O
15	,	O
16	NF	O
17	sows	O
18	)	O
19	and	O
20	eight	O
21	sows	O
22	were	O
23	induced	O
24	to	O
25	farrow	O
26	(	O
27	IF	O
28	sows	O
29	)	O
30	prematurely	O
31	by	O
32	injection	O
33	of	O
34	prostaglandin	O
35	F2	O
36	alpha	O
37	on	O
38	d	O
39	112	O
40	of	O
41	gestation	O
42	.	O
1	These	O
2	results	O
3	suggested	O
4	that	O
5	NfxB	B
6	negatively	O
7	autoregulates	O
8	the	O
9	expression	O
10	of	O
11	nfxB	B
12	itself	O
13	.	O
1	If	O
2	NCR	O
3	-	O
4	sensitive	O
5	gene	O
6	expression	O
7	occurs	O
8	exclusively	O
9	by	O
10	this	O
11	pathway	O
12	,	O
13	as	O
14	has	O
15	been	O
16	thought	O
17	to	O
18	be	O
19	the	O
20	case	O
21	,	O
22	then	O
23	the	O
24	NCR	O
25	sensitivity	O
26	of	O
27	a	O
28	gene	O
29	'	O
30	s	O
31	expression	O
32	should	O
33	be	O
34	abolished	O
35	by	O
36	a	O
37	ure2	B
38	delta	I
39	mutation	I
40	.	O
1	The	O
2	single	O
3	-	O
4	stranded	O
5	DNA	O
6	Pur	B
7	alpha	I
8	recognition	I
9	element	I
10	disrupts	O
11	these	O
12	complexes	O
13	.	O
1	Association	O
2	of	O
3	human	B
4	Pur	I
5	alpha	I
6	with	O
7	the	O
8	retinoblastoma	B
9	protein	I
10	,	O
11	Rb	B
12	,	O
13	regulates	O
14	binding	O
15	to	O
16	the	O
17	single	O
18	-	O
19	stranded	O
20	DNA	O
21	Pur	B
22	alpha	I
23	recognition	I
24	element	I
25	.	O
1	The	O
2	mouse	B
3	beta	I
4	2	I
5	-	I
6	syntrophin	I
7	gene	I
8	(	O
9	>	O
10	33	O
11	kilobases	O
12	)	O
13	contains	O
14	seven	O
15	exons	O
16	,	O
17	all	O
18	of	O
19	which	O
20	have	O
21	homologues	O
22	at	O
23	the	O
24	corresponding	O
25	position	O
26	in	O
27	the	O
28	alpha	B
29	1	I
30	-	I
31	syntrophin	I
32	gene	I
33	.	O
1	It	O
2	contains	O
3	three	O
4	putative	O
5	TATA	O
6	boxes	O
7	far	O
8	upstream	O
9	of	O
10	the	O
11	main	O
12	start	O
13	sites	O
14	region	O
15	,	O
16	one	O
17	AP	B
18	-	I
19	1	I
20	box	I
21	,	O
22	one	O
23	AP	B
24	-	I
25	2	I
26	box	I
27	,	O
28	one	O
29	Malt	B
30	box	I
31	,	O
32	one	O
33	GAGA	O
34	box	O
35	,	O
36	one	O
37	half	O
38	serum	O
39	-	O
40	responsive	O
41	element	O
42	,	O
43	and	O
44	putative	O
45	binding	O
46	sites	O
47	for	O
48	Sp1	B
49	(	O
50	five	O
51	),	O
52	GC	B
53	-	I
54	rich	I
55	binding	I
56	factor	I
57	(	O
58	five	O
59	),	O
60	CTF	B
61	-	I
62	NF1	I
63	(	O
64	one	O
65	),	O
66	Myb	B
67	(	O
68	one	O
69	),	O
70	p53	B
71	(	O
72	two	O
73	),	O
74	Ets	B
75	-	I
76	1	I
77	(	O
78	one	O
79	),	O
80	NF	B
81	-	I
82	IL6	I
83	(	O
84	two	O
85	),	O
86	MyoD	B
87	(	O
88	two	O
89	),	O
90	Zeste	B
91	(	O
92	one	O
93	),	O
94	and	O
95	hepatocyte	B
96	nuclear	I
97	factor	I
98	-	I
99	5	I
100	(	O
101	one	O
102	).	O
1	Deletion	O
2	of	O
3	the	O
4	NF	B
5	-	I
6	IL6	I
7	beta	I
8	leucine	I
9	zipper	I
10	domain	I
11	also	O
12	greatly	O
13	diminished	O
14	the	O
15	interaction	O
16	between	O
17	these	O
18	two	O
19	proteins	O
20	.	O
1	After	O
2	cells	O
3	were	O
4	stably	O
5	transfected	O
6	with	O
7	CIITA	B
8	,	O
9	endogenous	O
10	MHC	B
11	class	I
12	II	I
13	genes	I
14	were	O
15	constitutively	O
16	expressed	O
17	,	O
18	and	O
19	MHC	B
20	class	I
21	II	I
22	promoters	I
23	,	O
24	delivered	O
25	by	O
26	transfection	O
27	,	O
28	were	O
29	actively	O
30	transcribed	O
31	in	O
32	CIITA	B
33	-	O
34	expressing	O
35	cells	O
36	.	O
1	However	O
2	,	O
3	the	O
4	few	O
5	studies	O
6	that	O
7	address	O
8	antimicrobial	O
9	prophylaxis	O
10	in	O
11	bone	O
12	marrow	O
13	transplantation	O
14	have	O
15	not	O
16	always	O
17	shown	O
18	a	O
19	survival	O
20	benefit	O
21	.	O
1	Vestibular	O
2	adaptation	O
3	exercises	O
4	and	O
5	recovery	O
6	:	O
7	acute	O
8	stage	O
9	after	O
10	acoustic	O
11	neuroma	O
12	resection	O
13	.	O
1	A	O
2	cDNA	O
3	clone	O
4	corresponding	O
5	to	O
6	the	O
7	putative	O
8	GA	B
9	20	I
10	-	O
11	oxidase	B
12	genomic	O
13	sequence	O
14	was	O
15	constructed	O
16	with	O
17	the	O
18	reverse	O
19	transcription	O
20	-	O
21	PCR	O
22	method	O
23	,	O
24	and	O
25	the	O
26	identity	O
27	of	O
28	the	O
29	cDNA	O
30	clone	O
31	was	O
32	confirmed	O
33	by	O
34	analyzing	O
35	the	O
36	capability	O
37	of	O
38	the	O
39	fusion	O
40	protein	O
41	expressed	O
42	in	O
43	Escherichia	O
44	coli	O
45	to	O
46	convert	O
47	GA53	B
48	to	O
49	GA44	B
50	and	O
51	GA19	B
52	to	O
53	GA20	B
54	.	O
1	Piperacillin	O
2	-	O
3	tazobactam	O
4	can	O
5	be	O
6	used	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	infections	O
12	caused	O
13	by	O
14	gram	O
15	-	O
16	negative	O
17	,	O
18	gram	O
19	-	O
20	positive	O
21	,	O
22	aerobic	O
23	,	O
24	and	O
25	anaerobic	O
26	bacteria	O
27	.	O
1	Increase	O
2	in	O
3	urinary	O
4	calcium	O
5	and	O
6	oxalate	O
7	after	O
8	fructose	O
9	infusion	O
10	.	O
1	To	O
2	discern	O
3	whether	O
4	these	O
5	disorders	O
6	of	O
7	GnRH	B
8	deficiency	O
9	are	O
10	associated	O
11	with	O
12	altered	O
13	melatonin	O
14	secretion	O
15	profiles	O
16	,	O
17	we	O
18	compared	O
19	untreated	O
20	young	O
21	males	O
22	IGD	O
23	(	O
24	n	O
25	=	O
26	7	O
27	)	O
28	and	O
29	DP	O
30	(	O
31	n	O
32	=	O
33	7	O
34	)	O
35	to	O
36	normal	O
37	pubertal	O
38	male	O
39	controls	O
40	(	O
41	n	O
42	=	O
43	6	O
44	).	O
1	In	O
2	addition	O
3	,	O
4	depletion	O
5	of	O
6	Oct	B
7	-	I
8	1	I
9	from	O
10	the	O
11	nuclear	O
12	extract	O
13	by	O
14	using	O
15	Oct	B
16	-	I
17	1	I
18	-	O
19	specific	O
20	antiserum	O
21	or	O
22	a	O
23	sequence	O
24	-	O
25	specific	O
26	DNA	O
27	affinity	O
28	resin	O
29	decreased	O
30	in	O
31	vitro	O
32	transcription	O
33	from	O
34	the	O
35	wild	O
36	-	O
37	type	O
38	MMTV	O
39	promoter	O
40	to	O
41	a	O
42	level	O
43	identical	O
44	to	O
45	that	O
46	obtained	O
47	from	O
48	a	O
49	promoter	O
50	in	O
51	which	O
52	all	O
53	three	O
54	octamer	O
55	-	O
56	related	O
57	sequences	O
58	were	O
59	mutated	O
60	.	O
1	Finally	O
2	,	O
3	we	O
4	show	O
5	that	O
6	complexes	O
7	similar	O
8	to	O
9	the	O
10	C25	B
11	,	O
12	C30	B
13	and	O
14	C35	B
15	complexes	I
16	are	O
17	formed	O
18	by	O
19	rat	O
20	cortex	O
21	nuclear	O
22	extracts	O
23	and	O
24	the	O
25	SAA	O
26	element	O
27	in	O
28	EMSA	O
29	experiments	O
30	,	O
31	suggesting	O
32	the	O
33	relevance	O
34	of	O
35	our	O
36	in	O
37	vitro	O
38	observations	O
39	to	O
40	the	O
41	in	O
42	vivo	O
43	functioning	O
44	of	O
45	the	O
46	rat	B
47	APP	I
48	promoter	I
49	.	O
1	Oncological	O
2	,	O
3	clinical	O
4	and	O
5	psychological	O
6	aspects	O
7	are	O
8	evaluated	O
9	according	O
10	to	O
11	experience	O
12	accumulated	O
13	in	O
14	recent	O
15	years	O
16	,	O
17	with	O
18	immediate	O
19	and	O
20	delayed	O
21	reconstruction	O
22	,	O
23	carried	O
24	out	O
25	in	O
26	the	O
27	most	O
28	diverse	O
29	specialized	O
30	centers	O
31	.	O
1	In	O
2	human	O
3	proliferative	O
4	cells	O
5	,	O
6	the	O
7	NADP	O
8	-	O
9	dependent	O
10	ME	B
11	activity	O
12	is	O
13	poorly	O
14	expressed	O
15	and	O
16	barely	O
17	inducible	O
18	by	O
19	thyroid	O
20	hormones	O
21	.	O
1	It	O
2	was	O
3	proposed	O
4	that	O
5	the	O
6	synthetase	O
7	-	O
8	related	O
9	sequences	O
10	of	O
11	GCN2	B
12	stimulate	O
13	the	O
14	activity	O
15	of	O
16	the	O
17	kinase	O
18	by	O
19	interacting	O
20	directly	O
21	with	O
22	uncharged	O
23	tRNA	O
24	that	O
25	accumulates	O
26	during	O
27	amino	O
28	acid	O
29	limitation	O
30	.	O
1	To	O
2	compare	O
3	the	O
4	PAX3	B
5	and	O
6	putative	O
7	PAX3	B
8	-	O
9	FKHR	B
10	transactivation	O
11	domains	O
12	,	O
13	we	O
14	fused	O
15	C	O
16	-	O
17	terminal	O
18	test	O
19	fragments	O
20	to	O
21	the	O
22	heterologous	O
23	GAL4	B
24	DNA	I
25	-	I
26	binding	I
27	domain	I
28	and	O
29	tested	O
30	activation	O
31	of	O
32	a	O
33	reporter	O
34	gene	O
35	co	O
36	-	O
37	transfected	O
38	into	O
39	four	O
40	cell	O
41	types	O
42	.	O
1	All	O
2	subjects	O
3	were	O
4	submitted	O
5	to	O
6	ECG	O
7	and	O
8	arterial	O
9	blood	O
10	pressure	O
11	determination	O
12	and	O
13	were	O
14	assayed	O
15	for	O
16	TSH	B
17	,	O
18	thyroid	O
19	hormone	O
20	,	O
21	PRL	B
22	,	O
23	glucose	O
24	,	O
25	creatinine	O
26	,	O
27	nitrogen	O
28	,	O
29	glutamine	B
30	transaminase	I
31	,	O
32	cholesterol	O
33	and	O
34	triglycerides	O
35	plasma	O
36	levels	O
37	before	O
38	therapy	O
39	(	O
40	T0	O
41	),	O
42	after	O
43	30	O
44	treatment	O
45	days	O
46	(	O
47	T30	O
48	)	O
49	and	O
50	after	O
51	a	O
52	15	O
53	days	O
54	washout	O
55	(	O
56	T45	O
57	).	O
1	The	O
2	Drosophila	B
3	insulin	I
4	receptor	I
5	homolog	I
6	:	O
7	a	O
8	gene	O
9	essential	O
10	for	O
11	embryonic	O
12	development	O
13	encodes	O
14	two	O
15	receptor	O
16	isoforms	O
17	with	O
18	different	O
19	signaling	O
20	potential	O
21	.	O
1	We	O
2	have	O
3	found	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	GTPase	B
9	-	O
10	deficient	O
11	mutants	O
12	of	O
13	alpha	B
14	12	I
15	(	O
16	alpha	B
17	12Q229L	I
18	)	O
19	or	O
20	alpha	B
21	13	I
22	(	O
23	alpha	B
24	13Q226L	I
25	)	O
26	leads	O
27	to	O
28	robust	O
29	activation	O
30	of	O
31	the	O
32	Jun	B
33	kinase	I
34	/	O
35	stress	B
36	-	I
37	activated	I
38	protein	I
39	kinase	I
40	(	O
41	JNK	B
42	/	O
43	SAPK	B
44	)	O
45	pathway	O
46	.	O
1	The	O
2	objective	O
3	of	O
4	our	O
5	study	O
6	was	O
7	to	O
8	evaluate	O
9	the	O
10	age	O
11	,	O
12	sex	O
13	,	O
14	clinical	O
15	conditions	O
16	,	O
17	family	O
18	history	O
19	,	O
20	site	O
21	,	O
22	catheter	O
23	association	O
24	,	O
25	means	O
26	of	O
27	radiologic	O
28	evaluation	O
29	,	O
30	development	O
31	of	O
32	pulmonary	O
33	involvement	O
34	,	O
35	prevalence	O
36	of	O
37	antithrombin	B
38	III	I
39	,	O
40	protein	B
41	C	I
42	and	O
43	protein	B
44	S	I
45	deficiencies	O
46	,	O
47	and	O
48	lupus	O
49	anticoagulants	O
50	in	O
51	children	O
52	who	O
53	suffered	O
54	a	O
55	thrombotic	O
56	event	O
57	.	O
1	A	O
2	model	O
3	with	O
4	age	O
5	and	O
6	weight	O
7	described	O
8	the	O
9	best	O
10	fit	O
11	for	O
12	TBBMD	O
13	,	O
14	whereas	O
15	age	O
16	,	O
17	weight	O
18	,	O
19	and	O
20	height	O
21	described	O
22	the	O
23	best	O
24	fit	O
25	for	O
26	total	O
27	body	O
28	TBBMC	O
29	.	O
1	In	O
2	contrast	O
3	,	O
4	both	O
5	C	O
6	-	O
7	Lys	O
8	and	O
9	C	O
10	-	O
11	Thr	O
12	retained	O
13	high	O
14	levels	O
15	of	O
16	kinase	O
17	activity	O
18	and	O
19	were	O
20	capable	O
21	of	O
22	responding	O
23	to	O
24	stimulation	O
25	.	O
1	Here	O
2	we	O
3	describe	O
4	an	O
5	in	O
6	vitro	O
7	assay	O
8	where	O
9	the	O
10	NS3	B
11	-	I
12	4A	I
13	polyprotein	I
14	,	O
15	NS3	B
16	,	O
17	the	O
18	serine	O
19	proteinase	O
20	domain	O
21	(	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	181	O
27	residues	O
28	of	O
29	NS3	O
30	),	O
31	and	O
32	the	O
33	NS4A	B
34	cofactor	I
35	were	O
36	produced	O
37	by	O
38	cell	O
39	-	O
40	free	O
41	translation	O
42	and	O
43	tested	O
44	for	O
45	trans	O
46	-	O
47	processing	O
48	of	O
49	radiolabeled	O
50	substrates	O
51	.	O
1	The	O
2	most	O
3	likely	O
4	explanation	O
5	for	O
6	this	O
7	is	O
8	that	O
9	gold	O
10	principally	O
11	accumulates	O
12	in	O
13	the	O
14	Kupffer	O
15	cells	O
16	and	O
17	renal	O
18	cortex	O
19	and	O
20	these	O
21	cells	O
22	do	O
23	not	O
24	express	O
25	Type	B
26	I	I
27	deiodinase	I
28	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	different	O
6	models	O
7	of	O
8	intestinal	O
9	ischemia	O
10	have	O
11	different	O
12	cytokine	O
13	profiles	O
14	and	O
15	that	O
16	the	O
17	early	O
18	TNF	B
19	response	O
20	associated	O
21	with	O
22	SMA	O
23	occlusion	O
24	model	O
25	is	O
26	primarily	O
27	due	O
28	to	O
29	the	O
30	laparotomy	O
31	.	O
1	The	O
2	changes	O
3	after	O
4	treatment	O
5	were	O
6	observed	O
7	chiefly	O
8	by	O
9	electromyography	O
10	while	O
11	sensory	O
12	and	O
13	motor	O
14	improvement	O
15	were	O
16	also	O
17	recorded	O
18	as	O
19	auxiliary	O
20	indicators	O
21	.	O
1	However	O
2	,	O
3	the	O
4	relative	O
5	binding	O
6	affinity	O
7	for	O
8	the	O
9	motifs	O
10	is	O
11	different	O
12	.	O
1	Furthermore	O
2	,	O
3	microinjection	O
4	of	O
5	dominant	O
6	negative	O
7	forms	O
8	of	O
9	Rac	B
10	and	O
11	Cdc42	B
12	or	O
13	of	O
14	the	O
15	Rho	B
16	inhibitor	O
17	C3	B
18	transferase	I
19	blocked	O
20	serum	O
21	-	O
22	induced	O
23	DNA	O
24	synthesis	O
25	.	O
1	Key	O
2	areas	O
3	of	O
4	the	O
5	selection	O
6	process	O
7	including	O
8	medical	O
9	and	O
10	surgical	O
11	alternatives	O
12	to	O
13	transplantation	O
14	,	O
15	the	O
16	composition	O
17	of	O
18	the	O
19	transplant	O
20	work	O
21	-	O
22	up	O
23	,	O
24	specific	O
25	inclusion	O
26	criteria	O
27	as	O
28	well	O
29	as	O
30	specific	O
31	psychosocial	O
32	factors	O
33	and	O
34	specific	O
35	disease	O
36	etiologies	O
37	and	O
38	co	O
39	-	O
40	morbidities	O
41	that	O
42	might	O
43	represent	O
44	contraindications	O
45	were	O
46	extensively	O
47	reviewed	O
48	.	O
1	The	O
2	transport	O
3	of	O
4	a	O
5	genetically	O
6	engineered	O
7	chimeric	O
8	transmembrane	O
9	protein	O
10	connected	O
11	to	O
12	this	O
13	ER	O
14	leader	O
15	sequence	O
16	was	O
17	as	O
18	efficient	O
19	as	O
20	that	O
21	of	O
22	the	O
23	original	O
24	protein	O
25	from	O
26	which	O
27	the	O
28	ER	O
29	sequence	O
30	has	O
31	been	O
32	derived	O
33	.	O
1	Comparative	O
2	DNA	O
3	sequence	O
4	analysis	O
5	showed	O
6	the	O
7	Genethon	O
8	microsatellite	B
9	D19S596	I
10	lies	O
11	2	O
12	.	O
13	2	O
14	kb	O
15	downstream	O
16	of	O
17	the	O
18	coding	O
19	region	O
20	of	O
21	FUT1	B
22	,	O
23	indicating	O
24	that	O
25	the	O
26	cluster	O
27	comprising	O
28	the	O
29	closely	O
30	linked	O
31	FUT1	B
32	and	O
33	FUT2	B
34	genes	I
35	is	O
36	located	O
37	4	O
38	cM	O
39	distal	O
40	to	O
41	D19S412	B
42	(	O
43	lod	O
44	score	O
45	13	O
46	.	O
47	7	O
48	)	O
49	and	O
50	9	O
51	cM	O
52	proximal	O
53	to	O
54	D19S571	B
55	(	O
56	lod	O
57	score	O
58	11	O
59	.	O
60	7	O
61	).	O
1	We	O
2	conclude	O
3	that	O
4	transcription	O
5	activation	O
6	by	O
7	LEF	B
8	-	I
9	1	I
10	in	O
11	vitro	O
12	is	O
13	a	O
14	chromatin	O
15	-	O
16	dependent	O
17	process	O
18	that	O
19	requires	O
20	a	O
21	functional	O
22	trans	O
23	-	O
24	activation	O
25	domain	O
26	in	O
27	addition	O
28	to	O
29	the	O
30	HMG	B
31	domain	I
32	.	O
1	The	O
2	ubiquitous	O
3	transcription	O
4	factor	O
5	Oct	B
6	-	I
7	1	I
8	forms	O
9	complexes	O
10	with	O
11	an	O
12	octamer	O
13	motif	O
14	present	O
15	within	O
16	FPIV	O
17	by	O
18	gel	O
19	shift	O
20	analysis	O
21	with	O
22	liver	O
23	and	O
24	kidney	O
25	extracts	O
26	,	O
27	making	O
28	Oct	B
29	-	I
30	1	I
31	an	O
32	intriguing	O
33	candidate	O
34	for	O
35	partnership	O
36	in	O
37	androgen	O
38	regulation	O
39	.	O
1	A	O
2	new	O
3	non	O
4	-	O
5	LTR	O
6	retrotransposon	O
7	provides	O
8	evidence	O
9	for	O
10	multiple	O
11	distinct	O
12	site	O
13	-	O
14	specific	O
15	elements	O
16	in	O
17	Crithidia	O
18	fasciculata	O
19	miniexon	O
20	arrays	O
21	.	O
1	Primer	O
2	extension	O
3	and	O
4	S1	B
5	nuclease	I
6	mapping	O
7	experiments	O
8	were	O
9	used	O
10	to	O
11	locate	O
12	the	O
13	transcription	O
14	initiation	O
15	site	O
16	of	O
17	Nramp1	B
18	and	O
19	revealed	O
20	the	O
21	presence	O
22	of	O
23	one	O
24	major	O
25	and	O
26	several	O
27	minor	O
28	initiation	O
29	sites	O
30	.	O
1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	tmy	B
8	-	I
9	1	I
10	gene	I
11	was	O
12	determined	O
13	by	O
14	microinjection	O
15	of	O
16	a	O
17	promoter	B
18	/	I
19	lacZ	I
20	fusion	I
21	gene	I
22	and	O
23	with	O
24	immunohistochemistry	O
25	by	O
26	using	O
27	affinity	O
28	-	O
29	purified	O
30	tissue	B
31	-	I
32	specific	I
33	anti	I
34	-	I
35	tropomyosins	I
36	.	O
1	Mean	O
2	longitudinal	O
3	extension	O
4	of	O
5	the	O
6	epidural	O
7	lesion	O
8	was	O
9	2	O
10	.	O
11	6	O
12	vertebral	O
13	segments	O
14	.	O
1	The	O
2	tyrosine	O
3	-	O
4	phosphorylated	O
5	state	O
6	of	O
7	CAK	B
8	beta	I
9	was	O
10	not	O
11	reduced	O
12	on	O
13	trypsinization	O
14	,	O
15	nor	O
16	enhanced	O
17	in	O
18	response	O
19	to	O
20	plating	O
21	3Y1	O
22	cells	O
23	onto	O
24	fibronectin	B
25	.	O
1	Our	O
2	results	O
3	suggest	O
4	that	O
5	while	O
6	many	O
7	muscle	O
8	gene	O
9	E	O
10	-	O
11	boxes	O
12	are	O
13	capable	O
14	of	O
15	binding	O
16	the	O
17	previously	O
18	characterized	O
19	spectrum	O
20	of	O
21	MDF	B
22	/	I
23	bH	I
24	-	I
25	L	I
26	-	I
27	H	I
28	heterodimers	I
29	in	O
30	vitro	O
31	,	O
32	MCK	B
33	-	I
34	L	I
35	type	O
36	E	O
37	-	O
38	boxes	O
39	probably	O
40	bind	O
41	qualitatively	O
42	different	O
43	factors	O
44	in	O
45	vivo	O
46	.	O
1	In	O
2	one	O
3	glioblastoma	O
4	cell	O
5	line	O
6	,	O
7	a	O
8	Shc	B
9	-	O
10	associated	O
11	p190	B
12	was	O
13	identified	O
14	as	O
15	the	O
16	activated	O
17	PDGFR	B
18	.	O
1	A	O
2	significant	O
3	correlation	O
4	between	O
5	a	O
6	number	O
7	of	O
8	functional	O
9	parameters	O
10	of	O
11	gastric	O
12	secretion	O
13	,	O
14	incretion	O
15	and	O
16	histological	O
17	changes	O
18	of	O
19	gastric	O
20	mucosa	O
21	was	O
22	found	O
23	in	O
24	patients	O
25	with	O
26	chronic	O
27	gastritis	O
28	.	O
1	The	O
2	PDGFR	B
3	mutants	I
4	that	O
5	failed	O
6	to	O
7	associate	O
8	with	O
9	PLC	B
10	gamma	I
11	were	O
12	not	O
13	able	O
14	to	O
15	mediate	O
16	the	O
17	PDGF	B
18	-	O
19	dependent	O
20	production	O
21	of	O
22	inositol	O
23	phosphates	O
24	.	O
1	We	O
2	found	O
3	a	O
4	direct	O
5	correlation	O
6	between	O
7	the	O
8	levels	O
9	of	O
10	transcription	O
11	of	O
12	the	O
13	acc	B
14	genes	I
15	and	O
16	the	O
17	rate	O
18	of	O
19	cellular	O
20	growth	O
21	.	O
1	To	O
2	study	O
3	the	O
4	origin	O
5	of	O
6	different	O
7	fMLF	B
8	-	I
9	R	I
10	transcripts	I
11	,	O
12	the	O
13	genetic	O
14	linkage	O
15	of	O
16	chemotactic	O
17	receptor	O
18	genes	O
19	,	O
20	and	O
21	the	O
22	regulation	O
23	of	O
24	fMLF	B
25	-	I
26	R	I
27	gene	I
28	expression	O
29	,	O
30	we	O
31	determined	O
32	the	O
33	copy	O
34	number	O
35	,	O
36	chromosomal	O
37	location	O
38	,	O
39	structural	O
40	organization	O
41	,	O
42	and	O
43	5	O
44	'-	O
45	flanking	O
46	sequence	O
47	of	O
48	the	O
49	human	B
50	fMLF	I
51	-	I
52	R	I
53	gene	I
54	.	O
1	Using	O
2	the	O
3	polymerase	O
4	chain	O
5	reaction	O
6	,	O
7	Whipple	O
8	-	O
9	specific	O
10	DNA	O
11	fragments	O
12	of	O
13	284	O
14	base	O
15	pairs	O
16	from	O
17	the	O
18	genome	O
19	of	O
20	the	O
21	Whipple	O
22	bacterium	O
23	(	O
24	Tropheryma	O
25	whippelii	O
26	)	O
27	were	O
28	demonstrated	O
29	.	O
1	We	O
2	here	O
3	demonstrate	O
4	that	O
5	a	O
6	temperature	O
7	-	O
8	sensitive	O
9	fission	O
10	yeast	O
11	mutant	O
12	which	O
13	has	O
14	a	O
15	mutation	O
16	in	O
17	a	O
18	homologous	O
19	gene	O
20	,	O
21	and	O
22	two	O
23	of	O
24	three	O
25	additional	O
26	(	O
27	mtr1	B
28	/	O
29	prp20	B
30	/	O
31	srm1	B
32	)	O
33	mutants	O
34	accumulate	O
35	nuclear	O
36	poly	O
37	(	O
38	A	O
39	)+	O
40	RNA	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	.	O
1	Prostate	B
2	specific	I
3	antigen	I
4	shows	O
5	the	O
6	metastatic	O
7	cases	O
8	better	O
9	[	O
10	correction	O
11	of	O
12	worse	O
13	]	O
14	than	O
15	prostatic	B
16	acid	I
17	phosphatase	I
18	.	O
1	An	O
2	abundant	O
3	1	O
4	.	O
5	1	O
6	-	O
7	kb	O
8	virion	O
9	-	O
10	sense	O
11	polyadenylated	O
12	RNA	O
13	and	O
14	four	O
15	complementary	O
16	-	O
17	sense	O
18	polyadenylated	O
19	RNAs	O
20	of	O
21	1	O
22	.	O
23	7	O
24	,	O
25	1	O
26	.	O
27	5	O
28	,	O
29	1	O
30	.	O
31	3	O
32	,	O
33	and	O
34	0	O
35	.	O
36	7	O
37	kb	O
38	have	O
39	been	O
40	identified	O
41	by	O
42	northern	O
43	blot	O
44	hybridization	O
45	,	O
46	confirming	O
47	the	O
48	bidirectional	O
49	transcription	O
50	strategy	O
51	implied	O
52	by	O
53	the	O
54	arrangement	O
55	of	O
56	ORFs	O
57	.	O
1	In	O
2	addition	O
3	,	O
4	an	O
5	mck1	B
6	mds1	I
7	mrk1	I
8	triple	O
9	disruptant	O
10	was	O
11	viable	O
12	.	O
1	Cell	O
2	adhesion	O
3	and	O
4	migration	O
5	assays	O
6	demonstrate	O
7	that	O
8	alpha	B
9	6	I
10	beta	I
11	1	I
12	is	O
13	the	O
14	major	O
15	laminin	B
16	receptor	I
17	in	O
18	undifferentiated	O
19	F9	O
20	cells	O
21	as	O
22	well	O
23	as	O
24	F9	O
25	-	O
26	derived	O
27	PE	O
28	cells	O
29	.	O
1	Our	O
2	data	O
3	complement	O
4	other	O
5	studies	O
6	of	O
7	circumpolar	O
8	populations	O
9	and	O
10	reinforce	O
11	the	O
12	reported	O
13	high	O
14	prevalences	O
15	of	O
16	SPA	O
17	and	O
18	HLA	B
19	-	I
20	B27	I
21	among	O
22	those	O
23	populations	O
24	.	O
1	Immediate	O
2	-	O
3	early	O
4	transcription	O
5	from	O
6	the	O
7	channel	O
8	catfish	O
9	virus	O
10	genome	O
11	:	O
12	characterization	O
13	of	O
14	two	O
15	immediate	B
16	-	I
17	early	I
18	transcripts	I
19	.	O
1	Carnitine	B
2	palmitoyltransferase	I
3	(	I
4	CPT	I
5	)	I
6	II	I
7	deficiency	O
8	is	O
9	the	O
10	most	O
11	common	O
12	inherited	O
13	disorder	O
14	of	O
15	lipid	O
16	metabolism	O
17	affecting	O
18	skeletal	O
19	muscle	O
20	.	O
1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	B
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	B
31	the	O
32	weakest	O
33	.	O
1	Binding	O
2	of	O
3	meAda	B
4	is	O
5	necessary	O
6	to	O
7	activate	O
8	transcription	O
9	of	O
10	the	O
11	adaptive	O
12	response	O
13	genes	O
14	;	O
15	accordingly	O
16	,	O
17	in	O
18	vitro	O
19	transcription	O
20	of	O
21	aidB	B
22	is	O
23	dependent	O
24	on	O
25	the	O
26	presence	O
27	of	O
28	meAda	B
29	.	O
1	We	O
2	suggest	O
3	that	O
4	this	O
5	gene	O
6	cluster	O
7	codes	O
8	for	O
9	(	O
10	parts	O
11	of	O
12	)	O
13	a	O
14	multisubunit	B
15	cytochrome	I
16	c	I
17	haem	I
18	lyase	I
19	.	O
1	To	O
2	study	O
3	the	O
4	mechanisms	O
5	as	O
6	well	O
7	as	O
8	magnitude	O
9	of	O
10	the	O
11	transmembrane	O
12	transfer	O
13	of	O
14	bacterial	O
15	products	O
16	from	O
17	the	O
18	dialysate	O
19	,	O
20	we	O
21	developed	O
22	a	O
23	computerized	O
24	in	O
25	vitro	O
26	dialysis	O
27	model	O
28	which	O
29	provides	O
30	continuous	O
31	pressure	O
32	recording	O
33	from	O
34	the	O
35	arterial	O
36	,	O
37	venous	O
38	,	O
39	dialysate	O
40	inflow	O
41	and	O
42	outflow	O
43	ports	O
44	.	O
1	Each	O
2	dietary	O
3	treatment	O
4	was	O
5	fed	O
6	to	O
7	six	O
8	pen	O
9	replicates	O
10	of	O
11	five	O
12	chicks	O
13	per	O
14	pen	O
15	for	O
16	21	O
17	d	O
18	.	O
1	The	O
2	Ng	B
3	/	I
4	RC3	I
5	and	O
6	PKC	B
7	-	I
8	gamma	I
9	genes	I
10	have	O
11	a	O
12	similar	O
13	expression	O
14	pattern	O
15	in	O
16	the	O
17	brain	O
18	during	O
19	development	O
20	.	O
1	No	O
2	homologs	O
3	of	O
4	other	O
5	members	O
6	of	O
7	the	O
8	Surfeit	B
9	gene	I
10	cluster	I
11	were	O
12	detected	O
13	in	O
14	close	O
15	proximity	O
16	to	O
17	the	O
18	D	O
19	.	O
20	melanogaster	O
21	Surf	B
22	-	I
23	3	I
24	/	O
25	rpL7a	B
26	gene	O
27	.	O
1	By	O
2	creating	O
3	Pax	B
4	-	I
5	6	I
6	-	O
7	BSAP	B
8	fusion	O
9	proteins	O
10	,	O
11	we	O
12	were	O
13	able	O
14	to	O
15	identify	O
16	a	O
17	short	O
18	amino	O
19	acid	O
20	stretch	O
21	in	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	part	O
27	of	O
28	the	O
29	paired	B
30	domain	O
31	which	O
32	is	O
33	responsible	O
34	for	O
35	these	O
36	differences	O
37	in	O
38	DNA	O
39	-	O
40	binding	O
41	specificity	O
42	.	O
1	The	O
2	cases	O
3	included	O
4	35	O
5	de	O
6	novo	O
7	diffuse	O
8	aggressive	O
9	lymphomas	O
10	(	O
11	DAL	O
12	;	O
13	19	O
14	large	O
15	-	O
16	cell	O
17	,	O
18	4	O
19	mixed	O
20	-	O
21	cell	O
22	,	O
23	and	O
24	12	O
25	large	O
26	-	O
27	cell	O
28	immunoblastic	O
29	),	O
30	52	O
31	transformed	O
32	aggressive	O
33	lymphomas	O
34	derived	O
35	from	O
36	follicular	O
37	lymphomas	O
38	(	O
39	TFL	O
40	),	O
41	42	O
42	indolent	O
43	follicular	O
44	lymphomas	O
45	(	O
46	FL	O
47	),	O
48	14	O
49	mantle	O
50	cell	O
51	lymphomas	O
52	(	O
53	MCL	O
54	),	O
55	and	O
56	27	O
57	small	O
58	noncleaved	O
59	cell	O
60	lymphomas	O
61	(	O
62	SNCL	O
63	).	O
1	In	O
2	the	O
3	commercially	O
4	available	O
5	intravenous	O
6	formulation	O
7	of	O
8	Cyclosporin	O
9	A	O
10	(	O
11	Sandimmun	O
12	),	O
13	polyoxyethylated	O
14	castor	O
15	oil	O
16	(	O
17	Cremophor	O
18	EL	O
19	)	O
20	is	O
21	used	O
22	as	O
23	a	O
24	solubilizing	O
25	agent	O
26	.	O
1	Lung	O
2	function	O
3	tests	O
4	(	O
5	EFR	O
6	)	O
7	were	O
8	performed	O
9	on	O
10	these	O
11	patients	O
12	for	O
13	a	O
14	period	O
15	of	O
16	19	O
17	.	O
18	2	O
19	+/-	O
20	3	O
21	.	O
22	4	O
23	months	O
24	.	O
1	Sequence	O
2	comparisons	O
3	of	O
4	prokaryotic	B
5	RCR	I
6	initiators	I
7	has	O
8	revealed	O
9	a	O
10	set	O
11	of	O
12	three	O
13	common	O
14	motifs	O
15	,	O
16	two	O
17	of	O
18	which	O
19	,	O
20	a	O
21	putative	O
22	metal	O
23	coordination	O
24	site	O
25	and	O
26	a	O
27	downstream	O
28	active	O
29	-	O
30	site	O
31	tyrosine	O
32	motif	O
33	,	O
34	could	O
35	be	O
36	tentatively	O
37	identified	O
38	in	O
39	parvoviral	B
40	replicator	I
41	proteins	I
42	.	O
1	The	O
2	characterized	O
3	Aplysia	B
4	Afurin2	I
5	is	O
6	a	O
7	candidate	O
8	PC	B
9	that	O
10	may	O
11	play	O
12	an	O
13	important	O
14	role	O
15	in	O
16	the	O
17	processing	O
18	of	O
19	egg	B
20	-	I
21	laying	I
22	hormone	I
23	(	O
24	ELH	B
25	)-	O
26	related	O
27	precursors	O
28	in	O
29	the	O
30	secretory	O
31	cells	O
32	of	O
33	the	O
34	atrial	O
35	gland	O
36	.	O
1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	sGTH	B
6	alpha	I
7	subunit	I
8	promoter	I
9	by	O
10	the	O
11	transient	O
12	transfection	O
13	of	O
14	several	O
15	sGTH	B
16	alpha	I
17	/	O
18	CAT	B
19	chimeric	O
20	plasmids	O
21	into	O
22	rainbow	O
23	trout	O
24	pituitary	O
25	cells	O
26	suggests	O
27	that	O
28	its	O
29	pituitary	O
30	-	O
31	specific	O
32	expression	O
33	is	O
34	GSE	B
35	-	O
36	dependent	O
37	.	O
1	Indium	O
2	-	O
3	111	O
4	OncoScint	O
5	CR	O
6	/	O
7	OV	O
8	and	O
9	F	O
10	-	O
11	18	O
12	FDG	O
13	in	O
14	colorectal	O
15	and	O
16	ovarian	O
17	carcinoma	O
18	recurrences	O
19	.	O
1	The	O
2	Myc	B
3	LZ	I
4	was	O
5	found	O
6	to	O
7	prevent	O
8	homodimeric	O
9	interactions	O
10	,	O
11	thus	O
12	explaining	O
13	Myc	B
14	inability	O
15	to	O
16	homodimerize	O
17	efficiently	O
18	.	O
1	The	O
2	gene	O
3	pairs	O
4	psbB	B
5	-	O
6	psbT	B
7	and	O
8	psbH	B
9	-	O
10	psbN	B
11	are	O
12	cotranscribed	O
13	from	O
14	opposite	O
15	strands	O
16	.	O
1	The	O
2	emerging	O
3	complexity	O
4	of	O
5	the	O
6	5	O
7	'	O
8	regulatory	O
9	region	O
10	of	O
11	the	O
12	GH	B
13	receptor	I
14	gene	I
15	was	O
16	emphasised	O
17	by	O
18	the	O
19	observation	O
20	that	O
21	probes	O
22	derived	O
23	from	O
24	exon	O
25	1B	O
26	and	O
27	the	O
28	distal	O
29	3	O
30	'	O
31	intron	O
32	boundary	O
33	do	O
34	not	O
35	hybridise	O
36	with	O
37	previously	O
38	cloned	O
39	genomic	O
40	sequences	O
41	that	O
42	span	O
43	the	O
44	liver	O
45	-	O
46	specific	O
47	P1	O
48	promoter	O
49	and	O
50	exon	O
51	2	O
52	.	O
1	We	O
2	used	O
3	two	O
4	approaches	O
5	to	O
6	ascertain	O
7	whether	O
8	CDP	B
9	/	O
10	cut	B
11	serves	O
12	as	O
13	a	O
14	repressor	O
15	of	O
16	gp91	B
17	-	O
18	phox	B
19	gene	O
20	expression	O
21	.	O
1	Serum	O
2	induction	O
3	of	O
4	a	O
5	MEF2	B
6	reporter	I
7	gene	I
8	was	O
9	not	O
10	observed	O
11	in	O
12	a	O
13	line	O
14	of	O
15	NIH	O
16	3T3	O
17	cells	O
18	which	O
19	contain	O
20	low	O
21	MEF2	B
22	site	I
23	binding	O
24	activity	O
25	.	O
1	Since	O
2	AP	B
3	-	I
4	1	I
5	is	O
6	an	O
7	important	O
8	mediator	O
9	of	O
10	tumor	O
11	promoter	O
12	action	O
13	,	O
14	these	O
15	findings	O
16	may	O
17	explain	O
18	the	O
19	anti	O
20	-	O
21	tumor	O
22	-	O
23	promoting	O
24	activity	O
25	of	O
26	phenolic	O
27	antioxidants	O
28	.	O
1	The	O
2	timing	O
3	of	O
4	fla	B
5	gene	I
6	expression	O
7	in	O
8	the	O
9	cell	O
10	cycle	O
11	is	O
12	determined	O
13	by	O
14	specialized	O
15	forms	O
16	of	O
17	RNA	B
18	polymerase	I
19	and	O
20	the	O
21	appearance	O
22	and	O
23	/	O
24	or	O
25	activation	O
26	of	O
27	regulatory	O
28	proteins	O
29	.	O
1	Polypeptides	O
2	of	O
3	the	O
4	same	O
5	apparent	O
6	sizes	O
7	are	O
8	detected	O
9	in	O
10	spores	O
11	of	O
12	a	O
13	cotE	B
14	null	O
15	mutant	O
16	,	O
17	on	O
18	which	O
19	basis	O
20	we	O
21	infer	O
22	that	O
23	the	O
24	products	O
25	of	O
26	the	O
27	cotJ	B
28	operon	I
29	are	O
30	required	O
31	for	O
32	the	O
33	normal	O
34	formation	O
35	of	O
36	the	O
37	inner	O
38	layers	O
39	of	O
40	the	O
41	coat	O
42	or	O
43	are	O
44	themselves	O
45	structural	O
46	components	O
47	of	O
48	the	O
49	coat	O
50	.	O
1	Sensing	O
2	with	O
3	chemically	O
4	and	O
5	biologically	O
6	modified	O
7	carbon	O
8	electrodes	O
9	.	O
1	The	O
2	present	O
3	study	O
4	describes	O
5	the	O
6	cell	O
7	volume	O
8	dynamics	O
9	in	O
10	intact	O
11	rat	O
12	hearts	O
13	,	O
14	during	O
15	ischemia	O
16	and	O
17	after	O
18	reperfusion	O
19	.	O
1	We	O
2	found	O
3	that	O
4	PML	B
5	was	O
6	expressed	O
7	at	O
8	a	O
9	lower	O
10	level	O
11	in	O
12	S	O
13	,	O
14	G2	O
15	,	O
16	and	O
17	M	O
18	phases	O
19	and	O
20	at	O
21	a	O
22	significantly	O
23	higher	O
24	level	O
25	in	O
26	G1	O
27	phase	O
28	.	O
1	We	O
2	demonstrate	O
3	here	O
4	that	O
5	the	O
6	-	O
7	DEDDDL	O
8	sequence	O
9	stabilizes	O
10	GDP	O
11	binding	O
12	to	O
13	Ran	B
14	,	O
15	and	O
16	that	O
17	the	O
18	domain	O
19	is	O
20	required	O
21	for	O
22	high	O
23	affinity	O
24	interaction	O
25	with	O
26	a	O
27	Ran	B
28	-	I
29	binding	I
30	protein	I
31	,	O
32	HTF9A	B
33	/	O
34	RanBP1	B
35	.	O
1	Cytosolic	O
2	extracts	O
3	from	O
4	a	O
5	variety	O
6	of	O
7	mammalian	O
8	cell	O
9	lines	O
10	(	O
11	monkey	O
12	Cos7	O
13	,	O
14	several	O
15	mouse	O
16	fibrosarcomas	O
17	and	O
18	human	O
19	HeLa	O
20	S3	O
21	)	O
22	demonstrated	O
23	similar	O
24	TGF	B
25	-	I
26	beta	I
27	1	I
28	dependent	O
29	RNA	O
30	-	O
31	protein	O
32	band	O
33	shifts	O
34	as	O
35	cell	O
36	extract	O
37	from	O
38	BALB	O
39	/	O
40	c	O
41	3T3	O
42	mouse	O
43	fibroblasts	O
44	.	O
1	The	O
2	provisional	O
3	reports	O
4	are	O
5	based	O
6	mainly	O
7	upon	O
8	macroscopic	O
9	findings	O
10	,	O
11	whereas	O
12	the	O
13	final	O
14	reports	O
15	include	O
16	the	O
17	information	O
18	provided	O
19	by	O
20	supplementary	O
21	investigations	O
22	such	O
23	as	O
24	microscopy	O
25	,	O
26	histochemistry	O
27	,	O
28	more	O
29	rarely	O
30	electron	O
31	microscopy	O
32	,	O
33	immunohistochemistry	O
34	and	O
35	/	O
36	or	O
37	microbiology	O
38	.	O
1	Moreover	O
2	,	O
3	Western	O
4	blots	O
5	demonstrated	O
6	at	O
7	least	O
8	six	O
9	types	O
10	of	O
11	Ypt	B
12	in	O
13	both	O
14	Cr	O
15	and	O
16	Vc	O
17	,	O
18	suggesting	O
19	that	O
20	these	O
21	Ypt	B
22	are	O
23	used	O
24	for	O
25	household	O
26	functions	O
27	responsible	O
28	for	O
29	vesicle	O
30	transport	O
31	rather	O
32	than	O
33	for	O
34	cellular	O
35	differentiation	O
36	.	O
1	The	O
2	absence	O
3	of	O
4	other	O
5	regions	O
6	of	O
7	hybridization	O
8	suggests	O
9	that	O
10	there	O
11	are	O
12	no	O
13	closely	O
14	related	O
15	sequences	O
16	(	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	reverse	O
22	transcribed	O
23	pseudogenes	O
24	)	O
25	scattered	O
26	throughout	O
27	the	O
28	genome	O
29	and	O
30	that	O
31	if	O
32	there	O
33	are	O
34	closely	O
35	related	O
36	genes	O
37	,	O
38	they	O
39	must	O
40	be	O
41	clustered	O
42	near	O
43	GSTT2	B
44	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	an	O
5	amphibian	B
6	insulin	I
7	receptor	I
8	substrate	I
9	1	I
10	-	I
11	like	I
12	cDNA	I
13	and	O
14	involvement	O
15	of	O
16	phosphatidylinositol	B
17	3	I
18	-	I
19	kinase	I
20	in	O
21	insulin	B
22	-	O
23	induced	O
24	Xenopus	O
25	oocyte	O
26	maturation	O
27	.	O
1	ICP4	B
2	has	O
3	been	O
4	shown	O
5	to	O
6	form	O
7	tripartite	O
8	complexes	O
9	cooperatively	O
10	with	O
11	the	O
12	TATA	B
13	box	I
14	-	I
15	binding	I
16	protein	I
17	and	O
18	TFIIB	B
19	on	O
20	DNA	O
21	containing	O
22	an	O
23	ICP4	B
24	binding	I
25	site	I
26	and	O
27	a	O
28	TATA	O
29	box	O
30	(	O
31	C	O
32	.	O
1	Otte	O
2	,	O
3	Mol	O
4	.	O
1	SRY	B
2	-	I
3	related	I
4	cDNA	I
5	encoding	O
6	a	O
7	protein	O
8	with	O
9	a	O
10	high	B
11	-	I
12	mobility	I
13	-	I
14	group	I
15	(	O
16	HMG	B
17	)	O
18	box	O
19	and	O
20	a	O
21	leucine	O
22	zipper	O
23	motif	O
24	,	O
25	which	O
26	was	O
27	designated	O
28	SOX	B
29	-	I
30	LZ	I
31	,	O
32	was	O
33	isolated	O
34	from	O
35	a	O
36	rainbow	O
37	trout	O
38	testis	O
39	cDNA	O
40	library	O
41	.	O
1	Therefore	O
2	,	O
3	it	O
4	is	O
5	hoped	O
6	that	O
7	by	O
8	defining	O
9	the	O
10	transcriptional	O
11	control	O
12	of	O
13	the	O
14	L7	B
15	gene	I
16	insights	O
17	into	O
18	the	O
19	mechanisms	O
20	that	O
21	control	O
22	functional	O
23	fate	O
24	and	O
25	organization	O
26	in	O
27	the	O
28	nervous	O
29	system	O
30	can	O
31	be	O
32	gained	O
33	.	O
1	Characterization	O
2	of	O
3	the	O
4	promoter	O
5	for	O
6	the	O
7	human	B
8	85	I
9	kDa	I
10	cytosolic	I
11	phospholipase	I
12	A2	I
13	gene	I
14	.	O
1	Further	O
2	studies	O
3	established	O
4	that	O
5	the	O
6	Ep	B
7	-	O
8	induced	O
9	increase	O
10	in	O
11	beta	B
12	-	I
13	globin	I
14	mRNA	I
15	could	O
16	be	O
17	inhibited	O
18	by	O
19	the	O
20	tyrosine	B
21	kinase	I
22	inhibitor	O
23	genistein	O
24	and	O
25	the	O
26	protein	B
27	kinase	I
28	C	I
29	inhibitor	O
30	Compound	O
31	3	O
32	.(	O
33	ABSTRACT	O
34	TRUNCATED	O
35	AT	O
36	250	O
37	WORDS	O
38	)	O
1	This	O
2	structure	O
3	of	O
4	cucumisin	B
5	suggests	O
6	that	O
7	it	O
8	is	O
9	probably	O
10	synthesized	O
11	as	O
12	an	O
13	inactive	O
14	precursor	O
15	.	O
1	Molecular	O
2	dissection	O
3	of	O
4	the	O
5	multimeric	O
6	CD3	B
7	-	O
8	TCR	B
9	complex	O
10	revealed	O
11	that	O
12	at	O
13	least	O
14	two	O
15	associated	O
16	polypeptides	O
17	,	O
18	CD3	B
19	zeta	I
20	and	O
21	CD3	B
22	epsilon	I
23	,	O
24	autonomously	O
25	couple	O
26	antigenic	O
27	recognition	O
28	event	O
29	to	O
30	early	O
31	and	O
32	late	O
33	events	O
34	of	O
35	the	O
36	intracytoplasmic	O
37	activation	O
38	cascade	O
39	.	O
1	Oncogenic	O
2	capacity	O
3	of	O
4	the	O
5	E2F1	B
6	gene	I
7	.	O
1	A	O
2	unique	O
3	leucine	O
4	-	O
5	proline	O
6	repeat	O
7	element	O
8	found	O
9	N	O
10	-	O
11	terminal	O
12	to	O
13	the	O
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	of	O
19	EmBP	B
20	-	I
21	1	I
22	does	O
23	not	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	DNA	O
31	-	O
32	binding	O
33	or	O
34	dimerization	O
35	.	O
1	Another	O
2	full	O
3	ORF	O
4	was	O
5	found	O
6	on	O
7	the	O
8	opposite	O
9	strand	O
10	downstream	O
11	from	O
12	the	O
13	nspC	B
14	gene	I
15	.	O
1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	B
13	TATA	I
14	motif	I
15	.	O
1	Inclusion	O
2	in	O
3	this	O
4	family	O
5	of	O
6	proteins	O
7	suggests	O
8	that	O
9	FliQ	B
10	and	O
11	FliR	B
12	may	O
13	participate	O
14	in	O
15	an	O
16	export	O
17	pathway	O
18	required	O
19	for	O
20	flagellum	O
21	assembly	O
22	.	O
1	Furthermore	O
2	,	O
3	the	O
4	identification	O
5	of	O
6	a	O
7	Dr1	B
8	-	I
9	like	I
10	protein	I
11	in	O
12	A	O
13	.	O
14	thaliana	O
15	strongly	O
16	argues	O
17	for	O
18	the	O
19	ubiquity	O
20	of	O
21	this	O
22	protein	O
23	among	O
24	eukaryotic	O
25	genera	O
26	and	O
27	for	O
28	a	O
29	conserved	O
30	mechanism	O
31	to	O
32	regulate	O
33	transcription	O
34	initiation	O
35	that	O
36	involves	O
37	Dr1	B
38	.	O
1	The	O
2	introduction	O
3	of	O
4	an	O
5	acidic	O
6	residue	O
7	at	O
8	the	O
9	second	O
10	site	O
11	was	O
12	essential	O
13	for	O
14	suppression	O
15	of	O
16	the	O
17	Asn	O
18	-	O
19	285	O
20	mutation	O
21	because	O
22	Lys	O
23	-	O
24	220	O
25	and	O
26	Gln	O
27	-	O
28	220	O
29	second	O
30	-	O
31	site	O
32	mutants	O
33	of	O
34	the	O
35	Asn	O
36	-	O
37	285	O
38	mutant	O
39	showed	O
40	very	O
41	low	O
42	tetracycline	O
43	resistance	O
44	.(	O
45	ABSTRACT	O
46	TRUNCATED	O
47	AT	O
48	250	O
49	WORDS	O
50	)	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	EKLF	B
6	provides	O
7	a	O
8	crucial	O
9	transactivation	O
10	function	O
11	for	O
12	globin	B
13	expression	O
14	and	O
15	further	O
16	reinforce	O
17	the	O
18	idea	O
19	that	O
20	EKLF	B
21	is	O
22	an	O
23	important	O
24	regulator	O
25	of	O
26	CACCC	O
27	element	O
28	-	O
29	directed	O
30	transcription	O
31	in	O
32	erythroid	O
33	cells	O
34	.	O
1	Mutagenesis	O
2	of	O
3	IM1	B
4	enhances	O
5	the	O
6	ability	O
7	of	O
8	c	B
9	-	I
10	Fos	I
11	to	O
12	activate	O
13	an	O
14	AP1	B
15	bearing	I
16	promoter	I
17	.	O
1	This	O
2	failure	O
3	to	O
4	execute	O
5	regulated	O
6	G1	O
7	/	O
8	S	O
9	arrest	O
10	is	O
11	correlated	O
12	with	O
13	enhanced	O
14	thermosensitivity	O
15	of	O
16	colony	O
17	-	O
18	forming	O
19	ability	O
20	.	O
1	Mutations	O
2	that	O
3	alter	O
4	photoreceptor	O
5	cell	O
6	structure	O
7	and	O
8	development	O
9	were	O
10	isolated	O
11	that	O
12	fail	O
13	to	O
14	complement	O
15	these	O
16	deletions	O
17	.	O
1	It	O
2	is	O
3	possible	O
4	that	O
5	the	O
6	telomeres	O
7	of	O
8	the	O
9	two	O
10	nuclei	O
11	have	O
12	different	O
13	functions	O
14	.	O
1	Haplotype	O
2	mapping	O
3	and	O
4	sequence	O
5	analysis	O
6	of	O
7	the	O
8	mouse	O
9	Nramp	B
10	gene	I
11	predict	O
12	susceptibility	O
13	to	O
14	infection	O
15	with	O
16	intracellular	O
17	parasites	O
18	.	O
1	To	O
2	further	O
3	our	O
4	knowledge	O
5	about	O
6	the	O
7	systemic	O
8	humoral	O
9	immune	O
10	system	O
11	response	O
12	to	O
13	weak	O
14	hapten	O
15	-	O
16	syngeneic	O
17	or	O
18	allogeneic	O
19	protein	O
20	conjugates	O
21	(	O
22	corrosion	O
23	and	O
24	wear	O
25	products	O
26	of	O
27	metallic	O
28	orthopedic	O
29	devices	O
30	),	O
31	a	O
32	sensitive	O
33	enzyme	O
34	-	O
35	linked	O
36	immunosorbent	O
37	assay	O
38	(	O
39	ELISA	O
40	)	O
41	method	O
42	for	O
43	testing	O
44	for	O
45	antibody	O
46	(	O
47	humoral	O
48	immunity	O
49	)	O
50	to	O
51	metals	O
52	was	O
53	developed	O
54	.	O
1	Therefore	O
2	the	O
3	prevalences	O
4	of	O
5	total	O
6	diabetes	O
7	and	O
8	GDM	O
9	were	O
10	1	O
11	.	O
12	19	O
13	%	O
14	and	O
15	0	O
16	.	O
17	56	O
18	%,	O
19	respectively	O
20	.	O
1	Dissociation	O
2	and	O
3	complexation	O
4	of	O
5	the	O
6	fluoroquinolone	O
7	antimicrobials	O
8	--	O
9	an	O
10	update	O
11	.	O
1	These	O
2	studies	O
3	indicate	O
4	that	O
5	in	O
6	vitro	O
7	and	O
8	in	O
9	vivo	O
10	electrical	O
11	stimulation	O
12	generate	O
13	reactive	O
14	oxygen	O
15	species	O
16	and	O
17	affect	O
18	SOD	B
19	activity	O
20	,	O
21	which	O
22	in	O
23	part	O
24	are	O
25	responsible	O
26	for	O
27	decreased	O
28	sperm	O
29	motion	O
30	and	O
31	viability	O
32	.	O
1	Molecular	O
2	cloning	O
3	and	O
4	sequencing	O
5	of	O
6	a	O
7	cDNA	O
8	encoding	O
9	SR	B
10	beta	I
11	revealed	O
12	that	O
13	SR	B
14	beta	I
15	is	O
16	a	O
17	transmembrane	O
18	protein	O
19	and	O
20	,	O
21	like	O
22	SR	B
23	alpha	I
24	and	O
25	SRP54	B
26	,	O
27	is	O
28	a	O
29	member	O
30	of	O
31	the	O
32	GTPase	B
33	superfamily	I
34	.	O
1	Comparison	O
2	of	O
3	human	B
4	and	I
5	murine	I
6	blk	I
7	sequences	I
8	indicated	O
9	that	O
10	they	O
11	share	O
12	86	O
13	%	O
14	amino	O
15	acid	O
16	identity	O
17	,	O
18	the	O
19	most	O
20	conserved	O
21	region	O
22	being	O
23	the	O
24	catalytic	O
25	domain	O
26	(	O
27	93	O
28	%	O
29	identity	O
30	).	O
1	The	O
2	effect	O
3	of	O
4	ethanol	O
5	on	O
6	human	O
7	sensorimotor	O
8	reactivity	O
9	was	O
10	assessed	O
11	by	O
12	examining	O
13	the	O
14	acoustic	O
15	startle	O
16	response	O
17	.	O
1	VIII	O
2	in	O
3	doses	O
4	2	O
5	-	O
6	3	O
7	times	O
8	higher	O
9	than	O
10	usually	O
11	used	O
12	in	O
13	haemophiliacs	O
14	without	O
15	inhibitor	O
16	were	O
17	successful	O
18	.	O
1	Physical	O
2	analysis	O
3	maps	O
4	SAL6	B
5	to	O
6	chromosome	O
7	XVI	O
8	between	O
9	TPK2	B
10	and	O
11	spt14	B
12	.	O
1	A	O
2	major	O
3	task	O
4	for	O
5	sports	O
6	scientists	O
7	may	O
8	be	O
9	to	O
10	verify	O
11	empirically	O
12	the	O
13	nature	O
14	of	O
15	an	O
16	integrated	O
17	model	O
18	of	O
19	the	O
20	sport	O
21	performer	O
22	.	O
1	These	O
2	data	O
3	indicate	O
4	that	O
5	phosphorylation	O
6	of	O
7	M	B
8	protein	I
9	at	O
10	the	O
11	major	O
12	in	O
13	vivo	O
14	sites	O
15	is	O
16	not	O
17	essential	O
18	for	O
19	virus	O
20	assembly	O
21	.	O
1	The	O
2	mean	O
3	jitter	O
4	and	O
5	the	O
6	fiber	O
7	density	O
8	did	O
9	not	O
10	change	O
11	significantly	O
12	from	O
13	day	O
14	0	O
15	(	O
16	30	O
17	.	O
18	1	O
19	+/-	O
20	3	O
21	.	O
22	6	O
23	microseconds	O
24	;	O
25	1	O
26	.	O
27	4	O
28	+/-	O
29	0	O
30	.	O
31	07	O
32	)	O
33	to	O
34	day	O
35	30	O
36	(	O
37	34	O
38	.	O
39	5	O
40	+/-	O
41	2	O
42	.	O
43	7	O
44	microseconds	O
45	;	O
46	1	O
47	.	O
48	6	O
49	+/-	O
50	0	O
51	.	O
52	13	O
53	).	O
1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	show	O
7	that	O
8	TEP	B
9	has	O
10	an	O
11	apparent	O
12	molecular	O
13	mass	O
14	of	O
15	approximately	O
16	65	O
17	kDa	O
18	.	O
1	In	O
2	the	O
3	presence	O
4	of	O
5	inositol	O
6	and	O
7	choline	O
8	(	O
9	repressing	O
10	),	O
11	the	O
12	product	O
13	of	O
14	the	O
15	OPI1	B
16	gene	I
17	represses	O
18	transcription	O
19	dictated	O
20	by	O
21	the	O
22	UASINO	O
23	element	O
24	.	O
1	The	O
2	interleukin	B
3	2	I
4	receptor	I
5	alpha	I
6	-	I
7	chain	I
8	(	O
9	IL	B
10	-	I
11	2R	I
12	alpha	I
13	)	O
14	gene	O
15	is	O
16	rapidly	O
17	and	O
18	potently	O
19	induced	O
20	in	O
21	T	O
22	cells	O
23	in	O
24	response	O
25	to	O
26	mitogenic	O
27	stimuli	O
28	.	O
1	Constructs	O
2	designed	O
3	and	O
4	expressed	O
5	were	O
6	E2L1	O
7	(	O
8	1	O
9	-	O
10	98	O
11	),	O
12	E2L1	O
13	.	O
14	H1	O
15	(	O
16	1	O
17	-	O
18	128	O
19	),	O
20	E2L2	O
21	(	O
22	120	O
23	-	O
24	233	O
25	),	O
26	E2H1	O
27	.	O
28	L2	O
29	(	O
30	98	O
31	-	O
32	233	O
33	),	O
34	and	O
35	E2L1	O
36	.	O
37	H1	O
38	.	O
39	L2	O
40	(	O
41	1	O
42	-	O
43	233	O
44	),	O
45	where	O
46	numbers	O
47	in	O
48	parentheses	O
49	give	O
50	the	O
51	amino	O
52	acid	O
53	sequence	O
54	for	O
55	the	O
56	portions	O
57	of	O
58	the	O
59	E2	B
60	component	O
61	incorporated	O
62	into	O
63	a	O
64	construct	O
65	.	O
1	Similarly	O
2	,	O
3	in	O
4	mammalian	O
5	cells	O
6	PBP74	B
7	is	O
8	synthesized	O
9	as	O
10	a	O
11	pre	O
12	-	O
13	protein	O
14	that	O
15	requires	O
16	membrane	O
17	potential	O
18	-	O
19	dependent	O
20	import	O
21	into	O
22	mitochondria	O
23	for	O
24	its	O
25	maturation	O
26	.	O
1	When	O
2	expressed	O
3	per	O
4	kilogram	O
5	body	O
6	weight	O
7	,	O
8	mean	O
9	GIT	O
10	increased	O
11	in	O
12	the	O
13	dF	O
14	group	O
15	from	O
16	0	O
17	.	O
18	14	O
19	%	O
20	to	O
21	0	O
22	.	O
23	16	O
24	%	O
25	above	O
26	RMR	O
27	,	O
28	with	O
29	a	O
30	significant	O
31	decrease	O
32	from	O
33	0	O
34	.	O
35	15	O
36	%	O
37	to	O
38	0	O
39	.	O
40	13	O
41	%	O
42	in	O
43	the	O
44	P	O
45	group	O
46	.	O
1	However	O
2	,	O
3	inclusion	O
4	of	O
5	the	O
6	neighboring	O
7	CGGAAR	O
8	motifs	O
9	from	O
10	the	O
11	ICP4	B
12	promoter	I
13	,	O
14	which	O
15	bind	O
16	factors	O
17	GABP	B
18	alpha	I
19	and	I
20	beta	I
21	,	O
22	results	O
23	in	O
24	a	O
25	strong	O
26	synergistic	O
27	activation	O
28	.	O
1	Secondary	O
2	pancreatic	O
3	involvement	O
4	of	O
5	mycosis	O
6	fungoides	O
7	detected	O
8	by	O
9	a	O
10	clinically	O
11	palpable	O
12	mass	O
13	.	O
1	In	O
2	ICE	B
3	gamma	I
4	,	O
5	most	O
6	of	O
7	the	O
8	propeptide	O
9	(	O
10	amino	O
11	acids	O
12	20	O
13	-	O
14	112	O
15	)	O
16	is	O
17	deleted	O
18	,	O
19	which	O
20	suggests	O
21	that	O
22	it	O
23	may	O
24	function	O
25	as	O
26	a	O
27	catalyst	O
28	for	O
29	ICE	B
30	autoprocessing	O
31	in	O
32	vivo	O
33	.	O
1	Mutation	O
2	of	O
3	the	O
4	P450BM	B
5	-	I
6	3	I
7	Barbie	I
8	box	I
9	significantly	O
10	increased	O
11	the	O
12	expression	O
13	of	O
14	both	O
15	P450BM	B
16	-	I
17	3	I
18	and	O
19	Bm3P1	B
20	(	O
21	another	O
22	small	O
23	gene	O
24	located	O
25	upstream	O
26	of	O
27	the	O
28	P450BM	B
29	-	I
30	3	I
31	gene	I
32	that	O
33	encodes	O
34	a	O
35	second	O
36	putative	O
37	regulatory	O
38	protein	O
39	)	O
40	in	O
41	response	O
42	to	O
43	pentobarbital	O
44	induction	O
45	but	O
46	left	O
47	the	O
48	basal	O
49	levels	O
50	unaffected	O
51	.	O
1	In	O
2	addition	O
3	,	O
4	we	O
5	found	O
6	that	O
7	cell	O
8	-	O
9	specific	O
10	suppression	O
11	of	O
12	RA	O
13	-	O
14	stimulated	O
15	zif268	B
16	gene	I
17	expression	O
18	can	O
19	be	O
20	attributed	O
21	to	O
22	a	O
23	29	O
24	base	O
25	pair	O
26	nucleotide	O
27	sequence	O
28	,	O
29	located	O
30	downstream	O
31	of	O
32	the	O
33	RA	O
34	-	O
35	responsive	O
36	region	O
37	in	O
38	the	O
39	zif268	B
40	gene	I
41	.	O
1	Supplementary	O
2	Phase	O
3	Contraste	O
4	RSE	O
5	"("""	O
6	Rapid	O
7	Sequential	O
8	Excitation	O
9	""")"	O
10	sequences	O
11	were	O
12	carried	O
13	out	O
14	in	O
15	29	O
16	patients	O
17	.	O
1	Several	O
2	nuclear	O
3	factors	O
4	that	O
5	interact	O
6	with	O
7	sequences	O
8	in	O
9	the	O
10	5	O
11	'	O
12	flanking	O
13	region	O
14	of	O
15	the	O
16	mouse	B
17	tyrosinase	I
18	gene	I
19	were	O
20	identified	O
21	using	O
22	band	O
23	shift	O
24	and	O
25	methylation	O
26	interference	O
27	assays	O
28	.	O
1	PMEK1	B
2	displays	O
3	96	O
4	and	O
5	80	O
6	%	O
7	identity	O
8	respectively	O
9	with	O
10	the	O
11	tobacco	B
12	NTF3	I
13	and	O
14	Arabidopsis	B
15	ATMPK1	I
16	kinases	I
17	,	O
18	and	O
19	only	O
20	50	O
21	%	O
22	to	O
23	the	O
24	more	O
25	distantly	O
26	related	O
27	plant	O
28	MAP	O
29	kinase	O
30	MsERK1	B
31	from	O
32	alfalfa	O
33	.	O
1	Translation	O
2	of	O
3	the	O
4	coding	O
5	segment	O
6	,	O
7	which	O
8	was	O
9	designated	O
10	MsPRP2	B
11	,	O
12	suggested	O
13	it	O
14	encodes	O
15	a	O
16	chimeric	O
17	40	O
18	,	O
19	569	O
20	Da	O
21	cell	O
22	wall	O
23	protein	O
24	with	O
25	an	O
26	amino	O
27	-	O
28	terminal	O
29	signal	O
30	sequence	O
31	,	O
32	a	O
33	repetitive	O
34	proline	O
35	-	O
36	rich	O
37	sequence	O
38	,	O
39	and	O
40	a	O
41	cysteine	O
42	-	O
43	rich	O
44	carboxyl	O
45	-	O
46	terminal	O
47	sequence	O
48	homologous	O
49	to	O
50	nonspecific	O
51	lipid	O
52	transfer	O
53	proteins	O
54	.	O
1	The	O
2	presence	O
3	of	O
4	type	O
5	I	O
6	hypersensitivity	O
7	in	O
8	a	O
9	subgroup	O
10	of	O
11	aspergillomas	O
12	suggests	O
13	an	O
14	immunoallergic	O
15	component	O
16	to	O
17	this	O
18	disease	O
19	which	O
20	could	O
21	contribute	O
22	to	O
23	a	O
24	chronic	O
25	inflammatory	O
26	response	O
27	to	O
28	Aspergillus	O
29	in	O
30	some	O
31	aspergillomas	O
32	.	O
1	The	O
2	catenins	B
3	bind	O
4	to	O
5	APC	B
6	and	O
7	E	B
8	-	I
9	cadherin	I
10	in	O
11	a	O
12	similar	O
13	fashion	O
14	,	O
15	but	O
16	APC	B
17	and	O
18	E	B
19	-	I
20	cadherin	I
21	do	O
22	not	O
23	associate	O
24	with	O
25	each	O
26	other	O
27	either	O
28	in	O
29	the	O
30	presence	O
31	or	O
32	absence	O
33	of	O
34	catenins	B
35	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	gluconeogenic	O
6	genes	O
7	are	O
8	derepressed	O
9	upon	O
10	binding	O
11	of	O
12	Cat8p	B
13	,	O
14	whose	O
15	synthesis	O
16	depends	O
17	on	O
18	the	O
19	release	O
20	of	O
21	Cat4p	B
22	(	O
23	Mig1p	B
24	)	O
25	from	O
26	the	O
27	CAT8	B
28	promoter	I
29	.	O
1	Both	O
2	factors	O
3	demonstrated	O
4	significant	O
5	correlations	O
6	with	O
7	rCBF	O
8	in	O
9	the	O
10	medial	O
11	prefrontal	O
12	cortex	O
13	and	O
14	frontal	O
15	polar	O
16	cortex	O
17	while	O
18	for	O
19	each	O
20	factor	O
21	there	O
22	were	O
23	also	O
24	unique	O
25	patterns	O
26	of	O
27	correlations	O
28	with	O
29	posterior	O
30	brain	O
31	regions	O
32	.	O
1	The	O
2	wild	O
3	-	O
4	type	O
5	and	O
6	altered	O
7	forms	O
8	of	O
9	the	O
10	F	B
11	protein	I
12	were	O
13	expressed	O
14	in	O
15	BHK	O
16	-	O
17	21	O
18	and	O
19	HeLa	O
20	T4	O
21	cells	O
22	by	O
23	use	O
24	of	O
25	the	O
26	recombinant	B
27	vaccinia	I
28	virus	I
29	-	I
30	encoding	I
31	T7	I
32	polymerase	I
33	system	O
34	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	BOX	O
9	DNA	O
10	enhances	O
11	transcription	O
12	from	O
13	the	O
14	thymidine	B
15	kinase	I
16	(	O
17	TK	B
18	)	O
19	promoter	O
20	in	O
21	various	O
22	EC	O
23	cells	O
24	.	O
1	Analysis	O
2	of	O
3	disassociation	O
4	rates	O
5	indicates	O
6	that	O
7	the	O
8	Grf10	B
9	-	O
10	Swi5	B
11	-	O
12	DNA	O
13	complex	O
14	has	O
15	a	O
16	longer	O
17	half	O
18	-	O
19	life	O
20	than	O
21	protein	O
22	-	O
23	DNA	O
24	complexes	O
25	that	O
26	contain	O
27	only	O
28	Swi5	B
29	or	O
30	Grf10	B
31	.	O
1	The	O
2	presence	O
3	of	O
4	an	O
5	unusual	O
6	transcript	O
7	possessing	O
8	IVS2C	B
9	beta	I
10	1	I
11	at	O
12	the	O
13	5	O
14	'	O
15	terminus	O
16	suggests	O
17	that	O
18	cleavage	O
19	of	O
20	its	O
21	splice	O
22	acceptor	O
23	is	O
24	inefficient	O
25	or	O
26	negatively	O
27	regulated	O
28	.	O
1	ISIS	O
2	5	O
3	possibilities	O
4	.	O
1	At	O
2	the	O
3	MTD	O
4	(	O
5	8	O
6	mg	O
7	/	O
8	m2	O
9	/	O
10	day	O
11	),	O
12	the	O
13	dose	O
14	-	O
15	limiting	O
16	toxicity	O
17	of	O
18	this	O
19	agent	O
20	is	O
21	myelosuppression	O
22	.	O
1	Northern	O
2	analysis	O
3	of	O
4	RNA	O
5	samples	O
6	isolated	O
7	from	O
8	ammonium	O
9	-	O
10	grown	O
11	cultures	O
12	of	O
13	the	O
14	ntcA	B
15	mutant	I
16	showed	O
17	reduced	O
18	amounts	O
19	of	O
20	glnA	B
21	message	I
22	and	O
23	the	O
24	absence	O
25	of	O
26	a	O
27	1	O
28	.	O
29	7	O
30	-	O
31	kb	O
32	transcript	O
33	.	O
1	Comparison	O
2	of	O
3	cDNA	O
4	sequences	O
5	revealed	O
6	that	O
7	the	O
8	two	O
9	mRNA	O
10	species	O
11	arise	O
12	as	O
13	a	O
14	result	O
15	of	O
16	alternate	O
17	use	O
18	of	O
19	poly	O
20	(	O
21	A	O
22	)-	O
23	addition	O
24	sites	O
25	.	O
1	The	O
2	gene	O
3	for	O
4	the	O
5	RNA	B
6	-	I
7	dependent	I
8	eIF	I
9	-	I
10	2	I
11	alpha	I
12	protein	I
13	kinase	I
14	(	O
15	PKR	B
16	)	O
17	was	O
18	isolated	O
19	from	O
20	mouse	O
21	genomic	O
22	DNA	O
23	and	O
24	characterized	O
25	.	O
1	In	O
2	order	O
3	to	O
4	define	O
5	potential	O
6	candidate	O
7	genes	O
8	for	O
9	inherited	O
10	disorders	O
11	characterized	O
12	by	O
13	aberrant	O
14	gene	O
15	expression	O
16	,	O
17	we	O
18	utilized	O
19	Kruppel	B
20	-	I
21	related	I
22	sequences	I
23	to	O
24	isolate	O
25	zinc	O
26	finger	O
27	-	O
28	containing	O
29	cDNAs	O
30	.	O
1	The	O
2	novel	O
3	Notch	B
4	homologue	I
5	mouse	I
6	Notch	I
7	3	I
8	lacks	O
9	specific	O
10	epidermal	B
11	growth	I
12	factor	I
13	-	I
14	repeats	I
15	and	O
16	is	O
17	expressed	O
18	in	O
19	proliferating	O
20	neuroepithelium	O
21	.	O
1	Expression	O
2	is	O
3	exclusively	O
4	limited	O
5	to	O
6	the	O
7	CNS	O
8	at	O
9	this	O
10	and	O
11	later	O
12	stages	O
13	.	O
1	The	O
2	p73pct1	B
3	/	O
4	p85cdc10	B
5	complex	O
6	binds	O
7	both	O
8	in	O
9	vitro	O
10	and	O
11	in	O
12	vivo	O
13	to	O
14	MCB	B
15	but	O
16	not	O
17	SCB	B
18	or	O
19	E2F	B
20	sites	I
21	.	O
1	(	O
2	1992	O
3	)	O
4	Genomics	O
5	12	O
6	,	O
7	58	O
8	-	O
9	62	O
10	).	O
1	Identification	O
2	of	O
3	the	O
4	plakoglobin	B
5	-	O
6	binding	O
7	domain	O
8	in	O
9	desmoglein	B
10	and	O
11	its	O
12	role	O
13	in	O
14	plaque	O
15	assembly	O
16	and	O
17	intermediate	O
18	filament	O
19	anchorage	O
20	.	O
1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	TATA	O
8	element	O
9	is	O
10	critical	O
11	for	O
12	basal	O
13	and	O
14	Tat	B
15	-	O
16	induced	O
17	HIV	O
18	-	O
19	1	O
20	gene	O
21	expression	O
22	.	O
1	Expression	O
2	of	O
3	a	O
4	dominant	B
5	-	I
6	negative	I
7	ras	I
8	gene	I
9	also	O
10	blocks	O
11	TIS10	B
12	/	O
13	PGS2	B
14	induction	O
15	by	O
16	v	B
17	-	I
18	src	I
19	.	O
1	The	O
2	protein	O
3	encoded	O
4	is	O
5	114	O
6	kDa	O
7	and	O
8	contains	O
9	eight	O
10	zinc	O
11	finger	O
12	motifs	O
13	,	O
14	seven	O
15	of	O
16	which	O
17	are	O
18	present	O
19	in	O
20	two	O
21	clusters	O
22	at	O
23	opposite	O
24	ends	O
25	of	O
26	the	O
27	molecule	O
28	.	O
1	The	O
2	predominant	O
3	binding	O
4	activity	O
5	was	O
6	not	O
7	Ets	B
8	-	I
9	1	I
10	but	O
11	rather	O
12	two	O
13	independent	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	that	O
19	comigrated	O
20	in	O
21	mobility	O
22	shift	O
23	assays	O
24	.	O
1	Treatment	O
2	with	O
3	amphotericin	O
4	B	O
5	and	O
6	flucytosine	O
7	led	O
8	to	O
9	improvement	O
10	of	O
11	the	O
12	symptoms	O
13	but	O
14	did	O
15	not	O
16	eradicate	O
17	the	O
18	micro	O
19	-	O
20	organisms	O
21	from	O
22	the	O
23	cerebrospinal	O
24	fluid	O
25	(	O
26	CSF	O
27	).	O
1	The	O
2	parameters	O
3	of	O
4	nonspecific	O
5	humoral	O
6	immunity	O
7	--	O
8	serum	B
9	immunoglobulins	I
10	and	O
11	immune	O
12	complexes	O
13	--	O
14	were	O
15	evaluated	O
16	in	O
17	irradiated	O
18	group	O
19	of	O
20	patients	O
21	with	O
22	uterine	O
23	cervix	O
24	carcinoma	O
25	(	O
26	Stages	O
27	IIB	O
28	and	O
29	IIIB	O
30	),	O
31	during	O
32	one	O
33	year	O
34	follow	O
35	up	O
36	.	O
1	Mutation	O
2	of	O
3	KRKR	O
4	to	O
5	NGER	O
6	retains	O
7	MO15	B
8	in	O
9	the	O
10	cytoplasmic	O
11	compartment	O
12	,	O
13	whilst	O
14	the	O
15	wild	O
16	-	O
17	type	O
18	protein	O
19	is	O
20	detected	O
21	exclusively	O
22	in	O
23	the	O
24	nucleus	O
25	.	O
1	To	O
2	confirm	O
3	the	O
4	binding	O
5	of	O
6	protein	O
7	to	O
8	these	O
9	sites	O
10	in	O
11	cells	O
12	,	O
13	we	O
14	carried	O
15	out	O
16	an	O
17	in	O
18	vivo	O
19	genomic	O
20	footprinting	O
21	analysis	O
22	of	O
23	this	O
24	portion	O
25	of	O
26	the	O
27	TGF	B
28	alpha	I
29	promoter	I
30	in	O
31	normal	O
32	and	O
33	transformed	O
34	rat	O
35	liver	O
36	epithelial	O
37	cell	O
38	lines	O
39	that	O
40	express	O
41	the	O
42	endogenous	O
43	gene	O
44	at	O
45	varying	O
46	levels	O
47	.	O
1	Strikingly	O
2	,	O
3	this	O
4	subdomain	O
5	is	O
6	also	O
7	present	O
8	in	O
9	the	O
10	otherwise	O
11	unrelated	O
12	N	O
13	-	O
14	terminal	O
15	activating	O
16	region	O
17	of	O
18	p58c	B
19	-	I
20	ets	I
21	-	I
22	2	I
23	and	O
24	was	O
25	thus	O
26	named	O
27	BEC	B
28	for	O
29	Ets	B
30	-	I
31	1	I
32	-	I
33	beta	I
34	/	O
35	Ets	B
36	-	I
37	2	I
38	-	I
39	Conserved	I
40	sequence	I
41	.	O
1	Remarkably	O
2	,	O
3	U21	B
4	contains	O
5	a	O
6	long	O
7	stretch	O
8	(	O
9	13	O
10	nt	O
11	.)	O
12	of	O
13	complementarity	O
14	to	O
15	a	O
16	highly	O
17	conserved	O
18	sequence	O
19	in	O
20	28S	B
21	rRNA	I
22	.	O
1	Curiously	O
2	,	O
3	testololactone	O
4	was	O
5	earlier	O
6	and	O
7	more	O
8	widely	O
9	used	O
10	than	O
11	aminoglutethimide	O
12	in	O
13	treating	O
14	advanced	O
15	breast	O
16	carcinoma	O
17	.	O
1	Cestode	O
2	invasion	O
3	in	O
4	irradiated	O
5	host	O
6	organism	O
7	increases	O
8	the	O
9	negative	O
10	effect	O
11	of	O
12	ionizing	O
13	radiation	O
14	on	O
15	the	O
16	hamster	O
17	immune	O
18	system	O
19	.	O
1	During	O
2	heat	O
3	exposure	O
4	,	O
5	chicks	O
6	that	O
7	had	O
8	been	O
9	subjected	O
10	to	O
11	early	O
12	60	O
13	%	O
14	restriction	O
15	with	O
16	non	O
17	-	O
18	metyrapone	O
19	-	O
20	treated	O
21	food	O
22	had	O
23	lower	O
24	H	O
25	/	O
26	L	O
27	ratios	O
28	and	O
29	improved	O
30	resistance	O
31	to	O
32	marble	O
33	spleen	O
34	disease	O
35	infection	O
36	.	O
1	Cbf3	B
2	contains	O
3	three	O
4	proteins	O
5	,	O
6	Cbf3a	B
7	,	O
8	Cbf3b	B
9	and	O
10	Cbf3c	B
11	.	O
1	These	O
2	mutations	O
3	are	O
4	localized	O
5	in	O
6	the	O
7	same	O
8	region	O
9	where	O
10	the	O
11	HSV	B
12	transactivator	I
13	VP16	I
14	binds	O
15	,	O
16	but	O
17	did	O
18	not	O
19	coincide	O
20	with	O
21	the	O
22	VP16	B
23	contacts	O
24	.	O
1	In	O
2	general	O
3	,	O
4	the	O
5	filtration	O
6	rate	O
7	in	O
8	relevant	O
9	areas	O
10	appears	O
11	to	O
12	be	O
13	an	O
14	integrative	O
15	and	O
16	easily	O
17	determined	O
18	parameter	O
19	,	O
20	reflecting	O
21	hormonal	O
22	and	O
23	neurogenic	O
24	vascular	O
25	as	O
26	well	O
27	as	O
28	local	O
29	interstitial	O
30	control	O
31	of	O
32	the	O
33	Starling	O
34	forces	O
35	.	O
1	However	O
2	,	O
3	rapamycin	O
4	inhibited	O
5	proliferation	O
6	of	O
7	Ba	O
8	/	O
9	F3	O
10	-	O
11	EpoRgp55	O
12	but	O
13	not	O
14	of	O
15	MEL	O
16	cells	O
17	despite	O
18	inhibition	O
19	of	O
20	p70	B
21	S6	I
22	kinase	I
23	activity	O
24	in	O
25	both	O
26	cells	O
27	.	O
1	A	O
2	strong	O
3	trithorax	B
4	binding	I
5	site	I
6	was	O
7	found	O
8	at	O
9	the	O
10	cytological	O
11	location	O
12	of	O
13	the	O
14	fork	B
15	head	I
16	gene	I
17	,	O
18	a	O
19	region	O
20	-	O
21	specific	O
22	homeotic	B
23	gene	I
24	not	O
25	located	O
26	within	O
27	a	O
28	homeotic	B
29	complex	I
30	.	O
1	C	B
2	/	I
3	EBP	I
4	alpha	I
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	B
12	class	I
13	-	I
14	I	I
15	ADH	I
16	gene	I
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	Potter	O
25	et	O
26	al	O
27	.,	O
28	Arch	O
29	.	O
1	C	B
2	/	I
3	EBP	I
4	alpha	I
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	B
12	class	I
13	-	I
14	I	I
15	ADH	I
16	gene	I
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	Potter	O
25	et	O
26	al	O
27	.,	O
28	Arch	O
29	.	O
1	Homology	O
2	was	O
3	also	O
4	detected	O
5	between	O
6	the	O
7	putative	O
8	transit	O
9	peptide	O
10	sequence	O
11	of	O
12	cysteine	B
13	synthase	I
14	C	I
15	and	O
16	other	O
17	mitochondrion	O
18	-	O
19	targeting	O
20	leader	O
21	sequences	O
22	.	O
1	Rat	B
2	kidney	I
3	carboxylesterase	I
4	.	O
1	A	O
2	candidate	O
3	gene	O
4	for	O
5	Bcg	B
6	,	O
7	designated	O
8	natural	B
9	resistance	I
10	-	I
11	associated	I
12	macrophage	I
13	protein	I
14	(	O
15	Nramp	B
16	),	O
17	has	O
18	been	O
19	isolated	O
20	and	O
21	shown	O
22	to	O
23	encode	O
24	a	O
25	novel	O
26	macrophage	O
27	-	O
28	specific	O
29	membrane	O
30	protein	O
31	,	O
32	which	O
33	is	O
34	altered	O
35	in	O
36	susceptible	O
37	animals	O
38	.	O
1	The	O
2	defined	O
3	length	O
4	of	O
5	the	O
6	mRNA	O
7	,	O
8	1	O
9	,	O
10	838	O
11	nucleotides	O
12	,	O
13	was	O
14	in	O
15	agreement	O
16	with	O
17	that	O
18	of	O
19	a	O
20	1	O
21	.	O
22	9	O
23	-	O
24	kb	O
25	RNA	O
26	expressed	O
27	throughout	O
28	the	O
29	replication	O
30	cycle	O
31	,	O
32	starting	O
33	at	O
34	the	O
35	early	O
36	stages	O
37	of	O
38	infection	O
39	.	O
1	Infect	O
2	.	O
1	The	O
2	present	O
3	data	O
4	also	O
5	indicate	O
6	that	O
7	patients	O
8	with	O
9	TGBM	O
10	nephropathy	O
11	often	O
12	have	O
13	concomitant	O
14	IgA	B
15	nephropathy	O
16	and	O
17	mesangial	O
18	proliferative	O
19	glomerulonephritis	O
20	.	O
1	Regulators	O
2	responsible	O
3	for	O
4	the	O
5	pervasive	O
6	,	O
7	nonsex	O
8	-	O
9	specific	O
10	alternative	O
11	pre	O
12	-	O
13	mRNA	O
14	splicing	O
15	characteristic	O
16	of	O
17	metazoans	O
18	are	O
19	almost	O
20	entirely	O
21	unknown	O
22	or	O
23	uncertain	O
24	.	O
1	A	O
2	full	O
3	-	O
4	length	O
5	cDNA	O
6	clone	O
7	isolated	O
8	from	O
9	a	O
10	rat	O
11	lung	O
12	library	O
13	was	O
14	predicted	O
15	to	O
16	encode	O
17	a	O
18	55	O
19	-	O
20	kDa	O
21	protein	O
22	containing	O
23	at	O
24	its	O
25	amino	O
26	terminus	O
27	a	O
28	targeting	O
29	domain	O
30	that	O
31	binds	O
32	to	O
33	the	O
34	ANP	B
35	-	I
36	receptor	I
37	kinase	I
38	-	I
39	like	I
40	domain	I
41	and	O
42	containing	O
43	at	O
44	its	O
45	carboxyl	O
46	terminus	O
47	a	O
48	putative	O
49	protein	B
50	-	I
51	serine	I
52	phosphatase	I
53	domain	O
54	.	O
1	Human	O
2	adenovirus	O
3	type	O
4	41	O
5	contains	O
6	two	O
7	fibers	O
8	.	O
1	Outflow	O
2	obstruction	O
3	of	O
4	pancreatic	O
5	juice	O
6	,	O
7	i	O
8	.	O
9	e	O
10	.,	O
11	""""	O
12	relative	O
13	stenosis	O
14	of	O
15	the	O
16	minor	O
17	papilla	O
18	","""	O
19	was	O
20	considered	O
21	to	O
22	be	O
23	present	O
24	in	O
25	the	O
26	patients	O
27	with	O
28	type	O
29	II	O
30	papilla	O
31	,	O
32	and	O
33	,	O
34	therefore	O
35	,	O
36	the	O
37	patients	O
38	with	O
39	type	O
40	II	O
41	papilla	O
42	might	O
43	suffer	O
44	from	O
45	acute	O
46	pancreatitis	O
47	resulting	O
48	from	O
49	poor	O
50	drainage	O
51	of	O
52	pancreatic	O
53	juice	O
54	and	O
55	excessive	O
56	pressure	O
57	in	O
58	the	O
59	dorsal	O
60	duct	O
61	.	O
1	An	O
2	unusual	O
3	complication	O
4	in	O
5	an	O
6	unsuitable	O
7	patient	O
8	.	O
1	In	O
2	the	O
3	ISO	O
4	group	O
5	,	O
6	at	O
7	pre	O
8	-	O
9	DEX	O
10	,	O
11	CBF	O
12	increased	O
13	from	O
14	86	O
15	+/-	O
16	8	O
17	to	O
18	166	O
19	+/-	O
20	19	O
21	mL	O
22	.	O
23	min	O
24	-	O
25	1	O
26	.	O
27	100	O
28	g	O
29	-	O
30	1	O
31	in	O
32	response	O
33	to	O
34	hypercapnia	O
35	(	O
36	PCO2	O
37	approximately	O
38	90	O
39	mmHg	O
40	).(	O
41	ABSTRACT	O
42	TRUNCATED	O
43	AT	O
44	250	O
45	WORDS	O
46	)	O
1	Acta	O
2	572	O
3	,	O
4	113	O
5	-	O
6	120	O
7	].	O
1	ATX	B
2	,	O
3	like	O
4	PC	B
5	-	I
6	1	I
7	,	O
8	was	O
9	found	O
10	to	O
11	hydrolyze	O
12	the	O
13	type	B
14	I	I
15	phosphodiesterase	I
16	substrate	O
17	p	O
18	-	O
19	nitrophenyl	O
20	thymidine	O
21	-	O
22	5	O
23	'-	O
24	monophosphate	O
25	.	O
1	Recently	O
2	,	O
3	a	O
4	protein	O
5	designated	O
6	GF14	B
7	has	O
8	been	O
9	isolated	O
10	that	O
11	is	O
12	associated	O
13	with	O
14	the	O
15	GBF	B
16	protein	I
17	complex	I
18	.	O
1	This	O
2	technique	O
3	has	O
4	a	O
5	sensitivity	O
6	and	O
7	a	O
8	specificity	O
9	of	O
10	almost	O
11	100	O
12	%,	O
13	and	O
14	is	O
15	currently	O
16	the	O
17	best	O
18	way	O
19	to	O
20	diagnose	O
21	nodal	O
22	involvement	O
23	,	O
24	apart	O
25	from	O
26	laparotomy	O
27	.	O
1	A	O
2	sequence	O
3	representing	O
4	about	O
5	50	O
6	%	O
7	of	O
8	the	O
9	expected	O
10	complete	O
11	sequence	O
12	was	O
13	obtained	O
14	by	O
15	translation	O
16	of	O
17	the	O
18	two	O
19	open	O
20	reading	O
21	frames	O
22	present	O
23	on	O
24	a	O
25	1	O
26	.	O
27	6	O
28	kb	O
29	DNA	O
30	genomic	O
31	fragment	O
32	.	O
1	A	O
2	cDNA	O
3	clone	O
4	pCZ1	O
5	,	O
6	with	O
7	a	O
8	1	O
9	.	O
10	1	O
11	kb	O
12	insert	O
13	,	O
14	was	O
15	isolated	O
16	from	O
17	a	O
18	NaCl	O
19	-	O
20	adapted	O
21	tobacco	O
22	cell	O
23	cDNA	O
24	library	O
25	that	O
26	encodes	O
27	an	O
28	apparently	O
29	full	O
30	-	O
31	length	O
32	29	O
33	kDa	O
34	protein	O
35	(	O
36	251	O
37	amino	O
38	acids	O
39	)	O
40	with	O
41	a	O
42	calculated	O
43	pI	O
44	of	O
45	5	O
46	.	O
47	7	O
48	.	O
1	The	O
2	git1	B
3	,	O
4	git3	B
5	,	O
6	git5	B
7	,	O
8	git7	B
9	,	O
10	git8	B
11	and	O
12	git10	B
13	genes	I
14	act	O
15	upstream	O
16	of	O
17	adenylate	B
18	cyclase	I
19	,	O
20	presumably	O
21	encoding	O
22	an	O
23	adenylate	B
24	cyclase	I
25	activation	O
26	pathway	O
27	.	O
1	DNA	O
2	sequence	O
3	analysis	O
4	has	O
5	confirmed	O
6	that	O
7	this	O
8	mutation	O
9	affects	O
10	the	O
11	C	O
12	-	O
13	terminal	O
14	region	O
15	of	O
16	the	O
17	alpha	O
18	subunit	O
19	,	O
20	changing	O
21	a	O
22	leucine	O
23	residue	O
24	at	O
25	position	O
26	290	O
27	to	O
28	a	O
29	histidine	O
30	(	O
31	rpoAL290H	B
32	).	O
1	Using	O
2	this	O
3	reporter	O
4	gene	O
5	system	O
6	,	O
7	we	O
8	previously	O
9	showed	O
10	that	O
11	EPO	B
12	-	O
13	induced	O
14	activation	O
15	of	O
16	the	O
17	c	B
18	-	I
19	fos	I
20	promoter	I
21	can	O
22	be	O
23	detected	O
24	rapidly	O
25	and	O
26	sensitively	O
27	as	O
28	an	O
29	elevation	O
30	of	O
31	cellular	B
32	luciferase	I
33	activity	O
34	.	O
1	I	O
2	hypothesize	O
3	that	O
4	white	B
5	gene	I
6	expression	O
7	from	O
8	P	B
9	[	I
10	en	I
11	]	I
12	is	O
13	repressed	O
14	by	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	protein	O
20	complex	O
21	which	O
22	is	O
23	initiated	O
24	at	O
25	the	O
26	engrailed	B
27	PS	I
28	sites	I
29	and	O
30	also	O
31	requires	O
32	interactions	O
33	with	O
34	flanking	O
35	genomic	O
36	DNA	O
37	.	O
1	Standard	O
2	curve	O
3	correlation	O
4	coefficients	O
5	of	O
6	0	O
7	.	O
8	995	O
9	or	O
10	greater	O
11	were	O
12	obtained	O
13	during	O
14	validation	O
15	experiments	O
16	and	O
17	analysis	O
18	of	O
19	study	O
20	samples	O
21	.	O
1	2	O
2	.	O
1	INO2	B
2	,	O
3	a	O
4	regulatory	O
5	gene	O
6	in	O
7	yeast	O
8	phospholipid	O
9	biosynthesis	O
10	,	O
11	affects	O
12	nuclear	O
13	segregation	O
14	and	O
15	bud	O
16	pattern	O
17	formation	O
18	.	O
1	In	O
2	an	O
3	in	O
4	vitro	O
5	study	O
6	,	O
7	10	O
8	/	O
9	0	O
10	nylon	O
11	was	O
12	found	O
13	to	O
14	require	O
15	a	O
16	significantly	O
17	lower	O
18	laser	O
19	energy	O
20	density	O
21	to	O
22	produce	O
23	suture	O
24	lysis	O
25	following	O
26	a	O
27	single	O
28	shot	O
29	than	O
30	either	O
31	10	O
32	/	O
33	0	O
34	Dacron	O
35	or	O
36	10	O
37	/	O
38	0	O
39	prolene	O
40	.	O
1	The	O
2	proteins	O
3	encoded	O
4	downstream	O
5	of	O
6	rpoN	B
7	are	O
8	known	O
9	to	O
10	negatively	O
11	regulate	O
12	sigma	B
13	54	I
14	activity	O
15	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	microinjection	O
6	of	O
7	an	O
8	anti	B
9	-	I
10	CBP	I
11	antiserum	I
12	into	O
13	fibroblasts	O
14	can	O
15	inhibit	O
16	transcription	O
17	from	O
18	a	O
19	cAMP	O
20	responsive	O
21	promoter	O
22	.	O
1	65	O
2	,	O
3	3829	O
4	-	O
5	3838	O
6	,	O
7	1991	O
8	),	O
9	a	O
10	truncated	O
11	form	O
12	of	O
13	the	O
14	IE	B
15	polypeptide	I
16	lacking	O
17	IE	B
18	amino	I
19	acid	I
20	residues	I
21	1	I
22	-	I
23	322	I
24	(	O
25	and	O
26	,	O
27	therefore	O
28	lacks	O
29	the	O
30	deduced	O
31	transcriptional	O
32	activation	O
33	domain	O
34	),	O
35	fails	O
36	to	O
37	transactivate	O
38	the	O
39	EHV	B
40	-	I
41	1	I
42	tk	I
43	promoter	I
44	,	O
45	but	O
46	retains	O
47	the	O
48	ability	O
49	to	O
50	down	O
51	-	O
52	regulate	O
53	the	O
54	EHV	B
55	-	I
56	1	I
57	IE	I
58	promoter	I
59	.	O
1	At	O
2	least	O
3	some	O
4	of	O
5	the	O
6	difference	O
7	in	O
8	stability	O
9	of	O
10	the	O
11	two	O
12	kinds	O
13	of	O
14	complexes	O
15	was	O
16	due	O
17	to	O
18	the	O
19	fact	O
20	that	O
21	the	O
22	dissociation	O
23	rate	O
24	of	O
25	the	O
26	A	O
27	stem	O
28	substrate	O
29	from	O
30	the	O
31	protein	O
32	-	O
33	DNA	O
34	complexes	O
35	was	O
36	approximately	O
37	fourfold	O
38	faster	O
39	than	O
40	that	O
41	of	O
42	the	O
43	complete	O
44	TR	B
45	.	O
1	However	O
2	,	O
3	each	O
4	promoter	O
5	activated	O
6	by	O
7	IEP86	B
8	was	O
9	synergistically	O
10	affected	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	IEP72	B
16	.	O
1	Thus	O
2	,	O
3	YMIP	B
4	is	O
5	a	O
6	functional	O
7	homolog	O
8	of	O
9	RMIP	B
10	and	O
11	represents	O
12	a	O
13	new	O
14	component	O
15	of	O
16	the	O
17	yeast	O
18	mitochondrial	O
19	import	O
20	machinery	O
21	.	O
1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	kinetics	O
7	of	O
8	erythropoietin	B
9	(	O
10	EPO	B
11	)	O
12	production	O
13	and	O
14	address	O
15	the	O
16	pathogenesis	O
17	of	O
18	anemia	O
19	of	O
20	prematurity	O
21	,	O
22	we	O
23	measured	O
24	EPO	B
25	levels	O
26	in	O
27	infants	O
28	during	O
29	the	O
30	first	O
31	year	O
32	of	O
33	life	O
34	.	O
1	We	O
2	speculate	O
3	that	O
4	mast	O
5	cell	O
6	degranulation	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	the	O
12	pathogenesis	O
13	of	O
14	necrobiosis	O
15	by	O
16	altering	O
17	fibroblast	O
18	enzyme	O
19	activity	O
20	and	O
21	/	O
22	or	O
23	producing	O
24	prolonged	O
25	inflammatory	O
26	reactions	O
27	.	O
1	HupI	B
2	showed	O
3	strong	O
4	identity	O
5	to	O
6	rubredoxin	B
7	and	O
8	rubredoxin	B
9	-	I
10	like	I
11	proteins	I
12	from	O
13	many	O
14	other	O
15	bacteria	O
16	.	O
1	An	O
2	examination	O
3	was	O
4	performed	O
5	in	O
6	15	O
7	patients	O
8	who	O
9	had	O
10	developed	O
11	pronounced	O
12	osteomalacia	O
13	following	O
14	gastric	O
15	resection	O
16	.	O
1	Immunodepression	O
2	was	O
3	combined	O
4	with	O
5	the	O
6	increase	O
7	of	O
8	glucocorticoid	O
9	activity	O
10	of	O
11	adrenal	O
12	cortex	O
13	,	O
14	while	O
15	no	O
16	significant	O
17	changes	O
18	in	O
19	thyroid	O
20	hormones	O
21	were	O
22	registered	O
23	.	O
1	Tryptic	O
2	cleavage	O
3	and	O
4	peptide	O
5	sequence	O
6	analysis	O
7	demonstrated	O
8	that	O
9	the	O
10	98	O
11	-	O
12	kD	O
13	protein	O
14	is	O
15	identical	O
16	to	O
17	a	O
18	recently	O
19	cloned	O
20	protein	O
21	,	O
22	special	B
23	A	I
24	-	I
25	T	I
26	-	I
27	rich	I
28	binding	I
29	protein	I
30	1	I
31	(	O
32	SATB1	B
33	),	O
34	that	O
35	binds	O
36	selectively	O
37	to	O
38	nuclear	O
39	matrix	O
40	/	O
41	scaffold	O
42	-	O
43	associated	O
44	regions	O
45	of	O
46	DNA	O
47	(	O
48	MARs	O
49	/	O
50	SARs	O
51	).	O
1	A	O
2	single	O
3	NMSC	O
4	was	O
5	present	O
6	in	O
7	69	O
8	.	O
9	4	O
10	%,	O
11	two	O
12	in	O
13	16	O
14	%,	O
15	three	O
16	in	O
17	6	O
18	.	O
19	4	O
20	%,	O
21	four	O
22	in	O
23	3	O
24	.	O
25	5	O
26	%,	O
27	five	O
28	to	O
29	nine	O
30	in	O
31	4	O
32	.	O
33	2	O
34	%,	O
35	and	O
36	0	O
37	.	O
38	5	O
39	%	O
40	had	O
41	ten	O
42	or	O
43	more	O
44	.	O
1	CONCLUSION	O
2	:	O
3	Sonographic	O
4	angiography	O
5	has	O
6	a	O
7	possible	O
8	role	O
9	in	O
10	the	O
11	detection	O
12	of	O
13	small	O
14	nodules	O
15	in	O
16	patients	O
17	with	O
18	CRF	O
19	.	O
1	We	O
2	find	O
3	that	O
4	beta	B
5	II	I
6	PKC	I
7	phosphorylates	O
8	nuclear	B
9	envelope	I
10	lamin	I
11	B	I
12	at	O
13	10	O
14	-	O
15	20	O
16	times	O
17	the	O
18	rate	O
19	of	O
20	alpha	B
21	PKC	I
22	,	O
23	whereas	O
24	both	O
25	kinases	O
26	phosphorylate	O
27	soluble	B
28	lamin	I
29	B	I
30	at	O
31	similar	O
32	rates	O
33	.	O
1	Regulation	O
2	of	O
3	parathyroid	B
4	hormone	I
5	-	I
6	related	I
7	protein	I
8	(	O
9	PTHrP	B
10	)	O
11	gene	O
12	expression	O
13	.	O
1	We	O
2	conclude	O
3	that	O
4	c	B
5	-	I
6	Abl	I
7	activates	O
8	c	B
9	-	I
10	myc	I
11	transcription	O
12	indirectly	O
13	with	O
14	no	O
15	requirement	O
16	for	O
17	DNA	O
18	binding	O
19	by	O
20	c	B
21	-	I
22	Abl	I
23	.	O
1	The	O
2	Oct	B
3	-	I
4	2	I
5	glutamine	O
6	-	O
7	rich	O
8	and	O
9	proline	O
10	-	O
11	rich	O
12	activation	O
13	domains	O
14	can	O
15	synergize	O
16	with	O
17	each	O
18	other	O
19	or	O
20	duplicates	O
21	of	O
22	themselves	O
23	to	O
24	activate	O
25	transcription	O
26	.	O
1	Ariga	O
2	,	O
3	Biochem	O
4	.	O
1	Essential	O
2	features	O
3	of	O
4	this	O
5	model	O
6	are	O
7	bending	O
8	of	O
9	the	O
10	DNA	O
11	double	O
12	helix	O
13	and	O
14	contact	O
15	of	O
16	operator	O
17	sites	O
18	with	O
19	repressor	O
20	domains	O
21	bearing	O
22	sequence	O
23	homologies	O
24	with	O
25	the	O
26	helix	O
27	-	O
28	turn	O
29	-	O
30	helix	O
31	(	O
32	HTH	O
33	)	O
34	motifs	O
35	of	O
36	other	O
37	DNA	O
38	-	O
39	binding	O
40	proteins	O
41	.	O
1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	HrpJ2	B
15	.	O
1	The	O
2	binding	O
3	of	O
4	transcription	O
5	factor	O
6	AP	B
7	-	I
8	1	I
9	and	O
10	vitamin	B
11	D	I
12	receptor	I
13	(	O
14	VDR	B
15	)	O
16	to	O
17	the	O
18	composite	O
19	AP	B
20	-	I
21	1	I
22	plus	I
23	vitamin	I
24	-	I
25	D	I
26	-	I
27	responsive	I
28	promoter	I
29	region	O
30	(	O
31	AP	B
32	-	I
33	1	I
34	+	I
35	VDRE	I
36	)	O
37	of	O
38	the	O
39	human	B
40	osteocalcin	I
41	gene	I
42	was	O
43	characterized	O
44	in	O
45	osteocalcin	B
46	-	O
47	producing	O
48	(	O
49	MG	O
50	-	O
51	63	O
52	)	O
53	and	O
54	non	O
55	-	O
56	producing	O
57	(	O
58	U2	O
59	-	O
60	Os	O
61	,	O
62	SaOs	O
63	-	O
64	2	O
65	)	O
66	human	O
67	osteosarcoma	O
68	cell	O
69	lines	O
70	.	O
1	Use	O
2	of	O
3	Medi	O
4	-	O
5	Jector	O
6	EZ	O
7	dermojet	O
8	for	O
9	anesthesia	O
10	in	O
11	minor	O
12	surgery	O
1	Smoking	O
2	history	O
3	and	O
4	awake	O
5	oxygen	O
6	saturation	O
7	(	O
8	SaO2	O
9	)	O
10	was	O
11	recorded	O
12	in	O
13	all	O
14	of	O
15	them	O
16	.	O
1	(	O
2	LH	B
3	P	O
4	<	O
5	0	O
6	.	O
7	05	O
8	,	O
9	LH	B
10	/	O
11	FSH	B
12	P	O
13	<	O
14	0	O
15	.	O
16	01	O
17	).	O
1	We	O
2	describe	O
3	49	O
4	cases	O
5	with	O
6	papillary	O
7	tumor	O
8	<	O
9	1	O
10	cm	O
11	.	O
1	The	O
2	consensus	O
3	gene	O
4	order	O
5	deduced	O
6	by	O
7	combining	O
8	data	O
9	from	O
10	both	O
11	crosses	O
12	is	O
13	D2Mit1	B
14	-(	O
15	Dbh	B
16	,	O
17	Notch1	B
18	)-(	O
19	Col5a1	B
20	,	O
21	Rxra	B
22	)-	O
23	Spna2	B
24	-	O
25	Ab	B
26	l	I
27	-(	O
28	Ak1	B
29	,	O
30	Fpgs	B
31	)-	O
32	(	O
33	Grp78	B
34	,	O
35	Pbx3	B
36	)-(	O
37	Epb7	B
38	.	I
39	2	I
40	,	I
41	Hc	I
42	,	I
43	Gsn	I
44	)-	O
45	Acra	B
46	.	O
1	The	O
2	high	O
3	level	O
4	of	O
5	transformation	O
6	-	O
7	associated	O
8	deletions	O
9	in	O
10	the	O
11	human	O
12	YACs	O
13	was	O
14	reduced	O
15	over	O
16	10	O
17	-	O
18	fold	O
19	when	O
20	the	O
21	host	O
22	was	O
23	a	O
24	recombination	O
25	-	O
26	deficient	O
27	strain	O
28	deleted	O
29	for	O
30	the	O
31	RAD52	B
32	gene	I
33	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	megabase	O
6	region	O
7	surrounding	O
8	the	O
9	dagA	B
10	locus	I
11	was	O
12	mapped	O
13	.	O
1	SECONDARY	O
2	OUTCOME	O
3	MEASURE	O
4	--	O
5	Double	O
6	-	O
7	blind	O
8	caffeine	O
9	-	O
10	withdrawal	O
11	evaluation	O
12	.	O
1	We	O
2	present	O
3	evidence	O
4	that	O
5	DNA	B
6	polymerase	I
7	delta	I
8	of	I
9	Saccharomyces	I
10	cerevisiae	I
11	,	O
12	an	O
13	enzyme	O
14	that	O
15	is	O
16	essential	O
17	for	O
18	viability	O
19	and	O
20	chromosomal	O
21	replication	O
22	,	O
23	is	O
24	also	O
25	required	O
26	for	O
27	base	O
28	excision	O
29	repair	O
30	of	O
31	exogenous	O
32	DNA	O
33	methylation	O
34	damage	O
35	.	O
1	Mutagenesis	O
2	of	O
3	each	O
4	NRF	B
5	-	I
6	1	I
7	motif	I
8	in	O
9	the	O
10	ALAS	B
11	promoter	I
12	gave	O
13	substantially	O
14	lowered	O
15	levels	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	expression	O
20	,	O
21	whereas	O
22	mutagenesis	O
23	of	O
24	both	O
25	NRF	B
26	-	I
27	1	I
28	motifs	I
29	resulted	O
30	in	O
31	the	O
32	almost	O
33	complete	O
34	loss	O
35	of	O
36	expression	O
37	.	O
1	DNase	B
2	I	I
3	footprinting	O
4	analysis	O
5	indicated	O
6	that	O
7	DREF	B
8	binds	O
9	to	O
10	the	O
11	24	O
12	-	O
13	bp	O
14	DRE	O
15	region	O
16	of	O
17	the	O
18	DNA	B
19	polymerase	I
20	alpha	I
21	gene	I
22	in	O
23	which	O
24	8	O
25	-	O
26	bp	O
27	palindromic	O
28	sequences	O
29	are	O
30	centered	O
31	.	O
1	Novel	O
2	8	O
3	-	O
4	base	O
5	pair	O
6	sequence	O
7	(	O
8	Drosophila	O
9	DNA	O
10	replication	O
11	-	O
12	related	O
13	element	O
14	)	O
15	and	O
16	specific	O
17	binding	O
18	factor	O
19	involved	O
20	in	O
21	the	O
22	expression	O
23	of	O
24	Drosophila	O
25	genes	O
26	for	O
27	DNA	B
28	polymerase	I
29	alpha	I
30	and	O
31	proliferating	B
32	cell	I
33	nuclear	I
34	antigen	I
35	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	microsatellite	O
6	repeat	O
7	polymorphism	O
8	with	O
9	a	O
10	heterozygosity	O
11	of	O
12	71	O
13	%	O
14	at	O
15	the	O
16	RET	B
17	locus	I
18	and	O
19	a	O
20	restriction	O
21	fragment	O
22	length	O
23	polymorphism	O
24	with	O
25	a	O
26	heterozygosity	O
27	of	O
28	42	O
29	%	O
30	detected	O
31	by	O
32	a	O
33	lambda	O
34	clone	O
35	from	O
36	the	O
37	D10S94	B
38	locus	I
39	have	O
40	been	O
41	developed	O
42	for	O
43	high	O
44	-	O
45	resolution	O
46	genetic	O
47	linkage	O
48	mapping	O
49	and	O
50	predictive	O
51	diagnostic	O
52	testing	O
53	.	O
1	However	O
2	,	O
3	tyrA	B
4	can	O
5	be	O
6	expressed	O
7	efficiently	O
8	from	O
9	an	O
10	internal	O
11	promoter	O
12	which	O
13	appears	O
14	to	O
15	lie	O
16	within	O
17	the	O
18	3	O
19	'	O
20	portion	O
21	of	O
22	aroF	B
23	.	O
1	Double	O
2	-	O
3	staining	O
4	confirmed	O
5	that	O
6	there	O
7	were	O
8	separate	O
9	populations	O
10	of	O
11	CD68	B
12	-	O
13	positive	O
14	macrophages	O
15	and	O
16	XIIIa	B
17	-	O
18	positive	O
19	dendrocytes	O
20	.	O
1	The	O
2	concentrations	O
3	of	O
4	plasma	O
5	ACTH	B
6	and	O
7	cortisol	O
8	increased	O
9	by	O
10	40	O
11	%	O
12	and	O
13	60	O
14	%	O
15	after	O
16	MPTP	O
17	treatment	O
18	,	O
19	respectively	O
20	.	O
1	Clinical	O
2	aspects	O
3	of	O
4	early	O
5	increase	O
6	in	O
7	serum	O
8	gamma	B
9	-	I
10	glutamyl	I
11	transferase	I
12	in	O
13	cerebral	O
14	infarction	O
15	.	O
1	Anti	B
2	-	I
3	B	I
4	.	I
5	burgdorferi	I
6	,	O
7	anti	B
8	-	I
9	B	I
10	.	I
11	turicatae	I
12	and	O
13	anti	B
14	-	I
15	B	I
16	.	I
17	parkeri	I
18	antibodies	I
19	,	O
20	tested	O
21	by	O
22	the	O
23	indirect	O
24	immunofluorescent	O
25	assay	O
26	(	O
27	IFA	O
28	),	O
29	were	O
30	detected	O
31	in	O
32	10	O
33	.	O
34	8	O
35	,	O
36	16	O
37	.	O
38	1	O
39	and	O
40	8	O
41	.	O
42	2	O
43	%	O
44	of	O
45	the	O
46	serum	O
47	samples	O
48	tested	O
49	,	O
50	and	O
51	confirmed	O
52	by	O
53	IFA	O
54	-	O
55	ABS	O
56	in	O
57	1	O
58	.	O
59	3	O
60	,	O
61	1	O
62	.	O
63	3	O
64	and	O
65	1	O
66	.	O
67	0	O
68	%,	O
69	respectively	O
70	.	O
1	Comparative	O
2	analysis	O
3	with	O
4	an	O
5	antiandrogen	O
6	niftolid	O
7	and	O
8	synthetic	B
9	GnRH	I
10	was	O
11	carried	O
12	out	O
13	in	O
14	22	O
15	normal	O
16	subjects	O
17	,	O
18	14	O
19	patients	O
20	with	O
21	primary	O
22	and	O
23	20	O
24	ones	O
25	with	O
26	secondary	O
27	hypogonadism	O
28	,	O
29	and	O
30	in	O
31	5	O
32	patients	O
33	with	O
34	clinical	O
35	signs	O
36	of	O
37	gonadal	O
38	insufficiency	O
39	and	O
40	obscure	O
41	diagnosis	O
42	in	O
43	order	O
44	to	O
45	elucidate	O
46	the	O
47	pituitary	B
48	gonadotropin	I
49	reserves	O
50	.	O
1	This	O
2	indicates	O
3	that	O
4	the	O
5	mechanism	O
6	by	O
7	which	O
8	CX	O
9	blocks	O
10	rapid	O
11	degradation	O
12	of	O
13	tubulin	B
14	mRNA	I
15	in	O
16	vivo	O
17	is	O
18	not	O
19	simply	O
20	by	O
21	preventing	O
22	its	O
23	translation	O
24	and	O
25	suggests	O
26	the	O
27	involvement	O
28	of	O
29	an	O
30	altered	O
31	trans	O
32	-	O
33	factor	O
34	.	O
1	The	O
2	sequence	O
3	has	O
4	a	O
5	1092	O
6	-	O
7	bp	O
8	open	O
9	reading	O
10	frame	O
11	encoding	O
12	a	O
13	protein	O
14	of	O
15	364	O
16	amino	O
17	acids	O
18	.	O
1	Western	O
2	blotting	O
3	(	O
4	immunoblotting	O
5	)	O
6	with	O
7	an	O
8	antiserum	O
9	to	O
10	a	O
11	partial	O
12	SOD	B
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	revealed	O
18	two	O
19	proteins	O
20	with	O
21	estimated	O
22	molecular	O
23	masses	O
24	of	O
25	19	O
26	and	O
27	29	O
28	kDa	O
29	.	O
1	Members	O
2	of	O
3	the	O
4	myocyte	B
5	-	I
6	specific	I
7	enhancer	I
8	-	I
9	binding	I
10	factor	I
11	2	I
12	(	O
13	MEF2	B
14	)	O
15	family	O
16	of	O
17	transcription	O
18	factors	O
19	bind	O
20	a	O
21	conserved	O
22	A	O
23	/	O
24	T	O
25	-	O
26	rich	O
27	sequence	O
28	in	O
29	the	O
30	control	O
31	regions	O
32	of	O
33	numerous	O
34	muscle	O
35	-	O
36	specific	O
37	genes	O
38	.	O
1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	LBP	B
7	-	I
8	1	I
9	represses	O
10	HIV	O
11	-	O
12	1	O
13	transcription	O
14	by	O
15	inhibiting	O
16	the	O
17	binding	O
18	of	O
19	TFIID	B
20	to	O
21	the	O
22	TATA	O
23	box	O
24	.	O
1	Viral	O
2	genomic	O
3	RNA	O
4	for	O
5	these	O
6	reactions	O
7	was	O
8	obtained	O
9	directly	O
10	from	O
11	fecal	O
12	specimens	O
13	of	O
14	infected	O
15	infant	O
16	rats	O
17	.	O
1	Tumor	B
2	necrosis	I
3	factor	I
4	-	I
5	alpha	I
6	(	O
7	TNF	B
8	alpha	I
9	)	O
10	is	O
11	one	O
12	of	O
13	several	O
14	autocrine	O
15	/	O
16	paracrine	O
17	factors	O
18	known	O
19	to	O
20	exert	O
21	potent	O
22	inhibitory	O
23	effects	O
24	on	O
25	bone	O
26	.	O
1	Furthermore	O
2	,	O
3	in	O
4	vitro	O
5	decay	O
6	reaction	O
7	mixtures	O
8	supplemented	O
9	with	O
10	the	O
11	20	O
12	-	O
13	nt	O
14	sense	O
15	RNA	O
16	transcript	O
17	resulted	O
18	in	O
19	stabilization	O
20	of	O
21	R2	B
22	message	I
23	.	O
1	Sterol	O
2	analysis	O
3	of	O
4	the	O
5	disrupted	O
6	mutant	O
7	demonstrated	O
8	the	O
9	accumulation	O
10	of	O
11	ignosterol	O
12	,	O
13	indicating	O
14	a	O
15	loss	O
16	of	O
17	Erg24p	B
18	activity	O
19	.	O
1	The	O
2	alpha	O
3	7A	O
4	form	O
5	RNA	O
6	contains	O
7	an	O
8	additional	O
9	113	O
10	nucleotides	O
11	compared	O
12	to	O
13	the	O
14	B	O
15	form	O
16	,	O
17	and	O
18	a	O
19	common	O
20	coding	O
21	region	O
22	in	O
23	the	O
24	A	O
25	and	O
26	B	O
27	form	O
28	RNAs	O
29	is	O
30	used	O
31	in	O
32	alternate	O
33	reading	O
34	frames	O
35	.	O
1	Serial	O
2	levels	O
3	of	O
4	troponin	B
5	T	I
6	and	O
7	the	O
8	activity	O
9	of	O
10	CK	B
11	-	I
12	MB	I
13	were	O
14	measured	O
15	6	O
16	,	O
17	12	O
18	,	O
19	24	O
20	and	O
21	48	O
22	h	O
23	after	O
24	aortic	O
25	unclamping	O
26	.	O
1	The	O
2	c	B
3	-	I
4	myc	I
5	and	O
6	skeletal	B
7	alpha	I
8	-	I
9	actin	I
10	gene	I
11	promoters	I
12	contain	O
13	YY1	B
14	binding	I
15	sites	I
16	thought	O
17	to	O
18	act	O
19	either	O
20	as	O
21	positive	O
22	or	O
23	negative	O
24	cis	O
25	-	O
26	acting	O
27	elements	O
28	.	O
1	Specifically	O
2	,	O
3	by	O
4	oligonucleotide	O
5	-	O
6	directed	O
7	site	O
8	-	O
9	specific	O
10	mutagenesis	O
11	,	O
12	we	O
13	demonstrate	O
14	that	O
15	of	O
16	10	O
17	cysteine	O
18	residues	O
19	in	O
20	the	O
21	ORF4	O
22	polypeptide	O
23	,	O
24	only	O
25	C	O
26	-	O
27	421	O
28	and	O
29	C	O
30	-	O
31	426	O
32	are	O
33	essential	O
34	for	O
35	transactivator	O
36	function	O
37	and	O
38	suggest	O
39	that	O
40	these	O
41	cysteine	O
42	residues	O
43	may	O
44	participate	O
45	in	O
46	critical	O
47	protein	O
48	-	O
49	protein	O
50	interactions	O
51	rather	O
52	than	O
53	protein	O
54	-	O
55	nucleic	O
56	acid	O
57	interactions	O
58	to	O
59	mediate	O
60	ORF4	O
61	inducibility	O
62	.	O
1	Genetic	O
2	and	O
3	phenotypic	O
4	analysis	O
5	indicates	O
6	that	O
7	NHP6A	B
8	and	O
9	NHP6B	B
10	function	O
11	downstream	O
12	of	O
13	SLT2	B
14	.	O
1	To	O
2	achieve	O
3	complete	O
4	dissection	O
5	of	O
6	the	O
7	anterior	O
8	vitreous	O
9	,	O
10	we	O
11	remove	O
12	even	O
13	a	O
14	clear	O
15	lens	O
16	during	O
17	the	O
18	first	O
19	surgical	O
20	intervention	O
21	in	O
22	selected	O
23	cases	O
24	.	O
1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	alternative	O
7	sigma	B
8	factor	I
9	,	O
10	RpoN	B
11	,	O
12	in	O
13	Rhodobacter	O
14	capsulatus	O
15	;	O
16	physiological	O
17	relevance	O
18	of	O
19	an	O
20	autoactivated	O
21	nifU2	B
22	-	O
23	rpoN	B
24	superoperon	O
25	.	O
1	The	O
2	colony	B
3	-	I
4	stimulating	I
5	factors	I
6	(	O
7	CSFs	B
8	)	O
9	principally	O
10	involved	O
11	in	O
12	the	O
13	production	O
14	of	O
15	neutrophils	O
16	and	O
17	monocytes	O
18	are	O
19	granulocyte	B
20	CSF	I
21	,	O
22	granulocyte	B
23	-	I
24	macrophage	I
25	CSF	I
26	,	O
27	macrophage	B
28	CSF	I
29	,	O
30	and	O
31	interleukin	B
32	3	I
33	(	O
34	sometimes	O
35	called	O
36	multi	B
37	-	I
38	CSF	I
39	).	O
1	With	O
2	a	O
3	cutoff	O
4	level	O
5	for	O
6	TSST	B
7	-	I
8	1	I
9	of	O
10	less	O
11	than	O
12	100	O
13	pg	O
14	/	O
15	ml	O
16	,	O
17	28	O
18	samples	O
19	obtained	O
20	from	O
21	12	O
22	patients	O
23	were	O
24	positive	O
25	for	O
26	TSST	B
27	-	I
28	1	I
29	.	O
1	Mapping	O
2	of	O
3	intracellular	O
4	localization	O
5	domains	O
6	and	O
7	evidence	O
8	for	O
9	colocalization	O
10	interactions	O
11	between	O
12	the	O
13	IE110	B
14	and	O
15	IE175	B
16	nuclear	O
17	transactivator	O
18	proteins	O
19	of	O
20	herpes	O
21	simplex	O
22	virus	O
23	.	O
1	Mitochondrial	B
2	Mas70p	I
3	signal	I
4	anchor	I
5	sequence	I
6	.	O
1	Retrogradely	O
2	labelled	O
3	neurons	O
4	significantly	O
5	prevailed	O
6	in	O
7	the	O
8	ipsilateral	O
9	substantia	O
10	nigra	O
11	pars	O
12	compacta	O
13	.	O
1	Response	O
2	to	O
3	treatment	O
4	was	O
5	better	O
6	in	O
7	patients	O
8	with	O
9	less	O
10	pretreatment	O
11	(	O
12	one	O
13	-	O
14	two	O
15	prior	O
16	treatments	O
17	)	O
18	than	O
19	in	O
20	heavily	O
21	pretreated	O
22	ones	O
23	(	O
24	more	O
25	than	O
26	three	O
27	)	O
28	and	O
29	this	O
30	relation	O
31	was	O
32	found	O
33	to	O
34	be	O
35	statistically	O
36	significant	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	05	O
43	).	O
1	Northern	O
2	-	O
3	blot	O
4	analysis	O
5	of	O
6	mRNA	O
7	from	O
8	Avicel	O
9	-	O
10	grown	O
11	N	O
12	.	O
13	patriciarum	O
14	showed	O
15	that	O
16	xynB	B
17	hybridized	O
18	to	O
19	a	O
20	3	O
21	.	O
22	4	O
23	kb	O
24	mRNA	O
25	species	O
26	.	O
1	The	O
2	high	O
3	degree	O
4	of	O
5	conservation	O
6	between	O
7	NQO2	B
8	and	O
9	NQO1	B
10	gene	I
11	organization	O
12	and	O
13	sequence	O
14	confirmed	O
15	that	O
16	NQO2	B
17	gene	I
18	encodes	O
19	for	O
20	a	O
21	second	O
22	member	O
23	of	O
24	the	O
25	NQO	B
26	gene	I
27	family	I
28	in	O
29	human	O
30	.	O
1	The	O
2	efficacy	O
3	of	O
4	a	O
5	Propionibacterium	O
6	acnes	O
7	product	O
8	for	O
9	treatment	O
10	of	O
11	coliform	O
12	mastitis	O
13	was	O
14	evaluated	O
15	following	O
16	intramammary	O
17	infusion	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O
1	Alternative	O
2	splicing	O
3	of	O
4	RNA	O
5	transcripts	O
6	encoded	O
7	by	O
8	the	O
9	murine	O
10	p105	B
11	NF	I
12	-	I
13	kappa	I
14	B	I
15	gene	O
16	generates	O
17	I	B
18	kappa	I
19	B	I
20	gamma	I
21	isoforms	I
22	with	O
23	different	O
24	inhibitory	O
25	activities	O
26	.	O
1	The	O
2	baroreflex	O
3	latency	O
4	(	O
5	from	O
6	the	O
7	ECG	O
8	R	O
9	-	O
10	wave	O
11	to	O
12	the	O
13	integrated	O
14	MSNA	O
15	burst	O
16	peak	O
17	)	O
18	was	O
19	constant	O
20	at	O
21	approximately	O
22	1	O
23	.	O
24	20	O
25	s	O
26	during	O
27	sleep	O
28	,	O
29	suggesting	O
30	that	O
31	pulse	O
32	-	O
33	synchronicity	O
34	was	O
35	maintained	O
36	.	O
1	We	O
2	have	O
3	used	O
4	a	O
5	full	O
6	-	O
7	length	O
8	cDNA	O
9	clone	O
10	of	O
11	a	O
12	mouse	O
13	hepatitis	O
14	virus	O
15	strain	O
16	A59	O
17	defective	O
18	interfering	O
19	(	O
20	DI	O
21	)	O
22	RNA	O
23	,	O
24	pMIDI	B
25	-	I
26	C	I
27	,	O
28	and	O
29	cassette	O
30	mutagenesis	O
31	to	O
32	study	O
33	the	O
34	mechanism	O
35	of	O
36	coronavirus	O
37	subgenomic	O
38	mRNA	O
39	synthesis	O
40	.	O
1	A	O
2	partial	O
3	cDNA	O
4	sequence	O
5	indicated	O
6	that	O
7	the	O
8	T	B
9	lymphocyte	I
10	early	I
11	-	I
12	activation	I
13	gene	I
14	(	O
15	Tea	B
16	)	O
17	encodes	O
18	a	O
19	protein	O
20	related	O
21	to	O
22	the	O
23	dual	O
24	-	O
25	function	O
26	ecotropic	B
27	retrovirus	I
28	receptor	I
29	/	O
30	cationic	B
31	amino	I
32	acid	I
33	transporter	I
34	(	O
35	ecoR	B
36	/	O
37	CAT1	B
38	),	O
39	and	O
40	RNA	O
41	blots	O
42	suggested	O
43	highest	O
44	Tea	B
45	expression	O
46	in	O
47	T	O
48	lymphocytes	O
49	and	O
50	liver	O
51	(	O
52	MacLeod	O
53	,	O
54	C	O
55	.	O
56	L	O
57	.,	O
58	Finley	O
59	,	O
60	K	O
61	.,	O
62	Kakuda	O
63	,	O
64	D	O
65	.	O
1	Deletion	O
2	analysis	O
3	of	O
4	the	O
5	ICL1	B
6	promoter	I
7	led	O
8	to	O
9	the	O
10	identification	O
11	of	O
12	an	O
13	upstream	O
14	activating	O
15	sequence	O
16	element	O
17	,	O
18	UASICL1	O
19	(	O
20	5	O
21	'	O
22	CATTCATCCG	O
23	3	O
24	'),	O
25	necessary	O
26	and	O
27	sufficient	O
28	for	O
29	conferring	O
30	carbon	O
31	source	O
32	-	O
33	dependent	O
34	regulation	O
35	on	O
36	a	O
37	heterologous	O
38	reporter	O
39	gene	O
40	.	O
1	PRL	B
2	-	I
3	1	I
4	is	O
5	able	O
6	to	O
7	dephosphorylate	O
8	phosphotyrosine	O
9	substrates	O
10	,	O
11	and	O
12	mutation	O
13	of	O
14	the	O
15	active	O
16	-	O
17	site	O
18	cysteine	O
19	residue	O
20	abolishes	O
21	this	O
22	activity	O
23	.	O
1	50	O
2	kDa	O
3	and	O
4	130	O
5	-	O
6	170	O
7	kDa	O
8	were	O
9	detected	O
10	.	O
1	H	O
2	-	O
3	7	O
4	,	O
5	which	O
6	specifically	O
7	,	O
8	although	O
9	weakly	O
10	,	O
11	inhibited	O
12	PKC	B
13	activation	O
14	,	O
15	had	O
16	no	O
17	effect	O
18	on	O
19	tyrosine	O
20	phosphorylation	O
21	and	O
22	PtdIns	O
23	(	O
24	3	O
25	,	O
26	4	O
27	)	O
28	P2	O
29	production	O
30	.	O
1	In	O
2	the	O
3	case	O
4	of	O
5	congenital	O
6	protein	B
7	C	I
8	deficiency	O
9	,	O
10	vitamin	O
11	K	O
12	antagonists	O
13	must	O
14	be	O
15	started	O
16	cautiously	O
17	due	O
18	to	O
19	the	O
20	risk	O
21	of	O
22	skin	O
23	necrosis	O
24	.	O
1	On	O
2	physical	O
3	examination	O
4	a	O
5	mild	O
6	symmetrical	O
7	polyarthritis	O
8	of	O
9	small	O
10	and	O
11	large	O
12	joints	O
13	was	O
14	seen	O
15	.	O
1	We	O
2	conclude	O
3	that	O
4	the	O
5	SIMV	O
6	is	O
7	useful	O
8	in	O
9	weaning	O
10	neonates	O
11	from	O
12	the	O
13	ventilator	O
14	.	O
1	Simultaneous	O
2	,	O
3	bilateral	O
4	and	O
5	permanent	O
6	ventilation	O
7	with	O
8	a	O
9	diaphragm	O
10	pacing	O
11	in	O
12	childhood	O
13	:	O
14	the	O
15	implantation	O
16	technique	O
17	and	O
18	indications	O
1	Subunit	O
2	composition	O
3	and	O
4	domain	O
5	structure	O
6	of	O
7	the	O
8	Spo0A	B
9	sporulation	I
10	transcription	I
11	factor	I
12	of	I
13	Bacillus	I
14	subtilis	I
15	.	O
1	Electrophoretic	O
2	mobility	O
3	shift	O
4	analysis	O
5	indicates	O
6	that	O
7	NF	B
8	-	I
9	IL	I
10	-	I
11	6	I
12	,	O
13	as	O
14	well	O
15	as	O
16	other	O
17	related	O
18	members	O
19	of	O
20	this	O
21	family	O
22	,	O
23	bind	O
24	specifically	O
25	to	O
26	the	O
27	NF	B
28	-	I
29	IL	I
30	-	I
31	6	I
32	site	O
33	in	O
34	the	O
35	IL	B
36	-	I
37	8	I
38	promoter	I
39	.	O
1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	corresponding	O
7	cDNAs	O
8	indicates	O
9	that	O
10	,	O
11	via	O
12	alternative	O
13	splicing	O
14	,	O
15	the	O
16	rearranged	O
17	gene	O
18	codes	O
19	for	O
20	two	O
21	proteins	O
22	of	O
23	84	O
24	and	O
25	85	O
26	kD	O
27	(	O
28	p84	B
29	/	I
30	85	I
31	)	O
32	which	O
33	retain	O
34	the	O
35	DNA	O
36	-	O
37	binding	O
38	rel	B
39	domain	I
40	and	O
41	the	O
42	first	O
43	five	O
44	ankyrin	B
45	repeats	O
46	,	O
47	but	O
48	have	O
49	lost	O
50	their	O
51	carboxy	O
52	-	O
53	terminus	O
54	including	O
55	the	O
56	seventh	O
57	ankyrin	B
58	repeat	O
59	.	O
1	Open	O
2	reading	O
3	frames	O
4	in	O
5	a	O
6	4556	O
7	nucleotide	O
8	sequence	O
9	within	O
10	MDV	B
11	-	I
12	1	I
13	BamHI	I
14	-	I
15	D	I
16	DNA	I
17	fragment	I
18	:	O
19	evidence	O
20	for	O
21	splicing	O
22	of	O
23	mRNA	O
24	from	O
25	a	O
26	new	O
27	viral	O
28	glycoprotein	O
29	gene	O
30	.	O
1	SIN	O
2	-	O
3	1	O
4	had	O
5	no	O
6	influence	O
7	on	O
8	either	O
9	the	O
10	ischemic	O
11	parameters	O
12	in	O
13	the	O
14	surface	O
15	electrocardiogram	O
16	(	O
17	ECG	O
18	)	O
19	or	O
20	the	O
21	intracoronary	O
22	ECG	O
23	.	O
1	The	O
2	absence	O
3	of	O
4	H4PteGlun	O
5	bound	O
6	to	O
7	the	O
8	T	B
9	protein	I
10	in	O
11	our	O
12	experimental	O
13	conditions	O
14	demonstrates	O
15	that	O
16	H4PteGlun	O
17	is	O
18	not	O
19	covalently	O
20	linked	O
21	to	O
22	the	O
23	T	B
24	protein	I
25	.	O
1	GGS1	B
2	is	O
3	the	O
4	same	O
5	gene	O
6	as	O
7	TPS1	B
8	which	O
9	was	O
10	identified	O
11	as	O
12	encoding	O
13	a	O
14	subunit	O
15	of	O
16	the	O
17	trehalose	B
18	-	I
19	6	I
20	-	I
21	phosphate	I
22	synthase	I
23	/	I
24	phosphatase	I
25	complex	I
26	and	O
27	it	O
28	is	O
29	allelic	O
30	to	O
31	the	O
32	fdp1	B
33	,	O
34	byp1	B
35	,	O
36	glc6	B
37	and	O
38	cif1	O
39	mutations	O
40	.	O
1	Stroop	O
2	interference	O
3	:	O
4	aging	O
5	effects	O
6	assessed	O
7	with	O
8	the	O
9	Stroop	O
10	Color	O
11	-	O
12	Word	O
13	Test	O
14	.	O
1	Genomic	O
2	Southern	O
3	blot	O
4	analysis	O
5	of	O
6	rat	B
7	EFIA	I
8	(	O
9	gene	O
10	encoding	O
11	enhancer	B
12	factor	I
13	I	I
14	subunit	I
15	A	I
16	)	O
17	reveals	O
18	a	O
19	complex	O
20	band	O
21	pattern	O
22	when	O
23	cDNA	O
24	subfragment	O
25	probes	O
26	are	O
27	used	O
28	.	O
1	There	O
2	was	O
3	no	O
4	apparent	O
5	effect	O
6	of	O
7	growth	O
8	temperature	O
9	on	O
10	the	O
11	steady	O
12	-	O
13	state	O
14	levels	O
15	of	O
16	fad7	B
17	mRNA	I
18	in	O
19	wild	O
20	type	O
21	plants	O
22	.	O
1	The	O
2	major	O
3	myosin	B
4	-	I
5	binding	I
6	domain	I
7	of	O
8	skeletal	B
9	muscle	I
10	MyBP	I
11	-	I
12	C	I
13	(	O
14	C	B
15	protein	I
16	)	O
17	resides	O
18	in	O
19	the	O
20	COOH	O
21	-	O
22	terminal	O
23	,	O
24	immunoglobulin	B
25	C2	I
26	motif	I
27	.	O
1	By	O
2	using	O
3	total	O
4	-	O
5	protein	O
6	extracts	O
7	from	O
8	mycelia	O
9	grown	O
10	under	O
11	penicillin	O
12	producing	O
13	conditions	O
14	we	O
15	have	O
16	detected	O
17	a	O
18	DNA	O
19	-	O
20	binding	O
21	activity	O
22	that	O
23	specifically	O
24	shifts	O
25	a	O
26	promoter	O
27	fragment	O
28	located	O
29	between	O
30	-	O
31	654	O
32	and	O
33	-	O
34	455	O
35	(	O
36	relative	O
37	to	O
38	IPNS	B
39	tsp	I
40	).	O
1	The	O
2	bioavailability	O
3	of	O
4	etodolac	O
5	from	O
6	capsules	O
7	exposed	O
8	to	O
9	stressed	O
10	conditions	O
11	was	O
12	compared	O
13	in	O
14	both	O
15	dogs	O
16	and	O
17	humans	O
18	to	O
19	capsules	O
20	stored	O
21	at	O
22	RT	O
23	conditions	O
24	.	O
1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	the	O
7	36K	O
8	protein	O
9	and	O
10	known	O
11	structures	O
12	of	O
13	proteins	O
14	.	O
1	Four	O
2	forms	O
3	of	O
4	salmonellosis	O
5	were	O
6	recognised	O
7	in	O
8	feedlots	O
9	and	O
10	during	O
11	transport	O
12	by	O
13	sea	O
14	:	O
15	septicaemic	O
16	,	O
17	and	O
18	acute	O
19	,	O
20	subacute	O
21	and	O
22	chronic	O
23	enteric	O
24	.	O
1	These	O
2	cells	O
3	produce	O
4	a	O
5	low	O
6	level	O
7	of	O
8	IL	B
9	-	I
10	5	I
11	when	O
12	stimulated	O
13	with	O
14	PMA	O
15	alone	O
16	;	O
17	however	O
18	,	O
19	N6	O
20	,	O
21	O2	O
22	-	O
23	dibutyryl	O
24	cAMP	O
25	(	O
26	Bt2cAMP	O
27	),	O
28	in	O
29	combination	O
30	with	O
31	PMA	O
32	,	O
33	augmented	O
34	by	O
35	more	O
36	than	O
37	tenfold	O
38	the	O
39	IL	B
40	-	I
41	5	I
42	production	O
43	at	O
44	the	O
45	mRNA	O
46	and	O
47	the	O
48	protein	O
49	levels	O
50	.	O
1	Partial	O
2	engorgement	O
3	was	O
4	higher	O
5	in	O
6	the	O
7	treatments	O
8	.	O
1	Strains	O
2	bearing	O
3	the	O
4	drs2	B
5	mutation	I
6	process	O
7	the	O
8	20S	B
9	precursor	I
10	of	O
11	the	O
12	mature	B
13	18S	I
14	rRNA	I
15	slowly	O
16	and	O
17	are	O
18	deficient	O
19	in	O
20	40S	B
21	ribosomal	I
22	subunits	I
23	.	O
1	One	O
2	complex	O
3	most	O
4	likely	O
5	contained	O
6	Sp1	B
7	,	O
8	and	O
9	another	O
10	complex	O
11	showed	O
12	S	O
13	-	O
14	phase	O
15	-	O
16	specific	O
17	binding	O
18	,	O
19	suggesting	O
20	a	O
21	direct	O
22	role	O
23	in	O
24	the	O
25	cell	O
26	-	O
27	cycle	O
28	-	O
29	dependent	O
30	R1	B
31	gene	I
32	expression	O
33	.	O
1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O
1	A	O
2	cAMP	O
3	response	O
4	element	O
5	(	O
6	CRE	O
7	)	O
8	consensus	O
9	signal	O
10	was	O
11	identified	O
12	in	O
13	the	O
14	5	O
15	'-	O
16	noncoding	O
17	region	O
18	.	O
19	cAMP	O
20	regulates	O
21	the	O
22	expression	O
23	of	O
24	Kv1	B
25	.	I
26	5	I
27	gene	I
28	in	O
29	a	O
30	cell	O
31	-	O
32	specific	O
33	manner	O
34	.	O
1	A	O
2	number	O
3	of	O
4	serological	O
5	tests	O
6	measuring	O
7	the	O
8	presence	O
9	of	O
10	Helicobacter	O
11	pylori	O
12	-	O
13	specific	O
14	serum	O
15	immunoglobulin	B
16	G	I
17	(	O
18	IgG	B
19	)	O
20	are	O
21	now	O
22	commercially	O
23	available	O
24	.	O
1	CONCLUSIONS	O
2	:	O
3	In	O
4	our	O
5	patients	O
6	and	O
7	within	O
8	the	O
9	range	O
10	of	O
11	treatment	O
12	variables	O
13	studied	O
14	,	O
15	age	O
16	,	O
17	Karnofsky	O
18	index	O
19	,	O
20	and	O
21	graft	O
22	-	O
23	versus	O
24	-	O
25	host	O
26	disease	O
27	are	O
28	the	O
29	most	O
30	important	O
31	factors	O
32	related	O
33	with	O
34	early	O
35	mortality	O
36	.	O
1	By	O
2	using	O
3	the	O
4	full	O
5	-	O
6	length	O
7	cytoplasmic	O
8	domain	O
9	and	O
10	mutants	O
11	with	O
12	progressive	O
13	carboxy	O
14	-	O
15	terminal	O
16	deletions	O
17	,	O
18	internal	O
19	deletions	O
20	,	O
21	or	O
22	point	O
23	mutations	O
24	,	O
25	we	O
26	identified	O
27	the	O
28	first	O
29	150	O
30	amino	O
31	acid	O
32	residues	O
33	of	O
34	LIFR	B
35	as	O
36	the	O
37	minimal	O
38	region	O
39	necessary	O
40	for	O
41	signaling	O
42	.	O
1	Recombinant	O
2	expression	O
3	of	O
4	a	O
5	chimeric	O
6	EGFR	B
7	/	O
8	ErbB	B
9	-	I
10	3	I
11	receptor	I
12	in	O
13	NIH	O
14	3T3	O
15	fibroblasts	O
16	allowed	O
17	us	O
18	to	O
19	investigate	O
20	cytoplasmic	O
21	events	O
22	associated	O
23	with	O
24	ErbB	B
25	-	I
26	3	I
27	signal	O
28	transduction	O
29	upon	O
30	ligand	O
31	activation	O
32	.	O
1	The	O
2	227	O
3	-	O
4	to	O
5	-	O
6	239	O
7	region	O
8	blocked	O
9	ADR1	B
10	activity	O
11	independently	O
12	of	O
13	the	O
14	TAD	B
15	present	O
16	on	O
17	ADR1	B
18	,	O
19	ADR1	B
20	DNA	O
21	binding	O
22	,	O
23	and	O
24	specific	O
25	ADH2	B
26	promoter	I
27	sequences	I
28	.	O
1	Pentazocine	O
2	analgesia	O
3	:	O
4	is	O
5	there	O
6	a	O
7	niche	O
8	for	O
9	Talwin	O
10	Nx	O
11	?	O
12	Pentazocine	O
13	can	O
14	be	O
15	a	O
16	useful	O
17	analgesic	O
18	agent	O
19	for	O
20	the	O
21	management	O
22	of	O
23	acute	O
24	dental	O
25	pain	O
26	.	O
1	Response	O
2	durations	O
3	were	O
4	short	O
5	.	O
1	We	O
2	present	O
3	evidence	O
4	that	O
5	YY1	B
6	,	O
7	a	O
8	ubiquitously	O
9	expressed	O
10	DNA	O
11	-	O
12	binding	O
13	protein	O
14	,	O
15	regulates	O
16	the	O
17	activity	O
18	of	O
19	the	O
20	c	B
21	-	I
22	fos	I
23	promoter	I
24	primarily	O
25	through	O
26	an	O
27	effect	O
28	on	O
29	DNA	O
30	structure	O
31	.	O
1	267	O
2	,	O
3	4870	O
4	-	O
5	4877	O
6	))	O
7	indicates	O
8	an	O
9	overall	O
10	identity	O
11	of	O
12	58	O
13	and	O
14	56	O
15	%,	O
16	respectively	O
17	,	O
18	with	O
19	a	O
20	91	O
21	and	O
22	92	O
23	%	O
24	identity	O
25	in	O
26	the	O
27	highly	O
28	conserved	O
29	transmembrane	O
30	and	O
31	cytoplasmic	O
32	domains	O
33	.	O
1	S	O
2	.,	O
3	K	O
4	.	O
1	The	O
2	psaD	B
3	,	O
4	psaF	B
5	,	O
6	psaH	B
7	,	O
8	and	O
9	psaL	B
10	products	I
11	have	O
12	two	O
13	isoforms	O
14	each	O
15	that	O
16	are	O
17	distinguished	O
18	by	O
19	different	O
20	mobilities	O
21	in	O
22	polyacrylamide	O
23	gel	O
24	electrophoresis	O
25	,	O
26	and	O
27	the	O
28	psaE	B
29	product	I
30	has	O
31	four	O
32	isoforms	O
33	.	O
1	Plasma	O
2	,	O
3	LDL	B
4	and	O
5	liver	O
6	cholesterol	O
7	concentrations	O
8	were	O
9	higher	O
10	in	O
11	the	O
12	hyperlipidemic	O
13	control	O
14	than	O
15	the	O
16	nonhyperlipidemic	O
17	control	O
18	and	O
19	lower	O
20	in	O
21	the	O
22	groups	O
23	fed	O
24	diets	O
25	containing	O
26	pectin	B
27	or	O
28	prune	O
29	fiber	O
30	than	O
31	in	O
32	the	O
33	hyperlipidemic	O
34	control	O
35	group	O
36	.	O
1	Employing	O
2	this	O
3	sequence	O
4	information	O
5	from	O
6	c11	O
7	/	O
8	1	O
9	,	O
10	the	O
11	c11	O
12	/	O
13	1	O
14	-	O
15	specific	O
16	cDNA	O
17	was	O
18	generated	O
19	from	O
20	poly	O
21	(	O
22	A	O
23	)+	O
24	RNA	O
25	of	O
26	bovine	O
27	PMNLs	O
28	by	O
29	reverse	O
30	transcription	O
31	and	O
32	a	O
33	combination	O
34	of	O
35	polymerase	O
36	chain	O
37	reaction	O
38	(	O
39	PCR	O
40	)	O
41	methods	O
42	.	O
1	The	O
2	sequence	O
3	similarity	O
4	has	O
5	suggested	O
6	that	O
7	SCG10	B
8	and	O
9	stathmin	B
10	have	O
11	been	O
12	derived	O
13	from	O
14	structurally	O
15	and	O
16	evolutionarily	O
17	related	O
18	genes	O
19	.	O
1	A	O
2	complementary	O
3	DNA	O
4	was	O
5	isolated	O
6	from	O
7	Caenorhabditis	O
8	elegans	O
9	that	O
10	encoded	O
11	a	O
12	polypeptide	O
13	of	O
14	1438	O
15	amino	O
16	acid	O
17	residues	O
18	,	O
19	CeGAP	B
20	,	O
21	which	O
22	contains	O
23	a	O
24	domain	O
25	with	O
26	sequence	O
27	similarity	O
28	to	O
29	the	O
30	COOH	B
31	-	I
32	terminal	I
33	segment	I
34	(	I
35	GTPase	I
36	-	I
37	activating	I
38	protein	I
39	region	I
40	)	I
41	of	O
42	Bcr	B
43	and	O
44	other	O
45	known	O
46	GTPase	B
47	-	I
48	activating	I
49	proteins	I
50	of	O
51	the	O
52	Rho	B
53	subfamily	I
54	.	O
1	Repression	O
2	is	O
3	alleviated	O
4	when	O
5	the	O
6	two	O
7	(	O
8	for	O
9	E2	B
10	)	O
11	or	O
12	three	O
13	(	O
14	for	O
15	E2	B
16	-	I
17	C	I
18	)	O
19	promoter	O
20	-	O
21	proximal	O
22	copies	O
23	of	O
24	E2	B
25	-	O
26	RS	O
27	are	O
28	mutated	O
29	.	O
1	A	O
2	mutant	O
3	in	O
4	the	O
5	AAV	O
6	terminal	O
7	resolution	O
8	site	O
9	(	O
10	trs	O
11	)	O
12	was	O
13	defective	O
14	for	O
15	DNA	O
16	replication	O
17	in	O
18	the	O
19	in	O
20	vitro	O
21	assay	O
22	.	O
1	However	O
2	,	O
3	artificially	O
4	ventilated	O
5	rats	O
6	,	O
7	pretreated	O
8	with	O
9	MK	O
10	-	O
11	801	O
12	,	O
13	were	O
14	more	O
15	sensitive	O
16	(	O
17	lethal	O
18	cocaine	O
19	dose	O
20	,	O
21	76	O
22	.	O
23	6	O
24	+/-	O
25	8	O
26	.	O
27	0	O
28	mg	O
29	/	O
30	kg	O
31	,	O
32	n	O
33	=	O
34	5	O
35	)	O
36	than	O
37	vehicle	O
38	pretreated	O
39	rats	O
40	(	O
41	129	O
42	.	O
43	4	O
44	+/-	O
45	15	O
46	.	O
47	8	O
48	mg	O
49	/	O
50	kg	O
51	,	O
52	n	O
53	=	O
54	6	O
55	),	O
56	indicating	O
57	that	O
58	MK	O
59	-	O
60	801	O
61	may	O
62	increase	O
63	both	O
64	the	O
65	respiratory	O
66	and	O
67	the	O
68	cardiac	O
69	toxicity	O
70	of	O
71	cocaine	O
72	in	O
73	urethane	O
74	anesthetized	O
75	rats	O
76	.	O
1	Furthermore	O
2	,	O
3	the	O
4	negative	O
5	transcriptional	O
6	effect	O
7	of	O
8	COUP	B
9	-	I
10	TFs	I
11	is	O
12	dominant	O
13	over	O
14	the	O
15	activating	O
16	effect	O
17	of	O
18	the	O
19	Oct4	B
20	embryonic	I
21	stem	I
22	cell	I
23	-	I
24	specific	I
25	enhancer	I
26	.	O
1	Each	O
2	repeat	O
3	consists	O
4	of	O
5	12	O
6	nt	O
7	,	O
8	coding	O
9	for	O
10	the	O
11	reiterated	O
12	sequence	O
13	,	O
14	K	O
15	/	O
16	NPAG	O
17	.	O
1	These	O
2	data	O
3	indicate	O
4	that	O
5	activation	O
6	of	O
7	these	O
8	enzymes	O
9	is	O
10	not	O
11	sufficient	O
12	for	O
13	the	O
14	acute	O
15	stimulation	O
16	of	O
17	glucose	O
18	transport	O
19	.	O
1	The	O
2	inserted	O
3	region	O
4	,	O
5	which	O
6	represents	O
7	an	O
8	intron	O
9	in	O
10	brain	O
11	and	O
12	muscle	O
13	,	O
14	is	O
15	expressed	O
16	in	O
17	the	O
18	tumor	O
19	cell	O
20	lines	O
21	either	O
22	as	O
23	a	O
24	""""	O
25	readthrough	O
26	""""	O
27	form	O
28	or	O
29	with	O
30	78	O
31	residues	O
32	deleted	O
33	from	O
34	its	O
35	5	O
36	'	O
37	end	O
38	.	O
1	Concordance	O
2	of	O
3	IBDQ	O
4	scores	O
5	was	O
6	tested	O
7	in	O
8	280	O
9	stable	O
10	subjects	O
11	.	O
1	Amiodarone	O
2	,	O
3	seldom	O
4	used	O
5	as	O
6	first	O
7	-	O
8	line	O
9	treatment	O
10	,	O
11	appears	O
12	to	O
13	be	O
14	the	O
15	most	O
16	effective	O
17	drug	O
18	.	O
1	The	O
2	neglect	O
3	of	O
4	Richards	O
5	'	O
6	s	O
7	theory	O
8	demonstrates	O
9	the	O
10	range	O
11	of	O
12	factors	O
13	,	O
14	other	O
15	than	O
16	the	O
17	strictly	O
18	scientific	O
19	,	O
20	which	O
21	can	O
22	be	O
23	important	O
24	in	O
25	determining	O
26	the	O
27	influence	O
28	or	O
29	otherwise	O
30	of	O
31	a	O
32	psychological	O
33	theory	O
34	.	O
1	The	O
2	5	O
3	'	O
4	ends	O
5	of	O
6	F3R	B
7	late	O
8	transcripts	O
9	were	O
10	located	O
11	to	O
12	an	O
13	A	O
14	within	O
15	the	O
16	sequence	O
17	5	O
18	'-	O
19	TAAAG	O
20	,	O
21	41	O
22	nt	O
23	downstream	O
24	from	O
25	the	O
26	early	O
27	promoter	O
28	and	O
29	17	O
30	nt	O
31	upstream	O
32	from	O
33	the	O
34	initiation	O
35	codon	O
36	.	O
1	The	O
2	first	O
3	group	O
4	of	O
5	sequential	O
6	BMB	O
7	showed	O
8	a	O
9	significant	O
10	progress	O
11	to	O
12	myelofibrosis	O
13	in	O
14	so	O
15	-	O
16	called	O
17	""""	O
18	Chronic	O
19	Megakaryocytic	O
20	-	O
21	Granulocytic	O
22	Myelosis	O
23	"""--"	O
24	CMGM	O
25	-,	O
26	which	O
27	corresponds	O
28	to	O
29	Agnogenic	O
30	Myeloid	O
31	Metaplasia	O
32	-	O
33	AMM	O
34	-	O
35	in	O
36	72	O
37	.	O
38	4	O
39	%	O
40	(	O
41	21	O
42	/	O
43	29	O
44	patients	O
45	),	O
46	as	O
47	well	O
48	as	O
49	in	O
50	CML	O
51	with	O
52	megakaryocytic	O
53	increase	O
54	-	O
55	CML	O
56	.	O
57	MI	O
58	-	O
59	in	O
60	39	O
61	.	O
62	2	O
63	%	O
64	(	O
65	20	O
66	/	O
67	51	O
68	).	O
1	Chicken	O
2	sterol	B
3	carrier	I
4	protein	I
5	2	I
6	/	O
7	sterol	B
8	carrier	I
9	protein	I
10	x	I
11	:	O
12	cDNA	O
13	cloning	O
14	reveals	O
15	evolutionary	O
16	conservation	O
17	of	O
18	structure	O
19	and	O
20	regulated	O
21	expression	O
22	.	O
1	Previous	O
2	studies	O
3	indicated	O
4	that	O
5	the	O
6	20S	B
7	proteasome	I
8	is	O
9	a	O
10	catalytic	O
11	core	O
12	of	O
13	the	O
14	26S	B
15	proteolytic	I
16	complex	I
17	that	O
18	possesses	O
19	a	O
20	latent	O
21	multicatalytic	O
22	proteinase	O
23	activity	O
24	and	O
25	catalyzes	O
26	an	O
27	ATP	O
28	-	O
29	dependent	O
30	,	O
31	selective	O
32	breakdown	O
33	of	O
34	proteins	O
35	ligated	O
36	to	O
37	ubiquitin	B
38	.	O
1	The	O
2	O2	O
3	deficit	O
4	was	O
5	not	O
6	related	O
7	to	O
8	blood	O
9	lactate	O
10	during	O
11	submaximal	O
12	exercise	O
13	,	O
14	muscle	O
15	enzyme	O
16	activity	O
17	(	O
18	citrate	B
19	synthase	I
20	,	O
21	3	B
22	-	I
23	hydroxyacyl	I
24	-	I
25	CoA	I
26	-	I
27	dehydrogenase	I
28	,	O
29	lactate	B
30	dehydrogenase	I
31	),	O
32	number	O
33	of	O
34	muscle	O
35	capillaries	O
36	,	O
37	%	O
38	ST	O
39	fibres	O
40	or	O
41	muscle	O
42	buffer	O
43	capacity	O
44	.	O
1	Release	O
2	of	O
3	this	O
4	selective	O
5	pressure	O
6	,	O
7	however	O
8	,	O
9	gave	O
10	way	O
11	to	O
12	homologous	O
13	resolution	O
14	of	O
15	the	O
16	cointegrate	O
17	structures	O
18	.	O
1	Binding	O
2	of	O
3	U2	B
4	small	I
5	nuclear	I
6	ribonucleoprotein	I
7	was	O
8	partially	O
9	inhibited	O
10	.	O
1	Indeed	O
2	,	O
3	significant	O
4	level	O
5	of	O
6	CAT	B
7	activity	O
8	was	O
9	observed	O
10	in	O
11	human	O
12	lung	O
13	adenocarcinoma	O
14	(	O
15	A549	O
16	-	O
17	1	O
18	)	O
19	cells	O
20	which	O
21	had	O
22	been	O
23	incubated	O
24	with	O
25	a	O
26	complex	O
27	of	O
28	T7	B
29	RNA	I
30	polymerase	I
31	,	O
32	pT7	B
33	-	I
34	EMC	I
35	-	I
36	CAT	I
37	DNA	I
38	and	O
39	DC	O
40	-	O
41	chol	O
42	cationic	O
43	liposomes	O
44	.	O
1	The	O
2	influence	O
3	of	O
4	a	O
5	high	O
6	ionic	O
7	strength	O
8	on	O
9	the	O
10	resolution	O
11	was	O
12	clearly	O
13	shown	O
14	.	O
1	Similar	O
2	results	O
3	were	O
4	seen	O
5	on	O
6	Western	O
7	blots	O
8	of	O
9	Autographa	O
10	californica	O
11	MNPV	O
12	(	O
13	AcMNPV	O
14	)-	O
15	infected	O
16	Spodoptera	O
17	frugiperda	O
18	cells	O
19	.	O
1	Single	O
2	-	O
3	photon	O
4	emission	O
5	computed	O
6	tomography	O
7	(	O
8	SPECT	O
9	)	O
10	with	O
11	99mTc	O
12	-	O
13	hexamethylpropyleneamine	O
14	oxime	O
15	(	O
16	HMPAO	O
17	)	O
18	was	O
19	used	O
20	to	O
21	investigate	O
22	changes	O
23	in	O
24	cerebral	O
25	blood	O
26	flow	O
27	in	O
28	seven	O
29	patients	O
30	with	O
31	cortical	O
32	visual	O
33	impairment	O
34	.	O
1	2	O
2	-	O
3	AP	O
4	induced	O
5	marked	O
6	,	O
7	steady	O
8	rises	O
9	in	O
10	mRNA	O
11	accumulation	O
12	from	O
13	both	O
14	transfected	O
15	and	O
16	chromosomally	O
17	integrated	O
18	HIV	O
19	-	O
20	1	O
21	constructs	O
22	but	O
23	no	O
24	increases	O
25	from	O
26	an	O
27	endogenous	O
28	gene	O
29	encoding	O
30	gamma	B
31	-	I
32	actin	I
33	or	O
34	glucose	B
35	6	I
36	-	I
37	phosphate	I
38	dehydrogenase	I
39	.	O
1	Furthermore	O
2	,	O
3	a	O
4	p21X	B
5	protein	I
6	lacking	O
7	the	O
8	N	O
9	-	O
10	terminus	O
11	of	O
12	Rex1	B
13	was	O
14	expressed	O
15	at	O
16	high	O
17	levels	O
18	;	O
19	our	O
20	data	O
21	indicate	O
22	that	O
23	p21X	B
24	is	O
25	translated	O
26	from	O
27	the	O
28	1	O
29	.	O
30	6	O
31	-	O
32	kb	O
33	mRNA	O
34	which	O
35	is	O
36	derived	O
37	primarily	O
38	from	O
39	deleted	O
40	proviruses	O
41	.	O
1	XII	O
2	.	O
1	Cerebro	O
2	-	O
3	oculo	O
4	-	O
5	facioskeletal	O
6	syndrome	O
7	(	O
8	Pena	O
9	-	O
10	Shokeir	O
11	syndrome	O
12	II	O
13	)	O
1	Differences	O
2	in	O
3	profiles	O
4	of	O
5	viscosity	O
6	variables	O
7	between	O
8	subgroups	O
9	of	O
10	EAD	O
11	in	O
12	RA	O
13	patients	O
14	were	O
15	observed	O
16	.	O
1	Deletion	O
2	of	O
3	a	O
4	53	O
5	-	O
6	bp	O
7	early	O
8	promoter	O
9	region	O
10	containing	O
11	the	O
12	transcription	O
13	start	O
14	site	O
15	and	O
16	a	O
17	putative	O
18	TATA	O
19	box	O
20	completely	O
21	abolishes	O
22	the	O
23	ability	O
24	of	O
25	upstream	O
26	elements	O
27	to	O
28	drive	O
29	transcription	O
30	of	O
31	the	O
32	luciferase	B
33	cDNA	I
34	.	O
1	To	O
2	analyze	O
3	the	O
4	VH	O
5	regions	O
6	of	O
7	polyreactive	O
8	antibodies	O
9	,	O
10	with	O
11	particular	O
12	attention	O
13	at	O
14	their	O
15	somatically	O
16	mutated	O
17	status	O
18	,	O
19	we	O
20	generated	O
21	five	O
22	IgG	B
23	(	O
24	three	O
25	IgG1	B
26	and	O
27	two	O
28	IgG3	B
29	)	O
30	mAb	O
31	(	O
32	using	O
33	B	O
34	cells	O
35	from	O
36	a	O
37	healthy	O
38	subject	O
39	,	O
40	a	O
41	patient	O
42	with	O
43	insulin	B
44	-	O
45	dependent	O
46	diabetes	O
47	mellitus	O
48	and	O
49	a	O
50	patient	O
51	with	O
52	SLE	O
53	),	O
54	which	O
55	bound	O
56	with	O
57	various	O
58	efficiencies	O
59	a	O
60	number	O
61	of	O
62	different	O
63	self	O
64	and	O
65	foreign	O
66	Ag	O
67	.	O
1	These	O
2	findings	O
3	suggest	O
4	a	O
5	functional	O
6	cross	O
7	-	O
8	talk	O
9	between	O
10	RB	B
11	protein	I
12	and	O
13	p21ras	B
14	,	O
15	which	O
16	balances	O
17	the	O
18	cell	O
19	phenotype	O
20	between	O
21	normal	O
22	and	O
23	transformed	O
24	states	O
25	.	O
1	These	O
2	cell	O
3	lines	O
4	,	O
5	selected	O
6	for	O
7	the	O
8	ability	O
9	to	O
10	support	O
11	the	O
12	replication	O
13	of	O
14	a	O
15	temperature	O
16	-	O
17	sensitive	O
18	VP5	B
19	mutant	I
20	,	O
21	were	O
22	used	O
23	to	O
24	isolate	O
25	VP5	B
26	and	O
27	VP23	B
28	null	O
29	mutants	O
30	.	O
1	The	O
2	E1	B
3	nuclear	I
4	transport	I
5	motif	I
6	is	O
7	highly	O
8	conserved	O
9	in	O
10	the	O
11	animal	O
12	and	O
13	human	O
14	papillomaviruses	O
15	and	O
16	is	O
17	encoded	O
18	in	O
19	a	O
20	similar	O
21	region	O
22	in	O
23	the	O
24	related	O
25	E1	B
26	genes	I
27	.	O
1	A	O
2	sequence	O
3	comparison	O
4	reveals	O
5	two	O
6	CCAAT	B
7	/	I
8	enhancer	I
9	binding	I
10	protein	I
11	(	O
12	C	B
13	/	I
14	EBP	I
15	)	O
16	consensus	O
17	sequences	O
18	,	O
19	basic	O
20	DNA	O
21	binding	O
22	region	O
23	and	O
24	leucine	O
25	zippers	O
26	1	O
27	and	O
28	2	O
29	(	O
30	bZIP1	O
31	and	O
32	bZIP2	O
33	),	O
34	within	O
35	this	O
36	region	O
37	.	O
1	The	O
2	orf61	B
3	gene	I
4	product	I
5	,	O
6	when	O
7	expressed	O
8	from	O
9	an	O
10	exogenous	O
11	promoter	O
12	,	O
13	inhibited	O
14	int	B
15	-	O
16	mediated	O
17	integration	O
18	at	O
19	the	O
20	chromosomal	B
21	attB	I
22	site	I
23	.	O
1	Estrogen	O
2	treatment	O
3	in	O
4	high	O
5	doses	O
6	is	O
7	effective	O
8	in	O
9	reducing	O
10	adult	O
11	stature	O
12	in	O
13	constitutionally	O
14	tall	O
15	girls	O
16	.	O
1	Uracil	B
2	DNA	I
3	glycosylase	I
4	catalyzes	O
5	the	O
6	initial	O
7	step	O
8	in	O
9	the	O
10	repair	O
11	pathway	O
12	that	O
13	removes	O
14	potentially	O
15	mutagenic	O
16	uracil	O
17	from	O
18	duplex	O
19	DNA	O
20	.	O
1	A	O
2	sheep	O
3	testicular	O
4	cDNA	O
5	library	O
6	constructed	O
7	in	O
8	pcDNA1	O
9	vector	O
10	was	O
11	screened	O
12	with	O
13	a	O
14	probe	O
15	generated	O
16	by	O
17	polymerase	O
18	chain	O
19	reaction	O
20	(	O
21	PCR	O
22	)	O
23	and	O
24	corresponding	O
25	to	O
26	a	O
27	1	O
28	.	O
29	6	O
30	kb	O
31	fragment	O
32	of	O
33	the	O
34	rat	B
35	luteinizing	I
36	hormone	I
37	receptor	I
38	cDNA	I
39	.	O
1	Three	O
2	group	O
3	1	O
4	patients	O
5	developed	O
6	CMV	O
7	disease	O
8	;	O
9	1	O
10	group	O
11	2	O
12	patient	O
13	developed	O
14	CMV	O
15	hepatitis	O
16	.	O
1	The	O
2	ability	O
3	of	O
4	spt2	B
5	mutations	I
6	to	O
7	suppress	O
8	the	O
9	transcriptional	O
10	interference	O
11	caused	O
12	by	O
13	the	O
14	delta	B
15	promoter	I
16	insertion	I
17	his	I
18	-	I
19	4	I
20	-	I
21	912	I
22	delta	I
23	correlates	O
24	with	O
25	an	O
26	increase	O
27	in	O
28	wild	B
29	-	I
30	type	I
31	HIS4	I
32	mRNA	I
33	levels	O
34	.	O
1	BCR	B
2	-	O
3	ABL	B
4	and	O
5	v	B
6	-	I
7	abl	I
8	oncogenes	I
9	induce	O
10	distinct	O
11	patterns	O
12	of	O
13	thymic	O
14	lymphoma	O
15	involving	O
16	different	O
17	lymphocyte	O
18	subsets	O
19	.	O
1	A	O
2	new	O
3	bioencapsulation	O
4	technology	O
5	for	O
6	microbial	O
7	inoculants	O
8	.	O
1	Army	O
2	veterans	O
3	given	O
4	yellow	O
5	fever	O
6	vaccine	O
7	contaminated	O
8	with	O
9	hepatitis	O
10	B	O
11	virus	O
12	in	O
13	1942	O
14	and	O
15	controls	O
16	and	O
17	(	O
18	b	O
19	)	O
20	a	O
21	case	O
22	-	O
23	control	O
24	study	O
25	comparing	O
26	veterans	O
27	with	O
28	hepatocellular	O
29	carcinoma	O
30	in	O
31	Veterans	O
32	Affairs	O
33	hospitals	O
34	with	O
35	matched	O
36	controls	O
37	with	O
38	respect	O
39	to	O
40	receipt	O
41	of	O
42	contaminated	O
43	vaccine	O
44	in	O
45	1942	O
46	.	O
1	They	O
2	were	O
3	found	O
4	to	O
5	be	O
6	seropositive	O
7	for	O
8	antibodies	O
9	to	O
10	hepatitis	O
11	C	O
12	virus	O
13	by	O
14	second	O
15	-	O
16	generation	O
17	testing	O
18	(	O
19	RIBA	O
20	2	O
21	,	O
22	Ortho	O
23	Diagnostic	O
24	Systems	O
25	Inc	O
26	,	O
27	Westwood	O
28	,	O
29	MA	O
30	).	O
1	Hops	O
2	,	O
3	and	O
4	L	O
5	.	O
1	The	O
2	Ntl1	B
3	gene	I
4	is	O
5	present	O
6	as	O
7	a	O
8	unique	O
9	copy	O
10	in	O
11	the	O
12	diploid	O
13	N	O
14	.	O
15	plumbaginifolia	O
16	species	O
17	.	O
1	Transgenic	O
2	mice	O
3	harboring	O
4	the	O
5	rat	O
6	TnI	B
7	-	O
8	CAT	B
9	fusion	O
10	gene	O
11	expressed	O
12	the	O
13	reporter	O
14	specifically	O
15	in	O
16	the	O
17	skeletal	O
18	muscle	O
19	.	O
1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	one	O
6	healthy	O
7	eyes	O
8	,	O
9	169	O
10	ocular	O
11	hypertensive	O
12	eyes	O
13	with	O
14	normal	O
15	visual	O
16	fields	O
17	,	O
18	and	O
19	132	O
20	glaucomatous	O
21	eyes	O
22	with	O
23	early	O
24	visual	O
25	field	O
26	defects	O
27	were	O
28	evaluated	O
29	with	O
30	qualitative	O
31	and	O
32	quantitative	O
33	measures	O
34	of	O
35	structural	O
36	damage	O
37	to	O
38	the	O
39	optic	O
40	nerve	O
41	and	O
42	nerve	O
43	fiber	O
44	layer	O
45	.	O
1	The	O
2	ADP	B
3	-	I
4	ribosylation	I
5	factor	I
6	(	O
7	ARF	B
8	)	O
9	family	O
10	is	O
11	one	O
12	of	O
13	four	O
14	subfamilies	O
15	of	O
16	the	O
17	RAS	B
18	superfamily	I
19	of	O
20	low	B
21	molecular	I
22	weight	I
23	GTP	I
24	-	I
25	binding	I
26	proteins	I
27	(	O
28	G	B
29	proteins	I
30	).	O
1	The	O
2	E1	B
3	gene	I
4	is	O
5	located	O
6	within	O
7	the	O
8	first	O
9	intron	O
10	of	O
11	the	O
12	gene	O
13	for	O
14	RCC1	B
15	,	O
16	a	O
17	protein	O
18	that	O
19	regulates	O
20	onset	O
21	of	O
22	mitosis	O
23	.	O
1	To	O
2	identify	O
3	factors	O
4	that	O
5	may	O
6	modify	O
7	the	O
8	heterosexual	O
9	transmission	O
10	of	O
11	human	O
12	T	O
13	cell	O
14	leukemia	O
15	/	O
16	lymphoma	O
17	virus	O
18	type	O
19	I	O
20	(	O
21	HTLV	O
22	-	O
23	I	O
24	),	O
25	534	O
26	married	O
27	couples	O
28	enrolled	O
29	in	O
30	the	O
31	Miyazaki	O
32	Cohort	O
33	Study	O
34	between	O
35	November	O
36	1984	O
37	and	O
38	April	O
39	1989	O
40	were	O
41	studied	O
42	:	O
43	95	O
44	husband	O
45	HTLV	O
46	-	O
47	I	O
48	-	O
49	seropositive	O
50	(	O
51	H	O
52	+)/	O
53	wife	O
54	seropositive	O
55	(	O
56	W	O
57	+),	O
58	33	O
59	H	O
60	+/	O
61	W	O
62	-,	O
63	64	O
64	H	O
65	-/	O
66	W	O
67	+,	O
68	and	O
69	342	O
70	H	O
71	-/	O
72	W	O
73	-.	O
1	Biol	O
2	.	O
1	L	O
2	.,	O
3	Stange	O
4	,	O
5	G	O
6	.,	O
7	Markovich	O
8	,	O
9	D	O
10	.,	O
11	Biber	O
12	,	O
13	J	O
14	.,	O
15	Testar	O
16	,	O
17	X	O
18	.,	O
19	Zorzano	O
20	,	O
21	A	O
22	.,	O
23	Palacin	O
24	,	O
25	M	O
26	.,	O
27	and	O
28	Murer	O
29	,	O
30	H	O
31	.	O
1	The	O
2	use	O
3	of	O
4	this	O
5	model	O
6	for	O
7	investigating	O
8	pathophysiologically	O
9	significant	O
10	issues	O
11	in	O
12	denervating	O
13	diseases	O
14	is	O
15	illustrated	O
16	with	O
17	five	O
18	different	O
19	sets	O
20	of	O
21	parameters	O
22	.	O
1	Localization	O
2	of	O
3	the	O
4	intronless	O
5	gene	O
6	coding	O
7	for	O
8	calmodulin	B
9	-	I
10	like	I
11	protein	I
12	CLP	I
13	to	O
14	human	O
15	chromosome	O
16	10p13	O
17	-	O
18	ter	O
19	.	O
1	This	O
2	study	O
3	compared	O
4	the	O
5	gross	O
6	and	O
7	fine	O
8	motor	O
9	performance	O
10	of	O
11	14	O
12	traumatically	O
13	brain	O
14	-	O
15	injured	O
16	children	O
17	(	O
18	five	O
19	to	O
20	15	O
21	years	O
22	old	O
23	,	O
24	with	O
25	loss	O
26	of	O
27	consciousness	O
28	for	O
29	at	O
30	least	O
31	24	O
32	hours	O
33	)	O
34	to	O
35	14	O
36	normal	O
37	children	O
38	group	O
39	matched	O
40	for	O
41	age	O
42	and	O
43	sex	O
44	.	O
1	We	O
2	compared	O
3	the	O
4	parameters	O
5	pleural	B
6	adenosine	I
7	deaminase	I
8	(	O
9	PADA	B
10	,	O
11	determined	O
12	in	O
13	405	O
14	patients	O
15	),	O
16	the	O
17	PADA	B
18	/	O
19	serum	B
20	ADA	I
21	ratio	O
22	(	O
23	P	B
24	/	O
25	SADA	B
26	;	O
27	276	O
28	cases	O
29	),	O
30	pleural	B
31	lysozyme	I
32	(	O
33	PLYS	B
34	,	O
35	276	O
36	cases	O
37	),	O
38	the	O
39	PLYS	B
40	/	O
41	serum	B
42	LYS	I
43	ratio	O
44	(	O
45	P	B
46	/	O
47	SLYS	B
48	;	O
49	276	O
50	cases	O
51	),	O
52	and	O
53	pleural	B
54	interferon	I
55	gamma	I
56	(	O
57	IFN	B
58	,	O
59	145	O
60	cases	O
61	)	O
62	regarding	O
63	their	O
64	ability	O
65	to	O
66	differentiate	O
67	tuberculous	O
68	pleural	O
69	effusions	O
70	from	O
71	others	O
72	.	O
1	There	O
2	was	O
3	a	O
4	positive	O
5	correlation	O
6	between	O
7	pyridinium	O
8	cross	O
9	-	O
10	link	O
11	excretion	O
12	and	O
13	thyroid	O
14	hormone	O
15	concentrations	O
16	.	O
1	The	O
2	plateau	O
3	MO2	O
4	value	O
5	was	O
6	that	O
7	predicted	O
8	by	O
9	allometric	O
10	relation	O
11	.	O
1	While	O
2	the	O
3	latter	O
4	corresponded	O
5	to	O
6	a	O
7	protein	O
8	of	O
9	824	O
10	amino	O
11	acids	O
12	,	O
13	an	O
14	upstream	O
15	open	O
16	reading	O
17	frame	O
18	(	O
19	uORF	O
20	)	O
21	within	O
22	the	O
23	5	O
24	'	O
25	leader	O
26	could	O
27	potentially	O
28	encode	O
29	a	O
30	54	O
31	amino	O
32	acid	O
33	peptide	O
34	.	O
1	In	O
2	contrast	O
3	to	O
4	T	O
5	cells	O
6	,	O
7	in	O
8	fibroblasts	O
9	PILOT	B
10	gene	I
11	expression	O
12	requires	O
13	only	O
14	one	O
15	signal	O
16	(	O
17	PMA	O
18	)	O
19	and	O
20	is	O
21	not	O
22	affected	O
23	by	O
24	CyA	O
25	.	O
1	Localization	O
2	of	O
3	the	O
4	insertion	O
5	locus	O
6	in	O
7	the	O
8	yeast	O
9	genome	O
10	and	O
11	complementation	O
12	studies	O
13	with	O
14	the	O
15	temperature	O
16	-	O
17	sensitive	O
18	mutant	O
19	indicate	O
20	that	O
21	the	O
22	two	O
23	mutations	O
24	are	O
25	allelic	O
26	.	O
1	Type	O
2	II	O
3	could	O
4	be	O
5	divided	O
6	further	O
7	into	O
8	two	O
9	forms	O
10	(	O
11	IIA	O
12	and	O
13	IIB	O
14	)	O
15	that	O
16	may	O
17	represent	O
18	two	O
19	underscribed	O
20	species	O
21	or	O
22	developmental	O
23	stages	O
24	of	O
25	the	O
26	same	O
27	species	O
28	.	O
1	Ig	B
2	-	I
3	alpha	I
4	and	O
5	Ig	B
6	-	I
7	beta	I
8	contain	O
9	extended	O
10	cytoplasmic	O
11	structure	O
12	(	O
13	61	O
14	and	O
15	48	O
16	amino	O
17	acids	O
18	,	O
19	respectively	O
20	)	O
21	and	O
22	associate	O
23	with	O
24	cytoplasmic	O
25	effectors	O
26	indicating	O
27	that	O
28	they	O
29	are	O
30	directly	O
31	involved	O
32	in	O
33	signal	O
34	transduction	O
35	.	O
1	OBJECTIVE	O
2	:	O
3	Our	O
4	purpose	O
5	was	O
6	to	O
7	determine	O
8	the	O
9	simultaneous	O
10	concentrations	O
11	of	O
12	serum	O
13	cotinine	O
14	in	O
15	both	O
16	fetal	O
17	and	O
18	maternal	O
19	blood	O
20	.	O
1	Internal	O
2	amino	O
3	acid	O
4	sequence	O
5	has	O
6	now	O
7	been	O
8	obtained	O
9	from	O
10	this	O
11	protein	O
12	which	O
13	shares	O
14	50	O
15	-	O
16	100	O
17	%	O
18	sequence	O
19	identity	O
20	with	O
21	sequences	O
22	encoded	O
23	by	O
24	mammalian	B
25	G	I
26	alpha	I
27	11	I
28	and	O
29	G	B
30	alpha	I
31	q	I
32	cDNAs	I
33	.	O
1	Air	O
2	lead	O
3	was	O
4	not	O
5	a	O
6	significant	O
7	explanatory	O
8	variable	O
9	.	O
1	5	O
2	micrograms	O
3	/	O
4	l	O
5	was	O
6	detected	O
7	in	O
8	urine	O
9	from	O
10	some	O
11	non	O
12	-	O
13	occupationally	O
14	exposed	O
15	persons	O
16	.	O
1	Fibular	O
2	dimelia	O
3	with	O
4	deficiency	O
5	of	O
6	the	O
7	tibia	O
8	.	O
1	Further	O
2	evidence	O
3	for	O
4	a	O
5	clustered	O
6	organization	O
7	of	O
8	FAX	B
9	-	O
10	ZFP	B
11	transcription	O
12	units	O
13	is	O
14	provided	O
15	by	O
16	Southern	O
17	blot	O
18	analysis	O
19	of	O
20	large	O
21	genomic	O
22	restriction	O
23	fragments	O
24	separated	O
25	by	O
26	transverse	O
27	field	O
28	gel	O
29	electrophoresis	O
30	,	O
31	and	O
32	by	O
33	in	O
34	situ	O
35	hybridization	O
36	on	O
37	intact	O
38	chromosomes	O
39	.	O
1	In	O
2	F42A	O
3	-	O
4	stimulated	O
5	internalization	O
6	assays	O
7	on	O
8	forskolin	O
9	-	O
10	induced	O
11	YT	O
12	-	O
13	1	O
14	cells	O
15	,	O
16	the	O
17	IL	B
18	-	I
19	2R	I
20	alpha	I
21	chain	I
22	is	O
23	consistently	O
24	endocytosed	O
25	together	O
26	with	O
27	the	O
28	IL	B
29	-	I
30	2R	I
31	beta	I
32	subunit	I
33	indicating	O
34	that	O
35	IL	B
36	-	I
37	2R	I
38	alpha	I
39	is	O
40	stably	O
41	associated	O
42	with	O
43	the	O
44	F42A	B
45	-	I
46	IL	I
47	-	I
48	2R	I
49	beta	I
50	complex	I
51	even	O
52	though	O
53	the	O
54	alpha	O
55	-	O
56	subunit	O
57	contributes	O
58	little	O
59	if	O
60	any	O
61	affinity	O
62	to	O
63	the	O
64	F42A	O
65	binding	O
66	reaction	O
67	.	O
1	Nitric	O
2	oxide	O
3	inhalation	O
4	selectively	O
5	reduces	O
6	pulmonary	O
7	hypertension	O
8	in	O
9	porcine	O
10	endotoxin	O
11	shock	O
12	and	O
13	improves	O
14	arterial	O
15	oxygenation	O
16	and	O
17	pH	O
18	with	O
19	a	O
20	marked	O
21	attenuation	O
22	of	O
23	sympathetic	O
24	activation	O
25	.	O
1	Mutations	O
2	at	O
3	three	O
4	sites	O
5	have	O
6	larger	O
7	effects	O
8	in	O
9	muscle	O
10	than	O
11	nonmuscle	O
12	cells	O
13	;	O
14	an	O
15	A	O
16	/	O
17	T	O
18	-	O
19	rich	O
20	site	O
21	mutation	O
22	has	O
23	a	O
24	pronounced	O
25	effect	O
26	in	O
27	both	O
28	striated	O
29	muscle	O
30	types	O
31	,	O
32	mutations	O
33	at	O
34	the	O
35	MEF1	B
36	(	I
37	Right	I
38	E	I
39	-	I
40	box	I
41	)	I
42	site	I
43	are	O
44	relatively	O
45	specific	O
46	to	O
47	expression	O
48	in	O
49	skeletal	O
50	muscle	O
51	,	O
52	and	O
53	mutations	O
54	at	O
55	the	O
56	CArG	O
57	site	O
58	are	O
59	relatively	O
60	specific	O
61	to	O
62	expression	O
63	in	O
64	cardiac	O
65	muscle	O
66	.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	PTH	B
6	and	O
7	cAMP	O
8	can	O
9	repress	O
10	collagen	B
11	promoter	I
12	activity	O
13	in	O
14	calvariae	O
15	from	O
16	transgenic	O
17	mice	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	alpha	B
23	1	I
24	(	I
25	I	I
26	)	I
27	collagen	I
28	promoter	I
29	may	O
30	contain	O
31	cis	O
32	elements	O
33	down	O
34	-	O
35	stream	O
36	of	O
37	-	O
38	2	O
39	.	O
40	3	O
41	kilobases	O
42	that	O
43	mediate	O
44	PTH	B
45	and	O
46	cAMP	O
47	repression	O
48	of	O
49	collagen	B
50	gene	I
51	expression	O
52	in	O
53	bone	O
54	.	O
1	The	O
2	retention	O
3	of	O
4	75SeHCAT	O
5	was	O
6	low	O
7	.	O
1	Members	O
2	of	O
3	the	O
4	C	B
5	/	I
6	EBP	I
7	family	I
8	of	O
9	basic	B
10	-	I
11	leucine	I
12	zipper	I
13	(	I
14	bZip	I
15	)	I
16	transcription	I
17	factors	I
18	form	O
19	heterodimers	O
20	and	O
21	bind	O
22	to	O
23	the	O
24	CAAT	O
25	box	O
26	and	O
27	other	O
28	sequence	O
29	-	O
30	related	O
31	enhancer	O
32	motifs	O
33	.	O
1	Expression	O
2	of	O
3	this	O
4	protein	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	demonstrated	O
10	that	O
11	tyrosine	O
12	was	O
13	incorporated	O
14	during	O
15	suppression	O
16	and	O
17	that	O
18	yeast	B
19	cytoplasmic	I
20	TyrRS	I
21	activity	O
22	was	O
23	produced	O
24	.	O
1	Here	O
2	,	O
3	we	O
4	have	O
5	more	O
6	closely	O
7	investigated	O
8	transactivation	O
9	of	O
10	the	O
11	human	B
12	HSP70	I
13	promoter	I
14	by	O
15	Myb	B
16	proteins	I
17	.	O
1	A	O
2	second	O
3	hydrophobic	O
4	domain	O
5	,	O
6	bordered	O
7	by	O
8	two	O
9	hydrophilic	O
10	regions	O
11	strongly	O
12	suggests	O
13	a	O
14	transmembrane	O
15	region	O
16	.	O
1	This	O
2	gene	O
3	spans	O
4	23	O
5	kb	O
6	and	O
7	is	O
8	composed	O
9	of	O
10	five	O
11	exons	O
12	and	O
13	four	O
14	introns	O
15	.	O
1	The	O
2	remaining	O
3	RAD	B
4	+	I
5	cells	O
6	progressed	O
7	to	O
8	form	O
9	microcolonies	O
10	(<	O
11	30	O
12	cells	O
13	)	O
14	containing	O
15	aberrantly	O
16	shaped	O
17	inviable	O
18	cells	O
19	.	O
1	Embryo	O
2	coculture	O
3	system	O
4	may	O
5	contribute	O
6	to	O
7	understand	O
8	the	O
9	mechanisms	O
10	underlying	O
11	the	O
12	decrease	O
13	of	O
14	fertility	O
15	with	O
16	aging	O
17	.	O
1	The	O
2	5	O
3	'	O
4	flanking	O
5	regions	O
6	of	O
7	both	O
8	pelA	B
9	and	O
10	pelB	B
11	were	O
12	translationally	O
13	fused	O
14	to	O
15	the	O
16	beta	B
17	-	I
18	glucuronidase	I
19	gene	I
20	and	O
21	introduced	O
22	into	O
23	F	O
24	.	O
25	solani	O
26	f	O
27	.	O
28	sp	O
29	.	O
30	pisi	O
31	,	O
32	and	O
33	beta	B
34	-	I
35	glucuronidase	I
36	activities	O
37	of	O
38	the	O
39	transformants	O
40	were	O
41	measured	O
42	.	O
1	Similarly	O
2	,	O
3	expression	O
4	of	O
5	a	O
6	transiently	O
7	transfected	O
8	wild	B
9	-	I
10	type	I
11	prothymosin	I
12	alpha	I
13	gene	I
14	as	O
15	the	O
16	reporter	O
17	was	O
18	not	O
19	affected	O
20	by	O
21	a	O
22	repertoire	O
23	of	O
24	myc	B
25	-	I
26	derived	I
27	genes	I
28	,	O
29	including	O
30	myc	B
31	itself	O
32	and	O
33	dominant	O
34	or	O
35	recessive	O
36	negative	O
37	myc	B
38	mutants	I
39	.	O
1	Stems	O
2	contain	O
3	distinctly	O
4	less	O
5	P	B
6	protein	I
7	mRNA	I
8	and	O
9	the	O
10	relative	O
11	level	O
12	in	O
13	roots	O
14	is	O
15	very	O
16	low	O
17	but	O
18	still	O
19	clearly	O
20	detectable	O
21	.	O
1	The	O
2	minimal	O
3	region	O
4	of	O
5	overlap	O
6	of	O
7	Langer	O
8	-	O
9	Giedion	O
10	syndrome	O
11	deletions	O
12	,	O
13	previously	O
14	identified	O
15	by	O
16	analysis	O
17	of	O
18	15	O
19	patients	O
20	,	O
21	was	O
22	placed	O
23	on	O
24	the	O
25	map	O
26	by	O
27	analysis	O
28	of	O
29	2	O
30	patients	O
31	whose	O
32	deletions	O
33	define	O
34	the	O
35	endpoints	O
36	.	O
1	Consistent	O
2	with	O
3	the	O
4	hepatic	O
5	and	O
6	epidermal	O
7	expression	O
8	of	O
9	histidase	B
10	,	O
11	this	O
12	finding	O
13	suggests	O
14	that	O
15	histidase	B
16	transcription	O
17	may	O
18	be	O
19	regulated	O
20	by	O
21	these	O
22	factors	O
23	.	O
1	Transfection	O
2	analyses	O
3	indicate	O
4	that	O
5	mutation	O
6	of	O
7	any	O
8	one	O
9	of	O
10	these	O
11	TGACCT	O
12	motifs	O
13	or	O
14	truncation	O
15	of	O
16	the	O
17	entire	O
18	HD	B
19	PPRE	O
20	into	O
21	a	O
22	separate	O
23	DR1	O
24	and	O
25	DR2	O
26	element	O
27	significantly	O
28	reduced	O
29	the	O
30	transcriptional	O
31	response	O
32	of	O
33	HD	B
34	PPRE	O
35	to	O
36	peroxisome	O
37	proliferators	O
38	.	O
1	PTP	B
2	-	I
3	S3	I
4	differs	O
5	from	O
6	PTP	B
7	-	I
8	S4	I
9	in	O
10	having	O
11	a	O
12	deletion	O
13	of	O
14	19	O
15	amino	O
16	acids	O
17	corresponding	O
18	to	O
19	exon	O
20	E1	O
21	.	O
1	The	O
2	protein	O
3	kinase	O
4	domains	O
5	of	O
6	LIMK1	B
7	and	O
8	LIMK2	B
9	are	O
10	unique	O
11	in	O
12	that	O
13	they	O
14	contain	O
15	an	O
16	unusual	O
17	sequence	O
18	motif	O
19	Asp	O
20	-	O
21	Leu	O
22	-	O
23	Asn	O
24	-	O
25	Ser	O
26	-	O
27	His	O
28	-	O
29	Asn	O
30	in	O
31	subdomain	O
32	VIB	O
33	and	O
34	a	O
35	highly	O
36	basic	O
37	insert	O
38	between	O
39	subdomains	O
40	VII	O
41	and	O
42	VIII	O
43	.	O
1	A	O
2	human	O
3	recombinant	O
4	cDNA	O
5	clone	O
6	that	O
7	encoded	O
8	253	O
9	amino	O
10	acids	O
11	residues	O
12	of	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	protein	I
18	(	O
19	THZif	B
20	-	I
21	1	I
22	)	O
23	was	O
24	cloned	O
25	by	O
26	screening	O
27	a	O
28	cDNA	O
29	library	O
30	prepared	O
31	from	O
32	human	O
33	promyelocytic	O
34	leukemia	O
35	HL60	O
36	cells	O
37	with	O
38	synthetic	O
39	oligodeoxynucleotide	O
40	probes	O
41	that	O
42	corresponded	O
43	to	O
44	the	O
45	amino	O
46	acid	O
47	sequences	O
48	of	O
49	tryptic	O
50	peptides	O
51	derived	O
52	from	O
53	the	O
54	DNA	O
55	-	O
56	binding	O
57	protein	O
58	specific	O
59	for	O
60	the	O
61	nuclease	B
62	-	I
63	hypersensitive	I
64	element	I
65	(	O
66	NHE	B
67	)	O
68	of	O
69	the	O
70	human	B
71	c	I
72	-	I
73	myc	I
74	gene	I
75	.	O
1	Erythrocyte	O
2	AA	O
3	in	O
4	FO	O
5	+	O
6	EPO	B
7	-	O
8	supplemented	O
9	infants	O
10	remained	O
11	low	O
12	and	O
13	below	O
14	breast	O
15	-	O
16	and	O
17	placebo	O
18	formula	O
19	-	O
20	fed	O
21	levels	O
22	.	O
1	Taking	O
2	into	O
3	consideration	O
4	weight	O
5	and	O
6	seasonal	O
7	changes	O
8	in	O
9	bone	O
10	mass	O
11	,	O
12	total	O
13	(	O
14	TBBMC	O
15	)	O
16	and	O
17	regional	O
18	body	O
19	bone	O
20	mineral	O
21	content	O
22	were	O
23	measured	O
24	in	O
25	38	O
26	women	O
27	treated	O
28	with	O
29	GnRH	B
30	agonists	O
31	for	O
32	6	O
33	months	O
34	for	O
35	endometriosis	O
36	or	O
37	leiomyomata	O
38	.	O
1	The	O
2	XS2	B
3	gene	I
4	down	O
5	-	O
6	regulates	O
7	but	O
8	does	O
9	not	O
10	abolish	O
11	expression	O
12	of	O
13	LU	B
14	genes	I
15	and	O
16	does	O
17	not	O
18	affect	O
19	expression	O
20	of	O
21	CD44	B
22	.	O
1	According	O
2	to	O
3	the	O
4	investigation	O
5	,	O
6	the	O
7	recent	O
8	burst	O
9	of	O
10	pseudoterranovosis	O
11	in	O
12	this	O
13	area	O
14	can	O
15	be	O
16	attributed	O
17	to	O
18	the	O
19	increased	O
20	presence	O
21	of	O
22	sea	O
23	lions	O
24	,	O
25	which	O
26	proliferate	O
27	in	O
28	the	O
29	Arctic	O
30	region	O
31	,	O
32	then	O
33	migrate	O
34	to	O
35	the	O
36	northern	O
37	Japan	O
38	Sea	O
39	and	O
40	eat	O
41	the	O
42	intermediate	O
43	host	O
44	fish	O
45	.	O
1	Thus	O
2	,	O
3	SPECT	O
4	was	O
5	not	O
6	as	O
7	sensitive	O
8	as	O
9	PET	O
10	in	O
11	this	O
12	activation	O
13	task	O
14	.	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	bradycardic	O
7	agents	O
8	alinidine	O
9	and	O
10	zatebradine	O
11	do	O
12	not	O
13	exert	O
14	antiarrhythmic	O
15	efficacy	O
16	against	O
17	SVT	O
18	induced	O
19	during	O
20	subacute	O
21	myocardial	O
22	infarction	O
23	in	O
24	conscious	O
25	dogs	O
26	.	O
1	The	O
2	gene	O
3	was	O
4	uniquely	O
5	mapped	O
6	with	O
7	odds	O
8	>	O
9	1	O
10	,	O
11	000	O
12	:	O
13	1	O
14	on	O
15	chromosome	O
16	3p	O
17	in	O
18	Centre	O
19	d	O
20	'	O
21	Etude	O
22	du	O
23	Polymorphisme	O
24	Humain	O
25	pedigrees	O
26	.	O
1	The	O
2	promoter	O
3	of	O
4	the	O
5	first	O
6	gene	O
7	,	O
8	epiF	B
9	,	O
10	responded	O
11	to	O
12	the	O
13	activator	B
14	protein	I
15	EpiQ	I
16	and	O
17	contained	O
18	a	O
19	palindromic	O
20	sequence	O
21	similar	O
22	to	O
23	the	O
24	EpiQ	B
25	binding	I
26	site	I
27	of	O
28	the	O
29	epiA	B
30	promoter	I
31	,	O
32	which	O
33	is	O
34	also	O
35	activated	O
36	by	O
37	EpiQ	B
38	.	O
1	CXC	O
2	chemokines	O
3	bind	O
4	to	O
5	unique	O
6	sets	O
7	of	O
8	selectivity	O
9	determinants	O
10	that	O
11	can	O
12	function	O
13	independently	O
14	and	O
15	are	O
16	broadly	O
17	distributed	O
18	on	O
19	multiple	O
20	domains	O
21	of	O
22	human	O
23	interleukin	B
24	-	I
25	8	I
26	receptor	I
27	B	I
28	.	O
1	Consistent	O
2	with	O
3	a	O
4	possible	O
5	role	O
6	in	O
7	transcription	O
8	,	O
9	Paf1p	B
10	is	O
11	localized	O
12	to	O
13	the	O
14	nucleus	O
15	.	O
1	By	O
2	comparing	O
3	the	O
4	abundances	O
5	of	O
6	many	O
7	yeast	O
8	transcripts	O
9	in	O
10	isogenic	O
11	wild	O
12	-	O
13	type	O
14	and	O
15	paf1	B
16	mutant	I
17	strains	O
18	,	O
19	we	O
20	have	O
21	identified	O
22	genes	O
23	whose	O
24	expression	O
25	is	O
26	affected	O
27	by	O
28	PAF1	B
29	.	O
1	Clones	O
2	that	O
3	expressed	O
4	DBD	O
5	exhibited	O
6	a	O
7	dominant	O
8	negative	O
9	phenotype	O
10	and	O
11	did	O
12	not	O
13	elicit	O
14	antiviral	O
15	activity	O
16	against	O
17	vesicular	O
18	stomatitis	O
19	virus	O
20	(	O
21	VSV	O
22	)	O
23	infection	O
24	upon	O
25	IFN	B
26	treatment	O
27	.	O
1	Magnetic	O
2	storm	O
3	indicators	O
4	could	O
5	be	O
6	used	O
7	in	O
8	medicine	O
9	,	O
10	in	O
11	geophysics	O
12	and	O
13	for	O
14	special	O
15	purposes	O
16	.	O
1	Human	B
2	LAF	I
3	-	I
4	4	I
5	readily	O
6	hybridized	O
7	with	O
8	genes	O
9	in	O
10	mouse	O
11	and	O
12	chicken	O
13	,	O
14	thus	O
15	showing	O
16	that	O
17	this	O
18	gene	O
19	family	O
20	has	O
21	been	O
22	highly	O
23	conserved	O
24	during	O
25	vertebrate	O
26	evolution	O
27	.	O
1	Neither	O
2	class	O
3	II	O
4	nor	O
5	IV	O
6	infections	O
7	precluded	O
8	transplantation	O
9	.	O
1	Upstream	O
2	of	O
3	-	O
4	37	O
5	,	O
6	the	O
7	5	O
8	'	O
9	untranslated	O
10	sequences	O
11	of	O
12	the	O
13	isolates	O
14	differ	O
15	in	O
16	both	O
17	length	O
18	and	O
19	sequence	O
20	.	O
1	In	O
2	these	O
3	cases	O
4	,	O
5	greatly	O
6	increased	O
7	human	B
8	chorionic	I
9	gonadotropin	I
10	(	O
11	hCG	B
12	)	O
13	levels	O
14	and	O
15	suppressed	O
16	TSH	B
17	levels	O
18	suggest	O
19	that	O
20	hCG	B
21	has	O
22	thyrotropic	O
23	activity	O
24	.	O
1	This	O
2	study	O
3	determined	O
4	the	O
5	arthritogenic	O
6	potential	O
7	of	O
8	silicone	O
9	gel	O
10	by	O
11	either	O
12	mixing	O
13	it	O
14	with	O
15	bovine	B
16	collagen	I
17	II	I
18	(	O
19	BII	B
20	)	O
21	or	O
22	by	O
23	injecting	O
24	silicone	O
25	gel	O
26	alone	O
27	in	O
28	DA	O
29	rats	O
30	.	O
1	SBF	B
2	binds	O
3	to	O
4	the	O
5	promoter	O
6	prior	O
7	to	O
8	the	O
9	activation	O
10	of	O
11	transcription	O
12	in	O
13	late	O
14	G1	O
15	,	O
16	suggesting	O
17	that	O
18	Cln	B
19	/	O
20	Cdc28	B
21	kinase	O
22	regulates	O
23	the	O
24	ability	O
25	of	O
26	previously	O
27	bound	O
28	SBF	B
29	to	O
30	activate	O
31	transcription	O
32	.	O
1	This	O
2	5	O
3	'	O
4	splice	O
5	site	O
6	sequence	O
7	was	O
8	required	O
9	for	O
10	enhanced	O
11	polyadenylation	O
12	and	O
13	was	O
14	recognized	O
15	by	O
16	both	O
17	U1	B
18	small	I
19	nuclear	I
20	ribonucleoproteins	I
21	(	O
22	snRNPs	O
23	)	O
24	and	O
25	alternative	B
26	splicing	I
27	factor	I
28	/	O
29	splicing	B
30	factor	I
31	2	I
32	(	O
33	ASF	B
34	/	O
35	SF2	B
36	).	O
1	Although	O
2	the	O
3	consumption	O
4	of	O
5	myoglobin	B
6	-	O
7	bound	O
8	O2	O
9	(	O
10	MbO2	O
11	)	O
12	stores	O
13	in	O
14	seal	O
15	muscles	O
16	has	O
17	been	O
18	demonstrated	O
19	in	O
20	seal	O
21	muscles	O
22	during	O
23	laboratory	O
24	simulations	O
25	of	O
26	diving	O
27	,	O
28	this	O
29	may	O
30	not	O
31	be	O
32	a	O
33	feature	O
34	of	O
35	normal	O
36	field	O
37	diving	O
38	in	O
39	which	O
40	measurements	O
41	of	O
42	heart	O
43	rate	O
44	and	O
45	lactate	O
46	production	O
47	show	O
48	marked	O
49	differences	O
50	from	O
51	the	O
52	profound	O
53	diving	O
54	response	O
55	induced	O
56	by	O
57	forced	O
58	immersion	O
59	.	O
1	The	O
2	Clb5	B
3	kinase	I
4	,	O
5	which	O
6	promotes	O
7	S	O
8	phase	O
9	,	O
10	remains	O
11	active	O
12	during	O
13	the	O
14	G2	O
15	-	O
16	phase	O
17	arrest	O
18	of	O
19	cells	O
20	of	O
21	the	O
22	parental	O
23	strain	O
24	,	O
25	but	O
26	its	O
27	activity	O
28	declines	O
29	rapidly	O
30	in	O
31	sim	B
32	mutants	I
33	.	O
1	Rad6	B
2	mutants	I
3	display	O
4	a	O
5	remarkably	O
6	pleiotropic	O
7	phenotype	O
8	,	O
9	implicating	O
10	the	O
11	protein	O
12	in	O
13	DNA	O
14	damage	O
15	-	O
16	induced	O
17	mutagenesis	O
18	,	O
19	postreplication	O
20	repair	O
21	,	O
22	repression	O
23	of	O
24	retrotransposition	O
25	,	O
26	and	O
27	sporulation	O
28	.	O
1	With	O
2	current	O
3	methodology	O
4	beta	B
5	-	I
6	2	I
7	transferrin	I
8	does	O
9	not	O
10	appear	O
11	to	O
12	be	O
13	a	O
14	reliable	O
15	clinical	O
16	marker	O
17	for	O
18	perilymph	O
19	in	O
20	the	O
21	operative	O
22	setting	O
23	.	O
1	Significant	O
2	correlations	O
3	existed	O
4	between	O
5	FEV1	O
6	and	O
7	the	O
8	corresponding	O
9	values	O
10	of	O
11	Raw	O
12	,	O
13	MEF50	O
14	and	O
15	MEF25	O
16	,	O
17	although	O
18	there	O
19	were	O
20	considerable	O
21	individual	O
22	differences	O
23	between	O
24	test	O
25	results	O
26	.	O
1	Occupational	O
2	exposure	O
3	to	O
4	hepatitis	O
5	B	O
6	virus	O
7	and	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	:	O
12	a	O
13	comparative	O
14	risk	O
15	analysis	O
16	.	O
1	Regressing	O
2	microaneurysms	O
3	in	O
4	5	O
5	cases	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	related	O
11	polyarteritis	O
12	nodosa	O
13	.	O
1	One	O
2	hundred	O
3	units	O
4	/	O
5	kg	O
6	of	O
7	recombinant	B
8	human	I
9	erythropoietin	I
10	(	O
11	rhEPO	B
12	)	O
13	was	O
14	given	O
15	subcutaneously	O
16	3	O
17	times	O
18	a	O
19	week	O
20	for	O
21	3	O
22	weeks	O
23	.	O
1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	haemodialysis	O
6	patients	O
7	with	O
8	chronic	O
9	hepatitis	O
10	C	O
11	respond	O
12	well	O
13	to	O
14	interferon	B
15	treatment	O
16	and	O
17	that	O
18	a	O
19	long	O
20	-	O
21	term	O
22	response	O
23	is	O
24	achieved	O
25	in	O
26	a	O
27	high	O
28	proportion	O
29	of	O
30	patients	O
31	.	O
1	This	O
2	study	O
3	proposes	O
4	an	O
5	estimator	O
6	for	O
7	such	O
8	global	O
9	synchronizing	O
10	effects	O
11	upon	O
12	unit	O
13	-	O
14	pair	O
15	correlations	O
16	based	O
17	on	O
18	local	O
19	field	O
20	potentials	O
21	(	O
22	LFPs	O
23	).	O
1	Effects	O
2	of	O
3	repeated	O
4	exposures	O
5	of	O
6	hydrogen	O
7	sulphide	O
8	on	O
9	rat	O
10	hippocampal	O
11	EEG	O
12	.	O
1	The	O
2	gene	O
3	encodes	O
4	an	O
5	ATP	B
6	-	I
7	binding	I
8	cassette	I
9	,	O
10	ABC	B
11	transporter	I
12	.	O
1	The	O
2	T	O
3	-	O
4	box	O
5	motif	O
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O
1	Pseudomembranous	O
2	conjunctivitis	O
3	following	O
4	bone	O
5	marrow	O
6	transplantation	O
7	:	O
8	immunopathological	O
9	and	O
10	ultrastructural	O
11	study	O
12	of	O
13	one	O
14	case	O
15	.	O
1	In	O
2	view	O
3	of	O
4	the	O
5	presence	O
6	of	O
7	SECIS	O
8	elements	O
9	in	O
10	the	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	)	O
17	of	O
18	bacterial	B
19	selenoproteins	I
20	,	O
21	we	O
22	examine	O
23	the	O
24	effects	O
25	in	O
26	the	O
27	type	B
28	1	I
29	deiodinase	I
30	of	O
31	extending	O
32	the	O
33	ORF	O
34	into	O
35	the	O
36	SECIS	O
37	element	O
38	,	O
39	and	O
40	find	O
41	that	O
42	this	O
43	dramatically	O
44	inhibits	O
45	SECIS	O
46	function	O
47	.	O
1	This	O
2	spindle	O
3	defect	O
4	of	O
5	pds1	B
6	mutants	I
7	results	O
8	from	O
9	a	O
10	temperature	O
11	-	O
12	sensitive	O
13	step	O
14	that	O
15	occurs	O
16	around	O
17	the	O
18	G1	O
19	/	O
20	S	O
21	boundary	O
22	about	O
23	the	O
24	time	O
25	of	O
26	spindle	O
27	assembly	O
28	.	O
1	However	O
2	,	O
3	for	O
4	the	O
5	evaluable	O
6	cases	O
7	,	O
8	the	O
9	performances	O
10	of	O
11	the	O
12	CD3500	O
13	and	O
14	the	O
15	STKS	O
16	were	O
17	broadly	O
18	similar	O
19	and	O
20	generally	O
21	correlated	O
22	well	O
23	with	O
24	the	O
25	manual	O
26	reference	O
27	procedure	O
28	.	O
1	Carboxy	O
2	-	O
3	terminal	O
4	Spc110p	B
5	truncations	O
6	lacking	O
7	the	O
8	calmodulin	B
9	binding	O
10	site	O
11	can	O
12	support	O
13	growth	O
14	and	O
15	are	O
16	also	O
17	phosphorylated	O
18	in	O
19	a	O
20	cell	O
21	cycle	O
22	-	O
23	specific	O
24	manner	O
25	.	O
1	In	O
2	conclusion	O
3	,	O
4	IgM	B
5	class	O
6	CIC	O
7	is	O
8	the	O
9	predominant	O
10	CIC	O
11	in	O
12	acute	O
13	hepatitis	O
14	A	O
15	and	O
16	correlated	O
17	with	O
18	disease	O
19	activity	O
20	.	O
1	The	O
2	membrane	O
3	-	O
4	distal	O
5	cytoplasmic	O
6	region	O
7	of	O
8	human	B
9	granulocyte	I
10	colony	I
11	-	I
12	stimulating	I
13	factor	I
14	receptor	I
15	is	O
16	required	O
17	for	O
18	STAT3	B
19	but	O
20	not	O
21	STAT1	B
22	homodimer	I
23	formation	O
24	.	O
1	Although	O
2	some	O
3	residues	O
4	are	O
5	found	O
6	reactive	O
7	toward	O
8	dimethylsulphate	O
9	and	O
10	kethoxal	O
11	in	O
12	regions	O
13	predicted	O
14	to	O
15	be	O
16	unpaired	O
17	by	O
18	the	O
19	phylogenetic	O
20	secondary	O
21	structure	O
22	model	O
23	of	O
24	4	B
25	.	I
26	5S	I
27	RNA	I
28	,	O
29	generally	O
30	the	O
31	reactivity	O
32	is	O
33	low	O
34	,	O
35	and	O
36	some	O
37	residues	O
38	in	O
39	internal	O
40	loops	O
41	are	O
42	not	O
43	reactive	O
44	at	O
45	all	O
46	.	O
1	Forty	O
2	-	O
3	five	O
4	patients	O
5	with	O
6	pleural	O
7	lesions	O
8	identified	O
9	on	O
10	CT	O
11	scans	O
12	were	O
13	subsequently	O
14	examined	O
15	by	O
16	MR	O
17	imaging	O
18	at	O
19	0	O
20	.	O
21	5	O
22	T	O
23	.	O
1	We	O
2	observed	O
3	abundant	O
4	levels	O
5	of	O
6	Rev	B
7	-	O
8	erbA	B
9	alpha	I
10	mRNA	O
11	in	O
12	dividing	O
13	C2C12	O
14	myoblasts	O
15	,	O
16	which	O
17	were	O
18	suppressed	O
19	when	O
20	the	O
21	cells	O
22	differentiated	O
23	into	O
24	postmitotic	O
25	multinucleated	O
26	myotubes	O
27	.	O
1	We	O
2	then	O
3	demonstrated	O
4	that	O
5	1	O
6	)	O
7	GAL4	B
8	-	O
9	REV	B
10	-	O
11	erbA	B
12	alpha	I
13	chimeras	O
14	that	O
15	contain	O
16	the	O
17	'	O
18	AB	O
19	'	O
20	region	O
21	and	O
22	lack	O
23	the	O
24	'	O
25	E	O
26	'	O
27	region	O
28	activated	O
29	transcription	O
30	of	O
31	GAL4	B
32	response	I
33	elements	I
34	in	O
35	the	O
36	presence	O
37	of	O
38	8	O
39	-	O
40	Br	O
41	-	O
42	cAMP	O
43	and	O
44	2	O
45	)	O
46	the	O
47	ligand	O
48	-	O
49	binding	O
50	domain	O
51	(	O
52	LBD	O
53	)	O
54	contains	O
55	an	O
56	active	O
57	transcriptional	O
58	silencer	O
59	.	O
1	TNF	B
2	Treatment	O
3	of	O
4	cell	O
5	activated	O
6	the	O
7	p38	B
8	MAP	I
9	kinase	I
10	pathway	O
11	,	O
12	as	O
13	revealed	O
14	by	O
15	increased	O
16	phosphorylation	O
17	of	O
18	p38	B
19	MAP	I
20	kinase	I
21	itself	O
22	,	O
23	activation	O
24	of	O
25	the	O
26	substrate	O
27	protein	O
28	MAPKAP	B
29	kinase	I
30	-	I
31	2	I
32	,	O
33	and	O
34	culminating	O
35	in	O
36	the	O
37	phosphorylation	O
38	of	O
39	the	O
40	heat	B
41	shock	I
42	protein	I
43	27	I
44	(	O
45	hsp27	B
46	).	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	protein	O
7	from	O
8	Drosophila	O
9	nuclear	O
10	extracts	O
11	which	O
12	binds	O
13	specifically	O
14	to	O
15	a	O
16	site	O
17	in	O
18	this	O
19	second	O
20	region	O
21	.	O
1	Further	O
2	analysis	O
3	of	O
4	this	O
5	domain	O
6	by	O
7	in	O
8	vitro	O
9	mutagenesis	O
10	pointed	O
11	to	O
12	a	O
13	core	O
14	of	O
15	hydrophobic	O
16	and	O
17	acidic	O
18	residues	O
19	as	O
20	critical	O
21	for	O
22	the	O
23	activity	O
24	.	O
1	Analysis	O
2	of	O
3	RAR	B
4	alpha	I
5	mutants	I
6	in	O
7	transfection	O
8	studies	O
9	reveals	O
10	that	O
11	the	O
12	DNA	O
13	binding	O
14	domain	O
15	is	O
16	sufficient	O
17	for	O
18	inhibition	O
19	of	O
20	BZLF1	B
21	activity	O
22	.	O
1	We	O
2	measured	O
3	serum	B
4	hepatocyte	I
5	growth	I
6	factor	I
7	(	O
8	HGF	B
9	)	O
10	in	O
11	patients	O
12	with	O
13	acute	O
14	myocardial	O
15	infarction	O
16	,	O
17	angina	O
18	pectoris	O
19	,	O
20	and	O
21	other	O
22	heart	O
23	diseases	O
24	.	O
1	It	O
2	is	O
3	shown	O
4	that	O
5	the	O
6	(	O
7	G	O
8	+	O
9	C	O
10	)-	O
11	rich	O
12	element	O
13	of	O
14	the	O
15	aldolase	B
16	C	I
17	promoter	I
18	directs	O
19	transcription	O
20	in	O
21	neuronal	O
22	as	O
23	well	O
24	as	O
25	in	O
26	nonneuronal	O
27	cells	O
28	.	O
1	We	O
2	isolated	O
3	a	O
4	complementary	O
5	DNA	O
6	(	O
7	cDNA	O
8	)	O
9	clone	O
10	from	O
11	an	O
12	RL95	O
13	-	O
14	2	O
15	expression	O
16	library	O
17	that	O
18	encodes	O
19	the	O
20	C1	B
21	site	I
22	-	I
23	binding	I
24	protein	I
25	.	O
1	Thus	O
2	,	O
3	hGRbeta	B
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	hGRalpha	B
13	activity	O
14	.	O
1	Inclusion	O
2	of	O
3	the	O
4	extended	O
5	N	O
6	terminus	O
7	into	O
8	the	O
9	originally	O
10	reported	O
11	protein	O
12	resulted	O
13	in	O
14	a	O
15	striking	O
16	similarity	O
17	to	O
18	the	O
19	lymphoid	B
20	factor	I
21	Lef	I
22	-	I
23	1	I
24	.	O
1	The	O
2	large	O
3	subfamily	O
4	of	O
5	receptor	B
6	tyrosine	I
7	kinases	I
8	(	O
9	RTKs	B
10	)	O
11	for	O
12	which	O
13	EPH	B
14	is	O
15	the	O
16	prototype	O
17	have	O
18	likely	O
19	roles	O
20	in	O
21	intercellular	O
22	communication	O
23	during	O
24	normal	O
25	mammalian	O
26	development	O
27	,	O
28	but	O
29	the	O
30	biochemical	O
31	signalling	O
32	pathways	O
33	utilised	O
34	by	O
35	this	O
36	family	O
37	are	O
38	poorly	O
39	characterised	O
40	.	O
1	In	O
2	agreement	O
3	with	O
4	previous	O
5	in	O
6	vitro	O
7	data	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	UmuD	B
14	and	O
15	UmuD	B
16	'	I
17	are	O
18	able	O
19	to	O
20	form	O
21	both	O
22	homodimers	O
23	(	O
24	UmuD	B
25	-	O
26	UmuD	B
27	and	O
28	UmuD	O
29	'-	O
30	UmuD	O
31	')	O
32	and	O
33	a	O
34	heterodimer	O
35	(	O
36	UmuD	B
37	-	O
38	UmuD	O
39	').	O
1	Vertebrate	B
2	synapsins	I
3	constitute	O
4	a	O
5	family	O
6	of	O
7	synaptic	O
8	proteins	O
9	that	O
10	participate	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	neurotransmitter	O
16	release	O
17	.	O
1	This	O
2	result	O
3	suggested	O
4	that	O
5	mutant	O
6	I299	O
7	has	O
8	diminished	O
9	cap	O
10	-	O
11	binding	O
12	activity	O
13	.	O
1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	demonstrated	O
7	that	O
8	HSV	O
9	infection	O
10	caused	O
11	enhanced	O
12	binding	O
13	of	O
14	protein	O
15	factors	O
16	,	O
17	including	O
18	the	O
19	64	B
20	-	I
21	kDa	I
22	component	I
23	of	I
24	cleavage	I
25	stimulation	I
26	factor	I
27	(	O
28	CstF	B
29	),	O
30	to	O
31	poly	O
32	(	O
33	A	O
34	)	O
35	site	O
36	RNAs	O
37	from	O
38	virus	O
39	genes	O
40	of	O
41	all	O
42	temporal	O
43	classes	O
44	and	O
45	that	O
46	this	O
47	enhanced	O
48	binding	O
49	required	O
50	expression	O
51	of	O
52	IE63	B
53	.	O
1	In	O
2	synchronized	O
3	HeLa	O
4	cells	O
5	,	O
6	expression	O
7	of	O
8	luciferase	B
9	activity	O
10	was	O
11	induced	O
12	at	O
13	the	O
14	beginning	O
15	of	O
16	DNA	O
17	synthesis	O
18	and	O
19	was	O
20	dependent	O
21	on	O
22	the	O
23	presence	O
24	of	O
25	an	O
26	E2F	B
27	-	I
28	binding	I
29	site	I
30	in	O
31	the	O
32	H2A	B
33	.	I
34	1	I
35	promoter	I
36	.	O
1	A	O
2	developmentally	O
3	regulated	O
4	4	O
5	.	O
6	6	O
7	kb	O
8	mRNA	O
9	is	O
10	recognized	O
11	on	O
12	Northern	O
13	blots	O
14	of	O
15	oocyte	O
16	RNA	O
17	using	O
18	the	O
19	X	O
20	.	O
21	laevis	O
22	cDNA	O
23	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	increase	O
7	in	O
8	V	O
9	O2	O
10	may	O
11	have	O
12	been	O
13	a	O
14	consequence	O
15	of	O
16	the	O
17	increase	O
18	in	O
19	Q	O
20	O2	O
21	rather	O
22	than	O
23	a	O
24	response	O
25	to	O
26	the	O
27	procedure	O
28	itself	O
29	.	O
1	Several	O
2	cytokines	O
3	exhibit	O
4	a	O
5	high	O
6	degree	O
7	of	O
8	temporal	O
9	regulation	O
10	as	O
11	well	O
12	as	O
13	somnogenic	O
14	potency	O
15	(	O
16	e	O
17	.	O
18	g	O
19	.,	O
20	interleukin	B
21	-	I
22	1	I
23	[	O
24	IL	B
25	-	I
26	1	I
27	],	O
28	tumor	B
29	necrosis	I
30	factor	I
31	-	I
32	alpha	I
33	[	O
34	TNF	B
35	-	I
36	alpha	I
37	]).	O
1	The	O
2	members	O
3	of	O
4	the	O
5	Myb	B
6	family	I
7	of	I
8	transcription	I
9	factors	I
10	are	O
11	defined	O
12	by	O
13	homology	O
14	in	O
15	the	O
16	DNA	O
17	-	O
18	binding	O
19	domain	O
20	;	O
21	all	O
22	bind	O
23	the	O
24	Myb	B
25	-	I
26	binding	I
27	site	I
28	(	O
29	MBS	B
30	)	O
31	sequence	O
32	(	O
33	YG	O
34	(	O
35	A	O
36	/	O
37	G	O
38	)	O
39	C	O
40	(	O
41	A	O
42	/	O
43	C	O
44	/	O
45	G	O
46	)	O
47	GTT	O
48	(	O
49	G	O
50	/	O
51	A	O
52	)).	O
1	The	O
2	frequency	O
3	of	O
4	integrations	O
5	that	O
6	led	O
7	to	O
8	transcription	O
9	of	O
10	the	O
11	lacZ	B
12	gene	I
13	was	O
14	estimated	O
15	to	O
16	be	O
17	0	O
18	.	O
19	5	O
20	%	O
21	of	O
22	all	O
23	integrations	O
24	,	O
25	of	O
26	which	O
27	14	O
28	%	O
29	were	O
30	downregulated	O
31	on	O
32	differentiation	O
33	of	O
34	32D	O
35	cells	O
36	towards	O
37	neutrophils	O
38	.	O
1	Both	O
2	mutant	O
3	receptors	O
4	were	O
5	expressed	O
6	on	O
7	the	O
8	cell	O
9	surface	O
10	and	O
11	bound	O
12	insulin	B
13	normally	O
14	,	O
15	but	O
16	showed	O
17	markedly	O
18	impaired	O
19	autophosphorylation	O
20	in	O
21	response	O
22	to	O
23	insulin	B
24	.	O
1	OND	O
2	8	O
3	mg	O
4	tid	O
5	days	O
6	2	O
7	-	O
8	3	O
9	,	O
10	and	O
11	8	O
12	mg	O
13	tid	O
14	prn	O
15	days	O
16	4	O
17	-	O
18	5	O
19	and	O
20	prednisolone	O
21	75	O
22	-	O
23	100	O
24	mg	O
25	qds	O
26	days	O
27	2	O
28	-	O
29	5	O
30	and	O
31	2	O
32	)	O
33	MCP	O
34	30	O
35	mg	O
36	/	O
37	metylprednisolone	O
38	80	O
39	mg	O
40	i	O
41	.	O
42	v	O
43	.	O
44	before	O
45	CT	O
46	and	O
47	MCP	O
48	20	O
49	mg	O
50	p	O
51	.	O
52	r	O
53	.	O
54	after	O
55	4	O
56	and	O
57	8	O
58	h	O
59	respectively	O
60	.	O
1	The	O
2	dynamic	O
3	properties	O
4	of	O
5	this	O
6	protein	O
7	fragment	O
8	were	O
9	measured	O
10	and	O
11	analyzed	O
12	using	O
13	both	O
14	isotropic	O
15	and	O
16	anisotropic	O
17	models	O
18	of	O
19	molecular	O
20	motion	O
21	.	O
1	T	O
2	cell	O
3	leukemia	O
4	-	O
5	associated	O
6	human	O
7	Notch	B
8	/	O
9	translocation	O
10	-	O
11	associated	O
12	Notch	B
13	homologue	O
14	has	O
15	I	B
16	kappa	I
17	B	I
18	-	O
19	like	O
20	activity	O
21	and	O
22	physically	O
23	interacts	O
24	with	O
25	nuclear	B
26	factor	I
27	-	I
28	kappa	I
29	B	I
30	proteins	O
31	in	O
32	T	O
33	cells	O
34	.	O
1	An	O
2	apparent	O
3	N	O
4	-	O
5	terminal	O
6	transit	O
7	peptide	O
8	in	O
9	the	O
10	coding	O
11	region	O
12	and	O
13	a	O
14	3	O
15	'	O
16	poly	O
17	(	O
18	A	O
19	)	O
20	tail	O
21	exist	O
22	in	O
23	the	O
24	cDNA	O
25	clone	O
26	indicated	O
27	that	O
28	this	O
29	chloroplast	O
30	protein	O
31	as	O
32	nuclear	O
33	encoded	O
34	.	O
1	Subcellular	O
2	localizations	O
3	of	O
4	the	O
5	wild	B
6	-	I
7	type	I
8	CBFbeta	I
9	and	O
10	the	O
11	CBFbeta	B
12	-	O
13	SMMHC	B
14	fusion	O
15	protein	O
16	were	O
17	determined	O
18	by	O
19	immunofluorescence	O
20	of	O
21	NIH	O
22	3T3	O
23	cells	O
24	that	O
25	overexpress	O
26	wild	O
27	-	O
28	type	O
29	or	O
30	fusion	O
31	protein	O
32	.	O
1	Menstrual	O
2	-	O
3	cycle	O
4	phase	O
5	did	O
6	not	O
7	significantly	O
8	affect	O
9	personality	O
10	variables	O
11	in	O
12	either	O
13	group	O
14	.	O
1	The	O
2	Cdk2	B
3	-	O
4	cyclin	B
5	-	I
6	D1	I
7	complex	O
8	did	O
9	not	O
10	phosphorylate	O
11	any	O
12	tested	O
13	substrates	O
14	,	O
15	such	O
16	as	O
17	H1	B
18	histone	I
19	,	O
20	pRB	B
21	,	O
22	SV40	B
23	large	I
24	T	I
25	antigen	I
26	,	O
27	p53	B
28	,	O
29	E2F	B
30	-	I
31	1	I
32	or	O
33	a	O
34	preparation	O
35	of	O
36	nuclear	O
37	proteins	O
38	from	O
39	HeLa	O
40	cells	O
41	;	O
42	in	O
43	contrast	O
44	,	O
45	Cdk2	B
46	-	O
47	cyclin	B
48	-	I
49	E	I
50	and	O
51	Cdk2	B
52	-	O
53	cyclin	B
54	-	I
55	A	I
56	phosphorylated	O
57	these	O
58	proteins	O
59	.	O
1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	P2	B
6	-	I
7	proximal	I
8	CTCF	I
9	binding	I
10	site	I
11	and	O
12	transient	O
13	-	O
14	cotransfection	O
15	experiments	O
16	demonstrate	O
17	that	O
18	CTCF	B
19	is	O
20	a	O
21	transcriptional	O
22	repressor	O
23	of	O
24	the	O
25	human	B
26	c	I
27	-	I
28	myc	I
29	gene	I
30	.	O
1	The	O
2	heterogeneity	O
3	of	O
4	bovine	B
5	IgG2	I
6	--	I
7	VIII	I
8	.	O
1	Mesial	O
2	temporal	O
3	sclerosis	O
4	was	O
5	characterized	O
6	by	O
7	severe	O
8	neuronal	O
9	loss	O
10	accompanied	O
11	by	O
12	gliosis	O
13	occurring	O
14	in	O
15	the	O
16	CA1	O
17	/	O
18	prosubiculum	O
19	(	O
20	27	O
21	patients	O
22	,	O
23	100	O
24	%),	O
25	focally	O
26	in	O
27	the	O
28	dentate	O
29	gyrus	O
30	(	O
31	12	O
32	patients	O
33	,	O
34	44	O
35	%),	O
36	and	O
37	in	O
38	the	O
39	CA4	O
40	region	O
41	(	O
42	11	O
43	patients	O
44	,	O
45	41	O
46	%).	O
1	Therefore	O
2	,	O
3	magnetic	O
4	resonance	O
5	imaging	O
6	was	O
7	used	O
8	to	O
9	determine	O
10	liver	O
11	volume	O
12	in	O
13	pediatric	O
14	and	O
15	adolescent	O
16	patients	O
17	,	O
18	in	O
19	whom	O
20	systemic	O
21	clearance	O
22	of	O
23	three	O
24	model	O
25	substrates	O
26	[	O
27	lorazepam	O
28	(	O
29	0	O
30	.	O
31	03	O
32	mg	O
33	/	O
34	kg	O
35	),	O
36	antipyrine	O
37	(	O
38	10	O
39	mg	O
40	/	O
41	kg	O
42	),	O
43	and	O
44	indocyanine	O
45	green	O
46	(	O
47	ICG	O
48	;	O
49	0	O
50	.	O
51	5	O
52	mg	O
53	/	O
54	kg	O
55	)]	O
56	was	O
57	also	O
58	determined	O
59	.	O
1	The	O
2	transcription	O
3	start	O
4	point	O
5	of	O
6	the	O
7	proximal	O
8	promoter	O
9	aligns	O
10	to	O
11	that	O
12	of	O
13	mouse	O
14	promoter	O
15	P3	O
16	and	O
17	lies	O
18	within	O
19	a	O
20	conserved	O
21	region	O
22	of	O
23	sequence	O
24	.	O
1	MATERIALS	O
2	AND	O
3	METHODS	O
4	:	O
5	Coronal	O
6	3D	O
7	GRE	O
8	imaging	O
9	was	O
10	used	O
11	to	O
12	study	O
13	the	O
14	volar	O
15	,	O
16	middle	O
17	,	O
18	and	O
19	dorsal	O
20	portions	O
21	of	O
22	the	O
23	SLL	O
24	in	O
25	14	O
26	patients	O
27	with	O
28	an	O
29	arthroscopically	O
30	normal	O
31	SLL	O
32	and	O
33	in	O
34	five	O
35	cadaveric	O
36	wrists	O
37	that	O
38	had	O
39	a	O
40	normal	O
41	SLL	O
42	proved	O
43	with	O
44	dissection	O
45	.	O
1	The	O
2	exon	O
3	-	O
4	intron	O
5	distribution	O
6	of	O
7	Cdebp	B
8	appears	O
9	strikingly	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	the	O
15	App	B
16	gene	I
17	in	O
18	the	O
19	regions	O
20	encoding	O
21	the	O
22	conserved	O
23	domains	O
24	,	O
25	with	O
26	a	O
27	divergent	O
28	structure	O
29	in	O
30	the	O
31	other	O
32	parts	O
33	.	O
1	Oncogenic	B
2	Raf	I
3	-	I
4	1	I
5	activates	O
6	p70	B
7	S6	I
8	kinase	I
9	via	O
10	a	O
11	mitogen	B
12	-	I
13	activated	I
14	protein	I
15	kinase	I
16	-	O
17	independent	O
18	pathway	O
19	.	O
1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	B
6	PGS	I
7	-	I
8	2	I
9	gene	I
10	contains	O
11	a	O
12	CAAT	B
13	enhancer	I
14	-	I
15	binding	I
16	protein	I
17	consensus	I
18	site	I
19	(	I
20	CAAT	I
21	box	I
22	)	I
23	which	O
24	can	O
25	confer	O
26	hormone	O
27	inducibility	O
28	to	O
29	a	O
30	PGS	B
31	-	I
32	2	I
33	.	O
34	CAT	B
35	reporter	O
36	gene	O
37	,	O
38	as	O
39	well	O
40	as	O
41	a	O
42	putative	O
43	E	O
44	-	O
45	box	O
46	region	O
47	.	O
1	Clinical	O
2	evaluation	O
3	of	O
4	the	O
5	Allergan	O
6	Humphrey	O
7	500	O
8	autorefractor	O
9	and	O
10	the	O
11	Nidek	O
12	AR	O
13	-	O
14	1000	O
15	autorefractor	O
16	.	O
1	These	O
2	changes	O
3	may	O
4	be	O
5	the	O
6	result	O
7	of	O
8	,	O
9	on	O
10	the	O
11	one	O
12	hand	O
13	,	O
14	an	O
15	increased	O
16	sensitivity	O
17	of	O
18	the	O
19	neuromuscular	O
20	transmission	O
21	and	O
22	/	O
23	or	O
24	decreased	O
25	muscle	O
26	contractility	O
27	and	O
28	,	O
29	on	O
30	the	O
31	other	O
32	hand	O
33	,	O
34	the	O
35	result	O
36	of	O
37	a	O
38	reduced	O
39	plasma	O
40	clearance	O
41	during	O
42	hypothermia	O
43	.	O
1	YAC	O
2	and	O
3	cosmid	O
4	contigs	O
5	spanning	O
6	the	O
7	Batten	B
8	disease	I
9	(	O
10	CLN3	B
11	)	O
12	region	O
13	at	O
14	16p12	O
15	.	O
16	1	O
17	-	O
18	p11	O
19	.	O
20	2	O
21	.	O
1	The	O
2	introduction	O
3	of	O
4	hARF4	B
5	to	O
6	the	O
7	cells	O
8	maintained	O
9	the	O
10	balance	O
11	between	O
12	cytosolic	O
13	and	O
14	membrane	O
15	-	O
16	associated	O
17	Sec7p	B
18	pools	O
19	.	O
1	FTF	B
2	is	O
3	also	O
4	abundantly	O
5	expressed	O
6	in	O
7	the	O
8	pancreas	O
9	and	O
10	may	O
11	exert	O
12	differentiation	O
13	functions	O
14	in	O
15	endodermal	O
16	sublineages	O
17	,	O
18	similar	O
19	to	O
20	SF	B
21	-	I
22	1	I
23	in	O
24	steroidogenic	O
25	tissues	O
26	.	O
1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	MI	O
14	(	O
15	propofol	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	midazolam	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	O
33	or	O
34	non	O
35	Q	O
36	wave	O
37	MI	O
38	(	O
39	propofol	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	midazolam	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O
1	Interestingly	O
2	,	O
3	however	O
4	,	O
5	it	O
6	is	O
7	homologous	O
8	to	O
9	several	O
10	expressed	O
11	sequence	O
12	tags	O
13	(	O
14	EST	O
15	)	O
16	of	O
17	unknown	O
18	function	O
19	from	O
20	Caenorhabditis	O
21	elegans	O
22	,	O
23	Oryza	O
24	sativa	O
25	and	O
26	Homo	O
27	sapiens	O
28	.	O
1	RESULTS	O
2	:	O
3	The	O
4	bilinear	O
5	model	O
6	provided	O
7	a	O
8	significantly	O
9	better	O
10	fit	O
11	to	O
12	the	O
13	acuity	O
14	outcome	O
15	data	O
16	.	O
1	The	O
2	mean	O
3	values	O
4	of	O
5	protease	O
6	activity	O
7	were	O
8	significantly	O
9	higher	O
10	in	O
11	the	O
12	test	O
13	groups	O
14	than	O
15	in	O
16	the	O
17	control	O
18	group	O
19	at	O
20	baseline	O
21	.	O
1	However	O
2	,	O
3	one	O
4	3	O
5	'	O
6	splice	O
7	site	O
8	,	O
9	located	O
10	at	O
11	nucleotide	O
12	(	O
13	nt	O
14	)	O
15	3225	O
16	,	O
17	is	O
18	used	O
19	for	O
20	the	O
21	processing	O
22	of	O
23	most	O
24	BPV	O
25	-	O
26	1	O
27	pre	O
28	-	O
29	mRNAs	O
30	in	O
31	BPV	O
32	-	O
33	1	O
34	-	O
35	transformed	O
36	C127	O
37	cells	O
38	and	O
39	at	O
40	early	O
41	to	O
42	intermediate	O
43	times	O
44	in	O
45	productively	O
46	infected	O
47	warts	O
48	.	O
1	A	O
2	phylogenetic	O
3	tree	O
4	of	O
5	members	O
6	of	O
7	the	O
8	T2	B
9	/	I
10	S	I
11	-	I
12	RNase	I
13	superfamily	I
14	in	O
15	plants	O
16	was	O
17	obtained	O
18	.	O
1	Although	O
2	the	O
3	DSK2	B
4	-	I
5	1	I
6	mutation	I
7	alters	O
8	a	O
9	conserved	O
10	residue	O
11	in	O
12	the	O
13	Dsk2p	B
14	ubiquitin	I
15	-	I
16	like	I
17	domain	I
18	,	O
19	we	O
20	detect	O
21	no	O
22	differences	O
23	in	O
24	Dsk2p	B
25	or	O
26	Cdc31p	B
27	stability	O
28	.	O
1	Although	O
2	IL	B
3	-	I
4	2	I
5	and	O
6	IFN	B
7	-	I
8	alpha	I
9	activated	O
10	STAT1	B
11	alpha	I
12	and	O
13	STAT5	B
14	,	O
15	IL	B
16	-	I
17	2	I
18	predominantly	O
19	activated	O
20	STAT5	B
21	,	O
22	while	O
23	IFN	B
24	-	I
25	alpha	I
26	predominantly	O
27	activated	O
28	STAT1	B
29	alpha	I
30	.	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	compare	O
5	pregnancy	O
6	complications	O
7	in	O
8	women	O
9	having	O
10	genetic	O
11	amniocentesis	O
12	at	O
13	11	O
14	-	O
15	14	O
16	weeks	O
17	versus	O
18	those	O
19	undergoing	O
20	amniocentesis	O
21	at	O
22	16	O
23	-	O
24	19	O
25	weeks	O
26	'	O
27	gestation	O
28	.	O
1	Limited	O
2	role	O
3	for	O
4	PCR	O
5	-	O
6	based	O
7	diagnosis	O
8	of	O
9	Whipple	O
10	'	O
11	s	O
12	disease	O
13	from	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	.	O
1	The	O
2	ability	O
3	of	O
4	A20	B
5	to	O
6	block	O
7	NF	B
8	-	I
9	kappaB	I
10	activation	O
11	was	O
12	mapped	O
13	to	O
14	its	O
15	C	O
16	-	O
17	terminal	O
18	zinc	O
19	finger	O
20	domain	O
21	.	O
1	The	O
2	Pro	O
3	-	O
4	258	O
5	-->	O
6	Leu	O
7	(	O
8	P258L	O
9	)	O
10	mutation	O
11	caused	O
12	constitutive	O
13	receptor	O
14	signaling	O
15	that	O
16	was	O
17	equivalent	O
18	to	O
19	about	O
20	45	O
21	%	O
22	of	O
23	the	O
24	maximum	O
25	level	O
26	observed	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	cells	O
32	stimulated	O
33	with	O
34	alpha	B
35	-	I
36	factor	I
37	.	O
1	The	O
2	mechanism	O
3	involves	O
4	Gbetagamma	B
5	subunit	O
6	-	O
7	mediated	O
8	increases	O
9	in	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	Shc	B
15	adapter	I
16	protein	I
17	,	O
18	Shc	B
19	*	O
20	Grb2	B
21	complex	O
22	formation	O
23	,	O
24	and	O
25	recruitment	O
26	of	O
27	Ras	B
28	guanine	I
29	nucleotide	I
30	exchange	I
31	factor	I
32	activity	O
33	.	O
1	Initial	O
2	estimates	O
3	indicate	O
4	that	O
5	27	O
6	,	O
7	193	O
8	people	O
9	are	O
10	either	O
11	in	O
12	receipt	O
13	of	O
14	or	O
15	in	O
16	need	O
17	of	O
18	mental	O
19	handicap	O
20	services	O
21	.	O
1	It	O
2	is	O
3	exclusively	O
4	observed	O
5	in	O
6	smooth	O
7	muscle	O
8	cells	O
9	by	O
10	Northern	O
11	blotting	O
12	and	O
13	immunohistochemical	O
14	analysis	O
15	and	O
16	therefore	O
17	designated	O
18	""""	B
19	smoothelin	I
20	"."""	I
21	A	O
22	human	O
23	smooth	O
24	muscle	O
25	cDNA	O
26	library	O
27	was	O
28	screened	O
29	with	O
30	the	O
31	monoclonal	B
32	antibody	I
33	R4A	I
34	,	O
35	and	O
36	a	O
37	full	O
38	-	O
39	size	O
40	cDNA	O
41	of	O
42	the	O
43	protein	O
44	was	O
45	selected	O
46	.	O
1	Our	O
2	studies	O
3	also	O
4	excluded	O
5	the	O
6	possibility	O
7	that	O
8	the	O
9	phosphorylation	O
10	of	O
11	Ser	O
12	-	O
13	2	O
14	,	O
15	Ser	O
16	-	O
17	123	O
18	,	O
19	or	O
20	Ser	O
21	-	O
22	210	O
23	,	O
24	had	O
25	roles	O
26	in	O
27	the	O
28	trans	O
29	-	O
30	suppression	O
31	activity	O
32	of	O
33	the	O
34	large	B
35	HDAg	I
36	,	O
37	in	O
38	the	O
39	assembly	O
40	of	O
41	empty	O
42	virus	B
43	-	I
44	like	I
45	HDAg	I
46	particle	I
47	,	O
48	and	O
49	in	O
50	the	O
51	nuclear	O
52	transport	O
53	of	O
54	HDAgs	B
55	.	O
1	The	O
2	data	O
3	further	O
4	indicate	O
5	that	O
6	the	O
7	IL	B
8	-	I
9	7R	I
10	alpha	I
11	chains	I
12	are	O
13	directly	O
14	involved	O
15	in	O
16	the	O
17	activation	O
18	of	O
19	JAKs	B
20	and	O
21	STATs	B
22	and	O
23	have	O
24	a	O
25	major	O
26	role	O
27	in	O
28	proliferative	O
29	signaling	O
30	in	O
31	precursor	O
32	B	O
33	cells	O
34	.	O
1	5	O
2	)	O
3	We	O
4	'	O
5	ve	O
6	noticed	O
7	that	O
8	the	O
9	mean	O
10	value	O
11	of	O
12	the	O
13	cost	O
14	for	O
15	episode	O
16	of	O
17	pnx	O
18	s	O
19	.	O
20	in	O
21	class	O
22	A	O
23	was	O
24	more	O
25	than	O
26	15	O
27	%	O
28	compared	O
29	to	O
30	class	O
31	B	O
32	and	O
33	the	O
34	cost	O
35	for	O
36	patient	O
37	in	O
38	class	O
39	A	O
40	was	O
41	nearly	O
42	double	O
43	than	O
44	in	O
45	class	O
46	B	O
47	.	O
1	Laboratory	O
2	evaluation	O
3	was	O
4	normal	O
5	,	O
6	and	O
7	neuroimaging	O
8	failed	O
9	to	O
10	confirm	O
11	obstruction	O
12	of	O
13	venous	O
14	or	O
15	lymphatic	O
16	drainage	O
17	.	O
1	METHODS	O
2	:	O
3	DSF	O
4	was	O
5	instilled	O
6	in	O
7	one	O
8	eye	O
9	chosen	O
10	at	O
11	random	O
12	and	O
13	CF	O
14	in	O
15	the	O
16	fellow	O
17	eye	O
18	of	O
19	13	O
20	normal	O
21	subjects	O
22	and	O
23	in	O
24	13	O
25	patients	O
26	with	O
27	KCS	O
28	.	O
1	The	O
2	concentrations	O
3	of	O
4	vitamin	O
5	A	O
6	precursors	O
7	and	O
8	vitamin	O
9	E	O
10	in	O
11	the	O
12	hay	O
13	were	O
14	below	O
15	currently	O
16	recommended	O
17	dietary	O
18	levels	O
19	for	O
20	llamas	O
21	,	O
22	and	O
23	alfalfa	O
24	hay	O
25	appears	O
26	to	O
27	provide	O
28	an	O
29	unreliable	O
30	source	O
31	of	O
32	vitamins	O
33	A	O
34	and	O
35	E	O
36	in	O
37	this	O
38	species	O
39	.	O
1	Eight	O
2	cats	O
3	infected	O
4	with	O
5	H	O
6	.	O
7	pylori	O
8	were	O
9	used	O
10	in	O
11	the	O
12	study	O
13	.	O
1	Ten	O
2	weeks	O
3	after	O
4	reconstruction	O
5	,	O
6	the	O
7	regenerating	O
8	nerves	O
9	already	O
10	resembled	O
11	normal	O
12	nerves	O
13	.	O
1	Facioscapulohumeral	O
2	muscular	O
3	dystrophy	O
4	(	O
5	FSHD	O
6	)	O
7	is	O
8	an	O
9	autosomal	O
10	dominant	O
11	,	O
12	neuromuscular	O
13	disorder	O
14	characterized	O
15	by	O
16	progressive	O
17	weakness	O
18	of	O
19	muscles	O
20	in	O
21	the	O
22	face	O
23	,	O
24	shoulder	O
25	and	O
26	upper	O
27	arm	O
28	.	O
1	The	O
2	mature	O
3	chromosome	O
4	4	O
5	FRG1	B
6	transcript	I
7	is	O
8	1042	O
9	bp	O
10	in	O
11	length	O
12	and	O
13	contains	O
14	nine	O
15	exons	O
16	which	O
17	encode	O
18	a	O
19	putative	O
20	protein	O
21	of	O
22	258	O
23	amino	O
24	acid	O
25	residues	O
26	.	O
1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	crossover	O
7	AM	O
8	between	O
9	dissimilar	O
10	textures	O
11	was	O
12	investigated	O
13	,	O
14	and	O
15	it	O
16	was	O
17	found	O
18	that	O
19	the	O
20	more	O
21	salient	O
22	textures	O
23	carried	O
24	the	O
25	AM	O
26	.	O
1	Protein	O
2	films	O
3	are	O
4	distinctly	O
5	different	O
6	in	O
7	mechanical	O
8	profiles	O
9	from	O
10	those	O
11	films	O
12	made	O
13	of	O
14	other	O
15	materials	O
16	.	O
1	AIMS	O
2	/	O
3	METHODS	O
4	:	O
5	Reticuloendothelial	O
6	system	O
7	function	O
8	,	O
9	as	O
10	assessed	O
11	by	O
12	clearance	O
13	of	O
14	radiolabelled	O
15	bacteria	O
16	,	O
17	was	O
18	evaluated	O
19	in	O
20	acute	O
21	liver	O
22	injury	O
23	induced	O
24	by	O
25	D	O
26	-	O
27	galactosamine	O
28	in	O
29	rats	O
30	,	O
31	and	O
32	compared	O
33	with	O
34	that	O
35	after	O
36	70	O
37	%	O
38	liver	O
39	resection	O
40	model	O
41	.	O
1	The	O
2	upTRE	O
3	binds	O
4	more	O
5	T3R	B
6	homodimers	I
7	and	O
8	less	O
9	T3R	B
10	-	O
11	RXR	B
12	heterodimers	O
13	than	O
14	the	O
15	dnTRE	O
16	,	O
17	and	O
18	T3	O
19	more	O
20	readily	O
21	facilitates	O
22	heterodimer	O
23	binding	O
24	to	O
25	the	O
26	dn	O
27	-	O
28	than	O
29	to	O
30	the	O
31	upTRE	O
32	.	O
1	Mutants	O
2	lacking	O
3	the	O
4	3	O
5	'	O
6	stem	O
7	-	O
8	loop	O
9	exhibited	O
10	a	O
11	75	O
12	%	O
13	reduction	O
14	in	O
15	the	O
16	level	O
17	of	O
18	psaB	B
19	mRNA	O
20	.	O
1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	was	O
7	highly	O
8	conserved	O
9	across	O
10	the	O
11	wide	O
12	range	O
13	of	O
14	eukaryotes	O
15	(	O
16	vertebrates	O
17	,	O
18	invertebrates	O
19	,	O
20	fungi	O
21	,	O
22	plants	O
23	and	O
24	protozoa	O
25	)	O
26	in	O
27	which	O
28	this	O
29	gene	O
30	has	O
31	now	O
32	been	O
33	identified	O
34	.	O
1	Previous	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	the	O
7	616	O
8	amino	O
9	acid	O
10	,	O
11	70	B
12	-	I
13	kDa	I
14	subunit	I
15	of	I
16	RPA	I
17	(	O
18	RPA	B
19	70	I
20	)	O
21	is	O
22	composed	O
23	of	O
24	multiple	O
25	structural	O
26	/	O
27	functional	O
28	domains	O
29	.	O
1	It	O
2	is	O
3	the	O
4	oxidation	O
5	peak	O
6	of	O
7	this	O
8	product	O
9	,	O
10	arising	O
11	in	O
12	acidic	O
13	media	O
14	at	O
15	0	O
16	.	O
17	42	O
18	V	O
19	,	O
20	which	O
21	was	O
22	analysed	O
23	using	O
24	DPV	O
25	,	O
26	again	O
27	following	O
28	the	O
29	accumulation	O
30	of	O
31	clenbuterol	O
32	at	O
33	the	O
34	Nafion	O
35	-	O
36	modified	O
37	CPE	O
38	.	O
1	In	O
2	an	O
3	effort	O
4	to	O
5	isolate	O
6	genes	O
7	with	O
8	down	O
9	-	O
10	regulated	O
11	expression	O
12	at	O
13	the	O
14	mRNA	O
15	level	O
16	during	O
17	oncogenic	O
18	transformation	O
19	of	O
20	human	O
21	mammary	O
22	epithelial	O
23	cells	O
24	(	O
25	MECs	O
26	),	O
27	we	O
28	performed	O
29	subtractive	O
30	hybridization	O
31	between	O
32	normal	O
33	MEC	O
34	strain	O
35	76N	O
36	and	O
37	its	O
38	radiation	O
39	-	O
40	transformed	O
41	tumorigenic	O
42	derivative	O
43	76R	O
44	-	O
45	30	O
46	.	O
1	The	O
2	P	B
3	-	I
4	wr	I
5	and	O
6	P	B
7	-	I
8	rr	I
9	cDNA	I
10	sequences	I
11	are	O
12	very	O
13	similar	O
14	in	O
15	their	O
16	5	O
17	'	O
18	regions	O
19	.	O
1	We	O
2	have	O
3	previously	O
4	isolated	O
5	a	O
6	cDNA	O
7	for	O
8	a	O
9	transcription	O
10	factor	O
11	referred	O
12	to	O
13	as	O
14	Zfhep	B
15	(	O
16	zinc	B
17	finger	I
18	homeodomain	I
19	enhancer	I
20	-	I
21	binding	I
22	protein	I
23	)	O
24	containing	O
25	two	O
26	separate	O
27	zinc	O
28	finger	O
29	domains	O
30	,	O
31	ZD1	B
32	and	O
33	ZD2	B
34	,	O
35	each	O
36	of	O
37	which	O
38	binds	O
39	DNA	O
40	,	O
41	and	O
42	a	O
43	homeodomain	O
44	.	O
1	Subsequent	O
2	to	O
3	their	O
4	secretion	O
5	,	O
6	the	O
7	IGF	B
8	-	I
9	II	I
10	in	O
11	xz97	O
12	and	O
13	G11	O
14	cells	O
15	accumulated	O
16	in	O
17	the	O
18	conditioned	O
19	medium	O
20	mostly	O
21	as	O
22	two	O
23	partially	O
24	processed	O
25	species	O
26	with	O
27	appMr	O
28	,	O
29	of	O
30	17K	O
31	and	O
32	14K	O
33	,	O
34	respectively	O
35	.	O
1	Paradoxically	O
2	,	O
3	coexpression	O
4	of	O
5	the	O
6	transcriptionally	O
7	inactive	O
8	,	O
9	amino	O
10	-	O
11	terminally	O
12	deleted	O
13	IDX	B
14	-	I
15	1	I
16	mutant	I
17	proteins	I
18	,	O
19	either	O
20	with	O
21	the	O
22	wild	B
23	-	I
24	type	I
25	IDX	I
26	-	I
27	1	I
28	or	O
29	with	O
30	themselves	O
31	,	O
32	results	O
33	in	O
34	a	O
35	marked	O
36	enhancement	O
37	of	O
38	transactivation	O
39	of	O
40	the	O
41	transcriptional	O
42	TAAT	B
43	-	I
44	1	I
45	element	I
46	reporter	I
47	.	O
1	Improved	O
2	methods	O
3	have	O
4	been	O
5	developed	O
6	for	O
7	maintaining	O
8	and	O
9	breeding	O
10	the	O
11	neotropical	O
12	short	O
13	-	O
14	tailed	O
15	fruit	O
16	bat	O
17	,	O
18	Carollia	O
19	perspicillata	O
20	,	O
21	in	O
22	an	O
23	easily	O
24	-	O
25	reproduced	O
26	,	O
27	laboratory	O
28	setting	O
29	.	O
1	Using	O
2	fluorescence	O
3	in	O
4	situ	O
5	hybridization	O
6	,	O
7	we	O
8	mapped	O
9	the	O
10	chromosome	O
11	-	O
12	17	O
13	breakpoint	O
14	in	O
15	a	O
16	patient	O
17	with	O
18	acampomelic	O
19	CMPD	O
20	and	O
21	sex	O
22	reversal	O
23	,	O
24	who	O
25	carries	O
26	a	O
27	de	O
28	novo	O
29	constitutional	O
30	t	O
31	(	O
32	12	O
33	;	O
34	17	O
35	)	O
36	translocation	O
37	,	O
38	between	O
39	two	O
40	known	O
41	cosmid	O
42	markers	O
43	in	O
44	the	O
45	17q24	O
46	-	O
47	q25	O
48	region	O
49	.	O
1	Control	O
2	intact	O
3	rats	O
4	were	O
5	age	O
6	-	O
7	matched	O
8	to	O
9	the	O
10	different	O
11	treated	O
12	groups	O
13	.	O
1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	sectional	O
7	study	O
8	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	bZIP	O
7	structural	O
8	homology	O
9	,	O
10	meq	B
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	B
19	-	O
20	fos	B
21	gene	O
22	family	O
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O
1	Plasma	O
2	thrombomodulin	B
3	:	O
4	a	O
5	marker	O
6	for	O
7	microvascular	O
8	complications	O
9	in	O
10	diabetes	O
11	mellitus	O
12	.	O
1	The	O
2	characterization	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	indicated	O
8	that	O
9	three	O
10	distinct	O
11	regulatory	O
12	elements	O
13	corresponding	O
14	to	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	binding	I
20	site	I
21	(	O
22	or	O
23	TRE	O
24	),	O
25	a	O
26	PRDII	B
27	/	O
28	kappaB	B
29	domain	O
30	,	O
31	and	O
32	a	O
33	CAAT	O
34	box	O
35	are	O
36	involved	O
37	in	O
38	the	O
39	activation	O
40	by	O
41	pp60	B
42	(	I
43	v	I
44	-)	I
45	src	I
46	.	O
1	Cys	O
2	-	O
3	757	O
4	within	O
5	the	O
6	(	O
7	Fe4S4	O
8	)-	O
9	siroheme	O
10	-	O
11	binding	O
12	domain	O
13	was	O
14	essential	O
15	for	O
16	native	O
17	enzyme	O
18	activity	O
19	.	O
1	Altogether	O
2	,	O
3	our	O
4	results	O
5	indicate	O
6	that	O
7	the	O
8	transcriptional	O
9	activity	O
10	of	O
11	Cut	B
12	proteins	I
13	is	O
14	modulated	O
15	by	O
16	PKC	B
17	.	O
1	Transcripts	O
2	for	O
3	both	O
4	ODV	B
5	-	I
6	E18	I
7	and	O
8	ODV	B
9	-	I
10	EC27	I
11	initiate	O
12	from	O
13	conserved	O
14	TAAG	O
15	motifs	O
16	,	O
17	and	O
18	transcripts	O
19	are	O
20	detected	O
21	from	O
22	16	O
23	through	O
24	72	O
25	hr	O
26	p	O
27	.	O
28	i	O
29	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	isolated	O
6	genomic	O
7	clone	O
8	revealed	O
9	that	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	of	O
15	this	O
16	orphan	O
17	receptor	O
18	is	O
19	most	O
20	homologous	O
21	to	O
22	the	O
23	human	B
24	TR2	I
25	receptor	I
26	.	O
1	A	O
2	3	O
3	-	O
4	yr	O
5	retrospective	O
6	review	O
7	is	O
8	effective	O
9	and	O
10	detects	O
11	94	O
12	%	O
13	of	O
14	the	O
15	undercalls	O
16	.	O
1	PCNA	B
2	mRNA	I
3	has	O
4	a	O
5	3	O
6	'	O
7	UTR	O
8	antisense	O
9	to	O
10	yellow	O
11	crescent	O
12	RNA	O
13	and	O
14	is	O
15	localized	O
16	in	O
17	ascidian	O
18	eggs	O
19	and	O
20	embryos	O
21	.	O
1	Two	O
2	closely	O
3	related	O
4	variants	O
5	of	O
6	Stat5	B
7	,	O
8	Stat5a	B
9	and	O
10	Stat5b	B
11	,	O
12	are	O
13	encoded	O
14	by	O
15	distinct	O
16	genes	O
17	.	O
1	The	O
2	serine	B
3	/	I
4	threonine	I
5	kinase	I
6	Raf	I
7	-	I
8	1	I
9	functions	O
10	downstream	O
11	of	O
12	Rats	B
13	in	O
14	a	O
15	signal	O
16	transduction	O
17	cascade	O
18	which	O
19	transmits	O
20	mitogenic	O
21	stimuli	O
22	from	O
23	the	O
24	plasma	O
25	membrane	O
26	to	O
27	the	O
28	nucleus	O
29	.	O
1	The	O
2	retinoid	B
3	Z	I
4	receptor	I
5	beta	I
6	(	O
7	RZR	B
8	beta	I
9	),	O
10	an	O
11	orphan	O
12	receptor	O
13	,	O
14	is	O
15	a	O
16	member	O
17	of	O
18	the	O
19	retinoic	B
20	acid	I
21	receptor	I
22	(	O
23	RAR	B
24	)/	O
25	thyroid	B
26	hormone	I
27	receptor	I
28	(	O
29	TR	B
30	)	O
31	subfamily	O
32	of	O
33	nuclear	O
34	receptors	O
35	.	O
1	Almost	O
2	complete	O
3	sequence	O
4	identity	O
5	was	O
6	found	O
7	between	O
8	the	O
9	3	O
10	'	O
11	end	O
12	of	O
13	the	O
14	DXS6673E	B
15	gene	I
16	and	O
17	two	O
18	expressed	O
19	sequence	O
20	tags	O
21	(	O
22	ESTs	O
23	)	O
24	and	O
25	between	O
26	the	O
27	5	O
28	'	O
29	end	O
30	of	O
31	the	O
32	DXS6673E	B
33	gene	I
34	and	O
35	a	O
36	third	O
37	EST	O
38	.	O
1	The	O
2	fragments	O
3	are	O
4	separated	O
5	and	O
6	directly	O
7	sized	O
8	by	O
9	agarose	O
10	gel	O
11	electrophoresis	O
12	.	O
1	Several	O
2	of	O
3	the	O
4	exon	O
5	boundaries	O
6	correspond	O
7	to	O
8	the	O
9	boundaries	O
10	of	O
11	functional	O
12	domains	O
13	in	O
14	the	O
15	p55	B
16	protein	I
17	.	O
1	The	O
2	cytogenetic	O
3	expression	O
4	of	O
5	the	O
6	folate	O
7	sensitive	O
8	fragile	O
9	site	O
10	,	O
11	FRAXE	B
12	,	O
13	is	O
14	due	O
15	to	O
16	the	O
17	expansion	O
18	of	O
19	a	O
20	GCC	O
21	repeat	O
22	in	O
23	proximal	O
24	Xq28	O
25	of	O
26	the	O
27	human	O
28	X	O
29	chromosome	O
30	and	O
31	is	O
32	associated	O
33	with	O
34	a	O
35	mild	O
36	form	O
37	of	O
38	mental	O
39	handicap	O
40	.	O
1	DNA	O
2	sequence	O
3	analysis	O
4	of	O
5	a	O
6	3213	O
7	bp	O
8	BamHI	B
9	-	O
10	ClaI	B
11	fragment	O
12	revealed	O
13	that	O
14	three	O
15	open	O
16	reading	O
17	frames	O
18	(	O
19	ORFs	O
20	)	O
21	were	O
22	encoded	O
23	in	O
24	the	O
25	same	O
26	orientation	O
27	.	O
1	Analysis	O
2	of	O
3	human	O
4	genomic	O
5	DNA	O
6	reveals	O
7	an	O
8	intronless	O
9	sequence	O
10	with	O
11	strong	O
12	homology	O
13	to	O
14	human	B
15	G	I
16	alpha	I
17	q	I
18	cDNA	I
19	.	O
1	The	O
2	use	O
3	of	O
4	primary	O
5	GE	O
6	cells	O
7	thus	O
8	provides	O
9	a	O
10	convenient	O
11	in	O
12	vitro	O
13	system	O
14	for	O
15	further	O
16	study	O
17	of	O
18	the	O
19	endocrine	O
20	,	O
21	paracrine	O
22	,	O
23	and	O
24	autocrine	O
25	factors	O
26	regulating	O
27	endometrial	O
28	gene	O
29	expression	O
30	during	O
31	pregnancy	O
32	.	O
1	Both	O
2	verapamil	O
3	and	O
4	propranolol	O
5	can	O
6	exhibit	O
7	additive	O
8	effects	O
9	with	O
10	adenosine	O
11	in	O
12	prolonging	O
13	AV	O
14	nodal	O
15	conduction	O
16	time	O
17	;	O
18	however	O
19	,	O
20	only	O
21	verapamil	O
22	can	O
23	reduce	O
24	the	O
25	dose	O
26	of	O
27	adenosine	O
28	required	O
29	to	O
30	produce	O
31	AV	O
32	nodal	O
33	block	O
34	.	O
1	RVR	B
2	'	O
3	loss	O
4	of	O
5	function	O
6	'	O
7	studies	O
8	by	O
9	constitutive	O
10	over	O
11	-	O
12	expression	O
13	of	O
14	a	O
15	dominant	O
16	negative	O
17	RVR	B
18	delta	I
19	E	I
20	resulted	O
21	in	O
22	increased	O
23	levels	O
24	of	O
25	p21Cip1	B
26	/	O
27	Waf1	B
28	and	O
29	myogenin	B
30	mRNAs	I
31	after	O
32	serum	O
33	withdrawal	O
34	.	O
1	Neither	O
2	CES1	B
3	nor	O
4	CES4	B
5	is	O
6	essential	O
7	for	O
8	cell	O
9	growth	O
10	,	O
11	and	O
12	a	O
13	double	O
14	deletion	O
15	mutant	O
16	is	O
17	viable	O
18	.	O
1	A	O
2	stable	O
3	heterologous	O
4	cell	O
5	line	O
6	containing	O
7	the	O
8	mouse	B
9	TRH	I
10	receptor	I
11	was	O
12	constructed	O
13	by	O
14	transfection	O
15	of	O
16	nonexcitable	O
17	293	O
18	cells	O
19	,	O
20	which	O
21	lack	O
22	L	O
23	channel	O
24	activity	O
25	.	O
1	Constitutive	O
2	phosphorylation	O
3	of	O
4	the	O
5	CD30v	B
6	protein	I
7	was	O
8	demonstrated	O
9	by	O
10	in	O
11	vitro	O
12	labeling	O
13	with	O
14	[	O
15	32P	O
16	].	O
1	We	O
2	report	O
3	here	O
4	the	O
5	discovery	O
6	of	O
7	a	O
8	new	O
9	actin	B
10	-	I
11	related	I
12	gene	I
13	in	O
14	this	O
15	organism	O
16	,	O
17	which	O
18	we	O
19	have	O
20	named	O
21	ACT4	B
22	.	O
1	IMPLICATIONS	O
2	:	O
3	Given	O
4	the	O
5	small	O
6	size	O
7	of	O
8	this	O
9	study	O
10	and	O
11	the	O
12	inconsistency	O
13	of	O
14	results	O
15	among	O
16	the	O
17	few	O
18	prospective	O
19	studies	O
20	of	O
21	ovarian	O
22	cancer	O
23	conducted	O
24	to	O
25	test	O
26	these	O
27	associations	O
28	,	O
29	replications	O
30	of	O
31	these	O
32	findings	O
33	are	O
34	highly	O
35	desirable	O
36	.	O
1	Previous	O
2	work	O
3	showed	O
4	that	O
5	repA	B
6	(	O
7	initiator	O
8	protein	O
9	)	O
10	expression	O
11	requires	O
12	tap	B
13	(	O
14	leader	O
15	peptide	O
16	)	O
17	translation	O
18	.	O
1	A	O
2	system	O
3	is	O
4	described	O
5	in	O
6	which	O
7	the	O
8	volume	O
9	flow	O
10	rate	O
11	of	O
12	blood	O
13	in	O
14	a	O
15	vessel	O
16	is	O
17	determined	O
18	using	O
19	transverse	O
20	colour	O
21	Doppler	O
22	ultrasound	O
23	imaging	O
24	.	O
1	In	O
2	lean	O
3	mice	O
4	,	O
5	the	O
6	fat	O
7	/	O
8	water	O
9	intensity	O
10	ratio	O
11	was	O
12	about	O
13	1	O
14	:	O
15	4	O
16	,	O
17	about	O
18	half	O
19	that	O
20	in	O
21	normal	O
22	mice	O
23	.	O
1	This	O
2	GAP	B
3	activity	O
4	was	O
5	observed	O
6	in	O
7	3T3	O
8	-	O
9	L1	O
10	adipocyte	O
11	lysates	O
12	,	O
13	and	O
14	was	O
15	able	O
16	to	O
17	accelerate	O
18	the	O
19	hydrolysis	O
20	of	O
21	the	O
22	[	O
23	alpha	O
24	-	O
25	32P	O
26	]	O
27	GTP	O
28	bound	O
29	to	O
30	GST	B
31	-	O
32	Rab4	B
33	into	O
34	[	O
35	alpha	O
36	-	O
37	32P	O
38	]	O
39	GDP	O
40	.	O
1	The	O
2	reconstituted	O
3	RNA	B
4	polymerases	I
5	containing	O
6	the	O
7	mutant	O
8	alpha	O
9	subunits	O
10	were	O
11	examined	O
12	for	O
13	their	O
14	response	O
15	to	O
16	transcription	O
17	activation	O
18	by	O
19	cAMP	B
20	-	I
21	CRP	I
22	and	O
23	the	O
24	rrnBP1	B
25	UP	I
26	element	I
27	.	O
1	Consistent	O
2	with	O
3	this	O
4	similarity	O
5	,	O
6	the	O
7	cdc28	B
8	-	O
9	P8	O
10	mutant	O
11	accumulates	O
12	unspliced	O
13	precursors	O
14	at	O
15	the	O
16	restrictive	O
17	temperature	O
18	.	O
1	The	O
2	elevations	O
3	achieved	O
4	by	O
5	LDEE	O
6	given	O
7	s	O
8	.	O
9	c	O
10	.	O
11	were	O
12	higher	O
13	than	O
14	those	O
15	achieved	O
16	after	O
17	i	O
18	.	O
19	p	O
20	.	O
21	administration	O
22	and	O
23	lasted	O
24	for	O
25	longer	O
26	periods	O
27	.	O
1	Many	O
2	human	O
3	viruses	O
4	are	O
5	able	O
6	to	O
7	develop	O
8	suitable	O
9	strategies	O
10	for	O
11	modifying	O
12	apoptosis	O
13	in	O
14	virus	O
15	-	O
16	infected	O
17	cells	O
18	and	O
19	in	O
20	virus	O
21	-	O
22	primed	O
23	T	O
24	cells	O
25	.	O
1	It	O
2	is	O
3	suggested	O
4	that	O
5	the	O
6	observed	O
7	clinical	O
8	phenomena	O
9	in	O
10	response	O
11	to	O
12	morphine	O
13	can	O
14	be	O
15	explained	O
16	by	O
17	differences	O
18	in	O
19	expression	O
20	and	O
21	sensitivity	O
22	of	O
23	some	O
24	opioid	B
25	receptor	I
26	subtypes	O
27	in	O
28	migraine	O
29	.	O
1	B	B
2	cell	I
3	antigen	I
4	receptor	I
5	(	O
6	BCR	B
7	)-	O
8	induced	O
9	apoptosis	O
10	in	O
11	the	O
12	WEHI	O
13	-	O
14	231	O
15	B	O
16	lymphoma	O
17	cell	O
18	line	O
19	can	O
20	be	O
21	prevented	O
22	by	O
23	engaging	O
24	CD40	B
25	.	O
1	The	O
2	model	O
3	also	O
4	predicts	O
5	that	O
6	blood	O
7	flow	O
8	shunt	O
9	fraction	O
10	(	O
11	Qs	O
12	/	O
13	QT	O
14	)	O
15	is	O
16	directly	O
17	related	O
18	to	O
19	the	O
20	oxygen	O
21	sine	O
22	-	O
23	wave	O
24	amplitude	O
25	perturbations	O
26	transmitted	O
27	to	O
28	end	O
29	-	O
30	expired	O
31	air	O
32	and	O
33	arterial	O
34	and	O
35	mixed	O
36	-	O
37	venous	O
38	blood	O
39	through	O
40	two	O
41	simple	O
42	equations	O
43	.	O
1	Discrimination	O
2	between	O
3	HIV	O
4	-	O
5	1	O
6	and	O
7	HIV	O
8	-	O
9	2	O
10	showed	O
11	evidence	O
12	for	O
13	the	O
14	presence	O
15	of	O
16	HIV	O
17	-	O
18	1	O
19	only	O
20	.	O
1	The	O
2	mammalian	B
3	homeodomain	I
4	proteins	I
5	encoded	O
6	by	O
7	Hox	B
8	genes	I
9	play	O
10	an	O
11	important	O
12	role	O
13	in	O
14	embryonic	O
15	development	O
16	by	O
17	providing	O
18	positional	O
19	queues	O
20	which	O
21	define	O
22	developmental	O
23	identities	O
24	along	O
25	the	O
26	anteroposterior	O
27	axis	O
28	of	O
29	developing	O
30	organisms	O
31	.	O
1	As	O
2	extensively	O
3	examined	O
4	with	O
5	the	O
6	myogenin	B
7	promoter	I
8	,	O
9	presence	O
10	of	O
11	one	O
12	or	O
13	multiple	O
14	copies	O
15	of	O
16	Me	B
17	in	O
18	the	O
19	vectors	O
20	elevated	O
21	the	O
22	expression	O
23	activity	O
24	in	O
25	myotubes	O
26	by	O
27	4	O
28	.	O
29	5	O
30	-	O
31	to	O
32	19	O
33	-	O
34	fold	O
35	over	O
36	those	O
37	without	O
38	Me	B
39	,	O
40	but	O
41	not	O
42	significantly	O
43	in	O
44	myoblasts	O
45	.	O
1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	reporter	O
6	gene	O
7	constructs	O
8	containing	O
9	various	O
10	lengths	O
11	of	O
12	the	O
13	5	B
14	'	I
15	mdr1b	I
16	sequences	I
17	revealed	O
18	that	O
19	the	O
20	sequence	O
21	located	O
22	between	O
23	-	O
24	247	O
25	to	O
26	-	O
27	126	O
28	bp	O
29	was	O
30	important	O
31	for	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	reporter	O
37	gene	O
38	in	O
39	many	O
40	different	O
41	cell	O
42	lines	O
43	.	O
1	In	O
2	addition	O
3	,	O
4	carp	B
5	JAK1	I
6	shows	O
7	higher	O
8	sequence	O
9	homology	O
10	to	O
11	mammalian	B
12	JAK1	I
13	in	O
14	both	O
15	the	O
16	kinase	O
17	-	O
18	like	O
19	(	O
20	JH2	B
21	)	O
22	and	O
23	kinase	O
24	(	O
25	JH1	B
26	)	O
27	domains	O
28	(	O
29	approximately	O
30	70	O
31	%	O
32	identity	O
33	).	O
1	CsA	O
2	alone	O
3	resulted	O
4	in	O
5	elevated	O
6	bone	O
7	turnover	O
8	.	O
1	Physiol	O
2	.	O
1	Natural	O
2	FL	B
3	protein	I
4	has	O
5	been	O
6	purified	O
7	from	O
8	a	O
9	stromal	O
10	cell	O
11	line	O
12	and	O
13	shown	O
14	to	O
15	be	O
16	a	O
17	65	O
18	kD	O
19	nondisulfide	O
20	-	O
21	linked	O
22	homodimeric	O
23	glycoprotein	O
24	comprised	O
25	of	O
26	30	O
27	kD	O
28	subunits	O
29	,	O
30	each	O
31	containing	O
32	12	O
33	kD	O
34	of	O
35	N	O
36	-	O
37	and	O
38	O	O
39	-	O
40	linked	O
41	sugars	O
42	.	O
1	Growth	O
2	factors	O
3	induce	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	immediate	B
9	early	I
10	gene	I
11	products	I
12	MAP	I
13	kinase	I
14	phosphatase	I
15	-	I
16	1	I
17	(	O
18	MKP	B
19	-	I
20	1	I
21	),	O
22	c	B
23	-	I
24	Fos	I
25	and	O
26	c	B
27	-	I
28	Jun	I
29	.	O
1	The	O
2	evidence	O
3	in	O
4	support	O
5	of	O
6	this	O
7	was	O
8	derived	O
9	from	O
10	the	O
11	fact	O
12	that	O
13	the	O
14	affinity	O
15	or	O
16	interaction	O
17	between	O
18	the	O
19	two	O
20	subunits	O
21	was	O
22	impaired	O
23	as	O
24	indicated	O
25	by	O
26	the	O
27	first	O
28	order	O
29	rate	O
30	constant	O
31	of	O
32	hCG	B
33	alpha	I
34	1	I
35	beta	I
36	(	O
37	km	O
38	=	O
39	4	O
40	.	O
41	1	O
42	x	O
43	10	O
44	(-	O
45	2	O
46	)	O
47	min	O
48	-	O
49	1	O
50	)	O
51	at	O
52	pH	O
53	3	O
54	.	O
55	0	O
56	at	O
57	23	O
58	degrees	O
59	C	O
60	which	O
61	is	O
62	one	O
63	order	O
64	of	O
65	magnitude	O
66	greater	O
67	relative	O
68	to	O
69	rehCG	B
70	(	O
71	kw	O
72	=	O
73	4	O
74	.	O
75	6	O
76	x	O
77	10	O
78	(-	O
79	3	O
80	)	O
81	min	O
82	-	O
83	1	O
84	).	O
1	However	O
2	,	O
3	the	O
4	truncated	O
5	deer	B
6	receptor	I
7	lacks	O
8	the	O
9	most	O
10	C	O
11	-	O
12	terminal	O
13	tyrosine	O
14	residue	O
15	in	O
16	the	O
17	intracellular	O
18	domain	O
19	which	O
20	is	O
21	believed	O
22	to	O
23	be	O
24	essential	O
25	for	O
26	activation	O
27	of	O
28	the	O
29	beta	B
30	-	I
31	casein	I
32	promoter	I
33	.	O
1	Rifabutin	O
2	has	O
3	substantial	O
4	efficacy	O
5	when	O
6	combined	O
7	with	O
8	other	O
9	agents	O
10	.	O
1	This	O
2	enzyme	O
3	is	O
4	designated	O
5	(	B
6	1	I
7	-->	I
8	4	I
9	)-	I
10	beta	I
11	-	I
12	xylan	I
13	endohydrolase	I
14	isoenzyme	I
15	X	I
16	-	I
17	I	I
18	.	O
1	To	O
2	analyze	O
3	the	O
4	mechanism	O
5	of	O
6	fos	B
7	/	O
8	jun	B
9	activation	O
10	by	O
11	TCDD	O
12	we	O
13	have	O
14	used	O
15	electrophoretic	O
16	mobility	O
17	shift	O
18	and	O
19	transient	O
20	expression	O
21	assays	O
22	of	O
23	reporter	O
24	gene	O
25	constructs	O
26	containing	O
27	response	O
28	elements	O
29	for	O
30	12	O
31	-	O
32	O	O
33	-	O
34	tetradecanoyl	O
35	-	O
36	phorbol	O
37	-	O
38	13	O
39	-	O
40	acetate	O
41	(	O
42	TRE	O
43	),	O
44	serum	O
45	(	O
46	SRE	O
47	),	O
48	cAMP	O
49	(	O
50	CRE	O
51	),	O
52	and	O
53	aromatic	O
54	hydrocarbons	O
55	(	O
56	AhRE	O
57	)	O
58	from	O
59	the	O
60	fos	B
61	and	O
62	jun	B
63	genes	I
64	fused	O
65	to	O
66	the	O
67	firefly	B
68	luciferase	I
69	gene	I
70	under	O
71	the	O
72	control	O
73	of	O
74	the	O
75	SV40	B
76	minimal	I
77	promoter	I
78	.	O
1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	the	O
7	xFxFG	O
8	repeat	O
9	regions	O
10	of	O
11	p62	B
12	and	O
13	Nsplp	B
14	indicated	O
15	that	O
16	NTF2	B
17	was	O
18	probably	O
19	interacting	O
20	with	O
21	the	O
22	phenylalanine	O
23	-	O
24	containing	O
25	core	O
26	of	O
27	these	O
28	repeats	O
29	and	O
30	not	O
31	the	O
32	intervening	O
33	hydrophilic	O
34	linkers	O
35	.	O
1	A	O
2	given	O
3	standard	O
4	input	O
5	function	O
6	and	O
7	a	O
8	given	O
9	value	O
10	of	O
11	distribution	O
12	volume	O
13	(	O
14	Vd	O
15	)	O
16	used	O
17	for	O
18	the	O
19	rCBF	O
20	measurement	O
21	of	O
22	this	O
23	method	O
24	were	O
25	calculated	O
26	from	O
27	the	O
28	dynamic	O
29	study	O
30	by	O
31	six	O
32	normal	O
33	volunteers	O
34	.	O
1	It	O
2	can	O
3	be	O
4	concluded	O
5	that	O
6	in	O
7	normotensive	O
8	subjects	O
9	,	O
10	uric	O
11	acid	O
12	and	O
13	xanthine	B
14	oxidase	I
15	have	O
16	significant	O
17	association	O
18	with	O
19	blood	O
20	pressure	O
21	and	O
22	thus	O
23	are	O
24	one	O
25	of	O
26	the	O
27	many	O
28	factors	O
29	which	O
30	are	O
31	involved	O
32	in	O
33	the	O
34	cause	O
35	or	O
36	effect	O
37	of	O
38	hypertension	O
39	.	O
1	We	O
2	infer	O
3	that	O
4	the	O
5	dominant	O
6	negative	O
7	inhibition	O
8	results	O
9	from	O
10	both	O
11	direct	O
12	proteolysis	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	galactosidase	I
18	tetramer	I
19	by	O
20	the	O
21	fusion	O
22	subunit	O
23	and	O
24	detour	O
25	of	O
26	the	O
27	tetramer	O
28	to	O
29	the	O
30	lysosome	O
31	.	O
1	Several	O
2	agents	O
3	have	O
4	been	O
5	tried	O
6	for	O
7	treatment	O
8	,	O
9	often	O
10	limited	O
11	by	O
12	toxic	O
13	side	O
14	effects	O
15	.	O
1	PPAR	B
2	gamma	I
3	mRNA	I
4	levels	O
5	were	O
6	reduced	O
7	by	O
8	95	O
9	%	O
10	with	O
11	3	O
12	nM	O
13	TNF	B
14	alpha	I
15	treatment	O
16	for	O
17	24	O
18	h	O
19	.	O
1	Recombinant	B
2	erythropoietin	I
3	(	O
4	r	B
5	-	I
6	HuEPO	I
7	)	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	anemia	O
13	in	O
14	multiple	O
15	myeloma	O
1	Epidemiological	O
2	data	O
3	are	O
4	quite	O
5	controversial	O
6	but	O
7	sudden	O
8	death	O
9	occurring	O
10	during	O
11	sporting	O
12	activity	O
13	is	O
14	probably	O
15	not	O
16	a	O
17	rare	O
18	occurrence	O
19	.	O
1	Moreover	O
2	,	O
3	the	O
4	same	O
5	mutations	O
6	alter	O
7	the	O
8	structure	O
9	of	O
10	junB	B
11	5	O
12	'	O
13	flanking	O
14	DNA	O
15	within	O
16	chromatin	O
17	.	O
1	RESULTS	O
2	:	O
3	The	O
4	age	O
5	distribution	O
6	was	O
7	28	O
8	to	O
9	83	O
10	years	O
11	old	O
12	(	O
13	mean	O
14	was	O
15	54	O
16	.	O
17	1	O
18	years	O
19	).	O
1	In	O
2	3Y1	O
3	and	O
4	3Y1	O
5	v	B
6	-	I
7	crk	I
8	-	O
9	transformed	O
10	fibroblasts	O
11	,	O
12	almost	O
13	all	O
14	of	O
15	the	O
16	total	O
17	PTP1B	B
18	and	O
19	about	O
20	40	O
21	%	O
22	of	O
23	total	O
24	p130	B
25	(	O
26	Cas	B
27	)	O
28	co	O
29	-	O
30	sediment	O
31	with	O
32	membranes	O
33	composed	O
34	primarily	O
35	of	O
36	endoplasmic	O
37	reticulum	O
38	.	O
1	Replacing	O
2	residues	O
3	405	O
4	-	O
5	419	O
6	on	O
7	delta419	O
8	with	O
9	the	O
10	conserved	O
11	AF	O
12	-	O
13	2	O
14	domain	O
15	from	O
16	the	O
17	vitamin	B
18	D3	I
19	receptor	I
20	or	O
21	the	O
22	estrogen	B
23	receptor	I
24	results	O
25	in	O
26	a	O
27	receptor	O
28	with	O
29	wild	O
30	-	O
31	type	O
32	or	O
33	low	O
34	transcriptional	O
35	activity	O
36	,	O
37	respectively	O
38	.	O
1	But	O
2	,	O
3	as	O
4	Theriault	O
5	explains	O
6	,	O
7	improvements	O
8	in	O
9	assessing	O
10	exposure	O
11	have	O
12	not	O
13	yet	O
14	translated	O
15	into	O
16	clear	O
17	and	O
18	consistent	O
19	findings	O
20	.	O
1	The	O
2	0	O
3	.	O
4	22	O
5	-	O
6	kb	O
7	NheI	B
8	/	O
9	BglII	B
10	promoter	O
11	exhibited	O
12	PMA	O
13	inducibility	O
14	in	O
15	myeloid	O
16	cells	O
17	and	O
18	contained	O
19	a	O
20	PMA	O
21	-	O
22	responsive	O
23	element	O
24	recognized	O
25	by	O
26	Sp1	B
27	and	O
28	EGR	B
29	-	I
30	1	I
31	transcription	I
32	factors	I
33	.	O
1	Damage	O
2	to	O
3	the	O
4	BBB	O
5	was	O
6	judged	O
7	by	O
8	extravasation	O
9	of	O
10	Evans	O
11	Blue	O
12	(	O
13	EB	O
14	)	O
15	dye	O
16	,	O
17	which	O
18	was	O
19	administered	O
20	either	O
21	2	O
22	,	O
23	3	O
24	,	O
25	24	O
26	or	O
27	48	O
28	h	O
29	after	O
30	onset	O
31	of	O
32	MCAo	O
33	.	O
1	When	O
2	the	O
3	degree	O
4	of	O
5	exercise	O
6	was	O
7	maximal	O
8	,	O
9	mPAP	O
10	was	O
11	maintained	O
12	,	O
13	SVI	O
14	decreased	O
15	,	O
16	HR	O
17	was	O
18	unchanged	O
19	,	O
20	and	O
21	CO	O
22	and	O
23	VO2	O
24	decreased	O
25	.	O
1	In	O
2	Group	O
3	IV	O
4	dogs	O
5	that	O
6	received	O
7	alpha	B
8	-	I
9	MSH	I
10	only	O
11	during	O
12	reperfusion	O
13	,	O
14	BAEPs	O
15	were	O
16	increased	O
17	approximately	O
18	10	O
19	to	O
20	14	O
21	%	O
22	more	O
23	than	O
24	in	O
25	Group	O
26	II	O
27	during	O
28	the	O
29	late	O
30	reperfusion	O
31	period	O
32	.	O
1	The	O
2	imprinted	O
3	expression	O
4	of	O
5	the	O
6	endogenous	O
7	gene	O
8	can	O
9	be	O
10	recapitulated	O
11	in	O
12	mice	O
13	by	O
14	using	O
15	a	O
16	14	O
17	-	O
18	kb	O
19	transgene	O
20	encompassing	O
21	4	O
22	kb	O
23	of	O
24	5	O
25	'-	O
26	flanking	O
27	sequence	O
28	,	O
29	8	O
30	kb	O
31	of	O
32	3	O
33	'-	O
34	flanking	O
35	sequence	O
36	,	O
37	which	O
38	includes	O
39	the	O
40	two	O
41	endoderm	O
42	-	O
43	specific	O
44	enhancers	O
45	,	O
46	and	O
47	an	O
48	internally	O
49	deleted	O
50	structural	O
51	gene	O
52	.	O
1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	hGCN5	B
9	is	O
10	also	O
11	an	O
12	HAT	B
13	and	O
14	has	O
15	the	O
16	same	O
17	substrate	O
18	specificity	O
19	as	O
20	yGCN5	B
21	.	O
1	By	O
2	screening	O
3	a	O
4	cDNA	O
5	library	O
6	with	O
7	a	O
8	probe	O
9	derived	O
10	from	O
11	sequences	O
12	downstream	O
13	of	O
14	the	O
15	p53p2	B
16	start	O
17	site	O
18	,	O
19	we	O
20	have	O
21	cloned	O
22	and	O
23	characterized	O
24	a	O
25	cDNA	O
26	that	O
27	represents	O
28	a	O
29	mRNA	O
30	that	O
31	appears	O
32	to	O
33	have	O
34	been	O
35	initiated	O
36	from	O
37	the	O
38	p53p2	B
39	promoter	I
40	.	O
1	The	O
2	RI	B
3	alpha	I
4	gene	I
5	is	O
6	composed	O
7	of	O
8	nine	O
9	coding	O
10	exons	O
11	of	O
12	varying	O
13	lengths	O
14	,	O
15	separated	O
16	by	O
17	introns	O
18	,	O
19	giving	O
20	the	O
21	gene	O
22	a	O
23	total	O
24	length	O
25	of	O
26	at	O
27	least	O
28	21	O
29	kb	O
30	.	O
31	our	O
32	recent	O
33	cloning	O
34	of	O
35	a	O
36	processed	O
37	RI	B
38	alpha	I
39	pseudogene	I
40	with	O
41	a	O
42	5	O
43	'-	O
44	noncoding	O
45	region	O
46	different	O
47	from	O
48	the	O
49	previously	O
50	reported	O
51	RI	B
52	alpha	I
53	complementary	I
54	RNA	I
55	indicated	O
56	that	O
57	the	O
58	RI	B
59	alpha	I
60	gene	I
61	may	O
62	have	O
63	multiple	O
64	leader	O
65	exons	O
66	giving	O
67	rise	O
68	to	O
69	alternately	O
70	spliced	O
71	messenger	O
72	RNAs	O
73	(	O
74	mRNAs	O
75	).	O
1	Further	O
2	,	O
3	the	O
4	PIP2	O
5	content	O
6	of	O
7	the	O
8	85	O
9	-	O
10	90	O
11	kDa	O
12	protein	O
13	appeared	O
14	to	O
15	decrease	O
16	with	O
17	CSF	B
18	-	I
19	1	I
20	treatment	O
21	.	O
1	Reperfusion	O
2	caused	O
3	a	O
4	transient	O
5	reduction	O
6	in	O
7	lactate	O
8	production	O
9	and	O
10	a	O
11	significant	O
12	increase	O
13	in	O
14	LDH	B
15	release	O
16	.	O
1	To	O
2	evaluate	O
3	the	O
4	hepatic	O
5	regenerative	O
6	response	O
7	in	O
8	patients	O
9	with	O
10	alcoholic	O
11	liver	O
12	disease	O
13	,	O
14	sera	O
15	from	O
16	263	O
17	patients	O
18	with	O
19	severe	O
20	alcoholic	O
21	hepatitis	O
22	and	O
23	/	O
24	or	O
25	cirrhosis	O
26	were	O
27	analyzed	O
28	for	O
29	hepatocyte	B
30	growth	I
31	factor	I
32	(	O
33	HGF	B
34	)	O
35	and	O
36	alpha	B
37	-	I
38	fetoprotein	I
39	(	O
40	AFP	B
41	).	O
1	Finally	O
2	,	O
3	nonphotosynthetic	O
4	mutants	O
5	,	O
6	including	O
7	the	O
8	tscA	B
9	-	I
10	lacking	I
11	photosystem	I
12	I	I
13	mutant	I
14	,	O
15	H13	O
16	,	O
17	did	O
18	not	O
19	show	O
20	evidence	O
21	of	O
22	light	O
23	-	O
24	stimulated	O
25	RNA	O
26	processing	O
27	.	O
1	Ectopic	O
2	expression	O
3	of	O
4	Apo	B
5	-	I
6	3	I
7	in	O
8	HEK293	O
9	or	O
10	HeLa	O
11	cells	O
12	induced	O
13	marked	O
14	apoptosis	O
15	.	O
1	D	O
2	.	O
3	melanogaster	O
4	HeT	B
5	-	I
6	A	I
7	coding	O
8	sequences	O
9	have	O
10	a	O
11	polymorphic	O
12	region	O
13	with	O
14	insertions	O
15	/	O
16	deletions	O
17	of	O
18	1	O
19	-	O
20	31	O
21	codons	O
22	and	O
23	many	O
24	nucleotide	O
25	changes	O
26	.	O
1	Lack	O
2	of	O
3	sufficient	O
4	data	O
5	on	O
6	vibration	O
7	measurements	O
8	and	O
9	employment	O
10	durations	O
11	add	O
12	to	O
13	the	O
14	uncertainty	O
15	,	O
16	as	O
17	do	O
18	variations	O
19	in	O
20	tool	O
21	conditions	O
22	(	O
23	grinder	O
24	wheels	O
25	,	O
26	etc	O
27	)	O
28	and	O
29	inherent	O
30	difficulties	O
31	in	O
32	measurement	O
33	.	O
1	The	O
2	differences	O
3	among	O
4	subgenera	O
5	of	O
6	the	O
7	genus	O
8	Dermacentor	O
9	are	O
10	more	O
11	significant	O
12	.	O
1	Mutating	O
2	the	O
3	E	O
4	-	O
5	box	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	3	O
12	'-	O
13	flanking	O
14	region	O
15	confirmed	O
16	that	O
17	it	O
18	contributes	O
19	to	O
20	the	O
21	enhancement	O
22	of	O
23	transcriptional	O
24	activity	O
25	of	O
26	the	O
27	alpha1	B
28	(	I
29	I	I
30	)	I
31	collagen	I
32	gene	I
33	promoter	I
34	.	O
1	Expression	O
2	of	O
3	neuronal	O
4	traits	O
5	in	O
6	pancreatic	O
7	beta	O
8	cells	O
9	.	O
1	In	O
2	the	O
3	p51	B
4	subunit	I
5	,	O
6	the	O
7	Cys181	O
8	side	O
9	-	O
10	chain	O
11	is	O
12	oriented	O
13	in	O
14	a	O
15	similar	O
16	direction	O
17	to	O
18	the	O
19	Tyr181	O
20	side	O
21	-	O
22	chain	O
23	in	O
24	the	O
25	wild	O
26	-	O
27	type	O
28	complex	O
29	.	O
1	A	O
2	5	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	DNA	O
8	fragment	O
9	,	O
10	which	O
11	included	O
12	the	O
13	entire	O
14	structural	O
15	porin	B
16	gene	I
17	(	O
18	named	O
19	porCa	B
20	)	O
21	and	O
22	its	O
23	flanking	O
24	regions	O
25	,	O
26	was	O
27	identified	O
28	.	O
1	The	O
2	primary	O
3	structure	O
4	of	O
5	a	O
6	2671	O
7	bp	O
8	DNA	O
9	fragment	O
10	between	O
11	the	O
12	pla	B
13	gene	I
14	(	O
15	encoding	O
16	plasminogen	B
17	activator	I
18	)	O
19	and	O
20	the	O
21	origin	O
22	of	O
23	replication	O
24	of	O
25	the	O
26	wild	O
27	-	O
28	type	O
29	Yersinia	O
30	pestis	O
31	plasmid	O
32	pYP358	O
33	was	O
34	determined	O
35	.	O
1	CONCLUSION	O
2	:	O
3	Some	O
4	Gulf	O
5	War	O
6	veterans	O
7	may	O
8	have	O
9	delayed	O
10	,	O
11	chronic	O
12	neurotoxic	O
13	syndromes	O
14	from	O
15	wartime	O
16	exposure	O
17	to	O
18	combinations	O
19	of	O
20	chemicals	O
21	that	O
22	inhibit	O
23	butyrylcholinesterase	B
24	and	O
25	neuropathy	B
26	target	I
27	esterase	I
28	.	O
1	JNK	B
2	and	O
3	p38	B
4	are	O
5	constitutively	O
6	present	O
7	in	O
8	the	O
9	nucleus	O
10	,	O
11	and	O
12	DNA	O
13	-	O
14	bound	O
15	c	B
16	-	I
17	JUN	I
18	and	O
19	ATF	B
20	-	I
21	2	I
22	are	O
23	stably	O
24	contacted	O
25	by	O
26	JNK	B
27	and	O
28	p38	B
29	,	O
30	respectively	O
31	.	O
1	Mutant	O
2	enzyme	O
3	forms	O
4	were	O
5	prepared	O
6	to	O
7	eliminate	O
8	the	O
9	initial	O
10	autoprocessing	O
11	site	O
12	and	O
13	thus	O
14	form	O
15	an	O
16	active	O
17	single	O
18	-	O
19	chain	O
20	protein	O
21	for	O
22	structure	O
23	-	O
24	function	O
25	studies	O
26	.	O
1	The	O
2	primer	O
3	is	O
4	generated	O
5	by	O
6	a	O
7	cleavage	O
8	that	O
9	occurs	O
10	between	O
11	bases	O
12	11	O
13	and	O
14	12	O
15	of	O
16	the	O
17	Tf1	B
18	mRNA	I
19	.	O
1	Remarkably	O
2	,	O
3	both	O
4	TTD	O
5	-	O
6	A	O
7	and	O
8	XP	O
9	-	O
10	D	O
11	defects	O
12	are	O
13	associated	O
14	with	O
15	subunits	O
16	of	O
17	TFIIH	B
18	,	O
19	a	O
20	basal	O
21	transcription	O
22	factor	O
23	with	O
24	a	O
25	second	O
26	function	O
27	in	O
28	DNA	O
29	repair	O
30	.	O
1	In	O
2	Experiment	O
3	1	O
4	,	O
5	pups	O
6	that	O
7	had	O
8	received	O
9	an	O
10	injection	O
11	of	O
12	the	O
13	noncompetitive	O
14	N	B
15	-	I
16	methyl	I
17	-	I
18	D	I
19	-	I
20	aspartate	I
21	receptor	I
22	antagonist	O
23	MK	O
24	-	O
25	801	O
26	(	O
27	0	O
28	.	O
29	1	O
30	mg	O
31	/	O
32	kg	O
33	,	O
34	i	O
35	.	O
36	p	O
37	.)	O
38	either	O
39	30	O
40	min	O
41	before	O
42	or	O
43	immediately	O
44	after	O
45	conditioning	O
46	spent	O
47	less	O
48	time	O
49	over	O
50	the	O
51	conditioned	O
52	odor	O
53	than	O
54	saline	O
55	-	O
56	treated	O
57	controls	O
58	.	O
1	SIM1	B
2	and	O
3	SIM2	B
4	do	O
5	not	O
6	form	O
7	homodimers	O
8	,	O
9	and	O
10	they	O
11	do	O
12	not	O
13	interact	O
14	with	O
15	AHR	B
16	.	O
1	Moreover	O
2	,	O
3	the	O
4	effect	O
5	exerted	O
6	by	O
7	TIS1	B
8	appeared	O
9	to	O
10	be	O
11	selective	O
12	for	O
13	the	O
14	MCK	B
15	promoter	I
16	.	O
1	Because	O
2	L	B
3	-	I
4	plastin	I
5	expression	O
6	in	O
7	tissue	O
8	-	O
9	specifically	O
10	regulated	O
11	in	O
12	both	O
13	humans	O
14	and	O
15	rodents	O
16	,	O
17	it	O
18	is	O
19	likely	O
20	that	O
21	similar	O
22	mechanisms	O
23	regulate	O
24	L	B
25	-	I
26	plastin	I
27	gene	I
28	expression	O
29	in	O
30	human	O
31	and	O
32	rodent	O
33	cells	O
34	and	O
35	that	O
36	they	O
37	could	O
38	be	O
39	identified	O
40	by	O
41	comparing	O
42	the	O
43	function	O
44	and	O
45	nucleotide	O
46	sequences	O
47	of	O
48	the	O
49	human	O
50	and	O
51	murine	O
52	L	B
53	-	I
54	plastin	I
55	gene	O
56	promoters	O
57	.	O
1	The	O
2	dnaK	B
3	operon	I
4	of	I
5	Bacillus	I
6	subtilis	I
7	is	O
8	heptacistronic	O
9	.	O
1	Finally	O
2	,	O
3	antibody	O
4	binding	O
5	to	O
6	site	O
7	IIIa	O
8	on	O
9	the	O
10	hCG	B
11	-	I
12	ectodomain	I
13	complex	I
14	was	O
15	also	O
16	hindered	O
17	by	O
18	an	O
19	anti	O
20	-	O
21	peptide	O
22	mAb	O
23	directed	O
24	against	O
25	a	O
26	peptide	O
27	encoded	O
28	by	O
29	the	O
30	eighth	O
31	exon	O
32	(	O
33	pE	O
34	x	O
35	8	O
36	)	O
37	of	O
38	the	O
39	LHR	B
40	.	O
1	cDNA	O
2	cloning	O
3	,	O
4	expression	O
5	analysis	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	a	O
12	gene	O
13	with	O
14	high	O
15	homology	O
16	to	O
17	wheat	B
18	eIF	I
19	-(	I
20	iso	I
21	)	I
22	4F	I
23	and	O
24	mammalian	B
25	eIF	I
26	-	I
27	4G	I
28	.	O
1	The	O
2	interferon	B
3	(	O
4	IFN	B
5	)-	O
6	induced	O
7	double	B
8	-	I
9	stranded	I
10	RNA	I
11	(	I
12	dsRNA	I
13	)-	I
14	activated	I
15	Ser	I
16	/	I
17	Thr	I
18	protein	I
19	kinase	I
20	(	O
21	PKR	B
22	)	O
23	plays	O
24	a	O
25	role	O
26	in	O
27	the	O
28	antiviral	O
29	and	O
30	antiproliferative	O
31	effects	O
32	of	O
33	IFN	B
34	.	O
1	Most	O
2	kinases	O
3	are	O
4	not	O
5	significantly	O
6	inhibited	O
7	by	O
8	roscovitine	O
9	.	O
10	cdc2	B
11	/	O
12	cyclin	B
13	B	I
14	,	O
15	cdk2	B
16	/	O
17	cyclin	B
18	A	I
19	,	O
20	cdk2	B
21	/	O
22	cyclin	B
23	E	I
24	and	O
25	cdk5	B
26	/	O
27	p35	B
28	only	O
29	are	O
30	substantially	O
31	inhibited	O
32	(	O
33	IC50	O
34	values	O
35	of	O
36	0	O
37	.	O
38	65	O
39	,	O
40	0	O
41	.	O
42	7	O
43	,	O
44	0	O
45	.	O
46	7	O
47	and	O
48	0	O
49	.	O
50	2	O
51	microM	O
52	,	O
53	respectively	O
54	).	O
55	cdk4	B
56	/	O
57	cyclin	B
58	D1	I
59	and	O
60	cdk6	B
61	/	O
62	cyclin	B
63	D2	I
64	are	O
65	very	O
66	poorly	O
67	inhibited	O
68	by	O
69	roscovitine	O
70	(	O
71	IC50	O
72	>	O
73	100	O
74	microM	O
75	).	O
1	Interaction	O
2	of	O
3	Ets	B
4	-	I
5	1	I
6	and	O
7	the	O
8	POU	B
9	-	I
10	homeodomain	I
11	protein	I
12	GHF	I
13	-	I
14	1	I
15	/	O
16	Pit	B
17	-	I
18	1	I
19	reconstitutes	O
20	pituitary	O
21	-	O
22	specific	O
23	gene	O
24	expression	O
25	.	O
1	Furthermore	O
2	,	O
3	Rac1	B
4	activation	O
5	of	O
6	JNK	B
7	or	O
8	SRF	B
9	,	O
10	or	O
11	induction	O
12	of	O
13	lamellipodia	O
14	,	O
15	was	O
16	neither	O
17	necessary	O
18	nor	O
19	sufficient	O
20	for	O
21	Rac1	B
22	transforming	O
23	activity	O
24	.	O
1	These	O
2	data	O
3	support	O
4	the	O
5	idea	O
6	that	O
7	the	O
8	repression	O
9	activity	O
10	of	O
11	NRSF	B
12	/	O
13	REST	B
14	depends	O
15	upon	O
16	the	O
17	species	O
18	of	O
19	promoter	O
20	to	O
21	which	O
22	it	O
23	is	O
24	linked	O
25	and	O
26	upon	O
27	the	O
28	proteins	O
29	that	O
30	bind	O
31	to	O
32	those	O
33	promoters	O
34	.	O
1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	eight	O
6	patients	O
7	who	O
8	underwent	O
9	a	O
10	curative	O
11	hepatic	O
12	resection	O
13	for	O
14	HCC	O
15	and	O
16	whose	O
17	preoperative	O
18	AFP	B
19	levels	O
20	were	O
21	>	O
22	100	O
23	ng	O
24	/	O
25	ml	O
26	,	O
27	were	O
28	selected	O
29	for	O
30	this	O
31	study	O
32	.	O
1	Calmodulin	B
2	-	I
3	binding	I
4	peptide	I
5	(	O
6	CBP	B
7	),	O
8	a	O
9	peptide	O
10	of	O
11	26	O
12	amino	O
13	acids	O
14	derived	O
15	from	O
16	muscle	B
17	myosin	I
18	light	I
19	chain	I
20	kinase	I
21	(	O
22	MLCK	B
23	),	O
24	binds	O
25	to	O
26	calmodulin	B
27	with	O
28	nanomolar	O
29	affinity	O
30	.	O
1	Unlike	O
2	class	O
3	II	O
4	-	O
5	and	O
6	III	O
7	-	O
8	specific	O
9	TBP	B
10	-	O
11	TAF	B
12	complexes	O
13	,	O
14	the	O
15	corresponding	O
16	murine	O
17	and	O
18	human	O
19	class	O
20	I	O
21	-	O
22	specific	O
23	transcription	O
24	initiation	O
25	factor	O
26	TIF	B
27	-	I
28	IB	I
29	/	O
30	SL1	B
31	exhibits	O
32	a	O
33	pronounced	O
34	selectivity	O
35	for	O
36	its	O
37	homologous	O
38	promoter	O
39	.	O
1	In	O
2	this	O
3	regard	O
4	,	O
5	it	O
6	differs	O
7	from	O
8	a	O
9	recently	O
10	reported	O
11	BFA	O
12	-	O
13	sensitive	O
14	ARF	B
15	-	O
16	GEP	B
17	that	O
18	contains	O
19	a	O
20	Sec7	B
21	domain	I
22	.	O
1	These	O
2	elements	O
3	comprise	O
4	a	O
5	binding	O
6	site	O
7	for	O
8	Krox	B
9	proteins	I
10	,	O
11	one	O
12	for	O
13	nuclear	B
14	factor	I
15	1	I
16	,	O
17	an	O
18	octamer	O
19	motif	O
20	that	O
21	binds	O
22	POU	B
23	-	I
24	homeodomain	I
25	proteins	I
26	,	O
27	and	O
28	a	O
29	novel	O
30	TN	B
31	control	I
32	element	I
33	.	O
1	RESULTS	O
2	:	O
3	The	O
4	medians	O
5	of	O
6	average	O
7	daily	O
8	CD34	B
9	+	I
10	cell	O
11	yields	O
12	for	O
13	patients	O
14	who	O
15	received	O
16	paclitaxel	O
17	plus	O
18	CY	O
19	,	O
20	CE	O
21	,	O
22	and	O
23	CEP	O
24	with	O
25	G	B
26	-	I
27	CSF	I
28	were	O
29	12	O
30	.	O
31	9	O
32	,	O
33	11	O
34	.	O
35	03	O
36	,	O
37	and	O
38	5	O
39	.	O
40	37	O
41	x	O
42	10	O
43	(	O
44	6	O
45	)/	O
46	kg	O
47	,	O
48	respectively	O
49	,	O
50	compared	O
51	with	O
52	2	O
53	.	O
54	02	O
55	x	O
56	10	O
57	(	O
58	6	O
59	)/	O
60	kg	O
61	in	O
62	the	O
63	reference	O
64	group	O
65	that	O
66	received	O
67	CY	O
68	with	O
69	G	B
70	-	I
71	CSF	I
72	(	O
73	P	O
74	=	O
75	<	O
76	.	O
77	0001	O
78	,	O
79	.	O
80	002	O
81	,	O
82	and	O
83	.	O
84	09	O
85	,	O
86	respectively	O
87	).	O
1	The	O
2	intensity	O
3	of	O
4	the	O
5	SSTEs	O
6	is	O
7	an	O
8	order	O
9	of	O
10	magnitude	O
11	larger	O
12	than	O
13	that	O
14	of	O
15	the	O
16	MSEs	O
17	and	O
18	determines	O
19	the	O
20	signal	O
21	contrast	O
22	if	O
23	both	O
24	effects	O
25	are	O
26	selected	O
27	simultaneously	O
28	.	O
1	In	O
2	eukaryotic	O
3	cells	O
4	,	O
5	premature	O
6	termination	O
7	of	O
8	translation	O
9	at	O
10	nonsense	O
11	codons	O
12	has	O
13	been	O
14	implicated	O
15	as	O
16	the	O
17	cause	O
18	of	O
19	a	O
20	variety	O
21	of	O
22	posttranscriptional	O
23	events	O
24	,	O
25	including	O
26	rapid	O
27	mRNA	O
28	decay	O
29	in	O
30	the	O
31	cytoplasm	O
32	or	O
33	the	O
34	nucleus	O
35	,	O
36	altered	O
37	splice	O
38	site	O
39	selection	O
40	,	O
41	and	O
42	exon	O
43	skipping	O
44	.	O
1	The	O
2	region	O
3	of	O
4	plasmid	O
5	pCM2	O
6	encoding	O
7	the	O
8	pathogenicity	B
9	locus	I
10	pat	I
11	-	I
12	1	I
13	was	O
14	mapped	O
15	by	O
16	deletion	O
17	analysis	O
18	and	O
19	complementation	O
20	studies	O
21	to	O
22	a	O
23	1	O
24	.	O
25	5	O
26	-	O
27	kb	O
28	Bg	B
29	/	I
30	II	I
31	/	O
32	SmaI	B
33	DNA	O
34	fragment	O
35	.	O
1	RNase	B
2	protection	O
3	experiments	O
4	confirmed	O
5	the	O
6	presence	O
7	of	O
8	the	O
9	GHR1	B
10	-	I
11	279	I
12	variant	I
13	in	O
14	IM	O
15	-	O
16	9	O
17	cells	O
18	and	O
19	human	O
20	liver	O
21	.	O
1	Conversely	O
2	,	O
3	activated	O
4	glucocorticoid	B
5	receptors	I
6	suppressed	O
7	the	O
8	transactivation	O
9	function	O
10	of	O
11	p53	B
12	,	O
13	while	O
14	transrepression	O
15	by	O
16	p53	B
17	was	O
18	largely	O
19	unaffected	O
20	.	O
1	The	O
2	addition	O
3	of	O
4	zidovudine	O
5	did	O
6	not	O
7	influence	O
8	this	O
9	transfer	O
10	.	O
1	The	O
2	second	O
3	class	O
4	of	O
5	cDNA	O
6	hybridized	O
7	to	O
8	a	O
9	13	O
10	kb	O
11	transcript	O
12	,	O
13	which	O
14	was	O
15	approximately	O
16	twice	O
17	as	O
18	large	O
19	as	O
20	the	O
21	mammalian	B
22	lactase	I
23	mRNA	I
24	.	O
1	Antisense	O
2	transcription	O
3	of	O
4	a	O
5	murine	B
6	FGFR	I
7	-	I
8	3	I
9	psuedogene	I
10	during	O
11	fetal	O
12	developement	O
13	.	O
1	A	O
2	previous	O
3	report	O
4	described	O
5	that	O
6	a	O
7	548	O
8	-	O
9	bp	O
10	BglII	B
11	-	O
12	SmaI	B
13	fragment	O
14	has	O
15	an	O
16	SSO	O
17	activity	O
18	(	O
19	ori2	O
20	;	O
21	Kataoka	O
22	et	O
23	al	O
24	.,	O
25	Mol	O
26	.	O
1	During	O
2	the	O
3	febrile	O
4	period	O
5	,	O
6	pleocytosis	O
7	was	O
8	associated	O
9	with	O
10	high	O
11	levels	O
12	of	O
13	IgG	B
14	,	O
15	IL	B
16	-	I
17	6	I
18	,	O
19	TNF	B
20	-	I
21	alpha	I
22	,	O
23	and	O
24	PGE2	O
25	in	O
26	the	O
27	cerebrospinal	O
28	fluid	O
29	.	O
1	Syndecan	B
2	-	I
3	4	I
4	is	O
5	a	O
6	focal	O
7	adhesion	O
8	component	O
9	,	O
10	and	O
11	this	O
12	interaction	O
13	may	O
14	both	O
15	localize	O
16	PKC	B
17	and	O
18	amplify	O
19	its	O
20	activity	O
21	at	O
22	sites	O
23	of	O
24	forming	O
25	adhesions	O
26	.	O
1	The	O
2	reduced	O
3	NO	O
4	production	O
5	in	O
6	these	O
7	cells	O
8	was	O
9	associated	O
10	with	O
11	low	O
12	levels	O
13	of	O
14	mRNA	O
15	of	O
16	inducible	B
17	NO	I
18	synthetase	I
19	.	O
1	Molecular	O
2	characterization	O
3	of	O
4	a	O
5	large	O
6	Borrelia	O
7	burgdorferi	O
8	motility	O
9	operon	O
10	which	O
11	is	O
12	initiated	O
13	by	O
14	a	O
15	consensus	O
16	sigma70	B
17	promoter	I
18	.	O
1	Therefore	O
2	more	O
3	active	O
4	and	O
5	tolerable	O
6	salvage	O
7	regimens	O
8	are	O
9	needed	O
10	.	O
1	However	O
2	,	O
3	the	O
4	range	O
5	of	O
6	values	O
7	observed	O
8	is	O
9	suggestive	O
10	of	O
11	the	O
12	need	O
13	to	O
14	investigate	O
15	districts	O
16	with	O
17	contrasting	O
18	values	O
19	of	O
20	SYPLR	O
21	with	O
22	respect	O
23	to	O
24	the	O
25	inter	O
26	-	O
27	relationships	O
28	between	O
29	sociodemographic	O
30	characteristics	O
31	,	O
32	duration	O
33	of	O
34	symptoms	O
35	,	O
36	clinical	O
37	presentation	O
38	and	O
39	treatment	O
40	efficacy	O
41	.	O
1	The	O
2	prominent	O
3	lesions	O
4	were	O
5	confined	O
6	to	O
7	the	O
8	cerebral	O
9	surface	O
10	layer	O
11	and	O
12	leptomeningeal	O
13	tissue	O
14	including	O
15	the	O
16	arachnoid	O
17	vessels	O
18	,	O
19	which	O
20	were	O
21	all	O
22	bathed	O
23	in	O
24	the	O
25	cerebrospinal	O
26	fluid	O
27	,	O
28	suggesting	O
29	that	O
30	some	O
31	necrotizing	O
32	toxins	O
33	had	O
34	been	O
35	secreted	O
36	into	O
37	the	O
38	fluid	O
39	by	O
40	the	O
41	B	O
42	.	O
43	cereus	O
44	.	O
1	Analysis	O
2	for	O
3	DNA	O
4	-	O
5	protein	O
6	interactions	O
7	by	O
8	in	O
9	vitro	O
10	DNase	B
11	-	I
12	I	I
13	footprinting	O
14	identified	O
15	a	O
16	broad	O
17	region	O
18	of	O
19	protection	O
20	extending	O
21	from	O
22	nt	O
23	-	O
24	12	O
25	to	O
26	+	O
27	38	O
28	.	O
1	Analysis	O
2	of	O
3	homologous	O
4	DNA	O
5	sequences	O
6	within	O
7	the	O
8	first	O
9	intron	O
10	of	O
11	the	O
12	mouse	B
13	and	I
14	human	I
15	mts1	I
16	genes	I
17	:	O
18	kB	B
19	-	I
20	like	I
21	site	I
22	and	O
23	microsatellite	O
24	DNA	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	examined	O
8	the	O
9	regulation	O
10	of	O
11	B	B
12	-	I
13	Myb	I
14	activity	O
15	by	O
16	cyclin	B
17	-	O
18	Cdks	B
19	.	O
1	Based	O
2	on	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	conRTRE	B
8	,	O
9	we	O
10	located	O
11	a	O
12	putative	O
13	RTRE	B
14	,	O
15	referred	O
16	to	O
17	as	O
18	P2	B
19	-	I
20	RE	I
21	,	O
22	in	O
23	the	O
24	5	O
25	'	O
26	promoter	O
27	-	O
28	flanking	O
29	region	O
30	of	O
31	the	O
32	mouse	B
33	protamine	I
34	2	I
35	gene	I
36	,	O
37	which	O
38	is	O
39	induced	O
40	during	O
41	the	O
42	same	O
43	stage	O
44	of	O
45	spermatogenesis	O
46	as	O
47	RTR	B
48	.	O
1	The	O
2	new	O
3	FIGO	O
4	definition	O
5	of	O
6	cervical	O
7	cancer	O
8	stage	O
9	IA	O
10	:	O
11	a	O
12	critique	O
13	.	O
1	A	O
2	method	O
3	for	O
4	the	O
5	simultaneous	O
6	determination	O
7	of	O
8	de	O
9	(	O
10	N	O
11	-	O
12	methyl	O
13	)-	O
14	N	O
15	-	O
16	ethyl	O
17	-	O
18	8	O
19	,	O
20	9	O
21	-	O
22	anhydroerythromycin	O
23	A	O
24	6	O
25	,	O
26	9	O
27	-	O
28	hemiacetal	O
29	(	O
30	EM523	O
31	,	O
32	I	O
33	)	O
34	and	O
35	its	O
36	three	O
37	metabolites	O
38	in	O
39	human	O
40	plasma	O
41	and	O
42	urine	O
43	has	O
44	been	O
45	developed	O
46	using	O
47	high	O
48	-	O
49	performance	O
50	liquid	O
51	chromatography	O
52	(	O
53	HPLC	O
54	)	O
55	with	O
56	chemiluminescence	O
57	(	O
58	CL	O
59	)	O
60	detection	O
61	.	O
1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	gagging	O
7	induced	O
8	by	O
9	oropharyngeal	O
10	irritation	O
11	is	O
12	unclear	O
13	.	O
1	Cyclin	B
2	D1	I
3	could	O
4	not	O
5	be	O
6	displaced	O
7	from	O
8	cdk4	B
9	in	O
10	the	O
11	resistant	O
12	184A1L5R	O
13	cell	O
14	lysates	O
15	.	O
1	The	O
2	importance	O
3	of	O
4	posttranslational	O
5	regulation	O
6	of	O
7	p15INK4B	B
8	by	O
9	TGF	B
10	-	I
11	beta	I
12	is	O
13	underlined	O
14	by	O
15	the	O
16	observation	O
17	that	O
18	in	O
19	TGF	B
20	-	I
21	beta	I
22	-	O
23	resistant	O
24	184A1L5R	O
25	,	O
26	although	O
27	the	O
28	p15	B
29	transcript	I
30	increased	O
31	,	O
32	p15INK4B	B
33	protein	I
34	was	O
35	not	O
36	stabilized	O
37	and	O
38	did	O
39	not	O
40	accumulate	O
41	,	O
42	and	O
43	cyclin	B
44	D1	I
45	-	O
46	cdk	B
47	association	O
48	and	O
49	kinase	O
50	activation	O
51	were	O
52	not	O
53	inhibited	O
54	.	O
1	Furthermore	O
2	,	O
3	experiments	O
4	with	O
5	32D	O
6	temperature	O
7	-	O
8	sensitive	O
9	p53	B
10	cells	O
11	indicate	O
12	that	O
13	aberrant	O
14	tal	B
15	-	I
16	1	I
17	expression	O
18	at	O
19	the	O
20	permissive	O
21	temperature	O
22	does	O
23	not	O
24	exert	O
25	a	O
26	proliferative	O
27	effect	O
28	but	O
29	causes	O
30	p53	B
31	-	O
32	mediated	O
33	apoptosis	O
34	,	O
35	i	O
36	.	O
37	e	O
38	.,	O
39	the	O
40	tal	B
41	-	I
42	1	I
43	proliferative	O
44	effect	O
45	depends	O
46	on	O
47	the	O
48	integrity	O
49	of	O
50	the	O
51	cell	O
52	cycle	O
53	checkpoints	O
54	of	O
55	the	O
56	host	O
57	cell	O
58	,	O
59	as	O
60	observed	O
61	for	O
62	c	B
63	-	I
64	myc	I
65	and	O
66	other	O
67	oncogenes	O
68	.	O
69	tal	B
70	-	I
71	1	I
72	mutant	I
73	experiments	O
74	indicate	O
75	that	O
76	ectopic	O
77	tal	B
78	-	I
79	1	I
80	effects	O
81	are	O
82	mediated	O
83	by	O
84	both	O
85	the	O
86	DNA	O
87	-	O
88	binding	O
89	and	O
90	the	O
91	heterodimerization	O
92	domains	O
93	,	O
94	while	O
95	the	O
96	N	B
97	-	I
98	terminally	I
99	truncated	I
100	tal	I
101	-	I
102	1	I
103	variant	I
104	(	O
105	M3	B
106	)	O
107	expressed	O
108	in	O
109	T	O
110	-	O
111	ALL	O
112	malignant	O
113	cells	O
114	mimics	O
115	the	O
116	effects	O
117	of	O
118	the	O
119	wild	O
120	-	O
121	type	O
122	protein	O
123	.	O
1	However	O
2	,	O
3	in	O
4	some	O
5	of	O
6	them	O
7	either	O
8	pattern	O
9	may	O
10	predominate	O
11	or	O
12	be	O
13	exclusively	O
14	present	O
15	.	O
1	Little	O
2	is	O
3	known	O
4	about	O
5	the	O
6	mechanism	O
7	,	O
8	but	O
9	the	O
10	availability	O
11	of	O
12	rapid	O
13	facile	O
14	assays	O
15	for	O
16	monitoring	O
17	immunoglobulin	B
18	hypermutation	O
19	would	O
20	greatly	O
21	aid	O
22	the	O
23	development	O
24	of	O
25	culture	O
26	systems	O
27	for	O
28	hypermutating	O
29	B	O
30	cells	O
31	as	O
32	well	O
33	as	O
34	the	O
35	screening	O
36	for	O
37	individuals	O
38	deficient	O
39	in	O
40	the	O
41	process	O
42	.	O
1	L	O
2	-	O
3	canavanine	O
4	,	O
5	a	O
6	selective	O
7	inhibitor	O
8	of	O
9	the	O
10	inducible	O
11	nitric	B
12	oxide	I
13	synthase	I
14	,	O
15	increases	O
16	the	O
17	mean	O
18	systemic	O
19	filling	O
20	pressure	O
21	,	O
22	thereby	O
23	improving	O
24	venous	O
25	return	O
26	,	O
27	under	O
28	these	O
29	conditions	O
30	.	O
1	Malonate	O
2	decarboxylation	O
3	in	O
4	Malonomonas	O
5	rubra	O
6	involves	O
7	the	O
8	formation	O
9	of	O
10	malonyl	B
11	-	I
12	S	I
13	-[	I
14	acyl	I
15	-	I
16	carrier	I
17	protein	I
18	]	I
19	from	O
20	acetyl	B
21	-	I
22	S	I
23	-[	I
24	acyl	I
25	-	I
26	carrier	I
27	protein	I
28	]	I
29	and	O
30	malonate	O
31	,	O
32	carboxyltransfer	O
33	to	O
34	a	O
35	biotin	B
36	protein	I
37	and	O
38	its	O
39	decarboxylation	O
40	that	O
41	is	O
42	coupled	O
43	to	O
44	delta	O
45	mu	O
46	Na	O
47	+	O
48	generation	O
49	.	O
1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	protein	O
9	that	O
10	binds	O
11	to	O
12	enhancer	O
13	site	O
14	III	O
15	.	O
1	A	O
2	genetic	O
3	screen	O
4	applied	O
5	to	O
6	mutants	O
7	in	O
8	the	O
9	branch	O
10	site	O
11	region	O
12	shows	O
13	that	O
14	all	O
15	positions	O
16	in	O
17	the	O
18	conserved	O
19	TACTAAC	O
20	sequence	O
21	are	O
22	important	O
23	for	O
24	intron	O
25	recognition	O
26	.	O
1	RESULTS	O
2	:	O
3	Surprisingly	O
4	,	O
5	PAF	B
6	blockade	O
7	increased	O
8	mortality	O
9	after	O
10	trauma	O
11	(	O
12	5	O
13	of	O
14	11	O
15	WEB	O
16	-	O
17	2086	O
18	animals	O
19	versus	O
20	1	O
21	of	O
22	9	O
23	vehicle	O
24	animals	O
25	;	O
26	p	O
27	=	O
28	0	O
29	.	O
30	15	O
31	)	O
32	and	O
33	depressed	O
34	cardiac	O
35	index	O
36	and	O
37	O2	O
38	delivery	O
39	at	O
40	72	O
41	hours	O
42	(	O
43	p	O
44	<	O
45	0	O
46	.	O
47	05	O
48	).	O
1	In	O
2	a	O
3	model	O
4	of	O
5	the	O
6	ternary	O
7	complex	O
8	,	O
9	the	O
10	segment	O
11	of	O
12	NFAT	B
13	nearest	O
14	AP	B
15	-	I
16	1	I
17	is	O
18	the	O
19	Rel	B
20	insert	O
21	region	O
22	(	O
23	RIR	O
24	),	O
25	a	O
26	feature	O
27	that	O
28	is	O
29	notable	O
30	for	O
31	its	O
32	hypervariability	O
33	in	O
34	size	O
35	and	O
36	in	O
37	sequence	O
38	amongst	O
39	members	O
40	of	O
41	the	O
42	Rel	B
43	transcription	I
44	factor	I
45	family	I
46	.	O
1	Respiratory	O
2	chain	O
3	enzyme	O
4	activity	O
5	was	O
6	normal	O
7	.	O
1	Children	O
2	'	O
3	s	O
4	temperament	O
5	and	O
6	maternal	O
7	socialization	O
8	at	O
9	Time	O
10	1	O
11	(	O
12	n	O
13	=	O
14	103	O
15	,	O
16	aged	O
17	2	O
18	-	O
19	3	O
20	years	O
21	)	O
22	were	O
23	considered	O
24	predictors	O
25	of	O
26	future	O
27	conscience	O
28	,	O
29	assessed	O
30	using	O
31	new	O
32	observational	O
33	and	O
34	narrative	O
35	measures	O
36	.	O
1	One	O
2	P1	O
3	genomic	O
4	clone	O
5	and	O
6	six	O
7	subsequent	O
8	plasmid	O
9	subclones	O
10	were	O
11	isolated	O
12	and	O
13	analyzed	O
14	for	O
15	the	O
16	exon	O
17	-	O
18	intron	O
19	organization	O
20	of	O
21	the	O
22	Ctpct	B
23	gene	I
24	.	O
1	We	O
2	also	O
3	review	O
4	the	O
5	role	O
6	of	O
7	grains	O
8	in	O
9	the	O
10	formation	O
11	of	O
12	complex	O
13	molecules	O
14	in	O
15	interstellar	O
16	molecular	O
17	clouds	O
18	.	O
1	The	O
2	mRNA	O
3	from	O
4	this	O
5	gene	O
6	,	O
7	termed	O
8	HES1	B
9	,	O
10	is	O
11	ubiquitously	O
12	expressed	O
13	,	O
14	but	O
15	strongly	O
16	so	O
17	in	O
18	heart	O
19	and	O
20	skeletal	O
21	muscle	O
22	.	O
1	They	O
2	observed	O
3	depressed	O
4	protein	B
5	C	I
6	activity	O
7	that	O
8	significantly	O
9	(	O
10	p	O
11	<	O
12	0	O
13	.	O
14	005	O
15	)	O
16	increased	O
17	and	O
18	became	O
19	normal	O
20	immediately	O
21	after	O
22	hemodialysis	O
23	while	O
24	factor	B
25	X	I
26	and	O
27	factor	B
28	VII	I
29	increased	O
30	(	O
31	p	O
32	<	O
33	0	O
34	.	O
35	01	O
36	;	O
37	p	O
38	<	O
39	0	O
40	.	O
41	05	O
42	)	O
43	despite	O
44	heparinization	O
45	together	O
46	with	O
47	amount	O
48	of	O
49	serum	O
50	lipoprotein	O
51	(	O
52	a	O
53	).	O
1	Fourteen	O
2	patients	O
3	with	O
4	New	O
5	York	O
6	Heart	O
7	Association	O
8	class	O
9	II	O
10	congestive	O
11	heart	O
12	failure	O
13	were	O
14	enrolled	O
15	in	O
16	a	O
17	double	O
18	-	O
19	blind	O
20	,	O
21	cross	O
22	-	O
23	over	O
24	study	O
25	.	O
1	Using	O
2	various	O
3	techniques	O
4	,	O
5	we	O
6	have	O
7	undertaken	O
8	a	O
9	systematic	O
10	analysis	O
11	of	O
12	the	O
13	natural	O
14	TATA	O
15	-	O
16	less	O
17	human	B
18	DNA	I
19	polymerase	I
20	beta	I
21	(	O
22	beta	B
23	-	I
24	pol	I
25	)	O
26	gene	O
27	promoter	O
28	.	O
1	This	O
2	association	O
3	appears	O
4	to	O
5	be	O
6	mediated	O
7	by	O
8	Src	B
9	-	O
10	SH2	B
11	domain	O
12	,	O
13	because	O
14	PECAM	B
15	-	I
16	1	I
17	can	O
18	be	O
19	precipitated	O
20	by	O
21	a	O
22	GST	B
23	-	O
24	Src	B
25	-	O
26	SH2	B
27	affinity	O
28	matrix	O
29	.	O
1	We	O
2	have	O
3	used	O
4	a	O
5	site	O
6	-	O
7	directed	O
8	mutagenesis	O
9	approach	O
10	to	O
11	examine	O
12	how	O
13	the	O
14	Xaa	O
15	and	O
16	hydroxy	O
17	(	O
18	Ser	O
19	/	O
20	Thr	O
21	)	O
22	amino	O
23	acid	O
24	residues	O
25	in	O
26	sequons	O
27	influence	O
28	core	O
29	-	O
30	glycosylation	O
31	efficiency	O
32	.	O
1	MATERIAL	O
2	AND	O
3	METHODS	O
4	:	O
5	The	O
6	authors	O
7	analyzed	O
8	41	O
9	persons	O
10	formerly	O
11	submitted	O
12	to	O
13	surgery	O
14	(	O
15	after	O
16	8	O
17	years	O
18	and	O
19	4	O
20	months	O
21	,	O
22	as	O
23	a	O
24	mean	O
25	),	O
26	31	O
27	to	O
28	highly	O
29	selective	O
30	vagotomy	O
31	,	O
32	and	O
33	10	O
34	to	O
35	truncal	O
36	or	O
37	selective	O
38	vagotomy	O
39	plus	O
40	gastroduodenal	O
41	drainage	O
42	.	O
1	This	O
2	region	O
3	does	O
4	not	O
5	contain	O
6	an	O
7	identifiable	O
8	TATA	O
9	element	O
10	,	O
11	indicating	O
12	that	O
13	transcription	O
14	of	O
15	the	O
16	glutaminase	B
17	gene	I
18	is	O
19	driven	O
20	by	O
21	a	O
22	TATA	O
23	-	O
24	less	O
25	promoter	O
26	.	O
1	In	O
2	unc	B
3	-	I
4	4	I
5	mutants	I
6	,	O
7	VA	O
8	motor	O
9	neurons	O
10	assume	O
11	the	O
12	pattern	O
13	of	O
14	synaptic	O
15	input	O
16	normally	O
17	reserved	O
18	for	O
19	their	O
20	lineal	O
21	sister	O
22	cells	O
23	,	O
24	the	O
25	VB	O
26	motor	O
27	neurons	O
28	;	O
29	the	O
30	loss	O
31	of	O
32	normal	O
33	input	O
34	to	O
35	the	O
36	VAs	O
37	produces	O
38	a	O
39	distinctive	O
40	backward	O
41	movement	O
42	defect	O
43	.	O
1	No	O
2	patient	O
3	in	O
4	group	O
5	2	O
6	developed	O
7	HAT	O
8	(	O
9	P	O
10	=	O
11	0	O
12	.	O
13	006	O
14	versus	O
15	group	O
16	1	O
17	).	O
1	The	O
2	mammalian	B
3	phosphoinositide	I
4	3	I
5	-	I
6	kinases	I
7	(	O
8	PI3Ks	B
9	)	O
10	p110alpha	B
11	,	I
12	beta	I
13	,	I
14	and	I
15	delta	I
16	form	O
17	heterodimers	O
18	with	O
19	Src	B
20	homology	I
21	2	I
22	(	O
23	SH2	B
24	)	O
25	domain	O
26	-	O
27	containing	O
28	adaptors	O
29	such	O
30	as	O
31	p85alpha	B
32	or	O
33	p55	B
34	(	O
35	PIK	B
36	).	O
1	Surprisingly	O
2	,	O
3	the	O
4	RXR	B
5	-	O
6	specific	O
7	ligand	O
8	9	O
9	-	O
10	cis	O
11	-	O
12	retinoic	O
13	acid	O
14	induced	O
15	binding	O
16	of	O
17	SRC	B
18	-	I
19	1	I
20	to	O
21	the	O
22	RXR	B
23	component	I
24	of	O
25	the	O
26	TRE	O
27	-	O
28	bound	O
29	heterodimer	O
30	.	O
1	In	O
2	ciliates	O
3	,	O
4	both	O
5	mechanisms	O
6	are	O
7	readily	O
8	observed	O
9	.	O
1	The	O
2	most	O
3	important	O
4	one	O
5	among	O
6	them	O
7	is	O
8	Cyclosporin	O
9	A	O
10	,	O
11	which	O
12	is	O
13	a	O
14	selective	O
15	immunosuppressive	O
16	drug	O
17	.	O
1	Consistent	O
2	with	O
3	its	O
4	role	O
5	in	O
6	p53	B
7	ubiquitination	O
8	,	O
9	mE6	B
10	-	I
11	AP	I
12	was	O
13	found	O
14	both	O
15	in	O
16	the	O
17	nucleus	O
18	and	O
19	cytosol	O
20	,	O
21	while	O
22	Nedd	B
23	-	I
24	4	I
25	was	O
26	found	O
27	only	O
28	in	O
29	the	O
30	cytosol	O
31	.	O
1	Also	O
2	,	O
3	transient	O
4	overexpression	O
5	of	O
6	this	O
7	protein	O
8	in	O
9	C2C12	O
10	cells	O
11	reduced	O
12	the	O
13	transcription	O
14	of	O
15	a	O
16	CAT	B
17	-	O
18	reporter	O
19	regulated	O
20	by	O
21	an	O
22	E12	B
23	/	O
24	MyoD	B
25	driven	O
26	enhancer	O
27	.	O
1	Taurine	O
2	deficiency	O
3	significantly	O
4	depressed	O
5	the	O
6	amplitude	O
7	of	O
8	OP1	O
9	and	O
10	OP4	O
11	.	O
1	The	O
2	findings	O
3	suggest	O
4	that	O
5	ERP	O
6	effects	O
7	of	O
8	distinct	O
9	memory	O
10	processes	O
11	are	O
12	differentially	O
13	influenced	O
14	by	O
15	the	O
16	encoding	O
17	instructions	O
18	.	O
1	Using	O
2	mouse	O
3	-	O
4	human	O
5	somatic	O
6	hybrids	O
7	and	O
8	FISH	O
9	analysis	O
10	,	O
11	the	O
12	PE	B
13	-	I
14	2	I
15	gene	I
16	is	O
17	localized	O
18	to	O
19	human	O
20	chromosome	O
21	19q13	O
22	.	O
23	2	O
24	,	O
25	a	O
26	region	O
27	involved	O
28	in	O
29	translocations	O
30	and	O
31	deletions	O
32	in	O
33	leukemias	O
34	and	O
35	several	O
36	solid	O
37	tumors	O
38	,	O
39	suggesting	O
40	that	O
41	this	O
42	novel	O
43	ETS	B
44	factor	I
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	carcinogenesis	O
51	.	O
1	The	O
2	immunophilin	B
3	,	O
4	which	O
5	can	O
6	be	O
7	of	O
8	the	O
9	FK506	O
10	-	O
11	or	O
12	cyclosporin	O
13	A	O
14	-	O
15	binding	O
16	class	O
17	,	O
18	binds	O
19	to	O
20	hsp90	B
21	via	O
22	its	O
23	tetratricopeptide	O
24	repeat	O
25	(	O
26	TPR	O
27	)	O
28	domain	O
29	,	O
30	and	O
31	different	O
32	receptor	O
33	heterocomplexes	O
34	exist	O
35	depending	O
36	upon	O
37	which	O
38	immunophilin	B
39	occupies	O
40	the	O
41	TPR	O
42	-	O
43	binding	O
44	region	O
45	of	O
46	hsp90	B
47	.	O
1	In	O
2	adherent	O
3	macrophages	O
4	,	O
5	absence	O
6	of	O
7	CD45	B
8	led	O
9	to	O
10	the	O
11	hyperphosphorylation	O
12	and	O
13	hyperactivation	O
14	of	O
15	p56	B
16	/	I
17	59	I
18	(	O
19	hck	B
20	)	O
21	and	O
22	p53	B
23	/	I
24	56	I
25	(	O
26	lyn	B
27	),	O
28	but	O
29	not	O
30	of	O
31	p58	B
32	(	O
33	c	B
34	-	I
35	fgr	I
36	).	O
1	With	O
2	a	O
3	view	O
4	to	O
5	identifying	O
6	other	O
7	important	O
8	U14	B
9	interactions	O
10	,	O
11	a	O
12	stem	O
13	-	O
14	loop	O
15	domain	O
16	required	O
17	for	O
18	activity	O
19	of	O
20	Saccharomyces	B
21	cerevisiae	I
22	U14	I
23	RNAs	I
24	(	O
25	the	O
26	Y	O
27	domain	O
28	)	O
29	was	O
30	first	O
31	subjected	O
32	to	O
33	detailed	O
34	mutational	O
35	analysis	O
36	.	O
1	The	O
2	linear	O
3	plasmid	O
4	pDHL1	O
5	from	O
6	Debaryomyces	O
7	hansenii	O
8	encodes	O
9	a	O
10	protein	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	pGKL1	B
16	-	I
17	plasmid	I
18	DNA	I
19	polymerase	I
20	.	O
1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	bulbospinal	O
7	micturition	O
8	reflex	O
9	evoked	O
10	by	O
11	bladder	O
12	filling	O
13	and	O
14	L	O
15	-	O
16	dopa	O
17	involves	O
18	a	O
19	descending	O
20	pathway	O
21	where	O
22	transmission	O
23	is	O
24	partly	O
25	mediated	O
26	by	O
27	spinal	B
28	alpha	I
29	1	I
30	-	I
31	adrenoceptors	I
32	.	O
1	Disturbance	O
2	of	O
3	regeneration	O
4	in	O
5	the	O
6	above	O
7	pathological	O
8	condition	O
9	results	O
10	from	O
11	the	O
12	damage	O
13	to	O
14	tunica	O
15	propria	O
16	and	O
17	loss	O
18	of	O
19	its	O
20	function	O
21	for	O
22	the	O
23	support	O
24	of	O
25	structural	O
26	homeostasis	O
27	.	O
1	Sternocleidomastoid	O
2	,	O
3	neck	O
4	or	O
5	facial	O
6	muscles	O
7	wasting	O
8	were	O
9	also	O
10	found	O
11	in	O
12	three	O
13	cases	O
14	.	O
1	However	O
2	,	O
3	we	O
4	could	O
5	not	O
6	find	O
7	the	O
8	homologous	O
9	regions	O
10	with	O
11	guanine	B
12	nucleotide	I
13	exchange	I
14	factors	I
15	or	O
16	GTPase	B
17	-	I
18	activating	I
19	proteins	I
20	in	O
21	the	O
22	c	B
23	-	I
24	cbl	I
25	gene	I
26	.	O
1	The	O
2	ubiquitously	O
3	expressed	O
4	hypoxia	B
5	-	I
6	inducible	I
7	factor	I
8	-	I
9	1	I
10	(	O
11	HIF	B
12	-	I
13	1	I
14	)	O
15	is	O
16	involved	O
17	in	O
18	expression	O
19	of	O
20	a	O
21	large	O
22	number	O
23	of	O
24	oxygen	O
25	-	O
26	regulated	O
27	genes	O
28	.	O
1	Surveillance	O
2	for	O
3	preeclampsia	O
4	was	O
5	conducted	O
6	by	O
7	personnel	O
8	unaware	O
9	of	O
10	treatment	O
11	-	O
12	group	O
13	assignments	O
14	,	O
15	using	O
16	standardized	O
17	measurements	O
18	of	O
19	blood	O
20	pressure	O
21	and	O
22	urinary	O
23	protein	O
24	excretion	O
25	at	O
26	uniformly	O
27	scheduled	O
28	prenatal	O
29	visits	O
30	,	O
31	protocols	O
32	for	O
33	monitoring	O
34	these	O
35	measurements	O
36	during	O
37	the	O
38	hospitalization	O
39	for	O
40	delivery	O
41	,	O
42	and	O
43	reviews	O
44	of	O
45	medical	O
46	records	O
47	of	O
48	unscheduled	O
49	outpatient	O
50	visits	O
51	and	O
52	all	O
53	hospitalizations	O
54	.	O
1	We	O
2	have	O
3	initiated	O
4	studies	O
5	to	O
6	identify	O
7	candidate	O
8	signal	O
9	transducers	O
10	that	O
11	associate	O
12	with	O
13	the	O
14	cytosolic	O
15	domain	O
16	(	O
17	cd	O
18	)	O
19	of	O
20	the	O
21	IL	B
22	-	I
23	1R	I
24	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	sought	O
7	to	O
8	identify	O
9	mechanisms	O
10	that	O
11	could	O
12	account	O
13	for	O
14	the	O
15	antimitogenic	O
16	effects	O
17	of	O
18	IL	B
19	-	I
20	4	I
21	.	O
1	Pseudomonas	O
2	aeruginosa	O
3	strains	O
4	infecting	O
5	patients	O
6	with	O
7	cystic	O
8	fibrosis	O
9	(	O
10	CF	O
11	)	O
12	acquire	O
13	a	O
14	mucoid	O
15	phenotype	O
16	due	O
17	to	O
18	overproduction	O
19	of	O
20	alginate	O
21	.	O
1	Chloramphenicol	B
2	acetyltransferase	I
3	assays	O
4	examining	O
5	the	O
6	ability	O
7	of	O
8	IE86	B
9	to	O
10	repress	O
11	activity	O
12	from	O
13	the	O
14	HCMV	O
15	major	O
16	IE	B
17	promoter	I
18	or	O
19	activate	O
20	the	O
21	HCMV	B
22	early	I
23	promoter	I
24	for	O
25	the	O
26	2	O
27	.	O
28	2	O
29	-	O
30	kb	O
31	class	O
32	of	O
33	RNAs	O
34	demonstrated	O
35	the	O
36	functional	O
37	integrity	O
38	of	O
39	the	O
40	IE86	B
41	protein	I
42	.	O
1	ORF	O
2	M1	O
3	has	O
4	striking	O
5	homology	O
6	to	O
7	poxvirus	O
8	serpins	B
9	,	O
10	while	O
11	ORF	O
12	M11	O
13	encodes	O
14	a	O
15	potential	O
16	homolog	O
17	of	O
18	Bcl	B
19	-	I
20	2	I
21	-	I
22	like	I
23	molecules	I
24	encoded	O
25	by	O
26	other	O
27	gammaherpesviruses	O
28	(	O
29	gene	B
30	16	I
31	of	O
32	HVS	O
33	and	O
34	KSHV	O
35	and	O
36	the	O
37	BHRF1	B
38	gene	I
39	of	O
40	EBV	O
41	).	O
1	The	O
2	behavior	O
3	of	O
4	different	O
5	types	O
6	of	O
7	polytetrafluoroethylene	O
8	(	O
9	PTFE	O
10	)	O
11	prostheses	O
12	in	O
13	the	O
14	reparative	O
15	scarring	O
16	process	O
17	of	O
18	abdominal	O
19	wall	O
20	defects	O
21	.	O
1	The	O
2	control	O
3	group	O
4	revealed	O
5	significantly	O
6	higher	O
7	levels	O
8	of	O
9	coagulation	B
10	factors	I
11	II	I
12	,	I
13	V	I
14	and	I
15	VIII	I
16	,	O
17	compared	O
18	to	O
19	the	O
20	index	O
21	group	O
22	.	O
1	If	O
2	E	O
3	.	O
4	coli	O
5	is	O
6	present	O
7	in	O
8	any	O
9	source	O
10	water	O
11	sample	O
12	,	O
13	the	O
14	borehole	O
15	and	O
16	any	O
17	directly	O
18	connected	O
19	borehole	O
20	should	O
21	be	O
22	embargoed	O
23	.	O
1	In	O
2	summary	O
3	,	O
4	DDC	O
5	express	O
6	receptors	O
7	for	O
8	a	O
9	broad	O
10	panel	O
11	of	O
12	cytokines	O
13	,	O
14	even	O
15	receptors	O
16	for	O
17	cytokines	O
18	whose	O
19	effects	O
20	on	O
21	DC	O
22	are	O
23	still	O
24	unknown	O
25	(	O
26	i	O
27	.	O
28	e	O
29	.	O
1	Re	O
2	-	O
3	evaluation	O
4	of	O
5	the	O
6	biopsy	O
7	specimen	O
8	from	O
9	the	O
10	right	O
11	hip	O
12	taken	O
13	at	O
14	the	O
15	time	O
16	of	O
17	the	O
18	initial	O
19	operation	O
20	showed	O
21	areas	O
22	of	O
23	chondrosarcoma	O
24	arising	O
25	in	O
26	the	O
27	background	O
28	of	O
29	synovial	O
30	chondromatosis	O
31	.	O
1	Future	O
2	analysis	O
3	of	O
4	long	O
5	-	O
6	term	O
7	outcome	O
8	measures	O
9	of	O
10	performance	O
11	with	O
12	the	O
13	implant	O
14	will	O
15	confirm	O
16	or	O
17	dispute	O
18	the	O
19	benefit	O
20	of	O
21	ear	O
22	selection	O
23	using	O
24	the	O
25	Prom	O
26	-	O
27	EABR	O
28	.	O
1	Recent	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	Cbl	B
7	,	O
8	the	O
9	120	O
10	-	O
11	kDa	O
12	protein	O
13	product	O
14	of	O
15	the	O
16	c	B
17	-	I
18	cbl	I
19	proto	I
20	-	I
21	oncogene	I
22	,	O
23	serves	O
24	as	O
25	a	O
26	substrate	O
27	of	O
28	a	O
29	number	O
30	of	O
31	receptor	B
32	-	I
33	coupled	I
34	tyrosine	I
35	kinases	I
36	and	O
37	forms	O
38	complexes	O
39	with	O
40	SH3	B
41	and	O
42	SH2	B
43	domain	O
44	-	O
45	containing	O
46	proteins	O
47	,	O
48	pointing	O
49	to	O
50	its	O
51	role	O
52	in	O
53	signal	O
54	transduction	O
55	.	O
1	Although	O
2	neither	O
3	constitutively	O
4	activated	O
5	MEK	B
6	(	O
7	MEK	B
8	-	I
9	2E	I
10	)	O
11	nor	O
12	v	B
13	-	I
14	Src	I
15	was	O
16	sufficient	O
17	individually	O
18	to	O
19	differentiate	O
20	the	O
21	H19	O
22	-	O
23	7	O
24	cells	O
25	,	O
26	coexpression	O
27	of	O
28	constitutively	O
29	activated	O
30	MEK	B
31	and	O
32	v	B
33	-	I
34	Src	I
35	induced	O
36	neurite	O
37	outgrowth	O
38	.	O
1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	transrepression	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	activity	O
23	.	O
1	In	O
2	a	O
3	series	O
4	of	O
5	patients	O
6	with	O
7	neuroinfection	O
8	,	O
9	Lyme	O
10	disease	O
11	,	O
12	Guillain	O
13	Barre	O
14	syndrome	O
15	,	O
16	demyelinization	O
17	,	O
18	partial	O
19	or	O
20	generalized	O
21	,	O
22	epilepsy	O
23	,	O
24	we	O
25	have	O
26	investigated	O
27	antiphospholipid	O
28	antibodies	O
29	of	O
30	IgG	B
31	and	O
32	IgM	B
33	subtypes	O
34	,	O
35	together	O
36	with	O
37	anticoagulant	O
38	factors	O
39	,	O
40	member	O
41	of	O
42	thrombocytes	O
43	,	O
44	sedimentation	O
45	rate	O
46	of	O
47	erythrocytes	O
48	.	O
1	(	O
2	1996a	O
3	)	O
4	Biochemistry	O
5	35	O
6	,	O
7	1589	O
8	-	O
9	1598	O
10	].	O
1	Second	O
2	,	O
3	the	O
4	membrane	O
5	expression	O
6	of	O
7	alpha	O
8	and	O
9	beta	O
10	subunits	O
11	was	O
12	mimicked	O
13	by	O
14	cholesterol	O
15	and	O
16	17	O
17	-	O
18	ketocholesterol	O
19	,	O
20	both	O
21	of	O
22	which	O
23	inhibit	O
24	HMG	B
25	-	I
26	CoA	I
27	reductase	I
28	.	O
1	In	O
2	all	O
3	experimental	O
4	eyes	O
5	,	O
6	there	O
7	was	O
8	a	O
9	marked	O
10	reduction	O
11	,	O
12	but	O
13	never	O
14	a	O
15	complete	O
16	absence	O
17	of	O
18	adrenergic	O
19	nerves	O
20	in	O
21	the	O
22	iris	O
23	.	O
1	Therefore	O
2	,	O
3	use	O
4	of	O
5	presaturation	O
6	is	O
7	recommended	O
8	for	O
9	myocardial	O
10	motion	O
11	studies	O
12	using	O
13	cine	O
14	PC	O
15	velocity	O
16	data	O
17	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	DNA	O
6	-	O
7	binding	O
8	experiments	O
9	show	O
10	that	O
11	either	O
12	one	O
13	of	O
14	the	O
15	two	O
16	MADS	B
17	domains	I
18	of	O
19	a	O
20	dimer	O
21	can	O
22	be	O
23	sufficient	O
24	to	O
25	confer	O
26	a	O
27	particular	O
28	DNA	O
29	-	O
30	binding	O
31	specificity	O
32	to	O
33	the	O
34	complex	O
35	and	O
36	that	O
37	sequences	O
38	outside	O
39	the	O
40	amino	O
41	-	O
42	terminal	O
43	basic	O
44	region	O
45	of	O
46	the	O
47	MADS	B
48	domain	O
49	can	O
50	,	O
51	in	O
52	some	O
53	cases	O
54	,	O
55	contribute	O
56	to	O
57	the	O
58	DNA	O
59	-	O
60	binding	O
61	specificity	O
62	of	O
63	the	O
64	proteins	O
65	.	O
1	Two	O
2	related	O
3	studies	O
4	conducted	O
5	over	O
6	a	O
7	five	O
8	week	O
9	period	O
10	measured	O
11	and	O
12	typed	O
13	HLA	B
14	-	I
15	DQA1	I
16	from	O
17	accumulated	O
18	DNA	O
19	on	O
20	autopsy	O
21	room	O
22	and	O
23	Forensic	O
24	DNA	O
25	Laboratory	O
26	structures	O
27	.	O
1	Thirty	O
2	-	O
3	two	O
4	rats	O
5	were	O
6	divided	O
7	into	O
8	four	O
9	groups	O
10	.	O
1	Neural	O
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O
1	Reactive	O
2	lymphoid	O
3	hyperplasia	O
4	was	O
5	found	O
6	in	O
7	15	O
8	cases	O
9	,	O
10	2	O
11	cases	O
12	had	O
13	angiofollicular	O
14	lymphoid	O
15	hyperplasia	O
16	or	O
17	Castleman	O
18	'	O
19	s	O
20	disease	O
21	,	O
22	atypical	O
23	lymphoid	O
24	hyperplasia	O
25	suggestive	O
26	of	O
27	malignant	O
28	lymphoma	O
29	was	O
30	observed	O
31	in	O
32	3	O
33	cases	O
34	,	O
35	and	O
36	malignant	O
37	lymphoma	O
38	was	O
39	diagnosed	O
40	in	O
41	the	O
42	remaining	O
43	4	O
44	cases	O
45	.	O
1	For	O
2	E2	O
3	,	O
4	each	O
5	cat	O
6	was	O
7	given	O
8	either	O
9	5	O
10	(	O
11	group	O
12	[	O
13	G	O
14	]	O
15	1	O
16	)	O
17	or	O
18	10	O
19	(	O
20	G2	O
21	)	O
22	mg	O
23	of	O
24	itraconazole	O
25	/	O
26	kg	O
27	(	O
28	capsules	O
29	)	O
30	twice	O
31	daily	O
32	for	O
33	6	O
34	weeks	O
35	.	O
1	G	B
2	-	I
3	CSF	I
4	was	O
5	started	O
6	on	O
7	day	O
8	3	O
9	of	O
10	each	O
11	cycle	O
12	(	O
13	5	O
14	microg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	and	O
21	was	O
22	stopped	O
23	the	O
24	day	O
25	before	O
26	the	O
27	last	O
28	apheresis	O
29	or	O
30	when	O
31	absolute	O
32	neutrophil	O
33	count	O
34	was	O
35	above	O
36	0	O
37	.	O
38	5	O
39	x	O
40	10	O
41	(	O
42	9	O
43	)/	O
44	l	O
45	.	O
1	Supershift	O
2	assays	O
3	,	O
4	using	O
5	Jun	B
6	and	I
7	Fos	I
8	family	I
9	member	I
10	-	I
11	specific	I
12	antibodies	I
13	,	O
14	showed	O
15	that	O
16	protein	O
17	complexes	O
18	formed	O
19	by	O
20	AtT	O
21	-	O
22	20	O
23	cell	O
24	nuclear	O
25	extracts	O
26	bound	O
27	to	O
28	the	O
29	c	B
30	-	I
31	jun	I
32	AP	I
33	-	I
34	1	I
35	site	I
36	were	O
37	comprised	O
38	of	O
39	Jun	B
40	family	O
41	members	O
42	,	O
43	JunD	B
44	,	O
45	JunB	B
46	,	O
47	and	O
48	cJun	B
49	.	O
1	Using	O
2	lectin	B
3	-	O
4	affinity	O
5	chromatography	O
6	,	O
7	discordance	O
8	between	O
9	the	O
10	pattern	O
11	of	O
12	O	O
13	-	O
14	glycosylation	O
15	of	O
16	SSBP	B
17	and	O
18	DSBP	B
19	was	O
20	demonstrated	O
21	.	O
1	The	O
2	dose	O
3	was	O
4	50	O
5	Gy	O
6	/	O
7	20	O
8	fractions	O
9	/	O
10	5	O
11	weeks	O
12	.	O
1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	identify	O
7	and	O
8	characterize	O
9	two	O
10	overlapping	O
11	ELL	B
12	functional	I
13	domains	I
14	that	O
15	govern	O
16	its	O
17	interaction	O
18	with	O
19	RNA	B
20	polymerase	I
21	II	I
22	and	O
23	the	O
24	ternary	O
25	elongation	O
26	complex	O
27	.	O
1	Here	O
2	,	O
3	we	O
4	describe	O
5	directional	O
6	chromosome	O
7	walking	O
8	studies	O
9	starting	O
10	from	O
11	D8S260	B
12	as	O
13	well	O
14	as	O
15	D8S285	B
16	.	O
1	We	O
2	describe	O
3	a	O
4	novel	O
5	zinc	B
6	finger	I
7	protein	I
8	,	O
9	dsRBP	B
10	-	I
11	ZFa	I
12	,	O
13	isolated	O
14	by	O
15	screening	O
16	an	O
17	expression	O
18	library	O
19	with	O
20	dsRNA	O
21	.	O
1	Nasal	O
2	absorption	O
3	was	O
4	rapid	O
5	,	O
6	nasal	O
7	bioavailability	O
8	was	O
9	43	O
10	%,	O
11	and	O
12	the	O
13	iv	O
14	and	O
15	nasal	O
16	elimination	O
17	profiles	O
18	were	O
19	similar	O
20	.	O
1	Together	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	EGF	B
8	/	O
9	Ras	B
10	/	O
11	Raf	B
12	induces	O
13	transcription	O
14	via	O
15	combined	O
16	activation	O
17	of	O
18	ATF3	B
19	/	O
20	c	B
21	-	I
22	Jun	I
23	and	O
24	a	O
25	52	O
26	-	O
27	kDa	O
28	nuclear	O
29	factor	O
30	,	O
31	whereas	O
32	JunD	B
33	acts	O
34	as	O
35	a	O
36	repressor	O
37	of	O
38	this	O
39	response	O
40	.	O
1	Various	O
2	assays	O
3	demonstrate	O
4	promoter	O
5	activity	O
6	in	O
7	this	O
8	sequence	O
9	that	O
10	reproduces	O
11	the	O
12	normal	O
13	control	O
14	of	O
15	E2F2	B
16	expression	O
17	during	O
18	a	O
19	growth	O
20	stimulation	O
21	.	O
1	The	O
2	MCAD	B
3	nuclear	I
4	receptor	I
5	response	I
6	element	I
7	1	I
8	(	O
9	NRRE	B
10	-	I
11	1	I
12	)	O
13	interacts	O
14	in	O
15	vitro	O
16	with	O
17	ERR	B
18	alpha	I
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	7	O
24	cells	O
25	.	O
1	The	O
2	complete	O
3	response	O
4	(	O
5	CR	O
6	)	O
7	rate	O
8	was	O
9	34	O
10	%	O
11	in	O
12	the	O
13	CODE	O
14	with	O
15	rhG	B
16	-	I
17	CSF	I
18	group	O
19	and	O
20	23	O
21	%	O
22	in	O
23	the	O
24	CODE	O
25	alone	O
26	group	O
27	;	O
28	the	O
29	median	O
30	survival	O
31	was	O
32	59	O
33	and	O
34	32	O
35	weeks	O
36	,	O
37	respectively	O
38	,	O
39	in	O
40	these	O
41	groups	O
42	(	O
43	P	O
44	=	O
45	0	O
46	.	O
47	004	O
48	).	O
1	Myocardial	O
2	interstitial	O
3	edema	O
4	is	O
5	more	O
6	likely	O
7	a	O
8	potential	O
9	mechanism	O
10	of	O
11	diastolic	O
12	dysfunction	O
13	after	O
14	DC	O
15	shocks	O
16	.	O
1	Overexpression	O
2	of	O
3	CARP	B
4	in	O
5	cardiomyocytes	O
6	suppresses	O
7	cardiac	B
8	troponin	I
9	C	I
10	and	O
11	atrial	B
12	natriuretic	I
13	factor	I
14	transcription	O
15	.	O
1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	and	O
6	competition	O
7	experiments	O
8	showed	O
9	that	O
10	site	O
11	A	O
12	is	O
13	recognized	O
14	by	O
15	an	O
16	NF1	B
17	protein	I
18	.	O
1	ArgR	B
2	was	O
3	shown	O
4	to	O
5	be	O
6	a	O
7	dimer	O
8	of	O
9	two	O
10	equal	O
11	subunits	O
12	,	O
13	each	O
14	with	O
15	a	O
16	molecular	O
17	mass	O
18	of	O
19	37	O
20	,	O
21	000	O
22	Da	O
23	.	O
1	Neither	O
2	mutant	O
3	exhibited	O
4	derepression	O
5	of	O
6	the	O
7	silent	B
8	mating	I
9	type	I
10	loci	I
11	.	O
1	These	O
2	repressor	O
3	sites	O
4	are	O
5	pyrimidine	O
6	rich	O
7	and	O
8	bind	O
9	avidly	O
10	to	O
11	the	O
12	polypyrimidine	B
13	tract	I
14	binding	I
15	protein	I
16	(	O
17	PTB	B
18	)	O
19	in	O
20	HeLa	O
21	nuclear	O
22	extracts	O
23	as	O
24	determined	O
25	by	O
26	UV	O
27	crosslinking	O
28	/	O
29	competition	O
30	assays	O
31	.	O
1	Within	O
2	a	O
3	135	O
4	-	O
5	bp	O
6	core	O
7	homology	O
8	region	O
9	,	O
10	the	O
11	human	B
12	HS12	I
13	enhancers	I
14	are	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	the	O
21	murine	O
22	homolog	O
23	and	O
24	include	O
25	several	O
26	motifs	O
27	previously	O
28	demonstrated	O
29	to	O
30	be	O
31	important	O
32	for	O
33	function	O
34	of	O
35	the	O
36	murine	O
37	enhancer	O
38	;	O
39	additional	O
40	segments	O
41	of	O
42	high	O
43	sequence	O
44	conservation	O
45	suggest	O
46	the	O
47	possibility	O
48	of	O
49	previously	O
50	unrecognized	O
51	functional	O
52	motifs	O
53	.	O
1	The	O
2	ORF3	O
3	mutant	O
4	produced	O
5	reduced	O
6	levels	O
7	of	O
8	tabtoxin	B
9	,	O
10	indicating	O
11	that	O
12	ORF3	O
13	may	O
14	have	O
15	a	O
16	role	O
17	in	O
18	T	B
19	beta	I
20	L	I
21	biosynthesis	O
22	.	O
1	These	O
2	transcripts	O
3	contain	O
4	the	O
5	5	O
6	'	O
7	ends	O
8	of	O
9	mature	O
10	UbCRBP	B
11	mRNAs	I
12	;	O
13	extend	O
14	through	O
15	UbCRBP	B
16	,	O
17	across	O
18	the	O
19	intergenic	O
20	region	O
21	,	O
22	and	O
23	a	O
24	significant	O
25	distance	O
26	3	O
27	'	O
28	into	O
29	the	O
30	enolase	B
31	gene	I
32	.	O
1	For	O
2	sputum	B
3	interleukin	I
4	-	I
5	8	I
6	there	O
7	was	O
8	an	O
9	estimated	O
10	true	O
11	treatment	O
12	median	O
13	difference	O
14	of	O
15	142	O
16	pg	O
17	/	O
18	ml	O
19	(	O
20	95	O
21	%	O
22	confidence	O
23	interval	O
24	(	O
25	CI	O
26	)	O
27	8	O
28	to	O
29	2866	O
30	pg	O
31	/	O
32	ml	O
33	)	O
34	in	O
35	favour	O
36	of	O
37	placebo	O
38	;	O
39	while	O
40	for	O
41	maximal	O
42	expiratory	O
43	flow	O
44	at	O
45	25	O
46	%	O
47	(	O
48	MEF25	O
49	%)	O
50	remaining	O
51	forced	O
52	vital	O
53	capacity	O
54	predicted	O
55	for	O
56	sex	O
57	and	O
58	height	O
59	there	O
60	was	O
61	a	O
62	15	O
63	percentage	O
64	points	O
65	(	O
66	pp	O
67	)	O
68	(	O
69	95	O
70	%	O
71	CI	O
72	4	O
73	to	O
74	26	O
75	pp	O
76	)	O
77	mean	O
78	treatment	O
79	difference	O
80	in	O
81	favour	O
82	of	O
83	placebo	O
84	.	O
1	Six	O
2	tandem	O
3	repeats	O
4	of	O
5	the	O
6	P	B
7	element	I
8	linked	O
9	to	O
10	the	O
11	SV40	B
12	promoter	I
13	responded	O
14	to	O
15	phorbol	O
16	12	O
17	-	O
18	myristate	O
19	13	O
20	-	O
21	acetate	O
22	,	O
23	while	O
24	that	O
25	of	O
26	other	O
27	elements	O
28	did	O
29	not	O
30	.	O
1	The	O
2	cleavage	O
3	dipeptides	O
4	of	O
5	C1YVV	B
6	NIa	I
7	protease	I
8	are	O
9	Q	O
10	(	O
11	E	O
12	)/	O
13	S	O
14	(	O
15	A	O
16	,	O
17	G	O
18	).	O
1	These	O
2	effects	O
3	were	O
4	abrogated	O
5	by	O
6	co	O
7	-	O
8	expression	O
9	of	O
10	kinase	B
11	-	I
12	deficient	I
13	PKC	I
14	zeta	I
15	and	O
16	inhibition	O
17	of	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	p85alpha	I
23	-	O
24	p110	B
25	by	O
26	wortmannin	O
27	,	O
28	LY294002	O
29	and	O
30	a	O
31	dominant	O
32	-	O
33	negative	O
34	mutant	O
35	of	O
36	p85alpha	B
37	.	O
1	Underlying	O
2	the	O
3	clustering	O
4	of	O
5	these	O
6	risk	O
7	variables	O
8	were	O
9	three	O
10	factors	O
11	.	O
1	Deletion	O
2	of	O
3	the	O
4	POR2	B
5	gene	I
6	alone	O
7	had	O
8	no	O
9	detectable	O
10	phenotype	O
11	,	O
12	while	O
13	yeasts	O
14	with	O
15	deletions	O
16	of	O
17	both	O
18	the	O
19	POR1	B
20	and	O
21	POR2	B
22	genes	I
23	were	O
24	viable	O
25	and	O
26	able	O
27	to	O
28	grow	O
29	on	O
30	glycerol	O
31	at	O
32	30	O
33	degrees	O
34	C	O
35	,	O
36	albeit	O
37	more	O
38	slowly	O
39	than	O
40	delta	B
41	por1	I
42	single	I
43	mutants	I
44	.	O
1	THE	O
2	SCALING	O
3	OF	O
4	SONG	O
5	FREQUENCY	O
6	IN	O
7	CICADAS	O
1	In	O
2	this	O
3	study	O
4	we	O
5	have	O
6	introduced	O
7	mutations	O
8	into	O
9	the	O
10	corresponding	O
11	elements	O
12	of	O
13	two	O
14	cox3	B
15	promoters	I
16	and	O
17	show	O
18	that	O
19	while	O
20	the	O
21	core	O
22	element	O
23	is	O
24	essential	O
25	for	O
26	cox3	B
27	promoter	I
28	activity	O
29	,	O
30	upstream	O
31	element	O
32	mutations	O
33	have	O
34	little	O
35	or	O
36	no	O
37	effect	O
38	.	O
1	We	O
2	found	O
3	that	O
4	multiple	O
5	tumor	O
6	suppressor	O
7	genes	O
8	(	O
9	e	O
10	.	O
11	g	O
12	.,	O
13	p53	B
14	,	O
15	DCC	B
16	,	O
17	APC	B
18	,	O
19	MCC	B
20	,	O
21	BRCA1	B
22	,	O
23	and	O
24	WAF1	B
25	/	O
26	CIP1	B
27	)	O
28	were	O
29	inactivated	O
30	at	O
31	different	O
32	frequencies	O
33	via	O
34	various	O
35	mechanisms	O
36	[	O
37	e	O
38	.	O
39	g	O
40	.,	O
41	loss	O
42	of	O
43	heterozygosity	O
44	(	O
45	LOH	O
46	),	O
47	loss	O
48	of	O
49	expression	O
50	(	O
51	LOE	O
52	),	O
53	mutation	O
54	,	O
55	and	O
56	inactivation	O
57	by	O
58	cellular	O
59	binding	O
60	protein	O
61	].	O
1	Substrates	O
2	include	O
3	the	O
4	p21	B
5	(	O
6	ras	B
7	)	O
8	proteins	O
9	,	O
10	nuclear	B
11	lamins	I
12	,	O
13	and	O
14	a	O
15	series	O
16	of	O
17	retinal	O
18	proteins	O
19	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	UBP41	B
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	recycling	O
14	of	O
15	ubiquitin	B
16	by	O
17	hydrolysis	O
18	of	O
19	branched	B
20	poly	I
21	-	I
22	ubiquitin	I
23	chains	I
24	generated	O
25	by	O
26	the	O
27	action	O
28	of	O
29	26	B
30	S	I
31	proteasome	I
32	on	O
33	poly	O
34	-	O
35	ubiquitinated	O
36	protein	O
37	substrates	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	production	O
45	of	O
46	free	O
47	ubiquitin	B
48	from	O
49	linear	B
50	poly	I
51	-	I
52	ubiquitin	I
53	chains	I
54	and	O
55	of	O
56	certain	O
57	ribosomal	O
58	proteins	O
59	from	O
60	ubiquitin	B
61	fusion	I
62	proteins	I
63	.	O
1	This	O
2	is	O
3	the	O
4	first	O
5	study	O
6	in	O
7	which	O
8	mutation	O
9	screening	O
10	has	O
11	been	O
12	performed	O
13	for	O
14	both	O
15	the	O
16	EXT1	B
17	and	O
18	EXT2	B
19	genes	I
20	prior	O
21	to	O
22	any	O
23	linkage	O
24	analysis	O
25	.	O
1	Positron	O
2	emission	O
3	tomography	O
4	radioligands	O
5	for	O
6	dopamine	B
7	transporters	I
8	and	O
9	studies	O
10	in	O
11	human	O
12	and	O
13	nonhuman	O
14	primates	O
15	.	O
1	Attenuation	O
2	from	O
3	the	O
4	vit	B
5	A2	I
6	consensus	O
7	ERE	O
8	is	O
9	not	O
10	necessarily	O
11	dependent	O
12	on	O
13	DNA	O
14	binding	O
15	as	O
16	the	O
17	TR	B
18	alpha	I
19	DNA	O
20	binding	O
21	mutant	O
22	was	O
23	still	O
24	able	O
25	to	O
26	inhibit	O
27	E	O
28	-	O
29	dependent	O
30	transactivation	O
31	.	O
1	Expression	O
2	from	O
3	this	O
4	element	O
5	is	O
6	regulated	O
7	by	O
8	a	O
9	heteromeric	O
10	protein	O
11	complex	O
12	containing	O
13	ubiquitous	O
14	(	O
15	i	O
16	.	O
17	e	O
18	.	O
19	the	O
20	E2A	B
21	-	O
22	and	O
23	HEB	B
24	-	I
25	encoded	I
26	proteins	I
27	)	O
28	and	O
29	islet	O
30	-	O
31	enriched	O
32	members	O
33	of	O
34	the	O
35	bHLH	B
36	family	I
37	.	O
1	Thus	O
2	,	O
3	the	O
4	CCAAT	O
5	box	O
6	also	O
7	has	O
8	tissue	O
9	-	O
10	specific	O
11	characteristics	O
12	that	O
13	assist	O
14	in	O
15	targeting	O
16	expression	O
17	of	O
18	the	O
19	alpha	B
20	-	I
21	subunit	I
22	gene	I
23	to	O
24	trophoblasts	O
25	.	O
1	The	O
2	growth	O
3	-	O
4	promoting	O
5	properties	O
6	of	O
7	the	O
8	retroviral	B
9	v	I
10	-	I
11	erbA	I
12	oncogene	I
13	,	O
14	a	O
15	highly	O
16	mutated	O
17	version	O
18	of	O
19	the	O
20	chicken	B
21	thyroid	I
22	hormone	I
23	receptor	I
24	(	I
25	TR	I
26	)	I
27	alpha	I
28	,	O
29	have	O
30	so	O
31	far	O
32	exclusively	O
33	been	O
34	linked	O
35	to	O
36	dominant	O
37	repression	O
38	of	O
39	the	O
40	antimitogenic	O
41	roles	O
42	of	O
43	TR	B
44	and	O
45	retinoic	B
46	acid	I
47	receptors	I
48	.	O
1	Serum	O
2	concentrations	O
3	of	O
4	E2	O
5	and	O
6	TBOH	O
7	were	O
8	measured	O
9	on	O
10	d	O
11	0	O
12	,	O
13	1	O
14	,	O
15	3	O
16	,	O
17	5	O
18	,	O
19	7	O
20	,	O
21	13	O
22	,	O
23	21	O
24	,	O
25	28	O
26	,	O
27	42	O
28	,	O
29	56	O
30	,	O
31	84	O
32	,	O
33	112	O
34	,	O
35	and	O
36	140	O
37	in	O
38	finishing	O
39	heifers	O
40	administered	O
41	the	O
42	following	O
43	treatments	O
44	:	O
45	1	O
46	)	O
47	control	O
48	;	O
49	2	O
50	)	O
51	MGA	O
52	,	O
53	.	O
54	5	O
55	mg	O
56	per	O
57	heifer	O
58	daily	O
59	;	O
60	3	O
61	)	O
62	Revalor	O
63	-	O
64	H	O
65	(	O
66	140	O
67	mg	O
68	TBA	O
69	+	O
70	14	O
71	mg	O
72	E2	O
73	);	O
74	4	O
75	)	O
76	Revalor	O
77	-	O
78	H	O
79	+	O
80	MGA	O
81	;	O
82	5	O
83	)	O
84	Finaplix	O
85	-	O
86	H	O
87	(	O
88	200	O
89	mg	O
90	TBA	O
91	);	O
92	and	O
93	6	O
94	)	O
95	Finaplix	O
96	-	O
97	H	O
98	+	O
99	MGA	O
100	.	O
1	Because	O
2	of	O
3	the	O
4	operon	O
5	structure	O
6	of	O
7	this	O
8	organism	O
9	,	O
10	traditional	O
11	methods	O
12	such	O
13	as	O
14	insertional	O
15	mutagenesis	O
16	run	O
17	the	O
18	risk	O
19	of	O
20	introducing	O
21	polar	O
22	effects	O
23	on	O
24	downstream	O
25	genes	O
26	or	O
27	creating	O
28	secondary	O
29	mutations	O
30	elsewhere	O
31	in	O
32	the	O
33	genome	O
34	.	O
1	We	O
2	have	O
3	measured	O
4	the	O
5	kinetics	O
6	of	O
7	the	O
8	recovery	O
9	of	O
10	mRNA	O
11	synthesis	O
12	in	O
13	the	O
14	inducible	O
15	GAL10	B
16	and	O
17	RNR3	B
18	genes	I
19	after	O
20	exposure	O
21	of	O
22	yeast	O
23	cells	O
24	to	O
25	ultraviolet	O
26	(	O
27	UV	O
28	)	O
29	radiation	O
30	.	O
1	The	O
2	medium	O
3	chains	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	mu1	B
9	and	O
10	mu2	B
11	,	O
12	have	O
13	been	O
14	implicated	O
15	in	O
16	two	O
17	types	O
18	of	O
19	interaction	O
20	:	O
21	assembly	O
22	with	O
23	the	O
24	beta1	B
25	and	I
26	beta2	I
27	chains	I
28	of	O
29	the	O
30	corresponding	O
31	complexes	O
32	and	O
33	recognition	O
34	of	O
35	tyrosine	O
36	-	O
37	based	O
38	sorting	O
39	signals	O
40	.	O
1	Osmotic	O
2	shock	O
3	stimulates	O
4	GLUT4	B
5	translocation	O
6	in	O
7	3T3L1	O
8	adipocytes	O
9	by	O
10	a	O
11	novel	O
12	tyrosine	B
13	kinase	I
14	pathway	O
15	.	O
1	Likewise	O
2	,	O
3	rad6	B
4	-	I
5	delta	I
6	reduces	O
7	silencing	O
8	of	O
9	the	O
10	telomere	B
11	-	I
12	located	I
13	RNAP	I
14	II	I
15	-	I
16	transcribed	I
17	genes	I
18	URA3	I
19	and	O
20	ADE2	B
21	.	O
1	PET	O
2	activation	O
3	studies	O
4	are	O
5	performed	O
6	widely	O
7	to	O
8	study	O
9	human	O
10	brain	O
11	function	O
12	.	O
1	Interestingly	O
2	,	O
3	EGF	B
4	,	O
5	but	O
6	not	O
7	insulin	B
8	,	O
9	stimulated	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	c	B
14	-	I
15	cbl	I
16	and	O
17	its	O
18	association	O
19	with	O
20	Crk	B
21	-	I
22	II	I
23	.	O
1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	N	O
7	-	O
8	terminal	O
9	portion	O
10	common	O
11	to	O
12	various	O
13	chimeric	B
14	MLL	I
15	products	I
16	,	O
17	as	O
18	well	O
19	as	O
20	to	O
21	MLL	B
22	-	I
23	LTG9	I
24	and	O
25	MLL	B
26	-	I
27	LTG19	I
28	,	O
29	localizes	O
30	in	O
31	the	O
32	nuclei	O
33	,	O
34	and	O
35	therefore	O
36	suggested	O
37	that	O
38	it	O
39	might	O
40	play	O
41	an	O
42	important	O
43	role	O
44	in	O
45	leukemogenesis	O
46	.	O
1	Induction	O
2	of	O
3	AtP5CS1	B
4	mRNA	I
5	accumulation	O
6	in	O
7	salt	O
8	-	O
9	treated	O
10	seedlings	O
11	involves	O
12	an	O
13	immediate	O
14	early	O
15	transcriptional	O
16	response	O
17	regulated	O
18	by	O
19	ABA	O
20	signalling	O
21	that	O
22	is	O
23	not	O
24	inhibited	O
25	by	O
26	cycloheximide	O
27	,	O
28	but	O
29	abolished	O
30	by	O
31	the	O
32	deficiency	O
33	of	O
34	ABA	O
35	biosynthesis	O
36	in	O
37	the	O
38	aba1	B
39	Arabidopsis	I
40	mutant	I
41	.	O
1	It	O
2	thus	O
3	appears	O
4	that	O
5	MAPK	B
6	functions	O
7	in	O
8	meiotic	O
9	maturation	O
10	by	O
11	preventing	O
12	unfertilized	O
13	eggs	O
14	from	O
15	proceeding	O
16	into	O
17	parthenogenetic	O
18	development	O
19	.	O
1	Their	O
2	biosynthesis	O
3	proceeds	O
4	via	O
5	linear	O
6	precursors	O
7	that	O
8	become	O
9	branched	O
10	by	O
11	beta1	B
12	,	I
13	6	I
14	-	I
15	GlcNAc	I
16	transferases	I
17	(	O
18	IGnT6	O
19	,	O
20	GlcNAc	O
21	to	O
22	Gal	O
23	).	O
1	In	O
2	addition	O
3	,	O
4	mutation	O
5	of	O
6	the	O
7	Sp1	B
8	site	I
9	also	O
10	significantly	O
11	reduced	O
12	promoter	O
13	activity	O
14	.	O
1	Moreover	O
2	,	O
3	in	O
4	one	O
5	patient	O
6	with	O
7	a	O
8	sarcoma	O
9	who	O
10	underwent	O
11	a	O
12	leg	O
13	-	O
14	sparing	O
15	procedure	O
16	,	O
17	no	O
18	sciatic	O
19	nerve	O
20	enlargement	O
21	was	O
22	seen	O
23	postoperatively	O
24	.	O
1	20	O
2	%	O
3	of	O
4	total	O
5	HSL	B
6	transcripts	I
7	in	O
8	human	O
9	subcutaneous	O
10	adipocytes	O
11	.	O
1	A	O
2	DNase	B
3	I	I
4	-	I
5	hypersensitive	I
6	site	I
7	has	O
8	also	O
9	been	O
10	mapped	O
11	in	O
12	the	O
13	258	O
14	-	O
15	base	O
16	pair	O
17	enhancer	O
18	region	O
19	.	O
1	An	O
2	unusual	O
3	cysteine	O
4	triplet	O
5	conserved	O
6	in	O
7	the	O
8	sequences	O
9	of	O
10	TB	B
11	domains	I
12	is	O
13	localized	O
14	to	O
15	the	O
16	hydrophobic	O
17	core	O
18	,	O
19	at	O
20	the	O
21	C	O
22	-	O
23	terminus	O
24	of	O
25	an	O
26	alpha	O
27	-	O
28	helix	O
29	.	O
1	Protein	O
2	phosphatases	O
3	play	O
4	a	O
5	critical	O
6	role	O
7	in	O
8	the	O
9	regulation	O
10	of	O
11	the	O
12	eukaryotic	O
13	cell	O
14	cycle	O
15	and	O
16	signal	O
17	transduction	O
18	.	O
1	The	O
2	cell	O
3	cycle	O
4	-	O
5	regulated	O
6	transcription	O
7	factor	O
8	E2F	B
9	is	O
10	also	O
11	known	O
12	to	O
13	bend	O
14	DNA	O
15	upon	O
16	binding	O
17	.	O
1	Our	O
2	study	O
3	reveals	O
4	that	O
5	the	O
6	modular	O
7	structure	O
8	of	O
9	the	O
10	FSH	B
11	receptor	I
12	gene	O
13	generates	O
14	motifs	O
15	that	O
16	allows	O
17	coupling	O
18	to	O
19	different	O
20	effectors	O
21	.	O
1	PKA	B
2	phosphorylated	O
3	WT1	B
4	at	O
5	Ser	O
6	-	O
7	365	O
8	and	O
9	Ser	O
10	-	O
11	393	O
12	in	O
13	vitro	O
14	,	O
15	as	O
16	well	O
17	as	O
18	at	O
19	additional	O
20	sites	O
21	,	O
22	and	O
23	this	O
24	phosphorylation	O
25	abolished	O
26	the	O
27	DNA	O
28	-	O
29	binding	O
30	activity	O
31	of	O
32	WT1	B
33	in	O
34	vitro	O
35	.	O
1	Re	O
2	:	O
3	""""	O
4	Assessing	O
5	the	O
6	direction	O
7	of	O
8	causality	O
9	in	O
10	cross	O
11	-	O
12	sectional	O
13	studies	O
14	"""."	O
1	The	O
2	presence	O
3	of	O
4	an	O
5	additional	O
6	sequence	O
7	of	O
8	nucleotides	O
9	145	O
10	-	O
11	165	O
12	from	O
13	the	O
14	3	O
15	'	O
16	end	O
17	of	O
18	RNA3	B
19	enhanced	O
20	template	O
21	recognition	O
22	by	O
23	RdRp	B
24	in	O
25	vitro	O
26	and	O
27	accumulation	O
28	of	O
29	RNA3	B
30	in	O
31	vivo	O
32	to	O
33	wild	O
34	-	O
35	type	O
36	levels	O
37	.	O
1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	suggest	O
7	that	O
8	NF	B
9	-	I
10	kappaB	I
11	activity	O
12	may	O
13	be	O
14	regulated	O
15	by	O
16	its	O
17	interaction	O
18	with	O
19	the	O
20	cell	O
21	cycle	O
22	regulatory	O
23	protein	O
24	,	O
25	E2F	B
26	-	I
27	1	I
28	.	O
1	The	O
2	lysozyme	B
3	FEF	I
4	site	O
5	is	O
6	immediately	O
7	5	O
8	'	O
9	to	O
10	a	O
11	PU	B
12	.	O
1	However	O
2	,	O
3	one	O
4	CAK	B
5	-	O
6	phosphorylated	O
7	phosphopeptide	O
8	comigrates	O
9	with	O
10	a	O
11	Cdc2	B
12	-	O
13	phosphorylated	O
14	phosphopeptide	O
15	previously	O
16	shown	O
17	to	O
18	be	O
19	mitosis	O
20	-	O
21	specific	O
22	,	O
23	suggesting	O
24	that	O
25	,	O
26	in	O
27	vitro	O
28	,	O
29	CAK	B
30	is	O
31	able	O
32	to	O
33	phosphorylate	O
34	at	O
35	least	O
36	one	O
37	site	O
38	that	O
39	is	O
40	also	O
41	phosphorylated	O
42	in	O
43	vivo	O
44	.	O
1	One	O
2	of	O
3	these	O
4	,	O
5	an	O
6	AACA	O
7	motif	O
8	,	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	be	O
14	a	O
15	negative	O
16	regulator	O
17	in	O
18	non	O
19	-	O
20	seed	O
21	tissues	O
22	and	O
23	has	O
24	a	O
25	similarity	O
26	to	O
27	the	O
28	barley	O
29	gibberellin	O
30	responsive	O
31	element	O
32	recognized	O
33	by	O
34	MYB	B
35	-	I
36	like	I
37	DNA	I
38	binding	I
39	proteins	I
40	.	O
1	Expression	O
2	of	O
3	thiamin	O
4	biosynthetic	O
5	genes	O
6	(	O
7	thiCOGE	B
8	)	O
9	and	O
10	production	O
11	of	O
12	symbiotic	B
13	terminal	I
14	oxidase	I
15	cbb3	I
16	in	O
17	Rhizobium	O
18	etli	O
19	.	O
1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	region	O
8	encoding	O
9	a	O
10	lipase	B
11	operon	I
12	and	O
13	a	O
14	putative	O
15	,	O
16	previously	O
17	uncharacterized	O
18	metalloprotease	B
19	of	I
20	Vibrio	I
21	cholerae	I
22	O1	I
23	.	O
1	Furthermore	O
2	,	O
3	the	O
4	amount	O
5	of	O
6	tRNA	B
7	(	I
8	3Lys	I
9	)	I
10	that	O
11	was	O
12	placed	O
13	onto	O
14	viral	O
15	RNA	O
16	in	O
17	mutated	O
18	viruses	O
19	was	O
20	significantly	O
21	less	O
22	than	O
23	that	O
24	placed	O
25	in	O
26	the	O
27	wild	O
28	-	O
29	type	O
30	virus	O
31	.	O
1	Differential	O
2	regulation	O
3	of	O
4	the	O
5	pre	B
6	-	I
7	C	I
8	and	O
9	pregenomic	O
10	promoters	O
11	of	O
12	human	O
13	hepatitis	O
14	B	O
15	virus	O
16	by	O
17	members	O
18	of	O
19	the	O
20	nuclear	B
21	receptor	I
22	superfamily	I
23	.	O
1	Both	O
2	inserts	O
3	are	O
4	larger	O
5	than	O
6	their	O
7	homologues	O
8	in	O
9	eIF	B
10	-	I
11	2alpha	I
12	kinases	I
13	.	O
1	Epitopes	O
2	of	O
3	adhesion	O
4	-	O
5	perturbing	O
6	monoclonal	O
7	antibodies	O
8	map	O
9	within	O
10	a	O
11	predicted	O
12	alpha	O
13	-	O
14	helical	O
15	domain	O
16	of	O
17	the	O
18	integrin	B
19	beta	I
20	1	I
21	subunit	I
22	.	O
1	Furthermore	O
2	,	O
3	both	O
4	rhHR23	B
5	proteins	I
6	function	O
7	in	O
8	a	O
9	defined	O
10	NER	O
11	system	O
12	reconstituted	O
13	with	O
14	purified	O
15	proteins	O
16	,	O
17	indicating	O
18	direct	O
19	involvement	O
20	of	O
21	hHR23	B
22	proteins	I
23	in	O
24	the	O
25	DNA	O
26	repair	O
27	reaction	O
28	via	O
29	interaction	O
30	with	O
31	XPC	B
32	.	O
1	The	O
2	yeast	O
3	silent	B
4	information	I
5	regulator	I
6	Sir4p	I
7	anchors	O
8	and	O
9	partitions	O
10	plasmids	O
11	.	O
1	Two	O
2	sterol	O
3	regulatory	O
4	element	O
5	-	O
6	like	O
7	sequences	O
8	mediate	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	caveolin	B
14	gene	I
15	transcription	O
16	in	O
17	response	O
18	to	O
19	low	B
20	density	I
21	lipoprotein	I
22	free	O
23	cholesterol	O
24	.	O
1	First	O
2	,	O
3	two	O
4	MCTs	O
5	using	O
6	a	O
7	long	O
8	electrode	O
9	,	O
10	3	O
11	cm	O
12	in	O
13	size	O
14	,	O
15	were	O
16	performed	O
17	in	O
18	the	O
19	central	O
20	area	O
21	of	O
22	the	O
23	tumor	O
24	,	O
25	and	O
26	eight	O
27	MCTs	O
28	by	O
29	a	O
30	short	O
31	electrode	O
32	,	O
33	2	O
34	cm	O
35	in	O
36	size	O
37	,	O
38	were	O
39	done	O
40	in	O
41	the	O
42	peripheral	O
43	and	O
44	surrounding	O
45	area	O
46	of	O
47	the	O
48	tumor	O
49	.	O
1	Accumulated	O
2	evidence	O
3	indicates	O
4	that	O
5	,	O
6	upon	O
7	stimulation	O
8	with	O
9	interferon	B
10	-	I
11	gamma	I
12	(	O
13	IFN	B
14	-	I
15	gamma	I
16	),	O
17	three	O
18	beta	O
19	-	O
20	type	O
21	subunits	O
22	,	O
23	designated	O
24	LMP2	B
25	,	O
26	LMP7	B
27	,	O
28	and	O
29	PSMB10	B
30	,	O
31	are	O
32	incorporated	O
33	into	O
34	the	O
35	20S	B
36	proteasome	I
37	by	O
38	displacing	O
39	the	O
40	housekeeping	O
41	beta	O
42	-	O
43	type	O
44	subunits	O
45	designated	O
46	PSMB6	B
47	,	O
48	PSMB5	B
49	,	O
50	and	O
51	PSMB7	B
52	,	O
53	respectively	O
54	.	O
1	This	O
2	difference	O
3	may	O
4	result	O
5	from	O
6	the	O
7	lower	O
8	match	O
9	to	O
10	the	O
11	ARG	O
12	box	O
13	consensus	O
14	of	O
15	the	O
16	O	B
17	(	I
18	rocD	I
19	)	I
20	site	I
21	.	O
1	The	O
2	progress	O
3	of	O
4	morphological	O
5	research	O
6	on	O
7	the	O
8	parabrachial	O
9	nucleus	O
1	Inhibition	O
2	appears	O
3	to	O
4	result	O
5	from	O
6	titration	O
7	of	O
8	general	O
9	transcription	O
10	factors	O
11	because	O
12	MDM2	B
13	overexpression	O
14	inhibits	O
15	c	B
16	-	I
17	fos	I
18	as	O
19	well	O
20	as	O
21	other	O
22	promoters	O
23	in	O
24	vivo	O
25	and	O
26	basal	O
27	transcription	O
28	in	O
29	vitro	O
30	.	O
1	RESULTS	O
2	:	O
3	The	O
4	overall	O
5	FNF	O
6	for	O
7	1992	O
8	was	O
9	12	O
10	.	O
11	3	O
12	%	O
13	and	O
14	was	O
15	19	O
16	.	O
17	1	O
18	%,	O
19	22	O
20	.	O
21	2	O
22	%,	O
23	3	O
24	.	O
25	8	O
26	%	O
27	and	O
28	6	O
29	.	O
30	1	O
31	%	O
32	per	O
33	successive	O
34	quarters	O
35	in	O
36	1992	O
37	.	O
1	Western	O
2	blot	O
3	analysis	O
4	of	O
5	various	O
6	bovine	O
7	tissues	O
8	with	O
9	human	O
10	NMT	B
11	peptide	I
12	antibody	I
13	indicated	O
14	a	O
15	common	O
16	prominent	O
17	immunoreactive	O
18	band	O
19	with	O
20	an	O
21	apparent	O
22	molecular	O
23	mass	O
24	of	O
25	48	O
26	.	O
27	5	O
28	-	O
29	50	O
30	kDa	O
31	in	O
32	all	O
33	tissues	O
34	.	O
1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	find	O
9	out	O
10	whether	O
11	it	O
12	was	O
13	possible	O
14	to	O
15	detect	O
16	normal	O
17	lymph	O
18	nodes	O
19	by	O
20	high	O
21	-	O
22	resolution	O
23	mediastinal	O
24	US	O
25	.	O
1	CKbeta4GT	B
2	-	I
3	II	I
4	is	O
5	predicted	O
6	to	O
7	encode	O
8	a	O
9	type	B
10	II	I
11	transmembrane	I
12	glycoprotein	I
13	of	O
14	43	O
15	kDa	O
16	with	O
17	five	O
18	potential	O
19	N	O
20	-	O
21	linked	O
22	glycosylation	O
23	sites	O
24	.	O
1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	a	O
7	transfected	O
8	Chinese	O
9	hamster	O
10	ovary	O
11	(	O
12	CHO	O
13	)	O
14	cell	O
15	line	O
16	expressing	O
17	a	O
18	murine	B
19	CD4	I
20	fragment	I
21	containing	O
22	the	O
23	first	O
24	two	O
25	N	O
26	-	O
27	terminal	O
28	domains	O
29	secretes	O
30	both	O
31	monomeric	O
32	molecules	O
33	and	O
34	disulfide	O
35	-	O
36	linked	O
37	multimers	O
38	.	O
1	Coexpression	O
2	of	O
3	mouse	O
4	PKR	B
5	(	I
6	1	I
7	-	I
8	515	I
9	)	I
10	WT	I
11	as	O
12	a	O
13	Gal4	B
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	fusion	O
19	with	O
20	either	O
21	the	O
22	catalytic	O
23	-	O
24	deficient	O
25	human	O
26	PKR	B
27	(	I
28	1	I
29	-	I
30	551	I
31	)	I
32	K296R	O
33	mutant	O
34	,	O
35	the	O
36	RNA	O
37	-	O
38	binding	O
39	-	O
40	deficient	O
41	human	O
42	PKR	B
43	(	I
44	1	I
45	-	I
46	551	I
47	)	I
48	K64E	I
49	/	I
50	K296R	I
51	double	O
52	mutant	O
53	,	O
54	or	O
55	wild	O
56	-	O
57	type	O
58	mouse	O
59	PKR	B
60	(	I
61	1	I
62	-	I
63	515	I
64	)	I
65	WT	I
66	as	O
67	full	O
68	-	O
69	length	O
70	PKR	B
71	-	O
72	Gal4	B
73	activation	O
74	domain	O
75	fusions	O
76	resulted	O
77	in	O
78	activation	O
79	of	O
80	the	O
81	HIS3	B
82	and	O
83	lacZ	B
84	reporters	O
85	.	O
1	Interestingly	O
2	,	O
3	the	O
4	avirulent	O
5	strain	O
6	H37Ra	O
7	showed	O
8	weak	O
9	hybridization	O
10	with	O
11	these	O
12	two	O
13	probes	O
14	,	O
15	suggesting	O
16	that	O
17	these	O
18	genes	O
19	might	O
20	have	O
21	been	O
22	deleted	O
23	in	O
24	the	O
25	avirulent	O
26	strain	O
27	or	O
28	are	O
29	present	O
30	in	O
31	limited	O
32	copy	O
33	numbers	O
34	as	O
35	opposed	O
36	to	O
37	those	O
38	in	O
39	the	O
40	virulent	O
41	strain	O
42	H37Rv	O
43	.	O
1	Similarities	O
2	between	O
3	the	O
4	hIGFBP	B
5	-	I
6	1	I
7	and	O
8	phosphoenolpyruvate	B
9	kinase	I
10	(	O
11	PEPCK	B
12	)	O
13	promoters	O
14	,	O
15	including	O
16	regions	O
17	conferring	O
18	insulin	B
19	,	O
20	glucocorticoid	O
21	,	O
22	and	O
23	cyclic	O
24	adenosine	O
25	-	O
26	monophosphate	O
27	responses	O
28	,	O
29	are	O
30	consistent	O
31	with	O
32	our	O
33	previous	O
34	hypothesis	O
35	that	O
36	IGFBP	B
37	-	I
38	1	I
39	is	O
40	involved	O
41	in	O
42	regulation	O
43	of	O
44	glucose	O
45	metabolism	O
46	.	O
1	Moreover	O
2	,	O
3	moderate	O
4	overexpression	O
5	of	O
6	Chk1	B
7	suppresses	O
8	the	O
9	phenotypes	O
10	of	O
11	cut5	B
12	and	O
13	crb2	B
14	mutants	I
15	.	O
1	Bilateral	O
2	basal	O
3	arteries	O
4	were	O
5	measured	O
6	by	O
7	the	O
8	transtemporal	O
9	approach	O
10	with	O
11	a	O
12	2	O
13	MHz	O
14	pulsed	O
15	Doppler	O
16	instrument	O
17	(	O
18	TC	O
19	-	O
20	2	O
21	64B	O
22	EME	O
23	).	O
1	Gel	O
2	mobility	O
3	shift	O
4	and	O
5	super	O
6	-	O
7	shift	O
8	assays	O
9	using	O
10	liver	O
11	nuclear	O
12	extracts	O
13	from	O
14	either	O
15	rat	O
16	liver	O
17	or	O
18	DDT1MF	O
19	-	O
20	2	O
21	cells	O
22	demonstrated	O
23	that	O
24	the	O
25	CRE	O
26	in	O
27	the	O
28	alpha	B
29	1B	I
30	-	I
31	AR	I
32	gene	I
33	bound	O
34	CRE	B
35	binding	I
36	protein	I
37	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	in	O
7	this	O
8	experimental	O
9	model	O
10	,	O
11	ACE	B
12	inhibitors	O
13	limit	O
14	the	O
15	arrhythmias	O
16	following	O
17	ischemia	O
18	-	O
19	reperfusion	O
20	and	O
21	free	O
22	radical	O
23	scavenging	O
24	action	O
25	of	O
26	these	O
27	drugs	O
28	does	O
29	not	O
30	have	O
31	a	O
32	major	O
33	contributory	O
34	role	O
35	in	O
36	their	O
37	protective	O
38	effect	O
39	.	O
1	The	O
2	mean	O
3	values	O
4	of	O
5	the	O
6	first	O
7	three	O
8	components	O
9	were	O
10	not	O
11	significantly	O
12	different	O
13	in	O
14	ARVD	O
15	patients	O
16	and	O
17	control	O
18	subjects	O
19	.	O
1	One	O
2	R	O
3	-	O
4	EST	O
5	and	O
6	one	O
7	Pto	B
8	-	I
9	like	I
10	sequence	I
11	each	O
12	mapped	O
13	to	O
14	two	O
15	locations	O
16	.	O
1	MpB	B
2	GroEL	I
3	has	O
4	extensive	O
5	sequence	O
6	similarity	O
7	(	O
8	92	O
9	%)	O
10	with	O
11	Escherichia	B
12	coli	I
13	GroEL	I
14	and	O
15	other	O
16	members	O
17	of	O
18	the	O
19	chaperonin	B
20	-	I
21	60	I
22	family	I
23	.	O
1	IVOX	O
2	was	O
3	named	O
4	as	O
5	an	O
6	acronym	O
7	for	O
8	intravascular	O
9	oxygenator	O
10	.	O
1	Neuronal	O
2	mechanisms	O
3	underlying	O
4	stimulus	O
5	-	O
6	response	O
7	(	O
8	S	O
9	-	O
10	R	O
11	)	O
12	associations	O
13	in	O
14	S	O
15	-	O
16	R	O
17	compatibility	O
18	tasks	O
19	were	O
20	identified	O
21	in	O
22	2	O
23	experiments	O
24	with	O
25	monkeys	O
26	.	O
1	The	O
2	cglIM	B
3	gene	I
4	is	O
5	organized	O
6	in	O
7	an	O
8	unusual	O
9	operon	O
10	which	O
11	contains	O
12	,	O
13	in	O
14	addition	O
15	,	O
16	two	O
17	genes	O
18	encoding	O
19	stress	O
20	-	O
21	sensitive	O
22	restriction	O
23	enzymes	O
24	.	O
1	The	O
2	gene	O
3	contains	O
4	six	O
5	exons	O
6	separated	O
7	by	O
8	1	O
9	.	O
10	1	O
11	-	O
12	5	O
13	.	O
14	8	O
15	kb	O
16	introns	O
17	and	O
18	has	O
19	been	O
20	localized	O
21	to	O
22	the	O
23	murine	O
24	chromosome	O
25	2	O
26	by	O
27	linkage	O
28	analysis	O
29	.	O
1	In	O
2	Xenopus	O
3	embryos	O
4	,	O
5	the	O
6	engineered	B
7	PDGF	I
8	receptor	I
9	protein	I
10	induced	O
11	the	O
12	formation	O
13	of	O
14	mesoderm	O
15	from	O
16	animal	O
17	-	O
18	pole	O
19	explants	O
20	in	O
21	an	O
22	FK1012	O
23	-	O
24	dependent	O
25	manner	O
26	.	O
1	CONCLUSIONS	O
2	:	O
3	A	O
4	50	O
5	-	O
6	mg	O
7	daily	O
8	dose	O
9	of	O
10	bicalutamide	O
11	is	O
12	sufficient	O
13	when	O
14	given	O
15	in	O
16	combination	O
17	with	O
18	an	O
19	agent	O
20	,	O
21	such	O
22	as	O
23	a	O
24	LHRH	B
25	-	O
26	A	O
27	,	O
28	that	O
29	lowers	O
30	serum	O
31	testosterone	O
32	,	O
33	but	O
34	higher	O
35	doses	O
36	of	O
37	bicalutamide	O
38	may	O
39	be	O
40	needed	O
41	when	O
42	the	O
43	drug	O
44	is	O
45	given	O
46	as	O
47	monotherapy	O
48	.	O
1	Although	O
2	the	O
3	gene	O
4	is	O
5	substantially	O
6	smaller	O
7	than	O
8	the	O
9	human	O
10	genes	O
11	for	O
12	other	O
13	mitochondrial	O
14	enzymes	O
15	,	O
16	its	O
17	intron	O
18	/	O
19	exon	O
20	organization	O
21	is	O
22	very	O
23	similar	O
24	,	O
25	especially	O
26	to	O
27	that	O
28	of	O
29	P450scc	B
30	.	O
1	The	O
2	patient	O
3	underwent	O
4	two	O
5	intracytoplasmic	O
6	sperm	O
7	injection	O
8	cycles	O
9	with	O
10	thawed	O
11	epididymal	O
12	spermatozoa	O
13	,	O
14	in	O
15	which	O
16	,	O
17	due	O
18	to	O
19	a	O
20	pharmacist	O
21	'	O
22	s	O
23	mistake	O
24	,	O
25	ovarian	O
26	stimulation	O
27	was	O
28	carried	O
29	out	O
30	by	O
31	a	O
32	combination	O
33	of	O
34	long	O
35	-	O
36	acting	O
37	gonadotrophin	B
38	-	I
39	releasing	I
40	hormone	I
41	agonist	O
42	(	O
43	leuprolide	O
44	depot	O
45	)	O
46	and	O
47	gonadotrophins	B
48	.	O
1	To	O
2	examine	O
3	the	O
4	role	O
5	of	O
6	this	O
7	CE2	O
8	element	O
9	in	O
10	regulating	O
11	Hoxa1	B
12	expression	O
13	in	O
14	vivo	O
15	,	O
16	transgenic	O
17	mice	O
18	were	O
19	generated	O
20	which	O
21	express	O
22	a	O
23	Hoxa1	B
24	beta	I
25	-	I
26	galactosidase	I
27	reporter	O
28	gene	O
29	that	O
30	contains	O
31	a	O
32	mutation	O
33	in	O
34	the	O
35	CE2	O
36	element	O
37	.	O
1	Altogether	O
2	46	O
3	phase	O
4	III	O
5	activities	O
6	were	O
7	recorded	O
8	.	O
1	In	O
2	vitro	O
3	DNase	B
4	I	I
5	footprinting	O
6	of	O
7	the	O
8	200	O
9	-	O
10	bp	O
11	proximal	O
12	region	O
13	of	O
14	the	O
15	promoter	O
16	with	O
17	a	O
18	murine	O
19	Hepa	O
20	1	O
21	-	O
22	6	O
23	cell	O
24	nuclear	O
25	extract	O
26	revealed	O
27	a	O
28	clear	O
29	footprint	O
30	of	O
31	a	O
32	region	O
33	corresponding	O
34	to	O
35	-	O
36	80	O
37	to	O
38	-	O
39	28	O
40	bp	O
41	of	O
42	the	O
43	murine	B
44	fVII	I
45	gene	I
46	,	O
47	suggesting	O
48	that	O
49	liver	O
50	factors	O
51	interact	O
52	with	O
53	this	O
54	region	O
55	of	O
56	the	O
57	DNA	O
58	.	O
1	Both	O
2	increasing	O
3	basal	O
4	FSH	B
5	and	O
6	age	O
7	were	O
8	associated	O
9	significantly	O
10	with	O
11	increased	O
12	total	O
13	gonadotrophin	B
14	dose	O
15	,	O
16	and	O
17	reduced	O
18	number	O
19	of	O
20	oocytes	O
21	collected	O
22	and	O
23	pregnancy	O
24	rate	O
25	.	O
1	Our	O
2	results	O
3	establish	O
4	GKLF	B
5	as	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcription	O
11	factor	O
12	likely	O
13	involved	O
14	in	O
15	regulation	O
16	of	O
17	expression	O
18	of	O
19	endogenous	O
20	genes	O
21	.	O
1	In	O
2	addition	O
3	,	O
4	negatively	O
5	regulatory	O
6	region	O
7	may	O
8	exist	O
9	from	O
10	-	O
11	1782	O
12	to	O
13	-	O
14	1295	O
15	bp	O
16	.	O
1	We	O
2	have	O
3	cloned	O
4	a	O
5	kinase	O
6	,	O
7	Nlk	B
8	,	O
9	that	O
10	is	O
11	a	O
12	murine	B
13	homolog	I
14	of	I
15	the	I
16	Drosophila	I
17	nemo	I
18	(	O
19	nmo	B
20	)	O
21	gene	O
22	.	O
1	This	O
2	region	O
3	,	O
4	however	O
5	,	O
6	contains	O
7	a	O
8	CCAATC	O
9	box	O
10	in	O
11	the	O
12	reverse	O
13	complement	O
14	and	O
15	several	O
16	GC	O
17	boxes	O
18	that	O
19	are	O
20	recognition	O
21	sites	O
22	for	O
23	SP1	B
24	.	O
1	Surprisingly	O
2	,	O
3	the	O
4	COOH	O
5	-	O
6	terminal	O
7	domain	O
8	of	O
9	RanGAP1	B
10	was	O
11	also	O
12	found	O
13	to	O
14	harbor	O
15	a	O
16	nuclear	O
17	localization	O
18	signal	O
19	.	O
1	Resistance	O
2	to	O
3	thyroid	O
4	hormone	O
5	:	O
6	implications	O
7	for	O
8	neurodevelopmental	O
9	research	O
10	on	O
11	the	O
12	effects	O
13	of	O
14	thyroid	O
15	hormone	O
16	disruptors	O
17	.	O
1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	that	O
7	exposure	O
8	of	O
9	DT40	O
10	lymphoma	O
11	B	O
12	cells	O
13	to	O
14	low	O
15	energy	O
16	electromagnetic	O
17	field	O
18	(	O
19	EMF	O
20	)	O
21	results	O
22	in	O
23	a	O
24	tyrosine	B
25	kinase	I
26	-	O
27	dependent	O
28	activation	O
29	of	O
30	phospholipase	B
31	Cgamma2	I
32	(	O
33	PLC	B
34	-	I
35	gamma2	I
36	)	O
37	leading	O
38	to	O
39	increased	O
40	inositol	O
41	phospholipid	O
42	turnover	O
43	.	O
1	PATIENTS	O
2	AND	O
3	METHOD	O
4	:	O
5	Since	O
6	1986	O
7	,	O
8	62	O
9	patients	O
10	were	O
11	irradiated	O
12	stereotactically	O
13	.	O
1	Expression	O
2	and	O
3	characterization	O
4	of	O
5	recombinant	B
6	single	I
7	-	I
8	chain	I
9	Fv	I
10	and	O
11	Fv	B
12	fragments	I
13	derived	O
14	from	O
15	a	O
16	set	O
17	of	O
18	catalytic	O
19	antibodies	O
20	.	O
1	A	O
2	putative	O
3	inhibitor	O
4	(	O
5	s	O
6	)	O
7	appears	O
8	to	O
9	co	O
10	-	O
11	elute	O
12	in	O
13	the	O
14	inactive	O
15	fraction	O
16	that	O
17	blocked	O
18	the	O
19	L	B
20	(	I
21	alpha	I
22	)	I
23	activity	O
24	.	O
1	Cross	O
2	-	O
3	talking	O
4	among	O
5	Drosophila	O
6	nuclear	O
7	receptors	O
8	at	O
9	the	O
10	promiscuous	O
11	response	O
12	element	O
13	of	O
14	the	O
15	ng	B
16	-	I
17	1	I
18	and	O
19	ng	B
20	-	I
21	2	I
22	intermolt	I
23	genes	I
24	.	O
1	Sibling	O
2	aggregation	O
3	of	O
4	low	B
5	-	I
6	and	I
7	high	I
8	-	I
9	density	I
10	lipoprotein	I
11	cholesterol	I
12	and	O
13	apolipoproteins	B
14	B	I
15	and	I
16	A	I
17	-	I
18	I	I
19	levels	O
20	in	O
21	black	O
22	and	O
23	white	O
24	children	O
25	:	O
26	the	O
27	Bogalusa	O
28	Heart	O
29	Study	O
30	.	O
1	Northern	O
2	analysis	O
3	indicated	O
4	differential	O
5	expression	O
6	by	O
7	tissue	O
8	with	O
9	highest	O
10	expression	O
11	in	O
12	the	O
13	heart	O
14	.	O
1	It	O
2	may	O
3	also	O
4	be	O
5	suggested	O
6	that	O
7	particular	O
8	care	O
9	should	O
10	be	O
11	taken	O
12	when	O
13	such	O
14	a	O
15	trans	O
16	-	O
17	dominant	O
18	Rev	B
19	mutant	I
20	is	O
21	considered	O
22	to	O
23	be	O
24	used	O
25	as	O
26	a	O
27	genetic	O
28	therapy	O
29	against	O
30	HIV	O
31	-	O
32	I	O
33	infection	O
34	,	O
35	in	O
36	individuals	O
37	infected	O
38	with	O
39	both	O
40	HIV	O
41	-	O
42	I	O
43	and	O
44	HTLV	O
45	-	O
46	1	O
47	.	O
1	Competitive	O
2	reverse	O
3	transcription	O
4	-	O
5	polymerase	O
6	chain	O
7	reaction	O
8	and	O
9	HPLC	O
10	analysis	O
11	showed	O
12	that	O
13	RUSH	B
14	-	I
15	1alpha	I
16	is	O
17	the	O
18	progesterone	O
19	-	O
20	dependent	O
21	splice	O
22	variant	O
23	.	O
1	Transfection	O
2	studies	O
3	also	O
4	showed	O
5	that	O
6	3	O
7	'-	O
8	deletion	O
9	of	O
10	sequences	O
11	downstream	O
12	of	O
13	the	O
14	transcriptional	O
15	start	O
16	site	O
17	(+	O
18	1	O
19	/+	O
20	47	O
21	)	O
22	markedly	O
23	reduced	O
24	OSM	B
25	-	O
26	fold	O
27	induction	O
28	.	O
1	To	O
2	elucidate	O
3	the	O
4	regulatory	O
5	mechanism	O
6	of	O
7	human	B
8	AM	I
9	gene	I
10	expression	O
11	,	O
12	functional	O
13	elements	O
14	of	O
15	5	O
16	'-	O
17	flanking	O
18	region	O
19	of	O
20	AM	B
21	gene	I
22	were	O
23	studied	O
24	in	O
25	human	O
26	aortic	O
27	endothelial	O
28	cells	O
29	(	O
30	HAEC	O
31	).	O
1	When	O
2	tested	O
3	with	O
4	wild	O
5	-	O
6	type	O
7	(	O
8	DBA	O
9	/	O
10	2	O
11	)	O
12	p16	B
13	,	O
14	both	O
15	A134C	O
16	and	O
17	G232A	O
18	BALB	O
19	/	O
20	c	O
21	-	O
22	specific	O
23	variants	O
24	of	O
25	p16	B
26	were	O
27	inefficient	O
28	in	O
29	their	O
30	ability	O
31	to	O
32	inhibit	O
33	the	O
34	activity	O
35	of	O
36	cyclin	B
37	D2	I
38	/	O
39	CDK4	B
40	in	O
41	kinase	O
42	assays	O
43	with	O
44	retinoblastoma	B
45	protein	I
46	,	O
47	suggesting	O
48	this	O
49	defective	O
50	,	O
51	inherited	O
52	allele	O
53	plays	O
54	an	O
55	important	O
56	role	O
57	in	O
58	the	O
59	genetic	O
60	susceptibility	O
61	of	O
62	BALB	O
63	/	O
64	c	O
65	mice	O
66	for	O
67	plasmacytoma	O
68	induction	O
69	and	O
70	that	O
71	p16	B
72	(	O
73	INK4a	B
74	)	O
75	is	O
76	a	O
77	strong	O
78	candidate	O
79	for	O
80	the	O
81	Pctr1	B
82	locus	I
83	.	O
1	METHODS	O
2	:	O
3	A	O
4	population	O
5	survey	O
6	was	O
7	undertaken	O
8	in	O
9	10	O
10	,	O
11	148	O
12	individuals	O
13	to	O
14	measure	O
15	the	O
16	prevalence	O
17	and	O
18	identify	O
19	the	O
20	causes	O
21	of	O
22	blindness	O
23	in	O
24	Lebanon	O
25	.	O
1	The	O
2	TATA	B
3	box	I
4	-	I
5	binding	I
6	protein	I
7	(	O
8	TBP	B
9	)	O
10	plays	O
11	an	O
12	essential	O
13	role	O
14	in	O
15	transcription	O
16	by	O
17	all	O
18	three	O
19	eukaryotic	O
20	nuclear	B
21	RNA	I
22	polymerases	I
23	,	O
24	polymerases	B
25	(	I
26	Pol	I
27	)	I
28	I	I
29	,	I
30	II	I
31	,	I
32	and	I
33	III	I
34	.	O
1	To	O
2	determine	O
3	the	O
4	true	O
5	molecular	O
6	identity	O
7	of	O
8	SFD	B
9	,	O
10	both	O
11	the	O
12	50	O
13	-	O
14	and	O
15	57	O
16	-	O
17	kDa	O
18	polypeptides	O
19	were	O
20	directly	O
21	sequenced	O
22	.	O
1	Molecular	O
2	characterization	O
3	of	O
4	the	O
5	50	O
6	-	O
7	and	O
8	57	O
9	-	O
10	kDa	O
11	subunits	O
12	of	O
13	the	O
14	bovine	B
15	vacuolar	I
16	proton	I
17	pump	I
18	.	O
1	CONCLUSIONS	O
2	:	O
3	XCoe2	B
4	may	O
5	play	O
6	a	O
7	pivotal	O
8	role	O
9	in	O
10	the	O
11	transcriptional	O
12	cascade	O
13	that	O
14	specifies	O
15	primary	O
16	neurons	O
17	in	O
18	Xenopus	O
19	embryos	O
20	:	O
21	by	O
22	maintaining	O
23	Delta	B
24	-	O
25	Notch	B
26	signalling	O
27	,	O
28	XCoe2	B
29	stabilises	O
30	the	O
31	higher	O
32	neural	O
33	potential	O
34	of	O
35	selected	O
36	progenitor	O
37	cells	O
38	that	O
39	express	O
40	X	B
41	-	I
42	ngnr	I
43	-	I
44	1	I
45	,	O
46	ensuring	O
47	the	O
48	transition	O
49	between	O
50	neural	O
51	competence	O
52	and	O
53	irreversible	O
54	commitment	O
55	to	O
56	a	O
57	neural	O
58	fate	O
59	;	O
60	and	O
61	it	O
62	promotes	O
63	neuronal	O
64	differentiation	O
65	by	O
66	activating	O
67	XNeuroD	B
68	expression	O
69	,	O
70	directly	O
71	or	O
72	indirectly	O
73	.	O
1	Although	O
2	the	O
3	expression	O
4	of	O
5	the	O
6	4E	B
7	-	I
8	BP1	I
9	gene	I
10	alone	O
11	has	O
12	not	O
13	yet	O
14	been	O
15	accomplished	O
16	,	O
17	the	O
18	gene	O
19	was	O
20	expressed	O
21	in	O
22	Escherichia	O
23	coli	O
24	[	O
25	BL21	O
26	(	O
27	DE3	O
28	)]	O
29	as	O
30	a	O
31	fusion	O
32	gene	O
33	with	O
34	the	O
35	glutathione	B
36	-	I
37	S	I
38	-	I
39	transferase	I
40	(	O
41	GST	B
42	)	O
43	gene	O
44	using	O
45	a	O
46	prokaryotic	O
47	gene	O
48	fusion	O
49	vector	O
50	(	O
51	pGEX	O
52	-	O
53	4T	O
54	-	O
55	2	O
56	),	O
57	which	O
58	contains	O
59	a	O
60	gene	O
61	sequence	O
62	coding	O
63	the	O
64	cleavage	O
65	site	O
66	for	O
67	a	O
68	specific	O
69	protease	O
70	,	O
71	alpha	B
72	-	I
73	thrombin	I
74	.	O
1	Randomised	O
2	comparison	O
3	of	O
4	addition	O
5	of	O
6	autologous	O
7	bone	O
8	-	O
9	marrow	O
10	transplantation	O
11	to	O
12	intensive	O
13	chemotherapy	O
14	for	O
15	acute	O
16	myeloid	O
17	leukaemia	O
18	in	O
19	first	O
20	remission	O
21	:	O
22	results	O
23	of	O
24	MRC	O
25	AML	O
26	10	O
27	trial	O
28	.	O
1	Position	O
2	-	O
3	independent	O
4	expression	O
5	of	O
6	a	O
7	human	O
8	nerve	B
9	growth	I
10	factor	I
11	-	O
12	luciferase	B
13	reporter	O
14	gene	O
15	cloned	O
16	on	O
17	a	O
18	yeast	O
19	artificial	O
20	chromosome	O
21	vector	O
22	.	O
1	Alterations	O
2	in	O
3	DNase	B
4	I	I
5	reactivity	O
6	of	O
7	the	O
8	GC	O
9	-	O
10	response	O
11	element	O
12	region	O
13	suggest	O
14	that	O
15	GC	B
16	receptor	I
17	-	I
18	GC	I
19	complexes	I
20	may	O
21	associate	O
22	,	O
23	in	O
24	a	O
25	transient	O
26	manner	O
27	,	O
28	with	O
29	the	O
30	promoter	O
31	in	O
32	the	O
33	actively	O
34	transcribing	O
35	control	O
36	state	O
37	.	O
1	Most	O
2	pituitary	O
3	hormone	O
4	-	O
5	coding	O
6	gene	O
7	promoters	O
8	are	O
9	activated	O
10	by	O
11	Ptx1	B
12	.	O
1	One	O
2	of	O
3	these	O
4	small	B
5	inteins	I
6	might	O
7	be	O
8	inactive	O
9	or	O
10	a	O
11	""""	B
12	pseudo	I
13	intein	I
14	"."""	I
15	The	O
16	results	O
17	suggest	O
18	a	O
19	modular	O
20	architecture	O
21	for	O
22	inteins	B
23	,	O
24	clarify	O
25	their	O
26	origin	O
27	and	O
28	relationship	O
29	to	O
30	other	O
31	protein	O
32	families	O
33	,	O
34	and	O
35	extend	O
36	recent	O
37	experimental	O
38	findings	O
39	on	O
40	the	O
41	functional	O
42	roles	O
43	of	O
44	intein	B
45	N	I
46	,	I
47	C	I
48	,	I
49	and	I
50	EN	I
51	motifs	I
52	.	O
1	RT	O
2	-	O
3	PCR	O
4	indicated	O
5	that	O
6	p21	B
7	mRNA	I
8	was	O
9	induced	O
10	1	O
11	.	O
12	4	O
13	-,	O
14	2	O
15	.	O
16	0	O
17	-,	O
18	and	O
19	3	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	in	O
25	the	O
26	2	O
27	-	O
28	day	O
29	neonatal	O
30	,	O
31	7	O
32	-	O
33	day	O
34	neonatal	O
35	,	O
36	and	O
37	adult	O
38	stages	O
39	,	O
40	respectively	O
41	,	O
42	compared	O
43	to	O
44	the	O
45	17	O
46	-	O
47	day	O
48	fetal	O
49	stage	O
50	.	O
1	Ganciclovir	O
2	and	O
3	foscarnet	O
4	efficacy	O
5	in	O
6	AIDS	O
7	-	O
8	related	O
9	CMV	O
10	polyradiculopathy	O
11	.	O
1	The	O
2	PDH	B
3	complex	I
4	-	I
5	encoding	I
6	genes	I
7	were	O
8	identified	O
9	by	O
10	hybridization	O
11	experiments	O
12	and	O
13	sequence	O
14	analysis	O
15	in	O
16	two	O
17	separate	O
18	gene	O
19	regions	O
20	in	O
21	the	O
22	genome	O
23	of	O
24	Z	O
25	.	O
26	mobilis	O
27	.	O
1	The	O
2	study	O
3	enrolled	O
4	994	O
5	people	O
6	co	O
7	-	O
8	infected	O
9	with	O
10	CMV	O
11	and	O
12	HIV	O
13	,	O
14	with	O
15	at	O
16	least	O
17	one	O
18	CD4	B
19	count	O
20	recorded	O
21	<	O
22	100	O
23	x	O
24	10	O
25	(	O
26	6	O
27	)	O
28	cells	O
29	/	O
30	l	O
31	.	O
1	We	O
2	also	O
3	recovered	O
4	mutations	O
5	in	O
6	the	O
7	60A	B
8	gene	I
9	which	O
10	encodes	O
11	another	O
12	TGF	B
13	-	I
14	beta	I
15	-	I
16	related	I
17	factor	I
18	in	O
19	Drosophila	O
20	.	O
1	Cervicovaginal	O
2	foetal	B
3	fibronectin	I
4	in	O
5	the	O
6	prediction	O
7	of	O
8	preterm	O
9	labour	O
10	in	O
11	a	O
12	low	O
13	-	O
14	risk	O
15	population	O
16	.	O
1	A	O
2	constitutive	O
3	allele	O
4	of	O
5	GPA2	B
6	could	O
7	stimulate	O
8	growth	O
9	of	O
10	a	O
11	strain	O
12	lacking	O
13	both	O
14	RAS	B
15	genes	I
16	.	O
1	PCR	O
2	analysis	O
3	indicates	O
4	that	O
5	this	O
6	new	O
7	beta	B
8	-	I
9	adducin	I
10	isoform	I
11	is	O
12	expressed	O
13	in	O
14	fetal	O
15	brain	O
16	and	O
17	liver	O
18	,	O
19	bone	O
20	marrow	O
21	,	O
22	and	O
23	NT	O
24	-	O
25	2	O
26	(	O
27	neuroepithelial	O
28	)	O
29	cells	O
30	,	O
31	but	O
32	is	O
33	not	O
34	detected	O
35	in	O
36	several	O
37	other	O
38	tissues	O
39	.	O
1	Full	B
2	-	I
3	length	I
4	FLAP	I
5	clones	O
6	were	O
7	isolated	O
8	from	O
9	a	O
10	mouse	O
11	skeletal	O
12	muscle	O
13	cDNA	O
14	library	O
15	.	O
1	Rex	B
2	-	I
3	1	I
4	,	O
5	a	O
6	gene	O
7	encoding	O
8	a	O
9	transcription	O
10	factor	O
11	expressed	O
12	in	O
13	the	O
14	early	O
15	embryo	O
16	,	O
17	is	O
18	regulated	O
19	via	O
20	Oct	B
21	-	I
22	3	I
23	/	I
24	4	I
25	and	O
26	Oct	B
27	-	I
28	6	I
29	binding	O
30	to	O
31	an	O
32	octamer	O
33	site	O
34	and	O
35	a	O
36	novel	O
37	protein	O
38	,	O
39	Rox	B
40	-	I
41	1	I
42	,	O
43	binding	O
44	to	O
45	an	O
46	adjacent	O
47	site	O
48	.	O
1	Deletion	O
2	of	O
3	the	O
4	last	O
5	two	O
6	Ser	O
7	residues	O
8	,	O
9	including	O
10	one	O
11	PKC	B
12	consensus	O
13	site	O
14	in	O
15	the	O
16	receptor	O
17	tail	O
18	,	O
19	prevented	O
20	only	O
21	phorbol	O
22	12	O
23	-	O
24	myristate	O
25	13	O
26	-	O
27	acetate	O
28	-	O
29	induced	O
30	desensitization	O
31	by	O
32	30	O
33	%.	O
1	SNAC	O
2	or	O
3	PBS	O
4	was	O
5	infused	O
6	for	O
7	6	O
8	.	O
9	5	O
10	h	O
11	,	O
12	beginning	O
13	30	O
14	min	O
15	before	O
16	ischemia	O
17	and	O
18	continuing	O
19	throughout	O
20	the	O
21	duration	O
22	of	O
23	reperfusion	O
24	.	O
1	In	O
2	vitro	O
3	binding	O
4	studies	O
5	using	O
6	GST	B
7	fusion	O
8	proteins	O
9	and	O
10	yeast	O
11	extracts	O
12	defined	O
13	distinct	O
14	binding	O
15	sites	O
16	on	O
17	yAP180A	B
18	for	O
19	Pan1p	B
20	and	O
21	clathrin	B
22	.	O
23	yAP180	B
24	proteins	I
25	and	O
26	Pan1p	B
27	,	O
28	like	O
29	actin	B
30	,	O
31	localize	O
32	to	O
33	peripheral	O
34	patches	O
35	along	O
36	the	O
37	plasma	O
38	membrane	O
39	.	O
1	A	O
2	possible	O
3	decrease	O
4	in	O
5	theophylline	O
6	'	O
7	s	O
8	volume	O
9	of	O
10	distribution	O
11	at	O
12	4	O
13	days	O
14	,	O
15	but	O
16	not	O
17	immediately	O
18	,	O
19	after	O
20	administration	O
21	of	O
22	chloroquine	O
23	was	O
24	suggested	O
25	,	O
26	although	O
27	this	O
28	just	O
29	failed	O
30	to	O
31	achieve	O
32	statistical	O
33	significance	O
34	(	O
35	p	O
36	=	O
37	0	O
38	.	O
39	055	O
40	).	O
1	The	O
2	addition	O
3	of	O
4	a	O
5	Paf	B
6	-	O
7	containing	O
8	extract	O
9	does	O
10	not	O
11	lead	O
12	to	O
13	significant	O
14	protein	O
15	binding	O
16	to	O
17	these	O
18	two	O
19	hly	B
20	target	I
21	sequences	I
22	in	O
23	the	O
24	absence	O
25	of	O
26	PrfA	B
27	but	O
28	converts	O
29	the	O
30	complex	O
31	(	O
32	CIII	O
33	)	O
34	consisting	O
35	of	O
36	PrfA	B
37	and	O
38	the	O
39	109	B
40	bp	I
41	hly	I
42	DNA	I
43	fragment	I
44	to	O
45	a	O
46	slower	O
47	migrating	O
48	PrfA	B
49	-	O
50	Paf	B
51	-	O
52	DNA	O
53	complex	O
54	(	O
55	CI	O
56	).	O
1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	m	B
8	-	I
9	Staf	I
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	that	O
15	of	O
16	Staf	B
17	,	O
18	another	O
19	selenocysteine	B
20	tRNA	I
21	gene	I
22	transcription	I
23	activating	I
24	factor	I
25	of	O
26	Xenopus	O
27	laevis	O
28	.	O
1	Among	O
2	three	O
3	isoforms	O
4	,	O
5	the	O
6	beta	O
7	isoform	O
8	has	O
9	the	O
10	greatest	O
11	Vmax	O
12	value	O
13	for	O
14	the	O
15	PtdIns	B
16	(	I
17	4	I
18	)	I
19	P	I
20	kinase	I
21	activity	O
22	and	O
23	the	O
24	gamma	O
25	isoform	O
26	is	O
27	most	O
28	markedly	O
29	stimulated	O
30	by	O
31	phosphatidic	O
32	acid	O
33	.	O
1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	heterotrimeric	B
7	G	I
8	proteins	I
9	that	O
10	transduce	O
11	signals	O
12	across	O
13	the	O
14	plasma	O
15	membrane	O
16	is	O
17	made	O
18	up	O
19	of	O
20	an	O
21	amino	O
22	-	O
23	terminal	O
24	alpha	O
25	-	O
26	helical	O
27	segment	O
28	followed	O
29	by	O
30	seven	O
31	repeating	O
32	units	O
33	called	O
34	WD	O
35	(	O
36	Trp	O
37	-	O
38	Asp	O
39	)	O
40	repeats	O
41	that	O
42	occur	O
43	in	O
44	about	O
45	140	O
46	different	O
47	proteins	O
48	.	O
1	In	O
2	contrast	O
3	,	O
4	the	O
5	contractile	O
6	action	O
7	of	O
8	arachidonic	O
9	acid	O
10	,	O
11	via	O
12	a	O
13	presumed	O
14	cyclooxygenase	B
15	product	O
16	that	O
17	mediated	O
18	the	O
19	contractions	O
20	caused	O
21	by	O
22	both	O
23	TF	B
24	and	O
25	EGF	B
26	,	O
27	was	O
28	not	O
29	blocked	O
30	by	O
31	any	O
32	of	O
33	the	O
34	signal	O
35	pathway	O
36	probe	O
37	inhibitors	O
38	.	O
1	Recent	O
2	studies	O
3	have	O
4	revealed	O
5	unconventional	O
6	myosin	B
7	V	I
8	to	O
9	be	O
10	an	O
11	important	O
12	actin	B
13	-	O
14	based	O
15	molecular	O
16	motor	O
17	involved	O
18	in	O
19	vesicular	O
20	movement	O
21	.	O
1	Analysis	O
2	of	O
3	promoter	O
4	and	O
5	androgen	O
6	regulatory	O
7	sequences	O
8	required	O
9	for	O
10	optimal	O
11	transcription	O
12	of	O
13	the	O
14	rat	O
15	androgen	B
16	-	I
17	binding	I
18	protein	I
19	gene	O
20	.	O
1	The	O
2	mitochondrial	B
3	regulatory	I
4	region	I
5	(	O
6	mrr	B
7	)	O
8	located	O
9	between	O
10	the	O
11	tRNAPhe	B
12	and	O
13	tRNAPro	B
14	genes	I
15	of	O
16	mitochondrial	O
17	DNA	O
18	(	O
19	mtDNA	O
20	)	O
21	is	O
22	essential	O
23	for	O
24	regulation	O
25	of	O
26	replication	O
27	and	O
28	transcription	O
29	of	O
30	the	O
31	mitochondrial	O
32	genome	O
33	.	O
1	We	O
2	further	O
3	demonstrate	O
4	that	O
5	RU486	O
6	-	O
7	PR	B
8	-	I
9	B	I
10	interacts	O
11	physically	O
12	with	O
13	NCoR	B
14	in	O
15	vitro	O
16	.	O
1	ATP	O
2	-	O
3	dependent	O
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	mismatch	O
14	and	O
15	the	O
16	yeast	O
17	MSH2	B
18	-	O
19	MSH6	B
20	and	O
21	MLH1	B
22	-	O
23	PMS1	B
24	protein	O
25	complexes	O
26	.	O
1	Recombinant	B
2	HRMT1L2	I
3	protein	I
4	encoded	O
5	by	O
6	the	O
7	most	O
8	common	O
9	5	O
10	'-	O
11	variant	O
12	exhibited	O
13	methyltransferase	O
14	activity	O
15	in	O
16	vitro	O
17	.	O
1	Interestingly	O
2	,	O
3	the	O
4	activated	O
5	PDGF	B
6	beta	I
7	-	I
8	receptor	I
9	was	O
10	found	O
11	not	O
12	to	O
13	bind	O
14	Crk	B
15	proteins	I
16	.	O
1	Furthermore	O
2	,	O
3	interactions	O
4	were	O
5	identified	O
6	between	O
7	endogenous	B
8	E	I
9	-	I
10	cadherin	I
11	and	O
12	the	O
13	chimera	O
14	containing	O
15	the	O
16	E	B
17	-	I
18	cadherin	I
19	extracellular	I
20	domain	I
21	and	O
22	the	O
23	desmoglein	B
24	1	I
25	intracellular	I
26	domain	I
27	providing	O
28	in	O
29	vivo	O
30	evidence	O
31	for	O
32	previously	O
33	predicted	O
34	lateral	O
35	interactions	O
36	of	O
37	E	B
38	-	I
39	cadherin	I
40	extracellular	I
41	domains	I
42	.	O
1	Their	O
2	use	O
3	resulted	O
4	in	O
5	a	O
6	sensitivity	O
7	of	O
8	73	O
9	%	O
10	and	O
11	a	O
12	specificity	O
13	of	O
14	74	O
15	%	O
16	with	O
17	regard	O
18	to	O
19	predictability	O
20	of	O
21	ALT	B
22	levels	O
23	increasing	O
24	during	O
25	the	O
26	trial	O
27	.	O
1	Spatial	O
2	accuracy	O
3	of	O
4	primary	O
5	and	O
6	secondary	O
7	memory	O
8	-	O
9	guided	O
10	saccades	O
11	in	O
12	schizophrenic	O
13	patients	O
14	.	O
1	When	O
2	data	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	cumulative	O
8	manner	O
9	,	O
10	the	O
11	response	O
12	to	O
13	intravenous	O
14	adenosine	O
15	3	O
16	mg	O
17	,	O
18	6	O
19	mg	O
20	,	O
21	9	O
22	mg	O
23	and	O
24	12	O
25	mg	O
26	in	O
27	the	O
28	24	O
29	episodes	O
30	of	O
31	PSVT	O
32	were	O
33	5	O
34	episodes	O
35	(	O
36	21	O
37	%),	O
38	16	O
39	episodes	O
40	(	O
41	67	O
42	%),	O
43	20	O
44	episodes	O
45	(	O
46	83	O
47	%)	O
48	and	O
49	20	O
50	episodes	O
51	(	O
52	83	O
53	%)	O
54	respectively	O
55	.	O
1	To	O
2	study	O
3	retinoid	O
4	signalling	O
5	in	O
6	zebrafish	O
7	embryos	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	novel	O
13	method	O
14	to	O
15	detect	O
16	endogenous	O
17	retinoids	O
18	in	O
19	situ	O
20	in	O
21	embryos	O
22	,	O
23	using	O
24	a	O
25	fusion	O
26	protein	O
27	of	O
28	the	O
29	ligand	O
30	inducible	O
31	transactivation	O
32	domain	O
33	of	O
34	a	O
35	retinoic	B
36	acid	I
37	receptor	I
38	and	O
39	a	O
40	heterologous	O
41	DNA	O
42	binding	O
43	domain	O
44	.	O
1	To	O
2	identify	O
3	nuclear	O
4	regulatory	O
5	factors	O
6	,	O
7	we	O
8	have	O
9	located	O
10	and	O
11	functionally	O
12	characterized	O
13	the	O
14	CCR5	B
15	gene	I
16	promoter	I
17	.	O
1	Fluorescence	O
2	in	O
3	situ	O
4	hybridization	O
5	of	O
6	metaphase	O
7	spreads	O
8	of	O
9	chromosome	O
10	8	O
11	,	O
12	containing	O
13	hybrid	O
14	cell	O
15	line	O
16	706	O
17	-	O
18	B6	O
19	clone	O
20	17	O
21	(	O
22	CL	O
23	-	O
24	17	O
25	)	O
26	with	O
27	cosmid	O
28	c101F1	O
29	,	O
30	placed	O
31	the	O
32	9804	B
33	gene	I
34	close	O
35	to	O
36	the	O
37	telomere	O
38	at	O
39	8q24	O
40	.	O
41	3	O
42	.	O
1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	CAS	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	estrone	O
17	(	O
18	CAS	O
19	53	O
20	-	O
21	16	O
22	-	O
23	7	O
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	menopause	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	transdermal	O
43	patch	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	enhancers	O
51	designed	O
52	for	O
53	epicutaneous	O
54	applications	O
55	of	O
56	7	O
57	days	O
58	(	O
59	hereinafter	O
60	called	O
61	""""	O
62	patch	O
63	7D	O
64	""")."	O
1	We	O
2	previously	O
3	demonstrated	O
4	that	O
5	acute	O
6	expression	O
7	of	O
8	the	O
9	bovine	O
10	papillomavirus	O
11	type	O
12	1	O
13	(	O
14	BPV1	O
15	)	O
16	E2	B
17	protein	I
18	in	O
19	HeLa	O
20	and	O
21	HT	O
22	-	O
23	3	O
24	cervical	O
25	carcinoma	O
26	cell	O
27	lines	O
28	greatly	O
29	reduced	O
30	cellular	O
31	proliferation	O
32	by	O
33	imposing	O
34	a	O
35	specific	O
36	G1	O
37	/	O
38	S	O
39	phase	O
40	growth	O
41	arrest	O
42	.	O
1	Specialized	O
2	actin	B
3	tails	O
4	that	O
5	propel	O
6	IEV	O
7	particles	O
8	to	O
9	the	O
10	periphery	O
11	and	O
12	virus	O
13	-	O
14	tipped	O
15	microvilli	O
16	(	O
17	both	O
18	common	O
19	in	O
20	wild	O
21	-	O
22	type	O
23	-	O
24	infected	O
25	cells	O
26	)	O
27	were	O
28	absent	O
29	in	O
30	cells	O
31	infected	O
32	with	O
33	vA33delta	O
34	.	O
1	Post	O
2	-	O
3	translational	O
4	modifications	O
5	such	O
6	as	O
7	glycosylation	O
8	and	O
9	phosphorylation	O
10	could	O
11	be	O
12	excluded	O
13	as	O
14	potential	O
15	explanations	O
16	for	O
17	the	O
18	protein	O
19	heterogeneity	O
20	.	O
1	In	O
2	addition	O
3	to	O
4	restoring	O
5	checkpoint	O
6	control	O
7	,	O
8	overexpression	O
9	of	O
10	sum1	B
11	+	I
12	inhibits	O
13	the	O
14	normal	O
15	cell	O
16	cycle	O
17	response	O
18	to	O
19	osmotic	O
20	stress	O
21	.	O
1	All	O
2	three	O
3	genes	O
4	have	O
5	been	O
6	mapped	O
7	precisely	O
8	to	O
9	a	O
10	small	O
11	region	O
12	on	O
13	human	O
14	chromosome	O
15	16p12	O
16	.	O
17	1	O
18	-	O
19	p11	O
20	.	O
21	2	O
22	(	O
23	homologous	O
24	to	O
25	mouse	O
26	chromosome	O
27	7	O
28	),	O
29	using	O
30	somatic	O
31	cell	O
32	hybrids	O
33	and	O
34	cosmid	O
35	clones	O
36	.	O
1	Their	O
2	function	O
3	is	O
4	not	O
5	only	O
6	to	O
7	recruit	O
8	Pho2	B
9	to	O
10	the	O
11	promoter	O
12	but	O
13	to	O
14	allow	O
15	cooperative	O
16	binding	O
17	of	O
18	Pho4	B
19	together	O
20	with	O
21	Pho2	B
22	.	O
1	Fetal	O
2	growth	O
3	retardation	O
4	as	O
5	a	O
6	cause	O
7	of	O
8	impaired	O
9	ovarian	O
10	development	O
11	.	O
1	The	O
2	complete	O
3	exon	O
4	-	O
5	intron	O
6	organization	O
7	of	O
8	the	O
9	murine	O
10	gene	O
11	encoding	O
12	M	B
13	-	I
14	protein	I
15	,	O
16	a	O
17	structural	O
18	protein	O
19	of	O
20	sarcomeric	O
21	myofibrils	O
22	,	O
23	was	O
24	determined	O
25	.	O
1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O
1	The	O
2	localization	O
3	of	O
4	ZAP	B
5	-	I
6	70	I
7	to	O
8	the	O
9	cell	O
10	cortex	O
11	is	O
12	,	O
13	therefore	O
14	,	O
15	regulated	O
16	by	O
17	the	O
18	activity	O
19	of	O
20	SRC	B
21	-	I
22	family	I
23	kinases	I
24	,	O
25	independently	O
26	of	O
27	their	O
28	ability	O
29	to	O
30	phosphorylate	O
31	immunoreceptor	O
32	tyrosine	O
33	-	O
34	based	O
35	activation	O
36	motifs	O
37	of	O
38	the	O
39	TCR	B
40	.	O
1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	B
14	type	I
15	IV	I
16	than	O
17	similarly	O
18	sized	O
19	vessels	O
20	in	O
21	the	O
22	submucosa	O
23	,	O
24	and	O
25	perforating	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	O
40	mucosae	O
41	.	O
1	The	O
2	DNA	O
3	binding	O
4	activities	O
5	of	O
6	the	O
7	three	O
8	repressor	O
9	preparations	O
10	were	O
11	studied	O
12	using	O
13	fragments	O
14	containing	O
15	CIRs	O
16	(	O
17	CIR3	O
18	-	O
19	CIR6	O
20	)	O
21	from	O
22	the	O
23	essential	O
24	early	O
25	region	O
26	as	O
27	templates	O
28	for	O
29	DNase	B
30	I	I
31	footprinting	O
32	.	O
1	N	O
2	.,	O
3	and	O
4	Fanning	O
5	,	O
6	E	O
7	.	O
1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	GH3	O
7	cells	O
8	transfected	O
9	with	O
10	the	O
11	rat	B
12	GnRH	I
13	receptor	I
14	cDNA	I
15	(	O
16	GGH3	O
17	-	O
18	1	O
19	'	O
20	cells	O
21	)	O
22	support	O
23	the	O
24	expression	O
25	of	O
26	a	O
27	cotransfected	O
28	fusion	O
29	gene	O
30	composed	O
31	of	O
32	797	O
33	base	O
34	pairs	O
35	of	O
36	rat	B
37	LHbeta	I
38	gene	I
39	5	I
40	'-	I
41	flanking	I
42	sequence	I
43	and	O
44	the	O
45	first	O
46	5	O
47	base	O
48	pairs	O
49	of	O
50	the	O
51	5	O
52	'-	O
53	untranslated	O
54	region	O
55	fused	O
56	to	O
57	a	O
58	luciferase	B
59	reporter	I
60	(-	I
61	797	I
62	/+	I
63	5LHbetaLUC	I
64	)	I
65	and	O
66	respond	O
67	to	O
68	a	O
69	GnRH	B
70	agonist	O
71	with	O
72	a	O
73	10	O
74	-	O
75	fold	O
76	stimulation	O
77	of	O
78	activity	O
79	.	O
1	In	O
2	patients	O
3	with	O
4	type	O
5	IA	O
6	maple	O
7	syrup	O
8	urine	O
9	disease	O
10	,	O
11	the	O
12	E1alpha	B
13	subunit	I
14	is	O
15	affected	O
16	,	O
17	resulting	O
18	in	O
19	the	O
20	loss	O
21	of	O
22	E1	B
23	and	O
24	branched	B
25	-	I
26	chain	I
27	ketoacid	I
28	dehydrogenase	I
29	catalytic	O
30	activities	O
31	.	O
1	OBJECTIVES	O
2	:	O
3	To	O
4	measure	O
5	coagulation	B
6	factor	I
7	VIII	I
8	:	I
9	coagulant	I
10	(	O
11	F	B
12	.	I
13	VIII	I
14	:	I
15	C	I
16	)	O
17	and	O
18	C1	B
19	-	I
20	esterase	I
21	inhibitor	I
22	(	O
23	C1	B
24	-	I
25	INH	I
26	),	O
27	hemostasis	O
28	-	O
29	associated	O
30	acute	O
31	-	O
32	phase	O
33	reactant	O
34	proteins	O
35	and	O
36	coagulation	B
37	factors	I
38	VII	I
39	(	O
40	F	B
41	.	I
42	VII	I
43	),	O
44	IX	O
45	(	O
46	F	B
47	.	I
48	IX	I
49	),	O
50	and	O
51	X	O
52	(	O
53	F	B
54	.	I
55	X	I
56	),	O
57	hemostasis	O
58	proteins	O
59	not	O
60	associated	O
61	with	O
62	an	O
63	acute	O
64	-	O
65	phase	O
66	response	O
67	,	O
68	in	O
69	a	O
70	select	O
71	population	O
72	of	O
73	horses	O
74	with	O
75	colic	O
76	and	O
77	hemostasis	O
78	abnormalities	O
79	,	O
80	and	O
81	presumed	O
82	to	O
83	have	O
84	acute	O
85	-	O
86	phase	O
87	changes	O
88	.	O
1	Peptide	O
2	sequences	O
3	of	O
4	the	O
5	zinc	B
6	finger	I
7	protein	I
8	Ttk	I
9	and	O
10	the	O
11	transcription	B
12	factor	I
13	Adf	I
14	-	I
15	1	I
16	were	O
17	obtained	O
18	.	O
1	Immunohistochemically	O
2	,	O
3	anticytokeratin	B
4	19	I
5	antibody	I
6	revealed	O
7	strong	O
8	staining	O
9	in	O
10	both	O
11	epithelial	O
12	and	O
13	sarcomatous	O
14	MPM	O
15	tissues	O
16	.	O
1	Structural	O
2	features	O
3	of	O
4	the	O
5	minimal	O
6	DNA	O
7	binding	O
8	domain	O
9	(	O
10	M98	O
11	-	O
12	F219	O
13	)	O
14	of	O
15	human	B
16	nucleotide	I
17	excision	I
18	repair	I
19	protein	I
20	XPA	I
21	.	O
1	Recently	O
2	,	O
3	extremely	O
4	high	O
5	levels	O
6	of	O
7	endothelin	B
8	-	I
9	1	I
10	(	O
11	ET	B
12	-	I
13	1	I
14	)	O
15	were	O
16	detected	O
17	in	O
18	the	O
19	pericardial	O
20	fluid	O
21	of	O
22	patients	O
23	undergoing	O
24	cardiac	O
25	surgery	O
26	.	O
1	Comparative	O
2	mapping	O
3	of	O
4	the	O
5	Brassica	B
6	S	I
7	locus	I
8	region	I
9	and	O
10	its	O
11	homeolog	O
12	in	O
13	Arabidopsis	O
14	.	O
1	Substitution	O
2	of	O
3	bulky	O
4	hydrophobic	O
5	residues	O
6	with	O
7	charged	O
8	residues	O
9	within	O
10	PEP1	B
11	affects	O
12	the	O
13	fusion	O
14	activity	O
15	of	O
16	the	O
17	S	B
18	protein	I
19	without	O
20	affecting	O
21	processing	O
22	and	O
23	surface	O
24	expression	O
25	.	O
1	Tributyltin	O
2	and	O
3	its	O
4	breakdown	O
5	products	O
6	,	O
7	mono	O
8	-	O
9	and	O
10	di	O
11	-	O
12	butyltin	O
13	,	O
14	were	O
15	determined	O
16	in	O
17	water	O
18	birds	O
19	collected	O
20	from	O
21	Lake	O
22	Huron	O
23	(	O
24	the	O
25	Great	O
26	Lakes	O
27	),	O
28	marine	O
29	coastal	O
30	United	O
31	States	O
32	,	O
33	and	O
34	the	O
35	west	O
36	coast	O
37	of	O
38	British	O
39	Columbia	O
40	,	O
41	Canada	O
42	.	O
1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	of	O
7	the	O
8	CD1	B
9	gene	I
10	contained	O
11	the	O
12	binding	O
13	motifs	O
14	for	O
15	two	O
16	cytokine	O
17	-	O
18	inducible	O
19	transcription	O
20	factors	O
21	,	O
22	NF	B
23	-	I
24	IL2	I
25	-	I
26	A	I
27	and	O
28	NF	B
29	-	I
30	IL6	I
31	.	O
1	Combined	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	and	O
8	p65	B
9	induced	O
10	vigorous	O
11	transcription	O
12	of	O
13	IL	B
14	-	I
15	2	I
16	promoter	O
17	-	O
18	and	O
19	CD28RE	B
20	-	I
21	driven	I
22	reporter	I
23	constructs	I
24	in	O
25	both	O
26	LFA	B
27	-	I
28	3	I
29	-	O
30	and	O
31	B7	B
32	-	I
33	1	I
34	-	O
35	costimulated	O
36	Jurkat	O
37	cells	O
38	.	O
1	Liquid	O
2	chromatographic	O
3	method	O
4	for	O
5	analysis	O
6	of	O
7	all	O
8	-	O
9	rac	O
10	-	O
11	alpha	O
12	-	O
13	tocopheryl	O
14	acetate	O
15	and	O
16	retinyl	O
17	palmitate	O
18	in	O
19	milk	O
20	-	O
21	based	O
22	infant	O
23	formula	O
24	using	O
25	matrix	O
26	solid	O
27	-	O
28	phase	O
29	dispersion	O
30	.	O
1	Two	O
2	protease	O
3	-	O
4	resistant	O
5	fragments	O
6	spanning	O
7	the	O
8	N	O
9	-	O
10	and	O
11	C	O
12	-	O
13	terminal	O
14	halves	O
15	of	O
16	the	O
17	nuclease	O
18	were	O
19	identified	O
20	using	O
21	different	O
22	proteases	O
23	which	O
24	cleave	O
25	the	O
26	protein	O
27	in	O
28	the	O
29	same	O
30	region	O
31	.	O
1	The	O
2	ability	O
3	to	O
4	maintain	O
5	expression	O
6	of	O
7	FAS1	B
8	in	O
9	nmt1	B
10	-	O
11	451Dino2	B
12	Delta	O
13	cells	O
14	suggests	O
15	the	O
16	existence	O
17	of	O
18	another	O
19	transcription	O
20	factor	O
21	,	O
22	or	O
23	factors	O
24	,	O
25	whose	O
26	expression	O
27	/	O
28	activity	O
29	is	O
30	inversely	O
31	related	O
32	to	O
33	overall	O
34	levels	O
35	of	O
36	cellular	O
37	protein	O
38	N	O
39	-	O
40	myristoy	O
41	-	O
42	lation	O
43	.	O
1	Rev	B
2	-	O
3	erbAalpha	B
4	/	I
5	beta	I
6	),	O
7	Mxi	B
8	-	I
9	1	I
10	and	O
11	Mad	B
12	bHLH	O
13	-	O
14	zip	O
15	proteins	O
16	and	O
17	the	O
18	oncoproteins	O
19	PLZF	B
20	and	O
21	LAZ3	B
22	/	O
23	BCL6	B
24	is	O
25	mediated	O
26	by	O
27	the	O
28	corepressors	O
29	N	B
30	-	I
31	CoR	I
32	and	O
33	SMRT	B
34	.	O
1	A	O
2	large	O
3	deletion	O
4	in	O
5	the	O
6	CTD	B
7	-	I
8	binding	I
9	motif	I
10	blocks	O
11	down	O
12	-	O
13	regulation	O
14	but	O
15	does	O
16	not	O
17	affect	O
18	the	O
19	essential	O
20	function	O
21	of	O
22	Nrd1	B
23	.	O
1	In	O
2	mammals	O
3	,	O
4	the	O
5	Rb	B
6	protein	I
7	interacts	O
8	specifically	O
9	with	O
10	D	B
11	-	I
12	type	I
13	cyclins	I
14	and	O
15	regulates	O
16	cell	O
17	proliferation	O
18	by	O
19	binding	O
20	and	O
21	inhibiting	O
22	E2F	B
23	transcription	I
24	factors	I
25	.	O
1	The	O
2	importance	O
3	of	O
4	these	O
5	sites	O
6	for	O
7	transcriptional	O
8	activation	O
9	was	O
10	studied	O
11	by	O
12	site	O
13	-	O
14	directed	O
15	mutagenesis	O
16	followed	O
17	by	O
18	promoter	O
19	function	O
20	analysis	O
21	of	O
22	the	O
23	mutants	O
24	with	O
25	a	O
26	chloramphenicol	B
27	acetyltransferase	I
28	reporter	I
29	system	O
30	.	O
1	Routine	O
2	blood	O
3	examination	O
4	showed	O
5	leukocytosis	O
6	,	O
7	thrombocytopenia	O
8	,	O
9	positive	O
10	CRP	B
11	,	O
12	and	O
13	elevated	O
14	myocardial	O
15	enzymes	O
16	.	O
1	SETTING	O
2	:	O
3	University	O
4	hospital	O
5	-	O
6	based	O
7	,	O
8	tertiary	O
9	care	O
10	infertility	O
11	center	O
12	.	O
1	After	O
2	the	O
3	first	O
4	cycle	O
5	,	O
6	18	O
7	cases	O
8	were	O
9	treated	O
10	at	O
11	dose	O
12	level	O
13	1	O
14	,	O
15	after	O
16	a	O
17	second	O
18	cycle	O
19	,	O
20	13	O
21	cases	O
22	were	O
23	treated	O
24	at	O
25	dose	O
26	level	O
27	2	O
28	.	O
1	Despite	O
2	continuous	O
3	compliance	O
4	,	O
5	unexplained	O
6	resurgence	O
7	of	O
8	serum	O
9	ferritin	B
10	levels	O
11	occurred	O
12	in	O
13	4	O
14	/	O
15	7	O
16	patients	O
17	of	O
18	the	O
19	'	O
20	veteran	O
21	'	O
22	group	O
23	after	O
24	4	O
25	-	O
26	5	O
27	years	O
28	on	O
29	L1	O
30	.	O
1	After	O
2	profound	O
3	normovolemic	O
4	hemodilution	O
5	(	O
6	Hct	O
7	9	O
8	%)	O
9	superiority	O
10	of	O
11	LV	O
12	MC	O
13	and	O
14	LV	O
15	diastolic	O
16	properties	O
17	was	O
18	found	O
19	,	O
20	when	O
21	myocardial	O
22	oxygenation	O
23	was	O
24	supported	O
25	by	O
26	i	O
27	.	O
28	v	O
29	.	O
30	perflubron	O
31	emulsion	O
32	,	O
33	a	O
34	temporary	O
35	O2	O
36	carrier	O
37	.	O
1	In	O
2	this	O
3	report	O
4	we	O
5	studied	O
6	the	O
7	role	O
8	of	O
9	protein	B
10	-	I
11	tyrosine	I
12	phosphatase	I
13	SHP	I
14	-	I
15	2	I
16	in	O
17	ErbB	B
18	-	O
19	mediated	O
20	activation	O
21	of	O
22	mitogen	B
23	-	I
24	activated	I
25	protein	I
26	kinase	I
27	(	O
28	MAPK	B
29	)	O
30	by	O
31	overexpressing	O
32	SHP	B
33	-	I
34	2	I
35	mutants	I
36	in	O
37	COS	O
38	-	O
39	7	O
40	cells	O
41	.	O
1	The	O
2	intron	O
3	8	O
4	enhancer	O
5	region	O
6	was	O
7	not	O
8	activated	O
9	by	O
10	GATA	B
11	-	I
12	1	I
13	together	O
14	with	O
15	Sp1	B
16	in	O
17	transactivation	O
18	experiments	O
19	in	O
20	COS	O
21	-	O
22	1	O
23	cells	O
24	indicating	O
25	the	O
26	involvement	O
27	of	O
28	a	O
29	related	O
30	Sp1	B
31	protein	I
32	or	O
33	of	O
34	another	O
35	unidentified	O
36	erythroid	O
37	factor	O
38	.	O
1	Transcription	O
2	initiation	O
3	occurred	O
4	predominantly	O
5	at	O
6	the	O
7	putative	O
8	sigmaA	B
9	-	I
10	dependent	I
11	promoter	I
12	in	O
13	exponentially	O
14	growing	O
15	cells	O
16	and	O
17	was	O
18	induced	O
19	under	O
20	stress	O
21	conditions	O
22	.	O
1	A	O
2	major	O
3	pool	O
4	of	O
5	Dsg	B
6	-	O
7	plakoglobin	B
8	complexes	O
9	sedimented	O
10	at	O
11	8S	O
12	and	O
13	exhibited	O
14	a	O
15	1	O
16	:	O
17	1	O
18	stoichiometry	O
19	.	O
1	Examination	O
2	of	O
3	nuclear	O
4	magnetic	O
5	resonance	O
6	(	O
7	NMR	O
8	)	O
9	spectra	O
10	of	O
11	a	O
12	series	O
13	of	O
14	N	B
15	-	I
16	terminally	I
17	truncated	I
18	MIP	I
19	-	I
20	1	I
21	beta	I
22	variants	I
23	reveals	O
24	that	O
25	these	O
26	proteins	O
27	possess	O
28	a	O
29	range	O
30	of	O
31	ability	O
32	to	O
33	dimerize	O
34	.	O
1	Recently	O
2	,	O
3	a	O
4	human	B
5	transcription	I
6	elongation	I
7	factor	I
8	P	I
9	-	I
10	TEFb	I
11	,	O
12	consisting	O
13	of	O
14	CDK9	B
15	kinase	I
16	,	O
17	cyclin	B
18	T	I
19	and	O
20	other	O
21	associated	O
22	factors	O
23	,	O
24	has	O
25	been	O
26	shown	O
27	to	O
28	interact	O
29	with	O
30	Tat	B
31	to	O
32	restore	O
33	Tat	B
34	activation	O
35	in	O
36	HeLa	O
37	nuclear	O
38	extract	O
39	depleted	O
40	of	O
41	P	B
42	-	I
43	TEFb	I
44	.	O
1	Cystatin	B
2	A	I
3	,	O
4	a	O
5	cysteine	B
6	proteinase	I
7	inhibitor	O
8	,	O
9	is	O
10	one	O
11	of	O
12	the	O
13	precursor	O
14	proteins	O
15	of	O
16	cornified	B
17	cell	I
18	envelope	I
19	of	O
20	keratinocytes	O
21	and	O
22	is	O
23	expressed	O
24	during	O
25	the	O
26	late	O
27	stage	O
28	of	O
29	keratinocyte	O
30	differentiation	O
31	.	O
1	Blocked	O
2	shift	O
3	/	O
4	supershift	O
5	analysis	O
6	indicates	O
7	that	O
8	Fos	B
9	family	I
10	member	O
11	proteins	O
12	especially	O
13	Fra	B
14	-	I
15	1	I
16	and	O
17	Fra	B
18	-	I
19	2	I
20	are	O
21	related	O
22	to	O
23	progression	O
24	and	O
25	no	O
26	changes	O
27	found	O
28	in	O
29	the	O
30	Jun	B
31	family	I
32	member	O
33	proteins	O
34	although	O
35	they	O
36	are	O
37	present	O
38	in	O
39	the	O
40	AP	B
41	-	I
42	1	I
43	/	I
44	DNA	I
45	binding	I
46	complex	I
47	.	O
1	He	O
2	was	O
3	administered	O
4	recombinant	B
5	IFN	I
6	alpha	I
7	-	I
8	2b	I
9	under	O
10	the	O
11	diagnosis	O
12	of	O
13	chronic	O
14	hepatitis	O
15	C	O
16	.	O
1	Regulation	O
2	at	O
3	37	O
4	degrees	O
5	C	O
6	,	O
7	therefore	O
8	,	O
9	involves	O
10	the	O
11	action	O
12	of	O
13	three	O
14	protein	O
15	kinase	O
16	cascades	O
17	that	O
18	repress	O
19	HSF1	B
20	through	O
21	phosphorylation	O
22	of	O
23	serine	O
24	residues	O
25	303	O
26	,	O
27	307	O
28	,	O
29	and	O
30	363	O
31	and	O
32	may	O
33	promote	O
34	growth	O
35	by	O
36	suppressing	O
37	the	O
38	heat	O
39	shock	O
40	response	O
41	.	O
1	Tensile	O
2	bond	O
3	strengths	O
4	between	O
5	resin	O
6	composite	O
7	and	O
8	bovine	O
9	dentin	O
10	using	O
11	dentin	O
12	adhesive	O
13	systems	O
14	(	O
15	Clearfil	O
16	Liner	O
17	Bond	O
18	II	O
19	:	O
20	LB	O
21	II	O
22	;	O
23	Scotchbond	O
24	Multi	O
25	-	O
26	Purpose	O
27	:	O
28	MP	O
29	)	O
30	bonding	O
31	systems	O
32	showed	O
33	a	O
34	large	O
35	scatter	O
36	among	O
37	students	O
38	and	O
39	dentists	O
40	.	O
1	Fourteen	O
2	healthy	O
3	male	O
4	volunteers	O
5	completed	O
6	the	O
7	study	O
8	.	O
1	Manipulation	O
2	of	O
3	the	O
4	checkpoint	O
5	regulators	O
6	involved	O
7	in	O
8	cell	O
9	cycle	O
10	arrest	O
11	and	O
12	apoptosis	O
13	may	O
14	thus	O
15	provide	O
16	a	O
17	novel	O
18	strategy	O
19	to	O
20	cancer	O
21	therapy	O
22	.	O
1	""""	O
2	Complex	O
3	partial	O
4	""""	O
5	seizures	O
6	.	O
1	The	O
2	aim	O
3	of	O
4	the	O
5	study	O
6	was	O
7	to	O
8	correlate	O
9	the	O
10	responsiveness	O
11	to	O
12	bronchoprovocation	O
13	with	O
14	methacholine	O
15	in	O
16	subjects	O
17	a	O
18	with	O
19	allergic	O
20	rhinitis	O
21	during	O
22	and	O
23	out	O
24	of	O
25	the	O
26	pollen	O
27	season	O
28	with	O
29	total	O
30	serum	O
31	IgE	B
32	and	O
33	blood	O
34	eosinophils	O
35	.	O
1	These	O
2	results	O
3	provide	O
4	the	O
5	first	O
6	demonstration	O
7	that	O
8	an	O
9	SR	B
10	protein	I
11	can	O
12	influence	O
13	splicing	O
14	of	O
15	specific	O
16	pre	O
17	-	O
18	mRNAs	O
19	in	O
20	vivo	O
21	.	O
1	METHODS	O
2	:	O
3	Millipore	O
4	ultrafiltration	O
5	membranes	O
6	of	O
7	three	O
8	different	O
9	pore	O
10	sizes	O
11	were	O
12	used	O
13	as	O
14	model	O
15	lenticule	O
16	materials	O
17	.	O
18	The	O
19	nominal	O
20	membrane	O
21	pore	O
22	sizes	O
23	were	O
24	0	O
25	.	O
26	1	O
27	microm	O
28	,	O
29	0	O
30	.	O
31	45	O
32	microm	O
33	,	O
34	and	O
35	3	O
36	microm	O
37	;	O
38	the	O
39	surface	O
40	roughness	O
41	increased	O
42	in	O
43	the	O
44	same	O
45	order	O
46	The	O
47	membranes	O
48	were	O
49	coated	O
50	with	O
51	a	O
52	thin	O
53	layer	O
54	of	O
55	collagen	B
56	I	I
57	and	O
58	implanted	O
59	in	O
60	a	O
61	circular	O
62	pocket	O
63	of	O
64	the	O
65	anterior	O
66	cornea	O
67	of	O
68	adult	O
69	cats	O
70	,	O
71	and	O
72	were	O
73	clinically	O
74	evaluated	O
75	for	O
76	the	O
77	extent	O
78	of	O
79	epithelialization	O
80	and	O
81	the	O
82	persistence	O
83	of	O
84	epithelial	O
85	attachment	O
86	.	O
1	The	O
2	biochemical	O
3	and	O
4	molecular	O
5	spectrum	O
6	of	O
7	ornithine	B
8	transcarbamylase	I
9	deficiency	O
10	.	O
1	To	O
2	further	O
3	understand	O
4	the	O
5	role	O
6	of	O
7	cis	O
8	-	O
9	acting	O
10	elements	O
11	in	O
12	these	O
13	regulatory	O
14	mechanisms	O
15	,	O
16	we	O
17	have	O
18	characterized	O
19	a	O
20	transcriptional	O
21	promoter	O
22	that	O
23	drives	O
24	germline	O
25	expression	O
26	of	O
27	TCR	B
28	beta	I
29	gene	I
30	segments	I
31	in	O
32	vivo	O
33	.	O
1	A	O
2	prerequisite	O
3	for	O
4	the	O
5	synthesis	O
6	of	O
7	sialylated	O
8	glycoconjugates	O
9	is	O
10	the	O
11	activated	O
12	sugar	O
13	-	O
14	nucleotide	O
15	cytidine	O
16	5	O
17	'-	O
18	monophosphate	O
19	N	O
20	-	O
21	acetylneuraminic	O
22	acid	O
23	(	O
24	CMP	O
25	-	O
26	Neu5Ac	O
27	),	O
28	which	O
29	provides	O
30	a	O
31	substrate	O
32	for	O
33	Golgi	B
34	sialyltransferases	I
35	.	O
1	Specifically	O
2	,	O
3	I	O
4	use	O
5	molecular	O
6	markers	O
7	that	O
8	identify	O
9	particular	O
10	neuroectodermal	O
11	domains	O
12	,	O
13	all	O
14	neuroblasts	O
15	or	O
16	individual	O
17	neuroblasts	O
18	,	O
19	to	O
20	show	O
21	that	O
22	in	O
23	DER	B
24	mutant	I
25	embryos	O
26	(	O
27	1	O
28	)	O
29	intermediate	O
30	column	O
31	neuroblasts	O
32	do	O
33	not	O
34	form	O
35	,	O
36	(	O
37	2	O
38	)	O
39	medial	O
40	column	O
41	neuroblasts	O
42	often	O
43	acquire	O
44	identities	O
45	inappropriate	O
46	for	O
47	their	O
48	position	O
49	,	O
50	while	O
51	(	O
52	3	O
53	)	O
54	lateral	O
55	neuroblasts	O
56	develop	O
57	normally	O
58	.	O
1	Arnt3	B
2	mRNA	I
3	was	O
4	expressed	O
5	in	O
6	brain	O
7	,	O
8	skeletal	O
9	muscle	O
10	,	O
11	13	O
12	.	O
13	5	O
14	-	O
15	day	O
16	embryos	O
17	,	O
18	and	O
19	P19	O
20	cells	O
21	treated	O
22	with	O
23	retinoic	O
24	acid	O
25	.	O
1	The	O
2	genomic	O
3	structure	O
4	and	O
5	chromosomal	O
6	location	O
7	of	O
8	the	O
9	human	B
10	TR2	I
11	orphan	I
12	receptor	I
13	,	O
14	a	O
15	member	O
16	of	O
17	the	O
18	steroid	B
19	receptor	I
20	superfamily	I
21	.	O
1	The	O
2	effect	O
3	of	O
4	Rho	B
5	on	O
6	AP	B
7	-	I
8	1	I
9	is	O
10	independent	O
11	of	O
12	the	O
13	mitogen	B
14	-	I
15	activated	I
16	protein	I
17	kinase	I
18	pathway	O
19	,	O
20	as	O
21	a	O
22	dominant	B
23	-	I
24	negative	I
25	MEK	I
26	and	O
27	a	O
28	MEK	B
29	inhibitor	O
30	(	O
31	PD98059	O
32	)	O
33	did	O
34	not	O
35	affect	O
36	Rho	B
37	-	O
38	induced	O
39	AP	B
40	-	I
41	1	I
42	activity	O
43	.	O
1	Mutations	O
2	within	O
3	the	O
4	C	O
5	terminus	O
6	of	O
7	c	B
8	-	I
9	fos	I
10	at	O
11	serine	O
12	residues	O
13	that	O
14	are	O
15	phosphorylation	O
16	targets	O
17	for	O
18	growth	O
19	factors	O
20	and	O
21	MAP	B
22	kinase	I
23	completely	O
24	abrogate	O
25	transactivation	O
26	and	O
27	block	O
28	potentiation	O
29	by	O
30	MAP	B
31	kinase	I
32	.	O
1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	GluR2	B
6	gene	I
7	:	O
8	neural	O
9	-	O
10	specific	O
11	expression	O
12	,	O
13	multiple	O
14	promoters	O
15	,	O
16	and	O
17	regulatory	O
18	elements	O
19	.	O
1	The	O
2	binding	O
3	of	O
4	NF	B
5	-	I
6	ATp	I
7	,	O
8	although	O
9	not	O
10	NF	B
11	-	I
12	AT4	I
13	,	O
14	to	O
15	this	O
16	enhancer	O
17	also	O
18	occurs	O
19	along	O
20	with	O
21	HTLV	O
22	-	O
23	I	O
24	-	O
25	mediated	O
26	infection	O
27	of	O
28	human	O
29	peripheral	O
30	blood	O
31	T	O
32	-	O
33	cells	O
34	.	O
1	The	O
2	activity	O
3	of	O
4	the	O
5	minimal	O
6	promoter	O
7	was	O
8	found	O
9	to	O
10	be	O
11	controlled	O
12	by	O
13	a	O
14	combination	O
15	of	O
16	the	O
17	activities	O
18	of	O
19	the	O
20	transcription	O
21	factors	O
22	Sp1	B
23	,	O
24	Sp3	B
25	,	O
26	and	O
27	NF	B
28	-	I
29	Y	I
30	.	O
1	The	O
2	present	O
3	study	O
4	sought	O
5	to	O
6	develop	O
7	an	O
8	equation	O
9	to	O
10	estimate	O
11	VO2peak	O
12	in	O
13	peripheral	O
14	arterial	O
15	occlusive	O
16	disease	O
17	(	O
18	PAOD	O
19	)	O
20	patients	O
21	with	O
22	intermittent	O
23	claudication	O
24	and	O
25	to	O
26	determine	O
27	independent	O
28	predictors	O
29	of	O
30	VO2peak	O
31	in	O
32	this	O
33	population	O
34	.	O
1	The	O
2	Abbreviated	O
3	Injury	O
4	Scale	O
5	(	O
6	AIS	O
7	),	O
8	Injury	O
9	Severity	O
10	Scale	O
11	and	O
12	TRISS	O
13	methodology	O
14	comprise	O
15	a	O
16	mathematically	O
17	sound	O
18	system	O
19	for	O
20	the	O
21	analysis	O
22	of	O
23	injuries	O
24	and	O
25	injured	O
26	patients	O
27	.	O
1	Seventy	O
2	-	O
3	five	O
4	percent	O
5	of	O
6	children	O
7	who	O
8	received	O
9	a	O
10	second	O
11	transplant	O
12	for	O
13	HCV	O
14	hepatitis	O
15	had	O
16	early	O
17	histologic	O
18	recurrence	O
19	that	O
20	led	O
21	to	O
22	liver	O
23	failure	O
24	and	O
25	death	O
26	.	O
1	However	O
2	,	O
3	both	O
4	TPN	O
5	groups	O
6	showed	O
7	a	O
8	marked	O
9	increase	O
10	in	O
11	activities	O
12	of	O
13	liver	O
14	lysosomal	B
15	enzymes	I
16	.	O
1	Furthermore	O
2	,	O
3	we	O
4	demonstrated	O
5	that	O
6	Galpha11	B
7	Q209L	I
8	stimulated	O
9	Src	B
10	family	I
11	kinase	O
12	activity	O
13	and	O
14	induced	O
15	tyrosine	O
16	phosphorylation	O
17	of	O
18	several	O
19	proteins	O
20	in	O
21	HEK	O
22	-	O
23	293	O
24	cells	O
25	.	O
1	The	O
2	CBF1	B
3	site	I
4	within	O
5	HS2	O
6	resides	O
7	near	O
8	sites	O
9	for	O
10	hematopoietic	O
11	regulators	O
12	such	O
13	as	O
14	GATA	B
15	-	I
16	1	I
17	,	O
18	NF	B
19	-	I
20	E2	I
21	,	O
22	and	O
23	TAL1	B
24	.	O
1	The	O
2	rat	B
3	branched	I
4	-	I
5	chain	I
6	-	I
7	2	I
8	-	I
9	oxo	I
10	-	I
11	acid	I
12	dehydrogenase	I
13	(	I
14	BCOD	I
15	)	I
16	kinase	I
17	mRNA	I
18	is	O
19	transcribed	O
20	from	O
21	a	O
22	TATA	O
23	-	O
24	less	O
25	promoter	O
26	that	O
27	has	O
28	GC	O
29	-	O
30	rich	O
31	sequences	O
32	and	O
33	two	O
34	putative	O
35	Sp1	B
36	binding	I
37	sites	I
38	near	O
39	the	O
40	transcription	O
41	start	O
42	site	O
43	.	O
1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	the	O
9	cooperation	O
10	of	O
11	transcription	B
12	factors	I
13	NF	I
14	-	I
15	kappaB	I
16	and	O
17	AP	B
18	-	I
19	1	I
20	is	O
21	essential	O
22	for	O
23	transactivation	O
24	of	O
25	IL	B
26	-	I
27	8	I
28	gene	I
29	by	O
30	HTLV	B
31	-	I
32	I	I
33	Tax	I
34	.	O
1	Using	O
2	homology	O
3	cloning	O
4	techniques	O
5	,	O
6	we	O
7	identified	O
8	a	O
9	mouse	O
10	homologue	O
11	of	O
12	E	O
13	(	O
14	Pc	O
15	),	O
16	termed	O
17	Epc1	B
18	,	O
19	a	O
20	yeast	O
21	protein	O
22	that	O
23	we	O
24	name	O
25	EPL1	B
26	,	O
27	and	O
28	as	O
29	well	O
30	as	O
31	additional	O
32	ESTs	O
33	from	O
34	Caenorhabditis	O
35	elegans	O
36	,	O
37	mice	O
38	and	O
39	humans	O
40	.	O
1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	swa5	B
7	-	I
8	1	I
9	is	O
10	a	O
11	new	O
12	temperature	O
13	-	O
14	sensitive	O
15	allele	O
16	of	O
17	the	O
18	clathrin	B
19	heavy	I
20	chain	I
21	gene	I
22	(	O
23	chc1	B
24	-	I
25	5	I
26	),	O
27	which	O
28	carries	O
29	a	O
30	frameshift	O
31	mutation	O
32	near	O
33	the	O
34	3	O
35	'	O
36	end	O
37	of	O
38	the	O
39	CHC1	B
40	open	O
41	reading	O
42	frame	O
43	.	O
1	We	O
2	have	O
3	determined	O
4	the	O
5	molecular	O
6	lesions	O
7	of	O
8	nine	O
9	Scm	B
10	mutant	I
11	alleles	I
12	,	O
13	which	O
14	identify	O
15	functional	O
16	requirements	O
17	for	O
18	specific	O
19	domains	O
20	.	O
1	BACKGROUND	O
2	:	O
3	Fluoroquinolones	O
4	(	O
5	FQ	O
6	)	O
7	are	O
8	contraindicated	O
9	in	O
10	children	O
11	because	O
12	of	O
13	the	O
14	risk	O
15	of	O
16	cartilage	O
17	damage	O
18	.	O
1	Cotransfections	O
2	with	O
3	ATF	B
4	-	I
5	2	I
6	and	O
7	HNF	B
8	-	I
9	4	I
10	expression	O
11	plasmids	O
12	resulted	O
13	in	O
14	additive	O
15	transactivation	O
16	of	O
17	the	O
18	apoCIII	B
19	promoter	I
20	.	O
1	Phosphocreatine	O
2	hydrolysis	O
3	during	O
4	submaximal	O
5	exercise	O
6	:	O
7	the	O
8	effect	O
9	of	O
10	FIO2	O
11	.	O
1	The	O
2	human	O
3	T	O
4	cell	O
5	lymphotropic	O
6	retrovirus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	trans	O
15	-	O
16	activator	O
17	,	O
18	Tax	B
19	,	O
20	interacts	O
21	specifically	O
22	with	O
23	the	O
24	basic	B
25	-	I
26	domain	I
27	/	I
28	leucine	I
29	-	I
30	zipper	I
31	(	I
32	bZip	I
33	)	I
34	protein	I
35	,	O
36	cAMP	B
37	response	I
38	element	I
39	binding	I
40	protein	I
41	(	O
42	CREB	B
43	),	O
44	bound	O
45	to	O
46	the	O
47	viral	B
48	Tax	I
49	-	I
50	responsive	I
51	element	I
52	consisting	O
53	of	O
54	three	O
55	imperfect	O
56	21	O
57	-	O
58	base	O
59	pair	O
60	repeats	O
61	,	O
62	each	O
63	with	O
64	a	O
65	cAMP	O
66	response	O
67	element	O
68	core	O
69	flanked	O
70	by	O
71	G	O
72	/	O
73	C	O
74	-	O
75	rich	O
76	sequences	O
77	.	O
1	The	O
2	murine	B
3	facilitative	I
4	glucose	I
5	transporter	I
6	isoform	I
7	3	I
8	(	O
9	Glut	B
10	3	I
11	)	O
12	is	O
13	developmentally	O
14	regulated	O
15	and	O
16	is	O
17	predominantly	O
18	expressed	O
19	in	O
20	neurons	O
21	and	O
22	trophoblasts	O
23	.	O
1	The	O
2	levels	O
3	of	O
4	transactivation	O
5	are	O
6	correlated	O
7	with	O
8	the	O
9	respective	O
10	binding	O
11	affinities	O
12	of	O
13	the	O
14	response	O
15	elements	O
16	(	O
17	IRper	O
18	-	O
19	1	O
20	>	O
21	DR	O
22	-	O
23	4	O
24	>	O
25	IRhsp	O
26	-	O
27	1	O
28	).	O
1	Previous	O
2	genetic	O
3	studies	O
4	led	O
5	to	O
6	the	O
7	conclusion	O
8	that	O
9	nitrate	O
10	and	O
11	nitrite	O
12	induction	O
13	of	O
14	nasF	B
15	operon	I
16	expression	O
17	is	O
18	determined	O
19	by	O
20	a	O
21	transcriptional	O
22	antitermination	O
23	mechanism	O
24	.	O
1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	THOV	B
6	NP	I
7	contains	O
8	a	O
9	motif	O
10	(	O
11	KRxxxxxxxxxKTKK	O
12	)	O
13	at	O
14	amino	O
15	acid	O
16	positions	O
17	179	O
18	-	O
19	193	O
20	that	O
21	represents	O
22	a	O
23	classical	O
24	bipartite	O
25	nuclear	O
26	localization	O
27	signal	O
28	(	O
29	NLS	O
30	).	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	anthraquinone	O
6	sennoside	O
7	B	O
8	and	O
9	rhein	O
10	are	O
11	weakly	O
12	genotoxic	O
13	.	O
1	UGA	O
2	codon	O
3	position	O
4	affects	O
5	the	O
6	efficiency	O
7	of	O
8	selenocysteine	O
9	incorporation	O
10	into	O
11	glutathione	B
12	peroxidase	I
13	-	I
14	1	I
15	.	O
1	RESULTS	O
2	:	O
3	The	O
4	binding	O
5	of	O
6	99mTc	O
7	d	O
8	,	O
9	1	O
10	-	O
11	HMPAO	O
12	to	O
13	human	O
14	placenta	O
15	ranged	O
16	from	O
17	2	O
18	.	O
19	95	O
20	%	O
21	+/-	O
22	1	O
23	.	O
24	5	O
25	%	O
26	to	O
27	5	O
28	.	O
29	82	O
30	%	O
31	+/-	O
32	0	O
33	.	O
34	3	O
35	%	O
36	per	O
37	1	O
38	ml	O
39	standard	O
40	solution	O
41	.	O
1	CM	O
2	reduced	O
3	the	O
4	nuclear	O
5	binding	O
6	activity	O
7	of	O
8	transcription	B
9	factor	I
10	AP	I
11	-	I
12	1	I
13	.	O
1	A	O
2	simple	O
3	analytical	O
4	method	O
5	for	O
6	l	O
7	-	O
8	menthol	O
9	by	O
10	high	O
11	-	O
12	performance	O
13	liquid	O
14	chromatography	O
15	with	O
16	a	O
17	polarized	O
18	photometric	O
19	detector	O
20	was	O
21	established	O
22	.	O
1	The	O
2	predicted	O
3	domain	O
4	structures	O
5	of	O
6	FkbB	B
7	and	O
8	FkbC	B
9	are	O
10	analogous	O
11	to	O
12	that	O
13	of	O
14	FkbA	B
15	and	O
16	comprise	O
17	30	O
18	fatty	B
19	-	I
20	acid	I
21	-	I
22	synthase	I
23	(	O
24	FAS	B
25	)-	O
26	like	O
27	domains	O
28	arranged	O
29	in	O
30	6	O
31	modules	O
32	.	O
1	Analysis	O
2	of	O
3	Msy2	B
4	mRNA	I
5	expression	O
6	in	O
7	prepubertal	O
8	and	O
9	adult	O
10	mouse	O
11	testes	O
12	,	O
13	and	O
14	in	O
15	isolated	O
16	populations	O
17	of	O
18	germ	O
19	cells	O
20	,	O
21	reveals	O
22	maximal	O
23	expression	O
24	in	O
25	postmeiotic	O
26	round	O
27	spermatids	O
28	,	O
29	a	O
30	cell	O
31	type	O
32	with	O
33	abundant	O
34	amounts	O
35	of	O
36	stored	O
37	messenger	O
38	ribonucleoproteins	O
39	.	O
1	The	O
2	cwg2	B
3	-	I
4	1	I
5	mutation	I
6	was	O
7	identified	O
8	as	O
9	a	O
10	guanine	O
11	to	O
12	adenine	O
13	substitution	O
14	at	O
15	nucleotide	O
16	604	O
17	of	O
18	the	O
19	coding	O
20	region	O
21	,	O
22	originating	O
23	the	O
24	change	O
25	A202T	O
26	in	O
27	the	O
28	cwg2p	B
29	.	O
1	Analysis	O
2	of	O
3	chromosomal	O
4	DNA	O
5	sequence	O
6	immediately	O
7	downstream	O
8	of	O
9	the	O
10	transposon	O
11	insertion	O
12	identified	O
13	two	O
14	open	O
15	reading	O
16	frames	O
17	,	O
18	designated	O
19	csrR	B
20	and	O
21	csrS	B
22	,	O
23	which	O
24	exhibited	O
25	sequence	O
26	similarity	O
27	to	O
28	bacterial	O
29	two	O
30	-	O
31	component	O
32	regulatory	O
33	systems	O
34	.	O
1	633	O
2	+/-	O
3	258	O
4	aggregates	O
5	/	O
6	ml	O
7	at	O
8	0	O
9	rpm	O
10	;	O
11	P	O
12	<	O
13	0	O
14	.	O
15	001	O
16	).	O
1	Additionally	O
2	in	O
3	seven	O
4	subjects	O
5	adrenaline	O
6	(	O
7	A	O
8	)	O
9	and	O
10	noradrenaline	O
11	(	O
12	NA	O
13	)	O
14	concentrations	O
15	were	O
16	determined	O
17	.	O
1	Inhibition	O
2	of	O
3	the	O
4	apolipoprotein	B
5	B	I
6	mRNA	I
7	editing	O
8	enzyme	O
9	-	O
10	complex	O
11	by	O
12	hnRNP	B
13	C1	I
14	protein	I
15	and	O
16	40S	B
17	hnRNP	I
18	complexes	I
19	.	O
1	However	O
2	the	O
3	sequence	O
4	surrounding	O
5	the	O
6	transcription	O
7	start	O
8	site	O
9	CTCA	O
10	(+	O
11	1	O
12	)	O
13	TTCC	O
14	was	O
15	similar	O
16	to	O
17	the	O
18	consensus	O
19	CTCA	O
20	(+	O
21	1	O
22	)	O
23	NTCT	O
24	(	O
25	N	O
26	is	O
27	any	O
28	nucleoside	O
29	)	O
30	for	O
31	an	O
32	initiator	O
33	element	O
34	found	O
35	in	O
36	terminal	B
37	deoxynucleotidyltransferase	I
38	and	O
39	a	O
40	number	O
41	of	O
42	other	O
43	highly	O
44	regulated	O
45	genes	O
46	.	O
1	Ligand	O
2	binding	O
3	to	O
4	the	O
5	receptor	O
6	complex	O
7	leads	O
8	to	O
9	tyrosine	O
10	phosphorylation	O
11	and	O
12	activation	O
13	of	O
14	Janus	B
15	kinases	I
16	(	O
17	Jak	B
18	),	O
19	phosphorylation	O
20	of	O
21	the	O
22	signal	B
23	transducing	I
24	subunit	I
25	gp130	I
26	,	O
27	followed	O
28	by	O
29	recruitment	O
30	and	O
31	phosphorylation	O
32	of	O
33	the	O
34	signal	B
35	transducer	I
36	and	I
37	activator	I
38	of	I
39	transcription	I
40	factors	I
41	STAT3	I
42	and	O
43	STAT1	B
44	and	O
45	the	O
46	src	B
47	homology	I
48	domain	I
49	(	O
50	SH2	B
51	)-	O
52	containing	O
53	protein	B
54	tyrosine	I
55	phosphatase	I
56	(	O
57	SHP2	B
58	).	O
1	SRF	B
2	-	O
3	deficient	O
4	embryos	O
5	(	O
6	Srf	B
7	-/-)	O
8	have	O
9	a	O
10	severe	O
11	gastrulation	O
12	defect	O
13	and	O
14	do	O
15	not	O
16	develop	O
17	to	O
18	term	O
19	.	O
1	We	O
2	have	O
3	generated	O
4	a	O
5	computer	O
6	model	O
7	of	O
8	the	O
9	C	O
10	-	O
11	terminal	O
12	domain	O
13	of	O
14	the	O
15	434	O
16	repressor	O
17	based	O
18	on	O
19	the	O
20	crystal	O
21	structure	O
22	of	O
23	the	O
24	homologous	B
25	UmuD	I
26	'	I
27	protein	I
28	.	O
1	Large	O
2	-	O
3	scale	O
4	sequencing	O
5	of	O
6	two	O
7	regions	O
8	in	O
9	human	O
10	chromosome	O
11	7q22	O
12	:	O
13	analysis	O
14	of	O
15	650	O
16	kb	O
17	of	O
18	genomic	O
19	sequence	O
20	around	O
21	the	O
22	EPO	B
23	and	O
24	CUTL1	B
25	loci	I
26	reveals	O
27	17	O
28	genes	O
29	.	O
1	Based	O
2	on	O
3	sequence	O
4	homology	O
5	,	O
6	the	O
7	genes	O
8	were	O
9	identified	O
10	as	O
11	TEF	B
12	,	O
13	encoding	O
14	translation	B
15	elongation	I
16	factor	I
17	-	I
18	1	I
19	alpha	I
20	and	O
21	RPS7	B
22	,	O
23	encoding	O
24	ribosomal	O
25	protein	O
26	S7	B
27	.	O
1	Transcription	O
2	factors	O
3	of	O
4	the	O
5	Stat	B
6	family	I
7	are	O
8	controlled	O
9	by	O
10	protein	O
11	kinases	O
12	.	O
1	We	O
2	propose	O
3	that	O
4	two	O
5	pathways	O
6	regulate	O
7	Stat5	B
8	serine	O
9	phosphorylation	O
10	,	O
11	one	O
12	that	O
13	is	O
14	prolactin	B
15	-	O
16	activated	O
17	and	O
18	PD98059	O
19	-	O
20	resistant	O
21	and	O
22	one	O
23	that	O
24	is	O
25	constitutively	O
26	active	O
27	and	O
28	PD98059	O
29	-	O
30	sensitive	O
31	and	O
32	preferentially	O
33	targets	O
34	Stat5a	B
35	.	O
1	This	O
2	association	O
3	was	O
4	independently	O
5	significant	O
6	for	O
7	patients	O
8	treated	O
9	primarily	O
10	(	O
11	not	O
12	for	O
13	recurrence	O
14	).	O
1	An	O
2	open	O
3	reading	O
4	frame	O
5	encoding	O
6	a	O
7	protein	O
8	which	O
9	shows	O
10	significant	O
11	similarity	O
12	to	O
13	invertases	B
14	and	O
15	resolvases	B
16	was	O
17	located	O
18	immediately	O
19	upstream	O
20	of	O
21	the	O
22	Pac25I	B
23	R	I
24	-	I
25	M	I
26	operon	I
27	.	O
1	BACKGROUND	O
2	:	O
3	Studies	O
4	in	O
5	lean	O
6	men	O
7	show	O
8	poor	O
9	regulation	O
10	of	O
11	energy	O
12	(	O
13	EB	O
14	)	O
15	and	O
16	fat	O
17	balance	O
18	(	O
19	FB	O
20	)	O
21	during	O
22	manipulation	O
23	of	O
24	dietary	O
25	ratios	O
26	of	O
27	fat	O
28	to	O
29	carbohydrate	O
30	.	O
1	A	O
2	comparative	O
3	analysis	O
4	of	O
5	the	O
6	reported	O
7	MOCT	O
8	-	O
9	associated	O
10	malignant	O
11	melanomas	O
12	emphasizes	O
13	the	O
14	singularity	O
15	of	O
16	our	O
17	case	O
18	in	O
19	the	O
20	amelanotic	O
21	character	O
22	of	O
23	the	O
24	melanoma	O
25	,	O
26	its	O
27	lymphotropism	O
28	and	O
29	the	O
30	coexistence	O
31	of	O
32	invasive	O
33	squamous	O
34	cell	O
35	carcinoma	O
36	.	O
1	RESULTS	O
2	:	O
3	An	O
4	herpetic	O
5	seroconversion	O
6	is	O
7	observed	O
8	with	O
9	presence	O
10	of	O
11	type	O
12	I	O
13	herpes	O
14	simplex	O
15	virus	O
16	(	O
17	HSV	O
18	I	O
19	)	O
20	nucleic	O
21	acids	O
22	in	O
23	the	O
24	recipient	O
25	'	O
26	s	O
27	aqueous	O
28	humor	O
29	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	HIV	O
6	-	O
7	1	O
8	Gag	B
9	sequences	I
10	can	O
11	influence	O
12	the	O
13	viral	B
14	PR	I
15	-	O
16	mediated	O
17	processing	O
18	of	O
19	the	O
20	MuLV	O
21	TM	B
22	Env	I
23	protein	I
24	p15	O
25	(	O
26	E	O
27	).	O
1	These	O
2	results	O
3	demonstrate	O
4	a	O
5	specific	O
6	association	O
7	of	O
8	SIV	O
9	and	O
10	HIV	B
11	-	I
12	2	I
13	nef	I
14	,	O
15	but	O
16	not	O
17	HIV	B
18	-	I
19	1	I
20	nef	I
21	,	O
22	with	O
23	TCRzeta	B
24	.	O
1	GH	B
2	failed	O
3	to	O
4	stimulate	O
5	phosphorylation	O
6	or	O
7	activation	O
8	of	O
9	Jun	B
10	N	I
11	-	I
12	terminal	I
13	kinase	I
14	under	O
15	the	O
16	conditions	O
17	used	O
18	.	O
1	Expression	O
2	of	O
3	a	O
4	novel	O
5	murine	B
6	phospholipase	I
7	D	I
8	homolog	I
9	coincides	O
10	with	O
11	late	O
12	neuronal	O
13	development	O
14	in	O
15	the	O
16	forebrain	O
17	.	O
1	The	O
2	pharmacokinetic	O
3	parameters	O
4	which	O
5	helped	O
6	predict	O
7	these	O
8	toxicities	O
9	included	O
10	area	O
11	under	O
12	the	O
13	curve	O
14	and	O
15	peak	O
16	plasma	O
17	level	O
18	.	O
1	(	O
2	1992	O
3	)	O
4	Biochemistry	O
5	31	O
6	,	O
7	3351	O
8	-	O
9	3358	O
10	].	O
1	Levels	O
2	of	O
3	serum	O
4	IgE	B
5	were	O
6	measured	O
7	monthly	O
8	,	O
9	and	O
10	nasal	O
11	IgE	B
12	was	O
13	measured	O
14	at	O
15	the	O
16	height	O
17	and	O
18	end	O
19	of	O
20	the	O
21	season	O
22	.	O
1	Cyclophilins	B
2	are	O
3	cis	B
4	-	I
5	trans	I
6	-	I
7	peptidyl	I
8	-	I
9	prolyl	I
10	isomerases	I
11	that	O
12	bind	O
13	to	O
14	and	O
15	are	O
16	inhibited	O
17	by	O
18	the	O
19	immunosuppressant	O
20	cyclosporin	O
21	A	O
22	(	O
23	CsA	O
24	).	O
1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	mechanism	O
7	of	O
8	activation	O
9	of	O
10	HIF	B
11	-	I
12	1alpha	I
13	is	O
14	a	O
15	multi	O
16	-	O
17	step	O
18	process	O
19	which	O
20	includes	O
21	hypoxia	O
22	-	O
23	dependent	O
24	nuclear	O
25	import	O
26	and	O
27	activation	O
28	(	O
29	derepression	O
30	)	O
31	of	O
32	the	O
33	transactivation	O
34	domain	O
35	,	O
36	resulting	O
37	in	O
38	recruitment	O
39	of	O
40	the	O
41	CREB	B
42	-	I
43	binding	I
44	protein	I
45	(	O
46	CBP	B
47	)/	O
48	p300	B
49	coactivator	I
50	.	O
1	A	O
2	synergistic	O
3	effect	O
4	on	O
5	HCK	B
6	promoter	I
7	activity	O
8	was	O
9	observed	O
10	at	O
11	high	O
12	concentrations	O
13	of	O
14	Sp1	B
15	.	O
1	Quinone	O
2	-	O
3	binding	O
4	domain	O
5	and	O
6	amino	O
7	acid	O
8	residues	O
9	involved	O
10	in	O
11	quinone	O
12	binding	O
13	.	O
1	Western	O
2	analyses	O
3	with	O
4	antisera	O
5	raised	O
6	against	O
7	Lu	B
8	-	I
9	ECAM	I
10	-	I
11	1	I
12	peptides	I
13	show	O
14	that	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	predicted	O
23	open	O
24	reading	O
25	frame	O
26	is	O
27	present	O
28	only	O
29	in	O
30	the	O
31	larger	O
32	size	O
33	proteins	O
34	(	O
35	i	O
36	.	O
37	e	O
38	.	O
1	Mammalian	O
2	sperm	O
3	motility	O
4	is	O
5	regulated	O
6	by	O
7	a	O
8	cascade	O
9	of	O
10	cAMP	O
11	-	O
12	dependent	O
13	protein	O
14	phosphorylation	O
15	events	O
16	mediated	O
17	by	O
18	protein	B
19	kinase	I
20	A	I
21	.	O
1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	show	O
7	that	O
8	,	O
9	like	O
10	BAP2	B
11	,	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	BAP3	B
17	gene	I
18	in	O
19	S	O
20	.	O
21	cerevisiae	O
22	is	O
23	induced	O
24	by	O
25	the	O
26	addition	O
27	of	O
28	branched	O
29	-	O
30	chain	O
31	amino	O
32	acids	O
33	to	O
34	the	O
35	medium	O
36	.	O
1	Partial	O
2	characterization	O
3	of	O
4	the	O
5	active	O
6	site	O
7	human	B
8	platelet	I
9	cAMP	I
10	phosphodiesterase	I
11	,	O
12	PDE3A	B
13	,	O
14	by	O
15	site	O
16	-	O
17	directed	O
18	mutagenesis	O
19	.	O
1	Over	O
2	-	O
3	expression	O
4	of	O
5	the	O
6	cofactor	O
7	p300	B
8	,	O
9	which	O
10	functions	O
11	as	O
12	a	O
13	coactivator	O
14	of	O
15	myoD	B
16	-	O
17	mediated	O
18	transcription	O
19	,	O
20	alleviated	O
21	repression	O
22	by	O
23	COUP	B
24	-	I
25	TF	I
26	II	I
27	.	O
1	Expression	O
2	of	O
3	lacZ	B
4	from	O
5	the	O
6	promoter	O
7	of	O
8	the	O
9	Escherichia	B
10	coli	I
11	spc	I
12	operon	I
13	cloned	O
14	into	O
15	vectors	O
16	carrying	O
17	the	O
18	W205	O
19	trp	B
20	-	O
21	lac	B
22	fusion	O
23	.	O
1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	rat	B
12	placental	I
13	prolactin	I
14	(	O
15	PRL	B
16	)	O
17	family	O
18	,	O
19	PRL	B
20	-	O
21	like	O
22	protein	B
23	H	I
24	.	O
1	Interestingly	O
2	,	O
3	we	O
4	find	O
5	that	O
6	the	O
7	interaction	O
8	between	O
9	Tat	B
10	and	O
11	hCycT1	B
12	requires	O
13	zinc	O
14	as	O
15	well	O
16	as	O
17	essential	O
18	cysteine	O
19	residues	O
20	in	O
21	both	O
22	proteins	O
23	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	,	O
6	for	O
7	a	O
8	constant	O
9	amount	O
10	of	O
11	transfected	O
12	DNA	O
13	,	O
14	the	O
15	level	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	(	O
20	CAT	B
21	)	O
22	mRNA	O
23	is	O
24	increased	O
25	in	O
26	Vpr	B
27	-	O
28	expressing	O
29	cells	O
30	using	O
31	either	O
32	HIV	O
33	-	O
34	1	O
35	or	O
36	a	O
37	murine	O
38	leukemia	B
39	virus	I
40	(	I
41	MLV	I
42	)	I
43	SL3	I
44	-	I
45	3	I
46	LTR	I
47	-	O
48	CAT	B
49	reporter	O
50	construct	O
51	.	O
1	We	O
2	identified	O
3	telSMN	B
4	mutations	O
5	in	O
6	11	O
7	of	O
8	these	O
9	unrelated	O
10	SMA	O
11	-	O
12	like	O
13	individuals	O
14	who	O
15	carry	O
16	a	O
17	single	O
18	copy	O
19	of	O
20	telSMN	B
21	:	O
22	these	O
23	include	O
24	two	O
25	frameshift	O
26	mutations	O
27	(	O
28	800ins11	O
29	and	O
30	542delGT	O
31	)	O
32	and	O
33	three	O
34	missense	O
35	mutations	O
36	(	O
37	A2G	O
38	,	O
39	S262I	O
40	,	O
41	and	O
42	T274I	O
43	).	O
1	Here	O
2	we	O
3	have	O
4	investigated	O
5	the	O
6	structural	O
7	requirements	O
8	and	O
9	consequences	O
10	of	O
11	regulatory	O
12	phosphorylation	O
13	for	O
14	the	O
15	interaction	O
16	between	O
17	c	B
18	-	I
19	Jun	I
20	and	O
21	JNK	B
22	in	O
23	vivo	O
24	.	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	human	B
7	cyclin	I
8	,	O
9	cyclin	B
10	E2	I
11	,	O
12	that	O
13	contains	O
14	significant	O
15	homology	O
16	to	O
17	cyclin	B
18	E	I
19	.	O
1	The	O
2	dopamine	B
3	D4	I
4	receptor	I
5	as	O
6	well	O
7	as	O
8	many	O
9	other	O
10	catecholaminergic	B
11	receptors	I
12	contain	O
13	several	O
14	putative	O
15	SH3	B
16	binding	I
17	domains	I
18	.	O
1	The	O
2	US	O
3	National	O
4	Institute	O
5	on	O
6	Alcohol	O
7	Abuse	O
8	and	O
9	Alcoholism	O
10	(	O
11	NIAAA	O
12	)	O
13	recognizes	O
14	two	O
15	forms	O
16	of	O
17	problematic	O
18	drinking	O
19	:	O
20	'	O
21	willful	O
22	alcohol	O
23	abuse	O
24	',	O
25	a	O
26	behavioural	O
27	problem	O
28	,	O
29	and	O
30	'	O
31	alcohol	O
32	dependence	O
33	',	O
34	a	O
35	true	O
36	medical	O
37	disorder	O
38	,	O
39	which	O
40	includes	O
41	a	O
42	genetic	O
43	component	O
44	,	O
45	that	O
46	can	O
47	be	O
48	scientifically	O
49	understood	O
50	and	O
51	medically	O
52	treated	O
53	.	O
1	Jembrana	O
2	disease	O
3	virus	O
4	(	O
5	JDV	O
6	)	O
7	is	O
8	a	O
9	newly	O
10	identified	O
11	bovine	O
12	lentivirus	O
13	that	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	bovine	O
20	immunodeficiency	O
21	virus	O
22	(	O
23	BIV	O
24	).	O
1	Nhp2p	B
2	is	O
3	a	O
4	highly	O
5	basic	O
6	protein	O
7	that	O
8	belongs	O
9	to	O
10	a	O
11	family	O
12	of	O
13	putative	O
14	RNA	O
15	-	O
16	binding	O
17	proteins	O
18	.	O
1	Down	O
2	-	O
3	regulation	O
4	of	O
5	IRS	B
6	-	I
7	1	I
8	is	O
9	linked	O
10	to	O
11	its	O
12	serine	O
13	phosphorylation	O
14	dependent	O
15	on	O
16	PI	B
17	3	I
18	-	I
19	kinase	I
20	activity	O
21	and	O
22	appears	O
23	required	O
24	for	O
25	differentiation	O
26	to	O
27	occur	O
28	,	O
29	as	O
30	IRS	B
31	-	I
32	1	I
33	is	O
34	not	O
35	modified	O
36	and	O
37	continues	O
38	to	O
39	accumulate	O
40	in	O
41	a	O
42	nondifferentiating	O
43	myoblast	O
44	cell	O
45	line	O
46	.	O
1	However	O
2	,	O
3	no	O
4	studies	O
5	have	O
6	been	O
7	conducted	O
8	to	O
9	further	O
10	investigate	O
11	this	O
12	potentially	O
13	hazardous	O
14	effect	O
15	of	O
16	lidocaine	O
17	.	O
1	Both	O
2	NUP98	B
3	-	O
4	HOXA9	B
5	chimeras	O
6	transformed	O
7	NIH	O
8	3T3	O
9	fibroblasts	O
10	,	O
11	and	O
12	this	O
13	transformation	O
14	required	O
15	the	O
16	HOXA9	B
17	domains	I
18	for	O
19	DNA	O
20	binding	O
21	and	O
22	PBX	B
23	interaction	O
24	.	O
1	BIAcore	O
2	analysis	O
3	gave	O
4	a	O
5	Kaff	O
6	of	O
7	4	O
8	.	O
9	4	O
10	x	O
11	10	O
12	(	O
13	10	O
14	)	O
15	M	O
16	-	O
17	1	O
18	for	O
19	the	O
20	binding	O
21	of	O
22	N	B
23	-	I
24	A3	I
25	to	O
26	T84	B
27	.	I
28	1	I
29	and	O
30	2	O
31	.	O
32	2	O
33	x	O
34	10	O
35	(	O
36	10	O
37	)	O
38	M	O
39	-	O
40	1	O
41	for	O
42	the	O
43	binding	O
44	of	O
45	N	B
46	-	I
47	A3	I
48	to	O
49	T84	B
50	.	I
51	66	I
52	.	O
1	The	O
2	Og4C3	B
3	enzyme	O
4	-	O
5	linked	O
6	immunosorbent	O
7	assay	O
8	(	O
9	ELISA	O
10	)	O
11	to	O
12	detect	O
13	circulating	O
14	Wuchereria	B
15	bancrofti	I
16	antigen	I
17	uses	O
18	50	O
19	microL	O
20	of	O
21	serum	O
22	.	O
1	We	O
2	now	O
3	show	O
4	that	O
5	gp200	B
6	-	O
7	MR6	B
8	ligation	O
9	can	O
10	also	O
11	mimic	O
12	IL	B
13	-	I
14	4	I
15	and	O
16	have	O
17	an	O
18	anti	O
19	-	O
20	proliferative	O
21	pro	O
22	-	O
23	maturational	O
24	influence	O
25	within	O
26	the	O
27	immune	O
28	system	O
29	,	O
30	causing	O
31	up	O
32	-	O
33	regulation	O
34	of	O
35	co	O
36	-	O
37	stimulatory	O
38	molecules	O
39	on	O
40	B	O
41	lymphocytes	O
42	.	O
1	The	O
2	Mig1	B
3	repressor	I
4	is	O
5	a	O
6	zinc	B
7	finger	I
8	protein	I
9	that	O
10	mediates	O
11	glucose	O
12	repression	O
13	in	O
14	yeast	O
15	.	O
1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	the	O
9	FCR1	B
10	gene	I
11	behaves	O
12	as	O
13	a	O
14	negative	O
15	regulator	O
16	of	O
17	drug	O
18	resistance	O
19	in	O
20	C	O
21	.	O
22	albicans	O
23	and	O
24	constitute	O
25	the	O
26	first	O
27	evidence	O
28	that	O
29	FCZ	O
30	resistance	O
31	can	O
32	result	O
33	from	O
34	the	O
35	inactivation	O
36	of	O
37	a	O
38	regulatory	O
39	factor	O
40	such	O
41	as	O
42	Fcr1p	B
43	.	O
1	CONCLUSION	O
2	:	O
3	Our	O
4	study	O
5	shows	O
6	that	O
7	(	O
8	1	O
9	)	O
10	total	O
11	body	O
12	BMD	O
13	and	O
14	femoral	O
15	neck	O
16	BMD	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	study	O
23	group	O
24	that	O
25	performed	O
26	weight	O
27	-	O
28	bearing	O
29	exercises	O
30	than	O
31	in	O
32	control	O
33	subjects	O
34	,	O
35	(	O
36	2	O
37	)	O
38	swimming	O
39	exercise	O
40	had	O
41	no	O
42	effect	O
43	on	O
44	BMD	O
45	,	O
46	and	O
47	(	O
48	3	O
49	)	O
50	although	O
51	swimming	O
52	is	O
53	not	O
54	a	O
55	bone	O
56	-	O
57	building	O
58	exercise	O
59	,	O
60	it	O
61	can	O
62	significantly	O
63	improve	O
64	shoulder	O
65	,	O
66	back	O
67	,	O
68	and	O
69	grip	O
70	muscle	O
71	strength	O
72	.	O
1	This	O
2	suggests	O
3	roles	O
4	for	O
5	both	O
6	the	O
7	CE1	O
8	and	O
9	CE2	O
10	elements	O
11	in	O
12	regulating	O
13	Hoxb1	B
14	gene	I
15	expression	O
16	during	O
17	development	O
18	.	O
1	CAL	O
2	gain	O
3	amounted	O
4	to	O
5	4	O
6	.	O
7	2	O
8	+/-	O
9	1	O
10	.	O
11	3	O
12	mm	O
13	,	O
14	60	O
15	%	O
16	of	O
17	the	O
18	defects	O
19	showing	O
20	CAL	O
21	gain	O
22	>	O
23	or	O
24	=	O
25	4	O
26	mm	O
27	.	O
1	Lead	O
2	fixation	O
3	in	O
4	dogs	O
5	achieved	O
6	with	O
7	RF	O
8	energy	O
9	.	O
1	However	O
2	,	O
3	there	O
4	has	O
5	not	O
6	been	O
7	any	O
8	evidence	O
9	of	O
10	A	O
11	.	O
12	salmonicida	O
13	infections	O
14	,	O
15	specifically	O
16	furunculosis	O
17	,	O
18	associated	O
19	with	O
20	the	O
21	fish	O
22	in	O
23	this	O
24	loch	O
25	.	O
1	Phosphorylation	O
2	analyses	O
3	indicated	O
4	that	O
5	inhibition	O
6	of	O
7	ERK	B
8	-	I
9	1	I
10	/	I
11	2	I
12	decreased	O
13	okadaic	O
14	acid	O
15	-	O
16	elevated	O
17	phosphorylation	O
18	of	O
19	JunD	B
20	and	O
21	FosB	B
22	.	O
1	The	O
2	peroxisome	O
3	biogenesis	O
4	disorders	O
5	(	O
6	PBDs	O
7	)	O
8	are	O
9	a	O
10	set	O
11	of	O
12	lethal	O
13	genetic	O
14	diseases	O
15	characterized	O
16	by	O
17	peroxisomal	O
18	metabolic	O
19	deficiencies	O
20	,	O
21	multisystem	O
22	abnormalities	O
23	,	O
24	mental	O
25	retardation	O
26	,	O
27	and	O
28	premature	O
29	death	O
30	.	O
1	The	O
2	data	O
3	indicate	O
4	that	O
5	Bmp2	B
6	is	O
7	directly	O
8	regulated	O
9	by	O
10	retinoic	O
11	acid	O
12	-	O
13	bound	O
14	receptors	O
15	and	O
16	Sp1	B
17	.	O
1	A	O
2	motif	O
3	(	O
4	TGATGTCA	O
5	)	O
6	which	O
7	matches	O
8	a	O
9	CREB	B
10	site	I
11	and	O
12	is	O
13	similar	O
14	to	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	site	I
20	is	O
21	embedded	O
22	within	O
23	ER2	B
24	.	O
1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	-	I
6	encoded	I
7	latent	I
8	membrane	I
9	protein	I
10	1	I
11	activates	O
12	the	O
13	JNK	B
14	pathway	O
15	through	O
16	its	O
17	extreme	O
18	C	O
19	terminus	O
20	via	O
21	a	O
22	mechanism	O
23	involving	O
24	TRADD	B
25	and	O
26	TRAF2	B
27	.	O
1	However	O
2	,	O
3	serial	O
4	passages	O
5	of	O
6	fetal	O
7	lamb	O
8	kidney	O
9	(	O
10	FLK	O
11	)	O
12	cells	O
13	,	O
14	which	O
15	are	O
16	sensitive	O
17	to	O
18	infection	O
19	with	O
20	BLV	O
21	,	O
22	after	O
23	transient	O
24	transfection	O
25	revealed	O
26	that	O
27	mutation	O
28	of	O
29	a	O
30	second	O
31	tyrosine	O
32	residue	O
33	in	O
34	the	O
35	N	O
36	-	O
37	terminal	O
38	motif	O
39	completely	O
40	prevented	O
41	the	O
42	propagation	O
43	of	O
44	the	O
45	virus	O
46	.	O
1	These	O
2	genes	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	Saccharomyces	O
8	cerevisiae	O
9	mutant	O
10	in	O
11	which	O
12	the	O
13	endogenous	B
14	ferrochelatase	I
15	gene	I
16	(	O
17	HEM15	B
18	)	O
19	had	O
20	been	O
21	deleted	O
22	,	O
23	and	O
24	the	O
25	phenotypes	O
26	of	O
27	the	O
28	transformants	O
29	were	O
30	characterized	O
31	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	evidence	O
6	is	O
7	presented	O
8	that	O
9	temporally	O
10	and	O
11	spatially	O
12	specific	O
13	mef2	B
14	expression	O
15	is	O
16	controlled	O
17	by	O
18	a	O
19	complex	O
20	array	O
21	of	O
22	cis	O
23	-	O
24	acting	O
25	regulatory	O
26	modules	O
27	that	O
28	are	O
29	responsive	O
30	to	O
31	different	O
32	genetic	O
33	signals	O
34	.	O
1	Folded	O
2	tissue	O
3	and	O
4	crimped	O
5	collagen	B
6	fibers	O
7	in	O
8	the	O
9	tunica	O
10	albuginea	O
11	permit	O
12	its	O
13	expansion	O
14	during	O
15	erection	O
16	.	O
1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	attP	B
7	,	O
8	attB	B
9	and	O
10	bacteria	O
11	-	O
12	prophage	O
13	junctions	O
14	attL	B
15	and	O
16	attR	B
17	showed	O
18	a	O
19	26	O
20	bp	O
21	common	O
22	core	O
23	sequence	O
24	,	O
25	where	O
26	recombination	O
27	takes	O
28	place	O
29	,	O
30	near	O
31	the	O
32	5	O
33	'	O
34	end	O
35	of	O
36	the	O
37	integrase	B
38	gene	I
39	.	O
1	BACKGROUND	O
2	:	O
3	Diazepam	O
4	,	O
5	one	O
6	of	O
7	the	O
8	benzodiazepine	O
9	group	O
10	of	O
11	tranquilizers	O
12	,	O
13	is	O
14	used	O
15	as	O
16	an	O
17	adjunctive	O
18	drug	O
19	for	O
20	sedation	O
21	and	O
22	for	O
23	relief	O
24	of	O
25	anxiety	O
26	in	O
27	the	O
28	treatment	O
29	of	O
30	epilepsy	O
31	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	glycolate	I
6	oxidase	I
7	.	O
1	In	O
2	such	O
3	a	O
4	manner	O
5	,	O
6	activated	O
7	PKR	B
8	inhibits	O
9	cell	O
10	growth	O
11	and	O
12	induces	O
13	apoptosis	O
14	,	O
15	whereas	O
16	disruption	O
17	of	O
18	normal	O
19	PKR	B
20	signaling	O
21	results	O
22	in	O
23	unregulated	O
24	cell	O
25	growth	O
26	.	O
1	Five	O
2	different	O
3	subtypes	O
4	of	O
5	spondyloarthropathy	O
6	(	O
7	SpA	O
8	)	O
9	are	O
10	now	O
11	recognized	O
12	.	O
1	The	O
2	perifascicular	O
3	connective	O
4	tissue	O
5	sheath	O
6	is	O
7	important	O
8	in	O
9	organising	O
10	the	O
11	contraction	O
12	of	O
13	the	O
14	myocardium	O
15	by	O
16	preventing	O
17	lateral	O
18	spread	O
19	of	O
20	conduction	O
21	and	O
22	by	O
23	permitting	O
24	transmission	O
25	of	O
26	the	O
27	impulse	O
28	only	O
29	at	O
30	the	O
31	termination	O
32	of	O
33	the	O
34	purkinje	O
35	fibre	O
36	.	O
1	Here	O
2	we	O
3	describe	O
4	a	O
5	mutant	O
6	alpha	O
7	subunit	O
8	designed	O
9	to	O
10	inhibit	O
11	receptor	O
12	-	O
13	mediated	O
14	hormonal	O
15	activation	O
16	of	O
17	Gs	B
18	,	O
19	the	O
20	stimulatory	O
21	regulator	O
22	of	O
23	adenylyl	B
24	cyclase	I
25	.	O
1	Soft	O
2	-	O
3	x	O
4	-	O
5	ray	O
6	lasing	O
7	at	O
8	32	O
9	.	O
10	6	O
11	nm	O
12	in	O
13	Ne	O
14	-	O
15	like	O
16	Ti	O
17	ions	O
18	driven	O
19	by	O
20	40	O
21	J	O
22	of	O
23	energy	O
24	from	O
25	two	O
26	650	O
27	-	O
28	ps	O
29	laser	O
30	pulses	O
31	.	O
1	This	O
2	region	O
3	of	O
4	hsp90	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	chaperone	O
10	activity	O
11	,	O
12	overlaps	O
13	the	O
14	hsp90	B
15	dimerization	I
16	domain	I
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	B
25	receptor	I
26	interaction	O
27	.	O
1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	O
6	pgp2	B
7	/	O
8	mdr1b	B
9	gene	O
10	has	O
11	a	O
12	GC	O
13	-	O
14	rich	O
15	region	O
16	(	O
17	pgp2GC	B
18	)	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	in	O
24	mdr	B
25	genes	I
26	and	O
27	contains	O
28	an	O
29	consensus	O
30	Sp1	B
31	site	I
32	.	O
1	Transcription	O
2	readthrough	O
3	into	O
4	the	O
5	inverted	O
6	repeats	O
7	has	O
8	little	O
9	effect	O
10	on	O
11	this	O
12	event	O
13	.	O
1	All	O
2	stimulations	O
3	were	O
4	down	O
5	-	O
6	regulated	O
7	with	O
8	GnRH	B
9	-	I
10	a	I
11	commenced	O
12	on	O
13	day	O
14	21	O
15	in	O
16	a	O
17	long	O
18	protocol	O
19	before	O
20	gonadotropin	B
21	stimulation	O
22	.	O
1	Chem	O
2	.	O
1	We	O
2	used	O
3	expression	O
4	cloning	O
5	to	O
6	identify	O
7	interleukin	B
8	-	I
9	6	I
10	(	O
11	IL	B
12	-	I
13	6	I
14	)	O
15	as	O
16	one	O
17	factor	O
18	that	O
19	suppressed	O
20	growth	O
21	of	O
22	a	O
23	pre	O
24	-	O
25	B	O
26	-	O
27	cell	O
28	variant	O
29	line	O
30	,	O
31	1A9	O
32	-	O
33	M	O
34	.	O
1	The	O
2	odds	O
3	ratio	O
4	for	O
5	CHD	O
6	was	O
7	1	O
8	.	O
9	21	O
10	(	O
11	95	O
12	%	O
13	confidence	O
14	interval	O
15	,	O
16	0	O
17	.	O
18	84	O
19	-	O
20	1	O
21	.	O
22	75	O
23	)	O
24	given	O
25	a	O
26	positive	O
27	serostatus	O
28	of	O
29	specific	O
30	IgG	B
31	antibodies	O
32	after	O
33	adjustment	O
34	for	O
35	covariates	O
36	.	O
1	Another	O
2	group	O
3	of	O
4	HIPP	O
5	-	O
6	and	O
7	HCX	O
8	-	O
9	lesioned	O
10	animals	O
11	trained	O
12	on	O
13	the	O
14	tasks	O
15	after	O
16	the	O
17	lesion	O
18	showed	O
19	reduced	O
20	impairments	O
21	of	O
22	the	O
23	type	O
24	described	O
25	above	O
26	,	O
27	suggesting	O
28	that	O
29	extrahippocampal	O
30	structures	O
31	trained	O
32	after	O
33	the	O
34	lesion	O
35	can	O
36	assume	O
37	the	O
38	role	O
39	of	O
40	the	O
41	hippocampus	O
42	to	O
43	some	O
44	degree	O
45	.	O
1	Mutations	O
2	affecting	O
3	only	O
4	CD4	B
5	regulation	O
6	mapped	O
7	to	O
8	residues	O
9	previously	O
10	shown	O
11	to	O
12	mediate	O
13	the	O
14	binding	O
15	of	O
16	Nef	B
17	to	O
18	this	O
19	receptor	O
20	,	O
21	such	O
22	as	O
23	W57	O
24	and	O
25	L58	O
26	,	O
27	as	O
28	well	O
29	as	O
30	to	O
31	an	O
32	AP	B
33	-	I
34	recruiting	I
35	dileucine	I
36	motif	I
37	and	O
38	to	O
39	an	O
40	acidic	O
41	dipeptide	O
42	in	O
43	the	O
44	C	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	the	O
50	protein	O
51	.	O
1	Several	O
2	mutations	O
3	disrupted	O
4	the	O
5	endonuclease	O
6	and	O
7	helicase	B
8	activities	O
9	;	O
10	however	O
11	,	O
12	only	O
13	one	O
14	amino	B
15	-	I
16	terminal	I
17	-	I
18	charge	I
19	cluster	I
20	mutant	I
21	protein	I
22	(	O
23	D40A	O
24	-	O
25	D42A	O
26	-	O
27	D44A	O
28	)	O
29	completely	O
30	lost	O
31	AAV	O
32	hairpin	O
33	DNA	O
34	binding	O
35	activity	O
36	.	O
1	Crossover	O
2	in	O
3	the	O
4	specific	O
5	heat	O
6	of	O
7	dilute	O
8	magnets	O
9	induced	O
10	by	O
11	critical	O
12	spin	O
13	-	O
14	wave	O
15	dynamics	O
16	.	O
1	Interplane	O
2	coupling	O
3	in	O
4	the	O
5	superconductor	O
6	Y2Ba4Cu7O15	O
7	as	O
8	revealed	O
9	by	O
10	NQR	O
11	spin	O
12	-	O
13	echo	O
14	double	O
15	resonance	O
16	.	O
1	Electronic	O
2	structure	O
3	of	O
4	a	O
5	buried	O
6	NiSi2	O
7	or	O
8	CoSi2	O
9	layer	O
10	in	O
11	bulk	O
12	Si	O
13	.	O
1	However	O
2	,	O
3	deletions	O
4	of	O
5	the	O
6	C	O
7	terminal	O
8	11	O
9	or	O
10	14	O
11	amino	O
12	acids	O
13	had	O
14	more	O
15	substantial	O
16	effects	O
17	.	O
1	Quantum	O
2	-	O
3	statistical	O
4	theory	O
5	of	O
6	high	O
7	-	O
8	field	O
9	transport	O
10	phenomena	O
11	.	O
1	Testing	O
2	gravity	O
3	to	O
4	second	O
5	post	O
6	-	O
7	Newtonian	O
8	order	O
9	:	O
10	A	O
11	field	O
12	-	O
13	theory	O
14	approach	O
15	.	O
1	Genetic	O
2	experiments	O
3	using	O
4	mutants	O
5	defective	O
6	in	O
7	apontic	B
8	and	O
9	bruno	B
10	reveal	O
11	a	O
12	functional	O
13	interaction	O
14	between	O
15	these	O
16	genes	O
17	.	O
1	Elimination	O
2	of	O
3	ETH1	B
4	in	O
5	apn1	B
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O
1	The	O
2	Nmd3	B
3	protein	I
4	sequence	I
5	does	O
6	not	O
7	contain	O
8	readily	O
9	recognizable	O
10	motifs	O
11	of	O
12	known	O
13	function	O
14	.	O
1	Calcitonin	B
2	simultaneously	O
3	regulates	O
4	both	O
5	periosteal	O
6	hyperostosis	O
7	and	O
8	trabecular	O
9	osteopenia	O
10	in	O
11	the	O
12	spinal	O
13	hyperostotic	O
14	mouse	O
15	(	O
16	twy	B
17	/	O
18	twy	B
19	)	O
20	in	O
21	vivo	O
22	.	O
1	Electrophoretic	O
2	mobility	O
3	-	O
4	shift	O
5	assays	O
6	performed	O
7	with	O
8	the	O
9	HNF	B
10	-	I
11	3	I
12	X	O
13	and	O
14	Y	O
15	sites	O
16	demonstrated	O
17	that	O
18	both	O
19	sites	O
20	are	O
21	capable	O
22	of	O
23	binding	O
24	HNF	B
25	-	I
26	3alpha	I
27	and	O
28	HNF	B
29	-	I
30	3beta	I
31	.	O
1	Proteins	O
2	known	O
3	to	O
4	bind	O
5	the	O
6	PEPCK	B
7	CRE	O
8	include	O
9	the	O
10	CRE	B
11	-	I
12	binding	I
13	protein	I
14	(	O
15	CREB	B
16	)	O
17	and	O
18	members	O
19	of	O
20	the	O
21	CCAAT	B
22	/	I
23	enhancer	I
24	-	I
25	binding	I
26	protein	I
27	(	O
28	C	B
29	/	I
30	EBP	I
31	)	O
32	family	O
33	.	O
1	In	O
2	addition	O
3	,	O
4	in	O
5	vitro	O
6	mutagenesis	O
7	of	O
8	both	O
9	Engrailed	B
10	and	O
11	Pbx1	B
12	sites	I
13	indicated	O
14	that	O
15	other	O
16	unidentified	O
17	sites	O
18	are	O
19	responsible	O
20	for	O
21	the	O
22	transcriptional	O
23	enhancement	O
24	observed	O
25	with	O
26	the	O
27	intronic	O
28	fragment	O
29	.	O
1	Systematic	O
2	functional	O
3	analysis	O
4	of	O
5	V1a	B
6	/	I
7	V2	I
8	hybrid	I
9	receptors	I
10	showed	O
11	that	O
12	the	O
13	second	O
14	intracellular	O
15	loop	O
16	of	O
17	the	O
18	V1a	B
19	receptor	I
20	is	O
21	required	O
22	and	O
23	sufficient	O
24	for	O
25	efficient	O
26	coupling	O
27	to	O
28	Gq	B
29	/	I
30	11	I
31	,	O
32	whereas	O
33	the	O
34	third	O
35	intracellular	O
36	loop	O
37	of	O
38	the	O
39	V2	B
40	receptor	I
41	is	O
42	required	O
43	and	O
44	sufficient	O
45	for	O
46	coupling	O
47	to	O
48	Gs	B
49	.	O
1	Magnetic	O
2	trapping	O
3	of	O
4	spin	O
5	-	O
6	polarized	O
7	atomic	O
8	hydrogen	O
9	.	O
1	In	O
2	the	O
3	brain	O
4	,	O
5	muscarinic	B
6	receptors	I
7	mediate	O
8	motor	O
9	and	O
10	memory	O
11	function	O
12	by	O
13	interaction	O
14	with	O
15	their	O
16	ligand	O
17	acetylcholine	O
18	.	O
1	Early	O
2	-	O
3	onset	O
4	scleral	O
5	necrosis	O
6	after	O
7	iodine	O
8	I	O
9	125	O
10	plaque	O
11	radiotherapy	O
12	for	O
13	ciliochoroidal	O
14	melanoma	O
15	.	O
1	Vacuum	O
2	Rabi	O
3	splitting	O
4	as	O
5	a	O
6	feature	O
7	of	O
8	linear	O
9	-	O
10	dispersion	O
11	theory	O
12	:	O
13	Analysis	O
14	and	O
15	experimental	O
16	observations	O
17	.	O
1	High	O
2	-	O
3	pressure	O
4	effects	O
5	on	O
6	ultrafast	O
7	-	O
8	relaxation	O
9	kinetics	O
10	of	O
11	excitons	O
12	in	O
13	polydiacetylene	O
14	4BCMU	O
15	.	O
1	Recombinant	O
2	unr	B
3	acts	O
4	synergistically	O
5	with	O
6	recombinant	O
7	PTB	B
8	to	O
9	stimulate	O
10	translation	O
11	dependent	O
12	on	O
13	the	O
14	rhinovirus	O
15	IRES	O
16	.	O
1	Identification	O
2	of	O
3	RNase	B
4	T	I
5	as	O
6	a	O
7	high	O
8	-	O
9	copy	O
10	suppressor	O
11	of	O
12	the	O
13	UV	O
14	sensitivity	O
15	associated	O
16	with	O
17	single	B
18	-	I
19	strand	I
20	DNA	I
21	exonuclease	I
22	deficiency	O
23	in	O
24	Escherichia	O
25	coli	O
26	.	O
1	CPDs	O
2	at	O
3	these	O
4	three	O
5	sites	O
6	may	O
7	partially	O
8	displace	O
9	TFIIIA	B
10	,	O
11	thereby	O
12	enabling	O
13	rapid	O
14	repair	O
15	.	O
1	Cyclin	B
2	D1	I
3	-	I
4	associated	I
5	kinase	I
6	activity	O
7	and	O
8	protein	O
9	levels	O
10	were	O
11	increased	O
12	in	O
13	mammary	O
14	tumors	O
15	from	O
16	murine	O
17	mammary	O
18	tumor	O
19	virus	O
20	-	O
21	pp60	B
22	(	O
23	c	B
24	-	I
25	src527F	I
26	)	O
27	transgenic	O
28	mice	O
29	.	O
1	Independent	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	cassette	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O
1	In	O
2	addition	O
3	,	O
4	mapping	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	and	O
10	the	O
11	identification	O
12	of	O
13	putative	O
14	promoter	O
15	regulatory	O
16	sequences	O
17	should	O
18	give	O
19	insight	O
20	into	O
21	the	O
22	transcriptional	O
23	regulation	O
24	of	O
25	UCP2	B
26	expression	O
27	--	O
28	in	O
29	particular	O
30	by	O
31	anyone	O
32	of	O
33	the	O
34	above	O
35	mentioned	O
36	factors	O
37	--	O
38	in	O
39	vitro	O
40	and	O
41	in	O
42	vivo	O
43	.	O
1	The	O
2	rate	O
3	of	O
4	resectability	O
5	is	O
6	low	O
7	and	O
8	5	O
9	-	O
10	year	O
11	survival	O
12	is	O
13	very	O
14	poor	O
15	.	O
1	In	O
2	order	O
3	to	O
4	better	O
5	characterize	O
6	the	O
7	distribution	O
8	of	O
9	ML	O
10	and	O
11	MAP	O
12	estimates	O
13	under	O
14	these	O
15	conditions	O
16	,	O
17	we	O
18	derive	O
19	a	O
20	point	O
21	approximation	O
22	to	O
23	density	O
24	values	O
25	of	O
26	the	O
27	conditional	O
28	distribution	O
29	of	O
30	such	O
31	estimates	O
32	.	O
1	Nevertheless	O
2	,	O
3	inactivation	O
4	of	O
5	the	O
6	cyclin	B
7	E	I
8	-	O
9	Cdk2	B
10	complex	O
11	in	O
12	response	O
13	to	O
14	mitogen	O
15	starvation	O
16	occurs	O
17	normally	O
18	in	O
19	MEFs	O
20	that	O
21	have	O
22	a	O
23	homozygous	O
24	deletion	O
25	of	O
26	the	O
27	p27	B
28	gene	I
29	.	O
1	Functional	O
2	domains	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	promoter	I
8	binding	I
9	protein	I
10	1	I
11	involved	O
12	in	O
13	transcriptional	O
14	repression	O
15	and	O
16	cell	O
17	growth	O
18	regulation	O
19	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	ATF	B
6	-	I
7	2	I
8	plays	O
9	a	O
10	central	O
11	role	O
12	in	O
13	TGF	B
14	-	I
15	beta	I
16	signaling	O
17	by	O
18	acting	O
19	as	O
20	a	O
21	common	O
22	nuclear	O
23	target	O
24	of	O
25	both	O
26	Smad	B
27	and	O
28	TAK1	B
29	pathways	O
30	.	O
1	The	O
2	following	O
3	data	O
4	were	O
5	recorded	O
6	at	O
7	arrival	O
8	in	O
9	the	O
10	intensive	O
11	care	O
12	unit	O
13	6	O
14	,	O
15	12	O
16	,	O
17	24	O
18	,	O
19	and	O
20	48	O
21	hours	O
22	after	O
23	termination	O
24	of	O
25	CPB	O
26	:	O
27	heart	O
28	rate	O
29	,	O
30	blood	O
31	pressure	O
32	,	O
33	left	O
34	atrial	O
35	pressure	O
36	,	O
37	central	O
38	-	O
39	peripheral	O
40	temperature	O
41	difference	O
42	,	O
43	arterial	O
44	-	O
45	central	O
46	venous	O
47	oxygen	O
48	saturation	O
49	difference	O
50	,	O
51	urine	O
52	output	O
53	,	O
54	serum	O
55	creatinine	O
56	,	O
57	lactate	O
58	and	O
59	neutrophil	B
60	elastase	I
61	levels	O
62	,	O
63	the	O
64	Doppler	O
65	echocardiographic	O
66	factors	O
67	shortening	O
68	fraction	O
69	and	O
70	preejection	O
71	period	O
72	/	O
73	left	O
74	-	O
75	ventricular	O
76	ejection	O
77	time	O
78	,	O
79	and	O
80	cumulative	O
81	doses	O
82	of	O
83	catecholamines	O
84	(	O
85	epinephrine	O
86	),	O
87	enoximone	O
88	,	O
89	and	O
90	furosemide	O
91	.	O
1	The	O
2	JTc	O
3	delta	O
4	among	O
5	the	O
6	three	O
7	groups	O
8	did	O
9	not	O
10	differ	O
11	as	O
12	well	O
13	:	O
14	JTc	O
15	delta	O
16	of	O
17	the	O
18	VT	O
19	group	O
20	was	O
21	70	O
22	ms	O
23	+/-	O
24	30	O
25	ms	O
26	,	O
27	the	O
28	JTc	O
29	delta	O
30	of	O
31	the	O
32	PVC	O
33	group	O
34	was	O
35	60	O
36	msec	O
37	+/-	O
38	25	O
39	msec	O
40	,	O
41	and	O
42	the	O
43	JTc	O
44	delta	O
45	of	O
46	the	O
47	control	O
48	group	O
49	was	O
50	70	O
51	ms	O
52	+/-	O
53	30	O
54	ms	O
55	.	O
1	Schwab	O
2	and	O
3	England	O
4	ADL	O
5	scores	O
6	in	O
7	the	O
8	""""	O
9	off	O
10	""""	O
11	state	O
12	were	O
13	improved	O
14	by	O
15	18	O
16	%	O
17	and	O
18	in	O
19	the	O
20	""""	O
21	on	O
22	""""	O
23	state	O
24	the	O
25	scores	O
26	declined	O
27	by	O
28	2	O
29	%.	O
1	Topoisomerase	B
2	II	I
3	is	O
4	a	O
5	major	O
6	target	O
7	of	O
8	the	O
9	protein	B
10	kinase	I
11	casein	I
12	kinase	I
13	2	I
14	(	O
15	PK	B
16	CK2	I
17	)	O
18	in	O
19	vivo	O
20	.	O
1	Sequence	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	MEMA	B
7	protein	I
8	is	O
9	identical	O
10	with	O
11	a	O
12	160	B
13	kDa	I
14	nuclear	I
15	'	I
16	domain	I
17	rich	I
18	in	I
19	serines	I
20	'	I
21	(	I
22	DRS	I
23	)	I
24	protein	I
25	occurring	O
26	free	O
27	in	O
28	the	O
29	nucleoplasm	O
30	and	O
31	in	O
32	U2	B
33	-	I
34	ribonucleoprotein	I
35	structures	I
36	.	O
1	Four	O
2	CsA	O
3	-	O
4	treated	O
5	patients	O
6	developed	O
7	persistently	O
8	elevated	O
9	UAER	O
10	>	O
11	30	O
12	mg	O
13	/	O
14	24	O
15	h	O
16	(	O
17	n	O
18	=	O
19	3	O
20	with	O
21	microalbuminuria	O
22	),	O
23	whereas	O
24	all	O
25	the	O
26	17	O
27	placebo	O
28	-	O
29	treated	O
30	patients	O
31	had	O
32	normal	O
33	UAER	O
34	(<	O
35	30	O
36	mg	O
37	/	O
38	24	O
39	h	O
40	)	O
41	after	O
42	7	O
43	years	O
44	of	O
45	follow	O
46	-	O
47	up	O
48	.	O
1	In	O
2	all	O
3	trials	O
4	,	O
5	antigen	O
6	challenge	O
7	followed	O
8	1	O
9	h	O
10	after	O
11	the	O
12	last	O
13	treatment	O
14	.	O
1	31	O
2	,	O
3	1997	O
4	,	O
5	40	O
6	patients	O
7	had	O
8	died	O
9	(	O
10	35	O
11	in	O
12	the	O
13	ERA	O
14	-	O
15	II	O
16	group	O
17	and	O
18	5	O
19	in	O
20	the	O
21	ERA	O
22	-	O
23	III	O
24	group	O
25	),	O
26	for	O
27	a	O
28	crude	O
29	mortality	O
30	rate	O
31	of	O
32	8	O
33	.	O
34	0	O
35	%.	O
1	Holger	O
2	v	O
3	.	O
1	We	O
2	have	O
3	screened	O
4	the	O
5	elastin	B
6	gene	I
7	for	O
8	mutations	O
9	responsible	O
10	for	O
11	supravalvular	O
12	aortic	O
13	stenosis	O
14	(	O
15	SVAS	O
16	)	O
17	in	O
18	two	O
19	large	O
20	,	O
21	independently	O
22	collected	O
23	families	O
24	with	O
25	isolated	O
26	(	O
27	nonsyndromic	O
28	)	O
29	SVAS	O
30	.	O
1	Methanesulfonyl	O
2	fluoride	O
3	(	O
4	MSF	O
5	):	O
6	a	O
7	double	O
8	-	O
9	blind	O
10	,	O
11	placebo	O
12	-	O
13	controlled	O
14	study	O
15	of	O
16	safety	O
17	and	O
18	efficacy	O
19	in	O
20	the	O
21	treatment	O
22	of	O
23	senile	O
24	dementia	O
25	of	O
26	the	O
27	Alzheimer	O
28	type	O
29	.	O
1	Characterization	O
2	of	O
3	the	O
4	transcription	B
5	factor	I
6	MTF	I
7	-	I
8	1	I
9	from	O
10	the	O
11	Japanese	O
12	pufferfish	O
13	(	O
14	Fugu	O
15	rubripes	O
16	)	O
17	reveals	O
18	evolutionary	O
19	conservation	O
20	of	O
21	heavy	O
22	metal	O
23	stress	O
24	response	O
25	.	O
1	In	O
2	the	O
3	cell	O
4	-	O
5	free	O
6	import	O
7	assay	O
8	,	O
9	beta	B
10	-	I
11	catenin	I
12	rapidly	O
13	migrates	O
14	into	O
15	the	O
16	nucleus	O
17	without	O
18	the	O
19	exogenous	O
20	addition	O
21	of	O
22	cytosol	O
23	,	O
24	Ran	B
25	,	O
26	or	O
27	ATP	O
28	/	O
29	GTP	O
30	.	O
1	Plasma	O
2	glucose	O
3	,	O
4	immunoreactive	B
5	insulin	I
6	(	O
7	IRI	B
8	),	O
9	C	B
10	-	I
11	peptide	I
12	,	O
13	glucagon	B
14	,	O
15	and	O
16	GLP	B
17	-	I
18	1	I
19	levels	O
20	at	O
21	each	O
22	time	O
23	point	O
24	during	O
25	OGTT	O
26	were	O
27	measured	O
28	.	O
1	Technetium	O
2	-	O
3	99m	O
4	methylene	O
5	diphosphonate	O
6	scintimammography	O
7	for	O
8	evaluation	O
9	of	O
10	palpable	O
11	breast	O
12	masses	O
13	.	O
1	Bacteria	O
2	can	O
3	also	O
4	cause	O
5	a	O
6	labyrinthitis	O
7	acting	O
8	directly	O
9	on	O
10	the	O
11	inner	O
12	ear	O
13	:	O
14	among	O
15	these	O
16	,	O
17	Treponemas	O
18	Pallidum	O
19	,	O
20	a	O
21	spirochaete	O
22	which	O
23	causes	O
24	syphilis	O
25	and	O
26	Borrelia	O
27	Burgdorferi	O
28	,	O
29	a	O
30	spirochaete	O
31	that	O
32	causes	O
33	Lyme	O
34	Disease	O
35	,	O
36	must	O
37	be	O
38	mentioned	O
39	.	O
1	Concomitantly	O
2	,	O
3	the	O
4	total	O
5	cellular	O
6	level	O
7	of	O
8	p21	B
9	increased	O
10	severalfold	O
11	via	O
12	a	O
13	posttranscriptional	O
14	mechanism	O
15	.	O
1	The	O
2	Fyn	B
3	NH2	I
4	terminus	I
5	was	O
6	necessary	O
7	but	O
8	not	O
9	sufficient	O
10	for	O
11	interaction	O
12	with	O
13	zeta	O
14	and	O
15	both	O
16	Fyn	B
17	kinase	I
18	and	O
19	SH2	B
20	domains	I
21	were	O
22	required	O
23	,	O
24	directing	O
25	phosphorylation	O
26	of	O
27	zeta	B
28	ITAM	I
29	tyrosines	O
30	and	O
31	binding	O
32	to	O
33	zeta	B
34	ITAM	I
35	phosphotyrosines	O
36	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	,	O
6	despite	O
7	their	O
8	structural	O
9	and	O
10	functional	O
11	similarities	O
12	,	O
13	the	O
14	pop1	B
15	and	O
16	pop2	B
17	genes	I
18	fail	O
19	to	O
20	complement	O
21	each	O
22	other	O
23	'	O
24	s	O
25	deletion	O
26	phenotypes	O
27	,	O
28	indicating	O
29	that	O
30	they	O
31	perform	O
32	non	O
33	-	O
34	redundant	O
35	,	O
36	but	O
37	potentially	O
38	interdependent	O
39	,	O
40	functions	O
41	in	O
42	proteolysis	O
43	.	O
1	In	O
2	retrospect	O
3	,	O
4	the	O
5	diagnoses	O
6	were	O
7	reconsidered	O
8	applying	O
9	strict	O
10	criteria	O
11	.	O
1	Transforming	B
2	growth	I
3	factor	I
4	(	I
5	TGF	I
6	)-	I
7	beta1	I
8	induces	O
9	extracellular	O
10	matrix	O
11	deposition	O
12	and	O
13	proliferation	O
14	of	O
15	mesenchymal	O
16	cells	O
17	.	O
1	RESULTS	O
2	AND	O
3	CONCLUSIONS	O
4	:	O
5	Brandt	O
6	'	O
7	s	O
8	double	O
9	cuff	O
10	-	O
11	tubes	O
12	(	O
13	G2	O
14	)	O
15	succeed	O
16	in	O
17	avoiding	O
18	uncontrolled	O
19	increase	O
20	of	O
21	cuff	O
22	-	O
23	pressure	O
24	during	O
25	anaesthesia	O
26	with	O
27	N2O	O
28	.	O
1	The	O
2	binding	O
3	of	O
4	PH	B
5	domains	I
6	to	O
7	Gbetagamma	B
8	was	O
9	inhibited	O
10	by	O
11	preincubation	O
12	of	O
13	Gbetagamma	B
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	Gialpha	B
28	.	O
1	Constrictive	O
2	pericarditis	O
3	and	O
4	pleuropulmonary	O
5	disease	O
6	linked	O
7	to	O
8	ergot	O
9	dopamine	O
10	agonist	O
11	therapy	O
12	(	O
13	cabergoline	O
14	)	O
15	for	O
16	Parkinson	O
17	'	O
18	s	O
19	disease	O
20	.	O
1	An	O
2	undilated	O
3	type	O
4	of	O
5	APBD	O
6	is	O
7	frequently	O
8	associated	O
9	with	O
10	AMT	O
11	and	O
12	we	O
13	believe	O
14	,	O
15	therefore	O
16	,	O
17	that	O
18	clinicians	O
19	should	O
20	be	O
21	aware	O
22	of	O
23	a	O
24	possible	O
25	coexistence	O
26	of	O
27	APBD	O
28	and	O
29	AMT	O
30	.	O
1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	B
16	-	I
17	kappa	I
18	function	O
19	.	O
1	The	O
2	control	O
3	group	O
4	included	O
5	8	O
6	afterbirth	O
7	samples	O
8	from	O
9	physiological	O
10	full	O
11	-	O
12	term	O
13	pregnancies	O
14	.	O
1	However	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	gene	O
7	between	O
8	the	O
9	MDV2	B
10	UL54	I
11	and	O
12	UL55	B
13	genes	I
14	with	O
15	homology	O
16	to	O
17	the	O
18	first	B
19	ORF	I
20	(	I
21	ORF	I
22	-	I
23	1	I
24	)	I
25	of	I
26	equine	I
27	herpesvirus	I
28	type	I
29	1	I
30	and	O
31	corresponding	O
32	gene	O
33	identified	O
34	in	O
35	pseudorabies	O
36	virus	O
37	.	O
1	The	O
2	5	O
3	'	O
4	untranslated	O
5	and	O
6	coding	O
7	regions	O
8	are	O
9	contained	O
10	within	O
11	12	O
12	exons	O
13	,	O
14	with	O
15	the	O
16	translation	O
17	start	O
18	site	O
19	located	O
20	within	O
21	the	O
22	first	O
23	exon	O
24	.	O
1	A	O
2	Bub2p	B
3	-	O
4	dependent	O
5	spindle	O
6	checkpoint	O
7	pathway	O
8	regulates	O
9	the	O
10	Dbf2p	B
11	kinase	I
12	in	I
13	budding	I
14	yeast	I
15	.	O
1	We	O
2	show	O
3	that	O
4	other	O
5	cdc33	B
6	mutants	I
7	also	O
8	arrest	O
9	in	O
10	G1	O
11	.	O
1	Sequence	O
2	analysis	O
3	suggests	O
4	that	O
5	TtrA	B
6	contains	O
7	a	O
8	molybdopterin	O
9	guanine	O
10	dinucleotide	O
11	cofactor	O
12	and	O
13	a	O
14	[	O
15	4Fe	O
16	-	O
17	4S	O
18	]	O
19	cluster	O
20	,	O
21	that	O
22	TtrB	B
23	binds	O
24	four	O
25	[	O
26	4Fe	O
27	-	O
28	4S	O
29	]	O
30	clusters	O
31	,	O
32	and	O
33	that	O
34	TtrC	B
35	is	O
36	an	O
37	integral	O
38	membrane	O
39	protein	O
40	containing	O
41	a	O
42	quinol	O
43	oxidation	O
44	site	O
45	.	O
1	Online	O
2	LATCH	O
3	demonstrates	O
4	a	O
5	shift	O
6	in	O
7	identification	O
8	of	O
9	the	O
10	library	O
11	as	O
12	an	O
13	isolated	O
14	unit	O
15	to	O
16	an	O
17	interactive	O
18	resource	O
19	center	O
20	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	calpeptin	B
6	inhibits	O
7	tyrosine	B
8	phosphatases	I
9	,	O
10	enhancing	O
11	tyrosine	O
12	phosphorylation	O
13	particularly	O
14	of	O
15	paxillin	B
16	.	O
1	We	O
2	suggest	O
3	that	O
4	FlgN	B
5	and	O
6	FliT	B
7	are	O
8	substrate	O
9	-	O
10	specific	O
11	flagellar	O
12	chaperones	O
13	that	O
14	prevent	O
15	oligomerization	O
16	of	O
17	the	O
18	HAPs	B
19	by	O
20	binding	O
21	to	O
22	their	O
23	helical	O
24	domains	O
25	before	O
26	export	O
27	.	O
1	As	O
2	determined	O
3	in	O
4	a	O
5	modified	O
6	yeast	O
7	two	O
8	-	O
9	hybrid	O
10	system	O
11	,	O
12	mIRS3	B
13	bound	O
14	strongly	O
15	to	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	-	I
23	kinase	I
24	.	O
1	Insulin	B
2	stimulation	O
3	promoted	O
4	the	O
5	association	O
6	of	O
7	mIRS3	B
8	with	O
9	p85	B
10	,	O
11	SHP2	B
12	,	O
13	Nck	B
14	,	O
15	and	O
16	Shc	B
17	.	O
1	In	O
2	the	O
3	case	O
4	of	O
5	the	O
6	unspliceable	O
7	intron	O
8	,	O
9	repression	O
10	of	O
11	luciferase	B
12	expression	O
13	likely	O
14	involved	O
15	two	O
16	AUF1	B
17	-	I
18	binding	I
19	sequences	I
20	,	O
21	since	O
22	luciferase	B
23	expression	O
24	was	O
25	increased	O
26	by	O
27	deletion	O
28	of	O
29	these	O
30	sites	O
31	.	O
1	Additionally	O
2	,	O
3	deletion	O
4	analysis	O
5	of	O
6	the	O
7	UCP2	B
8	promoter	O
9	-	O
10	PLAP	B
11	constructs	O
12	indicated	O
13	that	O
14	the	O
15	minimal	O
16	region	O
17	exhibiting	O
18	the	O
19	promoter	O
20	activity	O
21	was	O
22	located	O
23	between	O
24	nt	O
25	-	O
26	33	O
27	and	O
28	+	O
29	100	O
30	,	O
31	and	O
32	that	O
33	a	O
34	strong	O
35	enhancer	O
36	was	O
37	present	O
38	within	O
39	601	O
40	bp	O
41	of	O
42	the	O
43	5	O
44	'-	O
45	promoter	O
46	region	O
47	.	O
1	Spc42p	B
2	also	O
3	was	O
4	identified	O
5	as	O
6	a	O
7	component	O
8	of	O
9	a	O
10	cytoplasmic	O
11	SPB	O
12	subcomplex	O
13	containing	O
14	Spc94p	B
15	/	O
16	Nud1p	B
17	,	O
18	Cnm67p	B
19	,	O
20	and	O
21	Spc42p	B
22	.	O
1	The	O
2	average	O
3	coefficients	O
4	of	O
5	correlation	O
6	were	O
7	0	O
8	.	O
9	9998	O
10	and	O
11	0	O
12	.	O
13	9993	O
14	for	O
15	the	O
16	QMF	O
17	and	O
18	the	O
19	QIT	O
20	system	O
21	,	O
22	respectively	O
23	.	O
1	The	O
2	5	O
3	-	O
4	year	O
5	OS	O
6	for	O
7	stage	O
8	IIIB	O
9	was	O
10	30	O
11	.	O
12	9	O
13	%,	O
14	compared	O
15	to	O
16	7	O
17	.	O
18	8	O
19	%	O
20	for	O
21	stage	O
22	IV	O
23	.	O
1	Furthermore	O
2	,	O
3	heparin	B
4	lyase	I
5	treatment	O
6	of	O
7	extracts	O
8	of	O
9	cells	O
10	expressing	O
11	recombinant	B
12	YD	I
13	-	I
14	repeat	I
15	protein	I
16	releases	O
17	this	O
18	protein	O
19	from	O
20	high	O
21	molecular	O
22	mass	O
23	aggregates	O
24	.	O
1	While	O
2	determination	O
3	of	O
4	the	O
5	protein	O
6	content	O
7	of	O
8	the	O
9	formulae	O
10	gave	O
11	no	O
12	valid	O
13	information	O
14	,	O
15	RAST	O
16	/	O
17	EAST	O
18	inhibition	O
19	was	O
20	highest	O
21	for	O
22	cow	O
23	'	O
24	s	O
25	milk	O
26	,	O
27	followed	O
28	by	O
29	the	O
30	partially	O
31	hydrolysed	O
32	whey	O
33	formula	O
34	,	O
35	partially	O
36	hydrolysed	O
37	whey	O
38	/	O
39	casein	B
40	formula	O
41	,	O
42	soy	B
43	/	I
44	pork	I
45	collagen	I
46	formula	O
47	,	O
48	and	O
49	the	O
50	amino	O
51	acid	O
52	formula	O
53	.	O
1	Although	O
2	it	O
3	has	O
4	two	O
5	potential	O
6	binding	O
7	sites	O
8	,	O
9	the	O
10	purified	O
11	MerR	B
12	homodimer	I
13	binds	O
14	only	O
15	one	O
16	Hg	O
17	(	O
18	II	O
19	)	O
20	ion	O
21	,	O
22	employing	O
23	Cys82	O
24	from	O
25	one	O
26	monomer	O
27	and	O
28	Cys117	O
29	and	O
30	Cys126	O
31	from	O
32	the	O
33	other	O
34	.	O
1	Latexin	B
2	,	O
3	a	O
4	carboxypeptidase	B
5	A	I
6	inhibitor	O
7	,	O
8	is	O
9	expressed	O
10	in	O
11	a	O
12	cell	O
13	type	O
14	-	O
15	specific	O
16	manner	O
17	in	O
18	both	O
19	central	O
20	and	O
21	peripheral	O
22	nervous	O
23	systems	O
24	in	O
25	the	O
26	rat	O
27	.	O
1	Regression	O
2	analyses	O
3	identified	O
4	7	O
5	risk	O
6	and	O
7	7	O
8	protective	O
9	factors	O
10	with	O
11	minimal	O
12	overlap	O
13	.	O
1	Developmental	O
2	follow	O
3	-	O
4	up	O
5	at	O
6	age	O
7	2	O
8	years	O
9	was	O
10	performed	O
11	.	O
1	Modulation	O
2	of	O
3	human	B
4	heat	I
5	shock	I
6	factor	I
7	trimerization	O
8	by	O
9	the	O
10	linker	O
11	domain	O
12	.	O
1	Three	O
2	subgenomes	O
3	also	O
4	comprised	O
5	15	O
6	to	O
7	75	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'	O
14	part	O
15	of	O
16	the	O
17	NS2	B
18	gene	I
19	.	O
1	Of	O
2	those	O
3	injuries	O
4	,	O
5	143	O
6	cases	O
7	were	O
8	snowboard	O
9	related	O
10	and	O
11	158	O
12	cases	O
13	were	O
14	ski	O
15	related	O
16	.	O
1	Green	O
2	fluorescent	O
3	protein	O
4	-	O
5	tagged	O
6	UNC	B
7	-	I
8	49B	I
9	and	O
10	UNC	B
11	-	I
12	49C	I
13	subunits	I
14	are	O
15	coexpressed	O
16	in	O
17	muscle	O
18	cells	O
19	and	O
20	are	O
21	colocalized	O
22	to	O
23	synaptic	O
24	regions	O
25	.	O
1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	spontaneous	O
11	reports	O
12	of	O
13	suspected	O
14	adverse	O
15	drug	O
16	reactions	O
17	,	O
18	observed	O
19	in	O
20	elderly	O
21	patients	O
22	(	O
23	over	O
24	65	O
25	years	O
26	of	O
27	age	O
28	)	O
29	in	O
30	Sicily	O
31	(	O
32	Italy	O
33	)	O
34	during	O
35	the	O
36	period	O
37	from	O
38	1	O
39	January	O
40	1995	O
41	to	O
42	31	O
43	December	O
44	1997	O
45	.	O
1	Identification	O
2	and	O
3	structure	O
4	of	O
5	the	O
6	Marek	B
7	'	I
8	s	I
9	disease	I
10	virus	I
11	serotype	I
12	2	I
13	glycoprotein	I
14	M	I
15	gene	I
16	:	O
17	comparison	O
18	with	O
19	glycoprotein	B
20	M	I
21	genes	I
22	of	O
23	Herpesviridae	O
24	family	O
25	.	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	perform	O
5	a	O
6	cost	O
7	-	O
8	effectiveness	O
9	analysis	O
10	(	O
11	CEA	O
12	)	O
13	between	O
14	a	O
15	standard	O
16	antiemetic	O
17	regimen	O
18	-	O
19	chlorpromazine	O
20	+	O
21	dexamethasone	O
22	(	O
23	CPM	O
24	-	O
25	DEX	O
26	)-	O
27	and	O
28	a	O
29	5	B
30	-	I
31	HT3	I
32	receptor	I
33	antagonist	O
34	-	O
35	tropisetron	O
36	(	O
37	TROP	O
38	)--	O
39	in	O
40	the	O
41	control	O
42	of	O
43	acute	O
44	emesis	O
45	induced	O
46	by	O
47	highly	O
48	emetogenic	O
49	chemotherapy	O
50	in	O
51	children	O
52	,	O
53	considering	O
54	two	O
55	analytic	O
56	perspectives	O
57	:	O
58	hospital	O
59	and	O
60	patients	O
61	.	O
1	A	O
2	comparison	O
3	of	O
4	the	O
5	nucleotide	O
6	and	O
7	deduced	O
8	amino	O
9	acid	O
10	sequences	O
11	of	O
12	the	O
13	core	O
14	regions	O
15	of	O
16	the	O
17	RNA	B
18	-	I
19	dependent	I
20	RNA	I
21	polymerase	I
22	domains	I
23	found	O
24	in	O
25	these	O
26	three	O
27	dsRNAs	O
28	suggested	O
29	that	O
30	these	O
31	dsRNAs	O
32	probably	O
33	evolved	O
34	independently	O
35	within	O
36	each	O
37	host	O
38	plant	O
39	from	O
40	a	O
41	common	O
42	ancestor	O
43	.	O
1	A	O
2	recently	O
3	described	O
4	protein	O
5	,	O
6	metaxin	B
7	1	I
8	,	O
9	serves	O
10	as	O
11	a	O
12	component	O
13	of	O
14	a	O
15	preprotein	O
16	import	O
17	complex	O
18	in	O
19	the	O
20	outer	O
21	membrane	O
22	of	O
23	the	O
24	mammalian	O
25	mitochondrion	O
26	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	rat	B
5	SH2	I
6	-	I
7	containing	I
8	inositol	I
9	phosphatase	I
10	2	I
11	(	O
12	SHIP2	B
13	)	O
14	and	O
15	its	O
16	role	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	insulin	B
22	signaling	O
23	.	O
1	Slp1	B
2	represses	O
3	transcription	O
4	via	O
5	this	O
6	binding	O
7	site	O
8	in	O
9	yeast	O
10	cells	O
11	,	O
12	consistent	O
13	with	O
14	its	O
15	role	O
16	as	O
17	a	O
18	direct	O
19	repressor	O
20	of	O
21	ftz	B
22	stripes	O
23	in	O
24	interstripe	O
25	regions	O
26	during	O
27	late	O
28	stages	O
29	of	O
30	embryogenesis	O
31	.	O
1	D3S1261	B
2	is	O
3	physically	O
4	located	O
5	at	O
6	or	O
7	near	O
8	the	O
9	MITF	B
10	locus	I
11	,	O
12	while	O
13	D3S2465	B
14	and	O
15	D3S1766	B
16	are	O
17	flanking	O
18	the	O
19	locus	O
20	at	O
21	about	O
22	17	O
23	.	O
24	5	O
25	cM	O
26	genetic	O
27	distance	O
28	each	O
29	side	O
30	.	O
1	This	O
2	scFv	O
3	was	O
4	therefore	O
5	used	O
6	as	O
7	control	O
8	in	O
9	experiments	O
10	where	O
11	another	O
12	anti	B
13	-	I
14	Ras	I
15	scFv	I
16	(	O
17	Y259	B
18	scFv	I
19	,	O
20	derived	O
21	from	O
22	the	O
23	neutralizing	O
24	anti	B
25	-	I
26	Ras	I
27	mAb	I
28	Y13	I
29	-	I
30	259	I
31	)	O
32	blocked	O
33	the	O
34	Ras	B
35	pathway	O
36	in	O
37	vitro	O
38	and	O
39	led	O
40	to	O
41	tumor	O
42	regression	O
43	in	O
44	a	O
45	nude	O
46	mouse	O
47	model	O
48	[	O
49	Cochet	O
50	,	O
51	O	O
52	.,	O
53	Kenigsberg	O
54	,	O
55	M	O
56	.,	O
57	Delumeau	O
58	,	O
59	I	O
60	.,	O
61	Virone	O
62	-	O
63	Oddos	O
64	,	O
65	A	O
66	.,	O
67	Multon	O
68	,	O
69	M	O
70	.	O
71	C	O
72	.,	O
73	Fridman	O
74	,	O
75	W	O
76	.	O
77	H	O
78	.,	O
79	Schweighoffer	O
80	,	O
81	F	O
82	.,	O
83	Teillaud	O
84	,	O
85	J	O
86	.	O
87	L	O
88	.,	O
89	Tocque	O
90	,	O
91	B	O
92	.,	O
93	1998	O
94	.	O
1	Moreover	O
2	,	O
3	a	O
4	high	O
5	proportion	O
6	of	O
7	blood	O
8	samples	O
9	from	O
10	a	O
11	random	O
12	sample	O
13	of	O
14	the	O
15	rest	O
16	of	O
17	the	O
18	suspects	O
19	tested	O
20	positive	O
21	for	O
22	trypanosome	O
23	-	O
24	specific	O
25	DNA	O
26	by	O
27	PCR	O
28	(	O
29	79	O
30	.	O
31	9	O
32	%	O
33	for	O
34	T	O
35	.	O
36	b	O
37	.	O
38	gambiense	O
39	and	O
40	13	O
41	.	O
42	9	O
43	%	O
44	for	O
45	T	O
46	.	O
47	b	O
48	.	O
49	rhodesiense	O
50	).	O
1	Simian	O
2	parainfluenza	O
3	virus	O
4	5	O
5	(	O
6	SV5	O
7	)	O
8	is	O
9	a	O
10	prototype	O
11	of	O
12	the	O
13	Paramyxoviridae	O
14	family	O
15	of	O
16	nonsegmented	O
17	negative	O
18	-	O
19	sense	O
20	RNA	O
21	viruses	O
22	.	O
1	The	O
2	results	O
3	of	O
4	these	O
5	analyses	O
6	indicate	O
7	that	O
8	the	O
9	proteinase	O
10	cleaves	O
11	at	O
12	amino	O
13	acid	O
14	residues	O
15	E960	O
16	-	O
17	A961	O
18	,	O
19	E1071	O
20	-	O
21	S1072	O
22	,	O
23	E1345	O
24	-	O
25	T1346	O
26	,	O
27	and	O
28	E1419	O
29	-	O
30	G1420	O
31	;	O
32	however	O
33	,	O
34	the	O
35	cleavage	O
36	efficiency	O
37	is	O
38	varied	O
39	.	O
1	In	O
2	a	O
3	prospective	O
4	randomized	O
5	study	O
6	,	O
7	287	O
8	patients	O
9	with	O
10	advanced	O
11	non	O
12	-	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	(	O
18	NSCLC	O
19	)	O
20	stage	O
21	IIIb	O
22	or	O
23	IV	O
24	with	O
25	ECOG	O
26	performance	O
27	status	O
28	(	O
29	PS	O
30	)	O
31	0	O
32	-	O
33	1	O
34	or	O
35	2	O
36	were	O
37	randomly	O
38	assigned	O
39	to	O
40	receive	O
41	either	O
42	best	O
43	supportive	O
44	care	O
45	(	O
46	BSC	O
47	)	O
48	or	O
49	supportive	O
50	care	O
51	plus	O
52	combination	O
53	chemotherapy	O
54	(	O
55	IEP	O
56	regimen	O
57	:	O
58	ifosfamide	O
59	3	O
60	gm	O
61	/	O
62	m2	O
63	IV	O
64	with	O
65	mesna	O
66	uroprotection	O
67	,	O
68	epirubicin	O
69	60	O
70	mg	O
71	/	O
72	m2	O
73	IV	O
74	on	O
75	day	O
76	1	O
77	and	O
78	cisplatin	O
79	60	O
80	mg	O
81	/	O
82	m2	O
83	IV	O
84	on	O
85	day	O
86	2	O
87	;	O
88	or	O
89	MVP	O
90	regimen	O
91	:	O
92	mitomycin	O
93	-	O
94	C	O
95	8	O
96	mg	O
97	/	O
98	m2	O
99	,	O
100	cisplatin	O
101	100	O
102	mg	O
103	/	O
104	m2	O
105	IV	O
106	on	O
107	day	O
108	1	O
109	,	O
110	vinblastine	O
111	4	O
112	mg	O
113	/	O
114	m2	O
115	IV	O
116	on	O
117	days	O
118	1	O
119	and	O
120	15	O
121	).	O
1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	O
7	-	O
8	length	O
9	promoter	O
10	(-	O
11	295	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	197	O
23	,	O
24	-	O
25	154	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	O
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O
1	Chemical	O
2	stability	O
3	tests	O
4	and	O
5	site	O
6	-	O
7	specific	O
8	mutagenesis	O
9	identified	O
10	amino	O
11	acids	O
12	H219	O
13	and	O
14	D63	O
15	of	O
16	RegS	B
17	and	O
18	RegR	B
19	,	O
20	respectively	O
21	,	O
22	as	O
23	the	O
24	phosphorylated	O
25	residues	O
26	.	O
1	An	O
2	overexpression	O
3	of	O
4	the	O
5	betaAPP	B
6	gene	I
7	in	O
8	certain	O
9	areas	O
10	of	O
11	the	O
12	AD	O
13	brain	O
14	has	O
15	been	O
16	suggested	O
17	to	O
18	be	O
19	an	O
20	important	O
21	factor	O
22	in	O
23	the	O
24	neuropathology	O
25	of	O
26	AD	O
27	.	O
1	Role	O
2	of	O
3	secondary	O
4	structure	O
5	in	O
6	discrimination	O
7	between	O
8	constitutive	O
9	and	O
10	inducible	O
11	activators	O
12	.	O
1	This	O
2	approximately	O
3	125	O
4	-	O
5	nt	O
6	RNA	O
7	proved	O
8	to	O
9	arise	O
10	via	O
11	RNase	B
12	E	I
13	cleavage	O
14	from	O
15	the	O
16	3	O
17	'-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	mRNAs	O
23	bearing	O
24	the	O
25	terminator	O
26	.	O
1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	the	O
5	cAMP	B
6	-	I
7	dependent	I
8	kinases	I
9	(	O
10	PKAs	B
11	)	O
12	promote	O
13	cytoplasmic	O
14	growth	O
15	and	O
16	modulate	O
17	the	O
18	growth	O
19	-	O
20	regulated	O
21	mechanism	O
22	triggering	O
23	the	O
24	begin	O
25	of	O
26	DNA	O
27	synthesis	O
28	.	O
1	Fifty	O
2	six	O
3	young	O
4	patients	O
5	(	O
6	age	O
7	<	O
8	45	O
9	yr	O
10	)	O
11	with	O
12	doppler	O
13	-	O
14	proven	O
15	DVT	O
16	were	O
17	investigated	O
18	for	O
19	the	O
20	presence	O
21	of	O
22	resistance	O
23	to	O
24	activated	B
25	protein	I
26	C	I
27	(	O
28	APC	B
29	-	I
30	R	I
31	),	O
32	lupus	O
33	anticoagulant	O
34	(	O
35	LA	O
36	),	O
37	anticardiolipin	B
38	antibodies	I
39	and	O
40	deficiencies	O
41	of	O
42	protein	B
43	C	I
44	,	O
45	protein	B
46	S	I
47	,	O
48	ATIII	B
49	activities	O
50	.	O
1	The	O
2	enzyme	O
3	displays	O
4	optimal	O
5	activity	O
6	at	O
7	about	O
8	0	O
9	.	O
10	5	O
11	mM	O
12	pantoate	O
13	(	O
14	k	O
15	(	O
16	cat	O
17	)	O
18	0	O
19	.	O
20	63	O
21	s	O
22	(-	O
23	1	O
24	))	O
25	and	O
26	at	O
27	pH	O
28	7	O
29	.	O
30	8	O
31	.	O
1	Bacterial	O
2	recovery	O
3	of	O
4	SA	O
5	from	O
6	the	O
7	liver	O
8	/	O
9	spleen	O
10	and	O
11	the	O
12	cecal	O
13	tonsil	O
14	in	O
15	contact	O
16	poults	O
17	and	O
18	SG	O
19	from	O
20	contact	O
21	chicks	O
22	treated	O
23	with	O
24	ILK	B
25	was	O
26	dramatically	O
27	reduced	O
28	when	O
29	compared	O
30	to	O
31	non	O
32	-	O
33	treated	O
34	contact	O
35	poults	O
36	and	O
37	chicks	O
38	.	O
1	Repair	O
2	of	O
3	double	O
4	-	O
5	strand	O
6	breaks	O
7	(	O
8	DSBs	O
9	)	O
10	in	O
11	chromosomal	O
12	DNA	O
13	by	O
14	nonhomologous	O
15	end	O
16	-	O
17	joining	O
18	(	O
19	NHEJ	O
20	)	O
21	is	O
22	not	O
23	well	O
24	characterized	O
25	in	O
26	the	O
27	yeast	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O
1	A	O
2	new	O
3	DNA	B
4	repair	I
5	gene	I
6	from	O
7	Schizosaccharomyces	O
8	pombe	O
9	with	O
10	homology	O
11	to	O
12	RecA	B
13	was	O
14	identified	O
15	and	O
16	characterized	O
17	.	O
1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	TraR	B
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	heteromultimers	O
18	with	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	activator	O
24	.	O
1	There	O
2	were	O
3	27	O
4	men	O
5	and	O
6	156	O
7	women	O
8	.	O
1	A	O
2	.,	O
3	Bowers	O
4	,	O
5	K	O
6	.	O
7	E	O
8	,	O
9	and	O
10	Matthews	O
11	,	O
12	C	O
13	.	O
1	METHODS	O
2	:	O
3	109	O
4	suspected	O
5	cases	O
6	with	O
7	SS	O
8	underwent	O
9	the	O
10	biopsies	O
11	.	O
1	We	O
2	also	O
3	identify	O
4	several	O
5	regulatory	O
6	domain	O
7	mutants	O
8	in	O
9	which	O
10	Cd	O
11	(	O
12	2	O
13	+)	O
14	tolerance	O
15	of	O
16	the	O
17	mutant	O
18	strain	O
19	and	O
20	transport	O
21	activity	O
22	of	O
23	the	O
24	protein	O
25	are	O
26	dissociated	O
27	.	O
1	Oligonucleotide	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	EpRE	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	super	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O
1	Adipocyte	O
2	differentiation	O
3	of	O
4	nontransformed	O
5	cells	O
6	also	O
7	markedly	O
8	represses	O
9	the	O
10	ability	O
11	of	O
12	SRF	B
13	to	O
14	bind	O
15	to	O
16	the	O
17	junB	B
18	SRE	O
19	,	O
20	the	O
21	c	B
22	-	I
23	fos	I
24	SRE	O
25	,	O
26	and	O
27	other	O
28	SREs	O
29	,	O
30	as	O
31	determined	O
32	by	O
33	mobility	O
34	shift	O
35	and	O
36	gel	O
37	supershift	O
38	assays	O
39	,	O
40	without	O
41	affecting	O
42	the	O
43	DNA	O
44	binding	O
45	characteristics	O
46	of	O
47	the	O
48	nuclear	O
49	protein	O
50	SP	O
51	-	O
52	1	O
53	.	O
1	The	O
2	STAT	B
3	protein	I
4	accumulation	O
5	resulting	O
6	from	O
7	C	B
8	/	I
9	EBP	I
10	expression	O
11	was	O
12	tightly	O
13	coupled	O
14	to	O
15	the	O
16	morphological	O
17	conversion	O
18	of	O
19	fibroblasts	O
20	to	O
21	adipocytes	O
22	and	O
23	represents	O
24	an	O
25	expression	O
26	profile	O
27	identical	O
28	to	O
29	that	O
30	reported	O
31	for	O
32	mature	O
33	adipocytes	O
34	in	O
35	vivo	O
36	.	O
1	The	O
2	present	O
3	investigation	O
4	conducted	O
5	in	O
6	a	O
7	population	O
8	of	O
9	258	O
10	dentally	O
11	aware	O
12	individuals	O
13	in	O
14	the	O
15	age	O
16	range	O
17	20	O
18	-	O
19	69	O
20	years	O
21	,	O
22	was	O
23	initiated	O
24	to	O
25	elucidate	O
26	the	O
27	relationship	O
28	between	O
29	tobacco	O
30	smoking	O
31	and	O
32	supragingival	O
33	calculus	O
34	,	O
35	taking	O
36	into	O
37	account	O
38	possible	O
39	confounding	O
40	factors	O
41	such	O
42	as	O
43	age	O
44	,	O
45	gender	O
46	,	O
47	oral	O
48	hygiene	O
49	and	O
50	gingival	O
51	inflammation	O
52	.	O
1	Patients	O
2	were	O
3	assessed	O
4	for	O
5	cardiac	O
6	MIBG	O
7	uptake	O
8	,	O
9	circulating	O
10	norepinephrine	O
11	concentration	O
12	,	O
13	LVEF	O
14	,	O
15	peak	O
16	Vo2	O
17	,	O
18	x	O
19	-	O
20	ray	O
21	cardiothoracic	O
22	ratio	O
23	,	O
24	M	O
25	-	O
26	mode	O
27	echographic	O
28	end	O
29	-	O
30	diastolic	O
31	diameter	O
32	and	O
33	right	O
34	-	O
35	sided	O
36	heart	O
37	catheterization	O
38	parameters	O
39	.	O
1	Nuclear	O
2	hormone	O
3	receptors	O
4	(	O
5	NRs	O
6	)	O
7	are	O
8	ligand	O
9	-	O
10	inducible	O
11	transcription	O
12	factors	O
13	that	O
14	mediate	O
15	critical	O
16	functions	O
17	in	O
18	many	O
19	species	O
20	.	O
1	These	O
2	cells	O
3	were	O
4	able	O
5	to	O
6	present	O
7	influenza	O
8	virus	O
9	particles	O
10	to	O
11	HLA	B
12	-	I
13	DR1	I
14	-	O
15	restricted	O
16	T	O
17	cell	O
18	clones	O
19	.	O
1	It	O
2	applies	O
3	Udry	O
4	'	O
5	s	O
6	biosocial	O
7	perspective	O
8	,	O
9	which	O
10	attempts	O
11	to	O
12	reconcile	O
13	the	O
14	biological	O
15	and	O
16	sociological	O
17	models	O
18	of	O
19	premarital	O
20	sexual	O
21	and	O
22	reproductive	O
23	behaviour	O
24	.	O
1	Interaction	O
2	of	O
3	HRI	B
4	with	O
5	Hsc70	B
6	was	O
7	required	O
8	for	O
9	the	O
10	transformation	O
11	of	O
12	HRI	B
13	,	O
14	as	O
15	the	O
16	Hsc70	B
17	antagonist	O
18	clofibric	O
19	acid	O
20	inhibited	O
21	the	O
22	folding	O
23	of	O
24	HRI	B
25	into	O
26	a	O
27	mature	O
28	-	O
29	competent	O
30	conformation	O
31	.	O
1	In	O
2	the	O
3	budding	O
4	yeast	O
5	,	O
6	Saccharomyces	O
7	cerevisiae	O
8	,	O
9	replicators	O
10	can	O
11	function	O
12	outside	O
13	the	O
14	chromosome	O
15	as	O
16	autonomously	O
17	replicating	O
18	sequence	O
19	(	O
20	ARS	O
21	)	O
22	elements	O
23	;	O
24	however	O
25	,	O
26	within	O
27	chromosome	O
28	III	O
29	,	O
30	certain	O
31	ARSs	O
32	near	O
33	the	O
34	transcriptionally	O
35	silent	O
36	HML	B
37	locus	I
38	show	O
39	no	O
40	replication	O
41	origin	O
42	activity	O
43	.	O
1	Viscosity	O
2	experiments	O
3	on	O
4	the	O
5	catalytic	O
6	fragment	O
7	kinase	O
8	reaction	O
9	demonstrated	O
10	that	O
11	the	O
12	chemical	O
13	(	O
14	phosphoryl	O
15	transfer	O
16	)	O
17	step	O
18	had	O
19	a	O
20	reduced	O
21	rate	O
22	.	O
1	The	O
2	intron	O
3	RNA	O
4	consists	O
5	of	O
6	2492	O
7	nucleotides	O
8	which	O
9	can	O
10	be	O
11	folded	O
12	into	O
13	a	O
14	secondary	O
15	structure	O
16	with	O
17	all	O
18	the	O
19	expected	O
20	sequence	O
21	motifs	O
22	of	O
23	subgroup	O
24	-	O
25	IIA1	O
26	introns	O
27	(	O
28	Michel	O
29	et	O
30	al	O
31	.	O
1	Like	O
2	DNA	O
3	binding	O
4	,	O
5	transcriptional	O
6	enhancement	O
7	required	O
8	amino	O
9	-	O
10	terminally	O
11	located	O
12	basic	O
13	amino	O
14	acid	O
15	residues	O
16	but	O
17	not	O
18	the	O
19	carboxyl	O
20	-	O
21	terminal	O
22	portion	O
23	of	O
24	Hap46	B
25	known	O
26	to	O
27	participate	O
28	in	O
29	hsp70	B
30	interaction	O
31	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	a	O
6	novel	O
7	isoform	O
8	of	O
9	Rapl	B
10	GTPase	I
11	-	I
12	activating	I
13	protein	I
14	,	O
15	called	O
16	rap1GAPII	B
17	,	O
18	binds	O
19	specifically	O
20	to	O
21	the	O
22	alpha	O
23	-	O
24	subunits	O
25	of	O
26	the	O
27	G	B
28	(	I
29	i	I
30	)	I
31	family	I
32	of	O
33	heterotrimeric	B
34	G	I
35	-	I
36	proteins	I
37	.	O
1	The	O
2	B	O
3	-	O
4	oligomer	O
5	of	O
6	pertussis	B
7	toxin	I
8	deactivates	O
9	CC	B
10	chemokine	I
11	receptor	I
12	5	I
13	and	O
14	blocks	O
15	entry	O
16	of	O
17	M	O
18	-	O
19	tropic	O
20	HIV	O
21	-	O
22	1	O
23	strains	O
24	.	O
1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O
1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O
1	TRAF2	B
2	is	O
3	a	O
4	potent	O
5	activator	O
6	of	O
7	a	O
8	95	B
9	-	I
10	kDa	I
11	serine	I
12	/	I
13	threonine	I
14	kinase	I
15	termed	O
16	germinal	B
17	center	I
18	kinase	I
19	related	I
20	(	O
21	GCKR	B
22	,	O
23	also	O
24	referred	O
25	to	O
26	as	O
27	KHS1	B
28	),	O
29	which	O
30	signals	O
31	activation	O
32	of	O
33	the	O
34	SAPK	B
35	pathway	O
36	.	O
1	Furthermore	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	transcription	O
7	from	O
8	the	O
9	MMTV	B
10	5	I
11	'	I
12	LTR	I
13	is	O
14	highly	O
15	active	O
16	in	O
17	the	O
18	absence	O
19	of	O
20	Stat5a	B
21	,	O
22	a	O
23	transcription	O
24	factor	O
25	that	O
26	had	O
27	been	O
28	shown	O
29	previously	O
30	to	O
31	be	O
32	required	O
33	for	O
34	transcription	O
35	from	O
36	the	O
37	MMTV	B
38	LTR	I
39	.	O
1	Immunohistochemical	O
2	staining	O
3	with	O
4	MIB	B
5	-	I
6	1	I
7	and	O
8	p53	B
9	antibodies	I
10	showed	O
11	low	O
12	(<	O
13	1	O
14	%)	O
15	and	O
16	negative	O
17	reaction	O
18	.	O
1	Immediately	O
2	before	O
3	surgery	O
4	patients	O
5	received	O
6	either	O
7	intravenous	O
8	hydrocortisone	O
9	100	O
10	mg	O
11	or	O
12	placebo	O
13	in	O
14	random	O
15	,	O
16	double	O
17	-	O
18	blind	O
19	order	O
20	.	O
1	A	O
2	tyrosine	O
3	-	O
4	based	O
5	sorting	O
6	signal	O
7	in	O
8	the	O
9	beta2	B
10	integrin	I
11	cytoplasmic	I
12	domain	I
13	mediates	O
14	its	O
15	recycling	O
16	to	O
17	the	O
18	plasma	O
19	membrane	O
20	and	O
21	is	O
22	required	O
23	for	O
24	ligand	O
25	-	O
26	supported	O
27	migration	O
28	.	O
1	The	O
2	injection	O
3	of	O
4	XDRP1	B
5	protein	I
6	into	O
7	fertilized	O
8	Xenopus	O
9	eggs	O
10	blocked	O
11	embryonic	O
12	cell	O
13	division	O
14	.	O
1	NF	B
2	-	I
3	kappaB	I
4	plays	O
5	a	O
6	critical	O
7	role	O
8	in	O
9	activation	O
10	of	O
11	HIV	O
12	-	O
13	1	O
14	gene	O
15	expression	O
16	by	O
17	cytokines	O
18	and	O
19	other	O
20	stimuli	O
21	,	O
22	but	O
23	the	O
24	signal	O
25	transduction	O
26	pathways	O
27	that	O
28	regulate	O
29	the	O
30	switch	O
31	from	O
32	latent	O
33	to	O
34	productive	O
35	infection	O
36	have	O
37	not	O
38	been	O
39	defined	O
40	.	O
1	These	O
2	studies	O
3	suggest	O
4	that	O
5	MAPK	B
6	acts	O
7	by	O
8	stimulating	O
9	AP	B
10	-	I
11	1	I
12	and	O
13	a	O
14	subsequent	O
15	physical	O
16	and	O
17	functional	O
18	interaction	O
19	of	O
20	AP	B
21	-	I
22	1	I
23	with	O
24	NF	B
25	-	I
26	kappaB	I
27	,	O
28	resulting	O
29	in	O
30	a	O
31	complex	O
32	that	O
33	synergistically	O
34	transactivates	O
35	the	O
36	HIV	B
37	-	I
38	1	I
39	LTR	I
40	.	O
1	A	O
2	human	O
3	nuclear	O
4	-	O
5	localized	O
6	chaperone	O
7	that	O
8	regulates	O
9	dimerization	O
10	,	O
11	DNA	O
12	binding	O
13	,	O
14	and	O
15	transcriptional	O
16	activity	O
17	of	O
18	bZIP	B
19	proteins	I
20	.	O
1	Montelukast	O
2	reduces	O
3	airway	O
4	eosinophilic	O
5	inflammation	O
6	in	O
7	asthma	O
8	:	O
9	a	O
10	randomized	O
11	,	O
12	controlled	O
13	trial	O
14	.	O
1	Treatment	O
2	of	O
3	unstable	O
4	angina	O
5	:	O
6	role	O
7	of	O
8	antithrombotic	O
9	therapy	O
10	.	O
1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	,	O
5	PHO85	B
6	encodes	O
7	a	O
8	cyclin	B
9	-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	Cdk	B
15	)	O
16	catalytic	O
17	subunit	O
18	with	O
19	multiple	O
20	regulatory	O
21	roles	O
22	thought	O
23	to	O
24	be	O
25	specified	O
26	by	O
27	association	O
28	with	O
29	different	O
30	cyclin	B
31	partners	O
32	(	O
33	Pcls	B
34	).	O
1	BCL6	B
2	encodes	O
3	a	O
4	POZ	B
5	/	I
6	Zn	I
7	finger	I
8	protein	I
9	,	O
10	a	O
11	structure	O
12	similar	O
13	to	O
14	that	O
15	of	O
16	many	O
17	Drosophila	O
18	developmental	O
19	regulators	O
20	and	O
21	to	O
22	another	O
23	protein	O
24	involved	O
25	in	O
26	a	O
27	human	O
28	hematopoietic	O
29	malignancy	O
30	,	O
31	PLZF	B
32	.	O
1	Optical	O
2	CD	O
3	,	O
4	and	O
5	spectral	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	HO	B
16	isozymes	I
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O
1	Serum	O
2	antibodies	O
3	were	O
4	detected	O
5	in	O
6	at	O
7	least	O
8	95	O
9	%	O
10	of	O
11	the	O
12	infected	O
13	guinea	O
14	pigs	O
15	between	O
16	4	O
17	-	O
18	30	O
19	WPI	O
20	and	O
21	rats	O
22	between	O
23	3	O
24	-	O
25	16	O
26	WPI	O
27	.	O
1	A	O
2	genetic	O
3	screen	O
4	in	O
5	yeast	O
6	has	O
7	allowed	O
8	us	O
9	to	O
10	identify	O
11	a	O
12	novel	O
13	transcriptional	O
14	factor	O
15	binding	O
16	to	O
17	the	O
18	GlRE	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	chicken	B
26	ovalbumin	I
27	upstream	I
28	promoter	I
29	-	I
30	transcription	I
31	factor	I
32	II	I
33	(	O
34	COUP	B
35	-	I
36	TFII	I
37	).	O
1	We	O
2	have	O
3	cloned	O
4	the	O
5	single	O
6	-	O
7	copy	O
8	gene	O
9	for	O
10	the	O
11	trans	B
12	-	I
13	spliceosomal	I
14	U5	I
15	snRNA	I
16	from	O
17	the	O
18	trypanosomatid	O
19	species	O
20	Leptomonas	O
21	seymouri	O
22	,	O
23	using	O
24	U5	B
25	RNA	I
26	affinity	O
27	selection	O
28	and	O
29	cDNA	O
30	cloning	O
31	.	O
1	All	O
2	were	O
3	experienced	O
4	hearing	O
5	aid	O
6	users	O
7	who	O
8	wore	O
9	linear	O
10	Class	O
11	D	O
12	instruments	O
13	with	O
14	input	O
15	compression	O
16	limiting	O
17	at	O
18	the	O
19	time	O
20	of	O
21	their	O
22	enrollment	O
23	in	O
24	this	O
25	study	O
26	.	O
1	Ribonuclease	O
2	protection	O
3	assays	O
4	revealed	O
5	that	O
6	hmg1	B
7	and	O
8	hmg2	B
9	are	O
10	differentially	O
11	expressed	O
12	in	O
13	a	O
14	developmentally	O
15	-	O
16	and	O
17	spatially	O
18	-	O
19	modulated	O
20	manner	O
21	during	O
22	morphogenesis	O
23	of	O
24	specialized	O
25	terpenoid	O
26	-	O
27	containing	O
28	pigment	O
29	glands	O
30	in	O
31	embryos	O
32	.	O
1	Inactivation	O
2	of	O
3	the	O
4	Neurospora	B
5	crassa	I
6	mitochondrial	I
7	outer	I
8	membrane	I
9	protein	I
10	TOM70	I
11	by	O
12	repeat	O
13	-	O
14	induced	O
15	point	O
16	mutation	O
17	(	O
18	RIP	O
19	)	O
20	causes	O
21	defects	O
22	in	O
23	mitochondrial	O
24	protein	O
25	import	O
26	and	O
27	morphology	O
28	.	O
1	A	O
2	panel	O
3	of	O
4	pharmacologic	O
5	inhibitors	O
6	was	O
7	used	O
8	to	O
9	investigate	O
10	the	O
11	signal	O
12	transduction	O
13	pathways	O
14	involved	O
15	in	O
16	TRAIL	B
17	gene	I
18	induction	O
19	following	O
20	T	O
21	lymphocyte	O
22	activation	O
23	.	O
1	A	O
2	total	O
3	of	O
4	174	O
5	primer	O
6	pairs	O
7	gave	O
8	interpretable	O
9	banding	O
10	patterns	O
11	,	O
12	137	O
13	(	O
14	79	O
15	%)	O
16	of	O
17	which	O
18	revealed	O
19	at	O
20	least	O
21	two	O
22	alleles	O
23	on	O
24	native	O
25	polyacrylamide	O
26	gels	O
27	.	O
1	IL	B
2	-	I
3	12	I
4	production	O
5	was	O
6	correlated	O
7	with	O
8	C3a	O
9	concentration	O
10	measured	O
11	at	O
12	the	O
13	outlet	O
14	of	O
15	hemodialyzer	O
16	after	O
17	15	O
18	min	O
19	of	O
20	dialysis	O
21	(	O
22	r	O
23	=	O
24	0	O
25	.	O
26	69	O
27	,	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	).	O
1	J	O
2	.	O
1	Our	O
2	results	O
3	implicate	O
4	TGF	B
5	-	I
6	beta	I
7	RII	I
8	as	O
9	a	O
10	direct	O
11	target	O
12	of	O
13	EWS	B
14	-	O
15	FLI1	B
16	.	O
1	A	O
2	local	O
3	,	O
4	high	O
5	-	O
6	density	O
7	,	O
8	single	O
9	-	O
10	nucleotide	O
11	polymorphism	O
12	map	O
13	used	O
14	to	O
15	clone	O
16	Caenorhabditis	B
17	elegans	I
18	cdf	I
19	-	I
20	1	I
21	.	O
1	High	O
2	-	O
3	level	O
4	expression	O
5	in	O
6	Escherichia	O
7	coli	O
8	of	O
9	selenocysteine	O
10	-	O
11	containing	O
12	rat	B
13	thioredoxin	I
14	reductase	I
15	utilizing	O
16	gene	O
17	fusions	O
18	with	O
19	engineered	O
20	bacterial	O
21	-	O
22	type	O
23	SECIS	O
24	elements	O
25	and	O
26	co	O
27	-	O
28	expression	O
29	with	O
30	the	O
31	selA	B
32	,	O
33	selB	B
34	and	O
35	selC	B
36	genes	I
37	.	O
1	In	O
2	Wnt	B
3	signaling	O
4	,	O
5	beta	B
6	-	I
7	catenin	I
8	and	O
9	plakoglobin	B
10	transduce	O
11	signals	O
12	to	O
13	the	O
14	nucleus	O
15	through	O
16	interactions	O
17	with	O
18	TCF	B
19	-	I
20	type	I
21	transcription	I
22	factors	I
23	.	O
1	For	O
2	EPV	O
3	3	O
4	,	O
5	10	O
6	,	O
7	or	O
8	40	O
9	,	O
10	the	O
11	bias	O
12	exceeded	O
13	25	O
14	%	O
15	for	O
16	7	O
17	,	O
18	3	O
19	,	O
20	and	O
21	1	O
22	in	O
23	the	O
24	8	O
25	-	O
26	predictor	O
27	model	O
28	respectively	O
29	,	O
30	when	O
31	a	O
32	conventional	O
33	selection	O
34	criterion	O
35	was	O
36	used	O
37	(	O
38	alpha	O
39	=	O
40	0	O
41	.	O
42	05	O
43	).	O
1	At	O
2	all	O
3	time	O
4	-	O
5	points	O
6	,	O
7	most	O
8	patients	O
9	(>/=	O
10	87	O
11	%)	O
12	were	O
13	receiving	O
14	irbesartan	O
15	/	O
16	HCTZ	O
17	alone	O
18	.	O
1	Although	O
2	upstream	O
3	regulators	O
4	of	O
5	Tec	B
6	family	I
7	kinases	I
8	are	O
9	relatively	O
10	well	O
11	characterized	O
12	,	O
13	little	O
14	is	O
15	known	O
16	of	O
17	the	O
18	downstream	O
19	effectors	O
20	of	O
21	these	O
22	enzymes	O
23	.	O
1	Efficient	O
2	phosphorylation	O
3	of	O
4	BRDG1	B
5	by	O
6	Tec	B
7	required	O
8	the	O
9	PH	B
10	and	O
11	SH2	B
12	domains	I
13	as	O
14	well	O
15	as	O
16	the	O
17	kinase	O
18	domain	O
19	of	O
20	the	O
21	latter	O
22	.	O
1	ESS	O
2	type	O
3	1	O
4	,	O
5	with	O
6	FT3	O
7	low	O
8	and	O
9	FT4	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O
1	The	O
2	factor	O
3	designated	O
4	B	O
5	formed	O
6	a	O
7	complex	O
8	centered	O
9	on	O
10	the	O
11	sequence	O
12	TGTGGT	O
13	,	O
14	a	O
15	core	O
16	motif	O
17	recognized	O
18	by	O
19	members	O
20	of	O
21	the	O
22	AML	B
23	/	I
24	CBFalpha	I
25	transcription	I
26	factor	I
27	family	I
28	.	O
1	RNase	B
2	MRP	I
3	is	O
4	a	O
5	ribonucleoprotein	O
6	endoribonuclease	O
7	that	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	have	O
13	roles	O
14	in	O
15	both	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	and	O
20	nuclear	B
21	5	I
22	.	I
23	8S	I
24	rRNA	I
25	processing	O
26	.	O
1	Rac	B
2	causes	O
3	uncapping	O
4	of	O
5	actin	B
6	filaments	I
7	(	O
8	F	B
9	-	I
10	actin	I
11	)	O
12	at	O
13	the	O
14	plus	O
15	-	O
16	ends	O
17	,	O
18	through	O
19	phosphatidylinositol	O
20	4	O
21	,	O
22	5	O
23	bisphosphate	O
24	(	O
25	PIP2	O
26	),	O
27	and	O
28	eventually	O
29	induces	O
30	membrane	O
31	ruffling	O
32	.	O
1	RESULTS	O
2	:	O
3	Factors	O
4	associated	O
5	with	O
6	significantly	O
7	(	O
8	P	O
9	<.	O
10	05	O
11	)	O
12	increased	O
13	risk	O
14	of	O
15	treatment	O
16	failure	O
17	in	O
18	a	O
19	Cox	O
20	multivariate	O
21	analysis	O
22	included	O
23	age	O
24	older	O
25	than	O
26	45	O
27	years	O
28	(	O
29	relative	O
30	hazard	O
31	,	O
32	1	O
33	.	O
34	17	O
35	;	O
36	95	O
37	%	O
38	confidence	O
39	interval	O
40	[	O
41	CI	O
42	],	O
43	1	O
44	.	O
45	02	O
46	-	O
47	1	O
48	.	O
49	33	O
50	),	O
51	Karnofsky	O
52	performance	O
53	score	O
54	less	O
55	than	O
56	90	O
57	%	O
58	(	O
59	1	O
60	.	O
61	27	O
62	;	O
63	95	O
64	%	O
65	CI	O
66	,	O
67	1	O
68	.	O
69	07	O
70	-	O
71	1	O
72	.	O
73	51	O
74	),	O
75	absence	O
76	of	O
77	hormone	O
78	receptors	O
79	(	O
80	1	O
81	.	O
82	31	O
83	;	O
84	95	O
85	%	O
86	CI	O
87	,	O
88	1	O
89	.	O
90	15	O
91	-	O
92	1	O
93	.	O
94	51	O
95	),	O
96	prior	O
97	use	O
98	of	O
99	adjuvant	O
100	chemotherapy	O
101	(	O
102	1	O
103	.	O
104	31	O
105	;	O
106	95	O
107	%	O
108	CI	O
109	,	O
110	1	O
111	.	O
112	10	O
113	-	O
114	1	O
115	.	O
116	56	O
117	),	O
118	initial	O
119	disease	O
120	-	O
121	free	O
122	survival	O
123	interval	O
124	after	O
125	adjuvant	O
126	treatment	O
127	of	O
128	no	O
129	more	O
130	than	O
131	18	O
132	months	O
133	(	O
134	1	O
135	.	O
136	99	O
137	;	O
138	95	O
139	%	O
140	CI	O
141	,	O
142	1	O
143	.	O
144	62	O
145	-	O
146	2	O
147	.	O
148	43	O
149	),	O
150	metastases	O
151	in	O
152	the	O
153	liver	O
154	(	O
155	1	O
156	.	O
157	47	O
158	;	O
159	95	O
160	%	O
161	CI	O
162	,	O
163	1	O
164	.	O
165	20	O
166	-	O
167	1	O
168	.	O
169	80	O
170	)	O
171	or	O
172	central	O
173	nervous	O
174	system	O
175	(	O
176	1	O
177	.	O
178	56	O
179	;	O
180	95	O
181	%	O
182	CI	O
183	,	O
184	0	O
185	.	O
186	99	O
187	-	O
188	2	O
189	.	O
190	46	O
191	[	O
192	approaches	O
193	significance	O
194	])	O
195	vs	O
196	soft	O
197	tissue	O
198	,	O
199	bone	O
200	,	O
201	or	O
202	lung	O
203	,	O
204	3	O
205	or	O
206	more	O
207	sites	O
208	of	O
209	metastatic	O
210	disease	O
211	(	O
212	1	O
213	.	O
214	32	O
215	;	O
216	95	O
217	%	O
218	CI	O
219	,	O
220	1	O
221	.	O
222	13	O
223	-	O
224	1	O
225	.	O
226	54	O
227	),	O
228	and	O
229	incomplete	O
230	response	O
231	vs	O
232	complete	O
233	response	O
234	to	O
235	standard	O
236	-	O
237	dose	O
238	chemotherapy	O
239	(	O
240	1	O
241	.	O
242	65	O
243	;	O
244	95	O
245	%	O
246	CI	O
247	,	O
248	1	O
249	.	O
250	36	O
251	-	O
252	1	O
253	.	O
254	99	O
255	).	O
1	The	O
2	N	O
3	-	O
4	terminal	O
5	domain	O
6	of	O
7	approximately	O
8	70	O
9	kDa	O
10	exhibits	O
11	11	O
12	imperfect	O
13	amino	O
14	acid	O
15	repeats	O
16	that	O
17	show	O
18	some	O
19	homology	O
20	to	O
21	promastigote	O
22	surface	O
23	glycoproteins	O
24	of	O
25	the	O
26	psa2	B
27	/	O
28	gp46	B
29	complex	O
30	.	O
1	Animals	O
2	were	O
3	put	O
4	to	O
5	death	O
6	8	O
7	weeks	O
8	later	O
9	and	O
10	the	O
11	grafts	O
12	were	O
13	sterilely	O
14	explanted	O
15	and	O
16	analyzed	O
17	via	O
18	microbiologic	O
19	culture	O
20	and	O
21	standard	O
22	histologic	O
23	procedures	O
24	for	O
25	evidence	O
26	of	O
27	infection	O
28	.	O
1	C	O
2	-	O
3	SP	O
4	duration	O
5	was	O
6	significantly	O
7	reduced	O
8	in	O
9	ALS	O
10	patients	O
11	compared	O
12	to	O
13	controls	O
14	at	O
15	low	O
16	stimulation	O
17	intensity	O
18	corresponding	O
19	to	O
20	an	O
21	MEP	O
22	threshold	O
23	increased	O
24	by	O
25	15	O
26	%.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	spv	B
7	virulence	I
8	genes	I
9	belong	O
10	simultaneously	O
11	to	O
12	several	O
13	regulons	O
14	in	O
15	the	O
16	cell	O
17	,	O
18	raising	O
19	the	O
20	possibility	O
21	that	O
22	spv	B
23	expression	O
24	can	O
25	be	O
26	fine	O
27	-	O
28	tuned	O
29	in	O
30	response	O
31	to	O
32	multiple	O
33	environmental	O
34	inputs	O
35	.	O
1	Intensive	O
2	synthesis	O
3	of	O
4	PNA	B
5	in	O
6	the	O
7	cells	O
8	of	O
9	microvascular	O
10	wall	O
11	evidenced	O
12	of	O
13	their	O
14	high	O
15	functional	O
16	activity	O
17	,	O
18	and	O
19	the	O
20	synthesis	O
21	of	O
22	DNA	O
23	in	O
24	them	O
25	showed	O
26	their	O
27	ability	O
28	for	O
29	proliferation	O
30	,	O
31	i	O
32	.	O
33	g	O
34	.--	O
35	for	O
36	growth	O
37	.	O
1	Albumin	O
2	expression	O
3	is	O
4	maintained	O
5	in	O
6	the	O
7	liver	O
8	by	O
9	a	O
10	combination	O
11	of	O
12	liver	O
13	-	O
14	enriched	O
15	transcription	O
16	factors	O
17	such	O
18	as	O
19	CAAT	B
20	enhancer	I
21	-	I
22	binding	I
23	protein	I
24	(	I
25	C	I
26	/	I
27	EBP	I
28	)	I
29	alpha	I
30	and	O
31	C	B
32	/	I
33	EBPbeta	I
34	.	O
1	We	O
2	also	O
3	show	O
4	that	O
5	activation	O
6	of	O
7	protein	B
8	kinase	I
9	A	I
10	(	O
11	PKA	B
12	)	O
13	signaling	O
14	is	O
15	sufficient	O
16	to	O
17	down	O
18	-	O
19	regulate	O
20	caveolin	B
21	-	I
22	1	I
23	protein	I
24	expression	O
25	and	O
26	promoter	O
27	activity	O
28	.	O
1	Despite	O
2	i	O
3	.	O
4	v	O
5	.	O
6	steroid	O
7	therapy	O
8	,	O
9	[	O
10	NOexh	O
11	]	O
12	remained	O
13	elevated	O
14	throughout	O
15	recovery	O
16	(	O
17	37	O
18	.	O
19	9	O
20	+/-	O
21	4	O
22	.	O
23	8	O
24	ppb	O
25	,	O
26	p	O
27	<	O
28	0	O
29	.	O
30	001	O
31	)	O
32	until	O
33	discharge	O
34	(	O
35	40	O
36	.	O
37	9	O
38	+/-	O
39	4	O
40	.	O
41	3	O
42	ppb	O
43	,	O
44	p	O
45	<	O
46	0	O
47	.	O
48	001	O
49	).	O
1	It	O
2	contains	O
3	binding	O
4	sites	O
5	for	O
6	several	O
7	transcription	O
8	factors	O
9	,	O
10	for	O
11	example	O
12	:	O
13	(	O
14	i	O
15	)	O
16	a	O
17	well	O
18	-	O
19	characterized	O
20	binding	O
21	site	O
22	for	O
23	rel	B
24	/	O
25	NF	B
26	-	I
27	kappaB	I
28	transcription	O
29	factors	O
30	in	O
31	its	O
32	3	O
33	'-	O
34	end	O
35	(	O
36	the	O
37	H2TF1	B
38	or	O
39	kappaB1	B
40	element	I
41	),	O
42	(	O
43	ii	O
44	)	O
45	a	O
46	second	O
47	kappaB	B
48	site	I
49	(	O
50	the	O
51	kappaB2	B
52	element	I
53	),	O
54	which	O
55	is	O
56	located	O
57	immediately	O
58	adjacent	O
59	5	O
60	'	O
61	to	O
62	the	O
63	H2TF1	B
64	element	I
65	and	O
66	which	O
67	is	O
68	recognized	O
69	by	O
70	p65	B
71	/	O
72	relA	B
73	in	O
74	the	O
75	human	B
76	HLA	I
77	system	O
78	,	O
79	and	O
80	(	O
81	iii	O
82	)	O
83	an	O
84	AP	B
85	-	I
86	1	I
87	/	O
88	ATF	B
89	recognition	O
90	sequence	O
91	in	O
92	the	O
93	5	O
94	'	O
95	end	O
96	(	O
97	EnA	B
98	-	I
99	TRE	I
100	).	O
1	FZD4	B
2	is	O
3	homologous	O
4	to	O
5	FZD9	B
6	and	O
7	FZD10	B
8	,	O
9	and	O
10	overall	O
11	amino	O
12	acid	O
13	identity	O
14	is	O
15	as	O
16	follows	O
17	:	O
18	FZD4	B
19	vs	O
20	FZD9	B
21	,	O
22	51	O
23	.	O
24	6	O
25	%;	O
26	FZD4	B
27	vs	O
28	FZD10	B
29	,	O
30	51	O
31	.	O
32	2	O
33	%;	O
34	FZD9	B
35	vs	O
36	FZD10	B
37	,	O
38	65	O
39	.	O
40	7	O
41	%.	O
1	EIAV	B
2	LTR	I
3	sequence	I
4	variability	O
5	is	O
6	confined	O
7	mostly	O
8	to	O
9	a	O
10	small	O
11	portion	O
12	of	O
13	the	O
14	enhancer	O
15	within	O
16	the	O
17	U3	O
18	segment	O
19	of	O
20	the	O
21	LTR	O
22	.	O
1	A	O
2	proportion	O
3	of	O
4	APC	B
5	wild	O
6	-	O
7	type	O
8	colon	O
9	carcinomas	O
10	and	O
11	melanomas	O
12	also	O
13	contains	O
14	constitutive	O
15	nuclear	O
16	Tcf	B
17	-	I
18	4	I
19	/	O
20	beta	B
21	-	I
22	catenin	I
23	complexes	O
24	as	O
25	a	O
26	result	O
27	of	O
28	dominant	O
29	mutations	O
30	in	O
31	the	O
32	N	O
33	terminus	O
34	of	O
35	beta	B
36	-	I
37	catenin	I
38	that	O
39	render	O
40	it	O
41	insensitive	O
42	to	O
43	downregulation	O
44	by	O
45	APC	B
46	,	O
47	GSK3	B
48	beta	I
49	,	O
50	and	O
51	Axin	B
52	/	O
53	Conductin	B
54	.	O
1	In	O
2	an	O
3	earlier	O
4	study	O
5	(	O
6	Kimura	O
7	,	O
8	Y	O
9	.,	O
10	Kurzydlowski	O
11	,	O
12	K	O
13	.,	O
14	Tada	O
15	,	O
16	M	O
17	.,	O
18	and	O
19	MacLennan	O
20	,	O
21	D	O
22	.	O
1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	O
7	1a	B
8	is	O
9	a	O
10	distant	O
11	homolog	B
12	of	I
13	alphavirus	I
14	nonstructural	I
15	protein	I
16	nsP1	I
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	O
23	capping	O
24	viral	O
25	RNAs	O
26	.	O
1	CONCLUSION	O
2	(	O
3	S	O
4	):	O
5	Measuring	O
6	urinary	O
7	LH	B
8	levels	O
9	is	O
10	an	O
11	excellent	O
12	method	O
13	for	O
14	determining	O
15	ovulation	O
16	.	O
1	We	O
2	present	O
3	a	O
4	case	O
5	of	O
6	carcinoma	O
7	of	O
8	the	O
9	breast	O
10	presenting	O
11	concurrently	O
12	with	O
13	SSc	O
14	that	O
15	subsequently	O
16	progressed	O
17	to	O
18	dialysis	O
19	-	O
20	dependent	O
21	renal	O
22	failure	O
23	in	O
24	just	O
25	1	O
26	month	O
27	.	O
1	In	O
2	contrast	O
3	,	O
4	AP	B
5	-	I
6	2	I
7	binding	O
8	activity	O
9	was	O
10	significantly	O
11	greater	O
12	in	O
13	T47D	O
14	cells	O
15	,	O
16	and	O
17	Western	O
18	blots	O
19	confirmed	O
20	increased	O
21	AP	B
22	-	I
23	2	I
24	protein	I
25	levels	O
26	in	O
27	these	O
28	cells	O
29	.	O
1	In	O
2	addition	O
3	,	O
4	all	O
5	three	O
6	Opa	B
7	proteins	I
8	of	O
9	C751	O
10	bind	O
11	equally	O
12	well	O
13	to	O
14	HeLa	O
15	cells	O
16	transfected	O
17	with	O
18	cDNA	O
19	encoding	O
20	the	O
21	carcinoembryonic	B
22	antigen	I
23	[	O
24	CEA	B
25	(	O
26	CD66e	B
27	)]	O
28	subgroup	O
29	of	O
30	the	O
31	CD66	B
32	family	I
33	,	O
34	but	O
35	show	O
36	distinct	O
37	tropism	O
38	for	O
39	CGM1	B
40	-	O
41	(	O
42	CD66d	B
43	)	O
44	and	O
45	NCA	B
46	(	O
47	CD66c	B
48	)-	O
49	expressing	O
50	cells	O
51	.	O
1	Additional	O
2	studies	O
3	revealed	O
4	that	O
5	bovine	B
6	brain	I
7	Galpha	I
8	(	I
9	q	I
10	/	I
11	11	I
12	)	I
13	could	O
14	also	O
15	bind	O
16	to	O
17	an	O
18	N	O
19	-	O
20	terminal	O
21	construct	O
22	of	O
23	GRK2	B
24	,	O
25	while	O
26	no	O
27	binding	O
28	of	O
29	Galpha	O
30	(	O
31	q	O
32	/	O
33	11	O
34	),	O
35	Galpha	O
36	(	O
37	s	O
38	),	O
39	Galpha	O
40	(	O
41	i	O
42	),	O
43	or	O
44	Galpha	B
45	(	I
46	12	I
47	/	I
48	13	I
49	)	I
50	to	O
51	comparable	O
52	constructs	O
53	of	O
54	GRK5	B
55	or	O
56	GRK6	B
57	was	O
58	observed	O
59	.	O
1	The	O
2	level	O
3	of	O
4	serum	B
5	creatine	I
6	kinase	I
7	was	O
8	significantly	O
9	high	O
10	2	O
11	days	O
12	after	O
13	ESWIB	O
14	,	O
15	but	O
16	it	O
17	recovered	O
18	in	O
19	a	O
20	week	O
21	.	O
1	A	O
2	phylogenetic	O
3	analysis	O
4	with	O
5	the	O
6	TK	B
7	domains	I
8	from	O
9	these	O
10	sequences	O
11	and	O
12	a	O
13	fourth	O
14	,	O
15	from	O
16	a	O
17	novel	O
18	scavenger	B
19	RTK	I
20	(	O
21	all	O
22	domains	O
23	comprise	O
24	the	O
25	signature	O
26	for	O
27	the	O
28	TK	B
29	class	I
30	II	I
31	receptors	I
32	),	O
33	showed	O
34	that	O
35	they	O
36	are	O
37	distantly	O
38	related	O
39	to	O
40	the	O
41	insulin	B
42	and	O
43	insulin	B
44	-	I
45	like	I
46	receptors	I
47	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	both	O
6	transcription	O
7	activators	O
8	depend	O
9	on	O
10	or	O
11	interact	O
12	with	O
13	different	O
14	subunits	O
15	of	O
16	RNA	B
17	polymerase	I
18	,	O
19	although	O
20	their	O
21	role	O
22	in	O
23	formation	O
24	of	O
25	proper	O
26	DNA	O
27	geometry	O
28	may	O
29	also	O
30	be	O
31	crucial	O
32	.	O
1	Klebsiella	O
2	oxytoca	O
3	can	O
4	assimilate	O
5	nitrate	O
6	and	O
7	nitrite	O
8	by	O
9	using	O
10	enzymes	O
11	encoded	O
12	by	O
13	the	O
14	nasFEDCBA	B
15	operon	I
16	.	O
1	Marked	O
2	hemolysis	O
3	significantly	O
4	increased	O
5	plasma	O
6	values	O
7	of	O
8	potassium	O
9	,	O
10	phosphorus	O
11	,	O
12	total	O
13	protein	O
14	,	O
15	and	O
16	aspartate	B
17	aminotransferase	I
18	.	O
1	Based	O
2	on	O
3	subcellular	O
4	fractionation	O
5	,	O
6	the	O
7	47	B
8	-	I
9	kDa	I
10	P	I
11	-	I
12	CIP2	I
13	protein	I
14	is	O
15	mostly	O
16	cytosolic	O
17	.	O
1	Conversely	O
2	,	O
3	E1A	B
4	binding	O
5	to	O
6	only	O
7	p300	B
8	/	O
9	CBP	B
10	results	O
11	in	O
12	an	O
13	increase	O
14	in	O
15	PARP	B
16	enzyme	I
17	activity	O
18	and	O
19	consequently	O
20	in	O
21	cell	O
22	death	O
23	susceptibility	O
24	to	O
25	irradiation	O
26	,	O
27	which	O
28	is	O
29	effectively	O
30	counteracted	O
31	by	O
32	the	O
33	PARP	B
34	chemical	O
35	inhibitor	O
36	3	O
37	-	O
38	aminobenzamide	O
39	.	O
1	This	O
2	distinction	O
3	was	O
4	based	O
5	upon	O
6	whether	O
7	the	O
8	diagnosis	O
9	provided	O
10	a	O
11	straightforward	O
12	range	O
13	of	O
14	prognoses	O
15	or	O
16	an	O
17	ambiguous	O
18	clinical	O
19	implication	O
20	.	O
1	The	O
2	availability	O
3	of	O
4	potent	O
5	regulatory	O
6	DNA	O
7	cassettes	O
8	harboring	O
9	the	O
10	murine	B
11	D1A	I
12	gene	I
13	promoter	I
14	could	O
15	aid	O
16	testing	O
17	the	O
18	neuronal	O
19	-	O
20	specific	O
21	expression	O
22	of	O
23	transgenes	O
24	in	O
25	vivo	O
26	.	O
1	Recombinant	B
2	prenylcysteine	I
3	lyase	I
4	was	O
5	produced	O
6	in	O
7	a	O
8	baculovirus	O
9	-	O
10	Sf9	O
11	expression	O
12	system	O
13	.	O
1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	low	O
8	binding	O
9	activity	O
10	of	O
11	CBF	B
12	to	O
13	the	O
14	wild	B
15	-	I
16	type	I
17	AtpC	I
18	promoter	I
19	sequence	I
20	was	O
21	observed	O
22	with	O
23	nuclear	O
24	extracts	O
25	from	O
26	tissue	O
27	with	O
28	low	O
29	AtpC	B
30	expression	O
31	levels	O
32	,	O
33	i	O
34	.	O
35	e	O
36	.	O
37	extracts	O
38	from	O
39	etiolated	O
40	and	O
41	photobleached	O
42	seedlings	O
43	,	O
44	whereas	O
45	high	O
46	binding	O
47	activity	O
48	was	O
49	detectable	O
50	with	O
51	extracts	O
52	from	O
53	tissues	O
54	with	O
55	high	O
56	AtpC	B
57	expression	O
58	levels	O
59	,	O
60	i	O
61	.	O
62	e	O
63	.	O
64	extracts	O
65	from	O
66	light	O
67	-	O
68	grown	O
69	seedlings	O
70	and	O
71	etiolated	O
72	seedlings	O
73	treated	O
74	with	O
75	cytokinin	B
76	.	O
1	They	O
2	are	O
3	subdivided	O
4	into	O
5	two	O
6	types	O
7	that	O
8	activate	O
9	transduction	O
10	pathways	O
11	via	O
12	different	O
13	cell	O
14	surface	O
15	receptors	O
16	.	O
1	Demyelinating	O
2	diseases	O
3	involving	O
4	the	O
5	grey	O
6	matter	O
7	were	O
8	very	O
9	rare	O
10	,	O
11	but	O
12	we	O
13	must	O
14	consider	O
15	the	O
16	presence	O
17	of	O
18	symmetrical	O
19	thalamic	O
20	involvement	O
21	in	O
22	patients	O
23	with	O
24	ADEM	O
25	.	O
1	To	O
2	define	O
3	the	O
4	minimal	O
5	VDRE	O
6	binding	O
7	domain	O
8	for	O
9	human	B
10	VDR	I
11	(	O
12	hVDR	B
13	),	O
14	a	O
15	series	O
16	of	O
17	C	O
18	-	O
19	terminally	O
20	truncated	O
21	hVDR	B
22	mutants	I
23	(	O
24	Delta134	O
25	,	O
26	Delta113	O
27	,	O
28	Delta102	O
29	,	O
30	Delta90	O
31	,	O
32	Delta84	O
33	,	O
34	Delta80	O
35	,	O
36	and	O
37	Delta60	O
38	)	O
39	was	O
40	generated	O
41	and	O
42	expressed	O
43	in	O
44	bacteria	O
45	.	O
1	By	O
2	an	O
3	induced	O
4	-	O
5	fit	O
6	mechanism	O
7	,	O
8	contacts	O
9	with	O
10	the	O
11	anticodon	O
12	can	O
13	activate	O
14	formation	O
15	of	O
16	a	O
17	robust	O
18	transition	O
19	state	O
20	at	O
21	a	O
22	site	O
23	over	O
24	70	O
25	A	O
26	away	O
27	.	O
1	Measurements	O
2	in	O
3	the	O
4	LWS	O
5	p	O
6	.	O
7	a	O
8	.	O
9	,	O
10	LWS	O
11	lat	O
12	.	O
13	and	O
14	at	O
15	Ward	O
16	'	O
17	s	O
18	triangle	O
19	were	O
20	made	O
21	in	O
22	a	O
23	total	O
24	of	O
25	100	O
26	patients	O
27	.	O
1	In	O
2	summary	O
3	,	O
4	WT1	B
5	is	O
6	enriched	O
7	by	O
8	oligo	O
9	(	O
10	dT	O
11	)	O
12	chromatography	O
13	,	O
14	as	O
15	are	O
16	U2AF65	B
17	,	O
18	the	O
19	U5	B
20	small	I
21	nuclear	I
22	RNP	I
23	-	I
24	associated	I
25	protein	I
26	p116	I
27	and	O
28	hnRNP	O
29	A1	B
30	.	O
1	Six	O
2	out	O
3	of	O
4	ten	O
5	hearts	O
6	from	O
7	macerated	O
8	stillborn	O
9	infants	O
10	showed	O
11	varying	O
12	degrees	O
13	of	O
14	positive	O
15	staining	O
16	.	O
1	There	O
2	were	O
3	minimal	O
4	negative	O
5	effects	O
6	on	O
7	hematological	O
8	parameters	O
9	,	O
10	acid	O
11	-	O
12	base	O
13	status	O
14	,	O
15	and	O
16	blood	O
17	gases	O
18	.	O
1	Twelve	O
2	out	O
3	of	O
4	43	O
5	renal	O
6	failure	O
7	patients	O
8	had	O
9	troponin	B
10	I	I
11	0	O
12	.	O
13	13	O
14	-	O
15	0	O
16	.	O
17	9	O
18	microg	O
19	/	O
20	l	O
21	using	O
22	Axsym	O
23	method	O
24	and	O
25	4	O
26	had	O
27	levels	O
28	of	O
29	0	O
30	.	O
31	07	O
32	-	O
33	0	O
34	.	O
35	13	O
36	microg	O
37	/	O
38	l	O
39	using	O
40	Immuno	O
41	1	O
42	.	O
1	GHB	O
2	,	O
3	2	O
4	CB	O
5	,	O
6	HMB	O
7	,	O
8	are	O
9	some	O
10	of	O
11	these	O
12	recent	O
13	substances	O
14	.	O
1	In	O
2	addition	O
3	,	O
4	SLK	B
5	displays	O
6	high	O
7	homology	O
8	to	O
9	microtubule	B
10	and	I
11	nuclear	I
12	associated	I
13	protein	I
14	(	O
15	M	B
16	-	I
17	NAP	I
18	)	O
19	and	O
20	AT1	B
21	-	I
22	46	I
23	,	O
24	both	O
25	of	O
26	unknown	O
27	function	O
28	.	O
1	STUDY	O
2	DESIGN	O
3	AND	O
4	METHODS	O
5	:	O
6	A	O
7	study	O
8	was	O
9	initiated	O
10	to	O
11	compare	O
12	the	O
13	collection	O
14	of	O
15	PBPCs	O
16	with	O
17	the	O
18	new	O
19	device	O
20	,	O
21	the	O
22	AutoPBSC	O
23	(	O
24	version	O
25	[	O
26	V	O
27	]	O
28	6	O
29	.	O
30	0	O
31	with	O
32	AutoPBSC	O
33	tubing	O
34	set	O
35	),	O
36	and	O
37	that	O
38	with	O
39	the	O
40	MNC	O
41	(	O
42	mononuclear	O
43	cell	O
44	)	O
45	procedure	O
46	(	O
47	V4	O
48	.	O
49	7	O
50	with	O
51	white	O
52	cell	O
53	tubing	O
54	set	O
55	),	O
56	for	O
57	patients	O
58	and	O
59	healthy	O
60	donors	O
61	.	O
1	Sak	B
2	kinase	I
3	gene	O
4	structure	O
5	and	O
6	transcriptional	O
7	regulation	O
8	.	O
1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O
1	Similar	O
2	to	O
3	Hp140	B
4	,	O
5	isolated	O
6	Hp55	B
7	binds	O
8	DNA	O
9	with	O
10	moderate	O
11	strength	O
12	and	O
13	was	O
14	a	O
15	specificity	O
16	for	O
17	double	O
18	-	O
19	stranded	O
20	primer	O
21	-	O
22	template	O
23	DNA	O
24	.	O
1	Northern	O
2	blot	O
3	and	O
4	reverse	O
5	transcription	O
6	-	O
7	PCR	O
8	analyses	O
9	of	O
10	human	O
11	mRNA	O
12	samples	O
13	demonstrate	O
14	that	O
15	RNR	B
16	is	O
17	expressed	O
18	exclusively	O
19	in	O
20	the	O
21	retina	O
22	,	O
23	with	O
24	transcripts	O
25	of	O
26	approximately	O
27	7	O
28	.	O
29	5	O
30	kb	O
31	,	O
32	approximately	O
33	3	O
34	.	O
35	0	O
36	kb	O
37	,	O
38	and	O
39	approximately	O
40	2	O
41	.	O
42	3	O
43	kb	O
44	by	O
45	Northern	O
46	blot	O
47	analysis	O
48	.	O
1	Statins	B
2	:	O
3	lower	O
4	lipids	O
5	and	O
6	better	O
7	bones	O
8	?	O
9	Although	O
10	statins	O
11	are	O
12	widely	O
13	used	O
14	as	O
15	cholesterol	O
16	-	O
17	lowering	O
18	drugs	O
19	,	O
20	a	O
21	recent	O
22	study	O
23	suggests	O
24	that	O
25	these	O
26	compounds	O
27	have	O
28	anabolic	O
29	effects	O
30	on	O
31	bone	O
32	and	O
33	could	O
34	be	O
35	developed	O
36	into	O
37	new	O
38	treatments	O
39	for	O
40	common	O
41	metabolic	O
42	bone	O
43	diseases	O
44	such	O
45	as	O
46	osteoporosis	O
1	The	O
2	accumulated	O
3	products	O
4	of	O
5	ancient	O
6	duplication	O
7	events	O
8	can	O
9	be	O
10	readily	O
11	observed	O
12	among	O
13	the	O
14	genes	O
15	encoding	O
16	voltage	O
17	-	O
18	dependent	O
19	Ca	O
20	(	O
21	2	O
22	+)	O
23	ion	O
24	channels	O
25	.	O
1	In	O
2	the	O
3	BF	O
4	ECT	O
5	group	O
6	the	O
7	-	O
8	age	O
9	based	O
10	dose	O
11	would	O
12	have	O
13	been	O
14	similarly	O
15	dependent	O
16	on	O
17	the	O
18	initial	O
19	seizure	O
20	threshold	O
21	level	O
22	.	O
1	Animal	O
2	studies	O
3	showed	O
4	that	O
5	beam	O
6	equalization	O
7	significantly	O
8	improved	O
9	fluoroscopic	O
10	and	O
11	angiographic	O
12	image	O
13	quality	O
14	.	O
1	Compared	O
2	to	O
3	those	O
4	with	O
5	normal	O
6	renal	O
7	functions	O
8	,	O
9	these	O
10	patients	O
11	were	O
12	older	O
13	(	O
14	P	O
15	<	O
16	or	O
17	=	O
18	0	O
19	.	O
20	01	O
21	),	O
22	had	O
23	significantly	O
24	elevated	O
25	blood	O
26	pressures	O
27	(	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	or	O
34	P	O
35	=	O
36	0	O
37	.	O
38	0001	O
39	),	O
40	and	O
41	in	O
42	the	O
43	case	O
44	of	O
45	Type	O
46	1	O
47	DM	O
48	,	O
49	with	O
50	a	O
51	higher	O
52	body	O
53	mass	O
54	index	O
55	(	O
56	P	O
57	=	O
58	0	O
59	.	O
60	0001	O
61	)	O
62	and	O
63	waist	O
64	-	O
65	hip	O
66	ratio	O
67	(	O
68	P	O
69	<	O
70	0	O
71	.	O
72	01	O
73	).	O
1	However	O
2	,	O
3	activation	O
4	of	O
5	the	O
6	cAMP	O
7	pathway	O
8	,	O
9	which	O
10	is	O
11	known	O
12	to	O
13	regulate	O
14	inhibin	B
15	alpha	I
16	expression	O
17	,	O
18	greatly	O
19	enhanced	O
20	the	O
21	actions	O
22	of	O
23	SF	B
24	-	I
25	1	I
26	.	O
1	Deletion	O
2	and	O
3	site	O
4	-	O
5	directed	O
6	mutagenesis	O
7	localized	O
8	a	O
9	novel	O
10	SF	B
11	-	I
12	1	I
13	regulatory	I
14	element	I
15	(	O
16	TCA	O
17	GGGCCA	O
18	;	O
19	-	O
20	137	O
21	to	O
22	-	O
23	129	O
24	)	O
25	adjacent	O
26	to	O
27	a	O
28	variant	O
29	cAMP	O
30	-	O
31	response	O
32	element	O
33	(	O
34	CRE	O
35	;	O
36	-	O
37	120	O
38	to	O
39	-	O
40	114	O
41	).	O
1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	APRE	O
8	is	O
9	a	O
10	cytokine	O
11	[	O
12	tumor	B
13	necrosis	I
14	factor	I
15	-	I
16	alpha	I
17	(	O
18	TNFalpha	B
19	)]-	O
20	inducible	O
21	enhancer	O
22	by	O
23	binding	O
24	the	O
25	heterodimeric	B
26	nuclear	I
27	factor	I
28	-	I
29	kappaB	I
30	(	O
31	NF	B
32	-	I
33	kappaB	I
34	)	O
35	complex	O
36	Rel	B
37	A	I
38	x	O
39	NF	B
40	-	I
41	kappaB1	I
42	.	O
1	In	O
2	addition	O
3	,	O
4	CaMig1	B
5	formed	O
6	specific	O
7	complexes	O
8	with	O
9	the	O
10	URS1	O
11	region	O
12	of	O
13	the	O
14	S	B
15	.	I
16	cerevisiae	I
17	FBP1	I
18	gene	I
19	.	O
1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	acetaminophen	O
7	overdose	O
8	that	O
9	was	O
10	treated	O
11	with	O
12	both	O
13	hemodialysis	O
14	(	O
15	HD	O
16	)	O
17	and	O
18	NAC	O
19	due	O
20	to	O
21	severe	O
22	intoxication	O
23	and	O
24	slow	O
25	drug	O
26	clearance	O
27	.	O
1	Induced	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	is	O
8	likely	O
9	to	O
10	contribute	O
11	to	O
12	the	O
13	proliferation	O
14	of	O
15	Stat1	B
16	-	O
17	null	O
18	cells	O
19	in	O
20	response	O
21	to	O
22	IFNs	B
23	.	O
1	Eastern	O
2	Cooperative	O
3	Oncology	O
4	Group	O
5	trial	O
6	E3186	O
7	was	O
8	initiated	O
9	to	O
10	explore	O
11	this	O
12	question	O
13	.	O
1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	B
7	-	I
8	FLAG	I
9	antibody	I
10	affinity	O
11	column	O
12	transferred	O
13	sulfate	O
14	to	O
15	heparan	O
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	glycosaminoglycans	O
24	.	O
1	Overexpression	O
2	of	O
3	ICBP90	B
4	in	O
5	COS	O
6	-	O
7	1	O
8	-	O
9	transfected	O
10	cells	O
11	induced	O
12	an	O
13	enhanced	O
14	expression	O
15	of	O
16	endogenous	B
17	topoisomerase	I
18	IIalpha	I
19	.	O
1	The	O
2	RNA	O
3	aptamer	O
4	contains	O
5	three	O
6	stems	O
7	separated	O
8	by	O
9	a	O
10	pair	O
11	of	O
12	two	O
13	-	O
14	base	O
15	bulges	O
16	,	O
17	and	O
18	adopts	O
19	an	O
20	unanticipated	O
21	fold	O
22	in	O
23	which	O
24	both	O
25	junctional	O
26	sites	O
27	are	O
28	anchored	O
29	through	O
30	base	O
31	triple	O
32	formation	O
33	.	O
1	To	O
2	quantify	O
3	any	O
4	mechanical	O
5	inhibitory	O
6	effect	O
7	of	O
8	nasal	O
9	intermittent	O
10	positive	O
11	pressure	O
12	ventilation	O
13	(	O
14	IPPV	O
15	)	O
16	on	O
17	inspiratory	O
18	activity	O
19	of	O
20	the	O
21	diaphragm	O
22	we	O
23	ventilated	O
24	five	O
25	conscious	O
26	relaxed	O
27	subjects	O
28	on	O
29	two	O
30	occasions	O
31	at	O
32	respiratory	O
33	rates	O
34	similar	O
35	to	O
36	quiet	O
37	breathing	O
38	(	O
39	QB	O
40	)	O
41	and	O
42	at	O
43	three	O
44	levels	O
45	of	O
46	applied	O
47	pressure	O
48	(	O
49	Pappl	O
50	)--	O
51	6	O
52	,	O
53	9	O
54	and	O
55	12	O
56	cmH2O	O
57	,	O
58	each	O
59	during	O
60	hypocapnia	O
61	(	O
62	P	O
63	(	O
64	CO2	O
65	)	O
66	allowed	O
67	to	O
68	decrease	O
69	)	O
70	and	O
71	eucapnia	O
72	(	O
73	CO2	O
74	added	O
75	to	O
76	inspired	O
77	gas	O
78	).	O
1	Neuronal	O
2	signaling	O
3	properties	O
4	are	O
5	largely	O
6	determined	O
7	by	O
8	the	O
9	quantity	O
10	and	O
11	combination	O
12	of	O
13	ion	O
14	channels	O
15	expressed	O
16	.	O
1	All	O
2	clones	O
3	and	O
4	strains	O
5	produced	O
6	have	O
7	been	O
8	deposited	O
9	in	O
10	the	O
11	EUROFAN	O
12	genetic	O
13	stock	O
14	centre	O
15	(	O
16	EUROSCARF	O
17	,	O
18	Frankfurt	O
19	).	O
1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	B
8	-	I
9	type	I
10	Fus3	I
11	intensifies	O
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	Ty1	B
17	transposition	O
18	and	O
19	invasive	O
20	growth	O
21	.	O
1	The	O
2	insulin	B
3	therapy	O
4	regimen	O
5	did	O
6	not	O
7	affect	O
8	the	O
9	evolution	O
10	of	O
11	the	O
12	patients	O
13	and	O
14	no	O
15	significant	O
16	relationship	O
17	existed	O
18	between	O
19	the	O
20	age	O
21	at	O
22	diagnosis	O
23	,	O
24	duration	O
25	of	O
26	diabetes	O
27	,	O
28	daily	O
29	insulin	B
30	dosage	O
31	or	O
32	metabolic	O
33	control	O
34	and	O
35	height	O
36	or	O
37	BMI	O
38	.	O
1	The	O
2	RING	O
3	finger	O
4	,	O
5	B2	O
6	box	O
7	,	O
8	and	O
9	coiled	O
10	-	O
11	coil	O
12	region	O
13	are	O
14	required	O
15	for	O
16	oligomerization	O
17	of	O
18	KAP	B
19	-	I
20	1	I
21	-	O
22	RBCC	B
23	and	O
24	KRAB	B
25	binding	O
26	,	O
27	as	O
28	mutations	O
29	in	O
30	these	O
31	domains	O
32	concomitantly	O
33	abolished	O
34	these	O
35	functions	O
36	.	O
1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	O
8	-	O
9	threonine	O
10	-	O
11	rich	O
12	peptides	O
13	.	O
1	We	O
2	critically	O
3	assess	O
4	current	O
5	systematic	O
6	uncertainties	O
7	and	O
8	determine	O
9	the	O
10	primordial	O
11	Li	O
12	abundance	O
13	within	O
14	new	O
15	,	O
16	much	O
17	tighter	O
18	limits	O
19	:	O
20	&	O
21	amp	O
22	;	O
23	parl0	O
24	;	O
25	Li	O
26	&	O
27	amp	O
28	;	O
29	solm0	O
30	;	O
31	H	O
32	&	O
33	amp	O
34	;	O
35	parr0	O
36	;	O
37	p	O
38	=	O
39	1	O
40	.	O
41	23	O
42	+	O
43	0	O
44	.	O
45	68	O
46	-	O
47	0	O
48	.	O
49	32x10	O
50	-	O
51	10	O
52	.	O
1	Thus	O
2	,	O
3	SOX8	B
4	is	O
5	a	O
6	good	O
7	candidate	O
8	gene	O
9	contributing	O
10	to	O
11	the	O
12	mental	O
13	retardation	O
14	phenotype	O
15	seen	O
16	in	O
17	ATR	O
18	-	O
19	16	O
20	patients	O
21	.	O
1	Diverse	O
2	endogenous	O
3	light	O
4	chains	O
5	contribute	O
6	to	O
7	basement	O
8	membrane	O
9	reactivity	O
10	in	O
11	nonautoimmune	O
12	mice	O
13	transgenic	O
14	for	O
15	an	O
16	anti	B
17	-	I
18	laminin	I
19	Ig	I
20	heavy	I
21	chain	I
22	.	O
1	ZK7	B
2	and	O
3	HZF16	B
4	genes	I
5	appear	O
6	to	O
7	be	O
8	the	O
9	splice	O
10	variants	O
11	transcribed	O
12	from	O
13	the	O
14	same	O
15	gene	O
16	.	O
1	Two	O
2	distinct	O
3	Salmonella	B
4	fimbrins	I
5	,	O
6	AgfA	B
7	and	O
8	SefA	B
9	,	O
10	comprising	O
11	thin	O
12	aggregative	O
13	fimbriae	O
14	SEF17	B
15	and	O
16	SEF14	B
17	,	O
18	respectively	O
19	,	O
20	were	O
21	each	O
22	genetically	O
23	engineered	O
24	to	O
25	carry	O
26	PT3	B
27	,	O
28	an	O
29	alpha	O
30	-	O
31	helical	O
32	16	O
33	-	O
34	amino	O
35	acid	O
36	Leishmania	O
37	T	O
38	-	O
39	cell	O
40	epitope	O
41	derived	O
42	from	O
43	the	O
44	metalloprotease	B
45	gp63	I
46	.	O
1	Multiple	O
2	mitogen	B
3	-	I
4	activated	I
5	protein	I
6	kinase	I
7	signaling	O
8	pathways	O
9	connect	O
10	the	O
11	cot	B
12	oncoprotein	I
13	to	O
14	the	O
15	c	B
16	-	I
17	jun	I
18	promoter	I
19	and	O
20	to	O
21	cellular	O
22	transformation	O
23	.	O
1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O
1	For	O
2	wild	O
3	type	O
4	MutT	B
5	and	O
6	its	O
7	E53D	B
8	and	O
9	E44D	B
10	mutants	I
11	,	O
12	plots	O
13	of	O
14	log	O
15	(	O
16	k	O
17	(	O
18	cat	O
19	))	O
20	versus	O
21	pH	O
22	exhibited	O
23	a	O
24	limiting	O
25	slope	O
26	of	O
27	1	O
28	on	O
29	the	O
30	ascending	O
31	limb	O
32	and	O
33	then	O
34	a	O
35	hump	O
36	,	O
37	i	O
38	.	O
39	e	O
40	.,	O
41	a	O
42	sharply	O
43	defined	O
44	maximum	O
45	near	O
46	pH	O
47	8	O
48	followed	O
49	by	O
50	a	O
51	plateau	O
52	,	O
53	yielding	O
54	apparent	O
55	pK	O
56	(	O
57	a	O
58	)	O
59	values	O
60	of	O
61	7	O
62	.	O
63	6	O
64	+/-	O
65	0	O
66	.	O
67	3	O
68	and	O
69	8	O
70	.	O
71	4	O
72	+/-	O
73	0	O
74	.	O
75	4	O
76	for	O
77	an	O
78	essential	O
79	base	O
80	and	O
81	a	O
82	nonessential	O
83	acid	O
84	catalyst	O
85	,	O
86	respectively	O
87	,	O
88	in	O
89	the	O
90	active	O
91	quaternary	O
92	MutT	B
93	-	O
94	Mg	O
95	(	O
96	2	O
97	+)-	O
98	dGTP	O
99	-	O
100	Mg	O
101	(	O
102	2	O
103	+)	O
104	complex	O
105	.	O
1	A	O
2	385	O
3	bp	O
4	Glucocorticoid	O
5	Response	O
6	Unit	O
7	(	O
8	GRU	O
9	)	O
10	was	O
11	identified	O
12	whose	O
13	glucocorticoid	O
14	induction	O
15	was	O
16	enhanced	O
17	by	O
18	dibutyryl	O
19	-	O
20	cAMP	O
21	and	O
22	reduced	O
23	by	O
24	phorbol	O
25	esters	O
26	.	O
1	Sulfhydryl	O
2	titration	O
3	with	O
4	iodoacetamide	O
5	,	O
6	monitored	O
7	by	O
8	quantitating	O
9	the	O
10	residual	O
11	thiols	O
12	after	O
13	reaction	O
14	with	O
15	a	O
16	maleimide	O
17	derivative	O
18	of	O
19	biotin	O
20	,	O
21	revealed	O
22	a	O
23	striking	O
24	difference	O
25	in	O
26	the	O
27	apparent	O
28	pK	O
29	(	O
30	a	O
31	)	O
32	values	O
33	of	O
34	the	O
35	cysteines	O
36	at	O
37	the	O
38	two	O
39	splice	O
40	junctions	O
41	.	O
1	The	O
2	requirement	O
3	of	O
4	3	O
5	'	O
6	complementarity	O
7	for	O
8	a	O
9	ligation	O
10	reaction	O
11	is	O
12	reaffirmed	O
13	by	O
14	results	O
15	from	O
16	1	O
17	nt	O
18	insertions	O
19	on	O
20	either	O
21	the	O
22	3	O
23	'-	O
24	or	O
25	5	O
26	'-	O
27	side	O
28	of	O
29	the	O
30	nick	O
31	.	O
1	NKX2	B
2	.	I
3	1	I
4	is	O
5	a	O
6	member	O
7	of	O
8	the	O
9	NK2	B
10	family	I
11	of	O
12	homeodomain	B
13	-	I
14	containing	I
15	transcription	I
16	factors	I
17	whose	O
18	targeted	O
19	disruption	O
20	in	O
21	mouse	O
22	results	O
23	in	O
24	the	O
25	absence	O
26	of	O
27	thyroid	O
28	tissue	O
29	and	O
30	a	O
31	severely	O
32	abnormal	O
33	lung	O
34	phenotype	O
35	.	O
1	This	O
2	repression	O
3	does	O
4	not	O
5	require	O
6	the	O
7	PU	B
8	.	I
9	1	I
10	transactivation	O
11	or	O
12	PEST	O
13	domains	O
14	and	O
15	cannot	O
16	be	O
17	reversed	O
18	by	O
19	p300	B
20	expression	O
21	.	O
1	First	O
2	,	O
3	human	O
4	erythroid	O
5	K562	O
6	cells	O
7	stably	O
8	integrated	O
9	with	O
10	various	O
11	HS	B
12	-	I
13	40	I
14	mutants	I
15	cis	O
16	linked	O
17	to	O
18	a	O
19	human	B
20	alpha	I
21	-	I
22	globin	I
23	promoter	I
24	-	O
25	growth	B
26	hormone	I
27	hybrid	O
28	gene	O
29	were	O
30	analyzed	O
31	by	O
32	genomic	O
33	footprinting	O
34	and	O
35	expression	O
36	analysis	O
37	.	O
1	Its	O
2	cognate	O
3	binding	O
4	protein	O
5	,	O
6	REST	B
7	/	O
8	NRSF	B
9	,	O
10	is	O
11	an	O
12	essential	O
13	transcription	O
14	factor	O
15	;	O
16	its	O
17	null	O
18	mutations	O
19	result	O
20	in	O
21	embryonic	O
22	lethality	O
23	,	O
24	and	O
25	its	O
26	dominant	O
27	negative	O
28	mutants	O
29	produce	O
30	aberrant	O
31	expression	O
32	of	O
33	neuron	O
34	-	O
35	specific	O
36	genes	O
37	.	O
1	Removal	O
2	of	O
3	all	O
4	core	B
5	histone	I
6	tail	O
7	domains	O
8	by	O
9	limited	O
10	trypsin	B
11	proteolysis	O
12	or	O
13	acetylation	O
14	of	O
15	the	O
16	core	B
17	histone	I
18	tails	O
19	significantly	O
20	relieves	O
21	this	O
22	inhibition	O
23	and	O
24	allows	O
25	TFIIIA	B
26	to	O
27	exhibit	O
28	high	O
29	-	O
30	affinity	O
31	binding	O
32	to	O
33	nucleosomal	O
34	DNA	O
35	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	M	O
7	.	O
8	jannaschii	O
9	as	O
10	well	O
11	as	O
12	related	O
13	archaeal	B
14	20S	I
15	proteasomes	I
16	require	O
17	a	O
18	nucleotidase	O
19	complex	O
20	such	O
21	as	O
22	PAN	B
23	to	O
24	mediate	O
25	the	O
26	energy	O
27	-	O
28	dependent	O
29	hydrolysis	O
30	of	O
31	folded	O
32	-	O
33	substrate	O
34	proteins	O
35	and	O
36	that	O
37	the	O
38	N	O
39	-	O
40	terminal	O
41	73	O
42	amino	O
43	acid	O
44	residues	O
45	of	O
46	PAN	B
47	are	O
48	not	O
49	absolutely	O
50	required	O
51	for	O
52	this	O
53	reaction	O
54	.	O
1	In	O
2	experiment	O
3	2	O
4	the	O
5	rats	O
6	had	O
7	free	O
8	access	O
9	to	O
10	two	O
11	bottles	O
12	,	O
13	one	O
14	of	O
15	which	O
16	contained	O
17	tap	O
18	water	O
19	,	O
20	and	O
21	the	O
22	other	O
23	contained	O
24	either	O
25	an	O
26	ethanol	O
27	(	O
28	6	O
29	%)	O
30	or	O
31	a	O
32	sucrose	O
33	(	O
34	5	O
35	%)	O
36	solution	O
37	.	O
1	The	O
2	patient	O
3	had	O
4	developed	O
5	left	O
6	-	O
7	sided	O
8	low	O
9	-	O
10	frequency	O
11	tremor	O
12	and	O
13	hemidystonia	O
14	after	O
15	a	O
16	severe	O
17	head	O
18	trauma	O
19	sustained	O
20	at	O
21	15	O
22	years	O
23	of	O
24	age	O
25	.	O
1	Strontium	O
2	nitrate	O
3	mixed	O
4	with	O
5	glycolic	O
6	acid	O
7	,	O
8	in	O
9	comparison	O
10	with	O
11	glycolic	O
12	acid	O
13	alone	O
14	,	O
15	markedly	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	01	O
22	)	O
23	shortened	O
24	the	O
25	duration	O
26	of	O
27	the	O
28	irritation	O
29	sensation	O
30	from	O
31	24	O
32	.	O
33	4	O
34	+/-	O
35	4	O
36	.	O
37	1	O
38	(	O
39	mean	O
40	+/-	O
41	SEM	O
42	)	O
43	min	O
44	to	O
45	8	O
46	.	O
47	9	O
48	+/-	O
49	3	O
50	.	O
51	7	O
52	(	O
53	mean	O
54	+/-	O
55	SEM	O
56	)	O
57	min	O
58	,	O
59	and	O
60	significantly	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	05	O
67	)	O
68	reduced	O
69	the	O
70	mean	O
71	magnitude	O
72	of	O
73	the	O
74	irritation	O
75	sensation	O
76	at	O
77	all	O
78	time	O
79	points	O
80	(	O
81	overall	O
82	).	O
1	However	O
2	,	O
3	when	O
4	,	O
5	where	O
6	and	O
7	how	O
8	the	O
9	DSPP	B
10	is	O
11	cleaved	O
12	into	O
13	DSP	B
14	and	O
15	DPP	B
16	is	O
17	not	O
18	clear	O
19	.	O
1	Thus	O
2	,	O
3	patients	O
4	with	O
5	metastatic	O
6	melanoma	O
7	are	O
8	not	O
9	tolerant	O
10	to	O
11	gp100	B
12	Ag	I
13	based	O
14	on	O
15	the	O
16	detection	O
17	of	O
18	CD8	B
19	+	I
20	T	O
21	cells	O
22	specific	O
23	for	O
24	multiple	O
25	HLA	B
26	-	I
27	A	I
28	*	I
29	0201	I
30	-	O
31	restricted	O
32	,	O
33	gp100	B
34	-	O
35	derived	O
36	epitopes	O
37	.	O
1	Approximately	O
2	20	O
3	%	O
4	of	O
5	ALCLs	O
6	that	O
7	express	O
8	ALK	B
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	ALK	B
29	expression	O
30	.	O
1	In	O
2	addition	O
3	,	O
4	expected	O
5	decreases	O
6	in	O
7	ATIC	B
8	enzymatic	O
9	function	O
10	in	O
11	ATIC	B
12	-	O
13	ALK	B
14	-	O
15	containing	O
16	lymphomas	O
17	may	O
18	render	O
19	these	O
20	tumors	O
21	more	O
22	sensitive	O
23	to	O
24	antifolate	O
25	drugs	O
26	such	O
27	as	O
28	methotrexate	O
29	.	O
1	Methysergide	O
2	is	O
3	a	O
4	serotonin	O
5	antagonist	O
6	and	O
7	has	O
8	been	O
9	demonstrated	O
10	to	O
11	reduce	O
12	wound	O
13	blood	O
14	flow	O
15	and	O
16	edema	O
17	formation	O
18	.	O
1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	IRF	B
7	-	I
8	1	I
9	is	O
10	degraded	O
11	via	O
12	the	O
13	ubiquitin	B
14	-	O
15	proteasome	O
16	pathway	O
17	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	IIIa	O
6	pre	O
7	-	O
8	mRNA	O
9	splicing	O
10	is	O
11	activated	O
12	more	O
13	than	O
14	200	O
15	-	O
16	fold	O
17	in	O
18	nuclear	O
19	extracts	O
20	prepared	O
21	from	O
22	late	O
23	adenovirus	O
24	-	O
25	infected	O
26	cells	O
27	(	O
28	Ad	O
29	-	O
30	NE	O
31	)	O
32	compared	O
33	to	O
34	uninfected	O
35	HeLa	O
36	cell	O
37	nuclear	O
38	extracts	O
39	(	O
40	HeLa	O
41	-	O
42	NE	O
43	).	O
1	3	O
2	'	O
3	RNA	O
4	boundary	O
5	experiments	O
6	indicate	O
7	that	O
8	the	O
9	5	O
10	'	O
11	structure	O
12	reduces	O
13	the	O
14	number	O
15	of	O
16	(	O
17	G	O
18	/	O
19	U	O
20	)	O
21	AG	O
22	repeats	O
23	required	O
24	for	O
25	stable	O
26	TRAP	B
27	-	O
28	trp	B
29	leader	O
30	RNA	O
31	association	O
32	.	O
1	Gene	O
2	silencing	O
3	associated	O
4	with	O
5	repeated	O
6	DNA	O
7	sequences	O
8	has	O
9	been	O
10	reported	O
11	for	O
12	many	O
13	eukaryotes	O
14	,	O
15	including	O
16	plants	O
17	.	O
1	We	O
2	show	O
3	,	O
4	by	O
5	injection	O
6	of	O
7	synthetic	O
8	mRNAs	O
9	,	O
10	that	O
11	the	O
12	cis	O
13	-	O
14	acting	O
15	sequences	O
16	responsible	O
17	for	O
18	repression	O
19	of	O
20	cyclin	B
21	B1	I
22	mRNA	I
23	reside	O
24	within	O
25	its	O
26	3	O
27	'	O
28	UTR	O
29	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	thioredoxin	I
6	reductases	I
7	.	O
1	Here	O
2	we	O
3	review	O
4	progress	O
5	to	O
6	date	O
7	in	O
8	this	O
9	area	O
10	.	O
1	Most	O
2	likely	O
3	they	O
4	might	O
5	represent	O
6	regulatory	O
7	RNAs	O
8	or	O
9	transcribed	O
10	transposable	O
11	elements	O
12	.	O
1	Here	O
2	we	O
3	describe	O
4	the	O
5	cloning	O
6	,	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	pattern	O
12	,	O
13	and	O
14	functional	O
15	characterization	O
16	of	O
17	two	O
18	novel	O
19	TEF	B
20	-	I
21	1	I
22	isoforms	I
23	,	O
24	TEF	B
25	-	I
26	1beta	I
27	and	O
28	TEF	B
29	-	I
30	1gamma	I
31	.	O
1	Transfection	O
2	with	O
3	a	O
4	CSF	B
5	-	I
6	1R	I
7	expression	O
8	plasmid	O
9	permitted	O
10	CSF	B
11	-	I
12	1	I
13	-	O
14	dependent	O
15	activation	O
16	of	O
17	the	O
18	signalling	O
19	pathway	O
20	targeting	O
21	an	O
22	Ets	B
23	/	O
24	AP1	B
25	(	O
26	activator	B
27	protein	I
28	1	I
29	)	O
30	element	O
31	in	O
32	the	O
33	uPA	B
34	promoter	I
35	that	O
36	has	O
37	been	O
38	shown	O
39	previously	O
40	to	O
41	be	O
42	a	O
43	target	O
44	of	O
45	oncogenic	B
46	ras	I
47	and	O
48	protein	O
49	kinase	O
50	C	O
51	pathways	O
52	.	O
1	Preliminary	O
2	use	O
3	of	O
4	the	O
5	Nottingham	O
6	Eczema	O
7	Severity	O
8	Score	O
9	would	O
10	support	O
11	further	O
12	development	O
13	as	O
14	a	O
15	research	O
16	tool	O
17	for	O
18	a	O
19	simple	O
20	assessment	O
21	of	O
22	disease	O
23	severity	O
24	that	O
25	could	O
26	be	O
27	used	O
28	in	O
29	epidemiological	O
30	studies	O
31	.	O
1	Advanced	O
2	adenoma	O
3	was	O
4	defined	O
5	as	O
6	an	O
7	adenoma	O
8	larger	O
9	than	O
10	10	O
11	mm	O
12	or	O
13	an	O
14	adenoma	O
15	of	O
16	any	O
17	size	O
18	with	O
19	villous	O
20	component	O
21	,	O
22	high	O
23	-	O
24	grade	O
25	dysplasia	O
26	or	O
27	invasive	O
28	carcinoma	O
29	.	O
1	Results	O
2	of	O
3	two	O
4	-	O
5	hybrid	O
6	assays	O
7	and	O
8	electrophoretic	O
9	mobility	O
10	shift	O
11	assays	O
12	strongly	O
13	suggest	O
14	that	O
15	all	O
16	HD	B
17	-	I
18	Zip	I
19	proteins	I
20	of	O
21	families	O
22	I	O
23	and	O
24	II	O
25	can	O
26	form	O
27	homodimers	O
28	and	O
29	also	O
30	heterodimers	O
31	with	O
32	all	O
33	HD	B
34	-	I
35	Zip	I
36	proteins	I
37	of	O
38	the	O
39	same	O
40	family	O
41	.	O
1	Southern	O
2	blotting	O
3	and	O
4	single	O
5	strand	O
6	conformation	O
7	polymorphism	O
8	analyses	O
9	did	O
10	not	O
11	show	O
12	tumor	O
13	-	O
14	specific	O
15	alterations	O
16	of	O
17	this	O
18	gene	O
19	in	O
20	gliomas	O
21	and	O
22	RT	O
23	-	O
24	PCR	O
25	studies	O
26	showed	O
27	expression	O
28	in	O
29	glioma	O
30	cell	O
31	lines	O
32	,	O
33	suggesting	O
34	that	O
35	ANOVA	B
36	is	O
37	not	O
38	the	O
39	chromosome	O
40	19q	O
41	glioma	O
42	tumor	O
43	suppressor	O
44	gene	O
45	.	O
1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O
1	By	O
2	electrophoresis	O
3	mobility	O
4	shift	O
5	assays	O
6	using	O
7	probes	O
8	corresponding	O
9	to	O
10	different	O
11	segments	O
12	of	O
13	the	O
14	putative	O
15	human	B
16	c	I
17	-	I
18	myb	I
19	intron	I
20	1	I
21	transcription	I
22	pause	I
23	region	I
24	and	O
25	nuclear	O
26	extracts	O
27	from	O
28	myeloid	O
29	leukemia	O
30	HL	O
31	60	O
32	and	O
33	fibroblast	O
34	WI	O
35	38	O
36	cells	O
37	,	O
38	we	O
39	detected	O
40	a	O
41	HL	O
42	-	O
43	60	O
44	-	O
45	specific	O
46	DNA	O
47	-	O
48	protein	O
49	complex	O
50	with	O
51	a	O
52	123	O
53	-	O
54	bp	O
55	fragment	O
56	containing	O
57	binding	O
58	sites	O
59	for	O
60	the	O
61	interferon	B
62	regulatory	I
63	factors	I
64	(	O
65	IRFs	B
66	)	O
67	nuclear	O
68	proteins	O
69	.	O
1	Invertases	B
2	are	O
3	responsible	O
4	for	O
5	the	O
6	breakdown	O
7	of	O
8	sucrose	O
9	to	O
10	fructose	O
11	and	O
12	glucose	O
13	.	O
1	Thus	O
2	,	O
3	both	O
4	the	O
5	hyperplasia	O
6	and	O
7	thrombotic	O
8	complications	O
9	which	O
10	often	O
11	follow	O
12	stenting	O
13	might	O
14	be	O
15	minimized	O
16	by	O
17	employing	O
18	gold	O
19	stents	O
20	,	O
21	which	O
22	have	O
23	a	O
24	greater	O
25	capacity	O
26	than	O
27	steel	O
28	in	O
29	supporting	O
30	a	O
31	functional	O
32	neo	O
33	-	O
34	endothelium	O
35	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	residue	O
6	266	O
7	serves	O
8	as	O
9	a	O
10	""""	O
11	protein	O
12	sensor	O
13	""""	O
14	of	O
15	altered	O
16	minor	O
17	groove	O
18	interactions	O
19	and	O
20	identifies	O
21	which	O
22	base	O
23	pair	O
24	interactions	O
25	are	O
26	altered	O
27	by	O
28	these	O
29	lesions	O
30	.	O
1	The	O
2	recombinant	O
3	enzymes	O
4	exist	O
5	as	O
6	monomers	O
7	.	O
1	Scanning	O
2	mutations	O
3	throughout	O
4	the	O
5	AC	O
6	element	O
7	interfered	O
8	with	O
9	induction	O
10	but	O
11	allowed	O
12	us	O
13	to	O
14	define	O
15	five	O
16	overlapping	O
17	sites	O
18	for	O
19	regulatory	O
20	factors	O
21	in	O
22	AC	O
23	and	O
24	to	O
25	design	O
26	probes	O
27	binding	O
28	just	O
29	one	O
30	or	O
31	two	O
32	factors	O
33	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	virulence	O
6	-	O
7	associated	O
8	genes	O
9	and	O
10	their	O
11	overall	O
12	chromosomal	O
13	arrangement	O
14	are	O
15	relatively	O
16	well	O
17	conserved	O
18	between	O
19	B	O
20	.	O
21	henselae	O
22	and	O
23	other	O
24	gram	O
25	-	O
26	negative	O
27	bacteria	O
28	such	O
29	as	O
30	A	O
31	.	O
32	tumefaciens	O
33	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	transcription	O
6	of	O
7	c	B
8	-	I
9	IAP2	I
10	promoter	I
11	was	O
12	strongly	O
13	up	O
14	-	O
15	regulated	O
16	when	O
17	CD40	B
18	or	O
19	Epstein	B
20	-	I
21	Barr	I
22	virus	I
23	latent	I
24	membrane	I
25	protein	I
26	1	I
27	was	O
28	overexpressed	O
29	.	O
1	CONCLUSION	O
2	:	O
3	Treatment	O
4	of	O
5	sepsis	O
6	with	O
7	the	O
8	platelet	B
9	-	I
10	activating	I
11	factor	I
12	antagonist	O
13	BB	O
14	-	O
15	882	O
16	offers	O
17	no	O
18	advantage	O
19	over	O
20	placebo	O
21	on	O
22	survival	O
23	,	O
24	hemodynamic	O
25	status	O
26	,	O
27	respiratory	O
28	function	O
29	,	O
30	or	O
31	organ	O
32	failure	O
33	scores	O
34	.	O
1	The	O
2	protein	O
3	was	O
4	associated	O
5	with	O
6	purified	O
7	vaccinia	O
8	virus	O
9	particles	O
10	and	O
11	with	O
12	membranes	O
13	of	O
14	immature	O
15	and	O
16	mature	O
17	virions	O
18	that	O
19	were	O
20	visualized	O
21	by	O
22	electron	O
23	microscopy	O
24	of	O
25	infected	O
26	cells	O
27	.	O
1	Our	O
2	data	O
3	suggest	O
4	that	O
5	,	O
6	at	O
7	least	O
8	at	O
9	high	O
10	temperature	O
11	,	O
12	a	O
13	critical	O
14	minimal	O
15	level	O
16	of	O
17	Ypt	B
18	protein	I
19	prenylation	O
20	is	O
21	required	O
22	for	O
23	maintaining	O
24	vesicle	O
25	polarization	O
26	.	O
1	The	O
2	MMA	B
3	,	I
4	DMA	I
5	,	I
6	and	I
7	TMA	I
8	methyltransferases	I
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	MMA	B
18	methyltransferase	I
19	gene	I
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	DMA	B
26	and	I
27	TMA	I
28	methyltransferases	I
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	amber	O
37	codon	O
38	.	O
1	After	O
2	phosphorylation	O
3	,	O
4	STAT	B
5	proteins	I
6	are	O
7	transported	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O
1	The	O
2	complete	O
3	cDNA	O
4	sequence	O
5	of	O
6	human	B
7	betaV	I
8	spectrin	I
9	is	O
10	available	O
11	from	O
12	GenBank	O
13	(	O
14	TM	O
15	)	O
16	as	O
17	accession	O
18	number	O
19	.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	alpha	O
7	-	O
8	helix	O
9	domain	O
10	of	O
11	p57	B
12	(	O
13	Kip2	B
14	),	O
15	which	O
16	is	O
17	conserved	O
18	in	O
19	the	O
20	Cip	B
21	/	O
22	Kip	B
23	proteins	O
24	,	O
25	is	O
26	implicated	O
27	in	O
28	protein	O
29	-	O
30	protein	O
31	interaction	O
32	and	O
33	confers	O
34	a	O
35	specific	O
36	regulatory	O
37	mechanism	O
38	,	O
39	outside	O
40	of	O
41	their	O
42	Cdk	B
43	-	O
44	inhibitory	O
45	activity	O
46	,	O
47	by	O
48	which	O
49	the	O
50	p57	B
51	(	O
52	Kip2	B
53	)	O
54	family	O
55	members	O
56	positively	O
57	act	O
58	on	O
59	myogenic	O
60	differentiation	O
61	.	O
1	Intra	O
2	-	O
3	operative	O
4	ultrasound	O
5	(	O
6	IOUS	O
7	)	O
8	has	O
9	been	O
10	widely	O
11	used	O
12	in	O
13	an	O
14	attempt	O
15	to	O
16	overcome	O
17	these	O
18	difficulties	O
19	,	O
20	but	O
21	is	O
22	limited	O
23	by	O
24	its	O
25	two	O
26	-	O
27	dimensional	O
28	nature	O
29	,	O
30	inter	O
31	-	O
32	user	O
33	variability	O
34	,	O
35	and	O
36	image	O
37	obliteration	O
38	with	O
39	ablative	O
40	or	O
41	resectional	O
42	techniques	O
43	.	O
1	Hailey	O
2	-	O
3	Hailey	O
4	disease	O
5	is	O
6	caused	O
7	by	O
8	mutations	O
9	in	O
10	ATP2C1	B
11	encoding	O
12	a	O
13	novel	O
14	Ca	O
15	(	O
16	2	O
17	+)	O
18	pump	O
19	.	O
1	Viral	O
2	cell	O
3	-	O
4	to	O
5	-	O
6	cell	O
7	movement	O
8	of	O
9	PVX	B
10	CP	I
11	mutant	I
12	was	O
13	complemented	O
14	in	O
15	Nicotiana	O
16	tabacum	O
17	cv	O
18	.	O
1	We	O
2	conclude	O
3	that	O
4	,	O
5	both	O
6	in	O
7	atrial	O
8	myocytes	O
9	and	O
10	in	O
11	Xenopus	O
12	oocytes	O
13	,	O
14	beta	O
15	-	O
16	adrenergic	O
17	stimulation	O
18	potentiates	O
19	the	O
20	ACh	O
21	-	O
22	evoked	O
23	GIRK	B
24	channels	I
25	via	O
26	a	O
27	pathway	O
28	that	O
29	involves	O
30	PKA	B
31	-	O
32	catalyzed	O
33	phosphorylation	O
34	downstream	O
35	from	O
36	beta	B
37	(	I
38	2	I
39	)	I
40	AR	I
41	.	O
1	Estrogen	B
2	receptor	I
3	-	I
4	related	I
5	receptor	I
6	alpha	I
7	1	I
8	interacts	O
9	with	O
10	coactivator	O
11	and	O
12	constitutively	O
13	activates	O
14	the	O
15	estrogen	O
16	response	O
17	elements	O
18	of	O
19	the	O
20	human	B
21	lactoferrin	I
22	gene	I
23	.	O
1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	protein	O
8	function	O
9	require	O
10	further	O
11	examination	O
12	.	O
1	Specific	O
2	and	O
3	heritable	O
4	genetic	O
5	interference	O
6	by	O
7	double	O
8	-	O
9	stranded	O
10	RNA	O
11	in	O
12	Arabidopsis	O
13	thaliana	O
14	.	O
1	The	O
2	interaction	O
3	does	O
4	not	O
5	depend	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O
1	The	O
2	rate	O
3	-	O
4	limiting	O
5	step	O
6	for	O
7	telomerase	B
8	activity	O
9	seems	O
10	to	O
11	be	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	catalytic	O
17	subunit	O
18	of	O
19	the	O
20	enzyme	O
21	,	O
22	encoded	O
23	by	O
24	the	O
25	human	B
26	telomerase	I
27	reverse	I
28	transcriptase	I
29	(	O
30	hTERT	B
31	)	O
32	gene	O
33	.	O
1	Regulation	O
2	of	O
3	mitochondrial	O
4	single	O
5	-	O
6	stranded	O
7	DNA	O
8	-	O
9	binding	O
10	protein	O
11	gene	O
12	expression	O
13	links	O
14	nuclear	O
15	and	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	in	O
20	drosophila	O
21	.	O
1	Genetic	O
2	and	O
3	molecular	O
4	complexity	O
5	of	O
6	the	O
7	position	O
8	effect	O
9	variegation	O
10	modifier	O
11	mod	B
12	(	O
13	mdg4	B
14	)	O
15	in	O
16	Drosophila	O
17	.	O
18	mod	B
19	(	O
20	mdg4	B
21	),	O
22	also	O
23	known	O
24	as	O
25	E	B
26	(	I
27	var	I
28	)	I
29	3	I
30	-	I
31	93D	I
32	,	O
33	is	O
34	involved	O
35	in	O
36	a	O
37	variety	O
38	of	O
39	processes	O
40	,	O
41	such	O
42	as	O
43	gene	O
44	silencing	O
45	in	O
46	position	O
47	effect	O
48	variegation	O
49	(	O
50	PEV	O
51	),	O
52	the	O
53	control	O
54	of	O
55	gypsy	B
56	insulator	I
57	sequences	I
58	,	O
59	regulation	O
60	of	O
61	homeotic	B
62	gene	I
63	expression	O
64	,	O
65	and	O
66	programmed	O
67	cell	O
68	death	O
69	.	O
1	This	O
2	tendency	O
3	is	O
4	likely	O
5	due	O
6	to	O
7	the	O
8	biased	O
9	nucleotide	O
10	composition	O
11	of	O
12	the	O
13	asparagus	O
14	genome	O
15	,	O
16	rather	O
17	than	O
18	to	O
19	the	O
20	translational	O
21	selection	O
22	for	O
23	specific	O
24	codons	O
25	.	O
1	Regulation	O
2	of	O
3	pituitary	O
4	vasopressin	B
5	V1b	I
6	receptors	I
7	plays	O
8	a	O
9	critical	O
10	role	O
11	in	O
12	regulating	O
13	pituitary	B
14	adrenocorticotropic	I
15	hormone	I
16	(	O
17	ACTH	B
18	)	O
19	secretion	O
20	during	O
21	adaptation	O
22	to	O
23	stress	O
24	.	O
1	The	O
2	models	O
3	were	O
4	tested	O
5	by	O
6	studying	O
7	their	O
8	response	O
9	to	O
10	disturbances	O
11	of	O
12	the	O
13	afferent	O
14	signal	O
15	from	O
16	the	O
17	bladder	O
18	.	O
1	Our	O
2	data	O
3	show	O
4	also	O
5	that	O
6	phagocytic	O
7	killing	O
8	of	O
9	meningococci	O
10	is	O
11	probably	O
12	a	O
13	more	O
14	consistent	O
15	assay	O
16	than	O
17	antibody	O
18	titer	O
19	levels	O
20	for	O
21	antimeningococcal	O
22	immunity	O
23	,	O
24	especially	O
25	in	O
26	LCC	O
27	-	O
28	deficient	O
29	patients	O
30	.	O
1	M	O
2	.	O
1	Our	O
2	data	O
3	provide	O
4	a	O
5	biochemical	O
6	explanation	O
7	for	O
8	the	O
9	similarity	O
10	in	O
11	phenotype	O
12	between	O
13	A	O
14	-	O
15	T	O
16	and	O
17	NBS	O
18	.	O
1	In	O
2	the	O
3	study	O
4	on	O
5	PCI	B
6	mRNA	I
7	expression	O
8	in	O
9	the	O
10	reproductive	O
11	organs	O
12	,	O
13	we	O
14	first	O
15	cloned	O
16	rat	B
17	PCI	I
18	cDNA	I
19	and	O
20	then	O
21	evaluated	O
22	the	O
23	effect	O
24	of	O
25	androgen	O
26	on	O
27	the	O
28	PCI	B
29	mRNA	I
30	expression	O
31	.	O
1	To	O
2	illustrate	O
3	its	O
4	performance	O
5	,	O
6	measurements	O
7	of	O
8	photoluminescence	O
9	in	O
10	GaAs	O
11	/	O
12	AlGaAs	O
13	heterostructures	O
14	are	O
15	presented	O
16	.	O
1	Much	O
2	evidence	O
3	indicates	O
4	that	O
5	p38	B
6	is	O
7	an	O
8	activator	O
9	of	O
10	MyoD	B
11	:	O
12	(	O
13	i	O
14	)	O
15	p38	B
16	kinase	I
17	activity	O
18	is	O
19	required	O
20	for	O
21	the	O
22	expression	O
23	of	O
24	MyoD	B
25	-	O
26	responsive	O
27	genes	O
28	,	O
29	(	O
30	ii	O
31	)	O
32	enforced	O
33	induction	O
34	of	O
35	p38	B
36	stimulates	O
37	the	O
38	transcriptional	O
39	activity	O
40	of	O
41	a	O
42	Gal4	B
43	-	O
44	MyoD	B
45	fusion	O
46	protein	O
47	and	O
48	allows	O
49	efficient	O
50	activation	O
51	of	O
52	chromatin	O
53	-	O
54	integrated	O
55	reporters	O
56	by	O
57	MyoD	B
58	,	O
59	and	O
60	(	O
61	iii	O
62	)	O
63	MyoD	B
64	-	O
65	dependent	O
66	myogenic	O
67	conversion	O
68	is	O
69	reduced	O
70	in	O
71	mouse	O
72	embryonic	O
73	fibroblasts	O
74	derived	O
75	from	O
76	p38alpha	B
77	(-/-)	I
78	embryos	O
79	.	O
1	The	O
2	serine	B
3	-	I
4	threonine	I
5	kinase	I
6	gene	I
7	is	O
8	likely	O
9	functional	O
10	,	O
11	whereas	O
12	the	O
13	zinc	O
14	finger	O
15	motif	O
16	is	O
17	likely	O
18	nonfunctional	O
19	.	O
1	RESULTS	O
2	:	O
3	Abnormal	O
4	color	O
5	perception	O
6	was	O
7	found	O
8	in	O
9	32	O
10	%	O
11	of	O
12	the	O
13	epilepsy	O
14	patients	O
15	treated	O
16	with	O
17	vigabatrin	O
18	monotherapy	O
19	and	O
20	28	O
21	%	O
22	of	O
23	the	O
24	epilepsy	O
25	patients	O
26	treated	O
27	with	O
28	carbamazepine	O
29	monotherapy	O
30	.	O
1	Consistent	O
2	with	O
3	this	O
4	,	O
5	we	O
6	show	O
7	that	O
8	peptides	O
9	representing	O
10	docking	O
11	sites	O
12	within	O
13	the	O
14	target	O
15	substrates	O
16	Elk	B
17	-	I
18	1	I
19	and	O
20	p90	B
21	(	O
22	rsk	B
23	)	O
24	inhibit	O
25	ERK	B
26	-	O
27	dependent	O
28	activation	O
29	of	O
30	MKP	B
31	-	I
32	3	I
33	.	O
1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O
1	Hierarchy	O
2	of	O
3	protein	B
4	tyrosine	I
5	kinases	I
6	in	O
7	interleukin	B
8	-	I
9	2	I
10	(	O
11	IL	B
12	-	I
13	2	I
14	)	O
15	signaling	O
16	:	O
17	activation	O
18	of	O
19	syk	B
20	depends	O
21	on	O
22	Jak3	B
23	;	O
24	however	O
25	,	O
26	neither	O
27	Syk	B
28	nor	O
29	Lck	B
30	is	O
31	required	O
32	for	O
33	IL	B
34	-	I
35	2	I
36	-	O
37	mediated	O
38	STAT	B
39	activation	O
40	.	O
1	The	O
2	so	O
3	-	O
4	called	O
5	""""	B
6	SH3	I
7	""""	I
8	segment	I
9	of	O
10	the	O
11	linker	O
12	domain	O
13	,	O
14	in	O
15	contrast	O
16	,	O
17	shows	O
18	species	O
19	-	O
20	specific	O
21	sequence	O
22	identity	O
23	in	O
24	all	O
25	but	O
26	one	O
27	amino	O
28	acid	O
29	residues	O
30	in	O
31	both	O
32	factors	O
33	,	O
34	in	O
35	cattle	O
36	,	O
37	human	O
38	,	O
39	and	O
40	mouse	O
41	.	O
1	The	O
2	model	O
3	indicates	O
4	that	O
5	a	O
6	0	O
7	.	O
8	076	O
9	%	O
10	reduction	O
11	in	O
12	cigarette	O
13	consumption	O
14	is	O
15	associated	O
16	with	O
17	the	O
18	availability	O
19	of	O
20	nicotine	O
21	patches	O
22	after	O
23	1992	O
24	.	O
1	Paper	O
2	alert	O
3	.	O
1	The	O
2	cellular	O
3	part	O
4	of	O
5	the	O
6	third	O
7	chimeric	O
8	clone	O
9	shows	O
10	significant	O
11	homology	O
12	to	O
13	an	O
14	exon	O
15	of	O
16	the	O
17	human	B
18	tyrosine	I
19	phosphatase	I
20	1	I
21	gene	I
22	,	O
23	although	O
24	oriented	O
25	in	O
26	the	O
27	antisense	O
28	direction	O
29	compared	O
30	to	O
31	the	O
32	adjacent	O
33	LTR	O
34	.	O
1	RESULTS	O
2	:	O
3	Fournier	O
4	'	O
5	s	O
6	gangrene	O
7	occurs	O
8	worldwide	O
9	.	O
1	Investigations	O
2	using	O
3	hippocampal	O
4	slices	O
5	maintained	O
6	in	O
7	vitro	O
8	have	O
9	demonstrated	O
10	that	O
11	bursts	O
12	of	O
13	oscillatory	O
14	field	O
15	potentials	O
16	in	O
17	the	O
18	gamma	O
19	frequency	O
20	range	O
21	(	O
22	30	O
23	-	O
24	80	O
25	Hz	O
26	)	O
27	are	O
28	followed	O
29	by	O
30	a	O
31	slower	O
32	oscillation	O
33	in	O
34	the	O
35	beta	O
36	1	O
37	range	O
38	(	O
39	12	O
40	-	O
41	20	O
42	Hz	O
43	).	O
1	Karger	O
2	AG	O
3	,	O
4	Basel	O
1	Basal	O
2	FVR	O
3	was	O
4	reduced	O
5	by	O
6	approximately	O
7	18	O
8	%	O
9	by	O
10	ERT	O
11	and	O
12	HRT	O
13	,	O
14	but	O
15	FVR	O
16	responses	O
17	to	O
18	noradrenaline	O
19	,	O
20	angiotensin	B
21	II	I
22	,	O
23	acetylcholine	O
24	and	O
25	nitroprusside	O
26	were	O
27	unaffected	O
28	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	mouse	O
6	ortholog	O
7	(	O
8	Mharp	B
9	/	O
10	Smarcal1	B
11	)	O
12	was	O
13	cloned	O
14	,	O
15	and	O
16	the	O
17	Caenorhabditis	O
18	elegans	O
19	ortholog	O
20	(	O
21	CEHARP	B
22	)	O
23	was	O
24	identified	O
25	in	O
26	the	O
27	GenBank	O
28	database	O
29	.	O
1	Sparfloxacin	O
2	and	O
3	clinafloxacin	O
4	were	O
5	evaluated	O
6	against	O
7	Enterococcus	O
8	faecium	O
9	SF2149	O
10	and	O
11	Enterococcus	O
12	faecalis	O
13	WH245	O
14	,	O
15	respectively	O
16	.	O
1	The	O
2	delta	B
3	srb10	I
4	mutation	I
5	also	O
6	influenced	O
7	on	O
8	the	O
9	transcript	O
10	levels	O
11	of	O
12	meiosis	O
13	-	O
14	inducing	O
15	genes	O
16	called	O
17	IME1	B
18	and	O
19	IME2	B
20	:	O
21	the	O
22	mutation	O
23	elevated	O
24	the	O
25	transcript	O
26	level	O
27	of	O
28	IME1	B
29	but	O
30	reduced	O
31	that	O
32	of	O
33	IME2	B
34	,	O
35	resulting	O
36	in	O
37	partial	O
38	defects	O
39	in	O
40	premeiotic	O
41	DNA	O
42	synthesis	O
43	and	O
44	meiosis	O
45	.	O
1	The	O
2	pJR	O
3	vectors	O
4	differ	O
5	among	O
6	them	O
7	in	O
8	:	O
9	(	O
10	a	O
11	)	O
12	the	O
13	selectable	O
14	marker	O
15	(	O
16	Saccharomyces	O
17	cerevisiae	O
18	LEU	B
19	2	I
20	gene	I
21	,	O
22	which	O
23	complements	O
24	S	B
25	.	I
26	pombe	I
27	leu1	I
28	-	I
29	gene	I
30	and	O
31	S	O
32	.	O
33	pombe	O
34	ura4	B
35	+	I
36	and	O
37	his3	B
38	+	I
39	genes	I
40	);	O
41	(	O
42	b	O
43	)	O
44	the	O
45	thiamine	O
46	-	O
47	repressible	O
48	nmt1	B
49	promoter	I
50	(	O
51	3X	O
52	,	O
53	41X	O
54	and	O
55	81X	O
56	with	O
57	extremely	O
58	high	O
59	,	O
60	moderate	O
61	or	O
62	low	O
63	transcription	O
64	efficiency	O
65	,	O
66	respectively	O
67	);	O
68	and	O
69	(	O
70	c	O
71	)	O
72	the	O
73	multiple	O
74	cloning	O
75	site	O
76	(	O
77	two	O
78	multiple	O
79	cloning	O
80	sites	O
81	,	O
82	with	O
83	12	O
84	restriction	O
85	sites	O
86	each	O
87	).	O
1	(	O
2	GUT	O
3	)	O
4	Sera	O
5	of	O
6	30	O
7	montoux	O
8	negative	O
9	healthy	O
10	adults	O
11	(	O
12	age	O
13	/	O
14	sex	O
15	matched	O
16	)	O
17	were	O
18	taken	O
19	as	O
20	control	O
21	by	O
22	detecting	O
23	IgG	B
24	anti	I
25	bodies	I
26	to	O
27	A60	B
28	antigen	I
29	.	O
1	RESULTS	O
2	:	O
3	The	O
4	introduction	O
5	of	O
6	the	O
7	PAIP	O
8	resulted	O
9	in	O
10	a	O
11	significant	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	reduction	O
20	in	O
21	contaminating	O
22	WBCs	O
23	(	O
24	median	O
25	,	O
26	30	O
27	,	O
28	000	O
29	)	O
30	from	O
31	the	O
32	numbers	O
33	seen	O
34	with	O
35	FIP	O
36	(	O
37	median	O
38	,	O
39	2	O
40	,	O
41	300	O
42	,	O
43	000	O
44	)	O
45	while	O
46	maintaining	O
47	the	O
48	separation	O
49	efficacy	O
50	(	O
51	47	O
52	%)	O
53	and	O
54	separation	O
55	time	O
56	.	O
1	The	O
2	antioxidant	O
3	agent	O
4	pyrrolidine	O
5	dithiocarbamate	O
6	(	O
7	PDTC	O
8	)	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	protect	O
14	endothelial	O
15	cells	O
16	(	O
17	EC	O
18	)	O
19	from	O
20	pro	O
21	-	O
22	inflammatory	O
23	-	O
24	induced	O
25	and	O
26	pro	O
27	-	O
28	oxidant	O
29	-	O
30	induced	O
31	NF	B
32	-	I
33	kappaB	I
34	activation	O
35	.	O
1	Neurofibromatosis	O
2	of	O
3	the	O
4	breast	O
5	in	O
6	a	O
7	patient	O
8	with	O
9	Morbus	O
10	von	O
11	Recklinghausen	O
1	In	O
2	situ	O
3	hybridization	O
4	with	O
5	the	O
6	antisense	O
7	RNA	O
8	probes	O
9	further	O
10	supported	O
11	the	O
12	expression	O
13	changes	O
14	of	O
15	these	O
16	six	O
17	clones	O
18	and	O
19	localized	O
20	the	O
21	changes	O
22	in	O
23	multiple	O
24	germ	O
25	cell	O
26	stages	O
27	as	O
28	well	O
29	as	O
30	other	O
31	cell	O
32	types	O
33	(	O
34	Sertoli	O
35	,	O
36	interstitial	O
37	and	O
38	peritubular	O
39	cells	O
40	).	O
1	Mutation	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	motif	O
7	TCCCCT	O
8	is	O
9	critical	O
10	for	O
11	PyRo1	B
12	interaction	O
13	.	O
1	As	O
2	with	O
3	VP16	B
4	,	O
5	the	O
6	transactivation	O
7	function	O
8	of	O
9	Luman	B
10	is	O
11	also	O
12	regulated	O
13	by	O
14	HCF	B
15	.	O
1	G	O
2	.,	O
3	and	O
4	Hyde	O
5	,	O
6	C	O
7	.	O
1	Activation	O
2	of	O
3	nuclear	B
4	factor	I
5	(	I
6	NF	I
7	)-	I
8	kappaB	I
9	and	O
10	subsequent	O
11	proinflammatory	O
12	gene	O
13	expression	O
14	in	O
15	human	O
16	airway	O
17	epithelial	O
18	cells	O
19	can	O
20	be	O
21	evoked	O
22	by	O
23	oxidative	O
24	stress	O
25	.	O
1	GAP	O
2	JUNCTIONS	O
3	IN	O
4	THE	O
5	BRAIN	O
6	:	O
7	PREFACE	O
8	.	O
1	Next	O
2	,	O
3	we	O
4	show	O
5	that	O
6	two	O
7	EMS	O
8	-	O
9	induced	O
10	mutations	O
11	,	O
12	previously	O
13	shown	O
14	to	O
15	interact	O
16	genetically	O
17	with	O
18	zipper	O
19	(	O
20	Ebr	B
21	),	O
22	disrupt	O
23	the	O
24	RhoA	B
25	locus	I
26	.	O
1	The	O
2	outer	O
3	diameter	O
4	and	O
5	the	O
6	thickness	O
7	of	O
8	the	O
9	rotor	O
10	are	O
11	60	O
12	mm	O
13	and	O
14	8	O
15	mm	O
16	,	O
17	respectively	O
18	.	O
1	Screening	O
2	,	O
3	counseling	O
4	,	O
5	and	O
6	treatment	O
7	for	O
8	alcohol	O
9	and	O
10	illicit	O
11	drug	O
12	use	O
13	should	O
14	be	O
15	essential	O
16	components	O
17	in	O
18	comprehensive	O
19	HBP	O
20	care	O
21	.	O
1	Following	O
2	EPI	O
3	-	O
4	C0401	O
5	,	O
6	but	O
7	not	O
8	saline	O
9	or	O
10	DepoFoam	O
11	vehicle	O
12	,	O
13	there	O
14	were	O
15	transient	O
16	(<	O
17	72	O
18	hr	O
19	)	O
20	decreases	O
21	in	O
22	food	O
23	consumption	O
24	,	O
25	arousal	O
26	,	O
27	hindlimb	O
28	muscle	O
29	tone	O
30	,	O
31	and	O
32	body	O
33	temperature	O
34	.	O
1	Atorvastatin	O
2	was	O
3	the	O
4	most	O
5	cost	O
6	-	O
7	effective	O
8	HMG	B
9	-	I
10	CoA	I
11	reductase	I
12	inhibitor	O
13	.	O
1	The	O
2	effectiveness	O
3	of	O
4	NRT	O
5	appears	O
6	to	O
7	be	O
8	largely	O
9	independent	O
10	of	O
11	the	O
12	intensity	O
13	of	O
14	additional	O
15	support	O
16	provided	O
17	to	O
18	the	O
19	smoker	O
20	.	O
1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	proline	O
6	-	O
7	rich	O
8	domain	O
9	of	O
10	SOS1	B
11	is	O
12	involved	O
13	in	O
14	the	O
15	interaction	O
16	with	O
17	the	O
18	PLC	B
19	-	I
20	gamma1	I
21	SH3	I
22	domain	I
23	.	O
1	From	O
2	transient	O
3	expression	O
4	studies	O
5	,	O
6	we	O
7	could	O
8	demonstrate	O
9	that	O
10	the	O
11	SH3	B
12	domain	I
13	of	O
14	PLC	B
15	-	I
16	gamma1	I
17	is	O
18	necessary	O
19	for	O
20	the	O
21	association	O
22	with	O
23	SOS1	B
24	in	O
25	vivo	O
26	.	O
1	Twenty	O
2	eligible	O
3	patients	O
4	with	O
5	cirrhosis	O
6	were	O
7	randomized	O
8	into	O
9	two	O
10	groups	O
11	:	O
12	10	O
13	patients	O
14	treated	O
15	with	O
16	6	O
17	million	O
18	units	O
19	of	O
20	natural	O
21	IFN	B
22	-	I
23	beta	I
24	twice	O
25	a	O
26	week	O
27	for	O
28	36	O
29	months	O
30	and	O
31	10	O
32	patients	O
33	without	O
34	IFN	B
35	therapy	O
36	.	O
1	Deletion	O
2	of	O
3	the	O
4	RVH	B
5	domain	I
6	resulted	O
7	in	O
8	loss	O
9	of	O
10	Ca	O
11	(	O
12	2	O
13	+)-	O
14	dependent	O
15	activation	O
16	.	O
1	VaI	O
2	and	O
3	VaII	O
4	co	O
5	-	O
6	immunoprecipitated	O
7	with	O
8	ErbB2	B
9	,	O
10	but	O
11	not	O
12	with	O
13	ErbB1	B
14	,	O
15	ErbB3	B
16	,	O
17	or	O
18	ErbB4	B
19	.	O
1	Activation	O
2	was	O
3	biphasic	O
4	;	O
5	peaking	O
6	at	O
7	5	O
8	-	O
9	10	O
10	min	O
11	and	O
12	24	O
13	h	O
14	after	O
15	treatment	O
16	.	O
1	Whereas	O
2	MARTA1	B
3	is	O
4	clearly	O
5	detectable	O
6	in	O
7	crude	O
8	lysates	O
9	,	O
10	cytosolic	O
11	and	O
12	ribosomal	O
13	salt	O
14	-	O
15	wash	O
16	fractions	O
17	,	O
18	and	O
19	in	O
20	nuclear	O
21	extracts	O
22	,	O
23	MARTA2	B
24	is	O
25	preferentially	O
26	found	O
27	in	O
28	the	O
29	ribosomal	O
30	salt	O
31	-	O
32	wash	O
33	preparation	O
34	.	O
1	The	O
2	optimum	O
3	technique	O
4	for	O
5	the	O
6	pathological	O
7	examination	O
8	of	O
9	sentinel	O
10	lymph	O
11	nodes	O
12	(	O
13	SLNs	O
14	)	O
15	is	O
16	still	O
17	under	O
18	debate	O
19	.	O
1	This	O
2	study	O
3	demonstrated	O
4	that	O
5	the	O
6	PFA	O
7	-	O
8	100	O
9	analyzer	O
10	can	O
11	accurately	O
12	assess	O
13	vWF	B
14	-	O
15	dependent	O
16	platelet	O
17	function	O
18	and	O
19	detect	O
20	other	O
21	platelet	O
22	defects	O
23	under	O
24	high	O
25	shear	O
26	stress	O
27	in	O
28	complex	O
29	patient	O
30	populations	O
31	.	O
1	The	O
2	loss	O
3	of	O
4	avirulence	O
5	activity	O
6	because	O
7	of	O
8	mutations	O
9	in	O
10	the	O
11	acidic	O
12	transcriptional	O
13	activation	O
14	domain	O
15	was	O
16	restored	O
17	by	O
18	addition	O
19	of	O
20	the	O
21	activation	O
22	domain	O
23	from	O
24	the	O
25	herpes	B
26	simplex	I
27	viral	I
28	protein	I
29	VP16	I
30	.	O
1	Mutations	O
2	in	O
3	the	O
4	RP2	B
5	locus	I
6	at	I
7	Xp11	I
8	.	I
9	3	I
10	were	O
11	found	O
12	in	O
13	a	O
14	further	O
15	10	O
16	-	O
17	20	O
18	%	O
19	of	O
20	XLRP	O
21	patients	O
22	,	O
23	as	O
24	predicted	O
25	from	O
26	linkage	O
27	studies	O
28	.	O
1	Subsequently	O
2	,	O
3	HD	O
4	inhibited	O
5	healing	O
6	because	O
7	it	O
8	significantly	O
9	delayed	O
10	epithelialization	O
11	and	O
12	caused	O
13	protracted	O
14	inflammation	O
15	.	O
1	The	O
2	genome	O
3	of	O
4	the	O
5	human	O
6	herpesvirus	O
7	8	O
8	(	O
9	HHV	O
10	-	O
11	8	O
12	)	O
13	contains	O
14	a	O
15	cluster	O
16	of	O
17	open	O
18	reading	O
19	frames	O
20	(	O
21	ORFs	O
22	)	O
23	encoding	O
24	proteins	O
25	with	O
26	homology	O
27	to	O
28	the	O
29	cellular	O
30	transcription	O
31	factors	O
32	of	O
33	the	O
34	interferon	B
35	regulatory	I
36	factor	I
37	(	O
38	IRF	B
39	)	O
40	family	O
41	.	O
1	TB	O
2	bone	O
3	area	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	001	O
10	),	O
11	height	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	01	O
18	),	O
19	years	O
20	in	O
21	present	O
22	colony	O
23	(	O
24	p	O
25	=	O
26	0	O
27	.	O
28	03	O
29	),	O
30	and	O
31	menses	O
32	(	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	)	O
39	predicted	O
40	TB	O
41	BMC	O
42	.	O
1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	PKCbeta	B
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	O
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	O
25	factor	O
26	mitogenic	O
27	signals	O
28	.	O
1	These	O
2	regions	O
3	may	O
4	be	O
5	differentially	O
6	involved	O
7	in	O
8	tissue	O
9	-	O
10	specificity	O
11	,	O
12	and	O
13	/	O
14	or	O
15	circadian	O
16	regulation	O
17	,	O
18	of	O
19	the	O
20	human	B
21	hPer1	I
22	gene	I
23	transcription	O
24	.	O
1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	newly	O
7	discovered	O
8	oasA2	B
9	gene	I
10	represents	O
11	a	O
12	pseudogene	O
13	that	O
14	is	O
15	still	O
16	transcribed	O
17	,	O
18	but	O
19	is	O
20	not	O
21	functionally	O
22	translated	O
23	.	O
1	Two	O
2	distinct	O
3	recessive	O
4	susceptibility	O
5	loci	O
6	for	O
7	vasculitis	O
8	were	O
9	mapped	O
10	on	O
11	chromosome	O
12	(	O
13	Chr	O
14	)	O
15	4	O
16	at	O
17	D4Mit89	B
18	and	O
19	D4Mit147	B
20	in	O
21	both	O
22	progenies	O
23	.	O
1	The	O
2	ability	O
3	of	O
4	U6	B
5	-	O
6	U57	B
7	mutants	O
8	to	O
9	influence	O
10	the	O
11	fidelity	O
12	of	O
13	both	O
14	branch	O
15	site	O
16	and	O
17	3	O
18	'	O
19	splice	O
20	site	O
21	recognition	O
22	suggests	O
23	that	O
24	this	O
25	nucleotide	O
26	may	O
27	participate	O
28	in	O
29	the	O
30	formation	O
31	of	O
32	the	O
33	active	O
34	site	O
35	(	O
36	s	O
37	)	O
38	of	O
39	the	O
40	spliceosome	O
41	.	O
1	Five	O
2	of	O
3	the	O
4	Aeromonas	O
5	strains	O
6	and	O
7	one	O
8	of	O
9	V	O
10	cholerae	O
11	non	O
12	-	O
13	O1	O
14	were	O
15	positive	O
16	for	O
17	enterotoxin	O
18	activity	O
19	.	O
1	TNF	B
2	-	I
3	alpha	I
4	induced	O
5	a	O
6	dose	O
7	-	O
8	and	O
9	time	O
10	-	O
11	dependent	O
12	increase	O
13	in	O
14	cyclooxygenase	B
15	-	I
16	2	I
17	(	O
18	COX	B
19	-	I
20	2	I
21	)	O
22	expression	O
23	and	O
24	PGE2	O
25	formation	O
26	in	O
27	human	O
28	NCI	O
29	-	O
30	H292	O
31	epithelial	O
32	cells	O
33	.	O
1	The	O
2	therapy	O
3	time	O
4	to	O
5	deliver	O
6	the	O
7	NCS	O
8	therapeutic	O
9	dose	O
10	of	O
11	10000	O
12	RBE	O
13	-	O
14	cGy	O
15	,	O
16	is	O
17	27	O
18	times	O
19	longer	O
20	when	O
21	157Gd	O
22	is	O
23	used	O
24	instead	O
25	of	O
26	10B	O
27	.	O
1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	preferred	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	3D	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	symmetric	O
31	ventricles	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O
1	We	O
2	have	O
3	also	O
4	identified	O
5	a	O
6	functional	O
7	domain	O
8	in	O
9	the	O
10	ORF	O
11	50	O
12	protein	O
13	,	O
14	an	O
15	immediate	B
16	-	I
17	early	I
18	gene	I
19	product	I
20	that	O
21	is	O
22	mainly	O
23	encoded	O
24	by	O
25	ORF	O
26	50	O
27	.	O
1	Once	O
2	HIT	O
3	II	O
4	is	O
5	suspected	O
6	,	O
7	heparin	O
8	(	O
9	and	O
10	low	O
11	-	O
12	molecular	O
13	-	O
14	weight	O
15	heparins	O
16	)	O
17	should	O
18	be	O
19	stopped	O
20	immediately	O
21	.	O
1	A	O
2	Y	B
3	.	I
4	lipolytica	I
5	Kar2p	I
6	mutant	I
7	was	O
8	isolated	O
9	that	O
10	restored	O
11	interaction	O
12	with	O
13	an	O
14	Sls1p	B
15	mutant	I
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	interaction	O
21	with	O
22	Sls1p	B
23	could	O
24	be	O
25	nucleotide	O
26	and	O
27	/	O
28	or	O
29	conformation	O
30	dependent	O
31	.	O
1	The	O
2	bases	O
3	of	O
4	this	O
5	comparison	O
6	are	O
7	reviewed	O
8	and	O
9	discussed	O
10	.	O
1	Promoter	O
2	activity	O
3	was	O
4	dose	O
5	-	O
6	dependently	O
7	inhibited	O
8	by	O
9	cotransfection	O
10	with	O
11	either	O
12	ras	B
13	or	O
14	mos	B
15	oncogenes	I
16	,	O
17	but	O
18	oncogene	O
19	inhibition	O
20	was	O
21	reversed	O
22	and	O
23	the	O
24	overall	O
25	activity	O
26	increased	O
27	when	O
28	cells	O
29	were	O
30	treated	O
31	with	O
32	the	O
33	MAP	B
34	kinase	I
35	kinase	I
36	(	O
37	MKK	B
38	)	O
39	inhibitor	O
40	PD98059	O
41	.	O
1	Because	O
2	GH	B
3	-	O
4	induced	O
5	Akt	B
6	activation	O
7	was	O
8	completely	O
9	inhibited	O
10	in	O
11	both	O
12	cells	O
13	by	O
14	the	O
15	same	O
16	concentration	O
17	of	O
18	LY294002	O
19	,	O
20	these	O
21	findings	O
22	indicate	O
23	that	O
24	the	O
25	wortmannin	O
26	sensitivity	O
27	of	O
28	both	O
29	the	O
30	IRS	B
31	-	I
32	1	I
33	-	O
34	independent	O
35	and	O
36	-	O
37	dependent	O
38	GH	B
39	-	O
40	induced	O
41	MAP	B
42	kinase	I
43	activation	O
44	may	O
45	reflect	O
46	the	O
47	activity	O
48	of	O
49	another	O
50	wortmannin	O
51	-	O
52	sensitive	O
53	target	O
54	(	O
55	s	O
56	)	O
57	in	O
58	addition	O
59	to	O
60	PI3K	B
61	in	O
62	mediation	O
63	of	O
64	GH	B
65	-	O
66	induced	O
67	MAP	B
68	kinase	I
69	activation	O
70	in	O
71	these	O
72	cells	O
73	.	O
1	It	O
2	was	O
3	found	O
4	that	O
5	increase	O
6	in	O
7	the	O
8	RH	O
9	level	O
10	boosts	O
11	the	O
12	current	O
13	values	O
14	by	O
15	2	O
16	-	O
17	3	O
18	orders	O
19	of	O
20	magnitude	O
21	;	O
22	contrariwise	O
23	,	O
24	the	O
25	voltage	O
26	values	O
27	rise	O
28	by	O
29	about	O
30	three	O
31	times	O
32	with	O
33	drop	O
34	in	O
35	the	O
36	RH	O
37	.	O
1	In	O
2	several	O
3	cell	O
4	lines	O
5	,	O
6	mTOR	B
7	or	O
8	its	O
9	downstream	O
10	targets	O
11	can	O
12	be	O
13	regulated	O
14	by	O
15	phosphatidylinositol	B
16	(	I
17	PI	I
18	)	I
19	3	I
20	-	I
21	kinase	I
22	;	O
23	protein	B
24	kinases	I
25	A	I
26	,	I
27	B	I
28	,	I
29	and	I
30	C	I
31	;	O
32	heterotrimeric	B
33	G	I
34	-	I
35	proteins	I
36	;	O
37	a	O
38	PD98059	O
39	-	O
40	sensitive	O
41	kinase	O
42	or	O
43	calcium	O
44	;	O
45	as	O
46	well	O
47	as	O
48	by	O
49	amino	O
50	acids	O
51	.	O
1	The	O
2	importance	O
3	of	O
4	this	O
5	new	O
6	epidemiological	O
7	profile	O
8	of	O
9	schistosomiasis	O
10	in	O
11	the	O
12	State	O
13	of	O
14	Pernambuco	O
15	relies	O
16	on	O
17	the	O
18	fact	O
19	that	O
20	it	O
21	can	O
22	be	O
23	related	O
24	with	O
25	the	O
26	drastic	O
27	human	O
28	interference	O
29	on	O
30	the	O
31	environment	O
32	.	O
1	RESULTS	O
2	:	O
3	No	O
4	significant	O
5	deformation	O
6	in	O
7	vertebral	O
8	artery	O
9	flow	O
10	was	O
11	noted	O
12	in	O
13	the	O
14	flexion	O
15	-	O
16	distraction	O
17	Stage	O
18	I	O
19	injuries	O
20	within	O
21	the	O
22	physiologic	O
23	range	O
24	of	O
25	cervical	O
26	flexion	O
27	.	O
1	We	O
2	screened	O
3	a	O
4	K562	O
5	cDNA	O
6	library	O
7	and	O
8	identified	O
9	novel	O
10	transcripts	O
11	,	O
12	MZF1B	B
13	and	O
14	MZF1C	B
15	.	O
1	RESULTS	O
2	:	O
3	Neither	O
4	basal	O
5	FSH	B
6	level	O
7	nor	O
8	stimulated	O
9	FSH	B
10	level	O
11	alone	O
12	were	O
13	statistically	O
14	significant	O
15	predictors	O
16	of	O
17	IVF	O
18	success	O
19	;	O
20	however	O
21	,	O
22	no	O
23	patient	O
24	with	O
25	a	O
26	day	O
27	3	O
28	FSH	B
29	level	O
30	>	O
31	11	O
32	.	O
33	1	O
34	mIU	O
35	/	O
36	ml	O
37	or	O
38	a	O
39	stimulated	O
40	day	O
41	10	O
42	FSH	B
43	level	O
44	>	O
45	13	O
46	.	O
47	5	O
48	mIU	O
49	/	O
50	ml	O
51	conceived	O
52	and	O
53	carried	O
54	a	O
55	pregnancy	O
56	.	O
1	These	O
2	include	O
3	NPF	O
4	repeats	O
5	,	O
6	a	O
7	leucine	O
8	heptad	O
9	repeat	O
10	enriched	O
11	in	O
12	charged	O
13	residues	O
14	,	O
15	and	O
16	a	O
17	proline	O
18	-	O
19	rich	O
20	SH3	B
21	-	I
22	like	I
23	and	O
24	/	O
25	or	O
26	WW	O
27	domain	O
28	-	O
29	binding	O
30	site	O
31	in	O
32	the	O
33	N	O
34	-	O
35	terminal	O
36	domain	O
37	,	O
38	which	O
39	is	O
40	followed	O
41	by	O
42	a	O
43	membrane	O
44	core	O
45	containing	O
46	four	O
47	putative	O
48	transmembrane	O
49	spans	O
50	and	O
51	three	O
52	amphiphilic	O
53	segments	O
54	that	O
55	are	O
56	the	O
57	most	O
58	highly	O
59	conserved	O
60	structural	O
61	elements	O
62	.	O
1	Mucosal	O
2	application	O
3	of	O
4	NCX	O
5	-	O
6	4016	O
7	,	O
8	however	O
9	,	O
10	did	O
11	not	O
12	cause	O
13	PD	O
14	reduction	O
15	and	O
16	luminal	O
17	H	O
18	+	O
19	loss	O
20	,	O
21	but	O
22	produced	O
23	a	O
24	marked	O
25	hyperemia	O
26	,	O
27	resulting	O
28	in	O
29	no	O
30	damage	O
31	in	O
32	the	O
33	stomach	O
34	of	O
35	both	O
36	normal	O
37	and	O
38	STZ	O
39	-	O
40	diabetic	O
41	rats	O
42	.	O
1	Whereas	O
2	both	O
3	MAP	O
4	and	O
5	MSNA	O
6	increase	O
7	during	O
8	SHG	O
9	,	O
10	the	O
11	transition	O
12	from	O
13	SHG	O
14	to	O
15	PHI	O
16	is	O
17	characterized	O
18	by	O
19	a	O
20	transient	O
21	reduction	O
22	in	O
23	MAP	O
24	but	O
25	sustained	O
26	elevation	O
27	in	O
28	MSNA	O
29	,	O
30	facilitating	O
31	separation	O
32	of	O
33	these	O
34	factors	O
35	in	O
36	vivo	O
37	.	O
1	METHODS	O
2	:	O
3	In	O
4	the	O
5	current	O
6	study	O
7	the	O
8	authors	O
9	reported	O
10	on	O
11	PPB	O
12	cases	O
13	from	O
14	a	O
15	national	O
16	retrospective	O
17	search	O
18	performed	O
19	in	O
20	18	O
21	Italian	O
22	Associations	O
23	for	O
24	Pediatric	O
25	Hematology	O
26	and	O
27	Oncology	O
28	centers	O
29	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	Cdc42p	B
6	is	O
7	in	O
8	fact	O
9	required	O
10	for	O
11	pheromone	O
12	response	O
13	and	O
14	that	O
15	interaction	O
16	with	O
17	the	O
18	PAK	B
19	Ste20p	I
20	is	O
21	critical	O
22	for	O
23	that	O
24	role	O
25	.	O
1	Deletion	O
2	of	O
3	an	O
4	intergenic	O
5	DNA	O
6	-	O
7	binding	O
8	site	O
9	for	O
10	this	O
11	complex	O
12	from	O
13	a	O
14	human	B
15	beta	I
16	-	I
17	globin	I
18	locus	I
19	construct	I
20	results	O
21	in	O
22	delayed	O
23	human	B
24	gamma	I
25	-	I
26	to	I
27	beta	I
28	-	I
29	globin	I
30	switching	O
31	in	O
32	transgenic	O
33	mice	O
34	,	O
35	suggesting	O
36	that	O
37	the	O
38	PYR	B
39	complex	I
40	acts	O
41	to	O
42	facilitate	O
43	the	O
44	switch	O
45	.	O
1	The	O
2	variable	O
3	phenotype	O
4	of	O
5	the	O
6	allotetraploids	O
7	could	O
8	not	O
9	be	O
10	explained	O
11	by	O
12	cytological	O
13	abnormalities	O
14	.	O
1	Primary	O
2	adrenal	O
3	hypersensitivity	O
4	to	O
5	ACTH	B
6	drive	O
7	in	O
8	obesity	O
9	has	O
10	also	O
11	been	O
12	suggested	O
13	.	O
1	HYPOTHESIS	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	investigate	O
11	the	O
12	oxidative	O
13	susceptibility	O
14	of	O
15	apolipoprotein	B
16	B	I
17	-	I
18	containing	I
19	lipoproteins	I
20	and	O
21	antioxidant	O
22	status	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	coronary	O
28	syndromes	O
29	and	O
30	chronic	O
31	stable	O
32	angina	O
33	pectoris	O
34	.	O
1	Intracellular	O
2	localization	O
3	studies	O
4	using	O
5	the	O
6	mDAP	B
7	-	I
8	3	I
9	/	O
10	EGFP	B
11	fusion	O
12	protein	O
13	,	O
14	cell	O
15	fractionation	O
16	and	O
17	protease	O
18	protection	O
19	experiments	O
20	localized	O
21	mDAP	B
22	-	I
23	3	I
24	to	O
25	the	O
26	mitochondrial	O
27	matrix	O
28	.	O
1	Nature	O
2	398	O
3	,	O
4	828	O
5	-	O
6	830	O
7	)	O
8	that	O
9	the	O
10	amino	O
11	acid	O
12	sequences	O
13	of	O
14	peptide	O
15	fragments	O
16	obtained	O
17	from	O
18	a	O
19	polypeptide	O
20	found	O
21	in	O
22	a	O
23	complex	O
24	of	O
25	proteins	O
26	that	O
27	alters	O
28	chromatin	O
29	structure	O
30	(	O
31	ARC	B
32	)	O
33	are	O
34	identical	O
35	to	O
36	portions	O
37	of	O
38	the	O
39	deduced	O
40	open	O
41	reading	O
42	frame	O
43	of	O
44	TIG	B
45	-	I
46	1	I
47	mRNA	I
48	.	O
1	Abnormalities	O
2	of	O
3	plasma	B
4	cholecystokinin	I
5	were	O
6	observed	O
7	only	O
8	in	O
9	patients	O
10	with	O
11	delayed	O
12	gastric	O
13	emptying	O
14	.	O
1	As	O
2	a	O
3	result	O
4	,	O
5	we	O
6	have	O
7	defined	O
8	two	O
9	arginine	O
10	-	O
11	rich	O
12	motifs	O
13	(	O
14	ARM1	O
15	and	O
16	ARM2	O
17	)	O
18	that	O
19	mediate	O
20	the	O
21	RNA	O
22	binding	O
23	activity	O
24	of	O
25	SU	O
26	(	O
27	S	O
28	).	O
1	Further	O
2	research	O
3	is	O
4	required	O
5	to	O
6	better	O
7	measure	O
8	treatment	O
9	effects	O
10	,	O
11	modification	O
12	of	O
13	MS	O
14	natural	O
15	history	O
16	,	O
17	and	O
18	net	O
19	societal	O
20	costs	O
21	of	O
22	IFN	B
23	beta	I
24	-	I
25	1b	I
26	in	O
27	RRMS	O
28	.	O
1	Vasoactive	B
2	intestinal	I
3	peptide	I
4	and	O
5	pituitary	B
6	adenylate	I
7	cyclase	I
8	-	I
9	activating	I
10	polypeptide	I
11	inhibit	O
12	nuclear	B
13	factor	I
14	-	I
15	kappa	I
16	B	I
17	-	I
18	dependent	I
19	gene	I
20	activation	O
21	at	O
22	multiple	O
23	levels	O
24	in	O
25	the	O
26	human	O
27	monocytic	O
28	cell	O
29	line	O
30	THP	O
31	-	O
32	1	O
33	.	O
1	Mn2	O
2	+	O
3	increased	O
4	both	O
5	the	O
6	junction	O
7	binding	O
8	and	O
9	cleaving	O
10	activities	O
11	of	O
12	the	O
13	mutant	O
14	proteins	O
15	.	O
1	Spores	O
2	from	O
3	Rhizopus	O
4	stolonifer	O
5	were	O
6	suspended	O
7	in	O
8	distilled	O
9	water	O
10	(	O
11	1	O
12	x	O
13	10	O
14	(	O
15	6	O
16	)	O
17	spores	O
18	/	O
19	mL	O
20	)	O
21	and	O
22	used	O
23	as	O
24	starter	O
25	.	O
1	For	O
2	this	O
3	purpose	O
4	,	O
5	the	O
6	writhing	O
7	test	O
8	,	O
9	capsaicin	O
10	and	O
11	formalin	O
12	induced	O
13	-	O
14	pain	O
15	in	O
16	mice	O
17	were	O
18	used	O
19	.	O
1	2000	O
2	update	O
3	of	O
4	recommendations	O
5	for	O
6	the	O
7	use	O
8	of	O
9	hematopoietic	B
10	colony	I
11	-	I
12	stimulating	I
13	factors	I
14	:	O
15	evidence	O
16	-	O
17	based	O
18	,	O
19	clinical	O
20	practice	O
21	guidelines	O
22	.	O
1	Dsh	B
2	is	O
3	required	O
4	for	O
5	two	O
6	different	O
7	pathways	O
8	,	O
9	the	O
10	Wnt	B
11	pathway	O
12	and	O
13	planar	O
14	polarity	O
15	pathway	O
16	in	O
17	Drosophila	O
18	.	O
1	The	O
2	small	B
3	monomeric	I
4	GTP	I
5	-	I
6	binding	I
7	proteins	I
8	of	O
9	the	O
10	RAB	B
11	subfamily	I
12	are	O
13	key	O
14	regulatory	O
15	elements	O
16	of	O
17	the	O
18	machinery	O
19	that	O
20	controls	O
21	membrane	O
22	traffic	O
23	in	O
24	eukaryotic	O
25	cells	O
26	.	O
1	Together	O
2	,	O
3	these	O
4	results	O
5	indicate	O
6	that	O
7	IL	B
8	-	I
9	1	I
10	beta	I
11	induces	O
12	VEGF	B
13	gene	I
14	expression	O
15	at	O
16	both	O
17	transcriptional	O
18	and	O
19	post	O
20	-	O
21	transcriptional	O
22	levels	O
23	,	O
24	and	O
25	IL	B
26	-	I
27	1	I
28	beta	I
29	evokes	O
30	p38	B
31	MAPK	O
32	and	O
33	JNK	B
34	signalings	O
35	,	O
36	which	O
37	in	O
38	turn	O
39	stimulate	O
40	the	O
41	transcription	O
42	of	O
43	the	O
44	VEGF	B
45	gene	I
46	through	O
47	Sp1	B
48	-	I
49	binding	I
50	sites	I
51	.	O
1	LMP2A	B
2	enhances	O
3	Lyn	B
4	and	O
5	Syk	B
6	ubiquitination	O
7	in	O
8	vivo	O
9	in	O
10	a	O
11	fashion	O
12	that	O
13	depends	O
14	on	O
15	the	O
16	activity	O
17	of	O
18	Nedd4	B
19	family	O
20	members	O
21	and	O
22	correlates	O
23	with	O
24	destabilization	O
25	of	O
26	the	O
27	Lyn	B
28	tyrosine	I
29	kinase	I
30	.	O
1	High	O
2	expression	O
3	of	O
4	the	O
5	peroxisome	B
6	proliferator	I
7	-	I
8	activated	I
9	receptor	I
10	alpha	I
11	(	O
12	PPARalpha	B
13	)	O
14	differentiates	O
15	brown	O
16	fat	O
17	from	O
18	white	O
19	,	O
20	and	O
21	is	O
22	related	O
23	to	O
24	its	O
25	high	O
26	capacity	O
27	of	O
28	lipid	O
29	oxidation	O
30	.	O
1	Aspirin	O
2	causes	O
3	peptic	O
4	ulcers	O
5	predominately	O
6	by	O
7	reducing	O
8	gastric	B
9	mucosal	I
10	cyclooxygenase	I
11	(	O
12	COX	B
13	)	O
14	activity	O
15	and	O
16	prostaglandin	O
17	synthesis	O
18	.	O
1	A	O
2	total	O
3	of	O
4	1060	O
5	clones	O
6	were	O
7	randomly	O
8	selected	O
9	for	O
10	sequencing	O
11	of	O
12	one	O
13	end	O
14	.	O
1	CONCLUSIONS	O
2	:	O
3	The	O
4	surgical	O
5	or	O
6	multimodality	O
7	treatment	O
8	of	O
9	MSGT	O
10	has	O
11	provided	O
12	a	O
13	good	O
14	locoregional	O
15	control	O
16	(	O
17	78	O
18	%)	O
19	and	O
20	68	O
21	%	O
22	10	O
23	-	O
24	year	O
25	survival	O
26	in	O
27	a	O
28	series	O
29	of	O
30	patients	O
31	treated	O
32	at	O
33	the	O
34	oncology	O
35	department	O
36	of	O
37	a	O
38	general	O
39	hospital	O
40	in	O
41	Quito	O
42	,	O
43	Ecuador	O
44	.	O
1	Among	O
2	the	O
3	total	O
4	CDSs	O
5	,	O
6	8	O
7	.	O
8	8	O
9	%	O
10	match	O
11	sequences	O
12	of	O
13	proteins	O
14	found	O
15	only	O
16	in	O
17	Bacillus	O
18	subtilis	O
19	and	O
20	66	O
21	.	O
22	7	O
23	%	O
24	are	O
25	widely	O
26	conserved	O
27	in	O
28	comparison	O
29	with	O
30	the	O
31	proteins	O
32	of	O
33	various	O
34	organisms	O
35	,	O
36	including	O
37	B	O
38	.	O
39	subtilis	O
40	.	O
1	Thus	O
2	,	O
3	IHHNV	O
4	is	O
5	closely	O
6	related	O
7	to	O
8	densoviruses	O
9	of	O
10	the	O
11	genus	O
12	Brevidensovirus	O
13	in	O
14	the	O
15	family	O
16	Parvoviridae	O
17	,	O
18	and	O
19	we	O
20	therefore	O
21	propose	O
22	to	O
23	rename	O
24	this	O
25	virus	O
26	Penaeus	O
27	stylirostris	O
28	densovirus	O
29	(	O
30	PstDNV	O
31	).	O
1	Stress	B
2	-	I
3	activated	I
4	protein	I
5	kinase	I
6	1	I
7	(	O
8	SAPK1	B
9	),	O
10	also	O
11	called	O
12	c	B
13	-	I
14	Jun	I
15	N	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	),	O
22	becomes	O
23	activated	O
24	in	O
25	vivo	O
26	in	O
27	response	O
28	to	O
29	pro	O
30	-	O
31	inflammatory	O
32	cytokines	O
33	or	O
34	cellular	O
35	stresses	O
36	.	O
1	Signal	O
2	transduction	O
3	via	O
4	modulation	O
5	of	O
6	phosphorylation	O
7	after	O
8	selective	O
9	inhibition	O
10	of	O
11	protein	B
12	phosphatase	I
13	(	I
14	PP	I
15	)	I
16	1	I
17	and	O
18	/	O
19	or	O
20	PP2A	B
21	appears	O
22	to	O
23	play	O
24	a	O
25	role	O
26	in	O
27	okadaic	O
28	acid	O
29	(	O
30	OA	O
31	)-	O
32	mediated	O
33	effects	O
34	.	O
1	Exon	O
2	A	O
3	is	O
4	located	O
5	approximately	O
6	7	O
7	kb	O
8	5	O
9	'	O
10	to	O
11	the	O
12	HSL	B
13	translation	I
14	start	I
15	site	I
16	.	O
1	NF	B
2	-	I
3	kappaB	I
4	is	O
5	a	O
6	redox	O
7	-	O
8	sensitive	O
9	transcription	O
10	factor	O
11	known	O
12	to	O
13	be	O
14	activated	O
15	by	O
16	oxidative	O
17	stress	O
18	as	O
19	well	O
20	as	O
21	chemical	O
22	and	O
23	biological	O
24	reductants	O
25	.	O
1	Characterization	O
2	of	O
3	a	O
4	Xenopus	B
5	laevis	I
6	CXC	I
7	chemokine	I
8	receptor	I
9	4	I
10	:	O
11	implications	O
12	for	O
13	hematopoietic	O
14	cell	O
15	development	O
16	in	O
17	the	O
18	vertebrate	O
19	embryo	O
20	.	O
1	Patients	O
2	had	O
3	to	O
4	have	O
5	adequate	O
6	liver	O
7	,	O
8	renal	O
9	,	O
10	and	O
11	marrow	O
12	functions	O
13	.	O
1	In	O
2	15	O
3	ventilator	O
4	-	O
5	dependent	O
6	,	O
7	SB	O
8	,	O
9	and	O
10	actively	O
11	expiring	O
12	patients	O
13	,	O
14	we	O
15	found	O
16	that	O
17	the	O
18	difference	O
19	PEEP	O
20	(	O
21	i	O
22	),	O
23	dyn	O
24	-	O
25	Pga	O
26	,	O
27	total	O
28	decay	O
29	(	O
30	mean	O
31	+/-	O
32	SD	O
33	,	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	1	O
39	.	O
40	9	O
41	cm	O
42	H	O
43	(	O
44	2	O
45	)	O
46	O	O
47	)	O
48	was	O
49	quite	O
50	similar	O
51	to	O
52	PEEP	O
53	(	O
54	i	O
55	),	O
56	dyn	O
57	ref	O
58	(	O
59	5	O
60	.	O
61	3	O
62	+/-	O
63	1	O
64	.	O
65	9	O
66	cm	O
67	H	O
68	(	O
69	2	O
70	)	O
71	O	O
72	).	O
1	Transcription	O
2	of	O
3	the	O
4	six	O
5	EBNA	B
6	genes	I
7	,	O
8	which	O
9	are	O
10	expressed	O
11	in	O
12	EBV	O
13	-	O
14	immortalized	O
15	primary	O
16	B	O
17	cells	O
18	,	O
19	arises	O
20	from	O
21	one	O
22	of	O
23	two	O
24	promoters	O
25	,	O
26	Cp	B
27	and	O
28	Wp	B
29	,	O
30	located	O
31	near	O
32	the	O
33	left	O
34	end	O
35	of	O
36	the	O
37	viral	O
38	genome	O
39	.	O
1	This	O
2	dynamic	O
3	response	O
4	strongly	O
5	suggests	O
6	that	O
7	the	O
8	p53	B
9	and	O
10	Rb	B
11	tumor	O
12	suppressor	O
13	pathways	O
14	are	O
15	intact	O
16	in	O
17	HeLa	O
18	cells	O
19	and	O
20	that	O
21	repression	O
22	of	O
23	HPV	B
24	E6	I
25	and	O
26	E7	B
27	mobilizes	O
28	these	O
29	pathways	O
30	in	O
31	an	O
32	orderly	O
33	fashion	O
34	to	O
35	deliver	O
36	growth	O
37	inhibitory	O
38	signals	O
39	to	O
40	the	O
41	cells	O
42	.	O
1	To	O
2	test	O
3	whether	O
4	or	O
5	not	O
6	SOCS	B
7	-	I
8	3	I
9	also	O
10	binds	O
11	to	O
12	the	O
13	IGFIR	B
14	,	O
15	we	O
16	cloned	O
17	human	B
18	SOCS	I
19	-	I
20	3	I
21	by	O
22	reverse	O
23	transcription	O
24	-	O
25	polymerase	O
26	chain	O
27	reaction	O
28	from	O
29	human	O
30	skeletal	O
31	muscle	O
32	mRNA	O
33	.	O
1	A	O
2	protein	O
3	lacking	O
4	the	O
5	SH2	B
6	and	O
7	RING	O
8	finger	O
9	domains	O
10	has	O
11	no	O
12	activity	O
13	,	O
14	but	O
15	a	O
16	chimeric	O
17	protein	O
18	with	O
19	the	O
20	SH2	B
21	and	O
22	RING	O
23	finger	O
24	domains	O
25	of	O
26	SLI	B
27	-	I
28	1	I
29	replaced	O
30	by	O
31	the	O
32	equivalent	O
33	domains	O
34	of	O
35	c	B
36	-	I
37	Cbl	I
38	has	O
39	activity	O
40	.	O
1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	mutant	B
6	desmin	I
7	in	O
8	SW13	O
9	(	O
10	vim	B
11	-)	O
12	cells	O
13	showed	O
14	aggregation	O
15	of	O
16	abnormal	O
17	coarse	O
18	clumps	O
19	of	O
20	desmin	B
21	positive	O
22	material	O
23	dispersed	O
24	throughout	O
25	the	O
26	cytoplasm	O
27	.	O
1	Patients	O
2	with	O
3	lesions	O
4	affecting	O
5	the	O
6	PRC	O
7	but	O
8	sparing	O
9	the	O
10	PHC	O
11	,	O
12	and	O
13	patients	O
14	with	O
15	lesions	O
16	affecting	O
17	both	O
18	PRC	O
19	and	O
20	PHC	O
21	,	O
22	performed	O
23	an	O
24	oculomotor	O
25	delayed	O
26	response	O
27	task	O
28	with	O
29	unpredictably	O
30	varied	O
31	memory	O
32	delays	O
33	of	O
34	up	O
35	to	O
36	30	O
37	s	O
38	.	O
1	The	O
2	QT	O
3	interval	O
4	was	O
5	related	O
6	to	O
7	various	O
8	components	O
9	of	O
10	the	O
11	insulin	B
12	resistance	O
13	syndrome	O
14	,	O
15	including	O
16	BP	O
17	and	O
18	insulin	B
19	sensitivity	O
20	.	O
1	The	O
2	wavenumbers	O
3	corresponding	O
4	to	O
5	the	O
6	normal	O
7	modes	O
8	of	O
9	vibration	O
10	were	O
11	calculated	O
12	using	O
13	the	O
14	DFT	O
15	(	O
16	B3LYP	O
17	/	O
18	6	O
19	-	O
20	31G	O
21	**)	O
22	approximation	O
23	and	O
24	their	O
25	agreement	O
26	with	O
27	the	O
28	measured	O
29	values	O
30	improved	O
31	after	O
32	scaling	O
33	of	O
34	the	O
35	associated	O
36	force	O
37	field	O
38	.	O
1	In	O
2	addition	O
3	,	O
4	npm3	B
5	,	O
6	which	O
7	is	O
8	usually	O
9	coactivated	O
10	with	O
11	fgf8	B
12	by	O
13	MMTV	O
14	insertion	O
15	,	O
16	was	O
17	not	O
18	up	O
19	-	O
20	regulated	O
21	by	O
22	androgens	O
23	in	O
24	SC	O
25	-	O
26	3	O
27	cells	O
28	.	O
1	Stoichiometric	O
2	phosphorylation	O
3	of	O
4	human	B
5	p53	I
6	at	O
7	Ser315	O
8	stimulates	O
9	p53	B
10	-	O
11	dependent	O
12	transcription	O
13	.	O
14	p53	B
15	protein	I
16	activity	O
17	as	O
18	a	O
19	transcription	O
20	factor	O
21	can	O
22	be	O
23	activated	O
24	in	O
25	vivo	O
26	by	O
27	antibodies	O
28	that	O
29	target	O
30	its	O
31	C	O
32	-	O
33	terminal	O
34	negative	O
35	regulatory	O
36	domain	O
37	suggesting	O
38	that	O
39	cellular	O
40	enzymes	O
41	that	O
42	target	O
43	this	O
44	domain	O
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	stimulating	O
51	p53	B
52	-	O
53	dependent	O
54	gene	O
55	expression	O
56	.	O
1	Interestingly	O
2	,	O
3	this	O
4	mutant	O
5	cell	O
6	line	O
7	lacks	O
8	expression	O
9	of	O
10	the	O
11	IKK	B
12	regulatory	I
13	protein	I
14	,	O
15	IKKgamma	B
16	.	O
1	The	O
2	Tax	B
3	/	O
4	IKKgamma	B
5	interaction	O
6	serves	O
7	to	O
8	recruit	O
9	Tax	B
10	to	O
11	the	O
12	IKK	B
13	catalytic	I
14	subunits	I
15	,	O
16	IKKalpha	B
17	and	O
18	IKKbeta	B
19	,	O
20	and	O
21	this	O
22	recruitment	O
23	appears	O
24	to	O
25	be	O
26	an	O
27	essential	O
28	mechanism	O
29	by	O
30	which	O
31	Tax	B
32	stimulates	O
33	the	O
34	activity	O
35	of	O
36	IKK	B
37	.	O
1	The	O
2	swa2	B
3	-	I
4	1	I
5	allele	I
6	recovered	O
7	from	O
8	the	O
9	original	O
10	screen	O
11	carries	O
12	a	O
13	point	O
14	mutation	O
15	in	O
16	its	O
17	tetratricopeptide	O
18	repeat	O
19	(	O
20	TPR	O
21	)	O
22	domain	O
23	,	O
24	a	O
25	motif	O
26	not	O
27	found	O
28	in	O
29	auxilin	B
30	but	O
31	known	O
32	in	O
33	other	O
34	proteins	O
35	to	O
36	mediate	O
37	interaction	O
38	with	O
39	heat	B
40	-	I
41	shock	I
42	proteins	I
43	.	O
1	A	O
2	thermal	O
3	Kubo	O
4	-	O
5	Martin	O
6	-	O
7	Schwinger	O
8	condition	O
9	arises	O
10	due	O
11	to	O
12	the	O
13	coupling	O
14	of	O
15	a	O
16	computer	O
17	to	O
18	a	O
19	strong	O
20	periodic	O
21	source	O
22	,	O
23	namely	O
24	,	O
25	the	O
26	daily	O
27	and	O
28	weekly	O
29	usage	O
30	patterns	O
31	of	O
32	the	O
33	system	O
34	.	O
1	The	O
2	transcription	O
3	and	O
4	alternative	O
5	splicing	O
6	of	O
7	human	B
8	ORL1	I
9	and	O
10	GAIP	B
11	are	O
12	cell	O
13	-	O
14	type	O
15	specific	O
16	.	O
1	Nevertheless	O
2	,	O
3	protein	B
4	kinase	I
5	A	I
6	stimulation	O
7	induces	O
8	CREMalpha	B
9	to	O
10	activate	O
11	the	O
12	complex	O
13	native	O
14	promoter	O
15	in	O
16	the	O
17	phosphoenolpyruvate	B
18	carboxykinase	I
19	(	O
20	PEPCK	B
21	)	O
22	gene	O
23	.	O
1	Another	O
2	putative	O
3	HNF3	B
4	site	I
5	in	O
6	close	O
7	apposition	O
8	to	O
9	a	O
10	NF1	B
11	/	O
12	CTF	B
13	site	O
14	was	O
15	localized	O
16	upstream	O
17	of	O
18	the	O
19	silencer	O
20	-	O
21	like	O
22	element	O
23	.	O
1	The	O
2	objectives	O
3	of	O
4	the	O
5	present	O
6	study	O
7	were	O
8	to	O
9	evaluate	O
10	the	O
11	effects	O
12	of	O
13	adding	O
14	Equex	O
15	to	O
16	a	O
17	TRIS	O
18	-	O
19	extender	O
20	,	O
21	diluting	O
22	the	O
23	semen	O
24	in	O
25	1	O
26	or	O
27	2	O
28	steps	O
29	,	O
30	freezing	O
31	according	O
32	to	O
33	2	O
34	methods	O
35	,	O
36	thawing	O
37	at	O
38	2	O
39	rates	O
40	,	O
41	and	O
42	the	O
43	interactions	O
44	between	O
45	these	O
46	treatments	O
47	,	O
48	on	O
49	the	O
50	post	O
51	-	O
52	thaw	O
53	survival	O
54	of	O
55	dog	O
56	spermatozoa	O
57	at	O
58	38	O
59	degrees	O
60	C	O
61	.	O
1	Antimicrobial	O
2	Susceptibility	O
3	of	O
4	Klebsiella	O
5	pneumoniae	O
6	Producing	O
7	Extended	B
8	-	I
9	Spectrum	I
10	beta	I
11	-	I
12	lactamase	I
13	(	O
14	ESBL	B
15	)	O
16	Isolated	O
17	in	O
18	Hospitals	O
19	in	O
20	Brazil	O
21	.	O
1	CONCLUSION	O
2	:	O
3	Our	O
4	results	O
5	suggest	O
6	that	O
7	AIF	O
8	peak	O
9	saturation	O
10	leads	O
11	to	O
12	a	O
13	significant	O
14	systematic	O
15	error	O
16	in	O
17	the	O
18	determination	O
19	of	O
20	CBV	O
21	and	O
22	CBF	O
23	values	O
24	and	O
25	has	O
26	necessarily	O
27	to	O
28	be	O
29	taken	O
30	into	O
31	account	O
32	for	O
33	dynamic	O
34	contrast	O
35	-	O
36	enhanced	O
37	MR	O
38	perfusion	O
39	studies	O
40	.	O
1	Toward	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	O
15	FAP	B
16	-	I
17	1	I
18	(	I
19	C	I
20	-	I
21	terminal	I
22	399	I
23	amino	I
24	acids	I
25	)	I
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	Cys2408	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	O
37	glutathione	B
38	-	I
39	S	I
40	-	I
41	transferase	I
42	(	O
43	GST	B
44	).	O
1	Acoust	O
2	.	O
1	Young	O
2	fish	O
3	(	O
4	Oreochromis	O
5	mossambicus	O
6	)	O
7	were	O
8	exposed	O
9	to	O
10	microgravity	O
11	(	O
12	micro	O
13	g	O
14	)	O
15	for	O
16	9	O
17	to	O
18	10	O
19	days	O
20	during	O
21	space	O
22	missions	O
23	STS	O
24	-	O
25	55	O
26	and	O
27	STS	O
28	-	O
29	84	O
30	,	O
31	or	O
32	to	O
33	hypergravity	O
34	(	O
35	hg	O
36	)	O
37	for	O
38	9	O
39	days	O
40	.	O
1	S6K2	B
2	is	O
3	highly	O
4	homologous	O
5	to	O
6	S6K1	B
7	in	O
8	the	O
9	core	O
10	kinase	O
11	and	O
12	linker	O
13	regulatory	O
14	domains	O
15	but	O
16	differs	O
17	from	O
18	S6K1	B
19	in	O
20	the	O
21	N	O
22	-	O
23	and	O
24	C	O
25	-	O
26	terminal	O
27	regions	O
28	and	O
29	is	O
30	differently	O
31	localized	O
32	primarily	O
33	to	O
34	the	O
35	nucleus	O
36	because	O
37	of	O
38	a	O
39	C	O
40	-	O
41	terminal	O
42	nuclear	O
43	localization	O
44	signal	O
45	unique	O
46	to	O
47	S6K2	B
48	.	O
1	Pretreatment	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	-	I
11	extracellular	I
12	signal	I
13	-	I
14	regulated	I
15	kinase	I
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	U0126	O
22	inhibited	O
23	S6K2	B
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	S6K1	B
31	.	O
1	Ketanserin	O
2	,	O
3	a	O
4	hypotensive	O
5	drug	O
6	with	O
7	5	B
8	-	I
9	HT2	I
10	receptor	I
11	antagonism	O
12	,	O
13	when	O
14	administered	O
15	by	O
16	topical	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	w	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	corneal	O
30	and	O
31	scleral	O
32	applications	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	intraocular	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	metabolite	O
48	,	O
49	ketanserinol	O
50	.	O
1	Our	O
2	data	O
3	show	O
4	that	O
5	multiple	O
6	MLSN1	B
7	transcripts	I
8	,	O
9	both	O
10	constitutively	O
11	expressed	O
12	and	O
13	inducible	O
14	,	O
15	are	O
16	present	O
17	in	O
18	cultured	O
19	pigmented	O
20	melanoma	O
21	cells	O
22	,	O
23	and	O
24	suggest	O
25	that	O
26	MLSN1	B
27	expression	O
28	can	O
29	be	O
30	regulated	O
31	at	O
32	the	O
33	level	O
34	of	O
35	both	O
36	transcription	O
37	and	O
38	mRNA	O
39	processing	O
40	.	O
1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O
1	Characterization	O
2	of	O
3	the	O
4	microtubule	O
5	binding	O
6	domain	O
7	of	O
8	microtubule	B
9	actin	I
10	crosslinking	I
11	factor	I
12	(	O
13	MACF	B
14	):	O
15	identification	O
16	of	O
17	a	O
18	novel	O
19	group	O
20	of	O
21	microtubule	B
22	associated	I
23	proteins	I
24	.	O
1	These	O
2	results	O
3	also	O
4	suggest	O
5	the	O
6	involvement	O
7	of	O
8	additional	O
9	elements	O
10	in	O
11	the	O
12	UPR	O
13	.	O
1	Since	O
2	MEK	B
3	acts	O
4	as	O
5	a	O
6	cytoplasmic	O
7	anchor	O
8	for	O
9	the	O
10	ERKs	B
11	,	O
12	the	O
13	lack	O
14	of	O
15	a	O
16	MEK	B
17	interaction	O
18	resulted	O
19	in	O
20	the	O
21	aberrant	O
22	nuclear	O
23	localization	O
24	of	O
25	ERK2	B
26	-	O
27	Delta19	B
28	-	I
29	25	I
30	mutants	O
31	in	O
32	serum	O
33	-	O
34	starved	O
35	cells	O
36	.	O
1	Regulation	O
2	of	O
3	RhoA	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	stationary	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	spreading	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O
1	These	O
2	cells	O
3	produced	O
4	P2Y	B
5	(	I
6	11	I
7	)	I
8	mRNA	I
9	during	O
10	culture	O
11	.	O
1	This	O
2	sensitivity	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	practical	O
8	limits	O
9	of	O
10	the	O
11	accuracy	O
12	of	O
13	the	O
14	used	O
15	screening	O
16	test	O
17	jeopardize	O
18	the	O
19	estimation	O
20	of	O
21	the	O
22	true	O
23	herd	O
24	prevalence	O
25	within	O
26	reasonable	O
27	confidence	O
28	limits	O
29	,	O
30	because	O
31	the	O
32	within	O
33	-	O
34	herd	O
35	PTB	O
36	true	O
37	prevalence	O
38	was	O
39	low	O
40	.	O
41	For	O
42	this	O
43	reason	O
44	we	O
45	augmented	O
46	the	O
47	herd	O
48	specificity	O
49	for	O
50	herds	O
51	with	O
52	larger	O
53	adult	O
54	herd	O
55	size	O
56	(>	O
57	5	O
58	).	O
1	The	O
2	transcription	O
3	factor	O
4	CHOP	B
5	/	O
6	GADD153	B
7	gene	O
8	is	O
9	induced	O
10	by	O
11	cellular	O
12	stress	O
13	and	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	apoptosis	O
19	.	O
1	Tec	B
2	kinase	I
3	signaling	O
4	in	O
5	T	O
6	cells	O
7	is	O
8	regulated	O
9	by	O
10	phosphatidylinositol	B
11	3	I
12	-	I
13	kinase	I
14	and	O
15	the	O
16	Tec	B
17	pleckstrin	I
18	homology	I
19	domain	I
20	.	O
1	The	O
2	structure	O
3	of	O
4	the	O
5	free	O
6	SH2	B
7	domain	I
8	has	O
9	been	O
10	compared	O
11	to	O
12	that	O
13	of	O
14	the	O
15	SH2	B
16	complexed	O
17	with	O
18	a	O
19	doubly	O
20	phosphorylated	O
21	peptide	O
22	derived	O
23	from	O
24	polyomavirus	B
25	middle	I
26	T	I
27	antigen	I
28	(	O
29	MT	B
30	).	O
1	Nucleotide	O
2	sequence	O
3	,	O
4	genome	O
5	organization	O
6	and	O
7	phylogenetic	O
8	analysis	O
9	of	O
10	pineapple	O
11	mealybug	O
12	wilt	O
13	-	O
14	associated	O
15	virus	O
16	-	O
17	2	O
18	.	O
1	All	O
2	9	O
3	untreated	O
4	patients	O
5	underwent	O
6	laparoscopy	O
7	,	O
8	which	O
9	identified	O
10	3	O
11	intra	O
12	-	O
13	abdominal	O
14	,	O
15	3	O
16	vanished	O
17	and	O
18	2	O
19	peeping	O
20	testes	O
21	,	O
22	and	O
23	1	O
24	atrophic	O
25	testis	O
26	in	O
27	the	O
28	inguinal	O
29	canal	O
30	.	O
1	Bupropion	O
2	to	O
3	aid	O
4	smoking	O
5	cessation	O
6	.	O
1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	B
14	-	I
15	6	I
16	(	O
17	IL	B
18	-	I
19	6	I
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	O
46	).	O
1	In	O
2	a	O
3	prospective	O
4	,	O
5	multicentre	O
6	trial	O
7	the	O
8	efficacy	O
9	of	O
10	an	O
11	Vitex	O
12	agnus	O
13	castus	O
14	L	O
15	extract	O
16	Ze	O
17	440	O
18	was	O
19	investigated	O
20	in	O
21	50	O
22	patients	O
23	with	O
24	pre	O
25	-	O
26	menstrual	O
27	syndrome	O
28	(	O
29	PMS	O
30	).	O
1	The	O
2	standard	O
3	method	O
4	for	O
5	calculating	O
6	the	O
7	composite	O
8	score	O
9	on	O
10	the	O
11	S	O
12	-	O
13	B	O
14	IV	O
15	excludes	O
16	subtests	O
17	with	O
18	a	O
19	raw	O
20	score	O
21	of	O
22	0	O
23	,	O
24	which	O
25	overestimates	O
26	cognitive	O
27	functioning	O
28	in	O
29	young	O
30	biologically	O
31	high	O
32	risk	O
33	children	O
34	.	O
1	Validity	O
2	of	O
3	NIR	O
4	spectroscopy	O
5	for	O
6	quantitatively	O
7	measuring	O
8	muscle	O
9	oxidative	O
10	metabolic	O
11	rate	O
12	in	O
13	exercise	O
14	.	O
1	The	O
2	murine	B
3	int	I
4	-	I
5	6	I
6	locus	I
7	,	O
8	identified	O
9	as	O
10	a	O
11	frequent	O
12	integration	O
13	site	O
14	of	O
15	mouse	O
16	mammary	O
17	tumor	O
18	viruses	O
19	,	O
20	encodes	O
21	the	O
22	48	B
23	-	I
24	kDa	I
25	eIF3e	I
26	subunit	I
27	of	I
28	translation	I
29	initiation	I
30	factor	I
31	eIF3	I
32	.	O
1	We	O
2	have	O
3	therefore	O
4	studied	O
5	the	O
6	molecular	O
7	mechanisms	O
8	of	O
9	TGF	B
10	-	I
11	beta1	I
12	action	O
13	on	O
14	thyroglobulin	B
15	(	O
16	TG	B
17	)	O
18	gene	O
19	expression	O
20	by	O
21	focusing	O
22	our	O
23	attention	O
24	on	O
25	TGF	B
26	-	I
27	beta1	I
28	regulation	O
29	of	O
30	thyroid	O
31	-	O
32	specific	O
33	transcription	O
34	factors	O
35	.	O
1	The	O
2	epitope	O
3	-	O
4	protected	O
5	lysine	O
6	(	O
7	K	O
8	)	O
9	was	O
10	present	O
11	in	O
12	a	O
13	30	B
14	-	I
15	aa	I
16	TPO	I
17	fragment	I
18	that	O
19	,	O
20	by	O
21	N	O
22	-	O
23	terminal	O
24	sequencing	O
25	,	O
26	was	O
27	found	O
28	to	O
29	be	O
30	K713	O
31	.	O
